NATIONAL TOXICOLOGY PROGRAM Technical Report Series No. 459



٢

# TOXICOLOGY AND CARCINOGENESIS

STUDIES OF

# E-BUTYLHYDROQUINONE

(CAS NO. 1948-33-0)

IN F344/N RATS AND B6C3F1 MICE

(FEED STUDIES)

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Public Health Service National Institutes of Health

### FOREWORD

The National Toxicology Program (NTP) is made up of four charter agencies of the U.S. Department of Health and Human Services (DHHS): the National Cancer Institute (NCI), National Institutes of Health; the National Institute of Environmental Health Sciences (NIEHS), National Institutes of Health; the National Center for Toxicological Research (NCTR), Food and Drug Administration; and the National Institute for Occupational Safety and Health (NIOSH), Centers for Disease Control. In July 1981, the Carcinogenesis Bioassay Testing Program, NCI, was transferred to the NIEHS. The NTP coordinates the relevant programs, staff, and resources from these Public Health Service agencies relating to basic and applied research and to biological assay development and validation.

The NTP develops, evaluates, and disseminates scientific information about potentially toxic and hazardous chemicals. This knowledge is used for protecting the health of the American people and for the primary prevention of disease.

The studies described in this Technical Report were performed under the direction of the NIEHS and were conducted in compliance with NTP laboratory health and safety requirements and must meet or exceed all applicable federal, state, and local health and safety regulations. Animal care and use were in accordance with the Public Health Service Policy on Humane Care and Use of Animals. The prechronic and chronic studies were conducted in compliance with Food and Drug Administration (FDA) Good Laboratory Practice Regulations, and all aspects of the chronic studies were subjected to retrospective quality assurance audits before being presented for public review.

These studies are designed and conducted to characterize and evaluate the toxicologic potential, including carcinogenic activity, of selected chemicals in laboratory animals (usually two species, rats and mice). Chemicals selected for NTP toxicology and carcinogenesis studies are chosen primarily on the bases of human exposure, level of production, and chemical structure. Selection *per se* is not an indicator of a chemical's carcinogenic potential. The interpretive conclusions presented in this Technical Report are based only on the results of these NTP studies. Extrapolation of these results to other species and quantitative risk analyses for humans require wider analyses beyond the purview of these studies.

These NTP Technical Reports are available for sale from the National Technical Information Service, U.S. Department of Commerce, 5285 Port Royal Road, Springfield, VA 22161 (703-487-4650). Single copies of this Technical Report are available without charge while supplies last from NTP Central Data Management, NIEHS, P.O. Box 12233, MD E1-02, Research Triangle Park, NC 27709 (919-541-3419). Listings of all published NTP reports and ongoing studies are also available from NTP Central Data Management. The Abstracts and other study information for 2-year studies are also available at the NTP's World Wide Web site: http://ntp-server.niehs.nih.gov. NTP TECHNICAL REPORT

# $\mathbb{ON} \ \mathbb{THE}$

# TOXICOLOGY AND CARCINOGENESIS

# STUDIES OF

# C-BUTHYLHYDROQUINONE

# (CAS NO. 1948-33-0)

# IN F344/N RATS AND B6C3F1 MICE

(FEED STUDIES)

# NATIONAL TOXICOLOGY PROGRAM P.O. Box 12233 Research Triangle Park, NC 27709

May 1997

### NTP TR 459

NIH Publication No. 97-3375

# U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Public Health Service National Institutes of Health

C,

# CONTRIBUTORS

# National Toxicology Program

Evaluated and interpreted results and reported findings

K.M. Abdo, Ph.D., Study Scientist
G.A. Boorman, D.V.M., Ph.D.
D.A. Bridge, B.S.
J.R. Bucher, Ph.D.
L.T. Burka, Ph.D.
M.R. Elwell, D.V.M., Ph.D.
J.R. Hailey, D.V.M.
J.K. Haseman, Ph.D.
G.N. Rao, D.V.M., Ph.D.
J.H. Roycroft, Ph.D.
G.S. Travlos, D.V.M.
D.B. Walters, Ph.D.
K.L. Witt, M.S., Oak Ridge Associated Universities

### Southern Research Institute

Conducted 13-week, 2-year, and long-term studies, evaluated pathology findings

J.D. Prejean, Ph.D., Principal Investigator D.R. Farnell, D.V.M., Ph.D. J.E. Heath, D.V.M. R.H. James, M.S. C. Lindamood, Ph.D.

# **Experimental Pathology Laboratories, Inc.**

Provided pathology quality assurance

J.F. Hardisty, D.V.M., Principal Investigator S. Botts, D.V.M., Ph.D. K. Yoshitomi, D.V.M., Ph.D.

### **Dynamac Corporation**

Prepared quality assurance audits

S. Brecher, Ph.D., Principal Investigator

### Analytical Sciences, Inc.

Provided statistical analyses

R.W. Morris, M.S., Principal Investigator N.G. Mintz, B.S. S. Rosenblum, M.S.

### NTP Pathology Working Group

Evaluated slides, prepared pathology report on rats (9 January 1995)

J.C. Seely, D.V.M., Chairperson PATHCO, Inc.

S. Botts, D.V.M., Ph.D. Experimental Pathology Laboratories, Inc.

- M.R. Elwell, D.V.M., Ph.D. National Toxicology Program
- J.R. Hailey, D.V.M. National Toxicology Program
- R.A. Herbert, D.V.M., Ph.D. National Toxicology Program
- A. Radovsky, D.V.M., Ph.D. National Toxicology Program
- B. Short, D.V.M., Ph.D. SmithKline-Beecham

Evaluated slides, prepared pathology report on mice (24 February 1994)

P.K. Hildebrandt, D.V.M., Chairperson PATHCO, Inc.

- J.R. Hailey, D.V.M. National Toxicology Program
- R.A. Herbert, D.V.M., Ph.D. National Toxicology Program
- J. Leininger, D.V.M, Ph.D. Chemical Industry Institute of Toxicology
- J. Mahler, D.V.M. National Toxicology Program
- C. Morris, D.V.M., M.S., Observer R.P.S.
- A. Radovsky, D.V.M., Ph.D. National Toxicology Program
- K. Yoshitomi, D.V.M., Ph.D. Experimental Pathology Laboratories, Inc.

### **Biotechnical Services, Inc.** Prepared Technical Report

S.R. Gunnels, M.A., Principal Investigator J.R. Carlton, B.A. L.M. Harper, B.S. T.A. King-Hunter, B.S. D.C. Serbus, Ph.D.

# CONTENTS

ABSTRACT	• • • • • • • • • • • • • • • • • • • •	5
EXPLANATION	9 OF LEVELS OF EVIDENCE OF CARCINOGENIC ACTIVITY	9
TECHNICAL R	EPORTS REVIEW SUBCOMMITTEE	1 <b>0</b>
SUMMARY OF	TECHNICAL REPORTS REVIEW SUBCOMMITTEE COMMENTS	11
INTRODUCTIO	DN	13
MATERIALS A	ND METHODS	21
RESULTS		33
DISCUSSION A	ND CONCLUSIONS	61
REFERENCES	• • • • • • • • • • • • • • • • • • • •	65
Appendix A	Summary of Lesions in Male Rats in the Long-term Feed Study of <i>t</i> -Butylhydroquinone	71
Appendix B	Summary of Lesions in Female Rats in the Long-term Feed Study of <i>t</i> -Butylhydroquinone	1 <b>29</b>
Appendix C	Summary of Lesions in Male Mice in the 2-Year Feed Study of <i>t</i> -Butylhydroquinone	181
Appendix D	Summary of Lesions in Female Mice in the 2-Year Feed Study of <i>t</i> -Butylhydroquinone	219
Appendix E	Genetic Toxicology	261
Appendix F	Organ Weights and Organ-Weight-to-Body-Weight Ratios	273
Appendix G	Hematology and Clinical Chemistry Results	279
Appendix H	Reproductive Tissue Evaluations, Estrous Cycle Characterization, and Teratology	<b>29</b> 1
Appendix I	Chemical Characterization and Dose Formulation Studies	295
Appendix J	Feed and Compound Consumption in the Long-term and 2-Year Feed Studies         of t-Butylhydroquinone	311
Appendix K	Ingredients, Nutrient Composition, and Contaminant Levels in NIH-07 Rat and Mouse Ration	317
Appendix L	Sentinel Animal Program	321

3

Ù

# ABSTRACT



### *t*-BUTYLHYDROQUINONE CAS No. 1948-33-0 Chemical Formula: C<sub>10</sub>H<sub>14</sub>O<sub>2</sub> Molecular Weight: 166.22

Synonyms: Tert-butyl-hydroquinone; 2-(1,1-dimethylethyl)-1,4-benzenediol; tert-butyl-1,4-benzenediol; mono-tertiary-butylhydroquinone; 2-(1,1-dimethyl)hydroquinone; TBHQ; MTBHQ Trade Names: Sustane; Tenox TBHQ; Banox 20BA

t-Butylhydroquinone is used as an antioxidant in cosmetic products such as lipsticks, eye shadows, perfumes, blushers, and skin care preparations at concentrations ranging from 0.1% to 1.0%; the chemical is also used at concentrations up to 0.02% in oils, fats, and meat products to prevent rancidity, and as a polymerization inhibitor for various polyunsaturated polyesters (CIR, 1986). t-Butylhydroquinone was nominated for toxicity and carcinogenicity testing by the Food and Drug Administration. Toxicology and carcinogenicity studies were conducted in F344/N rats and B6C3F<sub>1</sub> mice. Mice were exposed to t-butylhydroquinone (99% pure) in feed for 13 weeks or 2 years. For rats, exposure to t-butylhydroquinone began in utero and continued through lactation. After weaning, pups were fed diets containing the same levels of t-butylhydroquinone as those given to their respective dams for 13 weeks or for up to 30 months. The oral route of administration was selected for these studies because t-butylhydroquinone is used as a food additive and human exposure occurs predominantly through this route. In addition to the oral route of exposure, rats were exposed prenatally because perinatal exposure to butylated hydroxytoluene (a structurally related chemical) induced hepatocellular neoplasms in rats. Genetic toxicology studies were conducted in Salmonella typhimurium and cultured Chinese hamster ovary cells in vitro and in mouse bone marrow cells in vivo.

### **13-WEEK STUDY IN RATS**

In the perinatal exposure phase of the 13-week study, groups of 10 female rats ( $F_0$ ) were fed 0, 2,500, 5,000, 10,000, 20,000, or 40,000 ppm *t*-butylhydroquinone from 2 weeks prior to cohabitation until the  $F_1$  pups were weaned.  $F_0$  females exposed to 20,000 or 40,000 ppm did not litter. The number of pup deaths in the 5,000 and 10,000 ppm groups was greater than that in the control group, and the average number of surviving pups per litter in the 10,000 ppm group was less than that in the control group. Mean body weights of pups exposed perinatally to 5,000 or 10,000 ppm were lower than that of the controls at the time of weaning.

Groups of 10 male and 10 female  $F_1$  rats continued to receive diets containing 0, 2,500, 5,000, or 10,000 ppm *t*-butylhydroquinone for 13 weeks following weaning. These dietary levels corresponded to approximately 200, 400, or 800 mg *t*-butylhydroquinone/kg body weight (males) or 200, 400, or 750 mg/kg (females) per day. All rats survived to the end of the study. The final mean body weights of males and females in the 5,000 and 10,000 ppm groups were significantly lower than those of the controls, as was the mean body weight gain of males exposed to 10,000 ppm. However, interpretation of these findings was complicated by the significantly

5

lower initial mean body weights of the 10,000 ppm groups. Differences in initial body weights were due to in utero exposure to t-butylhydroquinone. Feed consumption by exposed groups of rats was lower than that by controls at week 2, and feed consumption by 5,000 and 10,000 ppm males and 10,000 ppm females was slightly lower than that by controls at the end of the study. Hair discoloration in all exposed groups of rats, except females exposed to 2,500 ppm, was the only clinical observation considered related to chemical exposure. The mean spermatid count, spermatid heads per testis, and spermatid heads per gram of testis were significantly decreased in males exposed to 5,000 ppm. The estrous cycles of females exposed to 2,500 or 5,000 ppm were significantly longer than that of the controls. There were no biologically significant changes in clinical pathology parameters or in organ weights.

Increased incidences of hyperplasia of the nasal respiratory epithelium were observed in males exposed to 5,000 ppm and males and females exposed to 10,000 ppm, and an increased incidence of nasal exudate was observed in males in the 10,000 ppm group. Increased incidences of pigmentation were observed in the spleen of male and female rats exposed to 5,000 or 10,000 ppm. Based on lower final mean body weights and decreased feed consumption in males and females exposed to 10,000 ppm *t*-butylhydroquinone, exposure concentrations selected for the long-term rat study were 1,250, 2,500, and 5,000 ppm.

# **13-WEEK STUDY IN MICE**

Groups of 10 male and 10 female mice were fed diets containing 0, 2,500, 5,000, 10,000, 20,000, or 40,000 ppm *t*-butylhydroquinone for 13 weeks. These dietary levels corresponded to approximately 440, 880, 1,950, 4,000, and 8,400 mg *t*-butylhydroquinone/kg body weight (males) or 500, 1,100, 2,200, 4,600, and 9,000 mg/kg body weight (females) per day. There were no exposure-related deaths. Final mean body weights and body weight gains of males and females exposed to 10,000, 20,000, or 40,000 ppm were significantly less than those of the controls. Feed consumption by exposed mice appeared to be similar to that by controls, but there was excessive scatter of feed by mice exposed to 10,000, 20,000, or 40,000 ppm. Therefore, feed consumption by male and female mice in these groups was likely less than that by controls. Significant increases in segmented neutrophil counts occurred at week 3 and at the end of the study in females exposed to 10,000 ppm and males and females exposed to 20,000 or 40,000 ppm. Left caudal, left epididymis, and left testis weights of males exposed to 10,000 or 40,000 ppm were generally significantly lower than those of the controls. The estrous cycle of females exposed to 40,000 ppm was significantly longer than that of the control group. There were no biologically significant differences in organ weights.

Increased incidences and severities of mucosal hyperplasia were observed in the forestomach of males exposed to 20,000 or 40,000 ppm and in females exposed to 10,000, 20,000, or 40,000 ppm. and increased incidences of inflammation were observed in the nose and skin of males and females exposed to 10,000, 20,000, or 40,000 ppm. Increased incidences of hyperplasia also occurred in the skin of males and females exposed to 10,000, 20,000, or 40,000 ppm. Based on lower final mean body weights, increased incidences of inflammation of the nose and skin, increased incidences of forestomach mucosal hyperplasia, and increased severity of nonneoplastic lesions observed in mice exposed to 10,000, 20,000, or 40,000 ppm, exposure concentrations selected for the 2-year study were 1,250, 2,500, and 5,000 ppm.

# LONG-TERM STUDY IN RATS

. .,

In the perinatal exposure phase of the long-term study, groups of 60 female F<sub>0</sub> rats were fed diets containing 0, 1,250, 2,500, or 5,000 ppm t-butylhydroquinone, beginning 2 weeks prior to cohabitation and continuing until F<sub>1</sub> pups were weaned. Following weaning, groups of 70 male and 70 female  $F_1$  rats continued to receive diets containing 0, 1,250, or 5,000 ppm, and groups of 68 male and 68 female rats continued to receive diets containing 2,500 ppm. The duration of dosing in feed was 123 weeks postweaning for males and 129 weeks for females. These exposure concentrations resulted in daily doses of approximately 50, 100, and 200 mg t-butylhydroquinone/kg body weight (males) or 60, 120, and 240 mg/kg (females). Ten male and ten female  $F_1$  rats from each exposure group were evaluated at 3 months.

# Survival, Body Weights, Feed Consumption, and Clinical Findings

Survival of females exposed to 5,000 ppm was significantly greater than that of the control group. The mean body weights of males and females exposed to 5,000 ppm were generally less than those of the controls throughout the study. Feed consumption by exposed groups was similar to that by controls. Clinical findings of hair discoloration in exposed groups of males and females were considered to be related to chemical exposure.

### Pathology Findings

No increased neoplasm incidences in male or female rats were attributed to *t*-butylhydroquinone exposure. The incidences of mammary gland fibroadenoma and fibroadenoma or adenoma (combined) were significantly decreased in males exposed to 1,250 ppm and in all exposed groups of females; and combined incidences of mammary gland fibroadenoma, adenoma, or carcinoma were significantly decreased in all groups of exposed females. The decreases occurred with significant negative trends. Incidences of renal cysts and inflammation were generally increased in exposed groups of male rats.

# 2-Year Study in Mice

Groups of 60 male and 60 female mice received 0, 1,250, 2,500, or 5,000 ppm *t*-butylhydroquinone in feed for 104 to 105 weeks. These exposure concentrations resulted in daily doses of approximately 150, 300, or 600 mg *t*-butylhydroquinone/kg body weight (males) or 150, 300, or 700 mg/kg (females). As many as 10 males and 10 females from each exposure group were evaluated at 15 months.

# Survival, Body Weights, and Feed Consumption

Survival of all exposed groups of males and females was similar to that of the control groups. Mean body

weights of the 5,000 ppm groups were generally lower than those of the control groups from week 13 until the end of the study. Feed consumption by exposed groups of males and females was similar to that by the controls. There were no biologically significant differences in clinical pathology parameters between control and exposed groups of mice.

### Pathology Findings

No increased incidences of neoplasms or nonneoplastic lesions in male or female mice were considered to be related to *t*-butylhydroquinone exposure.

# GENETIC TOXICOLOGY

*t*-Butylhydroquinone was not mutagenic in any of four strains of *Salmonella typhimurium*, with or without liver S9 metabolic activation enzymes. It did, however, induce sister chromatid exchanges and chromosomal aberrations in cultured Chinese hamster ovary cells in the presence, but not the absence, of S9. No increase in the frequency of micronucleated erythrocytes was observed in bone marrow of male mice treated with *t*-butylhydroquinone.

### CONCLUSIONS

Under the conditions of this long-term feed study, there was no evidence of carcinogenic activity\* of *t*-butylhydroquinone in male or female F344/N rats exposed to 1,250, 2,500, or 5,000 ppm. Under the conditions of this 2-year feed study, there was no evidence of carcinogenic activity of *t*-butylhydroquinone in male or female B6C3F<sub>1</sub> mice exposed to 1,250, 2,500, or 5,000 ppm.

Exposure of rats to *t*-butylhydroquinone in feed resulted in decreased incidences of mammary gland neoplasms in males and females.

\* Explanation of Levels of Evidence of Carcinogenic Activity is on page 9. A summary of the Technical Reports Review Subcommittee comments and the public discussion on this Technical Report appears on page 11.

Summary of the Long-te		Carcinogenesis and	Genetic Toxicology S	itudies
of <i>t</i> -Butylhydroquinone				· · · · · · · · · · · · · · · · · · ·
	Male	Female	Mala	Female

•••	Male F344/N Rats	Female F344/N Rats	Male B6C3F <sub>1</sub> Mice	Female B6C3F <sub>1</sub> Mice
Doses	0, 1,250, 2,500, or 5,000 ppm (approximately 50, 100, or 200 mg/kg per day)	0, 1,250, 2,500, or 5,000 ppm (approximately 60, 120, or 240 mg/kg per day)	0, 1,250, 2,500, or 5,000 ppm (approximately 150, 300, or 600 mg/kg per day)	0, 1,250, 2,500, or 5,000 ppm (approximately 150, 300, or 700 mg/kg per day)
Body weights	5,000 ppm group less than controls	5,000 ppm group less than controls	5,000 ppm group less than controls	5,000 ppm group less than controls
Survival rates	8/60, 7/60, 1/58, 14/60	10/60, 11/60, 16/58, 17/60	39/50, 46/50, 38/51, 42/51	38/51, 35/52, 40/51, 43/54
Nonneoplastic effects	None	None	None	None
Neoplastic effects	None	None	None	None
Decreased incidences	<u>Mammary gland:</u> fibroadenoma (10/60, 4/60, 4/58, 7/60); fibroadenoma or adenoma (11/60, 4/60, 5/58, 7/60)	<u>Mammary gland:</u> fibroadenoma (43/60, 33/60, 34/58, 27/60); fibroadenoma, adenoma, or carcinoma (48/60, 34/60, 34/58, 30/60)	None	None
Level of evidence of carcinogenic activity	No evidence	No evidence	No evidence	No evidence
Genetic toxicology Salmonella typhimuriun	t gene mutations:		Negative with and without S9 in	strains TA97, TA98,
Chromosomal aberratio	mster ovary cells in vitro:	I	A100, and TA102 Positive with S9; negative witho	
Micronucleated erythro			Positive with S9; negative witho	ut S9
Mouse bone marrow	in vivo:	1	Vegative	,

#### t-Butylhydroquinone, NTP TR 459

### EXPLANATION OF LEVELS OF EVIDENCE OF CARCINOGENIC ACTIVITY

The National Toxicology Program describes the results of individual experiments on a chemical agent and notes the strength of the evidence for conclusions regarding each study. Negative results, in which the study animals do not have a greater incidence of neoplasia than control animals, do not necessarily mean that a chemical is not a carcinogen, inasmuch as the experiments are conducted under a limited set of conditions. Positive results demonstrate that a chemical is carcinogenic for laboratory animals under the conditions of the study and indicate that exposure to the chemical has the potential for hazard to humans. Other organizations, such as the International Agency for Research on Cancer, assign a strength of evidence for conclusions based on an examination of all available evidence, including animal studies such as those conducted by the NTP, epidemiologic studies, and estimates of exposure. Thus, the actual determination of risk to humans from chemicals found to be carcinogenic in laboratory animals requires a wider analysis that extends beyond the purview of these studies.

Five categories of evidence of carcinogenic activity are used in the Technical Report series to summarize the strength of the evidence observed in each experiment: two categories for positive results (clear evidence and some evidence); one category for uncertain findings (equivocal evidence); one category for no observable effects (no evidence); and one category for experiments that cannot be evaluated because of major flaws (inadequate study). These categories of interpretative conclusions were first adopted in June 1983 and then revised in March 1986 for use in the Technical Report series to incorporate more specifically the concept of actual weight of evidence of carcinogenic activity. For each separate experiment (male rats, female rats, male mice, female mice), one of the following five categories is selected to describe the findings. These categories refer to the strength of the experimental evidence and not to potency or mechanism.

- Clear evidence of carcinogenic activity is demonstrated by studies that are interpreted as showing a dose-related
   (i) increase of malignant neoplasms, (ii) increase of a combination of malignant and benign neoplasms, or (iii) marked increase of benign neoplasms if there is an indication from this or other studies of the ability of such tumors to progress to malignancy.
- Some evidence of carcinogenic activity is demonstrated by studies that are interpreted as showing a chemical-related increased incidence of neoplasms (malignant, benign, or combined) in which the strength of the response is less than that required for clear evidence.
- Equivocal evidence of carcinogenic activity is demonstrated by studies that are interpreted as showing a marginal increase of neoplasms that may be chemical related.
- No evidence of carcinogenic activity is demonstrated by studies that are interpreted as showing no chemical-related increases in malignant or benign neoplasms.
- Inadequate study of carcinogenic activity is demonstrated by studies that, because of major qualitative or quantitative limitations, cannot be interpreted as valid for showing either the presence or absence of carcinogenic activity.

When a conclusion statement for a particular experiment is selected, consideration must be given to key factors that would extend the actual boundary of an individual category of evidence. Such consideration should allow for incorporation of scientific experience and current understanding of long-term carcinogenesis studies in laboratory animals, especially for those evaluations that may be on the borderline between two adjacent levels. These considerations should include:

- · adequacy of the experimental design and conduct;
- occurrence of common versus uncommon neoplasia;
- progression (or lack thereof) from benign to malignant neoplasia as well as from preneoplastic to neoplastic lesions;
- some benign neoplasms have the capacity to regress but others (of the same morphologic type) progress. At present, it is impossible to identify the difference. Therefore, where progression is known to be a possibility, the most prudent course is to assume that benign neoplasms of those types have the potential to become malignant;
- combining benign and malignant tumor incidence known or thought to represent stages of progression in the same organ or tissue;
- latency in tumor induction;
- multiplicity in site-specific neoplasia;
- metastases;
- supporting information from proliferative lesions (hyperplasia) in the same site of neoplasia or in other experiments (same lesion in another sex or species);
- presence or absence of dose relationships;
- statistical significance of the observed tumor increase;
- concurrent control tumor incidence as well as the historical control rate and variability for a specific neoplasm;
- survival-adjusted analyses and false positive or false negative concerns;
- structure-activity correlations; and
- in some cases, genetic toxicology.

### NATIONAL TOXICOLOGY PROGRAM BOARD OF SCIENTIFIC COUNSELORS TECHNICAL REPORTS REVIEW SUBCOMMITTEE

The members of the Technical Reports Review Subcommittee who evaluated the draft NTP Technical Report on *t*-butylhydroquinone on 20 June 1995, are listed below. Subcommittee members serve as independent scientists, not as representatives of any institution, company, or governmental agency. In this capacity, subcommittee members have five major responsibilities in reviewing NTP studies:

- to ascertain that all relevant literature data have been adequately cited and interpreted,
- to determine if the design and conditions of the NTP studies were appropriate,
- to ensure that the Technical Report presents the experimental results and conclusions fully and clearly,
- to judge the significance of the experimental results by scientific criteria, and
- to assess the evaluation of the evidence of carcinogenic activity and other observed toxic responses.

Arnold L. Brown, M.D., Chairperson University of Wisconsin Medical School Madison, WI

Thomas L. Goldsworthy, Ph.D. Department of Environmental Pathology and Toxicology Chemical Industry Institute of Toxicology Research Triangle Park, NC

Meryl H. Karol, Ph.D. Department of Environmental Occupational Health University of Pittsburgh Pittsburgh, PA

Curtis D. Klaassen, Ph.D. Department of Pharmacology and Toxicology University of Kansas Medical Center Kansas City, KS

Claudia S. Miller, M.D., Principal Reviewer University of Texas Health Sciences Center San Antonio, TX

Janardan K. Reddy, M.D., Principal Reviewer Department of Pathology Northwestern University Medical School Chicago, IL Irma Russo, M.D. Fox Chase Cancer Center Philadelphia, PA

Louise Ryan, Ph.D. Division of Biostatistics Dana-Farber Cancer Institute Boston, MA

Robert E. Taylor, M.D., Ph.D. Department of Pharmacology Howard University College of Medicine Washington, DC

Mary Jo Vodicnik, Ph.D., Principal Reviewer University of Indiana Indianapolis, IN

Jerrold M. Ward, D.V.M., Ph.D. National Cancer Institute Frederick, MD

### SUMMARY OF TECHNICAL REPORTS REVIEW SUBCOMMITTEE COMMENTS

On 20 June 1995, the draft Technical Report on the toxicology and carcinogenesis studies of *t*-butylhydroquinone received public review by the National Toxicology Program's Board of Scientific Counselors' Technical Reports Review Subcommittee. The review meeting was held at the National Institute of Environmental Health Sciences, Research Triangle Park, NC.

Dr. K.M. Abdo, NIEHS, introduced the toxicology and carcinogenesis studies of *t*-butylhydroquinone by discussing the uses of the chemical and rationale for study, describing the experimental design, reporting on survival and body weight effects, and commenting on compound-related nonneoplastic lesions in male and female rats and mice. The proposed conclusions were that there was *no evidence of carcinogenic activity* of *t*-butylhydroquinone in male or female F344/N rats or in male or female B6C3F<sub>1</sub> mice.

Dr. Vodicnik, a principal reviewer, agreed with the proposed conclusions. She complimented the staff on the comprehensive review of the literature while recommending that a reference to a flawed study be deleted. Dr. Miller suggested the reference be kept but with the limitations of the study noted in the text (see page 19).

Dr. Reddy, the second principal reviewer, agreed with the proposed conclusions. He inquired as to whether the splenic pigmentation was hemosiderin or whether this could be the compound or lipofuscin. Dr. J.R. Hailey, NIEHS, said some stains for hemosiderin and, perhaps, lipofuscin would be done (see page 46). Dr. Reddy asked whether the nephropathy in male rats was associated with increased levels of  $\alpha 2\mu$ -globulin. Dr. Hailey responded that a minor contribution could not be ruled out absolutely, but there was no evidence in the subchronic or chronic studies that this protein played a significant role.

Dr. Miller, the third principal reviewer, agreed with the proposed conclusions. She thought a comparison of the *t*-butylhydroquinone dose levels used in rats and mice and those found in a typical human diet would be useful for the reader (see page 13).

Dr. W. Faber, Eastman Chemical Company, commended the NTP on a well conducted study. He stated that the possible effect of t-butylhydroquinone on the male and female reproductive systems seemed rather tenuous given the lack of a clear dose-response relationship as well as lack of findings in the teratology and multigeneration studies. He said the mention of t-butylhydroquinone as being structurally related to hydroquinone and butylated hydroxy-toluene, which are described as carcinogenic chemicals, should be clarified to indicate these chemicals are carcinogenic in experimental animals.

Dr. Miller moved that the Technical Report on *t*-butylhydroquinone be accepted with the revisions discussed and with the conclusions as written for male and female rats and mice, *no evidence of carcinogenic activity*. Dr. Reddy seconded the motion, which was accepted unanimously with 10 votes.



### t-BUTYLHYDROQUINONE

CAS No. 1948-33-0

Chemical Formula: C<sub>10</sub>H<sub>14</sub>O<sub>2</sub> Molecular Weight: 166.22

Synonyms: Tert-butyl-hydroquinone; 2-(1,1-dimethylethyl)-1,4-benzenediol; tert-butyl-1,4-benzendiol; mono-tertiary-butylhydroquinone; 2-(1,1-dimethyl)hydroquinone; TBHQ; MTBHQ Trade Names: Sustane; Tenox TBHQ; Banox 20BA

Trade Names: Sustane; Tenox TBHQ; Banox 20BA

# CHEMICAL AND PHYSICAL PROPERTIES

*t*-Butylhydroquinone is a white to light tan crystalline solid with a very slight but characteristic odor and a melting point of 126.5° to 128.5° C. It is soluble in ethanol (60%), ethyl acetate (60%), propylene glycol (30%), and to a lesser extent in fats and oils (5% in lard at 50° C, 10% in cottonseed oil, corn oil, or soybean oil, and 5% in safflower oil at 25° C). *t*-Butylhydroquinone is only slightly soluble in water (less than 1% at 25° C) (Sims and Fioriti, 1980).

# PRODUCTION, USE, AND HUMAN EXPOSURE

*t*-Butylhydroquinone can be prepared by acidcatalyzed alkylation of hydroquinone with either isobutylene or *t*-butanol (*Kirk-Othmer*, 1981; CIR, 1986).

The public portion of the Toxic Substances Control Act (TSCA) Inventory of Chemicals in Commerce lists two manufacturers of *t*-butylhydroquinone. One manufacturer reported production ranging from 100,000 to 1,000,000 pounds in 1977. No production data were provided for the other manufacturer (USEPA, 1985). The U.S. International Trade Commission reported that 47,983 pounds of *t*-butylhydroquinone were imported in 1983 (USITC, 1984). More recent information was not available. According to the National Occupational Exposure Survey, a total of 18,167 workers were potentially exposed to this chemical. Of this total, 3,687 were females (NIOSH, 1990).

*t*-Butylhydroquinone is used as an antioxidant in cosmetic products such as lipsticks, eye shadows, perfumes, blushers, and skin care preparations at concentrations ranging from 0.1% to 1.0%; the chemical is also used at concentrations of up to 0.02% in oils, fats, and meat products to prevent rancidity and as a polymerization inhibitor for various poly-unsaturated polyesters (CIR, 1986).

*t*-Butylhydroquinone is permitted for use in any food at a maximum level of 200 mg *t*-butylhydroquinone/ kg fat or oil content of the food (21 CFR §172.185), and the entire United States population is potentially exposed. Based on the actual usage of *t*-butylhydroquinone and its typical level in food, the potential daily intake using actual body weights of individuals surveyed has been estimated to be 0.42 mg *t*-butylhydroquinone per day (0.008 mg *t*-butylhydroquinone per kg body weight per day) (Flamm *et al.*, 1982).

The amount of *t*-butylhydroquinone approved for use as a polymerization inhibitor in cross-linked polyesters resins used as articles or components of articles intended for use in contact with food is limited to less than or equal to 0.01% by weight of finished resin (21 CFR §177.2420). Based on the toxicology data available, the Cosmetic Ingredient Review Expert Panel concluded that *t*-butylhydroquinone may be safely used as a cosmetic ingredient at concentrations not to exceed 0.1% (CIR, 1991).

# ABSORPTION, DISTRIBUTION, METABOLISM, AND EXCRETION

# Experimental Animals

Orally administered t-butylhydroquinone is rapidly absorbed and excreted primarily in the urine as a sulfate conjugate and a glucuronide; small amounts are excreted as unchanged t-butylhydroquinone. Rats given single oral doses ranging from 0.1 to 0.4 g/kg body weight eliminated 65% to 95% of the administered dose in the urine in 3 to 4 days as 4-O-sulfate (57% to 80%), unchanged t-butylhydroquinone (4% to 12%), and 4-O-glucuronide (4%) (Astill et al., 1975). Dogs given a single oral dose of 0.1 g/kg eliminated virtually all of the dose in the urine in 4 days as 4-O-sulfate (69% to 85%), 4-O-glucuronide (24% to 31%), and unchanged t-butylhydroquinone (3%) (Astill et al., 1975).

Rats receiving single oral doses (0.015 to 0.92 g/kg) of t-butylhydroquinone radiolabeled at carbons 2, 3, 5, and 6 eliminated 82% to 88% of the label in urine, 2% to 6% in the feces, and less than 0.1% as CO<sub>2</sub>; less than 0.2% of the radiolabel remained in the body after 4 days (Astill and Roudabush, 1973). Because the amount of *t*-butylhydroquinone eliminated as  $CO_2$ was minimal, the authors concluded that t-butylhydroquinone was not catabolized via intermediary metabolic pathways. The proportion of metabolic compounds in the urine of dogs fed diets with up to 0.5% t-butylhydroquinone for 2 years remained unchanged throughout the study. However, in rats given up to 0.5% t-butylhydroquinone in the diet for 20 months, the proportion of glucuronide was somewhat elevated. Residues in liver, kidney, brain, and fat from rats in the 0.16% and 0.5% dose groups in the long-term study were negligible, suggesting that t-butylhydroquinone does not accumulate in the body with prolonged exposure (Astill et al., 1975).

3-t-Butyl hydroxyanisole undergoes oxidative demethylation to t-butylhydroquinone by the

cytochrome  $P_{450}$  system *in vivo* in dogs, rats, and man (Astill *et al.*, 1962; Verhagen *et al.*, 1989), and *in vitro* in rat liver microsomes (Rahimthula *et al.*, 1982; Armstrong and Wattenberg, 1985). *t*-Butylhydroquinone is subsequently oxidized to 2-*t*-butyl (1,4)paraquinone. The conversion of *t*-butylhydroquinone to 2-*t*-butyl-(1,4)paraquinone is substantially accelerated by prostaglandin H synthetase and lipoxygenase (Schilderman *et al.*, 1993).

### Humans

Human male volunteers administered a single dose (2 mg/kg) of t-butylhydroquinone in high-fat food (30% corn oil) excreted 95% to 103% of the dose in the urine in 2 to 3 days as 4-O-sulfate (73% to 88%), 4-O-glucuronide (15% to 22%), and unchanged t-butylhydroquinone (less than 1%). Human male volunteers administered single doses (1 to 2 mg/kg) of t-butylhydroquinone in low-fat food (10% corn oil) eliminated 18% to 51% of the dose in urine in 2 to 3 days as 4-O-sulfate (18% to 51%), 4-O-glucuronide (0% to 6%), and unchanged t-butylhydroquinone (less than 1%) (Astill et al., 1975). These results in human volunteers suggest that absorption of t-butylhydroquinone from high-fat diets is much greater than from low-fat diets. The glucuronide and sulfate derivatives of t-butylhydroquinone have also been identified by El-Rashidy and Niazi (1983) as metabolites of butylated hydroxyanisole in humans. The results in rats, dogs, and human volunteers suggest that these species metabolize *t*-butylhydroquinone in a similar manner.

# **BIOCHEMICAL EFFECTS**

### **Experimental Animals**

Feeding t-butylhydroquinone (up to 0.5% in the diet) to dogs for 2 years and to Sprague-Dawley rats for 20 months did not produce any significant changes in hepatic enzyme activities. No hepatic enlargement and no proliferation of hepatic smooth-surface endoplasmic reticulum were observed (Astill *et al.*, 1975). However, there was significant liver enlargement in Wistar rats receiving 0.5% t-butylhydroquinone in feed for 6 days, followed by a basal diet for 24 hours, but there was no concomitant increase in the activities of hepatic microsomal monooxygenase enzymes (Kawano *et al.*, 1981). t-Butylhydroquinone (100 mM) administered daily by gavage for 5 days to CD-1 mice caused an elevation

15

of glutathione transferase activity in the glandular stomach. The enzyme activity levels in the lung or kidney of CD-1 mice were unchanged (De Long *et al.*, 1985).

t-Butylhydroquinone inhibited the biosyntheses of prostaglandins  $E_1$  and  $E_2$  by the microsomal fraction of bovine seminal vesicles (Boehme and Branen, 1977). Astill and Mulligan (1977) studied the effect of the edible stabilizers propyl gallate, butylated hydroxyanisole, butylated hydroxytoluene, and t-butylhydroquinone on intragastric N-nitrosamine formation. Following a 12-hour fasting period, groups of 10 Sprague-Dawley rats were administered single doses of 125 mg sodium nitrite/kg body weight via gastric intubation in 2.5% (w/v) aqueous solution and 1,000 mg dimethylamine/kg body weight in 20% aqueous solution, followed immediately by the test compound in doses of 25, 75, or 225 mg/kg in corn oil. Sodium ascorbate (200 mg/kg) in 4% (w/v) aqueous solution was used as a positive control. The vehicle control group of ten animals was administered corn oil. The indices of N-nitrosamine formation 48 hours after dosing were the activities of serum glutamic-oxaloacetic transaminase (GOT), glutamicpyruvic transaminase (GPT). ornithine carbamoyltransferase (OCT), and the extent of hepatic The nitrosamine-forming mixture alone necrosis. induced extensive hepatic necrosis and 4-, 19-, and 24-fold increases in serum OCT, GPT, and GOT activities, respectively. Ascorbate completely suppressed enzyme induction. t-Butylhydroquinone administered at a dose level of 225 mg/kg gave 60% protection against hepatic necrosis and appreciably enzyme activities. suppressed increases in Administered at dose levels of 25 and 75 mg/kg, t-butylhydroquinone had no observable significant effect on the nitrosamine-forming system. The gross liver damage observed in the rats exposed to the nitrosamine-forming system was absent in the corn oil control group.

t-Butylhydroquinone appears to be a strong inactivator of phage DNA as well as a potent inducer of 7-hydroxy-8-oxo-2'-deoxyguanosine *in vitro* (Schilderman *et al.*, 1993). The latter compound is an oxidative DNA damage product resulting from C8 oxidation of deoxyguanosine. *t*-Butylhydroquinone induced excess production of superoxide anion in rat liver microsomes. Excess superoxide induces injury

of the hepatocyte plasma membranes (Bergmann et al., 1992).

### Humans

No information on the biochemical effects of *t*-butylhydroquinone in humans was found in a search of the available literature.

### TOXICITY

### **Experimental** Animals

The reported oral  $LD_{50}$  for *t*-butylhydroquinone ranges from 480 to 1,000 mg/kg for rats (Epstein *et al.*, 1967; Astill *et al.*, 1975) and is 1,000 mg/kg for mice (RTECS, 1983).

Compounds structurally related to *t*-butylhydroquinone (butylated hydroxyanisole and butylated hydroxytoluene) have been shown to induce lung lesions and increased prothrombin time (Takahashi and Hiraga, 1978). No lung lesions were observed in CRL:CD-1 male mice 5 days after administration of a single intraperitoneal injection of 62.5, 125, 250, or 500 mg *t*-butylhydroquinone/kg body weight. However, the two highest doses were lethal (Krasavage and O'Donohue, 1984). Intraperitoneal injections of 50, 100, or 150 mg/kg as a 10% solution in acetone:soy oil (1:10 v/v) did not increase prothrombin time or cause hemorrhagic death in male albino rats [CRL:COB CD(SD)BR] (Krasavage, 1984).

*t*-Butylhydroquinone fed to rats (sex and strain not specified) at a concentration of 1% in the diet for 22 days caused a slight depression in body weight gain, but did not cause death or pathologic alterations (Astill *et al.*, 1975).

Fischer rats receiving 1% *t*-butylhydroquinone in the diet (as a 4% solution in corn oil) developed hyperplasia of the basal cell layer in the forestomach epithelium (Nera *et al.*, 1984). Similar lesions were observed in Wistar rats consuming a diet containing 2% *t*-butylhydroquinone for 28 days (Altmann *et al.*, 1985). Twice-weekly applications of 1 mL/kg hair dye formulation containing a 1:1 mixture of 0.3% *t*-butylhydroquinone with 6% hydrogen peroxide for 13 weeks to the abraded skin of male and female New Zealand rabbits did not cause any compound-related toxicity (Burnett *et al.*, 1976). Data collected in this

study included clinical pathology (complete blood count, methemoglobin concentration, fasting blood sugar, blood urea nitrogen, alkaline phosphatase, serum glutamic-oxaloacetic transaminase, urine color, urine pH, urine albumin, urine glucose, and occult blood), relative liver, kidney, adrenal, heart, thyroid, spleen, and brain weights, observations of gross abnormalities, and histopathology.

Application of 0.1 mL hydrophilic ointment containing 1% or 5% *t*-butylhydroquinone to a  $3.2 \text{ cm}^2$ area of the skin of black guinea pigs 5 days per week for 13 weeks caused a weak depigmentation at the application site in females, but not in males. A similarly applied dose of 0.1% did not cause depigmentation in either males or females (CIR, 1991).

### Humans

*t*-Butylhydroquinone may be a skin irritant in humans. In patch testing, five out of 1,096 patients with facial dermatitis were shown to be allergic to *t*-butylhydroquinone present in their cosmetics (White *et al.*, 1984). A 71-year-old woman who for 15 years was observed to have dermatitis at various body sites was found to be allergic to *t*-butylhydroquinone (Calnan, 1981). Of a total of 271 subjects exposed to lipstick products containing 0.054%, 0.11%, 0.14%, or 0.15% *t*-butylhydroquinone by weight, only one subject exposed to the product containing 0.14% had intense erythema, suggesting a nonspecific irritant effect (CIR, 1986).

# **REPRODUCTIVE** AND **DEVELOPMENTAL TOXICITY** *Experimental Animals*

*t*-Butylhydroquinone produced no teratogenic effects when given to pregnant Sprague-Dawley rats at concentrations of 0.125%, 0.25%, or 0.5% in the diet from days 6 to 16 of gestation. Mean body weights and feed consumption of treated dams were similar to those of the controls. Average numbers of corpora lutea, implantation sites, viable fetuses, and resorptions and fetal body weights, mortality, and sex ratio were not affected at any dose. No external anomalies were observed in the 849 fetuses examined. Half of these fetuses were examined for soft-tissue abnormalities, and three were found to be abnormal. Of these three, one was from the control group and two were from a single litter in the 0.5% group. The abnormalities observed were low body weight and hydrocephalus (in the control and 0.5% groups) and transposition of a major blood vessel (in the 0.5% group) (Krasavage, 1977).

A diet containing 0% or 0.5% *t*-butylhydroquinone was fed to groups of 15 male and 15 female Sprague-Dawley rats for three successive generations (Astill et al., 1975). Rats were mated to produce two litters per generation, with the next generation selected from weanlings of the second litter. Littering throughout the study produced 2,090 rats. The gonadal following parameters were assessed: functions, estrus cycles, mating, conception rates, gestation rates, parturition, and lactation: measurements of these parameters in the treated group were similar to those in the control group. Slight increases in  $F_1$  pup weights were observed; however, no similar effect was produced in a second experiment designed to investigate these results. No difference between the treated and control groups was observed when the  $F_3$  pups were examined grossly for skeletal muscle and soft tissue abnormalities. The F<sub>3a</sub> groups were maintained on their diets for 11 months, then sacrificed. Electron microscopic examination of the livers of some animals indicated no abnormalities (Astill et al., 1975). The doses used in these reproductive studies may have been too low to adequately determine the potential of t-butylhydroquinone to have an effect on reproduction or to cause fetal malformations.

### Humans

No information on the reproductive and developmental toxicity of *t*-butylhydroquinone in humans was located in a search of the available literature.

# CARCINOGENICITY

### **Experimental Animals**

*t*-Butylhydroquinone at concentrations of 0%, 0.016%, 0.05%, 0.16%, or 0.5% in the diet was fed to groups of 55 male and 55 female Sprague-Dawley rats for up to 20 months. No differences in growth rate, feed intake and/or utilization, mortality, clinical chemistry, hematology, urinalysis, organ weights, or histopathology were observed between control and

treated groups at any time during the study (Terhaar and Krasavage, 1968a).

Diets containing 5% unheated or heated cottonseed oil solutions of 0.02%, 0.10%, or 0.50% *t*-butylhydroquinone were fed to groups of 15 male and 15 female Sprague-Dawley rats for 6 months (Astill et al., 1975). In this study, the temperature of cottonseed oil for heated diets was raised over a 1-hour period to 375° F, and this temperature was maintained for 3 hours. Growth rate, feed utilization, mortality, organ weights, hematology, clinical chemistry, and urinalysis parameters were measured, and gross and microscopic evaluations on 27 organs were made. The three deaths in the 0.50% group were not considered to be related to t-butylhydroquinone. No compound-related effects on body weight, feed utilization, hematology, urinalysis, or histopathology were observed. There were slight increases in the relative weights of the testes and liver of male rats in the 0.50% t-butylhydroquinone/heated oil group and in the relative weights of the liver of female rats in the 0.20% and 0.50% t-butylhydroquinone/heated oil groups (Astill et al., 1975).

These studies were considered inadequate for evaluating the carcinogenicity of t-butylhydroquinone for three reasons: t-butylhydroquinone was not tested at the maximum tolerated dose (previous short-term studies have shown that Sprague-Dawley rats can tolerate a dose of 1% t-butylhydroquinone); the duration of the studies was inadequate for carcinogenicity testing; and only 17 animals survived to the end of the Terhaar and Krasavage (1968a) study.

Groups of four male and four female beagle dogs were fed diets containing 0.05%, 0.15%, or 0.5% *t*-butylhydroquinone for 2 years (Astill *et al.*, 1975). Eight males and eight females served as controls. No compound-related effects on hematology, clinical chemistry, or urinalysis parameters were observed at weeks 12, 26, 52, 78, and 104 of the study. No compound-related changes (gross or microscopic) were noted in any of the tissues examined.

Recent studies have demonstrated that *t*-butylhydroquinone has a promoting effect on chemically induced tumors. The combined treatment with *t*-butylhydroquinone (1% in feed), sodium nitrite (0.3% in drinking water) and/or sodium ascorbate (1% in feed) increased the thickness of mucosae of the forestomach, glandular stomach, and esophagus of 4-week-old male F344/N rats following 4 to 6 weeks of treatment (Kawabe et al., 1994; Yoshida et al., In a multi-organ carcinogenesis model, 1994). t-butylhydroquinone (1% in the diet) significantly increased the incidences of esophageal papillary hyperplasia or nodular hyperplasias and papillomas, as well as forestomach papillomas, but significantly decreased the multiplicity of colon adenocarcinomas in male F344/N rats (Hirose et al., 1993). Tumors in this study were initiated by pretreatment with N-methyl-N'-nitro-N-nitrosoguanidine (100 mg/kg), N-ethyl-N-hydroxyethyl nitrosamine (750 mg/kg), N-methylbenzyl nitrosamine (two subcutaneous injections of 0.5 mg/kg), and 1,2-dimethyl hydrazine (40 mg/kg).

F344/N rats given 1% t-butylhydroquinone in the diet had decreased numbers and smaller sized diethyl nitrosamine-initiated preneoplastic liver foci (glutathione S-transferase placental form positive foci) than did the positive controls (Hasegawa et al., 1992). Mammary gland neoplasm development was reduced in female Sprague-Dawley rats fed diets containing 0.8% t-butylhydroquinone for 51 weeks following initiation with dimethylbenz(a)anthracene. However, in the same study, the incidence of induced ear duct tumors was not affected by t-butylhydroquinone treatment (Hirose et al., 1988). Six-week-old male F344/N rats treated with N-butyl-N-(4-hydroxybutyl)nitrosamine for 4 weeks then fed diets containing 2% t-butylhydroquinone had greater incidences of urinary bladder papillary or nodular hyperplasia than those controls receiving N-butylin N-(4-hydroxybutyl)nitrosamine only (Tamano et al., 1987).

*t*-Butylhydroquinone is structurally related to hydroquinone, butylated hydroxyanisole, and butylated hydroxytoluene. In a 2-year carcinogenicity study, 25 or 50 mg hydroquinone/kg body weight administered by gavage was carcinogenic to F344/N rats, causing increased incidences of renal tubule cell adenomas in males and mononuclear cell leukemia in females. Hydroquinone at doses of 50 or 100 mg/kg administered by gavage was carcinogenic to female B6C3F<sub>1</sub> mice causing an increased incidence of hepatocellular neoplasms (NTP, 1989). In 2-year carcinogenicity studies, butylated hydroxytoluene at concentrations of 3,000 or 6,000 ppm in feed was not carcinogenic to male or female F344/N rats or B6C3F1 mice. There was a significant increase in the incidence of lung neoplasms in 3,000 ppm female mice, but not in 6,000 ppm females; because there was no significant dose-related positive trend, this increase could not be clearly related to butylated hydroxytoluene exposure (NCI, 1979). No evidence of carcinogenicity was observed in male or female B6C3F<sub>1</sub> mice fed diets containing 200, 1,000, or 5,000 ppm butylated hydroxytoluene for 96 weeks, followed by a basal diet for an additional 8 weeks (Shirai et al., 1982). No carcinogenic effects were observed in male or female Wistar rats fed diets containing 0.25% or 1% butylated hydroxytoluene for up to 104 weeks (Hirose et al., 1981). Hepatocellular neoplasms were induced in Wistar rats exposed beginning in utero to butylated hydroxytoluene (Olsen et al., 1983). The carcinogenicity of butylated hydroxytoluene has been previously investigated in Wistar rats (Hirose et al., 1981) and B6C3F, mice (Shirai et al., 1982). Butylated hydroxytoluene administered in concentrations of up to 10,000 ppm (rats) and 6,000 ppm (mice) in feed did not produce carcinogenic effects. These studies were performed on one generation and were terminated at 108 weeks, while in the Olsen et al. (1983) study, the exposure began in utero and continued throughout lactation, weaning, and adulthood.

Male and female F344/N rats fed diets containing 0.5% or 2% butylated hydroxyanisole for 104 weeks followed by a basal diet for an additional 8 weeks had chemical-related increased incidences of squamous cell carcinoma of the forestomach. The incidences of these neoplasms in the 2% groups of males and females were significantly higher than those in the controls (Ito *et al.*, 1982). Feeding butylated hydroxyanisole to male F344/N rats at a concentration of 2% for 13 weeks caused proliferation of the forestomach epithelium. The rats recovered from these effects following 1 week on a basal diet (Iverson *et al.*, 1985).

# **GENETIC TOXICOLOGY**

*t*-Butylhydroquinone was not mutagenic in *Salmonella typhimurium* gene mutation assays performed with or without liver S9 activation enzymes

(Bonin and Baker, 1980; Hageman et al., 1988; Matsuoka et al., 1990; Zeiger et al., 1992). Additionally, it did not produce mitotic gene conversion or mutations, with or without S9, in Saccharomyces cerevisiae (Rogers et al., 1992). In cultured mammalian cells, no induction of mutations was noted at the HGPRT locus of Chinese hamster V79 lung cells incubated with primary hepatocytes after treatment with 0.17 to 3.4  $\mu$ g t-butylhydroquinone/mL medium (Rogers et al., 1992). However, oxidative damage was detected in single-strand phage PhiX 174 DNA (Schilderman et al., 1993) and double-strand phage PhiX 174 relaxed form DNA (Li and Trush, 1994) exposed to t-butylhydroquinone in the presence of micromolar concentrations of Cu<sup>++</sup>. No consistent induction of sister chromatid exchanges was observed in Chinese hamster V79 lung cells treated with *t*-butylhydroquinone, with or without S9 (Rogers et al., 1992), but a significant increase in the frequency of chromosomal aberrations was reported in Chinese hamster cells treated with 2.5 to 50  $\mu$ g/mL without S9 (Phillips et al., 1989; Matsuoka et al., 1990) or 20 to 40  $\mu$ g/mL in the presence of S9 (Matsuoka et al., 1990). The addition of catalase to the hamster cell cultures without S9 resulted in a substantial decrease in the frequency of t-butylhydroquinone-induced chromosomal aberrations (Phillips et al., 1989), thus indicating that generation of  $H_2O_2$ played a role in the observed induction of chromosomal damage. Because t-butylhydroquinone autooxidizes in solution to t-butylquinone, forming superoxide and  $H_2O_2$ , the mutagenic effects that are observed in cells exposed to t-butylhydroquinone are most likely the indirect result of the release of oxidative byproducts within the cell. Experiments with various radical scavengers provided evidence suggesting that either singlet oxygen or a singlet oxygen-like entity (possibly a copper-peroxide complex) rather than free hydroxyl radicals was responsible for DNA damage in phage induced by phenolic compounds such as t-butylhydroquinone (Li and Trush, 1994).

In vivo, dose-related increases in sister chromatid exchanges were induced in bone marrow cells of male Swiss albino mice given single intraperitoneal injections of 0.5 to 200 mg/kg *t*-butylhydroquinone dissolved in corn oil (Mukherjee *et al.*, 1989); the lowest effective dose in this experiment was 2 mg/kg. Induction of chromosomal aberrations (breaks, gaps, centric fusions, and other abnormalities) was reported in bone marrow cells of male mice administered a single intraperitoneal dose of 200 mg/kg t-butylhydroquinone or daily gavage doses of 2 mg/kg for 30 days (Giri *et al.*, 1984); bone marrow analysis was performed 24 hours after the final dosing. Because the authors included gaps in their analyses and did not present the individual classifications of the abnormalities scored, and because for the acute dosing experiment a 24-hour post-treatment harvest time is inappropriate (12 to 17 hours is preferable), these results require independent verification.

Much of the data obtained from studies with metabolites of *t*-butylhydroquinone derive from studies of the parent compound (butylated hydroxyanisole) and concern identification of metabolic pathways, investigations of oxygen radical scavengers or catalase inhibitors on particular endpoints of metabolism, and tumor initiating properties of various butylated hydroxyanisole metabolites. One of the most active metabolites appears to be *t*-butylquinone, which is generated in redox cycling reactions with t-butylhydroquinone. Neither of these compounds is active in many of the standard in vitro mutagenicity assays. t-Butylquinone did not induce gene conversions or reverse mutations in Saccharomyces cerevisiae, nor did it induce HGPRT gene mutations or sister chromatid exchanges in V79 cells (Rogers et al., 1992). However, it has been shown to be mutagenic in S. typhimurium strains TA98 and TA100 over a limited dose range (10 to 50  $\mu$ g/plate) and to induce DNA damage in repairdeficient strains of Bacillus subtilis; both responses were obtained in the absence of S9 activation (Mizuno et al., 1988). There is one report describing induced DNA damage in the forestomach cells of male rats.

In this experiment, single strand breaks were detected by alkaline elution in the DNA of forestomach squamous epithelial cells harvested from Fischer 344 rats 3 hours after the rats received 4 mL of 0.001% or 0.00001% (approximately 0.22 or 0.0022 mg/kg) *t*-butylquinone in corn oil by gavage (Morimoto *et al.*, 1991).

In summary, *t*-butylhydroquinone and the oxidized metabolite, *t*-butylquinone, showed limited evidence of mutagenicity, primarily in mammalian cell systems sensitive to the detection of oxygen radical-induced DNA damage.

# STUDY RATIONALE

t-Butylhydroquinone was nominated for toxicity and carcinogenicity testing by the Food and Drug Administration because of the potential for increased use of t-butylhydroquinone as a substitute for the phenolic antioxidants butylated hydroxyanisole and butylated hydroxytoluene; previous carcinogenicity studies supporting the safe use of t-butylhydroquinone were not considered adequate because the maximum tolerated dose was not tested, the studies were of short duration, and survival within the studies was poor. t-Butylhydroquinone is also structurally similar to carcinogenic chemicals such as hydroquinone and butylated hydroxyanisole. The oral route of administration was selected for these studies because t-butylhydroquinone is used as a food additive and human exposure occurs predominantly through this route. In addition to the oral route of exposure, rats were exposed in utero because butylated hydroxytoluene (a structurally related chemical) induced hepatocellular neoplasms in rats exposed in utero.

э

<sup>.</sup> 

# MATERIALS AND METHODS

## Procurement and

### CHARACTERIZATION

### OF *t*-BUTYLHYDROQUINONE

*t*-Butylhydroquinone was obtained in two lots (187-1 and 1089-1) from U.O.P., Inc., (Des Plaines, IL). Lot 187-1 was used in the 13-week, long-term, and 2-year studies. Lot 1089-1 was used in the long-term and 2-year studies. Identity, purity, and stability analyses were conducted by the analytical chemistry laboratory, Midwest Research Institute (Kansas City, MO) (Appendix I). Reports on analyses performed in support of the *t*-butylhydroquinone studies are on file at the National Institute of Environmental Health Sciences (NIEHS).

Each lot of the chemical, a fine beige powder, was identified as t-butylhydroquinone by infrared, ultraviolet/visible, and nuclear magnetic resonance spectroscopy. The purity of each lot was determined by elemental analyses, Karl Fischer water analysis, functional group titration, thin-layer chromatography, and high-performance liquid chromatography. Elemental analyses for carbon and hydrogen were in agreement with the theoretical values for t-butylhydroquinone. Karl Fischer water analysis indicated less than 0.4% water for lot 187-1 and 0.16% water for lot 1089-1. Functional group titration indicated a purity of 99.6%  $\pm$  0.5% for lot 187-1 and 99.1%  $\pm$  0.4% for lot 1089-1. Thin-layer chromatography of lot 187-1 indicated a major spot and two trace impurities using one system and a major spot, one minor impurity, and one trace impurity using a second system. For lot 1089-1, both thin-layer chromatography systems indicated a major spot, one minor impurity, and one trace impurity. High-performance liquid chromatography of lot 187-1 indicated a major peak and one impurity peak with an approximate area of 0.13% relative to the major peak. High-performance liquid chromatography of lot 1089-1 indicated a major peak and no impurities with peak areas greater than 0.1% relative to the major peak. Additional high-performance liquid chromatography analyses using a linear gradation in the solvent system resolved additional impurities with peak areas of 0.3% to 0.4% relative to the major peak in lots 187-1 and 1089-1. Lot 1089-1 and lot 187-1 were concomitantly analyzed by the same high-performance liquid chromatography method used for the initial purity analyses. The overall purity for each lot was 99%.

Stability studies of the bulk chemical, performed by the analytical chemistry laboratory using high-performance liquid chromatography, indicated that *t*-butylhydroquinone was stable as a bulk chemical when stored for 2 weeks, protected from light, at temperatures up to  $60^{\circ}$  C. To ensure stability, the chemical was stored at room temperature in sealed containers, protected from light. Stability was monitored 9 weeks after the beginning of the 13-week studies and within 30 days after the end of the studies. For the longterm and 2-year studies, stability was monitored at approximately 4-month intervals and within 30 days after the end of the studies. No degradation of the bulk chemical was detected.

# Preparation and Analysis of Dose Formulations

The dose formulations for the 13-week, long-term, and 2-year studies were prepared weekly (Table I1). Homogeneity and stability analyses of the dose formulations were conducted by the analytical chemistry laboratory using high-performance liquid chromatography. Homogeneity was confirmed, and the stability of the dose formulations was confirmed for at least 3 weeks when stored in sealed containers in the dark at 5° C. During the 13-week, long-term, and 2-year studies, the dose formulations were stored in sealed containers in the dark at 5° C for no longer than 3 weeks.

Periodic analyses of the dose formulations of t-butylhydroquinone were conducted at the study laboratory using high-performance liquid chromatography. For the 13-week studies, dose formulations were analyzed at the beginning, in the middle, and at the end of the studies (Table I2). During the long-term and 2-year studies, dose formulations were analyzed approximately every 8 weeks (Table I3). Of the dose formulations used in the 13-week studies, 98% (43/44) were within 10% of the target concentration with no value greater than 16% from the target concentration. In the long-term studies, 219 of the 220 dose formulations used for rats and 185 of the 186 dose formulations used for mice were within 10% of the target concentration. Results of periodic referee analyses performed by the analytical chemistry laboratory agreed with the results obtained by the study laboratory (Table I4).

# **13-WEEK RAT STUDY**

The 13-week study was performed to evaluate the cumulative toxic effects of *t*-butylhydroquinone with exposure to the chemical beginning *in utero* and to determine the appropriate doses to be used in the long-term study.

Male and female F344/N rats ( $F_0$  generation) were obtained from Taconic Farms (Germantown, NY). On receipt, the rats were 38 days old. Animals were quarantined for 19 days. Females were 57 days old on the first day of the study and 71 days old on the first day of cohabitation. Before initiation of the study, five male and five female rats were randomly selected for parasite evaluation and gross observation for evidence of disease.

Males acquired for the reproductive toxicity phase were used for breeding purposes only and were not considered part of the study. Groups of 10 female rats ( $F_0$  generation) were fed diets containing 0, 2,500, 5,000, 10,000, 20,000, or 40,000 ppm t-butylhydroquinone for approximately 6 weeks. Feed was available ad libitum for  $F_0$  females from 2 weeks prior to cohabitation until weaning of the  $F_1$  pups. Water was available *ad libitum*. During cohabitation, two  $F_0$ females were housed with one breeder male;  $F_0$ females were housed individually when pregnancy was confirmed. Clinical findings, body weights, and feed consumption were recorded weekly for  $F_0$ females during the first 2 weeks of the study (prior to cohabitation); clinical findings and body weights were also recorded weekly during lactation. Details of the study design and animal maintenance are summarized in Table 1.

During cohabitation, vaginal smears were taken daily from breeder females to determine the presence of sperm. Rats that did not litter by day 25 were killed and uteri were stained with ammonium sulfide and examined for implantation sites. After parturition, pups were examined and the number and sex of pups and the litter weight were recorded. On day 4 postpartum, litters were randomly culled to a maximum of eight rat pups per litter; pup weights were recorded on days 4, 11, 18, and 28. Pups were weaned on day 28.

Male and female F344/N rats for the 13-week base study were offspring ( $F_1$  generation) of the breeders from the perinatal phase of the study. Rats were approximately 34 days old on the first day of the study. At the end of the study, serologic analyses were performed on five male and five female control ( $F_1$  generation) rats using the protocols of the NTP Sentinel Animal Program (Appendix L).

Groups of 10 male and 10 female  $F_1$  rats were fed diets containing 0, 2,500, 5,000, or 10,000 ppm *t*-butylhydroquinone for 13 weeks after weaning. (No  $F_1$  offspring resulted from  $F_0$  females fed diets containing 20,000 or 40,000 ppm, so these exposure levels were not used in the 13-week rat study.) Feed and water were available *ad libitum*. Rats were housed five per cage. Clinical findings were recorded and the animals were weighed initially, weekly, and at the end of the study; feed consumption was recorded as an average of grams per animal per day. Details of the study design and animal maintenance are summarized in Table 1.

Blood was collected at week 13 from core study  $(F_1)$  rats for selected hematology, clinical chemistry, and coagulation analyses. Additionally, clinical pathology analyses were performed on special groups of 10 male and 10 female  $F_1$  rats fed diets containing 0, 2,500, 5,000, or 10,000 ppm *t*-butylhydroquinone for 3 weeks after weaning. Selected hematology and clinical chemistry parameters were measured for these animals on day 5 and at week 3.

For clinical pathology analyses, rats were anesthetized with  $CO_2$  and bled from the retroorbital sinus. Blood for hematology was collected in a tube containing ethylenediaminetetraacetic acid (EDTA); blood for clinical chemistry parameters was collected in a tube without anticoagulant; blood for coagulation analyses was collected in a plastic syringe containing 3.8% sodium citrate. Hematology determinations were performed on whole blood using an Ortho ELT-8 analyzer (Ortho Instruments, Westwood, MA). Leukocyte and reticulocyte counts, erythrocyte counts and morphologies, and differential counts were determined from blood smears by light microscopy. Clinical chemistry parameters were determined using a Roche Cobas Fara chemistry analyzer (Roche Diagnostics Systems, Inc., Montclair, NJ). Parameters evaluated are listed in Table 1.

At the end of the study, samples from 0, 2,500, 5,000, and 10,000 ppm  $F_1$  rats were collected for sperm motility and vaginal cytology evaluations. The parameters evaluated are listed in Table 1. Methods used were those described in the NTP's Technical Protocol for Sperm Morphology and Vaginal Cytology Evaluation in Toxicity Testing for Rats and Mice (NTP, 1987). For 7 consecutive days prior to scheduled terminal sacrifice, the vaginal vaults of the females were moistened with saline, if necessary, and samples of vaginal fluid and cells were stained. Relative numbers of leukocytes, nucleated epithelial cells, and large squamous epithelial cells were determined and used to ascertain estrous cycle stage (i.e., diestrus, proestrus, estrus, and metestrus). Male rats and mice were evaluated for sperm count and motility. The right testis and right epididymis were isolated and weighed. The tail of the epididymis (cauda epididymis) was then removed from the epididymal body (corpus epididymis) and weighed. Test yolk (rats) or modified Tyrode's buffer (mice) was applied to slides and a small incision was made at the distal border of the cauda epididymis. The sperm effluxing from the incision were dispersed in the buffer on the slides, and the numbers of motile and nonmotile spermatozoa were counted for five fields per slide by two observ-Following completion of sperm motility estiers. mates, each right cauda epididymis was placed in buffered saline solution. Cauda were finely minced, and the tissue was incubated in the saline solution and then heat fixed at 65° C. Sperm density was then determined microscopically with the aid of a hemacytometer. To quantify spermatogenesis, testicular spermatid head count was determined by removing the tunica albuginea and homogenizing the left testis in phosphate-buffered saline containing 10% dimethyl sulfoxide. Homogenization-resistant spermatid nuclei were counted with a hemacytometer.

A necropsy was performed on all core study  $F_1$ animals. The heart, right kidney, liver, lungs, right testis, and thymus were weighed. Tissues for microscopic examination were fixed and preserved in 10% neutral buffered formalin, processed and trimmed, embedded in paraffin, sectioned to a thickness of 5 to 6  $\mu$ m, and stained with hematoxylin and eosin. A complete histopathologic examination was performed on all control and 10,000 ppm rats. Additionally, the following tissues from selected exposure groups were examined: the nose of all exposed groups of male rats and 5,000 ppm female rats; the spleen of 5,000 and 10,000 ppm male rats and all exposed groups of female rats; the mesenteric lymph node of 5,000 ppm female rats; and the kidneys of 2,500 and 10,000 ppm female rats. Table 1 lists the tissues and organs routinely examined.

### 13-WEEK MOUSE STUDY

The 13-week study was performed to evaluate the cumulative toxic effects of t-butylhydroquinone and to determine the appropriate doses to be used in the 2-year study.

Male and female  $B6C3F_1$  mice were obtained from Taconic Farms (Germantown, NY). On receipt, the mice were approximately 29 days old, and the mice were quarantined for 13 days. Mice were approximately 42 days old on the first day of the study. Prior to the start of the 13-week study, five male and five female mice were randomly selected for parasite evaluation and gross observation for evidence of disease. At the end of the study, serologic analyses were performed on five male and five female sentinel mice using the protocols of the NTP Sentinel Animal Program (Appendix L).

Groups of 10 male and 10 female mice were fed diets containing 0, 2,500, 5,000, 10,000, 20,000, or 40,000 ppm *t*-butylhydroquinone for 13 weeks. Feed and water were available *ad libitum*. Mice were housed five per cage. Clinical findings were recorded and the animals were weighed initially, weekly, and at the and of the study; feed consumption was recorded as an average of grams per animal per day. Details of the study design and animal maintenance are summarized in Table 1.

Blood was collected at week 13 from core study  $(F_1)$  mice for selected hematology, clinical chemistry, and coagulation analyses. Additionally, clinical pathology analyses were performed on special groups of 10 male and 10 female  $F_1$  mice fed diets containing 0, 2,500, 5,000, or 10,000 ppm *t*-butylhydroquinone for 3 weeks after weaning. Selected hematology and clinical chemistry parameters were measured for these animals on day 5 and at week 3.

For clinical pathology analyses, mice were anesthetized with  $CO_2$  and bled from the retroorbital sinus. Clinical pathology parameters were measured as described for the 13-week rat study and the parameters evaluated are listed in Table 1.

At the end of the study, samples from 0, 2,500, 10,000, and 40,000 ppm mice were collected for sperm motility and vaginal cytology evaluations. The parameters evaluated are listed in Table 1. Methods used were those described for the 13-week rat study.

A necropsy was performed on all core study animals. The heart, right kidney, liver, lungs, right testis, and thymus were weighed. Tissues for microscopic examination were fixed and preserved in 10% neutral buffered formalin, processed and trimmed, embedded in paraffin, sectioned to a thickness of 5 to 6  $\mu$ m, and stained with hematoxylin and eosin. A complete histopathologic examination was performed on all control and 40,000 ppm mice. Additionally, the nose, skin, and forestomach of all exposed groups of male and female mice were examined. Table 1 lists the tissues and organs routinely examined.

# LONG-TERM RAT STUDY

### Study Design

Males acquired for the perinatal phase of the study were used for breeding purposes only. Groups of 60 female  $F_0$  rats were fed diets containing 0, 1,250, 2,500, or 5,000 ppm *t*-butylhydroquinone, beginning 2 weeks prior to cohabitation and continuing until  $F_1$  pups were weaned.

Following weaning, groups of as many as 70 male and 70 female  $F_1$  rats were fed diets containing 0, 1,250, 2,500, or 5,000 ppm for 30 months or until the

survival rate in any exposure group was less than 20%. Ten male and 10 female  $F_1$  rats were evaluated at 3 months.

### Source and Specification of Animals

Female F344/N  $F_0$  rats were obtained from Taconic Farms (Germantown, NY). On receipt, the animals were approximately 31 days old. Males and females were quarantined for 18 days and were approximately 49 days old on the first day they were given dosed feed. Before the start of the study, 10 male and 10 female  $F_0$  rats were selected for parasite evaluation and gross observation of disease. Serology samples for viral screening were collected from 10  $F_0$  females at the end of the reproductive phase of the study. The health of the animals was monitored during the study according to the protocols of the NTP Sentinel Animal Program (Appendix L).

Male and female F344/N  $F_1$  rats were offspring ( $F_1$  generation) of the breeders from the perinatal phase and were approximately 35 days old on the first day of exposure through feed. Pups from the  $F_1$  generation not selected for study were used for parasite evaluation and gross observation of disease.

### Animal Maintenance

During quarantine, breeder males were housed individually and F<sub>0</sub> females were housed two per cage. During cohabitation, one breeder male was housed with two  $F_0$  females.  $F_0$  females were housed individually for the remainder of the study.  $F_1$  rats were housed five per cage. Feed and water were available ad libitum to  $F_0$  and  $F_1$  rats. Feed consumption was not measured during the perinatal phase of the study, but was measured every 4 weeks by cage for  $F_1$  rats; additionally, control feed consumption by F<sub>1</sub> rats was measured weekly for the first 13 weeks of the study. Cages were changed twice weekly and racks were generally rotated once every 2 weeks. Further details of animal maintenance are given in Information on feed composition and Table 1. contaminants is provided in Appendix K.

### **Clinical Examinations and Pathology**

During the perinatal phase of the study, clinical findings and body weights were recorded for females weekly during cohabitation and on the first day of dosing.  $F_1$  rats were observed twice daily. Clinical

findings for  $F_1$  rats were recorded at the beginning of the long-term study, once weekly for the first 13 weeks, and monthly thereafter. Additionally, clinical findings were recorded for  $F_1$  rats on lactation days 4, 11, 18, and 28. As many as 10 male and 10 female rats were evaluated for hematology alterations at 3 months using the hematology methods described for the 13-week study. The parameters evaluated are listed in Table 1.

A complete necropsy and microscopic examination were performed on all  $F_1$  rats. At the 3-month interim evaluation, the right kidney, liver, right epididymis, and right testis were weighed. At necropsy, all organs and tissues were examined for grossly visible lesions, and all major tissues were fixed and preserved in 10% neutral buffered formalin, processed and trimmed, embedded in paraffin, sectioned to a thickness of 5 to 6  $\mu$ m, and stained with hematoxylin and eosin for microscopic examination. For all paired organs (i.e., adrenal gland, kidney, ovary), samples from each organ are examined. Tissues examined microscopically are listed in Table 1.

Microscopic evaluations were completed by the study laboratory pathologist, and the pathology data were entered into the Toxicology Data Management System. The slides, paraffin blocks, and residual wet tissues were sent to the NTP Archives for inventory, slide/block match, and wet tissue audit. The slides, individual animal data records, and pathology tables were evaluated by an independent quality assessment laboratory. The individual animal records and tables were compared for accuracy, the slide and tissue counts were verified, and the histotechnique was evaluated. For the long-term rat study, a quality assessment pathologist reviewed the following organs: bone marrow (females), clitoral gland, forestomach (males), kidney (males), liver, mammary gland, nose, pituitary gland, preputial gland, spleen, and thyroid gland (males).

The quality assessment report and the reviewed slides were submitted to the NTP Pathology Working Group (PWG) chairperson, who reviewed the selected tissues and addressed any inconsistencies in the diagnoses made by the laboratory and quality assessment pathologists. Representative histopathology slides containing examples of lesions related to chemical administration, examples of disagreements in diagnoses between the laboratory and quality assessment pathologists, or lesions of general interest were presented by the chairperson to the PWG for review. The PWG consisted of the quality assessment pathologist and other pathologists experienced in rodent toxicologic pathology. This group examined the tissues without any knowledge of dose groups or previously rendered diagnoses. When the PWG consensus differed from the opinion of the laboratory pathologist, the diagnosis was changed. Thus, the final diagnoses represent a consensus of quality assessment pathologists, the PWG chairperson, and PWG. Details of these review procedures have been described, in part, by Maronpot and Boorman (1982) and Boorman et al. (1985). For subsequent analyses of the pathology data, the diagnosed lesions for each tissue type were evaluated separately or combined according to the guidelines of McConnell et al. (1986).

# 2-Year Mouse Study

# Study Design

Groups of 60 male and 60 female mice were fed diets containing 0, 1,250, 2,500, or 5,000 ppm for 104 to 105 weeks. As many as 10 male and 10 female mice were evaluated at 15 months.

### Source and Specification of Animals

B6C3F<sub>1</sub> mice were obtained from Taconic Farms (Germantown, NY) and were approximately 32 days old on receipt. Mice were quarantined for 12 days and were approximately 44 days old on the first day of exposure. Before the initiation of the study, five male and five female mice were selected for parasite evaluation and gross observation of disease. Serology samples were collected for viral screening. The health of the animals was monitored during the study according to the protocols of the NTP Sentinel Animal Program (Appendix L).

### Animal Maintenance

Mice were housed individually. Feed and water were available *ad libitum*. Feed consumption per cage was measured every 1 to 6 weeks up to week 17 and monthly thereafter. Cages were changed twice weekly and racks were generally rotated every 2 weeks. Further details of animal maintenance are given in Table 1. Information on feed composition and contaminants is provided in Appendix K.

### **Clinical Examinations and Pathology**

Mice were observed twice daily. Clinical findings were recorded at the beginning of the 2-year study, once weekly for the first 12 (females) or 13 (males) weeks, and monthly thereafter. As many as 10 male and 10 female mice were evaluated for hematology alterations at 15 months using the methods described for the 13-week study. The parameters evaluated are listed in Table 1.

A complete necropsy and microscopic examination were performed on all mice. At 15-month interim evaluations, the right kidney, liver, right epididymis, and right testis were weighed. At necropsy, all organs and tissues were examined for grossly visible lesions, and all major tissues were fixed and preserved in 10% neutral buffered formalin, processed and trimmed, embedded in paraffin, sectioned to a thickness of 5 to 6  $\mu$ m, and stained with hematoxylin and eosin for microscopic examination. For all paired organs (i.e., adrenal gland, kidney, ovary), samples from each organ are examined. Tissues examined microscopically are listed in Table 1.

Microscopic evaluations were completed by the study laboratory pathologist, and the pathology data were entered into the Toxicology Data Management System. The microscopic slides, paraffin blocks, and residual wet tissues were sent to the NTP Archives for inventory, slide/block match, and wet tissue audit. The slides, individual animal data records, and pathology tables were evaluated by an independent quality assessment laboratory. The individual animal records and tables were compared for accuracy, the slide and tissue counts were verified, and the histotechnique was evaluated. The following organs were reviewed in mice: liver, harderian gland, and thyroid gland (females).

The quality assessment report and the reviewed slides were submitted to the NTP Pathology Working Group (PWG) chairperson, who reviewed the selected tissues and addressed any inconsistencies in the diagnosis made by the laboratory and quality assessment pathologists. Representative histopathology slides containing examples of lesions related to chemical administration, examples of disagreements in diagnoses between the laboratory and quality assessment pathologists, or lesions of general interest were presented by the chairperson to the PWG for review. The PWG consisted of the quality assessment pathologist and other pathologists experienced in rodent toxicologic pathology. This group examined the tissues without any knowledge of dose groups or previously rendered diagnoses. When the PWG consensus differed from the opinion of the laboratory pathologist, the diagnosis was changed. Thus, the final diagnoses represent a consensus of quality assessment pathologists, the PWG chairperson, and the PWG. Details of these review procedures have been described, in part, by Maronpot and Boorman (1982) and Boorman et al. (1985). For subsequent analyses of the pathology data, the diagnosed lesions for each tissue type were evaluated separately or combined according to the guidelines of McConnell et al. (1986).

# STATISTICAL METHODS Survival Analyses

The probability of survival was estimated by the product-limit procedure of Kaplan and Meier (1958) and is presented in the form of graphs. Animals found dead of other than natural causes were censored from the survival analyses; animals dying from natural causes were not censored. Statistical analyses for possible dose-related effects on survival used Cox's (1972) method for testing two groups for equality and Tarone's (1975) life table test to identify dose-related trends. All reported P values for the survival analyses are two sided.

### **Calculation of Incidence**

The incidences of neoplasms or nonneoplastic lesions as presented in Tables A1, A4, B1, B4, C1, C5, D1, and D5 are given as the number of animals bearing such lesions at a specific anatomic site and the number of animals with that site examined microscopically. For calculation of statistical significance, the incidences of most neoplasms (Tables A3, B3, C3, and D3) and all nonneoplastic lesions are given as the numbers of animals affected at each site examined microscopically. However, when macroscopic examination was required to detect neoplasms in certain tissues (e.g., harderian gland, intestine, mammary gland, and skin) before microscopic evaluation, or when neoplasms had multiple potential sites of occurrence (e.g., leukemia or lymphoma), the denominators consist of the number of animals on which a necropsy was performed. Tables A3, B3, C3, and D3 also give the survival-adjusted neoplasm rate for each group and each site-specific neoplasm, i.e., the Kaplan-Meier estimate of the neoplasm incidence that would have been observed at the end of the study in the absence of mortality from all other competing risks (Kaplan and Meier, 1958).

### Analysis of Neoplasm Incidences

The majority of neoplasms in these studies were considered to be incidental to the cause of death or not rapidly lethal. Thus, the primary statistical method used was logistic regression analysis, which assumed that the diagnosed neoplasms were discovered as the result of death from an unrelated cause and thus did not affect the risk of death. In this approach, neoplasm prevalence was modeled as a logistic function of chemical exposure and time. Both linear and quadratic terms in time were incorporated initially, and the quadratic term was eliminated if the fit of the model was not significantly enhanced. The neoplasm incidences of exposed and control groups were compared on the basis of the likelihood score test for the regression coefficient of dose. This method of adjusting for intercurrent mortality is the prevalence analysis of Dinse and Lagakos (1983), further described and illustrated by Dinse and Haseman (1986). When neoplasms are incidental, this comparison of the time-specific neoplasm prevalences also provides a comparison of the time-specific neoplasm incidences (McKnight and Crowley, 1984).

In addition to logistic regression, other methods of statistical analysis were used, and the results of these tests are summarized in the appendixes. These methods include the life table test (Cox, 1972; Tarone, 1975), appropriate for rapidly lethal neoplasms, and the Fisher exact test and the Cochran-Armitage trend test (Armitage, 1971; Gart *et al.*, 1979), procedures based on the overall proportion of neoplasm-bearing animals.

Tests of significance included pairwise comparisons of each exposed group with controls and a test for an overall dose-related trend. Continuity-corrected tests were used in the analysis of neoplasm incidence, and reported P values are one sided. The procedures described in the preceding paragraphs were also used to evaluate selected nonneoplastic lesions. For further discussion of these statistical methods, refer to Haseman (1984).

Analysis of Nonneoplastic Lesion Incidences Because all nonneoplastic lesions in this study were considered to be incidental to the cause of death or not rapidly lethal, the primary statistical analysis used was a logistic regression analysis in which nonneoplastic lesion prevalence was modeled as a logistic function of chemical exposure and time. For lesions detected at the interim evaluation, the Fisher exact test, a procedure based on the overall proportion of affected animals, was used.

### Analysis of Continuous Variables

Two approaches were employed to assess the significance of pairwise comparisons between exposed and control groups in the analysis of continuous variables. Organ and body weight data, which have approximately normal distributions, were analyzed using the parametric multiple comparison procedures of Dunnett (1955) and Williams (1971, 1972). Hematology, clinical chemistry, spermatid, and epididymal spermatozoa, which have typically skewed distributions, were analyzed using the nonparametric multiple comparison methods of Shirley (1977) and Dunn (1964). Jonckheere's test (Jonckheere, 1954) was used to assess the significance of the dose-related trends and to determine whether a trend-sensitive test (Williams' or Shirley's test) was more appropriate for pairwise comparisons than a test that does not assume a monotonic dose-related trend (Dunnett's or Dunn's test). Prior to statistical analysis, extreme values identified by the outlier test of Dixon and Massey (1951) were examined by NTP personnel, and implausible values were eliminated from the analysis. Average severity values were analyzed for significance using the Mann-Whitney U test (Hollander and Wolfe, 1973). Because the vaginal cytology data are proportions (the proportion of the observation period that an animal was in a given estrous stage), an arcsine transformation was used to bring the data into closer conformance with a normality assumption. Treatment effects were investigated by applying a multivariate analysis of variance (Morrison, 1976) to the transformed data to test for simultaneous equality of measurements across exposure levels.

Dam and pup data from the *in utero* phases of the rat 13-week and long-term studies were analyzed using

the variance test for homogeneity of the binomial distribution (Snedecor and Cochran, 1980). Baseline maternal body weight data, litter averages for percent mortality, and pup body weights were analyzed using Bartlett's test of homogeneity of variances (Sokal and Rohlf, 1981) and the analysis of variance (Snedecor and Cochran, 1980) when appropriate [i.e., if Bartlett's test was not significant (P > 0.05)]. If the analysis of variance was significant, Dunnett's test was used to identify the statistical significance of individual groups. If the analysis of variance was not appropriate [i.e., Bartlett's test was significant  $(P \le 0.05)$ ], the Kruskal-Wallis test (Sokal and Rohlf, 1981) was used when 75% or fewer ties were present; when more than 75% ties were present, the Fisher exact test was used. In cases where the Kruskal-Wallis test was statistically significant ( $P \le 0.05$ ), Dunn's method of multiple comparisons was used to identify statistical significance of individual groups. Natural delivery parameters involving discrete data were evaluated using the Kruskal-Wallis test.

### **Historical Control Data**

Although the concurrent control group is always the first and most appropriate control group used for evaluation, historical control data can be helpful in the overall assessment of neoplasm incidence in certain instances. Consequently, for B6C3F<sub>1</sub> mice, neoplasm incidences from the NTP historical control database (updated yearly) are included in this NTP report for neoplasms appearing to show compound-related effects during two-year studies. There are no studies of 30-month duration in the NTP historical control database for comparison to findings in the long-term F344/N rat studies.

### **QUALITY ASSURANCE METHODS**

The 13-week, long-term, and 2-year studies were conducted in compliance with Food and Drug Administration Good Laboratory Practice Regulations (21 CFR, Part 58). In addition, as records from the long-term and 2-year studies were submitted to the NTP Archives, these studies were audited retrospectively by an independent quality assurance contractor. Separate audits covering completeness and accuracy of the pathology data, pathology specimens, final pathology tables, and a draft of this NTP Technical Report were conducted. Audit procedures and findings are presented in the reports and are on file at NIEHS. The audit findings were reviewed and assessed by NTP staff, so all comments had been resolved or were otherwise addressed during the preparation of this Technical Report.

# **GENETIC TOXICOLOGY**

The genetic toxicity of *t*-butylhydroquinone was assessed by testing the ability of the chemical to induce mutations in *Salmonella typhimurium* and cultured Chinese hamster ovary cells. The protocols for these studies and the results are given in Appendix E.

The genetic toxicity studies of *t*-butylhydroquinone are part of a larger effort by the NTP to develop a database that would permit the evaluation of carcinogenicity in experimental animals from the structure and responses of the chemical in short-term *in vitro* and *in vivo* genetic toxicity tests. These genetic toxicity tests were originally developed to study mechanisms of chemically induced DNA damage and to predict carcinogenicity in animals, based on the electrophilic theory of chemical carcinogenesis and the somatic mutation theory (Miller and Miller, 1977; Straus, 1981; Crawford, 1985).

There is a strong correlation between a chemical's potential electrophilicity (structural alert to DNA reactivity), mutagenicity in Salmonella, and carcinogenicity in rodents. The combination of electrophilicity and Salmonella mutagenicity is highly correlated with the induction of carcinogenicity in rats and mice and/or at multiple tissue sites (Ashby and Tennant, 1991). Other in vitro genetic toxicity tests do not correlate well with rodent carcinogenicity (Tennant et al., 1987; Zeiger et al., 1990), although these other tests can provide information on the types of DNA and chromosome effects that can be induced by the chemical being investigated. Data from NTP studies show that a positive response in Salmonella is currently the most predictive in vitro test for rodent carcinogenicity (89% of the Salmonella mutagens were rodent carcinogens), and that there is no complementarity among the in vitro genetic toxicity tests. That is, no battery of tests that included the Salmonella test improved the predictivity of the Salmonella test alone. The predictivity for carcinogenicity of a positive response in bone marrow chromosome aberration or micronucleus tests is not yet defined.

### TABLE 1

9

# Experimental Design and Materials and Methods in the Feed Studies of t-Butylhydroquinone

13-Week Studies	Long-Term Rat and 2-Year Mouse Studies
Study Laboratory	
Southern Research Institute (Birmingham, AL)	Southern Research Institute (Birmingham, AL)
Strain and Species	
Rats: F344/N	Rats: F344/N
Mice: B6C3F <sub>1</sub>	Mice: B6C3F <sub>1</sub>
Animal Source	
Taconic Farms (Germantown, NY)	Taconic Farms (Germantown, NY)
Time Held Before Studies	
Rats: $F_0 - 19$ days	Rats: $F_0 - 18$ days
$F_1$ - No quarantine	$F_1$ - No quarantine
Mice: 13 days	Mice: 12 days
Average Age When Studies Began	
Rats: F <sub>0</sub> - 57 days	Rats: $F_0 - 49$ days
$F_1 - 34$ days	$F_1 - 35 \text{ days}$
Mice: 42 days	Mice: 44 days
Date of First Dose	
Rats: F <sub>0</sub> - 6 September 1988	Rats: $F_0 - 13$ November 1989
$F_1 - 21$ November 1988	$F_1 - 29$ January 1990
Mice: 5 December 1988	Mice: 29 November 1989
Duration of Desing	
Duration of Dosing Rats: F <sub>0</sub> - Approximately 10 weeks	Rats: $F_0$ - Approximately 12 weeks
$F_1 = 87-89$ days (clinical pathology study $F_1$ rats)	$F_1$ - Interim evaluation - 92 days (males)
93-94 days (core study $F_1$ rats)	or 93 days (females)
Mice: 87-88 days (clinical pathology study mice)	Terminal sacrifice - 123 weeks (males) or 129 weeks
93-95 days (core study mice)	(females)
	Mice: 104 to 105 weeks
Date of Last Dose	
Rats: F <sub>0</sub> - 16-18 November 1988	Rats: F <sub>0</sub> - 31 January 1990
F <sub>1</sub> - 15-17 February 1989	$F_1$ - 30 April 1990 (interim evaluation $F_1$ males)
(clinical pathology study $F_1$ rats)	1 May 1990 (interim evaluation $F_1$ females)
21-22 February 1989 (core study $F_1$ rats)	3 June 1992 (core study $F_1$ males)
Mice: 1-2 March 1989 (clinical pathology study mice) 7-9 March 1989 (core study mice)	14-15 July 1992 (core study F <sub>1</sub> females) Mice: 27-28 February 1991 (interim evaluation)
7-9 Watch 1989 (core study mice)	Mice: 27-28 February 1991 (interim evaluation) 25-27 November 1991 (core study males)
	2-4 December 1991 (core study finales)
Necropsy Dates	
Rats: $F_1 - 21-22$ February 1989	Rats: $F_1$ - Interim evaluation
Mice: 7-9 March 1989	30 April (males) or 1 May (females) 1990
	Terminal sacrifice
	3 June (males) or 14-15 July (females) 1992
	Mice: Interim evaluation
	27 (males) or 28 (females) February (1991)
	Terminal sacrifice
	25-27 November (males) or 2-4 December (females)

ę.

÷ b

# TABLE 1 Experimental Design and Materials and Methods in the Feed Studies of t-Butylhydroquinone (continued)

13-Week Studies	Long-Term Rat and 2-Year Mouse Studies
Average Age at Necropsy	
Rats: $F_1$ - 121-123 days (clinical pathology study rats) 127-128 days (core study rats)	Rats: F <sub>1</sub> - 127-128 days (interim evaluation rats) 128 weeks (males) or 134 weeks (females)
Mice: 129-130 days (clinical pathology study mice) 135-137 days (core study mice)	Mice: Interim evaluation - 72 weeks Core study - 110 weeks (males) or 111 weeks (females)
Size of Study Groups	
Rats: F <sub>0</sub> generation - 10 females F <sub>1</sub> generation	Rats: $F_0 = 60$ females $F_1 = 68-70$ males and 68-70 females
Core study - 10 males and 10 females Clinical pathology study - 10 males and 10 females	Mice: 60 males and 60 females
Mice: Core study - 10 males and 10 females Clinical pathology study - 10 males and 10 females	
Method of Distribution	
Animals were distributed randomly into groups of approximately equal initial mean body weights.	Same as 13-week studies
Animals per Cage	
Rats: $F_0$ - two females with one breeder male during cohabitation, then one female with litter per cage	Rats: $F_0$ - two females with one breeder male during cohabitation, then one female with litter per cage
$F_1$ - five per cage Mice: five per cage	F <sub>1</sub> - five per cage Mice: one per cage
Method of Animal Identification	
Rats: Breeder females and pups identified by tail tattoo Mice: Toeclip	Tail tattoo
Diet NIH-07 open formula mash diet (Zeigler Brothers, Inc.,	Same as 13-week studies
Gardners, PA), available ad libitum	
Water Distribution	Same on 12 work studion
Tap water (Birmingham, AL, municipal supply) via automatic watering system (Edstrom Industries, Waterford, WI); available	Same as 13-week studies
ad libitum	
Cages Polycarbonate (Lab Products, Inc., Maywood, NJ); changed	Same as 13-week studies
twice weekly, except (rats only) between day 18 of gestation until completion of delivery	
Bedding	
SaniChip (P.J. Murphy Forestry Products, Corp., Montville, NJ); changed twice weekly, except (rats only) between day 18 of gestation until completion of delivery	Same as 13-week studies
Rack Filters	
Reemay <sup>®</sup> spun-bonded polyester (Andico, Birmingham, AL); changed once every 2 weeks, except (rats only) between day 18 of gestation until completion of delivery	Same as 13-week studies
· · · ·	

ĵ,

### TABLE 1

Experimental Design and Materials and Methods in the Feed Studies of t-Butylhydroquinone (continued)

#### 13-Week Studies

#### Racks

Stainless steel (Lab Products, Inc., Maywood, NJ); changed once every 2 weeks, except (rats only) between day 18 of gestation until completion of delivery

#### Animal Room Environment

Temperature: 18.7° C to 24.2° C Relative humidity: 35.8%-79.3% Fluorescent light: 12 hours/day Room air: minimum of 10 changes per hour

#### Doses

Rats: F<sub>0</sub> - 0, 2,500, 5,000, 10,000, 20,000, or 40,000 ppm F<sub>1</sub> - 0, 2,500, 5,000, or 10,000 ppm Mice: 0, 2,500, 5,000, 10,000, 20,000, or 40,000 ppm

#### **Type and Frequency of Observation**

- Rats: F<sub>0</sub> Observed twice daily. Body weights and clinical findings were recorded weekly for breeder females during cohabitation and weekly for breeder females and pups during lactation. Feed consumption was recorded weekly for breeder females prior to cohabitation.
  F<sub>1</sub> Observed twice daily. For core study animals, clinical findings were recorded and the animals were weighed initially, weekly, and at the end of the study; feed consumption was recorded as an average of grams per animal per day.
  Mice: Observed twice daily. Clinical findings were recorded
- Mice: Observed twice daily. Clinical findings were recorded and the animals were weighed initially, weekly, and at the end of the study; feed consumption was recorded as an average of grams per animal per day.

#### **Method of Sacrifice**

Anesthetized with CO<sub>2</sub> followed by exsanguination

#### Necropsy

 $\mathcal{J}$ 

A necropsy was performed on all core study  $F_1$  rats and on all core study mice. Organs weighed were the heart, right kidney, liver, lungs, right testis, and thymus.

#### Long-Term Rat and 2-Year Mouse Studies

Same as 13-week studies

Temperature: 16.7° C to 29.1° C Relative humidity: 15.8%-86.1% Fluorescent light: 12 hours/day Room air: minimum of 10 changes per hour

Rats: F<sub>0</sub> and F<sub>1</sub> - 0, 1,250, 2,500, or 5,000 ppm Mice: 0, 1,250, 2,500, or 5,000 ppm

- Rats: F<sub>0</sub> Clinical findings and body weights recorded for females on the first day of the study and weekly prior to cohabitation. Feed consumption measured for breeder females weekdays through day 10 prior to cohabitation.
  F<sub>1</sub> Clinical findings and body weights recorded individually on lactation days 4, 11, 18, and 28; at the start of the long-term study; once weekly for the first 13 weeks; and every 4 weeks thereafter. Body weights recorded on all surviving animals at the end of the study. Feed consumption measured monthly for exposed groups; feed consumption measured weekly for the first 13 weeks for animals receiving 0 ppm.
- Mice: Observed twice daily. Clinical findings and body weights recorded on day 1, weekly for the first 12 (females) or 13 (males) weeks, then monthly, at the interim evaluation, and the end of the study. Feed consumption measured per animal every 1-6 weeks up to week 17 and monthly thereafter.

Same as 13-week studies

e.

A necropsy was performed on all  $F_1$  rats and on all mice. At the 3-month (rats) and 15-month (mice) interim evaluations, the right kidney, liver, right epididymis, and right testis were weighed.

ž.

### TABLE 1

### Experimental Design and Materials and Methods in the Feed Studies of t-Butylhydroquinone (continued)

#### 13-Week Studies

Long-Term Rat and 2-Year Mouse Studies

#### **Clinical Pathology**

Blood was collected for hematology, clinical chemistry, and coagulation analyses from the retroorbital sinus of core rats and mice at the end of the studies. Blood was collected from the retroorbital sinus of special study rats and mice on day 5 and at week 3 for hematology and clinical chemistry analyses. *Hematology:* Hematocrit level, hemoglobin concentration, erythrocyte count, reticulocyte count, nucleated erythrocyte count, mean cell wolume, mean cell hemoglobin, mean cell hemoglobin concentration, platelet count, and leukocyte count and differential.

*Clinical Chemistry:* Blood urea nitrogen, creatinine, total protein, albumin, alkaline phosphatase, creatine kinase, sorbitol dehydrogenase, and bile acids.

*Coagulation:* Thromboplastin time and activated partial thromboplastin time.

Sperm Motility and Vaginal Cytology Evaluation

Sperm and vaginal fluid samples were evaluated in 0, 2,500, 5,000, and 10,000 ppm  $F_1$  rats and in 0, 2,500, 10,000, and 40,000 ppm mice at the end of the studies. The parameters evaluated in males were sperm count and motility. The right cauda, right epididymis, and right testis were weighed. Vaginal fluid samples were collected for up to 7 consecutive days prior to the end of the studies for vaginal cytology evaluations. The parameters evaluated in females were relative frequency of estrous stages and estrous cycle length.

#### Histopathology

Complete histopathologic examinations were performed on all control F<sub>1</sub> rats and mice, 10,000 ppm F<sub>1</sub> rats, and 40,000 ppm mice. In addition to gross lesions, tissue masses, and associated lymph nodes, the tissues examined included: adrenal gland, bone and marrow, brain, clitoral gland, esophagus, gallbladder (mice only), heart (with aorta), large intestine (cecum, colon, rectum), kidneys, liver, lungs and mainstem bronchi, lymph nodes (mandibular and mesenteric), mammary gland, nasal cavity and turbinates, ovaries, pancreas, parathyroid gland, pituitary gland, preputial gland, prostate gland, salivary gland, skeletal muscle, skin, small intestine (duodenum, jejunum, ileum), spinal cord and sciatic nerve, spleen, stomach (forestomach and glandular stomach), testis with epididymis and seminal vesicle, thymus, thyroid gland, trachea, urinary bladder, and uterus. Additionally, the following tissues from selected exposure groups were examined: the nose of all exposed groups of male rats, 5,000 ppm female rats, and all exposed groups of male and female mice; the spleen of 5,000 and 10,000 ppm male rats and all exposed groups of female rats; the mesenteric lymph node of 5,000 ppm female rats; the kidneys of 2,500 and 10,000 ppm female rats; and the skin and forestomach of all exposed groups of male and female mice.

At 3 months (rats) or 15 months (mice), blood was collected from the retroorbital sinus of as many as 10 male and 10 female rats and mice.

*Hematology:* Hematocrit level, hemoglobin concentration, erythrocyte count, reticulocyte count, nucleated erythrocyte count, mean cell volume, mean cell hemoglobin, mean cell hemoglobin concentration, platelet count, and leukocyte count and differential.

None

Complete histopathologic examinations were performed on all  $F_1$  rats and on all mice. In addition to gross lesions, tissue masses and associated lymph nodes, the tissues examined included: adrenal glands, bone (including marrow), brain, clitoral gland, esophagus, gallbladder (mice only), heart (with aorta), kidneys, large intestine (cecum, colon, rectum), liver, lungs and mainstem bronchi, lymph nodes (mandibular and mesenteric), mammary gland, nasal cavity and turbinates, ovaries, pancreas, parathyroid glands, skin, small intestine (duodenum, jejunum, ileum), spinal cord and sciatic nerve, spleen, stomach (forestomach and glandular stomach), testis with epididymis and seminal vesicle, thymus, thyroid gland, trachea, urinary bladder, and uterus.

# RESULTS

# Rats

# 13-Week Study

In the perinatal exposure phase of the 13-week study, *t*-butylhydroquinone did not affect gestation length, the average number of pups born per litter, or the number of dams with stillborn pups for dams exposed to 2,500, 5,000, or 10,000 ppm (Table H2); dams exposed to 20,000 or 40,000 ppm did not litter. The number of pup deaths in the 5,000 and 10,000 ppm groups was greater than that in the control group, and the average number of surviving pups per litter in the 10,000 ppm group was lower than that in the control group. Mean body weights of pups in the 5,000 and 10,000 ppm groups at weaning were lower than that of the control.

All  $F_i$  rats survived to the end of the study (Table 2). The final mean body weights of males and females in the 5,000 and 10,000 ppm groups were significantly lower than those of the controls, as was the mean body weight gain of males in the 10,000 ppm group. However, interpretation of these findings was complicated by the significantly lower initial mean body weights observed in 10,000 ppm groups. Differences in initial mean body weights were due to *in utero* exposure to *t*-butylhydroquinone.

#### TABLE 2

Survival, Mean Body Weights, and Feed Consumption of Rats in the 13-Week Feed Study of *t*-Butylhydroquinone

Dose	Survival <sup>a</sup>	Me: Initial <sup>c</sup>	n Body Weight <sup>b</sup> (g) Final Change		Final Weight Relative to Controls		eed mption <sup>d</sup>
(ppm)				g-	(%)	Week 2	Week 13
Male							
0	10/10	96 ± 5	$328 \pm 6$	232 ± 4		17.0	14.6
2,500	10/10	$92 \pm 3$	$325 \pm 3$	$233 \pm 3$	99	15.8	15.7
5,000	10/10	86 ± 4	307 ± 7*	$221 \pm 6$	93	14.2	13.8
10,000	10/10	69 ± 3**	279 ± 5**	210 ± 5**	85	10.8	13.8
Female							
0	10/10	$82 \pm 3$	199 ± 5	117 ± 4		11.4	12.6
2,500	10/10	$81 \pm 3$	$198 \pm 3$	$117 \pm 3$	99	11.3	12.4
5,000	10/10	$78 \pm 3$	$185 \pm 2^{**}$	$108 \pm 2$	93	10.9	12.7
10,000	10/10	64 ± 2**	175 ± 3**	$111 \pm 3$	88	9.2	10.6

\* Significantly different (P<0.05) from the control group by Williams' or Dunnett's test.

\*\* P≤0.01

<sup>a</sup> Number of animals surviving/number initially in group

<sup>b</sup> Weights and weight changes are given as mean  $\pm$  standard error.

<sup>c</sup> Differences in initial body weights were due to *in utero* exposure of treated groups to *t*-butylhydroquinone.

\$

Feed consumption is expressed as grams of feed consumed per animal per day.

Feed consumption by exposed groups was lower than that by controls at week 2, and feed consumption by 5,000 and 10,000 ppm males and 10,000 ppm females was slightly lower than that consumed by controls at the end of the study. Dietary levels of 2,500, 5,000, and 10,000 ppm delivered daily doses of approximately 200, 400, and 800 mg *t*-butylhydroquinone/kg body weight to males and 200, 400, and 750 mg/kg to females. Hair discoloration was observed in all exposed groups of rats, with the exception of 2,500 ppm females; this was the only clinical observation considered to be related to chemical exposure.

The mean spermatid count, spermatid heads per testis, and spermatid heads per gram of testis were significantly decreased in  $F_1$  males exposed to 5,000 ppm; the estrous cycles of  $F_1$  females exposed to 2,500 or 5,000 ppm were significantly longer than that of the controls (Table H1). Exposure to *t*-butylhydroquinone for 13 weeks did not produce morphologic changes in reproductive organs.

Serum bile acid levels were generally significantly increased in 5,000 and 10,000 ppm male and female rats at day 5, at week 3, and at the end of the study (Table G1). Serum alanine aminotransferase activity levels were increased at day 5 in females exposed to 10,000 ppm, at week 3 in males and females exposed to 2,500, 5,000, or 10,000 ppm, and at the end of the study in males receiving 2,500 ppm. However, because the increases observed in these two parameters were marginal, and since histopathologic evaluation did not reveal evidence of liver toxicity, these marginal increases were not considered to be biologically significant changes. Differences in absolute and/or relative organ weights of control and exposed groups of rats were observed (Table F1). However, these organ weight differences were associated with histopathologic lesions and in many cases were secondary to lower body weights of exposed groups. Therefore, they were not considered clearly related to *t*-butylhydroquinone exposure.

Increased incidences of hyperplasia of the nasal respiratory epithelium were observed in males exposed to 5,000 ppm and males and females exposed to 10,000 ppm, and an increased incidence of nasal exudate was observed in males in the 10,000 ppm group (Table 3). The hyperplasia was of minimal severity and primarily involved an increase in the number of goblet cells along the nasal septum and medial aspect of the nasoturbinates. In a few male rats, there was also a mild nasal exudate composed of degenerated neutrophils and eosinophilic proteinaceous material. These nasal lesions suggest a mild irritant effect of t-butylhydroquinone possibly resulting from inhalation and/or aspiration of the dosed feed. Increased incidences of splenic pigmentation were observed in males and females exposed to 5,000 or 10,000 ppm, and incidences of atrophy of the red pulp were observed in these groups of females (Table 3). Because the pigment was golden brown and present within the phagocytic cells, it was considered to be hemosiderin. Atrophy of the splenic red pulp was characterized as a decrease in the number of hematopoietic cells. While the pathogenesis of these minimal changes was not determined, the biological significance is at most minimal because the bone marrow and hematologic parameters were normal. There was an exposure-related decrease in the incidences of renal mineralization in female rats (Table 3). Normally, a slight amount of mineral is observed near the corticomedullary junction in all females at 13 weeks. The pathogenesis of the observed decrease in this mineral is uncertain, although changes in feed and water consumption and decreased estrogen levels may affect mineral accumulation in the kidney.

Dose Selection Rationale: Based on lower final mean body weights and decreased feed consumption in males and females exposed to 10,000 ppm t-butylhydroquinone, exposure concentrations selected for the long-term rat study were 1,250, 2,500, and 5,000 ppm.

# TABLE 3 Incidences of Selected Nonneoplastic Lesions in Rats in the 13-Week Feed Study of *t*-Butylhydroquinone

	0 ppm	2,500 ppm	5 <b>,000</b> ppm	1 <b>0,000</b> ppm
Male		<b>.</b> <u>.</u>	in die Alexander voor die Staat van die Staat voor die Staat voor die Staat voor die Staat voor die Staat voor Voor die Staat voor die	
Vose <sup>a</sup>	10	10	10	10
Exudate <sup>b</sup>	0	10 0	0	4≑
Nasal Respiratory		-	·	•
Epithelial Hyperplasia	0	0	5° (1.0) <sup>c</sup>	10** (1.7)
Spleen	10	10	10	10
Pigmentation	0	10 1 (1.0)	3 (1.0)	5* (1.0)
Female		d		
Nose Nasal Respiratory	10	"	10	10
Epithelial Hyperplasia	0	_	0	7** (1.0)
			0	/ (1.0)
Spleen	10	10	10	10
Red Pulp, Atrophy	0	• 0	8 <sup>¢¢</sup> (1.8)	10** (1.8)
Pigmentation	0	5 <sup>‡</sup> (1.0)	8 <sup>¢‡</sup> (1.1)	10** (1.3)
-				
Kidney	10	10	10	10
Mineralization	10 (2.0)	10 (1.9)	6 (1.3)	4 <sup>**</sup> (1.2)

\* Significantly different (P<0.05) from the control group by the Fisher exact test \*\* P<0.01

a Number of animals with organ examined microscopically
 b Number of animals with lesion

<sup>c</sup> Average severity grade of lesions in affected rats: 1=minimal; 2=mild; 3=moderate; 4=marked <sup>d</sup> Organ not examined at this exposure level

ŝ,

÷
# **LONG-TERM STUDY**

## Survival

Estimates of survival probabilities for male and female rats are shown in Table 4 and in the Kaplan-Meier survival curves in Figure 1. Survival of females in the 5,000 ppm group was significantly greater than that of the control group. Males were killed at week 123 (28 months) post-weaning and females at week 129 (30 months) post-weaning.

# Body Weights, Feed and Compound Consumption, and Clinical Findings

Mean body weights of 5,000 ppm groups were generally lower than those of the control groups

throughout the study (Tables 5 and 6 and Figure 2). Feed consumption by exposed groups of males and females was similar to that by the controls (Tables J1 and J2). Dietary levels of 1,250, 2,500, or 5,000 ppm t-butylhydroquinone resulted in daily doses of approximately 50, 100, or 200 mg/kg body weight (males) or 60, 120, or 240 mg/kg (females). Clinical findings of hair discoloration in exposed groups of males and females were considered to be related to chemical exposure.

## Hematology

Results of hematology assays in all exposed groups of males and females were similar to those in the control groups (Table G2).

#### TABLE 4

Survival of Rats in the Long-Term Feed Study of t-Butylhydroquinone

	0 ppm	1,250 ppm	2,500 ppm	5,000 ppm
Male				
Animals initially in study	70	70	70	70
3-Month interim evaluation	10	10	10	10
Missexed <sup>a</sup>	. 0	0	2	0
Moribund	48	51	50	42
Natural deaths	4	2	7	4
Animals surviving to study termination	8	7	1	. 14
Percent probability of survival at the end of the study <sup>b</sup>	13	12	2	23
Mean survival (days) <sup>c</sup>	621	612	590	629
Survival analysis <sup>d</sup>	P=0.300N	P=0.856	P=0.075	P=0.361N
Female				· .
Animals initially in study	70	70	70	70
3-Month interim evaluation	10	10	10	10
Missexed <sup>a</sup>	0	0	2	0
Moribund	40	41	33	36
Natural deaths	10	8	9	7
Animals surviving to study termination	10	. 11	16	17
Percent probability of survival at the end of the study	17	18	28	- 28
Mean survival (days)	636	663	678	693
Survival analysis	P=0.017N	P=0.564N	P=0.063N	P=0.030N

<sup>a</sup> Censored from survival analyses

<sup>b</sup> Kaplan-Meier determinations

<sup>c</sup> Mean of all deaths (censored, uncensored, and terminal sacrifice)

<sup>d</sup> The result of the life table trend test (Tarone, 1975) is in the control column, and the results of the life table pairwise comparisons (Cox, 1972) with the controls are in the exposed columns. A negative trend or a lower mortality in an exposure group is indicated by N.



# FIGURE 1

Kaplan-Meier Survival Curves for Male and Female Rats Administered *t*-Butylhydroquinone in the Long-Term Feed Study

38

TABLE	5
-------	---

Weeks	<u> </u>			1.250 ppm		-	2.500 pp	m		5.000 p	pm
on	Av. Wt.	No. of		Wt. (% of	No. of		Wt. (% of	No. of	Av. Wt.	Wt. (% of	No. of
Study	.(g)	Survivors	. <b>(g)</b>	controls)	Survivors	(g)	controls)	Survivors	(g)	controls)	Survivors
1	99	70	106	108	70	102	103	70	91	92	70
2	141	70	148	105	70	141	99	70	127	90	70
· 3	175	70	181	104	70	174	99	70	157	90	70
4	209	70	213	102	70	206	99	70	188	90	70
5 <sup>a</sup>	233	70	237	102	70	232	99	<b>68</b> .	217	93	70
6	267	70	266	100	70	260	97	68	244	91	70
7	283	70	284	100	70	277	98	68	261	92	70
8	299	70	298	100	70	294	98	68	275	92	70
9	313	70	311	100	70	307	98	68	287	92	70
10	316	70	319	101	70	320	101	68	299	95	. 70
11	324	70	324	100	70	323	100	68	304	94	70
12	344	70	342	100	70	337	98	68	318	92	70
13	356	70	348	98	70	343	97	68	320	90	70
17 <sup>b</sup>	379	60	370	98	60	366	96	58	346	91	60
21	400	60	391	98	60	379	95	<b>58</b> -	358	89	60
25	413	60	408	99	60	399	97	58	376	91	60
29	419	60	416	99	60	408	97	58	386	92	60
33	428	60	425	99	<b>60</b>	417	97	58	392	92	60
37	437	60	435	100	60	430	98	<b>58</b>	402	92	60
41	450	60	445	<b>99</b> ·	60	437	97	58	416	92	60
45	452	60	450	100	59	439	97	58	415	92	60
49	444	60	448	101	59	440	<b>99</b> ·	58	415	94	60
53	468	60	466	100	<b>59</b> ·	457	98	58	431	92	60
57	468	59	468	100	57	462	99	58	435	93	60
61	467	59	468	100	57	463	99	57	440	94	60
65	470	59	471	100	57	463	99	57	440	94	59
69	468	57	472	101	56	463	99	55	437	93	59
73	472	56	471	100	56	459	97.	53 ·	433	92	57
77	463	55	463	100	56	458	99	52	438	95	55
. 81	464	52	466	101	51	458	99	47	436	94	53
85	462	51	470	102	49	457	99	45 ·	429	93	52
89	455	51	457	101	49	455	100	40	425	93	51
93	458	46	451	98	47	456	100	35	419	92	44
97	455	39	452	99	40	453	100	32	421	92	39
101	447	35	444	99	32	443	99	25	421	94	34
105	440	28	435	99	23	430	98	21	409	93	. 30
109	420	21	421	100	20	414	99	16	412	98	25
113	429	13	427	100	13	420	98	10	395	92	19
117	428	10	422	99	11	400	94	6	397	93	15
121	417	8	402	97	9	359	86.	5	386	93	14
Mean for	weeks										
1-13	258		260	101		-255	99		238	92	
14-52	425		421	99		413	97		390	92	
			451	100		443	98		422	93	

<sup>a</sup> Two rats in the 2,500 ppm group were missexed. These animals were removed from study during week 4.
<sup>b</sup> Interim evaluation occurred during week 14.

## 8-Butylhydroquinone, NTP TR 459

# TABLE 6

Mean Body Weights and Survival of Female Rats in the Long-Term Feed Study of &Butylhydroquinone

weeks <u>0 ppm</u>		Join		1,250 ppm			2,500 pp		·	<u>5.000 pr</u>	
on	Av. Wt.	No. of		. ₩t. (% of	No. of		Wt. (% of	No. of		Wt. (% of	
Study	(g)	Survivors	(g)	controls)	Survivors	(g)	controls)	Survivors	(g)	controls)	Survivors
1	92	70	97	105	70	93	101	70	83	91	70
2	121	70	124	103	70	120	100	70	110	91	70
3	135	70	137	101	70	134	99	70	125	92	70
4	147	70	148	101	70	143	98	70	134	92	70
5 <sup>a</sup>	159	70	159	100	70	155	97	68	146	92	70
6	171	70	168	98	70	162	95	68	154	90	70
7	177	70	174	98	70	170	96	68	161	91	70
8	181	70	178	99	70	174	96	68	165	92	70
9	186	70	184	99	70	180	97	68	173	93	70
10	176	70	181	103	70	183	104	68	176	100	70
11	193	70	192	99	70	187	97	68	181	94	70
12	196	70	194	99	70	188	96	68	181	92	70
13	198	70	194	98	70	191	97	68	184	93	70
17 <sup>b</sup>	203	60	203	100	60	197	97	58	188	93	60
21	224	60	212	95	60	205	92	58	200	89	60
25	222	60	216	97	60	212	96	58	203	91	60
29	229	60	222	97	60	217	94	57	210	91	60
33	231	60	227	98	60	219	95	57	210	91	60
37	232	60	230	99	60	223	96	57	213	92	60
41	240	60	238	99	60	231	97	57	219	92	60
45	248	58	246	99	60	239	96	57	227	91	60
49	257	58	256	100	60	244	95	57	232	90	60
53	264	58	263	100	60	247	94	57	236	90	60
57	279	57	277	99	60	264	95	57	246	88	60
61	285	55	285	100	60	269	94	57	257	90	60
65	292	55	291	100	60	274	94	56	263	90	60
69	301	55	299	99	58	282	94	56	265	88	60
73	309	54	301	98	57	286	93	55	270	87	59
77	315	54	311	99	56	297	94	55	274	87	59
81	323	51	319	99	55	300	93	55	278	86	59
85	327	49	325	100	53	308	94	54	282	87	57
89	333	48	327	98	52	309	93	52	287	86	54
93	342	43	339	99	48	316	93	50	290	85	50
97	348	42	343	99	43	325	93	45	299	86	46
101	347	39	346	100	40	329	95	43	301	87	43
105	345	35	347	100	37	333	96	42	303	88	42
109	341	31	354	104	32	329	97	39	300	88	40
113	337	24	350	104	29	337	100	30	301	89	37
117	348	18	355	102	22	337	97	27	309	89	33
121	341	16	353	104	18	335	98	24	315	92	27
Mean for	weeks										
1-13	164		164	100		160	98		152	93	
14-52	232		228	98		221	96 95		211	93 91	
			<u> 0</u>	20		<i>44</i> 1	<b>7</b> ,7		للسك	71	

Two rats in the 2,500 ppm group were missexed. These animals were removed from study during week 4. Interim evaluation occurred during week 14. a

b





#### t-Butylhydroquinone, NTP TR 459

#### Pathology and Statistical Analyses

This section describes the statistically significant or biologically noteworthy changes in the incidences of neoplasms and/or nonneoplastic lesions of the thyroid gland, testis, mammary gland, pituitary gland, kidney, nose, spleen, and other organs. Summaries of the incidences of neoplasms and nonneoplastic lesions, individual animal tumor diagnoses, and statistical analyses of primary neoplasms that occurred with an incidence of at least 5% in at least one animal group are presented in Appendix A for male rats and Appendix B for female rats.

Thyroid gland: At the end of the long-term study, follicular cell carcinomas were observed in three 5,000 ppm male rats and a follicular cell adenoma was observed in one 1,250 ppm male and one 2,500 ppm male (Table A1). However, the overall trend in neoplasm incidence was not significantly increased, and no thyroid gland hyperplasia was present in any group of male or female rats (Tables A4 and B4). At the 3-month interim evaluation, ultimobranchial cysts were found in one 1,250 ppm male and three 5,000 ppm males. These marginal effects were not considered to be chemical related (Table A4).

*Testis:* The incidences of testicular adenoma in exposed groups of males occurred with a statistically significant positive trend (0 ppm, 55/60; 1,250 ppm,

49/60; 2,500 ppm, 56/57; 5,000 ppm, 59/60; Table A3). This marginal effect was not considered to be chemical related. This is a neoplasm that typically occurs in male rats at 2 years of age and was observed in all control and exposed rats at terminal sacrifice. The increase was attributed to slightly improved survival in the 5,000 ppm group.

Mammary gland: Significantly decreased incidences of fibroadenoma and of fibroadenoma, adenoma, or carcinoma (combined) occurred in all exposed groups of females, and incidences of fibroadenoma and of fibroadenoma or adenoma (combined) were significantly decreased in 1,250 ppm males and marginally decreased in other exposed groups of males (Tables 9, A3, and B3). The incidences of dilatation of the mammary gland were significantly decreased in 5,000 ppm males and marginally decreased in 2,500 ppm males than in controls. In females, the incidence of mammary gland dilatation was greater in the group exposed to 1,250 ppm than in the control group (Tables 9 and B4). Mammary gland neoplasms occurred earlier in the male and female control groups than in exposed groups. Fibroadenomas of the mammary gland are benign neoplasms which occur spontaneously at a high rate in female F344/N rats, and while not generally considered life threatening, the large size of these neoplasms often necessitates removal of the animal from the study.

# TABLE 9

Incidences of Neoplasms and Nonneoplastic Lesions of the Mammary Gland in Rats in the Long-Term Feed Study of *t*-Butylhydroquinone

	0 ppm	1,250 ppm	2,500 ppm	5,000 ppm	
Male				······································	·
Number Examined Microscopically	57	57	56	58	
Dilatation <sup>a</sup>	23 (2.0) <sup>b</sup>	24 (2.2)	17 (2.4)	10** (1.7)	
Hyperplasia	7 (2.4)	4 (2.0)	5 (2.2)	6 (1.7)	
Fibroadenoma					
Overall rate <sup>c</sup>	10/60 (17%)	4/60 (7%)	4/58 (7%)	7/60 (12%)	
Adjusted rated	72.0%	40.7%	24.8%	40.2%	
Terminal rate <sup>e</sup>	5/8 (63%)	2/7 (29%)	0/1 (0%)	5/14 (36%)	
First incidence (days)	381	786	619	708	
Logistic regression test <sup>f</sup>	P=0.195N	P=0.033N	P=0.183N	P=0.107N	
Adenoma					
Overall rate	1/60 (2%)	0/60 (0%)	1/58 (2%)	0/60 (0%)	
Fibroadenoma or Adenoma			· •		
Overall rate	11/60 (18%)	4/60 (7%)	5/58 (9%)	7/60 (12%)	
Adjusted rate	72.6%	40.7%	43.6%	40.2%	
Terminal rate	5/8 (63%)	2/7 (29%)	0/1 (0%)	5/14 (36%)	
First incidence (days)	381	786	619	708	
Logistic regression test	P=0.145N	P=0.022N	P=0.213N	P=0.076N	

# Table 9

Incidences of Neoplasms and Nonneoplastic Lesions of the Mammary Gland in Rats in the Long-Term Feed Study of *t*-Butylhydroquinone (continued)

	0 ppm	1,250 ppm	2,500 ppm	5,000 ppm
Female	· · · · · ·	· ·	n	
Number Examined Microscopically	60	59	58	60
Dilatation	37 (2.1)	48* (2.1)	39 (2.3)	34 (2.0)
Hyperplasia	12 (2.3)	6 (2.3)	11 (2.2)	15 (2.3)
Fibroadenoma				
Overall rate	43/60 (72%)	33/60 (55%)	34/58 (59%)	27/60 (45%)
Adjusted rate	100.0%	96.6%	86.0%	74.4%
Terminal rate	10/10 (100%)	10/11 (91%)	11/16 (69%)	9/17 (53%)
First incidence (days)	418	537	600	596
Logistic regression test	P<0.001N	P=0.006N	P=0.009N	P<0.001N
Adenoma				
Overall rate	3/60 (5%)	0/60 (0%)	1/58 (2%)	2/60 (3%)
Adjusted rate	9.9%	0.0%	2.9%	8.6%
Terminal rate	0/10 (0%)	0/11 (0%)	0/16 (0%)	1/17 (6%)
First incidence (days)	613	g	774	807
Logistic regression test	P=0.562N	P=0.133N	P=0.345N	P=0.503N
Carcinoma				
Overall rate	8/60 (13%)	6/60 (10%)	2/58 (3%)	4/60 (7%)
Adjusted rate	29.3%	35.4%	10.8%	10.5%
Terminal rate	1/10 (10%)	3/11 (27%)	0/16 (0%)	0/17 (0%)
First incidence (days)	540	640	890	690
Logistic regression test	P=0.073N	P=0.345N	P=0.042N	P=0.177N
Fibroadenoma, Adenoma, or Carc	inoma			
Overall rate	48/60 (80%)	34/60 (57%)	34/58 (59%)	30/60 (50%)
Adjusted rate	100.0%	96.6%	86.0%	76.3%
Terminal rate	10/10 (100%)	10/11 (91%)	11/16 (69%)	9/17 (53%)
First incidence (days)	418	537	600	596
Logistic regression test	P<0.001N	P<0.001N	P<0.001N	P<0.001N

\* Significantly different (P<0.05) from the control group by the logistic regression test

\*\* P≤0.01

a Number of animals with lesion

Average severity grade of lesion in affected animals: 1=minimal; 2=mild; 3=moderate; 4=marked

<sup>c</sup> Number of animals with neoplasm per number of animals necropsied

d Kaplan-Meier estimated neoplasm incidence at the end of the study after adjustment for intercurrent mortality

<sup>e</sup> Observed incidence in animals surviving until the end of the study

f In the control column are the P values associated with the trend test. In the exposure group columns are the P values corresponding to pairwise comparisons between the controls and that exposure group. The logistic regression test regards lesions in animals dying prior to terminal kill as nonfatal. A negative trend or a lower incidence in an exposure group is indicated by N.

<sup>g</sup> Not applicable; no neoplasm in animal group

*Pituitary gland:* The incidences of pars distalis adenoma and adenoma or carcinoma (combined) in males in the 5,000 ppm group were significantly less than those in the controls (Tables 10 and A3). However, hyperplasia, adenoma, and carcinoma represent a morphological and biological continuum in the progression of proliferative lesions of the pituitary gland and incidences of hyperplasia and carcinoma were not decreased in the 5,000 ppm group. Additionally, there is a known positive correlation of pituitary gland neoplasms with body weight. The decrease in adenomas in this study may have been related to the decreased mean body weight of the 5,000 ppm group.

#### TABLE 10

Incidences of Neoplasms and Nonneoplastic Lesions of the Pituitary Gland (Pars Distalis) in Male Rats in the Long-Term Feed Study of *t*-Butylhydroquinone

·	0 ppm	1,250 ppm	2,500 ppm	5,000 ppm	
		· · · · · · · · · · · · · · · · · · ·	<u> </u>	·····	
Long-Term Study					
Number Examined Microscopically	60	58	57	60	
Hyperplasia, Focal <sup>a</sup>	10 (2.2) <sup>b</sup>	8 (1.9)	8 (1.6)	14 (2.2)	•
Adenoma			· · ·		· · ·
Overall rate <sup>c</sup>	19/60 (32%)	16/58 (28%)	17/57 (30%)	6/60 (10%)	
Adjusted rate <sup>d</sup>	63.8%	80.0%	100.0%	30.2%	
Terminal rate <sup>e</sup>	2/8 (25%)	4/6 (67%)	1/1 (100%)	3/14 (21%)	
First incidence (days)	528	562	562	668	
Logistic regression test <sup>f</sup>	P=0.003N	P=0.410N	P=0.573	P=0.002N	. •
Carcinoma			۲		
Overall rate	0/60 (0%)	1/58 (2%)	1/57 (2%)	1/60 (2%)	
Adjusted rate	0.0%	5.5%	4.2%	2.1%	
Terminal rate	0/8 (0%)	0/6 (0%)	0/1 (0%)	0/14 (0%)	
First incidence (days)	_g`´	766	725	627	
Logistic regression test	P=0.388	P=0.488	P=0.473	P=0.491	•
Adenoma or Carcinoma					
Overall rate	19/60 (32%)	17/58 (29%)	18/57 (32%)	7/60 (12%)	
Adjusted rate	63.8%	81.1%	100.0%	31.6%	
Terminal rate	2/8 (25%)	4/6 (67%)	1/1 (100%)	3/14 (21%)	· . ·
First incidence (days)	528	562	-562-	627	-
Logistic regression test	P=0.005N	P=0.494N	P=0.487	P=0.006N	

<sup>a</sup> Number of animals with lesion

<sup>b</sup> Average severity grade of lesion in affected animals: 1=minimal; 2=mild; 3=moderate; 4=marked

<sup>c</sup> Number of animals with neoplasm per number of animals with pituitary gland examined microscopically

<sup>d</sup> Kaplan-Meier estimated neoplasm incidence at the end of the study after adjustment for intercurrent mortality

<sup>e</sup> Observed incidence in animals surviving until the end of the study

<sup>t</sup> In the control column are the P values associated with the trend test. In the exposure group columns are the P values corresponding to pairwise comparisons between the controls and that exposure group. The logistic regression test regards lesions in animals dying prior to terminal kill as nonfatal. A negative trend or a lower incidence in an exposure group is indicated by N.

<sup>g</sup> Not applicable; no neoplasm in animal group

#### **t-Butylhydroquinone**, NTP TR 459

*Kidney:* In the long-term study, there was a slight increase in the incidences of cysts and suppurative inflammation in the kidney of male rats (Tables 11 and A4). The development of a progressive nephropathy in aging F344/N rats (especially males) is well documented. A spectrum of morphological changes is identified as part of the nephropathy, including marked dilatation (cysts) of renal tubules and occasional suppurative inflammation within renal tubule lumina. In the present study, these changes were observed in kidneys of control and exposed animals with the most severe (moderate to marked) nephropathy. While this finding may suggest a slight exacerbation of the nephropathy by *t*-butylhydroquinone, the nephropathy severity grades in the controls and in the 5,000 ppm males were not markedly different (Table 11). It is not clear whether *t*-butylhydroquinone exposure contributed to these marginal increases. Additionally, the incidence and severity of renal mineralization were slightly decreased in males and females.

#### Table 11

Incidences of Nonneoplastic Lesions of the Kidney in Rats in the Long-Term Feed Study of *t*-Butylhydroquinone

	0 ppm		1,250 ppm		2,500 ppm		5,000	ppm
Male					<u>1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997</u>			
Number Examined Microscopically	60		60		58		60	
Cyst <sup>a</sup>	2	(3.0) <sup>b</sup>	3	(3.0)	7*	(2.9)	11**	(3.0)
Inflammation, Suppurative	9	(1.0)	8	(1.0)	9	(1.3)	20*	(1.2)
Mineralization	12	(1.7)	3**	(2.3)	2**	(2.0)	1**	(1.0)
Nephropathy	60	(2.6)	60	(2.6)	58	(2.4)	60	(2.8)
Transitional Epithelium,		• •		. ,		• •		
Hyperplasia	13	(1.4)	12	(1.6)	11	(2.3)	21	(1.5)
Female								
Number Examined Microscopically	60		60		57		60	
Cyst	0		1	(4.0)	0		2	(3.0)
Inflammation, Suppurative	2	(2.0)	1	(1.0)	0		0	-
Mineralization	57	(2.4)	56	(2.4)	44*	(2.0)	48*	(1.6)
Nephropathy	37	(1.7)	38	(1.8)	37	(1.6)	39	(1.8)

\* Significantly different ( $P \le 0.05$ ) from the control group by the logistic regression test

\*\* P≤0.01

<sup>a</sup> Number of animals with lesion

<sup>b</sup> Average severity grade in affected animals: 1=minimal; 2=mild; 3=moderate; 4=marked

*Nose:* At the 3-month interim evaluation, goblet cell hyperplasia occurred in the nose of male rats exposed to 5,000 ppm (Tables 12 and A4). This lesion was observed in one exposed female at 3 months (Table B4), and was morphologically similar to the lesion (epithelial hyperplasia) in rats exposed to *t*-butylhydroquinone for 13 weeks (Table 3). Incidences of goblet cell hyperplasia were not significantly increased in males at the end of the study (Tables 12 and A4). The increased incidences at earlier time points may have resulted from direct contact of the chemical with the nasal mucosa during feeding.

Spleen: The incidences of splenic pigmentation (hemosiderin) were increased in exposed groups of males and females at the 3-month interim evaluation (Tables 12, A4, and B4) and the severity increased

with increasing exposure concentrations in females. This finding is similar to results from the 13-week study (Table 3). Increased incidences of pigmentation (hemosiderin, confirmed with Prussian Blue stain) were also observed in exposed groups of females at the end of the study (Tables 12 and B4), while the incidence and severity of pigmentation in exposed groups of males were similar to those of the controls (Table A4). Although the incidence differences between the female control group and the exposed female groups at the end of the long-term study were slight, the change was consistently observed at earlier time points (3-month interim evaluation and 13-week study) as well. As at earlier time points, however, other changes corroborating an anemia were not observed. The pathogenesis of this change remains uncertain, and the biological significance was considered minimal.

#### TABLE 12

Incidences of Nonneoplastic Lesions of the Nose and Spleen of Rats in the Long-Term Feed Study of *t*-Butylhydroquinone

	0 p	pm	1,250	ppm	2,500	ppm	5,000	ppm
Male						·		
3-Month Interim Evaluation								
Nose <sup>a</sup>	10		10		10		10	
Goblet Cell Hyperplasia <sup>b</sup>	0		0		0			(1.0) <sup>c</sup>
Spleen	10		10		10		10	
Pigmentation, Hemosiderin	0		0		3	(1.0)	5*	(1.0)
Long-Term Study								
Nose	60		60		58		60	
Goblet Cell Hyperplasia	5	(1.2)	3	(1.3)	9	(1.1)	13	(1.1)
Female		·						
3-Month Interim Evaluation								
Spleen	10		10		10		10	
Pigmentation, Hemosiderin	5	(1.2)	7	(1.4)	8	(1.3)	10*	(1.8)
Long-Term Study						·		
Spleen	60		60		57		60	
Pigmentation, Hemosiderin	24	(2.4)	27	(2.5)	33	(2.4)		(2.4)

\* Significantly different ( $P \le 0.05$ ) from the control group by the Fisher exact test

\*\* Significantly different (P≤0.01) from the control group by the Fisher exact test (3-month interim evaluation) or the logistic regression test (long-term study)

<sup>a</sup> Number of animals with organ examined microscopically

<sup>b</sup> Number of animals with lesion

<sup>c</sup> Average severity grade in affected animals: 1=minimal; 2=mild; 3=moderate; 4=marked

#### 8-Butylhydroquinone, NTP TR 459

*Other Organs:* There were a number of decreased incidences of nonneoplastic lesions in various organs of male and female rats. In male rats, decreased incidences included: adrenal medulla, hyperplasia (0 ppm, 26/60; 1,250 ppm, 22/60; 2,500 ppm, 15/58; 5,000 ppm, 12/60; Table A4); liver, cystic degeneration (23/60, 16/60, 11/58, 5/60; Table A4); liver, bile duct hyperplasia (52/60, 49/60, 43/58, 25/60; Table A4); preputial gland, chronic inflammation (26/60, 16/60, 18/58, 12/60; Table A4); and prostate gland, inflammation (36/60, 39/60, 40/58, 23/60;

Table A4). In exposed groups of females, the incidence of hepatocellular cytoplasmic vacuolization was decreased (14/60, 14/60, 9/58, 3/50; Table B4). In general, these nonneoplastic lesions often occur spontaneously and usually represent relatively insignificant changes within the individual organs or tissues. While the potential contribution of *t*-butyl-hydroquinone and/or body weight reductions as causal factors of these effects remains undetermined, the biological importance of the decreases are considered minimal.

# MICE 13-WEEK STUDY

One female in each of the 10,000 and 40,000 ppm groups died before the end of the study, but the deaths were not considered to be related to t-butylhydroquinone exposure (Table 13). Final mean body weights and body weight gains of male and female mice in the 10,000, 20,000, and 40,000 ppm groups were significantly lower than those of the control groups. Feed consumption by exposed groups appeared to be similar to that by controls, but there was excessive scatter of feed by mice in the 10,000, 20,000, and 40,000 ppm groups. Therefore, it is likely that feed consumption by male and female mice in these groups was less than that by controls. Dietary levels of 2,500, 5,000, 10,000, 20,000, and 40,000 ppm delivered daily doses of approximately 440, 880, 1,950, 4,000, and 8,400 mg *t*-butylhydro-quinone/kg body weight to males and 500, 1,100, 2,200, 4,600, and 9,000 mg/kg to females. Clinical observations of alopecia and hair discoloration were attributed to exposure to *t*-butylhydroquinone; because of feed spillage, these observations might have been due to dermal exposure to *t*-butylhydroquinone.

#### TABLE 13

Survival, Mean Body Weights, and Feed Consumption of Mice in the 13-Week Feed Study of *t*-Butylhydroquinone

		Mear	1 Body Weight <sup>b</sup> (g)	. I	Final Weight Relative	Feed			
Dose	Survival <sup>a</sup>	Initial	Final	Change	to Controls		nption <sup>c</sup>		
(ppm)				•	(%)	Week 2	Week 13		
fale		·····			•				
0	10/10	$23.1 \pm 0.3$	$32.4 \pm 1.6$	9.4 ± 1.7		5.0	4.5		
2,500	10/10	$23.0 \pm 0.4$	$32.4 \pm 0.7$	$9.4 \pm 0.5$	100	5.2	4.6		
5,000	10/10	$22.7 \pm 0.3$	$31.6 \pm 0.5$	8.9 ± 0.4	97	6.0	4.3		
10,000	10/10	$23.4 \pm 0.3$	$29.5 \pm 0.4*$	6.0 ± 0.2*	* 91	6.3	4.4		
20,000	10/10	$22.9 \pm 0.3$	$26.6 \pm 0.4 **$	3.7 ± 0.2*	* 82	8.0	3.8		
40,000	10/10	$22.4 \pm 0.2$	22.9 ± 0.5**	$0.6 \pm 0.6*$	* 71	6.4	4.3		
'emale									
0	10/10	$18.3 \pm 0.4$	$29.5 \pm 0.6$	$11.2 \pm 0.4$		5.8	4.2		
2,500	10/10	$17.7 \pm 0.4$	$28.7 \pm 0.6$	$11.0 \pm 0.6$	97	6.7	4.7		
5,000	10/10	$17.5 \pm 0.4$	$28.3 \pm 0.8$	$10.7 \pm 1.0$	96	6.6	4.4		
10,000	9/10 <sup>d</sup>	$17.6 \pm 0.1$	$24.0 \pm 0.4 **$	$6.3 \pm 0.4*$	* 81	6.5	3.9		
20,000	10/10	$17.5 \pm 0.5$	$21.6 \pm 0.4^{**}$	$4.1 \pm 0.5^{*}$	* 73	7.4	3.8		
40,000	9/10 <sup>e</sup>	$17.8 \pm 0.2$	19.8 ± 0.5**	$2.0 \pm 0.4^{*}$	* 67	6.0	4.6		

\* Significantly different (P≤0.05) from the control group by Williams' or Dunnett's test.

\*\* P≤0.01

<sup>a</sup> Number of animals surviving/number initially in group

b Weights and weight changes are given as mean ± standard error. Subsequent calculations are based on animals surviving to the end of the study.

<sup>c</sup> Feed consumption is expressed as grams of feed consumed per animal per day.

d Week of death: 8 (accidental death)

e Week of death: 4 (accidental death)

Significant increases in segmented neutrophil counts occurred at week 3 and at the end of the study in the 20,000 and 40,000 ppm groups of males and females and in the 10,000 ppm female group (Table G3); this was the only clinical pathology change that was related to chemical exposure. Other clinical pathology changes were attributed to dehydration from weight loss or were considered to be otherwise unrelated. There were no biologically significant differences in organ weights (Table F3).

Left caudal, left epididymis, and left testis weights of males exposed to 10,000 or 40,000 ppm were generally significantly lower than those of the controls (Table H4). The estrous cycle of females exposed to 40,000 ppm was significantly longer than that of the controls. Additionally, no lesions were observed in the reproductive system of exposed groups of mice; thus, differences in reproductive parameters were considered to be secondary to body weight changes.

Increased incidences of mucosal hyperplasia were observed in the forestomach of male mice exposed to 20,000 or 40,000 ppm and in female mice exposed to 10,000, 20,000, or 40,000. The severity of this lesion also increased with increasing exposure concentration (Table 14). This change was characterized by a slight focal to multifocal increased thickness of the squamous epithelium of the forestomach. Probable contributors to this effect include chemical irritation and reduced mechanical action of feed in the forestomach due to decreased feed consumption in the 10,000, 20,000, and 40,000 ppm groups. Increased incidences of inflammation occurred in the nose and skin of males and females exposed to 10,000, 20,000, or 40,000 ppm (Table 14). Nasal changes involved all areas of the nasal cavity and consisted of suppurative inflammation with serous exudation. Changes in the skin included a minimal to mild chronic inflammation and increased thickening of the epithelium (hyperplasia), including the keratin layer. Both nasal (inhalation or aspiration) and skin (contamination of bedding from feed spillage) lesions were likely associated with an irritant effect of t-butylhydroquinone.

Dose Selection Rationale: Based on lower final mean body weights, increased incidences of inflammation of the nose and skin, increased incidences of forestomach mucosal hyperplasia, and increased severity of nonneoplastic lesions observed in mice exposed to 10,000, 20,000, or 40,000 ppm, exposure concentrations selected for the 2-year study were 1,250, 2,500, and 5,000 ppm.

# TABLE 14 Incidences of Selected Nonneoplastic Lesions in Mice in the 13-Week Feed Study of *t*-Butylhydroquinone

	0 p	opm	2,50	0 ppm	5,00	0 ppm	10,00	0 ppm	20,00	0 ppm	40,00	) ppm
		× .							•		- **	
Male	10		10		10		10		10		10	
Nose <sup>a</sup>	10 0		10 0	1	10 0		10 6**	(1.3) <sup>c</sup>	10	(2.1)		(2.6)
Inflammation, Suppurative <sup>b</sup>	U		U		v		ų. v	(1.5)	10	(2.1)	10.1	(2.0)
Forestomach	10		10	· ·	10		10	·	10		10	
Mucosal Hyperplasia	6	(1.0)	10 6	(1.3)	10 7	(1.6)	5	(1.6)	10*	(2.2)	10*	(2.5)
· · · ·												
Skin	10		10		10	1 - A	10		10		10	
Inflammation, Chronic	0		0	•	0			(1.5)		(1.8)		(1.9)
Epithelial Hyperplasia	0		. 0		0		8**	(1.0)	10**	(1.4)	10**	(2.0)
•												
Female												
Nose	10		10		10		10		10		10	
Inflammation, Suppurative	0		0	<i></i>	0		10**	(1.8)	10**	(2.1)	10**	(3.0)
	40		10		••		10	<i>.</i>	10		10	
Forestomach	10	(1.0)	10	(1.0)	10	(1.0)	10 9**	( <b>A A</b> )	10 8**	00	10	(2 M)
Mucosal Hyperplasia	3.	(1.0)	• 4	(1.0)	6	(1.3)	9++	(2.0)	8++	(2.6)	10++	(2.9)
Skin	10		10		10		10		10		10	
Inflammation, Chronic	1	(1.0)	1	(1.0)	5	(1.0)	8**	(1.4)		(1.9)		(2.0)
Epithelial Hyperplasia	Ō	()	1	(1.0)	2	(1.0)	8**	(1.0)		(1.7)	10**	
			-	. ,				. ,				

С

\* Significantly different (P $\leq$ 0.05) from the control group by the Fisher exact test \*\* P $\leq$ 0.01

<sup>a</sup> Number of animals with organ examined microscopically

b Number of animals with lesion

С Average severity grade of lesions in affected mice: 1=minimal; 2=mild; 3=moderate; 4=marked

## 2-Year Study

#### Survival

Estimates of 2-year survival probabilities for male and female mice are shown in Table 15 and in the Kaplan-Meier survival curves (Figure 3). Survival of males and females in all exposed groups was similar to that of the control groups.

# Body Weights, Feed and Compound Consumption, and Clinical Findings

Mean body weights of males and females in the 5,000 ppm groups were generally lower than those of the controls from week 13 until the end of the study (Figure 4 and Tables 16 and 17). Feed consumption by exposed groups of males and females was

generally similar to that by controls (Tables J3 and J4). Dietary levels of 1,250, 2,500, or 5,000 ppm *t*-butylhydroquinone resulted in daily doses of approximately 150, 300, or 600 mg/kg body weight (males) or 150, 300, or 700 mg/kg (females). There were no clinical findings in exposed groups of male or female mice considered to be related to chemical exposure.

#### Hematology

The reticulocyte count in males in the 5,000 ppm group was greater than that in the control group (Table G3). There were no other biologically significant differences in hematology parameters between control and exposed groups of mice.

#### Table 15

Survival of Mice in the 2-Year Feed Study of t-Butylhydroquinone

	0 ppm	1 <b>,250 ppm</b>	2,500 ppm	5,000 ppm
Male			· ·	
Animals initially in study	60	60	60	60
15-Month interim evaluation <sup>a</sup>	10	10	9	9
Accidental death <sup>a</sup>	1	0	0	0
Moribund	6	3	7	7
Natural deaths	4	1	6	2
Animals surviving to study termination	39	46	38	42
Percent probability of survival at the end of the study <sup>b</sup>	80	92	75	82
Mean survival (days) <sup>c</sup>	711	721	700	701
Survival analysis <sup>d</sup>	P=0.780	P=0.143N	P=0.644	P=1.000N
Female				
Animals initially in study	60	60	60	60
15-Month interim evaluation <sup>a</sup>	9	8	9	6
Moribund	11	7	6	6
Natural deaths	2	10	5	5
Animals surviving to study termination	38 <sup>e</sup>	35	40	43 <sup>e</sup>
Percent probability of survival at the end of the study	75	67	78	80
Mean survival (days)	699	689	706	695
Survival analysis	P=0.348N	P=0.571	P=0.767N	P=0.663N

<sup>a</sup> Censored from survival analyses

<sup>b</sup> Kaplan-Meier determinations

<sup>c</sup> Mean of all deaths (censored, uncensored, and terminal sacrifice)

<sup>d</sup> The result of the life table trend test (Tarone, 1975) is in the control column, and the results of the life table pairwise comparisons

(Cox, 1972) with the controls are in the exposed columns. A negative trend or a lower mortality in an exposure group is indicated by N.

<sup>e</sup> Includes one animal that died during the last week of the study





Kaplan-Meier Survival Curves for Male and Female Mice Administered t-Butylhydroquinone in Feed for 2 Years



FIGURE 4

Growth Curves for Male and Female Mice Administered *t*-Butylhydroquinone in Feed for 2 Years

.

54

Mean Body Weights and Survival of Male Mice in the 2-Year Feed Study of t-Butylhydroquinone

Weeks	0			1.250 ppm		2,500 ppm				5.000 p	pm
on .	Av. Wt.	No. of	Av. Wt.	Wt. (% of	No. of	Av. Wt.	Wt. (% of	No. of	Av. Wt.	Wt. (% of	No. of
Study ,	(g)	Survivors	(g)	controls)	Survivors	(g)	controls)	Survivors	(g)	controls)	Survivors
1	23.7	60	23.5	99	60	23.4	99	60	23.0	97	60
2	25.4	60	25.3	100	60	25.3	100	60	24.7	97	60
3	26.7	60	26.3	99	60	26.3	99 :	. 60	25.8	97	60
5	28.4	60	28.0	99	60	28.2	. 99	60	27.5	· 97	60
6	30.0	60	29.6	99	60	29.7	. 99	60	29.2	97	60
7	31.1	· 60	30.7	99	60	30.3	97	60	29.8	96	60
8	31.3	60	31.0	99	60	30.7	98	60	30.0	- 96	60
9	32.3	60	32.1	99	60	31.7	98	60	30.5	94	60
10	33.1	60	32.9	99	60	32.8	. 99	60	30.8	93	60
11	34.2	60	33.6	98	60	33.4	98	<b>60</b>	31.9	93	60
12	35.4	60	34.2	97	60	34.5	<b>98</b> ·	60	32.8	. 93	60
13	36.6	60	35.6	97 :	60	35.2	96	60	33.4	91	60
17	38.8	60	38.3	99	60	38.0	98	60	35.4	91	60
21	39.4	60	39.6	101	60	39.2	100	60	36.7	93	60
25	41.9	60	41.3	99	60	40.9	98	60	38.3	91	60
29	44.4	60	43.3	98	60	43.1	97	60	40.2	91	
33	44.9	60	44.4	99	60	44.2	98	60	40.9	91	59
37	45.0	60	43.9	98	60	43.6	97	60	40.6	90	59
41	46.1	60	44.9	97	60	45.0	98	60	41.2	89	59
45	48.1	60	46.5	97	60	46.5	97	60	43.4	90	59
49	49.7	60	48.8	98	60	48.6	98	60	45.8	92	59
53	50.8	60	49.3	97	60	49.2	97	60	46.3	. 91	59
57	51.1	60	50.0	98 .	60	49.8	98	60	47.5	93	59
61	51.5	60	50.0	97	60	49.6	96	59	47.3	92	59
65	51.5	60	49.8	97	60	49.2	96	59	46.9	91	59
69 <sup>a</sup>	51.9	50	49.9	96	50	49.7	96	50	47.4	.91	50
73	51.8	50	49.8	96	50	49.8	96	50	47.6	92	50
77	52.7	50	51.0	97	50	50.3	95.	49	48.4	92	50
81	52.6	49	51.0	97	50	50.2	95	47	48.1	91	50
85	52.4	49	50.8	97	50	50.5		47	47.4	91	49
89	52.6	47	50.5	96	49	50.3	· 96	46	47.8	· 91	46
93	51.4	46	50.0	90 97	48	49.1	96:	46	48.0	93	44
97 97	51.4	43	49.6	97	47	49.4	96	41	47.3	92	44
101	49.9	41	48.2	97	47	49.4	99 ·		47.8	96	42
		41	. 40.2	91	47	43.4	<b>33</b> *	- 40	47.0	<b>90</b>	42
<b>Mean for</b> 1-13	weeks 30.7		20.2	98		30.1	98		29.1	95	
1-13 14-52	44.3		30.2 43.4			30.1 43.2			29.1 40.3	93 91	
				98 97			98 06			91 92	
53-101	51.7		50.0	97		49.7	96		47.5	92	· .

,

• •

<sup>a</sup> Interim evaluation occurred during week 66.

# e-Butylhydroquinone, NTP TR 459

# Table 17

Mean Body Weights and Survival of Female Mice in the 2-Year Feed Study of t-Butylhydroquimone

Weeks	0		1.250 ppm		2.500 0000		5.000 ppm				
on	Av. Wt.	No. of	Av. Wt.	Wt. (% o	No. of	Av. Wt.	Wt. (% o	f No. of	Av. Wt.	Wt. (% of	No. of
Study	(g)	Survivors	(g)	controls)	Survivors	(g)		Survivors	(g)	controls)	Survivors
1	17.7	60	17.9	101	60	17.8	101	60	17.8	101	60
2	20.1	60	20.4	102	60	20.2	101	60	20.1	100	60
3	21.5	60	21.6	101	60	21.3	99	60	20.9	97	60
4	22.8	60	23.1	101	60	22.9	100	60	22.6	99	60
5	24.0	60	24.1	100	60	23.9	100	60	23.7	99	60
6	24.9	60	25.2	101	60	25.0	100	60	24.5	98	60
7	26.0	60	26.3	101	60	26.2	101	60	25.2	97	60
8	27.4	60	27.7	101	60	27.4	100	60	26.1	95	60
9	27.9	60	27.9	100	60	27.5	99	60	26.6	95	60
10	28.3	60	28.5	101	60	28.0	99	60	26.7	94	60
11	28.9	60	29.3	101	60	28.8	100	60	27.5	95	60
12	30.3	60	30.5	101	60	30.0	99	60	28.3	93	60
13	30.9	60	30.9	100	60	30.3	98	60	28.7	93	59
17	33.9	60	34.9	103	60	34.1	101	60	31.8	94	59
21	36.0	60	36.2	101	60	35.6	99	60	33.6	93	59
25	37.1	60	37.1	100	60	35.6	96	60	32.8	88	59
29	38.5	60	39.2	102	60	38.0	99	60	35.1	91	59
33	39.9	60	40.8	102	60	39.8	100	60	36.7	92	59
37	39.9	60	40.8	102	60	39.9	100	· 60	36.5	92	59
41	41.5	60	42.1	101	60	41.2	99	60	37.7	91	59
45	43.2	60	44.3	103	60	43.4	101	59	39.0	90	58
49	46.4	60	47.6	103	60	46.5	100	59	41.9	90	58
53	48.5	59	49.5	102	59	48.7	100	59	43.5	90	58
57	50.2	59	51.4	102	59	50.5	101	59	44.9	89	58
61	51.3	59	52.9	102	58	51.6	101	59	45.6	89	57
65	52.3	59	53.2	102	58	51.0	99	59	46.6	89	56
69 <sup>a</sup>	52.6	49	53.7	102	49	52.7	100	49	46.8	89	50
73	53.9	49	55.4	102	47	54.3	100	49	47.9	89	50
77	55.4	49	56.0	103	47	54.9	99	49	47.9	87	50
81	55.5	48	56.8	101	46	55.1	99 99	47	48.5	88	49
85	56.2	46	56.9	102	40	55.7	99 99	47	49.0	88	49
89	56.0	40	57.8	101	44	55.5	99 99	46	49.0	89	49
93	56.1	42	57.8 57.9	103	44	55.7	99 99	40 46	49.7 49.6	88	49
93 97	55.1	42	57.9 57.0	103	42 40	55.7 54.7	99 99	40 44	49.0 49.0	89	48 48
101	54.5	39	55.8	103	40 39	54.7 54.2	99 99	44	49.0 48.6	89 89	40 47
Mean for	weeks								•	•	
1-13	25.4		25.6	101		25.3	100		24.5	96	
14-52	23.4 39.6		40.3	101		25.5 39.3	99		24.5 36.1	90	
53-101	53.7		40.3 54.9	102		53.5	100		30.1 47.6	89	
55-101		•	34.9	102		55.5	100		47.0	07	

<sup>a</sup> Interim evaluation occurred during week 66.

,\*

#### Pathology and Statistical Analyses

This section describes the statistically significant or biologically noteworthy changes in the incidences of neoplasms and/or nonneoplastic lesions of the liver and thyroid gland. Summaries of the incidences of neoplasms and nonneoplastic lesions, individual animal tumor diagnoses, statistical analyses of primary neoplasms that occurred with an incidence of at least 5% in at least one animal group, and historical incidences for the neoplasms mentioned in this section are presented in Appendix C for male mice and Appendix D for female mice.

Liver: The absolute liver weights of all exposed groups of males were greater than that of the controls (Table F4), although the differences were not statistically significant. Absolute liver weights of exposed groups of females were similar to that of the controls. The incidences of hepatocellular adenoma and hepatocellular adenoma or carcinoma (combined) in females administered 1,250 ppm were significantly greater than those in the control group (Tables 18 and D3), although the incidence of hepatocellular neoplasms occurred with a significant negative trend. Incidences of hepatocellular neoplasms in exposed groups of males generally decreased with increasing exposure concentration (Tables 18 and C3). The incidences of hepatocellular adenoma or carcinoma (combined) in control and exposed groups of males and females

were within the historical control range for mice from NTP 2-year feed studies (males, 10%-68%; females, 3%-56%; Tables 18, C4a, and D4a). Incidences of nonneoplastic lesions of the liver observed in exposed groups of males and females were similar to the incidences observed in the control groups (Tables 18, C5 and D5). There is a high rate of spontaneously occurring liver neoplasms in mice (particularly in males), and a positive correlation with body weights has been demonstrated (Seilkop, 1995).

The incidences of follicular cell Thyroid gland: adenoma in exposed groups of females were greater than that in the controls (0 ppm, 1/51; 1,250 ppm, 3/51; 2,500 ppm, 2/50; 5,000 ppm, 5/54; Table D3); however, the differences were not statistically significant, and the incidences did not exceed the historical control range for 2-year NTP feed studies (0% to 9%; Table D4b). Incidences of follicular cell hyperplasia in exposed groups of females were greater than those in controls at the end of the 2-year study (12/51, 19/51, 24/50, 24/54; Table D5), although, the severity of the hyperplasia in exposed groups was similar to that in the controls. This lesion was not observed at the 15-month interim evaluation. Additionally, significant increases of thyroid follicular cell proliferative lesions did not occur in female mice at the end of the 2-year study. Therefore, these marginal increases were not considered related to *t*-butylhydroquinone exposure.

# e-Butylhydroquinone, NTP TR 459

# TABLE 18

Incidences of Hepatocellular Neoplasms in Mice in the 2-Year Feed Study of &-Butylhydroquinone

-

	0 ppm	1,250 ppm	2,500 ppm	5,000 ppm	
Male	· · · · · · · · · · · · · · · · · · ·		· · · · · · · · · · · · · · · · · · ·	· · ·	
15-Month Interim Evalu		1	1		
Adenoma	uricion			,	
Overall rate <sup>a</sup>	1/10 (10%)	1/10/10//>	1/9 (11%)	0/0 (0%)	
Overall rate	1/10(10%)	1/10 (10%)	1/9 (1170)	0/9 (0%)	
Carcinoma					
Overall rate	0/10 (0%)	0/10 (0%)	0/9 (0%)	1/9 (11%)	
	0,10 (0,0)	_ 0/ 10 (0 <i>1</i> 0)	0/2 (0/0)		
2-Year Study	,				
Number Examined Microsc	opically 50	50	51	51	
Basophilic Focus <sup>b</sup>	3	2	2	5	
Clear Cell Focus	6	7	7	4	
Eosinophilic Focus	8	5	5	4	
Mixed Cell Focus	5	8	4	7	
Adenoma					
Overall rate	28/50 (56%)	22/50 (44%)	22/51 (43%)	14/51 (27%)	
Adjusted rate <sup>c</sup>	60.6%	47.8%	53.2%	31.7%	
Terminal rate <sup>d</sup>	21/39 (54%)	22/46 (48%)	19/38 (50%)	12/42 (29%)	
First incidence (days)		727 (T)	409	630	
Logistic regression te		P=0.144N	P=0.147N	P=0.004N	
Carcinoma				,	
Overall rate	8/50 (16%)	11/50 (22%)	12/51 (24%)	8/51 (16%)	
Adjusted rate	19.1%	22.8%	26.0%	17.6%	
Terminal rate	6/39 (15%)	9/46 (20%)	6/38 (16%)	5/42 (12%)	
First incidence (days)		619	409	615	
Logistic regression te	est P=0.370N	P=0.248	P=0.342	P=0.585N	•
Adenoma or Carcinoma	r.				
Overall rate	31/50 (62%)	28/50 (56%)	29/51 (57%)	17/51 (33%)	
Adjusted rate	65.8%	58.3%	63.8%	37.7%	
Terminal rate	23/39 (59%)	26/46 (57%)	22/38 (58%)	14/42 (33%)	
First incidence (days)		619	409	615	
Logistic regression te	•	P=0.369N	P=0.341N	P=0.004N	

. . •

#### TABLE 18

Incidences of Hepatocellular Neoplasms in Mice in the 2-Year Feed Study of t-Butylhydroquinone (continued)

	0 ppm	1,250 ppm	2,500 ppm	5,000 ppm	
	· · · ·				,
Female	· .	,			
15-Month Interim Evaluation				•	
Adenoma		1. State 1.	·		· . ·
Overall rate	0/9 (0%)	0/8 (0%)	1/9 (11%)	0/6 (0%)	
Carcinoma	•	•	an a		* .
Overall rate	0/9 (0%)	1/8 (13%)	0/9 (0%)	0/6 (0%)	
· ·					
2-Year Study					
Number Examined Microscopically	51	52	51	54	
Basophilic Focus	2	1	1	Ó	· · ·
Clear Cell Focus	0	0	2	2	
Eosinophilic Focus	7	14	10	12	1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
Mixed Cell Focus	1	3	2	1	
Adenoma					
Overall rate	9/51 (18%)	20/52 (38%)	16/51 (31%)	5/54 (9%)	• .
Adjusted rate	22.7%	51.0%	37.1%	11.6%	
Terminal rate	8/38 (21%)	16/35 (46%)	13/40 (33%)	5/43 (12%)	
First incidence (days)	582	598	555	734 (T)	
Logistic regression test	P=0.027N	P=0.011	P=0.096	P=0.146N	
Carcinoma					
Overall rate	8/51 (16%)	8/52 (15%)	8/51 (16%)	5/54 (9%)	1
Adjusted rate	18.4%	19.2%	17.6%	11.6%	
Terminal rate	4/38 (11%)	4/35 (11%)	4/40 (10%)	5/43 (12%)	
First incidence (days)	461	469	548	734 (T)	•
Logistic regression test	P=0.357N	P=0.559N	P=0.592	P=0.240N	
Adenoma or Carcinoma <sup>g</sup>				•	
Overall rate	17/51 (33%)	28/52 (54%)	23/51 (45%)	10/54 (19%)	
Adjusted rate	38.9%	64.7%	48.8%	23.3%	
Terminal rate	12/38 (32%)	20/35 (57%)	16/40 (40%)	10/43 (23%)	
First incidence (days)	461	469	548	734 (T)	
Logistic regression test	P=0.010N	P=0.025	P=0.155	P=0.064N	

(T) Terminal sacrifice

<sup>a</sup> Number of animals with neoplasm per number of animals with liver examined microscopically

<sup>b</sup> Number of animals with lesion

<sup>c</sup> Kaplan-Meier estimated neoplasm incidence at the end of the study after adjustment for intercurrent mortality

<sup>d</sup> Observed incidence in animals surviving until the end of the study

<sup>e</sup> In the control column are the P values associated with the trend test. In the exposure group columns are the P values corresponding to pairwise comparisons between the controls and that exposure group. The logistic regression test regards lesions in animals dying prior to terminal kill as nonfatal. A negative trend or a lower incidence in an exposure group is indicated by N.

f Historical incidence for 2-year NTP feed studies with untreated control groups (mean ± standard deviation): 509/1,316

 $(38.7\% \pm 13.9\%)$ ; range, 10%-68% g Historical incidence: 260/1,312 (19.8% ± 12.8%); range, 3%-56%

# GENETIC TOXICOLOGY

t-Butylhydroquinone (3 to 3,333  $\mu$ g/plate) was tested for induction of mutations in Salmonella typhimurium strains TA97, TA98, TA100, and TA102 with and without induced rat or hamster liver S9 (Zeiger et al., 1992; Table E1). No mutagenicity was detected in any of the strain/activation combinations. No induction of sister chromatid exchanges (Table E2) or chromosomal aberrations (Table E3) was noted in cultured Chinese hamster ovary cells treated with *t*-butylhydroquinone in the absence of S9 activation. However, in the presence of S9, positive dose-related responses were obtained in both these *in vitro* cytogenetic assays. The response obtained in the chromosomal aberrations test was particularly strong, and up to 90% of treated cells showed multiple chromosomal aberrations at the higher doses (200 to 249  $\mu$ g/mL). These positive results in cultured Chinese hamster ovary cells may have resulted from the generation of superoxide and H<sub>2</sub>O<sub>2</sub> within the cell from the autooxidation of t-butylhydroquinone to t-butylquinone and the further generation of oxidative byproducts, thereby indirectly producing chromosome breakage (Phillips *et al.*, 1989). In contrast to the positive results obtained in the *in vitro* assays for chromosome damage, results of an *in vivo* bone marrow micronucleus test were clearly negative (Table E4). No significant increase in the number of micronucleated erythrocytes was observed in male mice treated with three intraperitoneal injections of up to 300 mg t-butylhydroquinone/kg body weight.

# DISCUSSION AND CONCLUSIONS

*t*-Butylhydroquinone, a white to light tan crystalline solid, is primarily used as an antioxidant in fats, oils, and foods containing high fat concentrations, and in a large number of cosmetic preparations (CIR, 1986).

t-Butylhydroquinone was nominated for toxicity and carcinogenicity testing by the Food and Drug Administration because of the potential for its increased use, its structural relationship to carcinogenic chemicals such as hydroquinone, butylated hydroxytoluene, and butylated hydroxyanisole, and because of the lack of adequate t-butylhydroquinone carcinogenicity studies. Toxicology and carcinogenicity studies were conducted in F344/N rats and B6C3F<sub>1</sub> mice. Mice were exposed to the chemical in the feed for 13 weeks or 2 years. In the 13-week and longterm rat studies, dams were exposed to t-butylhydroquinone in feed beginning 2 weeks prior to cohabitation through weaning. Following weaning, pups selected for study were given dosed feed for 13 weeks or for 127 weeks (males) or 133 weeks (females). The oral route of administration was used because human exposure to the food additive occurs predominantly via this route. In addition, perinatal exposure was studied because butylated hydroxytoluene (a structurally related chemical) induced hepatocellular neoplasms in rats exposed in this manner.

Three chemicals structurally related to *t*-butylhydroquinone (hydroquinone, butylated hydroxytoluene, and butylated hydroxyanisole) were found to be carcinogenic to rats and/or mice. Hydroquinone (25 or 50 mg/kg body weight) given by gavage for 2 years was carcinogenic to F344 rats, causing increased incidences of renal tubule cell adenomas in males and mononuclear cell leukemia in females. Hydroquinone (50 or 100 mg/kg) administered similarly was carcinogenic to female mice, causing an increased incidence of hepatocellular neoplasms (Kari *et al.*, 1992). Butylated hydroxytoluene administered in feed for up to 2 years at concentrations up to 10,000 ppm was not carcinogenic to rats and mice (NCI, 1979; Hirose *et al.*, 1981; Shirai *et al.*, 1982). However, in utero exposure to butylated hydroxytoluene induced hepatocellular neoplasms in rats (Olsen et al., 1983). Feeding butylated hydroxyanisole to male F344 rats at a concentration of 2% for 13 weeks caused proliferation of the forestomach epithelium, which was a reversible effect following removal of the chemical from their diet (Iverson, et al., 1985). Butylated hydroxyanisole administered in feed at concentrations of up to 2% for 2 years caused an increase in the incidence of squamous cell carcinoma of the forestomach in male and female F344 rats (Ito et al., 1982).

Exposure concentrations greater than 10,000 ppm were not used in the 13-week rat study because dams exposed to 20,000 or 40,000 ppm did not litter. The inability to litter was likely due to lower mean body weights of the dams. Additionally, the average number of surviving pups per litter was less in dams exposed to 10,000 ppm than in control dams, and pups born to dams exposed to 5,000 or 10,000 ppm had lower mean body weights than pups born to control dams. These results were similar to those observed in an earlier reproductive study that examined three generations of Sprague-Dawley rats exposed to 5,000 ppm t-butylhydroquinone in feed (Terhaar and Krasavage, 1968b; Krasavage and Terhaar, 1970; Krasavage, 1977). There was a slight increase in pup mortality and a decrease in feed consumption, with a subsequent decrease in the pup body weight.

All male and female  $F_1$  rats exposed to 0, 2,500, 5,000, or 10,000 ppm *t*-butylhydroquinone in feed for 13 weeks survived to the end of the study. Decreased feed consumption might account for lower mean body weight gains of male rats exposed to 10,000 ppm and lower final mean body weights of  $F_1$  male and female rats exposed to 5,000 or 10,000 ppm. As in the present 13-week study, Astill *et al.* (1975) reported that 10,000 ppm *t*-butylhydroquinone given to rats for 22 days caused a decrease in mean body weights, but had no effect on survival.

o.

At various time points there were increases in serum bile acid levels and serum alanine aminotransferase activity levels in male and female rats exposed to *t*-butylhydroquinone. Such increases are generally associated with liver toxicity. However, because the increases observed in these two parameters were marginal, and since histopathologic evaluation did not reveal any evidence of liver toxicity, these marginal increases were not considered to be biologically significant. No biologically significant changes in clinical chemistry parameters were observed in Sprague-Dawley rats exposed to 10,000 ppm *t*-butylhydroquinone in feed for 3 weeks or to 5,000 ppm *t*-butylhydroquinone in feed for 20 months (Terhaar and Krasavage, 1968a; Astill *et al.*, 1975).

The effect of t-butylhydroquinone on reproductive parameters in rats included significantly lower mean spermatid counts, spermatid heads per testis, and spermatid heads per gram of testis only in males exposed to 5,000 ppm (the mid-dose). The estrous cycles of females exposed to 2,500 or 5,000 ppm were significantly longer than that of the control. The number of females with estrous cycles that were of unclear duration or were longer than 12 days was increased in the 10,000 ppm group. Together, these data suggest that t-butylhydroquinone has an as yet undefined effect on the female reproductive system.

Histopathologic changes observed in rats exposed to 5,000 or 10,000 ppm t-butylhydroquinone in the 13-week study included increased incidences of nasal respiratory epithelial hyperplasia, nasal exudate (males only), splenic pigmentation, splenic atrophy of the red pulp (females only), and kidney mineralization (females only). Since there was no other evidence of anemia, the cause for the observed splenic changes is not clear. In previous studies, the noses of rats exposed to 5,000 ppm t-butylhydroquinone for as long as 20 months were not examined (Astill et al., 1975). However, the authors did examine the spleen and bone marrow in addition to other organs and did not find any chemical-related changes. Administration of hydroquinone (50 mg/kg body weight per day, 5 days per week, for 13 weeks) caused a regenerative anemia and myelotoxicity in female rats (NTP, 1989). Hydroquinone caused a decrease in hematocrit levels, hemoglobin concentrations, and erythrocyte counts.

In the 13-week mouse study, there were no chemicalrelated deaths. Although feed consumption data indicate that consumption by exposed groups was similar to that by control male and female mice, excessive scatter of feed by mice in the 10,000, 20,000, and 40,000 ppm groups was observed. This in turn may have contributed to the lower mean body weights of mice in these exposure groups.

The effect of *t*-butylhydroquinone on reproductive parameters in mice included generally lower caudal, epididymis, and testis weights in males exposed to 10,000 or 40,000 ppm than in controls. The estrous cycle of female mice exposed to 40,000 ppm was significantly longer than that of the controls. Reproductive organ weight and estrous cycle data were different only in exposure groups that had corresponding significantly lower mean body weights. Based on previous studies (Chapin *et al.*, 1993), the body weight differences can account for these reproductive effects. This is also supported by the lack of difference in spermatogenesis efficiency.

Chemical-related histopathologic effects were generally observed in the nose and skin (inflammation) and the forestomach (hyperplasia of mucosal epithelium) of 10,000, 20,000, and 40,000 ppm mice. The effects were attributed to the direct irritating action of t-butylhydroquinone on these tissues. Increased segmented neutrophil counts in these exposure groups may have been a response to these inflammatory effects. Proliferative forestomach lesions have not been reported in other studies of *t*-butylhydroquinone in mice. However, proliferative forestomach lesions have been reported in mice exposed to hydroquinone and rats exposed to t-butylhydroquinone and butylated hydroxyanisole. Epithelial hyperplasia of the forestomach occurred in mice dosed with 400 mg hydroquinone/kg body weight per day, 5 days per week for 13 weeks (NTP, 1989). Hyperplasia of the forestomach was reported in male F344 rats exposed to 2,000 ppm butylated hydroxyanisole (a structurally related chemical) in feed for 13 weeks (Iverson et al., 1985) and Fischer rats exposed to 1,000 ppm t-butylhydroquinone in feed for 28 days (Nera et al., 1984). Similar lesions were observed in Wistar rats exposed to 2,000 ppm t-butylhydroquinone in feed for 28 days (Altmann et al., 1985).

#### 8-Butylhydroquinone, NTP TR 459

Although hyperplasia of the pulmonary pneumocytes was observed in mice treated with butylated hydroxytoluene (a structurally related chemical) (Marino and Mitchell, 1972; Witschi and Saheb, 1974; Saheb and Witschi, 1975), no chemical-related lesions were observed in the lungs of rats or mice in the present 13-week studies. Mizutani et al. (1982) have demonstrated the possibility that phenolic antioxidants can only exert toxic effects if the hydroxyl group of the antioxidants is hindered by a methyl group at the 4-position and an ortho-alkyl group on the phenolic ring. Since t-butylhydroquinone does not have the methyl group at the 4-position, it would not be expected to undergo metabolic transformation to an active lung toxicant, which may explain the lack of lung lesions in the present studies.

Based on lower final mean body weights, increased incidences of inflammation of the nose and skin, increased incidences of forestomach epithelial hyperplasia, and increased severity of nonneoplastic lesions observed in mice exposed to 10,000, 20,000, or 40,000 ppm, the exposure concentrations selected for the 2-year mouse study were 1,250, 2,500, and 5,000 ppm.

In the long-term (rats) and 2-year (mice) studies, rats and mice were exposed to 1,250, 2,500, or 5,000 ppm *t*-butylhydroquinone in feed. Based on the lower mean body weights in male and female rats and mice exposed to 5,000 ppm and on the presence of chemical-related kidney lesions in rats, the doses selected for the long-term and 2-year studies were considered adequate for evaluating the carcinogenic potential of *t*-butylhydroquinone.

In the long-term rat study, *t*-butylhydroquinone was not carcinogenic to male or female rats exposed to 1,250, 2,500, or 5,000 ppm in feed, as evidenced by the absence of chemical-related increased neoplasm incidences at any site. However, the incidence of mammary gland neoplasms in exposed groups of male and female rats and of pituitary gland neoplasms in exposed groups of males were decreased. The decreased incidences of these neoplasms may be related to mean body weight decreases of exposed

â

groups of rats. This observation is supported by Seilkop (1995), who found positive relationships between body weight and pituitary gland neoplasms in male and female rats and mammary gland neoplasms in female rats.

Nonneoplastic lesions observed in male rats exposed to *t*-butylhydroquinone included increased incidences of cysts and suppurative inflammation in the kidney. These increased incidences in rats were probably related to *t*-butylhydroquinone exposure. Hydroquinone was nephrotoxic to rats administered 25 or 50 mg/kg body weight for up to 2 years; the chemical caused increased severities of nonneoplastic renal lesions in males and females and increased incidences of nonneoplastic cortical lesions in males (Kari *et al.*, 1992).

Mild regenerative anemia was observed in female rats administered 50 mg hydroquinone/kg body weight per day, 5 days per week for as long as 2 years. This anemia was characterized by decreases in hematocrit levels, hemoglobin concentrations, and erythrocyte counts (Kari, *et al.*, 1992).

In the 2-year mouse study, *t*-butylhydroquinone did not cause carcinogenic effects in male or female mice exposed to 1,250, 2,500, or 5,000 ppm, nor did the chemical cause increased incidences of nonneoplastic lesions.

#### CONCLUSIONS

Under the conditions of this long-term feed study, there was no evidence of carcinogenic activity\* of t-butylhydroquinone in male or female F344/N rats exposed to 1,250, 2,500, or 5,000 ppm. Under the conditions of this 2-year feed study, there was no evidence of carcinogenic activity of t-butylhydroquinone in male or female B6C3F<sub>1</sub> mice exposed to 1,250, 2,500, or 5,000 ppm.

Exposure of rats to *t*-butylhydroquinone in feed resulted in decreased incidences of mammary gland neoplasms in males and females.

3

<sup>\*</sup> Explanation of Levels of Evidence of Carcinogenic Activity is on page 9. A summary of the Technical Reports Review Subcommittee comments and the public discussion on this Technical Report appears on page 11.

## t-Butylhydroquinone, NTP TR 459

# REFERENCES

Altmann, H.J., Wester, P.W., Matthiaschk, G., Grunow, W., and Van der Heijden, C.A. (1985). Induction of early lesions in the forestomach of rats by 3-tert-butyl-4-hydroxyanisole (BHA). *Food Chem. Toxicol.* 23, 723-731.

Armitage, P. (1971). Statistical Methods in Medical Research, pp. 362-365. John Wiley and Sons, New York.

Armstrong, K.E., and Wattenberg, L.W. (1985). Metabolism of 3-*tert*-butyl-4-hydroxyanisole to 3-*tert*-butyl-4,5-dihydroxyanisole by rat liver microsome. *Cancer Res.* 45, 1507-1510.

Ashby, J., and Tennant, R.W. (1991). Definitive relationships among chemical structure, carcinogenicity, and mutagenicity for 301 chemicals tested by the U.S. NTP. *Mutat. Res.* 257, 229-306.

Astill, B.D., and Mulligan, L.T. (1977). Phenolic antioxidants and the inhibition of hepatotoxicity from *N*-dimethylnitrosamine formed *in situ* in the rat stomach. *Food Cosmet. Toxicol.* 15, 167-171.

Astill, B.D., and Roudabush, R.L. (1973). Monotertiary butyl hydroquinone (TBHQ): Biochemical behavior in rats, dogs and humans. *Fed. Proc.* 32, 734a.

Astill, B.D., Mills, J., Fassett, D.W., Roudabush, R.L., and Terhaar, C.J. (1962). Fate of butylated hydroxyanisole in man and dog. *Agric*. *Food Chem.* 10, 315-322.

Astill, B.D., Terhaar, C.J., Krasavage, W.J., Wolf, G.L., Roudabush, R.L., and Fassett, D.W. (1975). Safety evaluation and biochemical behavior of monotertiarybutylhydroquinone. J. Am. Oil Chem. Soc. 52, 53-58. Bergmann, B., Dohrmann, J.K., and Kahl, R. (1992). Formation of the semiquinone anion radical from *tert*-butylquinone and from *tert*-butylhydroquinone in rat liver microsome. *Toxicology* 74, 127-133.

Boehme, M.A., and Branen, A.L. (1977). Effects of food antioxidants on prostaglandin biosynthesis. J. Food Sci. 42, 1243-1246.

Bonin, A.M., and Baker, R.S.U. (1980). Mutagenicity testing of some approved food additives with the *Salmonella*/microsome assay. *Food Technol. Aust. U.A.* 32, 608-611.

Boorman, G.A., Montgomery, C.A., Jr., Eustis, S.L., Wolfe, M.J., McConnell, E.E., and Hardisty, J.F. (1985). Quality assurance in pathology for rodent carcinogenicity studies. In *Handbook of Carcinogen Testing* (H.A. Milman and E.K. Weisburger, Eds.), pp. 345-357. Noyes Publications, Park Ridge, NJ.

Burnett, C., Goldenthal, E.I., Harris, S.B., Wazeter, F.X., Strausburg, J., Kapp, R., and Voelker, R. (1976). Teratology and percutaneous toxicity studies on hair dyes. *J. Toxicol. Environ. Health* 1, 1027-1040.

Calnan, C.D. (1981). Monotertiary butyl hydroquinone in lipstick. *Contact Dermatitis* 7, 280-281.

Chapin, R.E., Gulati, D.K., Fail, P.A., Hope, E., Russell, S.R., Heindel, J.J., George, J.D., Grizzle, T.B., Teague, J.L. (1993). The effects of feed restriction on reproductive function in Swiss CD-1 mice. *Fundam. Appl. Toxicol.* 20, 15-22.

Code of Federal Regulations (CFR) 21, Part 58

Code of Federal Regulations (CFR) 21, § 172.185

Code of Federal Regulations (CFR) 21, § 177.2420

Cosmetic Ingredient Review (CIR) (1986). Final Report on the Safety Assessment of *t*-Butyl Hydroquinone. J. Am. Coll. Toxicol. 5, 329-351.

Cosmetic Ingredient Review (CIR) (1991). Final Report on the Safety Assessment of *t*-Butyl Hydroquinone. J. Am. Coll. Toxicol. 10, 1-7.

Cox, D.R. (1972). Regression models and life-tables. J. R. Stat. Soc. **B34**, 187-220.

Crawford, B.D. (1985). Perspectives on the somatic mutation model of carcinogenesis. In Advances in Modern Environmental Toxicology: Mechanisms and Toxicity of Chemical Carcinogens and Mutagens (M.A. Mehlman, W.G. Flamm, and R.J. Lorentzen, Eds.), pp. 13-59. Princeton Scientific Publishing Co. Inc., Princeton, NJ.

De Long, M.J., Prochaska, H.J., and Talalay, P. (1985). Tissue-specific induction patterns of cancerprotective enzymes in mice by *tert*-butyl-4-hydroxyanisole and related substituted phenols. *Cancer Res.* **45**, 546-551.

Dinse, G.E., and Haseman, J.K. (1986). Logistic regression analysis of incidental-tumor data from animal carcinogenicity experiments. *Fundam. Appl. Toxicol.* **6**, 44-52.

Dinse, G.E., and Lagakos, S.W. (1983). Regression analysis of tumor prevalence data. *Appl. Statist.* 32, 236-248.

Dixon, W.J., and Massey, F.J., Jr. (1951). Introduction to Statistical Analysis, 1st ed., pp. 145-147. McGraw-Hill Book Company, Inc., New York.

Dunn, O.J. (1964). Multiple comparisons using rank sums. *Technometrics* 6, 241-252.

Dunnett, C.W. (1955). A multiple comparison procedure for comparing several treatments with a control. J. Am. Stat. Assoc. 50, 1096-1121.

El-Rashidy, R., and Niazi, S. (1983). A new metabolite of butylated hydroxyanisole in man. *Biopharm. Drug Dispos.* 4, 389-396.

Epstein, S.S., Saporoschetz, I.B., and Hutner, S.H. (1967). Toxicity of antioxidants to *Tetrahymena pyriformis*. J. Protozool. 14, 238-244.

Flamm, W.G., Weisburger, E., Clayson, D., Witschi, H., Conning, D., and Kawachi, T. (1982). Report of the Working Group on the Toxicology and Metabolism of Antioxidants. Unpublished section of the Four Nation Working Group Report. Food and Drug Administration, Washington, DC.

Galloway, S.M., Armstrong, M.J., Reuben, C., Colman, S., Brown, B., Cannon, C., Bloom, A.D., Nakamura, F., Ahmed, M., Duk, S., Rimpo, J., Margolin, B.H., Resnick, M.A., Anderson, B., and Zeiger, E. (1987). Chromosome aberrations and sister chromatid exchanges in Chinese hamster ovary cells: Evaluations of 108 chemicals. *Environ. Mol. Mutagen.* **10** (Suppl. 10), 1-175.

Gart, J.J., Chu, K.C., and Tarone, R.E. (1979). Statistical issues in interpretation of chronic bioassay tests for carcinogenicity. *J. Natl. Cancer Inst.* **62**, 957-974.

Giri, A.K., Sen, S., Talukder, G., Sharma, A., and Banerjee, T.S. (1984). Mutachromosomal effects of *tert*-butylhydroquinone in bone-marrow cells of mice. *Food Chem. Toxicol.* **22**, 459-460.

Hageman, G.J., Verhage, H., and Kleinjans, J.C.S. (1988). Butylated hydroxyanisole, butylated hydroxy-toluene and *tert*-butylhydroquinone are not mutagenic in the Salmonella/microsome assay using new tester strains. *Mutat. Res.* 208, 207-211.

Hasegawa, R., Tiwawech, D., Hirose, M., Takaba, K., Hoshiya, T., Shirai, T., and Ito, N. (1992). Suppression of diethylnitrosamine-initiated preneoplastic foci development in the rat liver by combined administration of four antioxidants at low doses. *Jpn. J. Cancer Res.* **83**, 431-437.

#### t-Butylhydroquinone, NTP TR 459

Haseman, J.K. (1984). Statistical issues in the design, analysis and interpretation of animal carcinogenicity studies. *Environ. Health Perspect.* 58, 385-392.

Hirose, M., Shibata, M., Hagiwara, A., Imaida, K., and Ito, N. (1981). Chronic toxicity of butylated hydroxytoluene in Wistar rats. *Food Cosmet. Toxicol.* 19, 147-151.

Hirose, M., Masuda, A., Fukushima, S., and Ito, N. (1988). Effects of subsequent antioxidant treatment on 7,12-dimethylbenz[a]anthracene-initiated carcinogenesis of the mammary gland, ear duct and forestomach in Sprague-Dawley rats. *Carcinogenesis* 9, 101-104.

Hirose, M., Yada, H., Hakoi, K., Takahashi, S., and Ito, N. (1993). Modification of carcinogenesis by  $\alpha$ -tocopherol, t-butylhydroquinone, propyl gallate and butylated hydroxytoluene in a rat multi-organ carcinogenesis model. *Carcinogenesis* 14, 2359-2364.

Hollander, M., and Wolfe, D.A. (1973). Nonparametric Statistical Methods, pp. 120-123. John Wiley and Sons, New York.

Ito, N., Hagiwara, A., Shibata, M., Ogiso, T., and Fukushima, S. (1982). Induction of squamous cell carcinoma in the forestomach of F344 rats treated with butylated hydroxyanisole. *Gann* 73, 332-334.

Iverson, F., Lok, E., Nera, E., Karpinski, K., and Clayson, D.B. (1985). A 13-week feeding study of butylated hydroxyanisole: The subsequent regression of the induced lesions in male Fischer 344 rat forestomach epithelium. *Toxicology* 35, 1-11.

Jonckheere, A.R. (1954). A distribution-free k-sample test against ordered alternatives. Biometrika 41, 133-145.

Kaplan, E.L., and Meier, P. (1958). Nonparametric estimation from incomplete observations. J. Am. Stat. Assoc. 53, 457-481.

Kari, F.W., Bucher, J., Eustis, S.L., Haseman, J.K., and Huff, J.E. (1992). Toxicity and carcinogenicity of hydroquinone in F344/N rats and B6C3F<sub>1</sub> mice. *Food Chem. Toxicol.*, 30, 737-747. Kawabe, M., Takaba, K., Yoshida, Y., and Hirose, M. (1994). Effects of combined treatment with phenolic compounds and sodium nitrite on two-stage carcinogenesis and cell proliferation in the rat stomach. *Jpn. J. Cancer Res.* 85, 17-25.

Kawano, S., Nakao, T., and Hiraga, K. (1981). Induction of hepatic microsomal monooxygenases in female rats given various substituted phenols and hydroquinones. *Jpn. J. Pharmacol.* 31, 459-462.

Kirk-Othmer Encyclopedia of Chemical Technology (1981). 3rd ed., Vol. 13, p. 60. John Wiley and Sons, New York.

Krasavage, W.J. (1977). Evaluation of the teratogenic potential of tertiary butylhydroquinone (TBHQ) in the rat. *Teratology* 16, 31-34.

Krasavage, W.J. (1984). The lack of effect of tertiary butylhydroquinone on prothrombin time in male rats. *Drug Chem. Toxicol.* 7, 329-334.

Krasavage, W.J., and O'Donohue, J.L. (1984). Lack of lung damage in mice following administration of tertiary butylhydroquinone. *Drug Chem. Toxicol.* 7, 335-343.

Krasavage, W.J., and Terhaar, C.J. (1970). The reproductive performance of rats fed monotertiary butylhydroquinone: A single generation study. Unpublished report from the Toxicology Laboratory, Eastman Kodak, submitted to the World Health Organization by Eastman Chemical Products, Inc.

Li, Y., and Trush, M.A. (1994). Reactive oxygendependent DNA damage resulting from the oxidation of phenolic compounds by a copper-redox cycle mechanism. *Cancer Res.* 54 (Suppl. 7), 1895s-1898s.

McConnell, E.E., Solleveld, H.A., Swenberg, J.A., and Boorman, G.A. (1986). Guidelines for combining neoplasms for evaluation of rodent carcinogenesis studies. *JNCI* 76, 283-289.

McKnight, B., and Crowley, J. (1984). Tests for differences in tumor incidence based on animal carcinogenesis experiments. J. Am. Stat. Assoc. 79, 639-648. Margolin, B.H., Risko, K.J., Frome, E.L., and Tice, R.R. (1990). A general purpose statistical analysis program for micronucleus assay data. Appendix 2: Micronucleus data management and analysis version 1.4a. Integrated Laboratory Systems, Research Triangle Park, NC.

Marino, A.A., and Mitchell, J.T. (1972). Lung damage in mice following intraperitoneal injection of butylated hydroxytoluene. *Proc. Soc. Exp. Biol. Med.* 140, 122-125.

Maronpot, R.R., and Boorman, G.A. (1982). Interpretation of rodent hepatocellular proliferative alterations and hepatocellular tumors in chemical safety assessment. *Toxicol. Pathol.* **10**, 71-80.

Matsuoka, A., Matsui, M., Miyata, N., Sofuni, T., and Ishidate, M., Jr. (1990). Mutagenicity of 3-tertbutyl-4-hydroxyanisole (BHA) and its metabolites in short-term tests *in vitro*. *Mutat. Res.* 241, 125-132.

Miller, J.A., and Miller, E.C. (1977). Ultimate chemical carcinogens as reactive mutagenic electrophiles. In *Origins of Human Cancer* (H.H. Hiatt, J.D. Watson, and J.A. Winsten, Eds.), pp. 605-627. Cold Spring Harbor Laboratory, Cold Spring Harbor, NY.

Mizuno, M., Toda, M., Danno, G., Kanazawa, K., and Natake, M. (1988). Desmutagenic effects of sulfhydryl compounds on a mutagen formed from butylated hydroxyanisole reacted with sodium nitrite. *Agric. Biol. Chem.* 52, 2843-2849.

Mizutani, T., Ishida, I., Yamamoto, K., and Tajima, K. (1982). Pulmonary toxicity of butylated hydroxytoluene and related alkylphenols: Structural requirements for toxic potency in mice. *Toxicol. Appl. Pharmacol.* **62**, 273-281.

Morimoto, K., Tsuji, K., Iio, T., Miyata, N., Uchida, A., Osawa, R., Kitsutaka, H., and Takahashi, A. (1991). DNA damage in forestomach epithelium from male F344 rats following oral administration of *tert*-butylquinone, one of the forestomach metabolites of 3-BHA. *Carcinogenesis* **12**, 703-708.

Morrison, D.F. (1976). *Multivariate Statistical Methods*, 2nd ed., pp. 170-179. McGraw-Hill Book Company, New York.

Mukherjee, A., Talukder, G., and Sharma, A. (1989). Sister chromatid exchanges induced by tertiary butyl hydroquinone in bone marrow cells of mice. *Environ. Mol. Mutagen.* 13, 234-237.

National Cancer Institute (NCI) (1976). Guidelines for Carcinogen Bioassay in Small Rodents. Technical Report Series No. 1. NIH Publication No. 76-801. U.S. Department of Health, Education, and Welfare, Public Health Service, National Institutes of Health, Bethesda, MD.

National Cancer Institute (NCI) (1979). Bioassay of Butylated Hydroxytoluene (BHT) for Possible Carcinogenicity (CAS No. 128-37-0). Technical Report Series No. 150. NIH Publication No. 79-1706. U.S. Department of Health, Education, and Welfare, Public Health Service, National Institutes of Health, Bethesda, MD.

National Institute for Occupational Safety and Health (NIOSH) (1990). National Occupational Exposure Survey (1981-1983), unpublished provisional data as of July 1, 1990. NIOSH, Cincinnati, OH.

National Institutes of Health (NIH) (1978). Open Formula Rat and Mouse Ration (NIH-07). Specification NIH-11-1335. U.S. Department of Health, Education, and Welfare, Public Health Service, National Institutes of Health, Bethesda, MD. National Toxicology Program (NTP) (1987). Technical Protocol for Sperm Morphology and Vaginal Cytology Evaluations in Toxicity Testing for Rats and Mice, 10/31/82 version (updated December 1987). U.S. Department of Health and Human Services, Public Health Service, National Institutes of Health, Research Triangle Park, NC.

National Toxicology Program (NTP) (1989). Toxicology and Carcinogenesis Studies of Hydroquinone (CAS No. 123-31-9) in F344/N Rats and B6C3F<sub>1</sub> Mice (Gavage Studies). Technical Report Series No. 366. NIH Publication No. 90-2821. U.S. Department of Health and Human Services, Public Health Service, National Institutes of Health, Research Triangle Park, NC.

Nera, E.A., Lok, E., Iverson, F., Ormsby, E., Karpinski, K.F., and Clayson, D.B. (1984). Short-term pathological and proliferative effects of butylated hydroxyanisole and other phenolic antioxidants in the forestomach of Fischer 344 rats *Toxicology* 32, 197-213.

Olsen, P., Bille, N., and Meyer, O. (1983). Hepatocellular neoplasms in rats induced by butylated hydroxytoluene (BHT). *Acta Pharmacol. Toxicol.* 53, 433-434.

Phillips, B.J., Carroll, P.A., Tee, A.C., and Anderson, D. (1989). Microsome-mediated clastogenicity of butylated hydroxyanisol (BHA) in cultured Chinese hamster ovary cells: The possible role of reactive oxygen species. *Mutat. Res.* 214, 105-114.

Rahimthula, A.D., Jernstrom, B., Dock, L., and Moldeus, P. (1982). Effects of dietary and in vitro 2(3)-*t*-butyl-4-hydroxyanisole and other phenols on hepatic enzyme activities in mice. *Br. J. Cancer* 45, 935-944.

RTECS [database online] (1983). National Institute for Occupational Safety and Health: 1971-. Updated quarterly. Available from: National Library of Medicine, Bethesda, MD. Rogers, C.G., Boyes, B.G., Matula, T.I., and Stapley, R. (1992). Evaluation of genotoxicity of *tert*-butylhydroquinone in an hepatocyte-mediated assay with V79 Chinese hamster lung cells and in strain D7 of *Saccharomyces cerevisiae*. *Mutat. Res.* 280, 17-27.

Sadtler Standard Spectra. IR No. 46130; UV No. 24724; NMR No. 21464. Sadtler Research Laboratories, Philadelphia, PA.

Saheb, W., and Witschi, H. (1975). Lung growth in mice after a single dose of butylated hydroxytoluene. *Toxicol. Appl. Pharmacol.* 33, 309-319.

Schilderman, P.A.E.L., van Maanen, J.M.S., ten Vaarwerk, F.J., Lafleur, M.V.M., Westmijze, E.J., ten Hoor, F., and Kleinjans, J.C.S. (1993). The role of prostaglandin H synthase-mediated metabolism in the induction of oxidative DNA damage by BHA metabolites. *Carcinogenesis* 14, 1297-1302.

Seilkop, S.K. (1995). The effect of body weight on tumor incidence and carcinogenicity testing in  $B6C3F_1$  mice and F344 rats. *Fundam. Appl. Toxicol.* 24, 247-259.

Shirai, T., Hagiwara, A., Kurata, Y., Shibata, M., Fukushima, S., and Ito, N. (1982). Lack of carcinogenicity of butylated hydroxytoluene on long-term administration to  $B6C3F_1$  mice. Food Chem. Toxicol. 20, 861-865.

Shirley, E. (1977). A non-parametric equivalent of Williams' test for contrasting increasing dose levels of a treatment. *Biometrics* 33, 386-389.

Sims, R.J., and Fioriti, J.A. (1980). Antioxidants as stabilizers for fats, oils, and lipid-containing foods. In *CRC Handbook of Food Additives* (T.E. Furia, Ed.), 2nd ed., Vol. II, pp. 13-56. CRC Press, Inc., Boca Raton, FL.

Snedecor, G.W., and Cochran, W.G., Eds. (1980). *Statistical Methods*, 7th ed., pp. 215-237, 252-254, 295. Iowa State University Press, Ames, IA.

Sokal, R.R., and Rohlf, F.J., Eds. (1981). *Biometry*, 7th Ed., pp. 403-405, 429-432. W.H. Freeman and Co., San Francisco.

Straus, D.S. (1981). Somatic mutation, cellular differentiation, and cancer causation. JNCI 67, 233-241.

Takahashi, O., and Hiraga, K. (1978). Doseresponse study of hemorrhagic death by dietary butylated hydroxytoluene (BHT) in male rats. *Toxicol. Appl. Pharmacol.* 43, 399-406.

Tamano, S., Fukushima, S., Shirai, T., Hirose, M., and Ito, N. (1987). Modification by  $\alpha$ -tocopherol, propyl gallate and tertiary butylhydroquinone of urinary bladder carcinogenesis in Fischer 344 rats pretreated with *N*-butyl-*N*-(4-hydroxybutyl)nitrosamine. *Cancer Lett.* 35, 39-46.

Tarone, R.E. (1975). Tests for trend in life table analysis. *Biometrika* 62, 679-682.

Tennant, R.W., Margolin, B.H., Shelby, M.D., Zeiger, E., Haseman, J.K., Spalding, J., Caspary, W., Resnick, M., Stasiewicz, S., Anderson, B., and Minor, R. (1987). Prediction of chemical carcinogenicity in rodents from *in vitro* genetic toxicity assays. *Science* 236, 933-941.

Terhaar, C.J., and Krasavage, W.J. (1968a). Dietary feeding of TBHQ and related compounds to rats and dogs: The response of liver processing enzymes and liver glucose-6-phosphatase activity. Unpublished report from the Biochemistry Laboratory, Eastman Kodak, submitted to the World Health Organization by Eastman Chemical Products, Inc.

Terhaar, C.J., and Krasavage, W.J. (1968b). The reproductive performance of rats fed monotertiary butylhydroquinone. Unpublished report from the Toxicology Laboratory, Eastman Kodak, submitted to the World Health Organization by Eastman Chemical Products, Inc.

U.S. Environmental Protection Agency (USEPA) (1985). Chemicals in Commerce Information System, Public File, U.S. Environmental Protection Agency, Washington, DC.

U.S. International Trade Commission (USITC) (1984). U.S. Government Printing Office, Washington, DC.

Verhagen, H., Thijssen, H.H.W., ten Hoor, F., and Kleinjans, J.C.S. (1989). Disposition of single oral doses of butylated hydroxyanisole in man and rat. *Food Chem. Toxicol.* 27, 151-158.

White, I.R., Lovell, C.R., and Cronin, E. (1984). Antioxidants in cosmetics. *Contact Dermatitis* 11, 265-267.

Williams, D.A. (1971). A test for differences between treatment means when several dose levels are compared with a zero dose control. *Biometrics* 27, 103-117.

Williams, D.A. (1972). The comparison of several dose levels with a zero dose control. *Biometrics* 28, 519-531.

Witschi, H., and Saheb, W. (1974). Stimulation of DNA synthesis in mouse lung following intraperitoneal injection of butylated hydroxytoluene. *Proc. Soc. Exp. Biol. Med.* 147, 690-693.

Yoshida, Y., Hirose, M., Takaba, K., Kimura, J., and Ito, N. (1994). Induction and promotion of forestomach tumors by sodium nitrite in combination with ascorbic acid or sodium ascorbate in rats with or without *N*-methyl-*N'*-nitro-*N*-nitrosoguanidine pretreatment. *Int. J. Cancer* **56**, 124-128.

Zeiger, E., Haseman, J.K., Shelby, M.D., Margolin, B.H., and Tennant, R.W. (1990). Evaluation of four *in vitro* genetic toxicity tests for predicting rodent carcinogenicity: Confirmation of earlier results with 41 additional chemicals. *Environ. Mol. Mutagen.* **16** (Suppl. 18), 1-14.

Zeiger, E., Anderson, B., Haworth, S., Lawlor, T., and Mortelmans, K. (1992). *Salmonella* mutagenicity tests: V. Results from the testing of 311 chemicals. *Environ. Mol. Mutagen.* **19** (Suppl. 21), 2-141.

# APPENDIX A SUMMARY OF LESIONS IN MALE RATS IN THE LONG-TERM FEED STUDY OF &BUTYLHYDROQUINONE

Table A1	Summary of the Incidence of Neoplasms in Male Rats	
	in the Long-Term Feed Study of t-Butylhydroquinone	72
Table A2	Individual Animal Tumor Pathology of Male Rats	
	in the Long-Term Feed Study of t-Butylhydroquinone	77
Table A3	Statistical Analysis of Primary Neoplasms in Male Rats	
	in the Long-Term Feed Study of t-Butylhydroquinone	113
Table A4	Summary of the Incidence of Nonneoplastic Lesions in Male Rats	
	in the Long-Term Feed Study of t-Butylhydroquinone	121
۰,

### TABLE A1

Summary of the Incidence of Neoplasms in Male Rats in the Long-Term Feed Study of t-Butylhydroquinone<sup>a</sup>

Disposition Summary         70         74         4         Survivors         71         1         14         71         71         71         71         71         70         7		0 ppm	1,250 ppm	2,500 ppm	5,000 ppm
Animats initially in study       70       70       70       70         Advertise investigation       10       10       10       10         Barly deaths       10       10       10       10         Moribund       48       51       50       42         Namual deaths       4       2       7       4         Niversons       2       7       4         Niversons       8       7       1       14         dissected       0       0       2       0         Animals examined microscopically       70       70       68       70         Systems Examined At 3 Months With No Neoplasms Observed       Alimentary System       Cardiovascular System       Cardiovascular System         Cardiovascular System       General Body System       General Body System       General Body System         Cardiovascular System       Integumentary System       (60)       (58)       (58)       (60)         Urinary System       (58)       (58)       (58)       (60)       (59)       (60)         Leiomyosarcoma       (59)       (60)       (58)       (60)       (60)       (60)       (61)       (62)       (62)       (61)       (62)	Disnosition Summary	······································	- <u></u>	<u> </u>	
1-Month interime valuation         10         10         10         10           Monthold         48         51         50         42           Monthold         48         51         50         42           Numith deaths         4         2         7         4           Survivors         8         7         1         14           Missexed         0         0         2         0           Animals examined microscopically         70         70         68         70           Systems Examined At 3 Months With No Neoplasms Observed         Allimentary System         7         4           Cardiovascular System         Cardiovascular System         668         70           System System         Cardiovascular System         7         68         70           Hematopoietic System         General Body System         7         69         60           Integumentary System         Nusculoskeletal System         7         69         60           Leimoyosarcoma         1         12%         60         60         63         60           Leimoyosarcoma         60         (58)         (58)         (58)         (69)         60         60 <td< td=""><td></td><td>70</td><td>70</td><td>70</td><td>70</td></td<>		70	70	70	70
Sardy deaths       48       51       50       42         Namul deaths       4       2       7       4         arrivors       7       1       14         dissexed       0       0       2       0         unimals examined microscopically       70       70       68       70         Systems Examined At 3 Months With No Neoplasms Observed       Junentary System       3       3         Sardiovascular System       3       3       7       1       14         Sardiovascular System       3       3       7       1       14         Sardiovascular System       3       3       7       0       0       68       70         Systems Examined At 3 Months With No Neoplasms Observed       Juneation System       3<					
Morbund       48       51       50       42         Natural deaths       4       2       7       4         urvivors       6       7       1       14         itsexed       0       0       2       0         nimals examined nicroscopically       70       70       68       70         vistems Examined At 3 Months With No Neoplasms Observed       1       14       14         itimentary System       2       0       0       0         Cardiovascular System       2       0       0       0       0         Cardiovascular System       2       0       0       0       0       0         Cardiovascular System       2       0					
University Terminal sacrifice         8         7         1         14           Terminal secrifice         8         7         1         14           issexed         0         0         2         0           xninals examined microscopically         70         70         68         70           Systems Examined At 3 Months With No Neoplasms Observed         Alimentary System         7         70         68         70           Arafdorsexular System         Sardiovascular System         Sardiovascular System         7         7         68         70           Seneral Body System         Sardiovascular System         Sardiova	•	48	51	50	42
Terminal sacrifice       8       7       1       14         fissexed       0       0       2       0         ninuals examined microscopically       70       70       68       70         systems Examined At 3 Months With No Neoplasms Observed       1       1       14         ulimentary System       3       70       68       70         indocrine System       5       6       70       70       68       70         indocrine System       5       5       5       70 </td <td>Natural deaths</td> <td></td> <td>2</td> <td>7</td> <td>4</td>	Natural deaths		2	7	4
tissexed 0 0 0 2 0 nimals examined microscopically 70 70 68 70 vestems Examined At 3 Months With No Neoplasms Observed Lilimentary System Aradiovascular System Seneral Body System Seneral Body System Seneral Body System Integumentary System Ausculoskeletal System integumentary System Ausculoskeletal System integrine targs, colon (58) (58) (60) Leiomyosarcoma (59) (60) (58) (59) Leiomyosarcoma (59) (60) (58) (60) Intestine targs, cecum (60) (58) (58) (60) Intestine small, duodenum (60) (59) (59) (59) Leiomyoarcoma (77) (60) (58) (60) Intestine small, duodenum (60) (59) (58) (60) Intestine small, duodenum (60) (59) (58) (60) Intestine small, ileum (60) (59) (58) (60) Intestine small, ileum (60) (59) (58) (60) Intestine small, ileum (60) (59) (58) (60) Leiomyoma (60) (59) (58) (60) Leiomyoma (60) (59) (58) (60) Leiomyoma (60) (59) (58) (60) Intestine small, ileum (60) (59) (58) (60) Leiomyoma (60) (59) (58) (60) Leiomyoma (60) (59) (58) (60) Leiomyoma (60) (59) (58) (58) (60) Leiomyoma (60) (59) (58) (58) (60) Leiomyoma (60) (59) (58) (58) (59) Leiomyoma (60) (59) (58) (58) (58) Leiomyoma (60) (59) (58) (58) (58) Leiomyoma (60) (59) (58) (58) (58) Leiomyoma (60) (59) (58) (58) Leiomyoma (60) (58) (58) (58) Leiomyoma (60) (59) (58) (58) Leiomyoma (60) (59) (58) (58) Leiomyoma (60) (58) (58) (58) Leiomyoma (60) (58) Le	urvivors				
nimals examined microscopically     70     70     68     70       Vystems Examined At 3 Months With No Neoplasms Observed     Alimentary System     Alimentary System       Pardiovascular System     System     Seneral Body System       General Body System     Seneral Body System       Benatopoietic System     Seneral System       Respiratory System     Musculoskeletal System       Respiratory System     Sesses System       Infrary System     (58)     (58)       Leiomyosarcoma     1 (2%)       mestine large, colon     (58)     (58)       Carcinoma     1 (2%)       mestine large, cecum     (60)     (58)       Carcinoma     1 (2%)       mestine large, cecum     (60)     (59)       Carcinoma     1 (2%)       mestine small, duodenum     (60)     (59)       Leiomyosarcoma     1 (2%)       mestine small, leum     (60)     (59)       Leiomoyoarcoma     1 (2%)       Leiomoyoarcoma     1 (2%)       Hepatocelhular carcinoma     2 (3%)       Hepatocelhular acterinema     4 (7%)     4 (7%)       Hepatocelhular acterinema     4 (7%)     4 (7%)	Terminal sacrifice	8	. 7	1	14
Systems Examined At 3 Months With No Neoplasms Observed Limentary System Tardiovascular System Tandocrine System Seneral Body System Seneral Body System Testine System tespiratory	lissexed	0	0	2	0
Alimentary System Cardiovascular System Seneral Body System Seneral Body System Iematopoletic System Iematopoletic System Musculoskeletal System Nervous System Sepcial Senses System Jrinary System Cong-Term Study Alimentary System Irinary System Cong-Term Study Alimentary System Cong-Term Study Alimentary System Irinary System Cong-Term Study Alimentary System Irinary System Cong-Term Study Alimentary System Irinary System Cong-Term Study Alimentary System Irinary System Irinary System Cong-Term Study Alimentary System Irinary System Iri	nimals examined microscopically	70	70	68	70
Alimentary System ardiovascular System Andocrine System ieneral Body System iental System Iematopoietic System Integumentary System Intervous System Ierous System Ierous System Irinary System Irinary System Intestine large, colon (58) (58) (58) (60) Leiomyosarcoma 1 (2%) Carcinoma (59) (60) (58) (59) (59) Carcinoma (58) (58) (60) Intestine large, cecum (60) (58) (58) (60) Intestine large, cecum (60) (58) (58) (60) Intestine large, cecum (60) (58) (58) (60) Intestine small, jejunum (60) (60) (59) (58) (60) Intestine small, jejunum (60) (59) (59) (58) (59) Leiomyoma (1 (2%)) Intestine small, jejunum (60) (59) (58) (59) Leiomyoma (1 (2%)) Intestine small, jejunum (60) (59) (58) (59) Leiomyoma (1 (2%)) Iterine small, jejunum (60) (59) (58) (59) Leiomyosarcoma, metastatic, intestine large, colon (1 (2%))	vstems Examined At 3 Months With	No Neoplasm	s Observed	<u></u>	<u> </u>
Cardiovascular System Indocrine System Senital System Hematopoietic System Integunentary System Masculoskeltal System Vervous System Ve					1977 - 19
Endocrine System Seneral Body System Senital System Itematopoletic System Ausculoskeletal System Vervous System Sepcial Senses System Jrinary System Long-Term Study Milmentary System Lieimyosarcoma ntestine large, colon Carcinoma ntestine large, cecum (59) Carcinoma ntestine large, cecum (60) Carcinoma (60) Carcinoma (60) Carcinoma (60) (58) (58) (58) (60) (58) (58) (60) (58) (58) (58) (60) (58) (5					
General Body System         Jental System         Idenatopoletic System         Ausculoskeletal System         Ausculoskeletal System         Respiratory System         Special Sense System         Jrinary System         Long-Term Study         Millimentary System         Leiomyosarcoma         1 (2%)         ntestine large, colon       (58)       (58)       (60)         Leiomyosarcoma       1 (2%)         ntestine large, cecum       (60)       (58)       (59)         Carcinoma       1 (2%)       (60)       (60)         ntestine small, duodenum       (60)       (60)       (58)       (60)         nestine small, jejunum       (60)       (59)       (58)       (60)         nestine small, jejunum       (60)       (59)       (58)       (60)         netsine small, jejunum       (60)       (59)       (58)       (60)         Leiomyoma       1 (2%)       (2%)       (58)       (60)         Leiomyoma       1 (2%)       (2%)       (3%)       (5%)         Leiomyoma       1 (2%)       3 (5%)       (5%)       (5%)       (5%)         Leiomyoma       1 (2%)<					
Senital System Iematopoietic System Integunentary System Iasculoskeletal System Iervous System Iervous System Iervous System Ierona System Irinary System Nimentary System Intestine large, colon (58) (58) (58) (60) Leiomyosarcoma 1 (2%) Intestine large, rectum (59) (60) (58) (58) (60) Leiomyosarcoma 1 (2%) Intestine large, cecum (60) (58) (58) (60) Intestine large, cecum (60) (58) (58) (60) Intestine large, cecum (60) (58) (58) (60) Intestine small, duodenum (60) (60) (57) (60) Carcinoma 1 (2%) Intestine small, leum (60) (59) (58) (60) Intestine small, leum (60) (59) (58) (59) Leiomyona 1 (2%) Iver (60) (60) (59) (58) (60) Hepatocellular carcinoma 4 (7%) 4 (7%) 3 (5%) Histiocytic sarcoma 1 (2%) Leiomyosarcoma, metastatic, intestine large, colon 1 (2%)					
Itematopoletic System         ntegunentary System         fusculoskeletal System         tervous System         pecial Senses System         Jrinary System         Jimentary System         Leiomyosarcoma       1 (2%)         Actiona       1 (2%)         Carcinoma       1 (2%)         Leistine large, rectum       (59)       (60)         Carcinoma       1 (2%)         Restine ismail, duodenum       (60)       (58)       (58)         Leiomyosarcoma       1 (2%)       (60)         Carcinoma       1 (2%)       (60)         Intestine large, cecum       (60)       (58)       (60)         Intestine small, duodenum       (60)       (60)       (57)       (60)         Carcinoma       1 (2%)       (58)       (60)       (60)       (57)       (60)         Carcinoma       1 (2%)       (58)       (59)       (58)       (60)       (59)       (58)       (60)         Leiomyoma       1 (2%)       1 (2%)       (58)       (60)       (59)       (58)       (60)         Ver       (60)       (60)       (58)       (60)       (58)       (60)         Leiomyom					
Integunentary System         fusculoskeletal System         lervous System         tespiratory System         pocial Senses System         Jrinary System         ong-Term Study         Limentary System         testine large, colon       (58)         testine large, colon       (58)         testine large, colon       (59)         Carcinoma       1 (2%)         testine large, cecum       (60)         testine small, jejunum       (60)         testine small, jejunum       (60)         testine small, jejunum       (60)         teionyoma       1 (2%)         tiver       (60)         teionyoma       1 (2%)         tiver       (60)       (58)       (60)         Hepatocellular adenoma       4 (7%)       4 (7%)       3 (5%)         Histocytic sarcoma       1 (2%)       3 (5%)					
fusculoskeletal System         lervous System         pecial Senses System         prinary System					· · · ·
tervous System         tespiratory System         pecial Senses System         Jrinary System         cong-Term Study         Lilimentary System         testine large, colon       (58)       (58)       (60)         Leiomyosarcoma       1       (2%)         nestine large, rectum       (59)       (60)       (58)       (59)         Carcinoma       1       (2%)       (60)       (60)       (58)       (60)         testine large, rectum       (60)       (58)       (58)       (60)				n	•
tespiratory System         pecial Senses System         Irinary System         cong-Term Study         limentary System         testine large, colon       (58)       (58)       (60)         Leiomyosarcoma       1       (2%)         testine large, cecum       (59)       (60)       (58)       (59)         Carcinoma       1       (2%)       (60)       (58)       (60)         testine large, cecum       (60)       (58)       (58)       (60)         testine small, duodenum       (60)       (60)       (58)       (60)         testine small, jejunum       (60)       (60)       (57)       (60)         Carcinoma       1       (2%)       1       (2%)         testine small, jelum       (60)       (59)       (58)       (59)         Leiomyoma       1       (2%)       1       (2%)         testine small, ileum       (60)       (60)       (58)       (60)         Hepatocellular carcinoma       1       (2%)       2       (3%)         teiomyosarcoma, metastatic, intestine large, colon       1       (2%)       3       (5%)					
pecial Senses System         Jrinary System         Julimentary System         intestine large, colon       (58)       (58)       (60)         Leiomyosarcoma       1       (2%)         ntestine large, cecum       (60)       (58)       (59)         Carcinoma       1       (2%)         ntestine large, cecum       (60)       (58)       (60)         ntestine large, cecum       (60)       (58)       (60)         ntestine small, duodenum       (60)       (60)       (58)       (60)         ntestine small, jeunum       (60)       (60)       (57)       (60)         Carcinoma       1       (2%)       1       12%)         Leiomyoma       1       (2%)       1       12%)         Leiomyoma       1       (2%)       (58)       (60)         Leiomyoma       1       (2%)       1       2       (3%)         Hepatocellular carcinoma       2       (3%)       3       (5%)       3       (5%)         Hepatocellular adenoma       4       (7%)       4       (7%)       3       (5%)       3       (5%)         Leiomyosarcoma, metastatic, intestine large, colon       1 <td< td=""><td>lervous System</td><td></td><td></td><td></td><td>the second second</td></td<>	lervous System				the second second
Jung-Term Study         Nilmentary System         ntestine large, colon       (58)       (58)       (60)         Leiomyosarcoma       1 (2%)       1 (2%)         nestine large, rectum       (59)       (60)       (58)       (59)         Carcinoma       1 (2%)       1 (2%)       1 (2%)       1 (2%)         nestine large, cecum       (60)       (58)       (60)       60)       1 (2%)         Carcinoma       1 (2%)       (60)       (58)       (60)       1 (2%)         Intestine small, duodenum       (60)       (60)       (57)       (60)         Carcinoma       1 (2%)       1 (2%)       1 (2%)       1 (2%)         Intestine small, jejunum       (60)       (59)       (58)       (60)         Carcinoma       1 (2%)       1 (2%)       1 (2%)       1 (2%)         Itestine small, jieum       (60)       (59)       (58)       (60)       1 (2%)         Leiomyona       1 (2%)       2 (3%)       2 (3%)       3 (5%)       1 (2%)         Hepatocellular carcinoma       2 (3%)       3 (5%)       3 (5%)       1 (2%)       1 (2%)         Leiomyosarcoma, metastatic, intestine large, colon       1 (2%)       3 (5%) <t< td=""><td>Respiratory System</td><td></td><td></td><td></td><td></td></t<>	Respiratory System				
Jung-Term Study         Nilmentary System         ntestine large, colon       (58)       (58)       (60)         Leiomyosarcoma       1 (2%)       1 (2%)         nestine large, rectum       (59)       (60)       (58)       (59)         Carcinoma       1 (2%)       1 (2%)       1 (2%)       1 (2%)         nestine large, cecum       (60)       (58)       (60)       60)       1 (2%)         Carcinoma       1 (2%)       (60)       (58)       (60)       1 (2%)         Intestine small, duodenum       (60)       (60)       (57)       (60)         Carcinoma       1 (2%)       1 (2%)       1 (2%)       1 (2%)         Intestine small, jejunum       (60)       (59)       (58)       (60)         Carcinoma       1 (2%)       1 (2%)       1 (2%)       1 (2%)         Itestine small, jieum       (60)       (59)       (58)       (60)       1 (2%)         Leiomyona       1 (2%)       2 (3%)       2 (3%)       3 (5%)       1 (2%)         Hepatocellular carcinoma       2 (3%)       3 (5%)       3 (5%)       1 (2%)       1 (2%)         Leiomyosarcoma, metastatic, intestine large, colon       1 (2%)       3 (5%) <t< td=""><td>pecial Senses System</td><td></td><td></td><td></td><td></td></t<>	pecial Senses System				
Alimentary System       (58)       (58)       (58)       (60)         Leiomyosarcoma       1 (2%)       (59)       (60)       (58)       (59)         Carcinoma       1 (2%)       1 (2%)       (60)       (58)       (60)         Carcinoma       1 (2%)       1 (2%)       (60)       (60)       (60)       (60)         Carcinoma       (60)       (58)       (60)       (59)       (58)       (60)		· .	· · · ·	··· · ·	
Alimentary System       (58)       (58)       (58)       (60)         Leiomyosarcoma       1 (2%)       1       (2%)         ntestine large, rectum       (59)       (60)       (58)       (59)         Carcinoma       1 (2%)       1       (2%)         ntestine large, cecum       (60)       (58)       (60)         ntestine small, duodenum       (60)       (60)       (58)       (60)         ntestine small, jejunum       (60)       (60)       (57)       (60)         Carcinoma       1 (2%)       1       (2%)       1       (2%)         ntestine small, lieum       (60)       (59)       (58)       (59)       (60)         Carcinoma       1 (2%)       1       (2%)       1       (2%)         Leiomyoma       1 (2%)       58)       (59)       (58)       (60)         Leiomyoma       1 (2%)       2 (3%)       3 (5%)       3 (5%)         Hepatocellular adenoma       4 (7%)       4 (7%)       3 (5%)       3 (5%)         Histiocytic sarcoma       1 (2%)       1 (2%)       1 (2%)       1 (2%)	Long-Term Study				······································
ntestine large, colon       (58)       (58)       (58)       (60)         Leiomyosarcoma       1       (2%)       1       (2%)         ntestine large, rectum       (59)       (60)       (58)       (59)         Carcinoma       1       (2%)       1       (2%)         ntestine large, cecum       (60)       (58)       (58)       (60)         ntestine small, duodenum       (60)       (60)       (58)       (60)         ntestine small, jejunum       (60)       (60)       (57)       (60)         Carcinoma       1       (2%)       (59)       (58)       (59)         Carcinoma       1       (2%)       (59)       (58)       (59)         Leiomyoma       1       (2%)       (59)       (58)       (59)         Leiomyoma       1       (2%)       (2%)       (60)       (60)       (58)       (60)         Hepatocellular carcinoma       2       (3%)       (3%)       (3%)       (4       (7%)       3       (5%)         Hepatocellular adenoma       4       (7%)       4       (7%)       3       (5%)         Leiomyosarcoma, metastatic, intestine large, colon       1       1       (2%)					
Leiomyosarcoma       1 (2%)         ntestine large, rectum       (59)       (60)       (58)       (59)         Carcinoma       1 (2%)       1 (2%)       1 (2%)         ntestine large, cecum       (60)       (58)       (60)         ntestine small, duodenum       (60)       (60)       (58)       (60)         ntestine small, jejunum       (60)       (60)       (57)       (60)         Carcinoma       1 (2%)       1 (2%)       1 (2%)         ntestine small, ileum       (60)       (59)       (58)       (59)         Leiomyoma       1 (2%)       1 (2%)       1 (2%)         Leiomyoma       4 (7%)       4 (7%)       3 (5%)         Hepatocellular adenoma       1 (2%)       3 (5%)       (5%)         Leiomyosarcoma, metastatic, intestine large, colon       1 (2%)       1 (2%)       1 (2%)		(58)	(58)	(58)	(60)
Intestine large, rectum       (59)       (60)       (58)       (59)         Carcinoma       1       (2%)         Intestine large, cecum       (60)       (58)       (60)         Intestine small, duodenum       (60)       (60)       (58)       (60)         Intestine small, jejunum       (60)       (60)       (57)       (60)         Carcinoma       1       (2%)       (60)       (59)       (60)         Carcinoma       1       (2%)       (59)       (60)       (60)       (58)       (60)         Carcinoma       1       (2%)       1       (2%)       (60)       (60)       (58)       (60)         Leiomyoma       1       (2%)       1       (2%)       (60)       (60)       (58)       (60)         Hepatocellular carcinoma       1       (2%)       2       (3%)       (3%)       (5%) <td></td> <td>()</td> <td></td> <td></td> <td></td>		()			
Carcinoma       1 (2%)         ntestine large, cecum       (60)       (58)       (60)         ntestine small, duodenum       (60)       (60)       (58)       (60)         ntestine small, jejunum       (60)       (60)       (57)       (60)         Carcinoma       1 (2%)       1 (2%)       1 (2%)         ntestine small, ileum       (60)       (59)       (58)       (59)         Leiomyoma       1 (2%)       1 (2%)       1 (2%)         Hepatocellular carcinoma       2 (3%)       3 (5%)         Hepatocellular adenoma       4 (7%)       4 (7%)       3 (5%)         Histiocytic sarcoma       1 (2%)       1 (2%)       1 (2%)	•	(59)		(58)	(59)
ntestine small, duodenum       (60)       (60)       (58)       (60)         ntestine small, jejunum       (60)       (60)       (57)       (60)         Carcinoma       1       (2%)       1       (2%)         ntestine small, ileum       (60)       (59)       (58)       (59)         Leiomyoma       1       (2%)       1       (2%)         Hepatocellular carcinoma       2       (3%)       1         Hepatocellular adenoma       4       (7%)       4       (7%)       3       (5%)         Leiomyosarcoma, metastatic, intestine large, colon       1       (2%)       1       2       (3%)				1 (2%)	
nestine small, jejunum       (60)       (60)       (57)       (60)         Carcinoma       1 (2%)       1 (2%)       1         ntestine small, ileum       (60)       (59)       (58)       (59)         Leiomyoma       1 (2%)       1       2       (3%)         iver       (60)       (60)       (58)       (60)         Hepatocellular carcinoma       2 (3%)       2 (3%)         Hepatocellular adenoma       4 (7%)       4 (7%)       3 (5%)         Histiocytic sarcoma       1 (2%)       1       2         Leiomyosarcoma, metastatic, intestine large, colon       1 (2%)       1       2	ntestine large, cecum	(60)			
Carcinoma       1 (2%)         ntestine small, ileum       (60)       (59)       (58)       (59)         Leiomyoma       1 (2%)       1 (2%)       (60)       (60)       (60)         Hepatocellular carcinoma       4 (7%)       4 (7%)       2 (3%)         Hepatocellular adenoma       4 (7%)       4 (7%)       3 (5%)         Histiocytic sarcoma       1 (2%)       1 (2%)       1 (2%)         Leiomyosarcoma, metastatic, intestine large, colon       1 (2%)       1 (2%)	ntestine small, duodenum				
Leiomyoma1 (2%)iver(60)(60)(58)(60)Hepatocellular carcinoma2 (3%)Hepatocellular adenoma4 (7%)4 (7%)3 (5%)Histiocytic sarcoma1 (2%)12Leiomyosarcoma, metastatic, intestine large, colon1 (2%)11	Carcinoma			1 (2%)	
Liver(60)(60)(58)(60)Hepatocellular carcinoma2 (3%)Hepatocellular adenoma4 (7%)4 (7%)3 (5%)Histiocytic sarcoma1 (2%)Leiomyosarcoma, metastatic, intestine large, colon1 (2%)1 (2%)	· ·	(60)	A (0.01)	(58)	(59)
Hepatocellular carcinoma       2 (3%)         Hepatocellular adenoma       4 (7%)       4 (7%)       3 (5%)         Histiocytic sarcoma       1 (2%)       1 (2%)       1 (2%)         Leiomyosarcoma, metastatic, intestine large, colon       1 (2%)       1 (2%)	÷	((0))		(59)	(60)
Hepatocellular adenoma 4 (7%) 4 (7%) 3 (5%) Histiocytic sarcoma 1 (2%) Leiomyosarcoma, metastatic, intestine large, colon 1 (2%)		(60)	(00)	(38)	
Histiocytic sarcoma 1 (2%) Leiomyosarcoma, metastatic, intestine large, colon 1 (2%)		A ("10/\	<i>A 17</i> 01		
Leiomyosarcoma, metastatic, intestine large, colon 1 (2%)			4 (/70)		5 (570)
colon 1 (2%)		1 (270)			
			1 (2%)		•
	Osteosarcoma, metastatic, mesentery		1 (270)	1 (2%)	

Ç,

Ξ.

Summary of the Incidence of Neoplasms in Male Rats in the Long-Term Feed Study of t-Butylhydroquinone (continued)

, <sup>.</sup>	0 ppm	1,250 ppm	2,500 ppm	5,000 ppm
Long-Term Study (continued)			<u>, , , , , , , , , , , , , , , , , , , </u>	
limentary System (continued)				
Aesentery	(20)	(11)	(7)	(16)
Histiocytic sarcoma	(20) 1 (5%)	(11)	(7)	(16)
•				
Leiomyosarcoma, metastatic, intestine large	,	1 (00)		
colon		1 (9%)	1 (1401)	
Osteosarcoma	1 (501)		1 (14%)	
Schwannoma malignant	1 (5%)			•
Dral mucosa	(1)	(2)	(2)	
Squamous cell carcinoma	1 (100%)	1 (50%)	2 (100%)	
Squamous cell papilloma	((0))	1 (50%)	(50)	
ancreas	(60)	(59)	(58)	(60)
Leiomyosarcoma, metastatic, intestine large	,	1 (6.00)		
colon		1 (2%)		
Acinus, adenoma	3 (5%)		1 (2%)	(60)
Salivary glands	(60)	(60)	(58)	(60)
Carcinoma			1 (2%)	
Fibrosarcoma, metastatic, skin			1 (2%)	
Stomach, forestomach	(60)	(60)	(58)	(59)
Squamous cell papilloma			1 (2%)	1 (2%)
Stomach, glandular	(60)	(60)	(58)	(60)
Fongue	(1)	(2)	(1)	(4)
Squamous cell carcinoma	1 (100%)			
Squamous cell papilloma				2 (50%)
Footh	(1)		(2)	(1)
Odontoma			1 (50%)	
Cardiovascular System	<u></u>		· .	
Heart	(60)	(60)	(58)	(60)
Schwannoma malignant	1 (2%)	(00)	(00)	(00)
		<u></u>		- <u></u>
Endocrine System				
Adrenal cortex	(60)	· (60)	(58)	(60)
Adenoma	1 (2%)		(50)	1 (2%)
Adrenal medulla	(60)	(60)	(58)	(60)
Pheochromocytoma malignant	1 (2%)	3 (5%)	1 (2%)	3 (5%)
Pheochromocytoma benign	13 (22%)	16 (27%)	11 (19%)	11 (18%)
Pheochromocytoma benign, multiple	1 (2%)	4 (7%)	4 (7%)	1 (2%)
slets, pancreatic	(60)	(59)	(58)	(60)
Adenoma	5 (8%)	2 (3%)	1 (2%)	3 (5%)
Carcinoma	1 (2%)			
Pituitary gland	(60)	(58)	(57)	(60)
Pars distalis, adenoma	19 (32%)	16 (28%)	17 (30%)	6 (10%)
Pars distalis, carcinoma		1 (2%)	1 (2%)	1 (2%)
Thyroid gland	(60)	(60)	(58)	(60)
C-cell, adenoma	5 (8%)	2 (3%)	2 (3%)	4 (7%)
C-cell, carcinoma		1 (2%)		2 (3%)
Follicular cell, adenoma		1 (2%)	1 (2%)	
Follicular cell, carcinoma				3 (5%)

5

9 74

· . .

# TABLE A1

-

Summary of the Incidence of Neoplasms in Male Rats in the Long-Term Feed Study of t-Butylhydroquinone (continued)

	ана (1997) Алагана (1997) Алагана (1997)	0 p	pm	1,2	50 ppm		2,50	0 ppm		5,0	00 ppm	L
General Body System           Perioneum         (1)         (1)         (3)           Genital System         (60)         (60)         (53)         (60)         (3)           Teppinal gland         (60)         (60)         (53)         (10, 3)         (55)         (53)         (60)         (35)           Carsinoma         2 (35)         2 (35)         1 (25)         (60)         (60)         (53)         (60)           Carsinoma, multiple         (60)         (60)         (53)         (60)         (53)         (60)         (60)         (53)         (60)           Seminal vesicle         (60)         (60)         (57)         (60)         (63)         (57)         (60)           Bilateri, interstitial cell, adenoma         42 (70, %)         40 (67, %)         45 (79, %)         50 (83, %)           Interstitial cell, adenoma         13 (22, %)         9 (15, %)         10 (38)         (158)           Bilateri, interstitial cell, adenoma         42 (70, %)         40 (60)         (58)         (60)           Kediastital, osteosarcoma, metastatic, insertine         (60)         (58)         (57)         (60)           Lymph node, mandibular         (60)         (60)         (58)	Torm Study (continued)					<u></u>						
Peritoneum       (1)       (1)       (3)         Genital System       Freputal gland       (60)       (60)       (58)       (60)         Adenoma       5 (8%)       3 (5%)       6 (10%)       3 (5%)       5 (8%)         Carcinoma       1 (2%)       1 (2%)       5 (8%)       3 (5%)       6 (10%)       3 (5%)         Carcinoma, multiple       1 (2%)       1									•			
Canial System         Preputial gland         (60)         (53)         (60)         (53)         (60)         (53)         (60)         (53)         (60)         (53)         (60)         (53)         (60)         (53)         (60)         (53)         (53)         (53)         (53)         (53)         (53)         (53)         (53)         (53)         (53)         (53)         (53)         (53)         (53)         (53)         (53)         (53)		(1)					(1)		· · · · · · · · · · · · · · · · · · ·	(2)	•	
Preputal gland (60) (60) (58) (60) (60) (58) (60) (58) (60) (58) (60) (58) (58) (58) (58) (58) (58) (58) (58		(1)				· · · · · · · · · · · · · · · · · · ·	· (1)			(3)		
$\begin{array}{cccc} Adenoma & 5 (8\%) & 3 (5\%) & 6 (10\%) & 3 (5\%) \\ Carcinoma & 2 (3\%) & 2 (3\%) & 1 (2\%) & 5 (8\%) \\ Carcinoma & 2 (3\%) & 2 (3\%) & 1 (2\%) & 5 (8\%) \\ Carcinoma & 2 (3\%) & 2 (3\%) & 1 (2\%) & 1 (2\%) & 1 (2\%) \\ Seminal vesicle & (60) & (60) & (50) & (50) & (60) \\ Exists & (60) & 1 (2\%) & 1 ($	l System					•••					•	: *
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	l gland	(60)		(60)			(58)			(60)		1 N N N
$\begin{array}{c ccccccccccccccccccccccccccccccccccc$		5	(8%)		(5%)	. *	6	(10%)	÷	3	(5%)	:
$\begin{array}{c ccccccccccccccccccccccccccccccccccc$	noma	2	(3%)	2	(3%)	•	1	(2%)		. 5	(8%)	· ·
Prostate (60) (60) (58) (60) (60) (58) (60) Leiomyosarcoma, metastatic, intestine large, (60) (60) (57) (60) Testes (60) (60) (57) (60) (57) (60) Erstes (77) (58) (60) (58) (60) (58) (57) (58) (58) (58) (58) (58) (58) (58) (58	noma, multiple		• •		. ,							<b>4</b>
Adenoma $(2,3\%)$ $(2,3\%)$ $(1,2\%)$ $(1,2\%)$ berninal vesicle $(60)$ $(60)$ $(58)$ $(60)$ colon $1,2\%)$ $(60)$ $(57)$ $(60)$ Biatersl, interstitial cell, adenoma $42,(70\%)$ $40,(67\%)$ $45,(79\%)$ $50,(83\%)$ Interstitial cell, adenoma $13,(22\%)$ $9,(15\%)$ $11,(19\%)$ $9,(15\%)$ Hematopoietic System		(60)		(60)						(60)	• ·	. ·
Jerninal vesicle       (60)       (60)       (58)       (60)         Leiomyostrooma, metastatic, intestine large, colon       1       (2%)       (60)       (60)         Peters       (60)       (60)       (67%)       45       (79%)       50       (83%)         Interstitial cell, adenoma       13       (22%)       9       (15%)       11       (19%)       9       (15%)         Hematopoietic System			(3%)		(3%)		ĺ	(2%)				
Leionyosarcoma, metastatic, intestine large, colon       1 (2%)         Perats       (60)       (60)       (57)       (60)         Bilateral, interstitial cell, adenoma       42 (70%)       40 (67%)       45 (79%)       50 (83%)         Interstitial cell, adenoma       13 (22%)       9 (15%)       11 (19%)       9 (15%)         Hematopoietic System       50       (60)       (60)       (58)       (60)         Some marrow       (60)       (60)       (58)       (60)       (60)         Lymph node       (33)       (36)       (34)       (35)         Mediastinal, osteosarcoma, metastatic, mesentery       1 (2%)       1 (2%)       1 (2%)         Lymph node, mandibular       (60)       (58)       (60)       (58)       (60)         Carcinoma, metastatic, zymbal's gland       1 (2%)       1 (2%)       1 (2%)       1 (2%)         Fibrosarcoma, metastatic, sint       1 (2%)       1 (2%)       1 (2%)       1 (2%)         Spleen       (60)       (60)       (58)       (60)       (58)       (50)         Fibrosarcoma, metastatic, intestine large, colon       1 (2%)       1 (2%)       1 (2%)       1 (2%)         Colon       1 (2%)       1 (2%)       1 (2%)       1					(- ···/	• . • • •		(+···/	*			
Festes       (60)       (60)       (57)       (60)         Bilateral, interstitial cell, adenoma       42 (70%)       40 (67%)       45 (79%)       50 (83%)         Interstitial cell, adenoma       13 (22%)       9 (15%)       11 (19%)       9 (15%)         Interstitial cell, adenoma       13 (22%)       9 (15%)       11 (19%)       9 (15%)         Bore marrow       (60)       (60)       (58)       (60)         Lymph node       (33)       (36)       (34)       (35)         Mediastinal, osteosarcoma, metastatic, mesentery       1 (3%)       (2%)       1 (2%)         Lymph node, mesenteric       (60)       (60)       (58)       (60)         Carcinoma, metastatic, skin       1 (2%)       1 (2%)       1 (2%)         Fibrosarcoma, metastatic, skin       1 (2%)       1 (2%)       1 (2%)         Spleen       (60)       (60)       (58)       (60)         Fibrosarcoma, metastatic, intestine large, colon       1 (2%)       1 (2%)       1 (2%)         Colon       1 (2%)       1 (2%)       1 (2%)       1 (2%)         Thymus       (58)       (55)       (54)       (56)         Thymus       (1 (2%)       1 (2%)       1 (2%)       1 (2%)	nyosarcoma, metastatic, intestine large,				(2%)		(00)			,		1. A. S. A.
Bitterstinal cell, adenoma       42       (70 %)       40       (67 %)       45       (79 %)       50       (83 %)         Interstinal cell, adenoma       13       (22 %)       9       (15 %)       11       (19 %)       9       (15 %)         Hematopoletic System       50       (60)       (60)       (58)       (60)       (60)       (58)       (60)         Sone marrow       (60)       (60)       (58)       (60)       (58)       (60)       (58)       (60)       (60)       (58)       (60)       (60)       (28)       (60)       (28)       (60)       (28)       (60)       (58)       (57)       (60)       (60)       (58)       (57)       (60)       (28)       (60)       (60)       (58)       (50)		(60)			(= / • / )		(57)			(60)		
Interstitial cell, adenoma       13 (22%)       9 (15%)       11 (19%)       9 (15%)         Hematopoletic System       660       (60)       (60)       (58)       (60)         Bone marrow       (33)       (36)       (34)       (35)       (60)         Mediastinal, osteosarcoma, metastatic, mesentery       1 (3%)       1 (2%)       1 (2%)       1 (2%)         Lymph node, mandibular       (60)       (60)       (58)       (60)       (60)       (60)       (58)       (60)         Carcinoma, metastatic, skin       1 (2%)       1 (2%)       (60)       (60)       (58)       (60)         Hemagioma       2 (3%)       1 (2%)       1 (2%)       (60)       (60)       (58)       (60)       (60)       (58)       (60)       (60)       (58)       (60)       (60)       (58)       (60)       (60)       (58)       (60)       (60)       (58)       (50)       (2%)       (58)       (50)       (58)       (50)       (58)       (50)	ral interstitial cell adenoma				(67%)			(79%)				
Hematopoletic System       600       (60)       (58)       (60)         Lymph node       (33)       (36)       (34)       (35)         Mediastinal, osteosarcoma, metastatic, mesentery       1       (3%)       (58)       (60)         Lymph node, mandibular       (60)       (60)       (58)       (60)       (60)       (58)       (60)         Carcinoma, metastatic, Skin       1       (2%)       1       (2%)       1       (2%)         Hemangioma       (60)       (58)       (57)       (60)       (60)       (58)       (60)       (60)       (58)       (60)       (60)       (58)       (60)       (60)       (58)       (60)       (60)       (58)       (57)       (60)       (58)       (57)       (60)       (58)       (57)       (60)       (58)       (50)       (58)       (50)       (58)       (50)       (58)       (50)       (58)       (56)       (58)       (56)       (56)       (58)       (56)       (58)       (56)       (58)       (56)       (58)       (56)       (58)       (56)       (58)       (56)       (58)       (56)       (58)       (56)       (58)       (56)       (58)       (56)       (58) <td< td=""><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></td<>												
Bone marrow       (60)       (60)       (58)       (60)         Lymph node       (33)       (36)       (34)       (35)         Mediastinal, osteosarcoma, metastatic,       1       (3%)       (58)       (60)         Lymph node, mandibular       (60)       (60)       (58)       (60)       1       (2%)         Lymph node, mesanteric       (60)       (60)       (58)       (57)       (60)       1       (2%)         Lymph node, mesenteric       (60)       (60)       (58)       (57)       (60)       (60)       1       (2%)         Lymph node, mesenteric       (60)       (60)       (58)       (57)       (60)       1       (2%)         Spleen       (60)       (60)       (58)       (58)       (50)       1       (2%)         Leiomyosarcoma, metastatic, intestine large, colon       1       (2%)       1       (2%)       1       (2%)       1       (2%)       1       (2%)       1       (2%)       1       (2%)       1       (2%)       1       (2%)       1       (2%)       1       (2%)       1       (2%)       1       (2%)       1       (2%)       1       (2%)       1       (2%)       1						<u></u>				- <u></u>	•	.•
ymph node       (33)       (36)       (34)       (35)         Mediastinal, osteosarcoma, metastatic,       1       (3%)       (60)         Imsentery       1       (3%)       (60)         Carcinoma, metastatic, Symal's gland       1       (2%)         Fibrosarcoma, metastatic, skin       1       (2%)         Lymph node, mesenteric       (60)       (58)       (57)       (60)         Hemangioma       1       (2%)       1       (2%)         Spleen       (60)       (60)       (58)       (60)       (58)       (60)         Fibrosarcoma, metastatic, intestine large,       1       (2%)       1       (2%)         Leiomyosarcoma, metastatic, intestine large,       1       (2%)       1       (2%)         Sarcoma       1       (2%)       1       (2%)       1       (2%)         Thymus       (58)       (55)       (54)       (56)       1       (2%)         Mammary glad       (57)       (56)       (58)       1       (2%)       1       (2%)         Skin       (60)       (60)       (60)       (57)       (56)       (58)       (56)       1       (2%)       1       (2%)       1<	•			((0))	<b>.</b>		(50)			ico		
Mediastinal, osteosarcoma, metastatic, mesentery       1 (3%)         ymph node, mandibular       (60)       (58)       (60)         Carcinoma, metastatic, Zymbal's gland       1 (2%)       1 (2%)         Fibrosarcoma, metastatic, skin       1 (2%)       1 (2%)         Lymph node, mesenteric       (60)       (58)       (57)       (60)         Hemangioma       1 (2%)       1 (2%)       1 (2%)         Spleen       (60)       (60)       (58)       (60)         Fibroma       2 (3%)       1 (2%)       1 (2%)       1 (2%)         Leiomyosarcoma, metastatic, intestine large, colon       1 (2%)       1 (2%)       1 (2%)         Sarcoma       1 (2%)       1 (2%)       1 (2%)       1 (2%)         Sarcoma       1 (2%)       1 (2%)       1 (2%)       1 (2%)         Thymona malignant       (58)       (55)       (54)       (56)         Mammary gland       (57)       (57)       (56)       (58)         Adenoma       1 (2%)       1 (2%)       1 (2%)       1 (2%)         Skin       (60)       (60)       (60)       (57)       (60)         Skin       (60)       (60)       (60)       (57)       (60)												
mesentery       1 (3%)         Lymph node, mandibular       (60)       (60)       (58)       (60)         Carcinoma, metastatic, Skin       1 (2%)       1 (2%)       1 (2%)         Lymph node, mesenteric       (60)       (58)       (57)       (60)         Lymph node, mesenteric       (60)       (58)       (57)       (60)         Lymph node, mesenteric       (60)       (58)       (57)       (60)         Spleen       (60)       (60)       (58)       (60)       (2%)         Phomas       2 (3%)       1 (2%)       1 (2%)       (2%)       (2%)         Leiomyosarcoma, metastatic, intestine large, colon       1 (2%)       1 (2%)       (56)       (56)       (56)       (56)       (56)       (56)       (57)       (56)       (56)       (57)       (56)       (56)       (2%)       1 (2%) <t< td=""><td></td><td>(33)</td><td></td><td>(36)</td><td></td><td></td><td>(34)</td><td></td><td></td><td>(35)</td><td>•</td><td></td></t<>		(33)		(36)			(34)			(35)	•	
Lymph node, mandibular       (60)       (60)       (58)       (60)         Carcinoma, metastatic, Zymbal's gland       1 $(2\%)$ 1 $(2\%)$ Fibrosarcoma, metastatic, skin       1 $(2\%)$ 1 $(2\%)$ Lymph node, mesenteric       (60)       (58)       (57)       (60)         Hemangioma       1 $(2\%)$ 1 $(2\%)$ Spleen       (60)       (60)       (58)       (60)         Fibrona       2 $(3\%)$ 1 $(2\%)$ Histiocytic sarcoma       1 $(2\%)$ 1 $(2\%)$ Colon       1 $(2\%)$ 1 $(2\%)$ 1 $(2\%)$ Streoma       1 $(2\%)$ 1 $(2\%)$ 1 $(2\%)$ Streoma       1 $(2\%)$ 1 $(2\%)$ 1 $(2\%)$ Thymus       (58)       (55)       (54)       (56) $(58)$ Adenoma       1 $(2\%)$ 1 $(2\%)$ 1 $(2\%)$ Fibroadenoma       9 $(16\%)$ 4 $(7\%)$ 6 $(10\%)$ Skin <td>astinal, osteosarcoma, metastatic,</td> <td></td>	astinal, osteosarcoma, metastatic,											
Carcinoma, metastatic, Zymbal's gland       1 (2%)         Fibrosarcoma, metastatic, skin       1 (2%)         Lymph node, mesenteric       (60)       (58)       (57)       (60)         Hemangioma       2 (3%)       1 (2%)       1 (2%)       1 (2%)         Spleen       (60)       (60)       (58)       (60)       (60)       (58)       (60)         Fibrona       2 (3%)       1 (2%)	•							(3%)				· .
Fibrosarcoma, metastatic, skin       1 (2%)         Lymph node, mesenteric       (60)       (58)       (57)       (60)         Hemangioma       1 (2%)       1 (2%)       (60)       (58)       (60)         Fibroma       2 (3%)       1 (2%)       (58)       (60)       (60)       (58)       (60)         Fibroma       2 (3%)       1 (2%)       1 (2%)       (58)       (50)       (57)       (50)       (57)       (50)       (57)       (50)       (57)       (50)       (56)       (57)       (56)       (57)       (56)       (57)       (56)       (58)       (56)       (58)       (56)       (58)       (56)       (58)       (56)       (58)       (56)       (56)       (58)       (56)       (58)       (56)       (58)       (56)       (58)       (56)       (58)       (56)       (56)       (58)       (56)       (58)       (56)       (56)       (58)       (56)       (58)       (56)       (57)       (56)       (58)       (57)       (56)       (58)       (56)       (57)       (56)       (58)       (57)       (56)       (58)       (57)       (56)       (57)       (56)       (57)       (56)       (57)       (56) </td <td>node, mandibular</td> <td>(60)</td> <td></td> <td>(60)</td> <td></td> <td></td> <td>(58)</td> <td></td> <td></td> <td></td> <td></td> <td></td>	node, mandibular	(60)		(60)			(58)					
Lymph node, mesenteric       (60)       (58)       (57)       (60)         Hemangioma       1 (2%)       1 (2%)         Spleen       (60)       (60)       (58)       (60)         Fibroma       2 (3%)       1 (2%)       (60)       (60)         Histiocytic sarcoma       1 (2%)       1 (2%)       (60)       (60)         Soleon       1 (2%)       1 (2%)       1 (2%)       1 (2%)         Sarcoma, metastatic, mesentery       1 (2%)       1 (2%)       1 (2%)       1 (2%)         Thymus       (58)       (55)       (54)       (56)       1 (2%)         Thymoma malignant       1 (2%)       1 (2%)       1 (2%)       1 (2%)         Integumentary System       1 (2%)       1 (2%)       1 (2%)       1 (2%)         Fibroadenoma       1 (2%)       1 (2%)       1 (2%)       1 (2%)         Fibroadenoma, multiple       1 (2%)       1 (2%)       1 (2%)       1 (2%)       1 (2%)         Skin       (60)       (60)       (60)       (57)       (60)       8asal cell carcinoma       1 (2%)       1 (2%)       1 (2%)         Skin       (60)       (60)       (60)       (57)       (60)       8asal cell carcinoma	noma, metastatic, Zymbal's gland									1	(2%)	· * •.
Jernational       1 (2%)         Spleen       (60)       (60)       (58)       (60)         Fibroma       2 (3%)       1 (2%)       1       1         Histiocytic sarcoma       1 (2%)       1       1       2%)         Leiomyosarcoma, metastatic, intestine large, colon       1 (2%)       1       2%)       1       2%)         Sarcoma       1 (2%)       1 (2%)       1 (2%)       1       2%)       1       2%)         Thymus       (58)       (55)       (54)       (56)       1       (2%)         Thymoma malignant       1 (2%)       1 (2%)       1       (2%)       1       (2%)         Mammary gland       (57)       (57)       (56)       (58)       (56)       (58)         Adenoma       1 (2%)       1 (2%)       1 (2%)       6 (10%)       1       (2%)         Fibroadenoma, multiple       1 (2%)       1 (2%)       1 (2%)       1 (2%)       6 (10%)         Skin       (60)       (60)       (60)       (57)       (60)       8asal cell carcinoma       1 (2%)       2 (3%)       2 (3%)         Keratoacanthoma       3 (5%)       4 (7%)       4 (7%)       4 (7%)       2 (3%)       2 (	sarcoma, metastatic, skin							(2%)				
Hemangioma       1 (2%)         Spleen       (60)       (60)       (58)       (60)         Fibroma       2 (3%)       1 (2%)       1 (2%)       1 (2%)       1 (2%)         Leiomyosarcoma, metastatic, intestine large, colon       1 (2%)       1 (2%)       1 (2%)       1 (2%)         Sarcoma       1 (2%)       1 (2%)       1 (2%)       1 (2%)       560       (56)         Thymus       (58)       (55)       (54)       (56)       1 (2%)         Integumentary System       1 (2%)       1 (2%)       1 (2%)       1 (2%)         Mammary gland       (57)       (57)       (56)       (58)         Adenoma       1 (2%)       1 (2%)       1 (2%)       1 (2%)         Fibroadenoma, multiple       1 (2%)       1 (2%)       1 (2%)       6 (10%)         Skin       (60)       (60)       (60)       (57)       (60)         Basal cell carcinoma       1 (2%)       4 (7%)       4 (7%)       4 (7%)         Keratoacanthoma       3 (5%)       4 (7%)       4 (7%)       4 (7%)         Keratoacanthoma, multiple       1 (2%)       2 (3%)       2 (3%)         Squamous cell papilloma       2 (3%)       1 (2%)       2 (3%)	node, mesenteric	(60)	•	(58)	· · · ·		(57)	x + P		(60	) -	
Spleen       (60)       (60)       (60)       (58)       (60)         Fibroma       2 (3%)       1 (2%)       1 (2%)       1 <td< td=""><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>1</td><td>(2%)</td><td></td></td<>										1	(2%)	
Fibroma       2 ( $3\%$ )       1 ( $2\%$ )         Histiocytic sarcoma       1 ( $2\%$ )         Leiomyosarcoma, metastatic, intestine large, colon       1 ( $2\%$ )         Osteosarcoma, metastatic, mesentery       1 ( $2\%$ )         Sarcoma       1 ( $2\%$ )         Thymus       ( $58$ )         Thymoma malignant       ( $57$ )         Integumentary System       1 ( $2\%$ )         Mammary gland       ( $57$ )         Adenoma       1 ( $2\%$ )         Fibroadenoma       9 ( $16\%$ )         Fibroadenoma, multiple       1 ( $2\%$ )         Skin       ( $60$ )         Basal cell carcinoma       1 ( $2\%$ )         Keratoacanthoma       3 ( $5\%$ )         Squamous cell papilloma, multiple       1 ( $2\%$ )         Squamous cell papilloma, multiple       2 ( $3\%$ )	0	(60)		(60)			(58)			(60)	)	· ·
Histiocytic sarcoma       1 (2%)         Leiomyosarcoma, metastatic, intestine large, colon       1 (2%)         Osteosarcoma, metastatic, mesentery       1 (2%)         Sarcoma       1 (2%)         Sarcoma       1 (2%)         Thymus       (58)         (58)       (55)         Thymoma malignant       1 (2%)         Integumentary System         Marmary gland       (57)         (57)       (56)         Adenoma       1 (2%)         Fibroadenoma       9 (16%)         Fibroadenoma, multiple       1 (2%)         Skin       (60)         (60)       (60)         Basal cell carcinoma       1 (2%)         Keratoacanthoma       3 (5%)       4 (7%)       4 (7%)         Keratoacanthoma, multiple       1 (2%)       2 (3%)       2 (3%)         Squamous cell papilloma       2 (3%)       1 (2%)       2 (3%)	ma			1	(2%)							
Leiomyosarcoma, metastatic, intestine large, colon       1 (2%)         Osteosarcoma, metastatic, mesentery       1 (2%)         Sarcoma       1 (2%)         Thymus       (58)         (58)       (55)         Thymoma malignant       1 (2%)         Integumentary System         Marmary gland       (57)         (57)       (57)         Fibroadenoma       1 (2%)         Fibroadenoma, multiple       1 (2%)         Skin       (60)         (60)       (60)         Skin       (60)         Keratoacanthoma       3 (5%)         4 (7%)       4 (7%)         Keratoacanthoma, multiple       1 (2%)         Squamous cell papilloma       2 (3%)         Squamous cell papilloma, multiple       1 (2%)					. ,							
colon       1 (2%)         Osteosarcoma, metastatic, mesentery       1 (2%)         Sarcoma       1 (2%)         Thymus       (58)         Thymoma malignant       (58)         Integumentary System       1 (2%)         Mammary gland       (57)         Adenoma       1 (2%)         Fibroadenoma       9 (16%)         Fibroadenoma, multiple       1 (2%)         Skin       (60)         Skin       (60)         Keratoacanthoma       3 (5%)         Keratoacanthoma, multiple       1 (2%)         Squamous cell papilloma       2 (3%)         Squamous cell papilloma, multiple       1 (2%)		-	<b>(</b> - · · · <b>)</b>									
Osteosarcoma, metastatic, mesentery       1 (2%)       1 (2%)         Sarcoma       1 (2%)       1 (2%)         Thymus       (58)       (55)       (54)       (56)         Thymoma malignant       1 (2%)       1 (2%)       1 (2%)         Integumentary System         Mammary gland       (57)       (57)       (56)       (58)         Adenoma       1 (2%)       1 (2%)       1 (2%)         Fibroadenoma       9 (16%)       4 (7%)       4 (7%)       6 (10%)         Fibroadenoma, multiple       1 (2%)       1 (2%)       1 (2%)       1 (2%)         Skin       (60)       (60)       (57)       (60)       60)       1 (2%)         Keratoacanthoma       3 (5%)       4 (7%)       4 (7%)       4 (7%)       4 (7%)         Keratoacanthoma       2 (3%)       1 (2%)       2 (3%)       2 (3%)       2 (3%)         Squamous cell papilloma       2 (3%)       1 (2%)       2 (3%)       2 (3%)				1	(2%)						1. 1. 1.	4
Sarcoma       1 (2%)       1 (2%)       1 (2%)       1 (2%)         Thymus       (58)       (55)       (54)       (56)         Thymoma malignant       (57)       (57)       (56)       (1 (2%)         Integumentary System         Mammary gland       (57)       (57)       (56)       (58)         Adenoma       1 (2%)       1 (2%)       6 (10%)         Fibroadenoma       9 (16%)       4 (7%)       4 (7%)       6 (10%)         Fibroadenoma, multiple       1 (2%)       1 (2%)       1 (2%)       1 (2%)         Skin       (60)       (60)       (57)       (60)       60)       60)         Basal cell carcinoma       1 (2%)       4 (7%)       4 (7%)       4 (7%)         Keratoacanthoma       3 (5%)       4 (7%)       4 (7%)       4 (7%)         Keratoacanthoma, multiple       1 (2%)       2 (3%)       2 (3%)       2 (3%)         Squamous cell papilloma, multiple       1 (2%)       2 (3%)       2 (3%)				-	(-(.)	•	1	(2%)				1 - A
Thymus       (58)       (55)       (54)       (56)       1 $(2\%)$ Integumentary System       Mammary gland       (57)       (57)       (56)       (58)         Adenoma       1       (2%)       1       (2%)       6       (10%)         Fibroadenoma       9       (16%)       4       (7%)       4       (7%)       6       (10%)         Fibroadenoma, multiple       1       (2%)       1       (2%)       1       (2%)       1       (2%)       55)       (60)       (57)       (60)       60)       6       (10%)       1       (2%)       1       (2%)       1       (2%)       1       (2%)       1       (2%)       1       (2%)       1       (2%)       2       (3%)       1       (2%)       2       (3%)       2       (3%)       2       (3%)       3       3       3       3       3       3       3       3       3       3       3       1       2       (3%)       3		1	(2%)								(2%)	
Thymoma malignant       1 (2%)         Integumentary System       1       1 (2%)         Mammary gland       (57)       (57)       (56)       (58)         Adenoma       1 (2%)       1 (2%)       6 (10%)         Fibroadenoma       9 (16%)       4 (7%)       4 (7%)       6 (10%)         Fibroadenoma, multiple       1 (2%)       1 (2%)       1 (2%)         Skin       (60)       (60)       (57)       (60)         Basal cell carcinoma       1 (2%)       4 (7%)       4 (7%)       4 (7%)         Keratoacanthoma       3 (5%)       4 (7%)       4 (7%)       4 (7%)         Squamous cell papilloma       2 (3%)       1 (2%)       2 (3%)       2 (3%)				(55)				(270)				
Mammary gland $(57)$ $(57)$ $(56)$ $(58)$ Adenoma1 (2%)1 (2%)Fibroadenoma, multiple9 (16%)4 (7%)4 (7%)6 (10%)Fibroadenoma, multiple1 (2%)1 (2%)1 (2%)Skin(60)(60)(57)(60)Basal cell carcinoma1 (2%)4 (7%)4 (7%)Keratoacanthoma3 (5%)4 (7%)4 (7%)Keratoacanthoma, multiple1 (2%)2 (3%)Squamous cell papilloma2 (3%)1 (2%)2 (3%)		(56)		(55)			(34)		*			
Mammary gland $(57)$ $(57)$ $(56)$ $(58)$ Adenoma1 (2%)1 (2%)Fibroadenoma, multiple9 (16%)4 (7%)4 (7%)6 (10%)Fibroadenoma, multiple1 (2%)1 (2%)1 (2%)Skin(60)(60)(57)(60)Basal cell carcinoma1 (2%)4 (7%)4 (7%)Keratoacanthoma3 (5%)4 (7%)4 (7%)Keratoacanthoma, multiple1 (2%)2 (3%)Squamous cell papilloma2 (3%)1 (2%)2 (3%)			. <u></u>							. <u></u>		
Adenoma       1 (2%)       1 (2%)         Fibroadenoma       9 (16%)       4 (7%)       4 (7%)       6 (10%)         Fibroadenoma, multiple       1 (2%)       1 (2%)       1 (2%)       1 (2%)         Skin       (60)       (60)       (57)       (60)         Basal cell carcinoma       1 (2%)       4 (7%)       4 (7%)         Keratoacanthoma       3 (5%)       4 (7%)       4 (7%)       4 (7%)         Keratoacanthoma, multiple       1 (2%)       2 (3%)       2 (3%)       2 (3%)         Squamous cell papilloma, multiple       1 (2%)       2 (3%)       1 (2%)	mentary bystem						100			100		
Fibroadenoma       9 (16%)       4 (7%)       4 (7%)       6 (10%)         Fibroadenoma, multiple       1 (2%)       1 (2%)       1 (2%)       1 (2%)         Skin       (60)       (60)       (57)       (60)         Basal cell carcinoma       1 (2%)       4 (7%)       4 (7%)       4 (7%)         Keratoacanthoma       3 (5%)       4 (7%)       4 (7%)       4 (7%)         Keratoacanthoma, multiple       1 (2%)       2 (3%)       2 (3%)         Squamous cell papilloma       2 (3%)       1 (2%)       2 (3%)				(57)	ł			(3.01)		(58	)	
Fibroadenoma, multiple       1 (2%)       1 (2%)         Skin       (60)       (60)       (57)       (60)         Basal cell carcinoma       1 (2%)       4 (7%)       4 (7%)       4 (7%)         Keratoacanthoma       3 (5%)       4 (7%)       4 (7%)       4 (7%)         Keratoacanthoma, multiple       1 (2%)       2 (3%)       2 (3%)         Squamous cell papilloma, multiple       1 (2%)       2 (3%)					( <b>1</b>							•
Skin         (60)         (60)         (57)         (60)           Basal cell carcinoma         1 (2%)         (60)         (7%)         4 (7%)         4 (7%)           Keratoacanthoma, multiple         1 (2%)         4 (7%)         4 (7%)         2 (3%)         2 (3%)           Squamous cell papilloma, multiple         1 (2%)         1 (2%)         2 (3%)         2 (3%)				. 4	. (7%)		4	(7%)				
Basal cell carcinoma1(2%)Keratoacanthoma3(5%)4(7%)4(7%)Keratoacanthoma, multiple1(2%)2(3%)2(3%)Squamous cell papilloma2(3%)1(2%)2(3%)Squamous cell papilloma, multiple1(2%)2(3%)1(2%)	adenoma, multiple											
Keratoacanthoma         3 (5%)         4 (7%)         4 (7%)         4 (7%)           Keratoacanthoma, multiple         1 (2%)         2 (3%)         1 (2%)         2 (3%)           Squamous cell papilloma, multiple         1 (2%)         1 (2%)         2 (3%)         2 (3%)				(60)	ł	•	(57)			(60	)	
Keratoacanthoma, multiple1 (2%)Squamous cell papilloma2 (3%)1 (2%)Squamous cell papilloma, multiple1 (2%)	l cell carcinoma											
Squamous cell papilloma2 (3%)1 (2%)2 (3%)Squamous cell papilloma, multiple1 (2%)1 (2%)1	toacanthoma	3	(5%)	. 4	(7%)		4	(7%)			4 (7%)	, ·
Squamous cell papilloma2 (3%)1 (2%)2 (3%)Squamous cell papilloma, multiple1 (2%)1 (2%)	toacanthoma, multiple	1	(2%)								,	÷
Squamous cell papilloma, multiple 1 (2%)	mous cell papilloma			. 1	(2%)						2 (3%)	
	mous cell papilloma, multiple											
Trichoepithelioma         2 (3%)         1 (2%)         1 (2%)		2	2 (3%)			•			~		1 (2%)	

ι

# Table A1

Summary of the Incidence of Neoplasms in Male Rats in the Long-Term Feed Study of t-Butylhydroquinone (continued)

	0 ppm	1,250 ppm	2,500 ppm	5,000 ppm	
Long-Term Study (continued)					
Integumentary System (continued)					
Skin (continued)	(60)	(60)	(57)	(60)	
Sebaceous gland, adenoma	1 (2%)	1 (2%)			
Subcutaneous tissue, fibroma	3 (5%)	8 (13%)	6 (11%)	6 (10%)	
Subcutaneous tissue, fibroma, multiple	1 (2%)	1 (27)	1 (20)		
Subcutaneous tissue, fibrosarcoma Subcutaneous tissue, hemangioma	1 (2%) 1 (2%)	1 (2%)	1 (2%)	1 (2%)	
Subcutaneous tissue, hemangiosarcoma	1 (2%)				
Subcutaneous tissue, schwannoma benign	1 (2%)				
Subcutaneous tissue, schwannoma malignant			1 (2%)	1 (2%)	
Musculoskeletal System	, <b>* * * * * *</b>				
Bone	(60)	(60)	(58)	(60)	
Osteosarcoma			1 (2%)		
Skeletal muscle		(2)	(2)		
Leiomyosarcoma, metastatic, intestine large,		1 (500)		a.	
colon Osteosarcoma, metastatic, mesentery	· ·	1 (50%)	1 (50%)		
Nervous System Brain Astrocytoma malignant Oligodendroglioma malignant	(60) 1 (2%) 1 (2%)	(60) 1 (2%)	(58)	(60)	
Spinal cord	(2)	(3)	(1)	(1)	
Respiratory System					
Lung	(60)	. (60) 2 (2 %)	(58)	(60)	
Alveolar/bronchiolar adenoma Alveolar/bronchiolar carcinoma	3 (5%)	2 (3%)	1 (2%)	1 (2%) 1 (2%)	
Carcinoma, metastatic, salivary glands			1 (2%)	1 (270)	
Histiocytic sarcoma	1 (2%)				
Squamous cell carcinoma, metastatic, oral					
mucosa	((0)		1 (2%)	((0))	
Nose Squamous cell carcinoma	(60)	(60)	(58)	(60)	
Squamous cell papilloma	1 (2%)	1 (2%)			
Pleura	- (		(1)		
Special Senses System	<u></u>		. <u>, , , , , , , , , , , , , , , , , , ,</u>		
Ear		(1)	(1)		
Squamous cell papilloma		1 (100%)			
Eye	(4)	(2)	(1)	(2)	
Carcinoma, metastatic, salivary glands	(2)	(1)	1 (100%)		
Zymbal's gland Adenoma	(2)	(1)	(3)	(4) 1 (25%)	
Carcinoma	2 (100%)	1 (100%)	3 (100%)	3 (75%)	

Summary of the Incidence of Neoplasms in Male Rats in the Long-Term Feed Study of t-Butylhydroquinone (continued)

	0 ppm	1,250 ppm	2,500 ppm	5,000 ppm
	<u> </u>	· · · · ·		<u> </u>
Long-Term Study (continued)	×.			
Urinary System	· · · · ·			
Kidney	(60)	(60)	(58)	(60)
Lipoma	1 (2%)			
Osteosarcoma, metastatic, mesentery			1 (2%)	
Renal tubule, adenoma	2 (3%)		1 (2%)	1 (2%)
Transitional epithelium, carcinoma	1 (2%)			
Urinary bladder	(60)	(60)	(58)	(60)
Papilloma			1 (2%)	1 (2%)
Systemic Lesions		······································	······································	
Multiple organs <sup>b</sup>	(60)	(60)	(58)	(60)
Histiocytic sarcoma	1 (2%)	(66)	(50)	(00)
Leukemia mononuclear	39 (65%)	47 (78%)	40 (69%)	32 (53%)
Lymphoma malignant	1 (2%)	47 (7070)	40 (0270)	52 (5576)
Mesothelioma malignant	1 (2%)		1 (2%)	3 (5%)
	<u></u>	· <u> </u>	. <u></u>	
Neoplasm Summary				
Total animals with primary neoplasms <sup>c</sup>	60	59	57	60
Total primary neoplasms	207	185	178	179
Total animals with benign neoplasms	60	56	56	59
Total benign neoplasms	148	125	120	120
Total animals with malignant neoplasms	51	53	50	47
Total malignant neoplasms	59	60	58	59
Fotal animals with metastatic neoplasms		- 1	5	2
Total metastatic neoplasms	· · ·	· 6	11	. 2

a Number of animals examined microscopically at the site and the number of animals with neoplasm

b

Number of animals with any tissue examined microscopically Primary neoplasms: all neoplasms except metastatic neoplasms с

	2	A	4	5	5	<	5	5	5	6	6	6	6	6	6	6	6	6	6	6	6	6	6	6	6	
Number of Days on Study	8	-				3	4	5			1						6	7	7	7	7	7	8	8		
	. 1	-	.9		_	4	-		3	8	8	2	6			7	8	3	4	4	4	4	-	7		
<u></u>	0	0	0	0	0		0	0	0	0	0	0	Δ	Δ	0	0	0	0	0	0	0	0	0	0	0	 ·
Carcass ID Number	5					4	4	2	3	1	2	õ	4	0	0	3	5		1	1				0		
	9					4	•						3						5		7		-	9	-	
Alimentary System	*****																								-	 <u> </u>
Esophagus	-		+ -		+ +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Intestine large, colon	-			+	- +	+	+	+	+	+	+	+	+	+		М	+	+	+	M	+	+	+	+	+	•
Intestine large, rectum	-				+ +	+	+	+	+	+	+	+	+	+	+	+	+	М	+	+	+	+	+	+	+	
Intestine large, cecum	-				- +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Intestine small, duodenum	-		+ -		- +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Intestine small, jejunum	-				- +	+	+	+	+	+	+	+	+	+	+	+	+	· +	+	+	+	+	+	+	+	
Intestine small, ileum	4		+ -			• +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Liver	-		F 4		- +	• +	+	+	+	+	+	+	+	+	+	÷	+	+	+	+	+	+	+	+	+	
Hepatocellular adenoma					•	•	•		•	•	•	•	•	x	•	•	•	•	•	•	•	•	•	•	•	
Histiocytic sarcoma									х					~												
Mesentery			F	-	F			+			+		+			+	+		+			+	+			
Histiocytic sarcoma								·	x		•		•			•	•		•			·	•			
Schwannoma malignant											х															
Oral mucosa			⊦																							
Squamous cell carcinoma		2																								
Pancreas	-	L -	- 	F 4	⊢ +		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Acinus, adenoma						•	•	·		•	•	·		•		•			•	•	•	·	•	•	•	
Salivary glands	_	L -		L .		. <b>.</b>	+	ц,	Ŧ	+	+	Ŧ	Ŧ	+	+	+	+	+	+	+	+	Ŧ	+	+	+	
Stomach, forestomach					г т ц ц		т -	т -	т 	т - т	т Т	-	т - Т	- <b>T</b>	т Т	т Т	т Т		т Т					Ť		
Stomach, glandular	_		L .		 		÷	÷	+	- -	÷	÷	, Т	+	+	+	÷		+	+	÷	، ــــــــــــــــــــــــــــــــــــ		+		
Tongue								1	Ŧ	т	r		т	т	,	'	т	T	1	'		'	T	'	'	
Squamous cell carcínoma																										
Tooth					۲																					
· · · · · · · · · · · · · · · · · · ·		_		-	, 									-		<u> </u>	_			_						 
Cardiovascular System Blood vessel	•																			4	,	,	i	,		
Heart	-			r 7	г т 1. 1	·		Ţ		Ţ		- <b>T</b>	<b>. .</b>	Ţ		- <b>T</b>	T	T	+	+	+	+	T	+	+	
Schwannoma malignant	•		<b>-</b> -	•	гт		т	т	т	т	т	T	T	Ŧ	Ŧ	т	.т	т	T	T	x	-	Ŧ	Ŧ	т	
Endocrine System										·				-		_			_							 
Adrenal cortex	_	ь.	÷ .	+ -	<b>н</b> 4	- +	-+-	+	+	+	+	+	+	+	+	+	÷	+	+	+	+	4	+	+	+	
Adenoma		•	•	•			•			•	•				'	'	•		,	•	•			•		
Adrenal medulla		<b>۴</b> .	L.	÷ -	L 4		+	+	+	+	·+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Pheochromocytoma malignant		•	•	•		•	•			•		•	•	'		•	•	•			•		'	•		
Pheochromocytoma benign																х						x				
Pheochromocytoma benign, multiple																~						~				
Islets, pancreatic	-	÷ .	+ .	+ -	+ +		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Adenoma		•	•	•	• •	ſ						'	1	•	•	x			•	•	•	ſ		'		
Carcinoma																л										
Parathyroid gland		•	÷ -	<b>ب</b>	<b>د</b> ـ	- +	. <b>.</b>	4	<b>.</b>	+	+	÷	+	+	+	+	÷	+	+	+	+	+	+	+	+	
Pituitary gland			Ļ.,	+ -									+												+	
Pars distalis, adenoma	-	•	•	•	X			ſ	r	1		x			x			1	ſ		x			x		
Thyroid gland		+ -	+ •	+ -	+ +			+	<b>.</b> .	+	+							+	+	-			+		+	
C-cell, adenoma	-	•	•	,		, r		r	r.	۰.	'				•									•	'	

+: Tissue examined microscopically A: Autolysis precludes examination M: Missing tissue I: Insufficient tissue X: Lesion present Blank: Not examined - 19 -

÷.,

TABLE A2

Individual Animal Tumor Pathology of Male Rats in the Long-Term Feed Study of t-Butylhydroquinone: 0 ppm (continued)

Number of Days on Study		7 0 4	7 0 5	7 0 8	7 1 0	1	2	3	3	7 7 3 5 8 (	5 :	7 · 7 5 · 5 2 · 2	5	77 55 78	5	7 6 1	7 7 4	7 7 4	7 8 5	7 8 6	7 8 6	7 8 6	7 9 5	8 •0 7	0				*4
Carcass ID Number		0 3 4	4	0 1 4		4	5		5	0 ( 1 3 9 2	3 2	2 3	3 4	0 0 4 3 1 0	0	3	3	0 5 4	2	2	0 3 3	0 5 1	0 5 2	0 0 2	0		,	• • •	
Alimentary System																													
Esophagus		+	+	+	÷	+	+	+	+	+	+ ·	+ •	+ · ·	+ +	+ +	• +	+	+	+	+	+	+	+	+	+			٠,	~
Intestine large, colon		_ <b>+</b>	+	+	+	+	+	+	+	+ ·	+ •	+ -	+ ·	+ +	- +	• +	+	+	+	+	+	+	+	+	+		•		
Intestine large, rectum	•	, <b>+</b>	+	+	+	+	+	+	+	+ -	+ ·	+ -	+ · ·	+ +	+ +	• +	+	+	+	+	÷	+	+	; <del>†</del>	+		·		
Intestine large, cecum		+	+	+	+	+	+	+	+.	+	+ ·	+/ -	<b>+</b> ∙ ·	+ +	<u>+</u> +	• +	+	+	+	+	+	+	+	+	+				
Intestine small, duodenum	· .	. +	+	+	+	+	÷	+	+	+	+ ·	+: ·	+ · ·	+ -	+ +	• +	+	+	÷	+	+	+	.+	+	+		4		
Intestine small, jejunum		+	+	+	+	+	+	+	+	+ ·	+ ·	+ •	+ ·	+ +	+.+	• +	+	+	+	Ŧ	.+	+	+	+	+		••		• •
Intestine small, ileum		+	+	+	+	+	+	+	+	+	+	+ -	+	+ -	+ +	• +	+	+	+	+	+	+	+	+	+				
Liver		+	+	+	+,	+	+	+	+	+	+ -	+ •	+	+ +	+ +	• +	+	· +	+	+	+	+	+	+	+				
Hepatocellular adenoma Histiocytic sarcoma												•								X		х		•.•	• •		÷ '		
Mesentery		+			+	+	+						•									+							
Histiocytic sarcoma																					,			÷.,	:		;	•	
Schwannoma malignant																													
Oral mucosa																													
Squamous cell carcinoma																						•							
Pancreas		+	+	+	Ŧ	+	+	+	+	+	+ .	+ ·	+	+ -	- +	- +	+	+	+	+	+	+	+	Ŧ	. +				
Acinus, adenoma																								i	· •		-		
Salivary glands Stomach, forestomach		+	+	+	+	+	+	+	+	+	+ '	т · 	+	+ -		• +	+	+	+	+	+	+	+	+	+	٠,			
Stomach, glandular			· +	Ť	· T	. <b>T</b>	· <b>T</b>	т - т	т ц	т _	T .	т : _	+ +	т - 	г т ∟ _	- <u>-</u>	· +	+ +	- T - L	- -	- -	т 	+	т 	+				•
Tongue		· T	т	Τ.	· •	т	Τ.		т	Ŧ	τ	Τ .	т	+ -	гт	· •	· +	т	т	т	т	т	т	т	т				
Squamous cell carcinoma																:	x						۰.	•	,	,		•	•
Tooth	•																Λ												•
Cardiovascular System												-						_			-					• •			
Blood vessel		+	+	+	+	+	+	+	+	+:	+	+	+	<b>+</b> -	+ +	- +	. +	+	+	+	+	+	+	+	·+				
Heart		+	- <b>+</b> -	+	+	÷	+	÷	÷	+	÷	÷ .	÷	+ -	, , , ,		. +	·+	+	+	+	+	+	+	+				
Schwannoma malignant				•	•	•	•	•	•		•	•	•	•		•	•	•	·	•	•		•	•	•				
Endocrine System						_		-		_								_							_				· .
Adrenal cortex		+	+	+	+	+	+-	+	+	<b>+</b> .	+	+	+	+ -	+ →	- +	+	+	+	+	+	+	+	+	+		÷.,		
Adenoma		r		•	•	1	•	'		•		•	•		. 1				•	x		•		•	•			•	
Adrenal medulla		+	+	+	+	+	+	+	+	+	+	+	+	+ -	+ 4	- +	• +	+	+	+	+	+	+	+	+				
Pheochromocytoma malignant		•	•	. •	x	•	•						-	-				•	-									•	
Pheochromocytoma benign		·x				х			х					х				х				X	х	X					
Pheochromocytoma benign, multiple						-												-	e .				•						
Islets, pancreatic		+	+	+	+	+	+	+	+	+	+	+	+	+ •	+ +	+ +	• +	+	+	+	+	+	+	+	+				
Adenoma																	Х					Х							
Carcinoma		•																								·· ·			
Parathyroid gland		+	: +	+	+	+	М	М	+	+	+	+	+	+ •	+ +	+ +	·M	[ +	+	+	+	+	+	M	[ +	*		•	
Pituitary gland		+	• +	+	+	+	+	+	+	+	+				+ +	+ +		+	+					+	+				
Pars distalis, adenoma							х	Х					х	X		Х		Х			X			. •					
Thyroid gland		+	• +	+	+	+	+	+	+	+	+	+	+	+ ·	+ +		• +	+	<b>+</b>	+	+	+					.•	•	,
C-cell, adenoma								Х			Х				Z	ζ							Х	X					•

Individual Animal Tumor Pathology of Male Rats in the Long-Term Feed Study of t-Butylhydroquinone: 0 ppm (continued)

Number of Days on Study	8 8 8 8 8 8 8 8 8 8 2 3 5 5 5 5 5 5 5 5	
	4 1 7 7 7 7 7 7 7 7 7	
	0 0 0 0 0 0 0 0 0 0	Total
Carcass ID Number	5 0 1 1 1 3 4 4 4 5 3 4 1 2 3 9 0 2 5 7	Tissues/ Tumors
Alimentary System	╕╶╴╕╧╶╶┑╧╌╴┑╗╧╺╖╝╧╺┑┑╧╺╖╎╧╺╖╎┪┙┑╕╧╵╗╬┶╸┑┪╧╺╕╝┙┑╕╝╄╖╖╗╩ <sup>╄</sup> ╵╖╗ <sup>╋</sup> ╵╖╗ <sup>╋</sup> ╵╸╝ <sup>╋</sup> ╵╸╝ <sup>╋</sup> ╵	- <u> </u>
Esophagus	+ + + + + + + + +	60
intestine large, colon	+ + + + + + + + +	58
ntestine large, rectum	· + + + + + + + + +	59
ntestine large, cecum	+ + + + + + + + +	60
ntestine small, duodenum	+ + + + + + + + +	60
ntestine small, jejunum	+ + + + + + + + +	60
ntestine small, ileum	+ + + + + + + + +	60
iver	+ + + + + + + + +	60
Hepatocellular adenoma	X	4
Histiocytic sarcoma		1
Aesentery	+ + + +	20
Histiocytic sarcoma		1
Schwannoma malignant		· . 1
)ral mucosa		. 1
Squamous cell carcinoma		1
ancreas	* * * * + * * * *	60
Acinus, adenoma	X X X	3
alivary glands	+ + + + + + + +	60
tomach, forestomach	+ + + + + + + + +	60
stomach, glandular	+ + + + + + + +	60
Fongue		1
Squamous cell carcinoma	,	• 1
Footh		1
Cardiovascular System	· · · ·	
Blood vessel	+ + + + + + + + +	60
Heart	+ + + + + + + + +	, 60
Schwannoma malignant		1
Endocrine System		
Adrenal cortex	+ + + + + + + + +	60
Adenoma		1
Adrenal medulla	+ + + + + + + + +	60
Pheochromocytoma malignant		1
Pheochromocytoma benign	XX	13
Pheochromocytoma benign, multiple	X	1
slets, pancreatic	+ + + + + + + + +	60
Adenoma	X X	5
Carcinoma	X	1
Parathyroid gland	+ M + + + + + + + +	55
Pituitary gland	+ + + + + + + + +	60
Pars distalis, adenoma	X X X	. 19
Thyroid gland	+ + + + + + + + +	60
C-cell, adenoma		5

79

																	,	_					_						
	3	4	4	5	5	5	5	5	5	6	6	6	6.	6	6	6	6	6	6	6	6	6	6	6	6				
Number of Days on Study	8	8	9	0	2	-					1	_	-					7		7	-	7	8	-	9			•	
	1	9	9	0	8	4	4	6	3	8	8	2	6	2	9	7	8	3	4	4	4	4	7	7	<u>, 4</u> ,				
· · · · · · · · · · · · · · · · · · ·	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0				
Carcass ID Number	5	2	1	6	4	4	4			1	2	0	4			3	5	2	1	1	2	5	0	0	_	, î			
	. 9	4	6	0	8	4	6	0	1		5	0	3	1	/	5	0	8	5	8	7	8	3		2		••	•	·,
General Body System Peritoneum																			、					-					
Genital System																													
Epididymis	+	+	+	+	+	+	+	+	+	+	+	+	÷	+	+	+	+	+	÷	+	+	+	+	+	+				
Preputial gland	+	+	+	+	+	+	+	+	+	+	+	+	+	÷	+	+	+	+	+	+	+	+	+	+	+		•		
Adenoma					Х																			Х					
Carcinoma	Х									Х																			
Prostate	+	+	+	+	+	+	+	+	+	+	+	÷	+	÷	+	+	÷	+	+	+	+	.+	+	+	+				
Adenoma																													
Seminal vesicle	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+				
Testes	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+				
Bilateral, interstitial cell, adenoma							х		х	х			Х		Х	Χ.	х		х	х	х		X		· X				
Interstitial cell, adenoma		х	х	X		Х		х			х			Х				<b>X</b> ,				X			•	•			-
Hematopoietic System																										· •	:		
Bone marrow	+	+	+	ť	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+				
Lymph node	+						+	+	+	+		+			+	+	+		+		÷	+	+		,				
Lymph node, mandibular	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	` <b>+</b>				
Lymph node, mesenteric	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	·+	÷				
Spleen	+	+	+	+	+	+	+	+	+	+	+	+	+	÷	+	+	+	+	+	+	+	÷	+	+	+				
Fibroma																													
Histiocytic sarcoma									Х																				
Sarcoma																									•				•
Thymus	+	+	+	+	+	+	+	+	+	+	+	<b>+</b>	+	÷	+	+	+	+	+	+	+	+	:+	·+	+	<u>t</u>			
Integumentary System																													
Mammary gland	+	+	+	+	+	+	+	+	+	+	+	+	М	+	+	+	+	+	М	+	+	+	Μ	( +	+			÷ .	
Adenoma																	Х												
Fibroadenoma	Х																											•	
Fibroadenoma, multiple																								×*					
Skin	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+				
Basal cell carcinoma																									٠.	•			. 1
Keratoacanthoma																х													
Keratoacanthoma, multiple																								х	• •				
Squamous cell papilloma																								۱.		•	•		
Trichoepithelioma																													
Sebaceous gland, adenoma																	х								•				
Subcutaneous tissue, fibroma																							$\cdot$ ,						
Subcutaneous tissue, fibroma, multiple																					,								
Subcutaneous tissue, fibrosarcoma																									•				
Subcutaneous tissue, hemangioma															•							. •			•	· .			
Subcutaneous tissue, hemangiosarcoma													х																
Subcutaneous tissue, schwannoma benign																•								· ·					
Musculoskeletal System	<u></u>																										•		

# t-Butylhydroquimone, NTP TR 459

### TABLE A2

Individual Animal Tumor Pathology of	1 MIBIIG		nus	IM	UMO	e IL	on;	<b>g-</b> 1	ll er	mi	шe	ea	SU	nai	y. O)	l <i>8</i> -	-IRA	ку	liny	ar	ođi	UAR		e: ,	U P	opm (	continued
	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	8	8		
Number of Days on Study	0		0								5	5	5	5	5	6		7	8	8		8		. 0			
······································	-	-	8					6		0	2	2	7		9	1	4	4		6	6	6		7			
	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
Carcass ID Number	3	4	1	1	4	5	2	5	1	3	2	3	4	3	0	3	3	5	2	2	3	5	5	0	0		
		9	-	0			_	-	9																		
General Body System Peritoneum	<u>.</u>																										
Genital System																											
Epididymis	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		
Preputial gland	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		
Adenoma												х															
Carcinoma												-															
Prostate	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		
Adenoma	•		•.	•		•	•		•	•	•		•	•	•	•	•	•	•	•	•	•	•	·	•		
Seminal vesicle	Ŧ	Ŧ	Ŧ	ъ	ъ	ᆂ	Ŧ	ъ	4	т.	Ŧ	Ŧ	Ŧ	۰	Ъ	÷	4	Ŧ	+	+	Ŧ	L.	<u>ب</u>	Ŧ	+		
Testes	т Ц	т —	1	т. - д	1	1	+	+		1	+	+	+	+	1	1	<u> </u>	Ĺ.	+	+	1	1	+		+		
Bilateral, interstitial cell, adenoma	T V	Y	v	Y	x	Ý	r	г	Y	Ŷ			x		т	v	x	Ŷ	Ŧ	T	Y	Y			x		
Interstitial cell, adenoma	л	Λ.	•	•	л	л	х	v	Λ	Λ	Λ	Λ	Λ	Λ	х	Λ	Λ	л	х		Λ	л	А	л	л		
						_	~			_			-		^					_				_			·····
Hematopoietic System												-	ъ	·	Т					-			-	-	ь		
Bone marrow	+	+	+	+	+	+	+	+	+	+	Ŧ	T	Ŧ	-	. <u>T</u>	-	+	+	+		+	т	- <b>-</b>	T	+		
Lymph node		+	+		+	+		+	+	+				+	+	+	+		+	+			+		+		
Lymph node, mandibular	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		
Lymph node, mesenteric	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	• +	+	+		
Spleen	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+			+		
Fibroma																							Х				
Histiocytic sarcoma																											
Sarcoma										х																	
Thymus	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	M		
Integumentary System																											
Mammary gland	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	• +	+		
Adenoma							•-																				
Fibroadenoma							х														Х		Х		Х		
Fibroadenoma, multiple																											
Skin	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	• +	+	+		
Basal cell carcinoma																Х											
Keratoacanthoma																											
Keratoacanthoma, multiple																											
Squamous cell papilloma																							Х				
Trichoepithelioma															Х								Х				
Sebaceous gland, adenoma																											
Subcutaneous tissue, fibroma																Х											
Subcutaneous tissue, fibroma, multiple																	Х										
Subcutaneous tissue, fibrosarcoma										·																	
Subcutaneous tissue, hemangioma																											
Subcutaneous tissue, hemangiosarcoma																											
Subcutaneous tissue, schwannoma benign																	Х										
Musculoskeletal System			_																							·	
Bone		+	• +	+																							

81

Individual Animal Tumor Pathology of Male Rats in the Long-Term Feed Study of t-Butylhydroquinone: 0 ppm (continued) 8 8 8 8 8 8 8 8 8 8 Number of Days on Study 2 3 5 5 5 5 5 5 5 5 7 7 7 7 7 7 7 4 1 7 0 0 0 0 0 0 0 0 0 0 Total 0 1 1 1 3 4 4 4 5 **Carcass ID Number** 5 Tissues/ 3 4 1 2 3 9025 7 Tumors **General Body System** Peritoneum + 1 **Genital System** Epididymis 60 Preputial gland 60 5 Adenoma Carcinoma 2 60 Prostate Adenoma 2 x х Seminal vesicle ÷ 60 + + + + + Testes Ή 60 ++ + + + + + + + Bilateral, interstitial cell, adenoma x х Х Х Х Х Х Х Х х 42 Interstitial cell, adenoma 13 **Hematopoietic System** Bone marrow 60 33 Lymph node 4 + Lymph node, mandibular 60 + 60 Lymph node, mesenteric Spleen 60 2 Fibroma Histiocytic sarcoma 1 Sarcoma 1 58 Thymus + + + ·M + + + + + + **Integumentary System** 57 Mammary gland 1 + Adenoma 1 ххх Q Fibroadenoma Х х Fibroadenoma, multiple 1 Skin 60 + 1 Basal cell carcinoma хх 3 Keratoacanthoma 1 Keratoacanthoma, multiple Squamous cell papilloma Х 2 2 Trichoepithelioma Sebaceous gland, adenoma 1 Х х Subcutaneous tissue, fibroma 3 Subcutaneous tissue, fibroma, multiple Х Subcutaneous tissue, fibrosarcoma 1 Х Subcutaneous tissue, hemangioma 1 Subcutaneous tissue, hemangiosarcoma 1 1 Subcutaneous tissue, schwannoma benign **Musculoskeletal System** 60 Bone + + + + + + + + + +

Individual Animal Tumor Pathology o	of Male	Ra	ts i	m tl	ne I	Lor	1 <b>g-</b> ′	<b>Fe</b> i	m	Fe	ed	St	udy	y o	f t	-Bı	ıty	lhy	dr	oq	uin	on	ıe:	0	ppm (continued)
Number of Days on Study	3 8 1		9 (			5 4 4	5		1	1	2	2		5	6	6	7	7	7			8		9	
Carcass ID Number	0 5 9	0 2 4	1 (	) 0 5 4 ) 8	4	4	0 2 0	3	0 1 7	2	0	4	0	0	3	0 5 0	2	1	1	2	0 5 8	0		2	
Nervous System Brain Astrocytoma malignant Oligodendroglioma malignant Peripheral nerve Spinal cord	+	+	+	+ +	- +	- +	+ x	+	+	+	+	+	+	+	+	+	+	+	+	+	+	4	- +	4	-
Respiratory System Lung Alveolar/bronchiolar adenoma Histiocytic sarcoma Nose Squamous cell papilloma Trachea	+ + +	+ + +	+ ·	 + + + +	- + - +	- + - +	+++++++++++++++++++++++++++++++++++++++	+ X +	+ x +	++++	++++	++++	++++	++++	+++++	+ x +	++++	++++	++++	+++++	+ +	· +			
Special Senses System Eye Zymbal's gland Carcinoma		+		+ x							<u> </u>	+	,									_			<u>, , , , , , , , , , , , , , , , , , , </u>
Urinary System Kidney Lipoma Renal tubule, adenoma Transitional epithelium, carcinoma Urethra Urinary bladder	+	+ +, +	+	+ + X X + +	+ + {	 +	· +	+	+	+	+	+	+	+	+	+	+	+	+	+	· +	· +	, ⊦ ⊣	- + X	
Systemic Lesions Multiple organs Histiocytic sarcoma Leukemia mononuclear Lymphoma malignant Mesothelioma malignant	+	+	+	+ +	+ + X	+ + x x	+	+ X	+	+	+ x	+	+ x	+ x	+ x	+ x	+ X	+ X	+ x	+ x	+ : x	- + : X	+ + x X	+ - : >	μ.

ŝ

84

TABLE A2

Individual Animal Tumor Patholog	gy of Male Rats in the Long-Term Feed Study of t-Butylhydroquinone: 0 ppm	(continued
Number of Days on Study	7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7	
Carcass ID Number	0       0	
Nervous System Brain Astrocytoma malignant Oligodendroglioma malignant Peripheral nerve Spinal cord	+ + + + + + + + + + + + + + + + + + +	
Respiratory System Lung Alveolar/bronchiolar adenoma Histiocytic sarcoma	+ + + + + + + + + + + + + + + + + + +	· · · · ·
Nose Squamous cell papilloma Trachea	+ + + + + + + + + + + + + + + + + + +	
Special Senses System Eye Zymbal's gland Carcinoma	+ X	
Urinary System Kidney Lipoma Renal tubule, adenoma	+ + + + + + + + + + + + + + + + + + +	
Transitional epithelium, carcinoma Urethra Urinary bladder	+ + + + + + + + + + + + + + + + + + + +	
Systemic Lesions Multiple organs Histiocytic sarcoma Leukemia mononuclear Lymphoma malignant Mesothelioma malignant	+ + + + + + + + + + + + + + + + + + +	

د. به

Individual Animal Tumor Pathology of Male Rats in the Long-Term Feed Study of t-Butylhydroquinone: 0 ppm (continued)

		n offeringues o blann (sour
Number of Days on Study	8 8 8 8 8 8 8 8 8 8 2 3 5 5 5 5 5 5 5 5	
	4 1 7 7 7 7 7 7 7 7 7	
	0 0 0 0 0 0 0 0 0 0	Total
Càrcass IID Number	5 0 1 1 1 3 4 4 4 5	Tissues/
	3 4 1 2 3 9 0 2 5 7	Tumors
Vervous System		
Brain	* + + + + + + + +	60
Astrocytoma malignant		1
Oligodendroglioma malignant		1
Peripheral nerve		2
Spinal cord		2
Respiratory System		
Lung	* * + + + + + + +	60
Alveolar/bronchiolar adenoma		3
Histiocytic sarcoma		1
Nose	+ + + + + + + + +	60
Squamous cell papilloma		1
Trachea	+ + + + + + + + +	60
Special Senses System		
Eye	+ +	4
Zymbal's gland		2
Carcinoma		2
Urinary System		
Kidney	* * * + + + + + +	60
Lipoma		1
Renal tubule, adenoma		2
Transitional epithelium, carcinoma		1
Urethra		1
Urinary bladder	+ + + + + + + + + +	60
Systemic Lesions		
Multiple organs	+ + + + + + + + +	60
Histiocytic sarcoma		. 1
Leukemia mononuclear	X X X X	39
Lymphoma malignant	X	. 1
Mesothelioma malignant	X	1

Individual Animal Tumor Pathology of Male Rats in the Long-Term Feed Study of t-Butylhydroquinone: 1,250 ppm

																•									_					
Number of Days on Study			2 8 9	3 7 3	3 9 4	4 6 7	5 3 5	5 3 5	4	5	5 6 2	5 6 4	8	1			5 -		6.		6		6 7 7	6 8 2	6 8 4	6 8 4	6 9 7	•		
Carcass ID Number			0 9 5	0 7 4	0 9 0	1 1 0	1 0 2	1 2 2	1 0 7	1 1 9	1 1 5	8	2	0	2		2	2	2	1	2	7	0 9 9	1 0 3	0 8 7	0 9 3	0 7 3			
Alimentary System																														
Esophagus Intestine large, colon Leiomyosarcoma	•		+ +	+ +	+ +	+ М	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+ ;+	+ +	+ +	+ +	+ М	+ +	+	+ +	+ +	`+ +	M .+			
Intestine large, rectum			+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	•+	+	+	÷	·+-			
Intestine large, cecum			+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	M	+	+	+	+	+	+	+			
Intestine small, duodenum			+	+	+	+	+	+	+	+	+		+		+	+					+	+	· +	+	÷	•+	.+			
Intestine small, jejunum Intestine small, ileum			+ +	+ +	+ +	+ +	+ +	+ +	+ +	+ +	.+ +	+ +	+ +	+ м	+ +	+ +	+ +	+ +	+++	+	+ +	+ +	+ +	+ +	+ +	+ +	+ +		•	
Leiomyoma										.,		٤.		,						÷	•	.1								
Liver Hepatocellular adenoma Leiomyosarcoma, metastatic,		ŝ	+	+		+	Ŧ.	+	+	+	+	+	+	+	+	+	+	+	+	+ ;	+	+	+	+	+	+	. +			
intestine large, colon Mesentery						+										•	+			+			+	+						
Leiomyosarcoma, metastatic, intestine large, colon						•														,				·						
Oral mucosa Squamous cell carcinoma	k.	•	+ x												,															
Squamous cell papilloma Pancreas Leiomyosarcoma, metastatic,			+	+	+	+	+	+	+	+	+	+	+	+	+	÷	+	+	+	, <b>+</b>	+	М	+	+	+	+	+			
intestine large, colon								× .											·								·			
Salivary glands			+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+			
Stomach, forestomach Stomach, glandular Tongue			+++++++++++++++++++++++++++++++++++++++	+ +	++	+	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+ +.	++	+ +	+	+ +	++	+ + +	+ +	+	++	+ +	+ +	+	+ +			
		·	-		<u>.</u>									<u>.</u>				<del>.</del>			·	_								
Cardiovascular System Blood vessel			ι.								,					L		L	-			.1	.1.			-				
Heart			+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	,+	+	+	+	+	+			
Endocrine System			i-																											
Adrenal cortex		•	+	+.	+	+	+	+	+	÷	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	. •		
Adrenal medulla			+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+			
Pheochromocytoma malignant Pheochromocytoma benign																	x	x	x		x		x			х	x			
Pheochromocytoma benign, multiple Islets, pancreatic			+	+	.+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	м	[ +	+	+	+	+			
Adenoma					•	•	•	•	•	·	•	•	•		•	•	•	•	·	•	-		·	2	·		•			
Parathyroid gland			+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	М	+	Μ	( +	+	+	+			
Pituitary gland			+	+	М	+	+	+	+	+	.+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	.+			
Pars distalis, adenoma											х								Х		х		Х							
Pars distalis, carcinoma					_			•			•																			
Thyroid gland C-cell, adenoma			+	+	+	+	+	+	+	. <b>+</b>	+	+	+	+	÷	+	+	+	+	+			+	+	+	+	+			
C-cell, carcinoma Follicular cell, adenoma	· .		. •	•							•										х									

ŝ,

Individual Animal Tumor Pathology of Male Rats in the Long-Term Feed Study of *t*-Butylhydroquinone: 1,250 ppm (continued)

Number of Days on Study	6		7	7	7 0	7 2		7 2	7 2	7 3	7 3	7 3	7 4	7 4	7 4			7 6	7 6	7 7	7 8	7 8	8 0	8	8			
Camber of Days on Staay	7		2	8	8				õ			õ					5				6		8					
······································	1	1	.0	0	0	0	1	1	0	0	0	1	0	0	0	0	1	1	1			0	1	1	0			
Carcass ID Number	. 0 4	1 3	9 4	8 1	8 5	7 9					8 8				8 4	8 2	1 7			2 6	9 6		2 9					
Alimentary System												_														 <u> </u>		
Esophagus	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+			
Intestine large, colon Leiomyosarcoma	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	÷	+	+	+	. +	+	+	+			
Intestine large, rectum	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+			
Intestine large, cecum	+	+	· +	+	+	+	+	+	÷	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	М			
Intestine small, duodenum	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+			
Intestine small, jejunum	+	+	• +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+			
Intestine small, ileum Leiomyoma	+	+	• +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+			
Liver	+	+	• +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+			
Hepatocellular adenoma Leiomyosarcoma, metastatic,	X				•	x	•	•	•	•	•	•	•	·	•	•	x	·	•	•	•	•		•	•			
intestine large, colon Mesentery																												
Leiomyosarcoma, metastatic,	+							+										+		+				+				
intestine large, colon																												
Oral mucosa Squamous cell carcinoma															+													
Squamous cell papilloma															Х													
Pancreas Leiomyosarcoma, metastatic, intestine large, colon	+	• +	• +	• +	+	+	+	+	+	+	+	+	. <b>+</b>	+	+	+	•+	+	+	+	+	+	+	+	+			
Salivary glands	+				+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+			
Stomach, forestomach				. +	. +	+	÷	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+			
Stomach, glandular	+	• +		· +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+			
Tongue	•		•	•					•	•				·						•				+				
Cardiovascular System			-	-	-																							
Blood vessel	+	• +	• +	• +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+			
Heart	+	+ +	- +	• +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	 	,	
Endocrine System																												
Adrenal cortex	+	• +	- +	• +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+			
Adrenal medulla	+	• +	-		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		+			
Pheochromocytoma malignant Pheochromocytoma benign			Х	x		x				x									x					X X				
Pheochromocytoma benign, multiple																					X		X					
Islets, pancreatic	+			• +	• +	+	+	+	+	+	+	+	+	+	+	+		+	+	+	+	+	+	+	+			
Adenoma		X														X											•	
Parathyroid gland	+		+	- +	·M	. +			· +																· + · +			
Pituitary gland Pars distalis, adenoma	4	- 1 X	1	X		+	+	x +		+	x +		+	Ŧ	Ŧ		x		х		· +	+	+	· +	• +			
Pars distalis, carcinoma Thyroid gland			ہے ا	بر .	ـ .	L.	-	. ا	+	L	<b>.</b>	<b>.</b>	-	+	+	L.	<u>н</u>	X		Ŧ		4			• +			
C-cell, adenoma	+	- 1	- <b>-1</b>	- +	- +	Ť	Ŧ	Ŧ	· •	÷	T	+	т	Ŧ	т	Ŧ	Ť	Ŧ	T	Ŧ	T	7	т	Ŧ	т			
C-cell, carcinoma Follicular cell, adenoma																											•	
									_					_												 _		

۔ پ

1

.3

Individual Animal Tumor Pathology of Male Rats in the Long-Term Feed Study of *t*-Butylhydroquinone: 1,250 ppm (continued)

Number of Days on Study	8 8 8 8 3 5 5 5 1 2 2 7	8 8 8 8 5 5 5 5 7 7 7 7	8 8 5 5 7 7			
Carcass ID Number	1 1 1 0 1 1 3 7 6 4 0 1	0 0 0 0 7 7 8 8 6 7 0 3	0 1 9 0 1 5		- <u></u>	Total Tissues/ Tumors
Alimentary System						
Esophagus	+ + + +	+ + + +	+ +			59
Intestine large, colon	+ + + +	+ + + +	+ +			58
Leiomyosarcoma	Х					. 1
Intestine large, rectum	+ + + +	+ + + +	+ +		÷	60
Intestine large, cecum	++++	+ + + +	+ +			58
Intestine small, duodenum	+ + + +	· + + + +	+ +	1		60
Intestine small, jejunum	+ + + +	+ + + +	+ +			60
Intestine small, ileum	+ + + +	+ + + +	+ +	×		59
Leiomyoma		x				1
Liver	+ + + +	+ + + +	+ +			60
Hepatocellular adenoma		x				4
Leiomyosarcoma, metastatic,				•		•
intestine large, colon	х					1
Mesentery	+					11
Leiomyosarcoma, metastatic,	T					11
	Х				•	1
intestine large, colon Oral mucosa	л			· · ·		2
						1
Squamous cell carcinoma						
Squamous cell papilloma						1 59
Pancreas	+ + + +	+ + + +	<del>+</del> +		· ·	59
Leiomyosarcoma, metastatic,	v					
intestine large, colon	<b>X</b>					1
Salivary glands	+ + + +	+ + + +	+ +			60
Stomach, forestomach	+ + + +	+ + + +	+ +			60
Stomach, glandular Tongue	+ + + +	+ + + +	+ +		·····	60 2
Cardiovascular System					•	
Blood vessel	+ + + +	+ + + +	+ +			60
Heart	+ + + +	+ + + +	+ +			60
Endocrine System						
Adrenal cortex	+ + + +	+ + + +	+ +			60
Adrenal medulla	+ + + +	+ + + +	+ +			60
Pheochromocytoma malignant	Х					3
Pheochromocytoma benign	Х	хх	х			16
Pheochromocytoma benign, multiple	X		х		· · · ·	4
Islets, pancreatic	+ + + +	+ + + +	+ +			59
Adenoma						2
Parathyroid gland	M + + +	+ + + +	+ +	•		54
Pituitary gland	+ + + +	+ + + +	+ M .			58
Pars distalis, adenoma	X	x x x				16
Pars distalis, carcinoma	А		<b>71</b>			10
Thyroid gland	+ + + +	+ + + +	+ +			60
C-cell, adenoma	+ + + + X	г т <b>т</b>	X			. 2
C-cell, carcinoma	л		<b>A</b>			·
Follicular cell, adenoma		х				
romeular cell, auchoilla		А	•			. 4

88

.

Individual Animal Tumor Pathology of Male Rats in the Long-Term Feed Study of *t*-Butylhydroquinone: 1,250 ppm (continued)

(continued)																												
Number of Days on Study	2 8 9	7		4 6 7	3	5 3 5	4	5 5 4	5 6 2	6	5 8 3	1	3	4	6 5 5	5	6	6	6 6 7	6 6 8	6 7 7	6 8 2	6 8 4	8	6 9 7			
Carcass ID Number	095	7		1 1 0	1 0 2	1 2 2	0	1	1	0 8	1 2	1		1 2	1 2	1 2	1 2	1	_	0 7	-	1 0	0 8 7		0 7 3			
General Body System None							_		_																-			
Genital System																												
Epididymis Preputial gland Adenoma	4	 -	⊦ + ⊦ +	• +	+	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+ +			
Carcinoma Prostate Adenoma	4		+ +	× +		+	+	+	+	+	+	+ X	+	+	+	+	+	+	+	+	+	+	÷	+	+			
Seminal vesicle Leiomyosarcoma, metastatic, intestine large, colon	H	+ -	⊦ +	• +	+	+	+	+	+	+	+		+	ł	+	+	+	+	+	+	+	+	+	+	+			
Testes Bilateral, interstitial cell, adenoma Interstitial cell, adenoma	4		+ +	• +	+ + x	+ x	+ x		+	+ X		+ x		+ X		+ x	+	+ X	+						+ X			
Hematopoietic System							-	_		-			_				_					_			_			
Bone marrow	-	۴ ۰	+ +	• +	• +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+			
Lymph node			-	-	+	+	+	+			+		+	+	+		+	+	+	+	+	+	+					
Lymph node, mandibular	-	+ -	+ +	• +	· +	+	+	+	+	+	+	+	+		+	+	+	+	+	+	+	+	+	+	+			
Lymph node, mesenteric	-	+ •	+ +	- +	• +	+	+	+	+	+	+	+	+	M		+	+	+	+	+	+	+	· +	+	+		•	
Spleen	-	+ -	+ +	- +	• +	+	+	+	+	+		+	+	+	+	+	+	+	+	+	+	+	+	• +	+			
Fibroma Leiomyosarcoma, metastatic, intestine large, colon	·									Х																		
Thymus	-	+ •	+ +	- +	• +	+	+	+	+	+	+	+	+	+	+	Μ	+	+	I	+	+	+	+	+	+			
Integumentary System		-	_				-																					
Mammary gland Fibroadenoma	P	<b>1</b> -	+ +	- +	• +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	• +	• +	M			
Skin Keratoacanthoma	-	+ -	+ +	- +	- +	+	+	+	+	+	+	+	+ X		+	+	+	+	+	+	+	+	+	• +	• +			
Squamous cell papilloma Squamous cell papilloma, multiple													л															
Trichoepithelioma Sebaceous gland, adenoma										x																		
Subcutaneous tissue, fibroma Subcutaneous tissue, fibrosarcoma												Х													Х			
Musculoskeletal System	·															_				_					_			10
Bone		+ -	+ -	⊦ +	+ +	· +	+	+	+	+	+	+	• +	• +	+	+	+	+	+	+	- +	• +		- +	• +			
Skeletal muscle Leiomyosarcoma, metastatic, intestine large, colon			-	F																								
Nervous System						_						-	_			_			-									
Brain Astrocytoma malignant		+	+ -	+ -1	+ +	• +	+	+	+	+ x	+	+	• +	• +	· +	+	+	+	+	+	- +	- +		- +	• +	•		
Peripheral nerve			+ -	+						л								+										
Spinal cord			, + ·															+										
							~			_		_							_							_		

3

Ý

Individual Animal Tumor Pathology of Male Rats in the Long-Term Feed Study of *t*-Butylhydroquinone: 1,250 ppm (continued)

~ .--

(continued)												_ 、		•												·				
Number of Days on Study	<u>`</u>	6 9 7	6 9 7	7 0 2	7 0 8	0	2			2	3	7 3 0	3	4	7 4 4	4	6	6	7 6 6		7	7 8 6	7 8 6	8 0 8	8 1 4					
Carcass ID Number		1 0 4	1 1 3	0 9 4	0 8 1	8	7		0	0 7 8	8	8	0	0 7 2	9		8	1	0	1 1 1	2	9	9	2	1 -0 1	9			•	
General Body System None		_																												
Genital System																					_									
Epididymis Preputial gland Adenoma Carcinoma		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+ X	+ X	+ + X	+	+	+	+	+	,			
Prostate		+	+	+	+	+	+	+	+	+	+	+	+	4	+	+	+	+	+	+	+	+	+	+	Ŧ	+				
Adenoma Seminal vesicle Leiomyosarcoma, metastatic, intestine large, colon		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	Ŧ	+	+	+	+	+				
Testes Bilateral, interstitial cell, adenoma Interstitial cell, adenoma		+ X	+	+ X	+	+ x	+ x	х	+ X	+ X	+ X	+				+ X	+ X	÷	+ X			+ X				+ X				
Hematopoietic System																														
Bone marrow Lymph node		+	+	+	+	+	+	.+ +	+	+	+	+	+	+	.+ .+	+	+	+++++++++++++++++++++++++++++++++++++++	+	.+	+	+	+	+	+++++++++++++++++++++++++++++++++++++++	++			•	
Lymph node, mandibular		+	+	+	+	+	+	+	+	·+	+	+	+	+	·+	+	+	+	+	+	+	+	+	+	+	+		·		
Lymph node, mesenteric		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+				
Spleen		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+				
Fibroma Leiomyosarcoma, metastatic, intestine large, colon																														
Thymus		+	+	+	+	+	+	.+	+	+	+	+	• +	+	+	+	М	+	+	+	I	+	+	+	+	+		•		
Integumentary System																														
Mammary gland Fibroadenoma		. +	м	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+ X		+	+	+				
Skin		+	+	+	+	+	+	+	+	+	+,	+	+	+	. +	+	+	+	+	+	+			+	+	+				
Keratoacanthoma												Х								Х					Х	•				
Squamous cell papilloma Squamous cell papilloma, multiple Trichoepithelioma																					x									
Sebaceous gland, adenoma Subcutaneous tissue, fibroma Subcutaneous tissue, fibrosarcoma		x								x	x																			
Musculoskeletal System										-				_														· .,	ę t	• •
Bone Skeletal muscle Leiomyosarcoma, metastatic, intestine large, colon		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	• +	+	• +	- 4	- +	-	3.		, <sup>*</sup>
Nervous System Brain Astrocytoma malignant Peripheral nerve		+		• +	• +	.+	+	+	Ŧ	+	+	+	+	+	+	+	+	+	+	+	+	+	+	• +	- +	- +	-		1.5	
Spinal cord	1																		_											-1

e

Individual Animal Tumor Pathology of Male Rats in the Long-Term Feed Study of *t*-Butylhydroquinone: 1,250 ppm (continued)

(continued)		
	8 8 8 8 8 8 8 8 8	
Number of Days on Study	3 5 5 5 5 5 5 5 5 5 1 2 2 7 7 7 7 7 7 7	,
₩ <u>₩</u> ₩₩₩₩₩₩₩₩₩₩₩₩₩₩₩₩₩₩₩₩₩₩₩₩₩₩₩₩₩₩₩₩₩₩	1 1 1 0 0 0 0 0 1	Total
Carcass ID Number	1 1 3 7 7 7 8 8 9 0 6 4 0 1 6 7 0 3 1 5	Tissues/ Tumors
General Body System None		
Genital System		
Epididymis	* + + * + + + + + +	60
Preputial gland	+ + + + + + + + + +	60
Adenoma	Х	3
Carcinoma Prostate		2 60
Adenoma	+ + + + + + + + + + + + + + + + + + +	2
Seminal vesicle	~ + + + + + + + + +	60
Leiomyosarcoma, metastatic,		00
intestine large, colon	х	. 1
Testes	 + + .+ + + + + + +	60
Bilateral, interstitial cell, adenoma	x x x x x x x x x x x x	40
Interstitial cell, adenoma		9
Hematopoietic System		
Bone marrow	+ + + + + + + + +	60 .
Lymph node	+ + + + +	36
Lymph node, mandibular	+ + + + + + + + +	60
Lymph node, mesenteric	+ M + + + + + + +	58
Spleen	+ + + + + + + + +	60
Fibroma		1
Leiomyosarcoma, metastatic, intestine large, colon	x	1
Thymus	M + + + + + + + + +	55
Integumentary System		
Mammary gland	+ + + + + + + + +	57
Fibroadenoma	X X X	4
Skin	+ + + + + + + + +	60
Keratoacanthoma		4
Squamous cell papilloma	X	1
Squamous cell papilloma, multiple	X	1
Trichoepithelioma		1
Sebaceous gland, adenoma	<b>X7 X7 X7 X7</b>	1
Subcutaneous tissue, fibroma Subcutaneous tissue, fibrosarcoma	X X X X X	8 1
Musculoskeletal System		<u> </u>
Bone	+ + + + + + + + +	60
Skeletal muscle	+	2
Leiomyosarcoma, metastatic,		
intestine large, colon	X	1
Nervous System		
Brain	+ + + + + + + + +	<b>60</b>
Astrocytoma malignant		1
Peripheral nerve		3
Spinal cord		3

Individual Animal Tumor Pathology of Male Rats in the Long-Term Feed Study of *t*-Butylhydroquinone: 1,250 ppm (continued)

\_

- -

Number of Days on Study	2       3       4       5       5       5       5       5       6       7       8       8       9       9       3       4       7       5       6       2       6       7       8       7       4       2       4       3       9       4       7       5       6       7       8       7       2       4       4	
Carcass ID Number	0 0 0 1 1 1 1 1 1 0 1 1 1 1 1 1 1 1 0 0 1 0 0 0 0 9 7 9 1 0 2 0 1 1 8 2 0 2 2 2 2 2 1 2 7 9 0 8 9 7 5 4 0 0 2 2 7 9 5 9 3 9 7 5 4 0 8 8 1 5 9 3 7 3 3	
Respiratory System Lung Alveolar/bronchiolar adenoma	+ + + + + + + + + + + + + + + + + + + +	· .
Nose Squamous cell carcinoma Trachea	+ + + + + + + + + + + + + + + + + + +	
Special Senses System Ear		<b></b>
Squamous cell papilloma Eye Zymbal's gland Carcinoma	+ * X	
Urinary System Kidney Urethra	+ + + + + + + + + + + + + + + + + + +	
Urinary bladder	+++++++++++++++++++++++++++++++++	
Systemic Lesions Multiple organs Leukemia mononuclear	+ + + + + + + + + + + + + + + + + + +	

#### Table A2

Individual Animal Tumor Pathology of Male Rats in the Long-Term Feed Study of *t*-Butylhydroquinone: 1,250 ppm (continued)

																											_
Number of Days on Study	6 9 7	6 9 7	7 0 2	7 0 8	7 0 8	7 2 2	7 2 2	7 2 5	7 2 9	7 3 0	7 3 0	7 3 0	7 4 4	7 4 4	7 4 5	7 6 1	7 6 5	7 6 6	7 6 8	7 7 3	7 8 6	7 8 6	8 0 8	8 1 4	8 3 0		
Carcass ID Number	1 0 4	-	0 9 4	0 8 1	0 8 5	0 7 9	1 1 2	1 0 8	0 7 8	0 8 6	0 8 8	1 0 6	0 7 2	0 9 2	0 8 4	0 8 2	1 1 7	1 0 0	1 1 1	1 2 6	0 9 6	0 9 7	1 2 9	1 0 1	-	,	
Respiratory System Lung Alveolar/bronchiolar adenoma Nose Squamous cell carcinoma Trachea	+ + +	+			+ X + +	+ + +	+ + +	++++	+ + +	++++	+ + +	+ + +	+ + +	+ + +	+ + +	+ + +	+ X +		+ + +	+ + +	+ + +	++++	+	- + - +	• -	ŀ	
Special Senses System Ear Squamous cell papilloma Eye Zymbal's gland Carcinoma							+												+ X								
Urinary System Kidney Urethra Urinary bladder	++	•	+++	++	++	+	++	++	++	++	++	++	++	++	+ +	+ +	+++	+++	++	+	+	· +	+ +		 		
Systemic Lesions Multiple organs Leukemia mononuclear	+ x	+ x	+ X	+ x	+ X	+ x	+ x	+	+ X	+	+	+ X	+ X	+ X	+ X												

Individual Animal Tumor Pathology of Male Rats in the Long-Term Feed Study of *t*-Butylhydroquinone: 1,250 ppm (continued)

-

Number of Days on Study		8 3 1	8 8 5 5 2 2	8 8 5 5 7 7	8 8 5 5 7 7	8 8 5 5 7 7	8 5 7					
Carcass ID Number		1 1 6	1 1 1 3 4 0	0 <sup>:</sup> 0 7 7 1 6	0 0 7 8 7 0	0 0 8 9 3 1	0	· ·		 		Total Tissues/ Tumors
Respiratory System Lung Alveolar/bronchiolar adenoma Nose Squamous cell carcinoma Trachea		+ + +	+ + + + + + + + + + + + + + + + + + + +	+ + + + + +	+ + + + + +	+ + + + + +	+ + +				· · · · · · · · · · · · · · · · · · ·	60 2 60 1 60
Special Senses System Ear Squamous cell papilloma Eye Zymbal's gland Carcinoma						•					·.	1 1 2 1 1
Urinary System Kidney Urethra Urinary bladder	<u> </u>	· +	++	+ + + +	+ + + +	+ + + +	+		<u>,                                     </u>		- <u></u>	60 1 60
Systemic Lesions Multiple organs Leukemia mononuclear		+ X	+ +	+ + X X	+ + x x	+ + x x	+	- -				60 47
								-	-			
										× ·	•	•
		· •							• •			
							a ,					
· · ·	e										. • •	
	· .						,	•				
. · · -		•						•		r		

Individual Animal Tumor Pathology of Male Rats in the Long-Term Feed Study of t-Butylhydroquinone: 2,500 ppm

Number of Days on Study	4 0 8	4 6 4	4 7 3	-	0		3	3	5	6	5 6 2	7	7	9	9	9	0	1	1	1	2	4	.4	5	6		
Carcass ID Number		5	9	1 9 3	7	7	4	5.	1 8 9	5	7	8	7		7	8	5	9	8	6	5	9	5	4	9		
Alimentary System																											
Esophagus	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		
Intestine large, colon Intestine large, rectum Carcinoma	+	+	++	++	+	+	++	+	++	+	++	+	+	+	+	+	+	++	++	+	++	+	+		+		
Intestine large, cecum	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		+		
Intestine small, duodenum Intestine small, jejunum Carcinoma	+	+	+	+ - +	+	+	+	+ +	+ +	+ +	+		+ + X	+ +	+ +	+ +	+ +	+ +	+ +	+	+ +	+ +	+	+ +	+ +		
Intestine small, ileum Liver Osteosarcoma, metastatic, mesentery	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+ + X	+ +	+ +	+ +	+ +	+ +	+ +	+ +		
Mesentery Osteosarcoma												+						т + Х			+				+		
Oral mucosa Squamous cell carcinoma Pancreas	÷	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+ X +	+	+	+	+	+		
Acinus, adenoma Salivary glands Carcinoma	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		
Fibrosarcoma, metastatic, skin Stomach, forestomach	•	+	+	+	+	+	+	+	+	+	х +	+	+	+	+	+	+	+	+	+	+	х +	+	+	+		
Squamous cell papilloma Stomach, glandular Tongue	. +	• +	. +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		
Tooth Odontoma																											
Cardiovascular System																										 	
Blood vessel Heart	+ +	+	+ +	+ +	+ +	+ +	+ +	+ +	,+ +	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+ +		
Endocrine System					_																						
Adrenal cortex Adrenal medulla Pheochromocytoma malignant	+	++	+ +	++	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+ +		
Pheochromocytoma benign Pheochromocytoma benign, multiple			х																								
Islets, pancreatic Adenoma Parathyroid gland	+	· +	+	· +	+	+	+	+	+	+	+	+	+	+ м		++	+	++	+	+	+	+	+	+	+		
Pituitary gland Pars distalis, adenoma Pars distalis, carcinoma	+	+	+	+	+	+	+	+	+	+ X	+	+ X	+		+	+ X	+		M	+	+	+ X		+ X	+		
Thyroid gland C-cell, adenoma Follicular cell, adenoma	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		

a PL PA

Individual Animal Tumor Pathology of Male Rats in the Long-Term Feed Study of t-Butylhydroquinone: 2,500 ppm (continued)

Number of Dave or Stade		6	6							7					77			7		7	7	7	7	7					
Number of Days on Study		7 3	7 4	7 7	8 2	9 1			9 5						34 84		-	6 1	6 6	6 7	7 3	7 7	8 6	9 2				•	
Carcass ID Number		1 4	1	1	17		1						1		1 1			1	1	1	1	1	1	1	1	÷.,			
		•	5	-													8 8	4 6	6 3	4 1	6 0	5 3	7 7	4 9	0 1	,			
Alimentary System																						_			•	·. :	•		
Esophagus		+	+	+	+	+	+	+	+	+	+	+	+	+	+ -	+ +	+ +	+	+	+	+	+	+	+	+				
Intestine large, colon		+	+	+	+	+	+	+	+	+	+	+	+	+	+ -	+ +	+ +	+	+	+	+	+	+	+	+			•	
Intestine large, rectum		+	+	·+	+	`+	+	+	+	+	+	+	+	+	+ -	+ +	+ +	+	+	+	+	+	+	÷	+				
Carcinoma	•												х														•		
Intestine large, cecum		+	+	+	+	+	+	+	+	+	+	+		+	+ -	+ +	+ +	+	+	+	+	+	+	Ŧ	+				
Intestine small, duodenum		+	+	+	+	+	+	+	+	+	+	+	+	+	+ -	+ +	+ +	+	+	+	+	+	+	÷	+		;		-
Intestine small, jejunum		+	+	A	+	+	+	+	+	+	+	+	+	+ `	+ -	+ +	- +	+	+	+	+	+	+	+	+		1		
Carcinoma													•						•		•			·					
Intestine small, ileum		+	+	+	+	+	+	+	+	+	+	+1	+	+	+ -	+ +	- +	+	+	+	+	+	+	+	+				
Liver		+	+	+	+	+	+	+	+	÷	+	+	÷	+	+ -	+ +		+	+	+	+	+	+	+	÷				
Osteosarcoma, metastatic, mesentery		,	•	•	•	•	·	•	•	·	•	•	•	·	•			•		•	•	•			•				
Mesentery												+		+				+											
Osteosarcoma												•		·				•							,	λ			
Oral mucosa	•													+														•	
Squamous cell carcinoma														x															
Pancreas		<u>т</u>	-	L.	Т	1	ъ	ц,	Ъ	т	*	т,	т	<u>л</u>	<u> </u>	L .	<u>ـ</u> ـــ	-	ъ	ъ	<u>۔</u>	<u>ــ</u>		Ŧ	L.				
Acinus, adenoma		•	1			1					1.		т		1					F				+	T				·
Salivary glands			Ъ.	Т	<u>ь</u>	т	ъ	L.	ъ	Т	ъ	т	т	т	<b>-</b> -		L L	<u> </u>	÷	-	+	<u>.</u>	<b>_</b>	Т	т				
Carcinoma		т	т	т	т	т	т	т	т	т	т	т	т	т	т -	<b>r</b> 7	г. <b>т</b>	. <b>т</b>	т	т	т	. –	т	т	Ŧ				
Fibrosarcoma, metastatic, skin																								,					
Stomach, forestomach		ъ	Ъ	<b></b>	1	Т	Т	т	т	ъ	ъ	Ŧ	<b>_</b>	т.					<u>т</u>		т	Ŧ	+	л.	·				
Squamous cell papilloma		т	т	т	т	т	т	т	т	т	т	т	x	т	τ -	<b>r</b> 7	· •	т	т	т	т	т	· T	т	Τ.			·	
Stomach, glandular				1					1.		-	1.	<u>^</u>	<b>т</b>	ı	i u			т	.1	т.		1	т					
		т	т	т	т	т	т	т	т	Ŧ	т	т	<b>T</b> '	т	<b>T</b> -	<b>-</b> 7	•	т	т	т	т	. <b>T</b>	т	т	т		•		
Tongue Tooth																													
Odontoma			+													2													
		_	_					<u> </u>				÷	_										;			<u> </u>			
Cardiovascular System																							· •						
Blood vessel		+	+	+	+	+	+	+	+	+	+	+	+	+	+ •	+ +	+ +	+	+	+	+	+	+	+	+				•
Heart		+	+	.+	+	+	+	+	+	+	+	+	+	+	+ •	+ .+	+ +	+	+	+	+	+	+	+	+				÷ .
Endocrine System											-															-			
Adrenal cortex		+	+	+	+	+	+	+	+	+	+	+	+	+	+ -	+ +	- +	+	+	+	+	+	+	+	+			ŕ	
Adrenal medulla			+	÷	+	÷	÷	+	+	÷	+	+	+	+	+ .				+	+	+	+	- ÷	÷	÷				
Pheochromocytoma malignant		•	•	:		•	•	·	•	•	·	•	•		x	•		·	•	•	•	•	•	. '					
Pheochromocytoma benign						х			х			х		x	-	2	ζ.				х				х				
Pheochromocytoma benign, multiple						~			~			~		~		•	•						х				•		
		-	ъ	ᆂ	ᆂ	ж.	ᆂ	+	+	+	÷	Ŧ	+	+	÷ -	<b>ـ</b> ـ	<b>ь</b> д		+	-	+	4	. <del>.</del>	+	Ŧ		κ.		
Adenoma		Ŧ	т	-	T	r.	F			r	r	f	•	•	' <b>1</b>	ĸ		ſ		1.	•	•	•	•					
Parathyroid gland		L	• •	ъ	ъ	ъ	ъ	Ŧ	+	M	J.	L.	+	Ŧ	، بد	ъ 			<u>ـ</u> ـــ	Ŧ	Ŧ	-	ىلە .	Ŧ	<u>ь</u>				
		T J	т 	т 	ᅮ	т 	т Т	+ -	т +	TAT TAT	т _	- -		т -	т. -		. T	<del>ب</del> ر.	Ť	- -	- -	- -	т 	т Т	т. Т			• •	
Pituitary gland Pars distalia, adenoma		т	-1-	т	v	x	Ŧ	Ŧ	x	Ŧ	Ŧ	T	Ŧ	Ŧ	x	, v	, + (	X	7	X	Ŧ	- <b>-</b>	्र	· •	т		, ·		
Pars distalis, adenoma					Λ	Λ			Λ		х				<u>n</u> /	n. 2	•	~		л				•	•				
Pars distalis, carcinoma	· .	,			л.			J.	. س		<u>^</u>	L	÷	ъ	<b>т</b>	<b>_</b>			-	4	ᆂ	ـ	. د.	Ŧ	ᆂ				
Thyroid gland		+	+	+	+	+ v	+	Ŧ	Ŧ	1	+	+	Ŧ	т	Τ.	<b>-</b> -	r †		T	Ŧ	X	т	Ψ.	Ŧ	т				
C-cell, adenoma						х															~								
																				•									_
Follicular cell, adenoma			_																				The second se	-	The second se				
General Body System			_																					•					

### Table A2

Individual Animal Tumor Pathology of Male Rats in the Long-Term Feed Study of *t*-Butylhydroquinone: 2,500 ppm (continued)

Carcass ID Number       4       6       5       5       5       6       8       6       Tissue         Sophags       +       +       +       +       +       +       +       Tissue         Sophags       +		8888888	
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	Number of Days on Study		
Carcass ID Number       4       6       5       5       5       8       6       Tissue         Sophagus       +       +       +       +       +       +       Tissue         Sophagus       +       +       +       +       +       +       +       +         Sophagus       +		6 0 5 5 2 2 2 7	
5         4         6         4         9         5         1         9         Tumo           Alimentary System         Sophagus         +		1 1 1 1 1 1 1	Total
5         4         6         4         9         5         1         9         Tumo           Alimentary System         Sophagus         +	Carcass ID Number	.4 6 5 5 .5 6 8 6	Tissues/
Stophagus       + + + + + + + +       5         Inestine large, colon       + + + + + + + +       5         Inestine large, cocum       + + + + + + + +       5         Inestine large, cocum       + + + + + + + +       5         Inestine large, cocum       + + + + + + + +       5         Inestine small, doudenum       + + + + + + + + +       5         Inestine small, lejumum       + + + + + + + + +       5         Carcinoma       + + + + + + + + +       5         Inestine small, leum       + + + + + + + + +       5         Osteosarcoma, metastatic, mesentry       Seteosarcoma       5         Osteosarcoma       Squamous cell carcinoma       X         Squamous cell carcinoma       X       S         Salivary glands       + + + + + + + + + +       5         Carcinoma       X       S         Stomach, forestomach       + + + + + + + + +       5         Stomach, forestomach       + + + + + + + + + +       5         Stomach, forestomach       + + + + + + + + + + +       5         Stomach, forestomach       + + + + + + + + + + + + +       5         Odontoma			Tumors
Stoppags       + + + + + + + +       5         intestine large, colon       + + + + + + + +       4         intestine large, colon       + + + + + + + +       5         intestine large, cocum       + + + + + + + +       5         intestine large, cocum       + + + + + + + +       5         intestine small, joinnum       + + + + + + + + +       5         intestine small, joinnum       + + + + + + + + +       5         Carcinoma       + + + + + + + + + +       5         intestine small, leum       + + + + + + + + +       5         Oktosarcoma, metastatic, mesentery       5       5         Vesentery       5       5         Sotasorcoma       -       X         Salivary glands       + + + + + + + + + +       5         Carcinoma       -       X         Stomach, forestomach       + + + + + + + + +       5         Stonach, forestomach       + + + + + + + + + +       5         Stonach, forestomach       + + + + + + + + + + +       5         Stonach, forestomach       + + + + + + + + + + +       5         Odonoma       -       -       5         Blood vessel       + + + + + + + + + + +       5         Adrenal cortex	Alimentary System		
intestine large, colon $+ + + + + + + + + +$ intestine large, creatum $+ + + + + + + + + + + + +$ intestine small, duodenum $+ + + + + + + + + + + + +$ intestine small, jejunum $+ + + + + + + + + + + + + + + + + + +$		+ + + + + + +	58
Carcinoma intesting large, cecum $+ + + + + + + + + + + + + + + + + + +$		+ + + + + + + +	58
intestine large, cecum $+ + + + + + + + +$ intestine small, duodenum $+ + + + + + + + +$ intestine small, jejunum $+ + + + + + + + +$ Carcinoma intestine small, ikum $+ + + + + + + + + + +$ Cotcoarcoma, metastatic, mesentery Mesentery Osteosarcoma Oral mucosa Squamous cell carcinoma Pancreas $+ + + + + + + + + + + +$ Acimes, adenoma $X$ Squamous cell papilloma Stomach, forestomach $+ + + + + + + + + + + + + + + + + + +$	intestine large, rectum	+ + + + + + +	58
instine small, duodenum $+ + + + + + + +$ instine small, jejuman $+ + + + + + + + +$ instine small, jejuman $+ + + + + + + + + +$ instine small, ileum $+ + + + + + + + + +$ intestine small, ileum $+ + + + + + + + + + +$ Osteosarcoma, metastatic, mesentery Mesentery Osteosarcoma Oral mucosa Squamous cell carcinoma Pancreas $+ + + + + + + + + +$ Acinus, adenoma $X$ Salivary glands $+ + + + + + + + + + + +$ Stomach, forestomach $+ + + + + + + + + + + + + + + + + + +$			1
Intestine small, jejunum $+ + + + + + + + +$ Carcinoma Intestine small, lieum $+ + + + + + + + + +$ Liver $+ + + + + + + + + + + +$ Subscream of the sentery $+ + + + + + + + + + + + + + + + + + +$		+ + + + + + +	58
Carcinoma Intestine small, ileum $+ + + + + + + + + + + + + + + + + + + $		· + + + + + + +	58
intestine small, ileum $+ + + + + + + + + + + + + + + + + + +$		+ + + + + + +	57
Liver $+ + + + + + + + +$ Ostosarcoma, metastatic, mesentery Mesentery Ostosarcoma Oral mucosa Squamous cell carcinoma Pancreas $+ + + + + + + + +$ Acinus, adenoma $X$ Salivary glands $+ + + + + + + + +$ Carcinoma Fibrosarcona, metastatic, skin Stomach, forestomach $+ + + + + + + + +$ Squamous cell papilloma Stomach, glandular $+ + + + + + + + + + + + + + + + + + +$			1
Osteosarcoma, metastatic, mesentery Mesentery Osteosarcoma Squamous cell carcinoma PancreasSquamous cell carcinoma Pancreas+ + + + + + + + + + + + + + + + + + +			58
Mesentery Ostosarcoma Souamous cell carcinoma Pancreas Acinus, adenoma Salivary glands Carcinoma Fibrosarcoma, metastatic, skin Stomach, forestomach Souamous cell papiloma Stomach, glandular Tongue Carcinoma Fibrosarcoma, metastatic, skin Stomach, forestomach Stomach, forestomach Stomach, glandular Tongue Carcinoma Carcinowa Carc		+ + + + + + +	58
OsteosarcomaOral mucosaSquanous cell carcinomaPancreas $+ + + + + + + + + + + + + + + + + + + $			1
Oral mucosa Squamous cell carcinoma Pancreas $+ + + + + + + + + + + + + + + + + + + $	•		7
Squamous cell carcinomaPancreas+ + + + + + + + + + + + + + + + + + +	•		1
Pancreas $+ + + + + + + + + + + + + + + + + + +$			2
Acinus, adenomaXSalivary glands+ + + + + + + + +Salivary glands+ + + + + + + + +CarcinomaFibrosarcoma, metastatic, skinStomach, forestomach+ + + + + + + +Squamous cell papillomaStomach, glandular+ + + + + + + +TongueCardiovascular SystemBlood vessel+ + + + + + + +HeartHeartAdrenal cortexAdrenal medullaPheochromocytoma malignantPheochromocytoma malignantPheochromocytoma benign, multipleXXPheochromacParathyroid glandM+ + + + + + + +Parathyroid glandM+ + + + + + + +Parathyroid glandM+ + + + + + + +PhotogramaXXParadistis, acteriomaThyroid gland+ + + + + + + + + +C-cell, adeoma			2
Salivary glands $+ + + + + + + +$ Carcinoma Fibrosarona, metastatic, skin Stomach, forestomach $+ + + + + + + + +$ Squamous cell papilloma Stomach, glandular $+ + + + + + + + +$ Tongue $+ + + + + + + + + + +$ Tongue $+ + + + + + + + + + + + + + + + + + +$			58
CarcinomaFibrosarcoma, metastatic, skinStomach, forestomach $+ + + + + + + + + + + + + + + + + + + $			. 1
Fibrosarcoma, metastatic, skinStomach, forestomach $+ + + + + + + + + + + + + + + + + + + $		+ + + + + + + +	58
Stomach, forestomach $+ + + + + + + + + + + + + + + + + + + $			1
Squamous cell papillomaStomach, glandular $+ + + + + + + + + + + + + + + + + + + $			58
Stomach, glandular $+ + + + + + + + + + + + + + + + + + + $		<b>T</b> . <b>T T T T T T</b>	
Tongue+Tooth		* * * * * * * *	58
Tooth OdontomaCardiovascular SystemBlood vessel $+ + + + + + + + + + + + + + + + + + + $		4 · · · · · · · · · · · · · · · · · · ·	1
OdontomaCardiovascular SystemBlood vessel $+ + + + + + + + + + + + + + + + + + + $		·	2
Blood vessel $+$ <			1
Blood vessel $+$ <	Cardiovascular System		· · ·
Endocrine SystemAdrenal cortex $+ + + + + + + + + + + + + + + + + + + $		+ + + + + + +	58
Adrenal cortex $+$		+ + + + + + +	58
Adrenal cortex $+$		······································	
Adrenal medulla $+$			
Pheochromocytoma malignant         Pheochromocytoma benign       X       X         Pheochromocytoma benign, multiple       X       X         Islets, pancreatic       + + + + + + + + +         Adenoma		· · · · · · · · ·	58 58
Pheochromocytoma benignXXXPheochromocytoma benign, multipleXXIslets, pancreatic $+ + + + + + + + + + + + + + + + + + + $		<b>T T T T T T T T</b>	
Pheochromocytoma benign, multiple     X     X       Islets, pancreatic     + + + + + + + +     4       Adenoma		Y Y Y	11
Islets, pancreatic       + + + + + + + +       1         Adenoma       Parathyroid gland       M + + + + + + +         Parathyroid gland       M + + + + + + +         Pituitary gland       + + + + + + + +         Pars distalis, adenoma       X X         Pars distalis, carcinoma       X         Thyroid gland       + + + + + + +         C-cell, adenoma       -			4
Adenoma         Parathyroid gland       M + + + + + + +         Pituitary gland       + + + + + + + +         Pars distalis, adenoma       X X X         Pars distalis, carcinoma       Thyroid gland         Thyroid gland       + + + + + + + +         C-cell, adenoma	siete nancreatic		58
Parathyroid gland     M + + + + + +     +       Pituitary gland     + + + + + + +       Pars distalis, adenoma     X X     X       Pars distalis, carcinoma     X     X       Thyroid gland     + + + + + + +     +       C-cell, adenoma     -     -		і і т., і т. г.	1
Pituitary gland + + + + + + + Pars distalis, adenoma X X X Pars distalis, carcinoma Thyroid gland + + + + + + + + C-cell, adenoma		M + + + + + +	55
Pars distalis, adenoma     X X     X       Pars distalis, carcinoma     Thyroid gland     + + + + + + + +       C-cell, adenoma			57
Pars distalis, carcinoma Thyroid gland + + + + + + + + C-cell, adenoma			17
Thyroid gland         + + + + + + +         :           C-cell, adenoma         .         .			1
C-cell, adenoma		+ + + + + + + +	58
			2
	Follicular cell, adenoma	X	. 1

Individual Animal Tumor Pathology of Male Rats in the Long-Term Feed Study of *t*-Butylhydroquinone: 2,500 ppm (continued)

(commutur)																													
Number of Days on Study	4 0 8	4 6 4	4 7 3	4 9 3	5 0 1	5 2 6	3	3	5	5 6 2	5 6 2	5 7 0	5 7 8		9	9	0	6 1 4	6 1 8	6 1 9	6 2 5	6 4 0	6 4 2	6 5 5	6 6 1		· .		
Carcass ID Number	1 7 8	1 5 8	1 9 8	1 9 3	1 7 4	1 7 1	1 4 8		•	1 5 7	1 7 9	1 8 2	1 7 0				1 5 2	1 9 0	1 8 7	1 6 2	1 5 1	1 9 1	1 5 0	1 4 4	1 9 2	·		- ,.	•
Genital System																					_					•			
Epididymis	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+.	+	+	+	+				
Preputial gland Adenoma	+	+	+	+	+	x +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	x +	+	+			1	
Carcinoma						Λ											X X						л						
Carcinoma, multiple																	Λ				•			,			· .		
Prostate	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+				
Adenoma	•		•	-		•	•	•	•		-		-	·	-	-	·							•	-				
Seminal vesicle	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	÷	+	+	+	+				
Testes	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+.	+	+	+	+	+	+	+	+	+				
Bilateral, interstitial cell, adenoma				Х		Х		Х	Х	х	х	х	х		Х	х	Х	х	х	Х			X.						
Interstitial cell, adenoma		Х			х		х							х							Х			X					
Hematopoietic System																													
Bone marrow	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+			× ,	
Lymph node			+	+		+		+	+					+	+			+	+		+	+	+		+				
Mediastinal, osteosarcoma, metastatic, mesentery														•				x				,		۰.				•	
Lymph node, mandibular	. +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	. +	+			<u>-</u> -	
Fibrosarcoma, metastatic, skin											Х																		
Lymph node, mesenteric	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	.+	+		•		3
Spleen	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	÷				
Osteosarcoma, metastatic, mesentery Sarcoma														1				х					<i>د</i> د			f			
Thymus	+	+	+	+	+	+	+	+	+	+	+	+	+	·+	+	+	+	+	+	+	+	·+	M	( +	+			,	
						·					-										_							_	
Integumentary System																									•				•
Mammary gland	+	+	+	+	Μ	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+				
Adenoma Fibroadenoma																				x			•						
Skin	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	4	+	+	+	+	+				
Keratoacanthoma		•			•		x	•	•		•	•	·			·	·	-	·				·		-				
Subcutaneous tissue, fibroma																				Х	Х		Х		·		•		
Subcutaneous tissue, fibrosarcoma											Х											-					1	٠	
Subcutaneous tissue, schwannoma malignant												Х															•		
Musculoskeletal System																											. •		
Bone	+	+	• +	· +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+				
Osteosarcoma					X																						·		;
Skeletal muscle																		+										1	
Mesothelioma malignant, metastatic, peritoneum																												÷	
Ostoosaasaama matastatia masantami																		x									÷.		
Osteosarcoma, metastatic, mesentery		-																											
																												•••••	
Nervous System Brain	+		- +	- +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	• +	• +	• +	+			•	
Nervous System	+	+	- +	- +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	• +	• +	+			• • • •	

-----

the construction of the second second

Individual Animal Tumor Pathology of Male Rats in the Long-Term Feed Study of *t*-Butylhydroquinone: 2,500 ppm (continued)

(continued)																										
Number of Days on Study	6 7 3	6 7 4	6 7 7	6 8 2		9	6 9 5	9	7 1 0	7 2 5	7 2 9	7 2 9	7 3 0	3	4	7 5 7	7 5 7	7 6 1	7 6 6		7 7 3	7 7 7 7	7 8 6	7 9 2	9	 
Carcass ID Number	4	1 7 5	1 9 4	1 7 3	0	8	1 7 6	9	8	9	4	6	8	4	6	8	8	4	6	4	6	5	7	4	6	
Genital System																										
Epididymis Preputial gland Adenoma							+ +							+ +				+ +	+ +	+ +	+ +	+ +	+ +	+ +	+ +	
Carcinoma Carcinoma, multiple							х																			
Prostate Adenoma	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+ X	+	+	+	+	+	+	+	+	
Seminal vesicle Testes	+	+		+ +		+ +	+				+		+ +	+											+	
Bilateral, interstitial cell, adenoma Interstitial cell, adenoma		x		x		x	х	т Х			+ X												x			
Hematopoietic System																						<u> </u>				 
Bone marrow Lymph node Mediastinal, osteosarcoma,	+	+	+ +	+ +	+ +	+ +	+	+	+	+	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+	+ +	+ +	+	+ +	+	+ +	+	
metastatic, mesentery Lymph node, mandibular Fibrosarcoma, metastatic, skin	+	+	+	+	<u>.</u> +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	÷	+	+	+	
Lymph node, mesenteric Spleen	+ +	+ +	+ +	+ +	·+ +	+ +	+ +	+ +	+ +	+ +			.+ +										+ +	+ +	+ +	
Osteosarcoma, metastatic, mesentery Sarcoma Thymus	+.	+	+	+	+	+	+	x +	+	+	+	+	+	+	•	+	+	+	+	+	+	+	+	+	+	
			-			-																				 
Integumentary System Mammary gland Adenoma	I	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Fibroadenoma Skin Keratoacanthoma	I	+	+	+	+	Х +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		Х +	
Subcutaneous tissue, fibroma Subcutaneous tissue, fibrosarcoma Subcutaneous tissue, schwannoma malignant							x													х					x	
Musculoskeletal System Bone	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Osteosarcoma Skeletal muscle Mesothelioma malignant, metastatic, peritoneum Osteosarcoma, metastatic, mesentery									~									+ X								
Nervous System Brain Peripheral nerve Spinal cord	+		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		- + +	- +		<u> </u>

2

4

99

-

. . .

### TABLE A2

Ľ

Individual Animal Tumor Pathology of Male Rats in the Long-Term Feed Study of *t*-Butylhydroquinone: 2,500 ppm (continued)

(continued)						<u>.</u>							 					, <u>,</u> .		· ·
Number of Days on Study	0	1	8 8 1 4 5 5	4 :	5 5	5 5	8 8 5 5 2 7				•								× .	
Carcass ID Number	1 4 5	-			1 1 5 6 9 5		1 3 6 1 9		•									To Fissu Tum		
Genital System Epididymis Preputial gland Adenoma Carcinoma Carcinoma, multiple	+ +	+ +	+ +	+ · + · X	+ - + -	+ -	+ + + + X						_		:		, , ,	•	57 58 6 1	
Prostate Adenoma Seminal vesicle Testes Bilateral, interstitial cell, adenoma Interstitial cell, adenoma	+ + X		+ · + · * · X	+ · + · X X	+ - + - + - X X	+ - + - { }	+ + + + + + X X					<b>**</b> *	·		۹ ب	•	-		58 1 58 57 45 11	
Hematopoietic System Bone marrow Lymph node Mediastinal, osteosarcoma, metastatic, mesentery Lymph node, mandibular Fibrosarcoma, metastatic, skin Lymph node, mesenteric	+++++++++++++++++++++++++++++++++++++++	+++++++++++++++++++++++++++++++++++++++	+ · + ·	 + · + ·	 + - + -	 + - + -	+ + + +	<u> </u>				• .						· · ·	58 34 1 58 1 57	
Spleen Osteosarcoma, metastatic, mesentery Sarcoma Thymus	+ +	+ +	+ 1	+ ·	- + - + N	+ . N N	+ + M +					-		-7					58 1 1 54	• .
Integumentary System Mammary gland Adenoma Fibroadenoma Skin Keratoacanthoma Subcutaneous tissue, fibroma Subcutaneous tissue, fibrosarcoma Subcutaneous tissue, schwannoma malignant	+ + X	+ + x	+ · + ·	+ ·	+ -	+ -	+ + + + X	*12	<u>,</u>	_									56 1 4 57 4 6 1 1	
Musculoskeletal System Bone Osteosarcoma Skeletal muscle Mesothelioma malignant, metastatic, peritoneum Osteosarcoma, metastatic, mesentery	+	+	+	+	+ -	+	+ +												58 1 2 1 1	
Nervous System Brain Peripheral nerve Spinal cord	+	+	+	+ ·	+	+ -	+ +	`											58 1 1	:

ŕ

### 8-Butylhydroquinone, NTP TR 459

## TABLE A2

- States

- The second second

Individual Animal Tumor Pathology of Male Rats in the Long-Term Feed Study of *t*-Butylhydroquinone: 2,500 ppm (continued)

(*********											_														_	
Number of Days on Study	4 0 8	4 6 4	4 7 3	4 9 3		5 2 6	5 3 5	5 3 5	5	5 6 2	5 6 2	5 7 0	5 7 8	5 9 1	5 9 1	5 9 1.	6 0 4	6 1 4	6 1 8	6 1 9	6 2 5	6 4 0	6 4 2	6 5 5	6 6 1	
Carcass ID Number	1 7 8	1 5 8	9	1 9 3	1 7 4	1 7 1	1 4 8	1 5 5	1 8 9	1 5 7	1 7 9	1 8 2	1 7 0	1 6 6	1 7 2	1 8 3	1 5 2	1 9 0	1 8 7	1 6 2	1 5 1	1 9 1	1 5 0	1 4 4	1 9 2	
Respiratory System Lung Alveolar/bronchiolar adenoma Carcinoma, metastatic, salivary glands Squamous cell carcinoma, metastatic,		• •		+ 4	+ +	- +	+	+	+	+	+	+	+	+	+	+	+ X	+	+	+	+	+ x		+	· +	
oral mucosa Nose Pleura Trachea	ب ب	• •	⊦ 4 ⊦ 4	⊢ 4 ⊢ 4	⊦ 4 ⊦ 4	- +	· +	+ +	+	+ +	+ +	+	+	+ +	+	+	+	+ +	+	X + +	+ +	+	+	+	+	
Special Senses System Ear Eye Carcinoma, metastatic, salivary glands Zymbal's gland Carcinoma									+													+ X				
Urinary System Kidney Osteosarcoma, metastatic, mesentery Renal tubule, adenoma Urinary bladder Papilloma					 F -1	 - +	· +	+	+	+	+	· +	+	+	+	++	+	+ x +		+	+				+ +	
Systemic Lesions Multiple organs Leukemia mononuclear Mesothelioma malignant		>	+ +	+ -	+ + ( )	+ + x x	- + : x	+ X	+ x	+	 +	· +	• +	+ x	+ x	+ x	+	+	+ x	+	+ X	+	· +	+	+ X	

101

.

Individual Animal Tumor Pathology of Male Rats in the Long-Term Feed Study of *t*-Butylhydroquinone: 2,500 ppm (continued)

(conmuce)													_						_		-								
Number of Days on Study		6 7 3	6 7 4	6 7 7	6 8 2	6 9 1	6 9 4	6 9 5	6 9 5	7 1 0	7 2 5	7 2 9	7 2 9	7 3 0	7 3 8	7 4 4	7 5 7	7 5 7	7 6 1	7 6 6	7 6 7	7 7 3	7 7 7	7 8 6	7 9 2	7 9 5			
Carcass ID Number	·	4	1 7 5	9	1 7 3	2 0 0	1 8 0	7	1 9 5	1 8 4	1 9 7	1 4 7	1 6 8	1 8 5	4	1 6 7	1 8 6	1 8 8	1 4 6	1 6 3	1 4 ,1	1 6 0	1 5 3	1 7 7	1 4 9	1 6 1			
Respiratory System Lung Alveolar/bronchiolar adenoma Carcinoma, metastatic, salivary glands Squamous cell carcinoma, metastatic, oral mucosa		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	<b>.</b> .	 • <b>•</b>	
Nose Pleura Trachea		+ +	+ +	+ +	+	+ +	++	+ +	+	.+ +	+	+	+ +	+	+	+	+ +	+	+	+	+	+	+	+ +	+	+			
Special Senses System Ear Eye Carcinoma, metastatic, salivary glands	· · ·											-																	
Zymbal's gland Carcinoma			*							•••										•			•.			+ X			
Urinary System Kidney Osteosarcoma, metastatic, mesentery Renal tubule, adenoma		+	+	+	+	+	+	+	+	+	+	÷	+	+	+	+	+	+	+	+	+	+	+	+ x	+	+	- -		
Urinary bladder Papilloma Systemic Lesions		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	· +		 	
Multiple organs Leukemia mononuclear Mesothelioma malignant		+ X	+	+ x	+ X	΄+ Χ	<del>,+</del>	+	+ X		-	•																	

Individual Animal Tumor Pathology of Male Rats in the Long-Term Feed Study of t-Butylhydroquinone: 2,500 ppm (continued)

Number of Days on Study	8 8 8 8 8 8 8 8 8 0 1 1 4 5 5 5 5 6 0 5 5 2 2 2 7	
Carcass ID Number	1 1 1 1 1 1 1 1 4 6 5 5 5 6 8 6 5 4 6 4 9 5 1 9	Total Tissues/ Tumors
Respiratory System Lung Alveolar/bronchiolar adenoma Carcinoma, metastatic, salivary glands Squamous cell carcinoma, metastatic,	+ + + + + + +	58 1 1
oral mucosa Nose Pleura Trachea	^ + + + + + + + + + + + + + +	1 58 1 58
Special Senses System Ear Eye Carcinoma, metastatic, salivary glands Zymbal's gland Carcinoma		1 1 1 3 3
Urinary System Kidney Osteosarcoma, metastatic, mesentery Renal tubule, adenoma	+ + + + + + +	58 1 1
Urinary bladder Papilloma	+ + + + + + +	58 1
Systemic Lesions Multiple organs Leukemia mononuclear Mesothelioma malignant	+ + + + + + + + + + + + + + + + + + +	58 40 1

5)

ī.

103

TABLE A2

a

ę

																	•										 	
Number of Days on Study	4	4 8	4 8	5 0	5 2	5 3	5 5			6 2		6 2	6. 2		6 3	6 4		6 4	6 4	6 5	6 6	6 7	6	6 9				
• •	. 3	7	7	8	0	7	1	9	3	1	6	6	6	7	2	2	7	7	7	5	8	5	2	1	2			
	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2		 	
Carcass ID Number	4	4	-	_	_	-				6	_	4	5	-	_	2	-	4			5	6	2					
	2	5	4	7	0	0	8	7	5	3	4	6	3	4	6	9	9	4	0	8	1	5	5	7	0			
Alimentary System	_																										 	
Esophagus	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	М	+	+	+	+	+	+	+			
Intestine large, colon	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+			
Intestine large, rectum	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	Μ	+	+	+			
Intestine large, cecum	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	÷	+	+	+	+	+	+	+	+	+			
Intestine small, duodenum	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+			
Intestine small, jejunum	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	.+	+	+	+	+			
Intestine small, ileum	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+			
Liver	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+			
Hepatocellular carcinoma			•																									
Hepatocellular adenoma																												
Mesothelioma malignant, metastatic, peritoneum																		-										
Mesentery									+		+			+	+	+			+		+							
Pancreas	+	+	+	+	+	+	÷	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+			
Salivary glands	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+			
Stomach, forestomach	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+			
Squamous cell papilloma																			Х									
Stomach, glandular	· +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+			
Tongue																			+									
Squamous cell papilloma																			Х									
Tooth													_			_				•				_			 	۰.
Cardiovascular System						•						-									-							•
Blood vessel	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+			
Heart	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+			
Endocrine System																-												
Adrenal cortex	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+			
Adenoma																												
Adrenal medulla	+	+	÷	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+			
Pheochromocytoma malignant																												
Pheochromocytoma benign			Х							Х									•		Х			Х				
Pheochromocytoma benign, multiple																												
Islets, pancreatic	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	÷	+	+	+	+	+			•
Adenoma											•																	
Parathyroid gland	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	М	+	+	+	+	+			
Pituitary gland	+	+	+	+	+	+	+	+	+	+	+	+	+	+	÷	+	+	+	+	+			+	÷	+			
Pars distalis, adenoma																					х							
Pars distalis, carcinoma														X										•	÷			
Thyroid gland	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	'		
C-cell, adenoma									х	х																		
C-cell, carcinoma																												
Follicular cell, carcinoma																												
General Body System													_				_	_										
Peritoneum											+							+										
																		•										

c

# t-Butylhydroquinone, NTP TR 459

#### TABLE A2

Individual Animal Tumor Pathology of Male Rats in the Long-Term Feed Study of *t*-Butylhydroquinone: 5,000 ppm (continued)

		-	-	_	~	~	-	-		-	-	~		-	~	-	_	0	<u> </u>	_			~		0	 	
Number of Deve on Standar										-		-	7	_		-					8		8				
Sumber of Days on Study	0	0	1	3	3	3	3	4	4	5	6	6	7	7		8		0	0	1	3	5	5	5			
	2	8	9	0	0	0	9	5	5	0	6		3	3	0	6	6	7	8	0	9	7	7	7		 	
	. 2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2		
Carcass ID Number	4	1	5	2	4	5	6	2	2	3	5	3	3	6	2	3	2	3	6	6	1	1	1	1	1		
	7	1	9	1	3	6	2	7	8	2	2	1	4	9	0	7	3	8	0	1	3	2	4	5	6		
Alimentary System										-																 	
Esophagus	+	+	+	Μ	( +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		
intestine large, colon	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	÷	+	+	+	+	+	+	+	+	+		
ntestine large, rectum	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		
Intestine large, cecum	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		
intestine small, duodenum	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		
Intestine small, jejunum	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		
Intestine small, ileum	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	Μ	+	+	+		
Liver	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	÷	+	+	+	+	+		
Hepatocellular carcinoma												х						Х									
Hepatocellular adenoma		Х			Х																						
Mesothelioma malignant, metastatic, peritoneum						Х																					
Mesentery				+		+	+		+					+			+				+		+				
Pancreas	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		
Salivary glands	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		
Stomach, forestomach	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	I	+	+	+	+		
Squamous cell papilloma																											
Stomach, glandular	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		
Fongue				+				+																			
Squamous cell papilloma																											
Footh							_			+		_					_									 	
Cardiovascular System																											
Blood vessel	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		
Heart	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		
Endocrine System																÷										 	
Adrenal cortex	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		
Adenoma																x											
Adrenal medulla	+	+	+	+	+	+	+	+	+	+	+	+	+	+			+	+	+	+	+	+	+	+	+		
Pheochromocytoma malignant																								х			•
Pheochromocytoma benign									Х									х		х					х		
Pheochromocytoma benign, multiple																											
slets, pancreatic	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		
Adenoma		х																			X						
Parathyroid gland	+	+	+	+	• +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		
Pituitary gland	+	+	+	+	• +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		
						х													х					x			
Pars distalis, adenoma																											
								т.	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		
Pars distalis, carcinoma	+	+	+	· +	• +		- +																				
Pars distalis, carcinoma	+	+	+	• +	• +	+	+		•	•														Х			
Pars distalis, carcinoma Thyroid gland	+ x		+	• +	• +	•	+	1		•														х			

ć

2

Individual Animal Tumor Pathology of Male Rats in the Long-Term Feed Study of *t*-Butylhydroquinone: 5,000 ppm (continued)

(continued)						_								 			
Number of Days on Study		8 8 5 5 7 7			88 55 77	5	8 5 7		8 5 7 ·					• 4			
Carcass ID Number	·. · ·	2 2 1 1 8 9	2	2	22 34 31	4	2 4 9	2 5 5	6							Tota Tissue Tumor	s/
Alimentary System																	
Esophagus		+ •	+ +	+	+ +	+ +	+	+	+							5	58
Intestine large, colon		+ -	+ +	+	+ +	+ +	+	+	+								50
Intestine large, rectum		+ •	+ +	+	+ +	+ +	+	+	+								59
Intestine large, cecum		+ ·	+ • +	+	+ +	+ +	+	+	+							6	50
Intestine small, duodenum		+ -	+ +	+	+ +	+ +	+	+	+							6	50
Intestine small, jejunum		+ ·	+ +	+	+ +	⊦ +	+	+	+							6	50.
Intestine small, ileum		· + ·	+ +	+	+ +	+ +	+	+	+								59
Liver		+ •	+ +	+	+ +	+ +	+	+	+ ·							. e	50
Hepatocellular carcinoma	• •													· .	-	••	2
Hepatocellular adenoma			Х														3
Mesothelioma malignant, metastatio	c, peritoneum										,	. •	£				1
Mesentery					+										· · .		l6 ·
Pancreas		· + ·	+ +	+	+ +	+ +	+	+	+								50
Salivary glands		• + •	+ +	+	+ +	+ +	+	+	+								50
Stomach, forestomach		+ ·	+ +	+	+ +	+ +	+	+	+								59
Squamous cell papilloma										•					· · .		1
Stomach, glandular		+ ·	+ +	+	+ +	- +	+	+	+								50
Tongue									+								4
Squamous cell papilloma Tooth									х					 			2
Cardiovascular System						_	_										
Blood vessel	· ·	+	+ +	+	+ +	+ +	+	+	+								50
Heart		+	+ +	+	+ -	+ +	+	+	+					 	:		50
Endocrine System																	
Adrenal cortex		+	+ +	+	+ -	+ +	+	+	+							e	50
Adenoma																	1 .
Adrenal medulla		+	+ +	+	+ -	+ +	+	+	+							C	50
Pheochromocytoma malignant			X			Х								<i>.</i>			3
Pheochromocytoma benign		<b>X</b> 2	X			Х										<b> 1</b>	
Pheochromocytoma benign, multip	le					K											1
Islets, pancreatic		. +	+ +	+	+ -	+ +	• +	+	+							. (	50
Adenoma				Х													3
Parathyroid gland	•	. +	+ · +	+	+ -	+ +	• +										58
Pituitary gland		+	+ +	+		+ +	• +		+							• • • •	60
Pars distalis, adenoma		•			2	K		Х									6
Pars distalis, carcinoma		•															1
Thyroid gland		+	+ +	+	+ -	+ + X	• +	+	+								1
C-cell, adenoma					2												2
C-cell, carcinoma						Х	•	v								,	3
Follicular cell, carcinoma								X						 			
General Body System Peritoneum																· · · · · ·	3

ŀ

Q.

# t-Butylhydroquinone, NTP TR 459

### TABLE A2

and a fill to be a set of a standard based and the standard set of the set of the set of the set of the set of A set of the A set of the Individual Animal Tumor Pathology of Male Rats in the Long-Term Feed Study of *t*-Butylhydroquinone: 5,000 ppm (continued)

$\begin{array}{cccccccccccccccccccccccccccccccccccc$	0 2 4 0 + + + + + +
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	4 0 + + + + +
X + + + + + + + + + + + + + + + + + + +	+ + +
X + + + + + + + + + + + + + + + + + + +	+ + +
X + + + + + + + + + + + + + + + + + + +	+ + +
+ + + + + + + + + + + + + + + + + + +	+
+ + + + + + + + + + + + + + + + + + +	+
+ + + + + + + + + + + + + + + + + + +	+
+ + + + + + + + + + + + + + + + + + +	+
+ + + + + + + + + + + + + + + + + + +	+
x x x x x x x x x x x x x x x x x x x	
	<b>X</b>
X X X	
+ + + + + + + + + + + + + + + + + + + +	+
+ + + + + + + + +	
+ + + + + + + + + + + + + + + + + + + +	+ .
	•
* * * * * * * * * * * * * * * * * * *	+
* * * * * * * * * * * * * * * * * *	+
X	
	+ .
+ + + + + + + + + + + + + + + + + + + +	+
+ + + + + + + + + + + + + + + + + + + +	+
X	
	X
Х	
X	
	· ·
+ + + + + + + + + + + + + + + + + + + +	+ .
+ + + + + + + + + + + + + + + + + + + +	+
+ + + + + + + + + + + + + + + + + + + +	+
+ + + + + + + + + + + + + + + + + + + +	+
+ + + + + + + + + + + + + + + + + + + +	+
+ + + + +	<pre>* * * * * * * * * * * * * * * * * * *</pre>
Individual Animal Tumor Pathology of Male Rats in the Long-Term Feed Study of *t*-Butylhydroquinone: 5,000 ppm (continued)

(	_																										
Number of Days on Study	7 0 2	7 0 8	7 1 9	7 3 0	3	7 3 0		4 4	7 ·7 4 ·5 5 (	56	6	7 7 3	7 7 3	7 8 6	7 8 6	0	8 0 7		8 1 0	8 3 9	8 5 7	8 5 7	8 5 7	8 5 7			
Carcass ID Number	2 4 7	1	5	2 2 1	4	5		2 2	2 2 2 3 8 2	3 5	3	2 3 4		2 2 0			2 3 8	2 6 0	2 6 1	2 1 3	2 1 2	2 1 4	2 1 5	2 1 6			 
Genital System																											
Epididymis	+	+	+	+	+	+	+	+	+ •	+ +	+ +	+	+	+	+	+	+	+	+	+	+	+	+	+			
Preputial gland	+	+	+	+	+	+	+	+	+ -	+ +	+ +	+	+	+	+	+	+	+	+	+	+	+	+	+			
Adenoma															Х							Х					
Carcinoma			Х															х						Х			
Prostate	+	+	+	+	+	+	+	+	+ •	+ +	+ +	+	+	+	+	+	+	+	+	+	+	+	+	+			
Adenoma																											
Seminal vesicle	+	+	+	+	+	+	+	+	+ •	+ +	+ +	+	+	+	+	+	+	+	+	+	+	+	+	+			
Testes	+		+		+		+		+ •					+				+		+	+		+				
Bilateral, interstitial cell, adenoma Interstitial cell, adenoma	x	х		x		x	X	x :	X	х х 	( X	х	X	х	X	X	x	x	<b>X</b> .	x	X	х 	х 	х			
Hematopoietic System																											
Bone marrow	+	+	+	+	+	+	+	+	+ -	+ +	+ +	+	+	+	+	+	+	+	+	+	+	+	+	+			
Lymph node	+	+	+	+	+	+	+	+ 1	+ •	+	+	+	+			+	+		+	+			+				
Lymph node, mandibular	+	+	+	+	+	+	+	+.	+ ·	+ +	+ +	+	+	+	+	÷	+	+	+	+	+	+	+	+			
Carcinoma, metastatic, Zymbal's gland																											
Lymph node, mesenteric	+	+	+	+	+	+	+	+	+ •	+ +	+ +	+	+	+	+	+	+	+	+	+	+	+	+	+			
Hemangioma																											
Spleen	. +	+	+	+	+	+	+	+	+ ·	+ +	+ +	+	. +	+	+	+	+	+	+	÷	+	+	+	+			
Sarcoma																											
Thymus	+	+	+	+	+	+	+	+	+ •	+ +	+ +	+		+	+	+	+	+	+	+	+	+	+	М			
Thymoma malignant													Х							•				•		•	
Integumentary System																					-	-	-				
Mammary gland	+	+	+	+	+	+	+	+	+ •	+ +	+ +	+	+	+	М	+	+	+	+	+	+	+	+	+			
Fibroadenoma	·	X		-	-						x																
Fibroadenoma, multiple																								•			
Skin	+	+	+	+	+	+	+	+	+ •	+ +	+ +	+	+	+	+	+	+	+	+	+	+	+	+	+			
Keratoacanthoma		•	Х							λ																	
Squamous cell papilloma																								Х			
Trichoepithelioma																											
Subcutaneous tissue, fibroma										2	C	Х		Х													
Subcutaneous tissue, fibrosarcoma								X																			
Subcutaneous tissue, schwannoma malignant																					X		_			,	
Musculoskeletal System																						:	•		i		,
Bone	+	+	+	+	+	+	+	+	+ ·	+ •	+ +	+	+	+	+	+	+	+	+	+	+	+	+	+			
Nervous System																											
Brain	+	• +	+	+	+	+	+	+	+	+ •	+ +	• +	+	+	+	+	+	+	+	+	+	+	+	+			
Peripheral nerve																				+							
Spinal cord																				+							
Respiratory System								_																	_		_
Respiratory System		• +	• +	+	+	+	+	+	÷.	+ •	+ +	• +	+	+	+	+	+	+	+	+	+	+	+	+			
Lung	+												Х														
	+				•																						
Lung	+																					Х					
Lung Alveolar/bronchiolar adenoma	+	• +	· +	+	+	+	+	+	+	+ ·	+ +	• +	• +	+	+	+	+	+	+	+	+	Х +	+	+			

#### t-Butylhydroquinone, NTP TR 459

# Table A2

-

Individual Animal Tumor Pathology of Male Rats in the Long-Term Feed Study of *t*-Butylhydroquinone: 5,000 ppm (continued)

Number of Days on Study	8 8 8 8 8 8 8 8 8 8 8 8 5 5 5 5 5 5 5 5	
Carcass ID Number	2       2       2       2       2       2       2       2         1       1       2       2       3       4       4       5       6         8       9       2       6       3       1       8       9       5       6	Total Tissues/ Tumors
Genital System		
Epididymis	+ + + + + + + + +	60
reputial gland	+ + + + + + + + +	60
Adenoma	Х	3
Carcinoma		5
rostate	+ + + + + + + + +	60
Adenoma	Х	1
eminal vesicle	+ + + + + + + + +	60
estes	* + + + + + + + +	60
Bilateral, interstitial cell, adenoma	X X X X X X X X	50
Interstitial cell, adenoma	X X	9
Tematopoietic System	+ + + + + + + + +	60
ymph node		35
	т тт ,,,,,,,,,,	60
ymph node, mandibular	+ + + + + + + + +	
Carcinoma, metastatic, Zymbal's gland		1
ymph node, mesenteric	+ + + + + + + + + + + + + + + + + + +	60
Hemangioma	X	1
pleen	+ + + + + + + + +	60
Sarcoma		1
hymus Thymoma malignant	+ + M M M + + + + +	56 1
ntegumentary System		1 
Mammary gland	+ + + + + + + + +	58
Fibroadenoma	+ + + + + + + + + + + + + + + + + + +	6
Fibroadenoma, multiple	X	: 1
kin		60
Keratoacanthoma	+ + + + + + + + + + + X	4
Squamous cell papilloma	А	2
Trichoepithelioma		2
Subcutaneous tissue, fibroma	x x	6
Subcutaneous tissue, fibrosarcoma	Λ Λ	1
Subcutaneous tissue, schwannoma malignant	·	. 1
		· · ·
Musculoskeletal System Bone	+ + + + + + + + +	60
Nervous System		
rain	+ + + + + + + + +	60
Peripheral nerve		1
pinal cord		1
Respiratory System		
ung	+ + + + + + + + +	60
Alveolar/bronchiolar adenoma	, , , , , , , , , , , , , , , , , , ,	1
Alveolar/bronchiolar carcinoma		1
Nose	* * * * * * * * * * *	1 60
rachea	+ + + + + + + + + +	60
. Iaulica	, , , , , , , , , , , , <b>, , , , , , , </b>	00

\_\_\_\_

Individual Animal Tumor Pathology of Male Rats in the Long-Term Feed Study of *t*-Butylhydroquinone: 5,000 ppm (continued)

(continued)									_																		•	·. ·
Number of Days on Study		 4 2 3	4 8 7	4 8 7	5 0 8	5 2 0	5 : 3 : 7	5 5 5 8 1 9	56 80 93	5 6 ) 2 } 1	6 2 6	6 2 6	6 2 6	6 2 7	6 3 2	6 4 2	6 4 7	6 4 7	6 4 7	6 5 5	6 6 8	6 7 5	6 8 2	6 9 1	7 0 2		• `.	
Carcass ID Number		 2 4 2	2 4 5	2 6 4	2 5 7	2 3 0	2 7 0	2 2 5 1 8 7	2 2 1 3 7 5	2 2 3 6 5 3	2 2 4	2 4 6	2 5 3	2 5 4	2 3 6	2 2 9	2 3 9	2 4 4	2 5 0	2 6 8	2 5 1	2 6 5	2 2 5	2 6 7	2 .4 0		•••••	
Special Senses System		· · · ·																		_						; ,		
Eye Harderian gland Zymbal's gland Adenoma			+						+												+				+ X	, :		' .
Carcinoma		 _	<u>x</u>																	_	X					~~~~~	` <u>`</u>	· ·
Urinary System Kidney Renal tubule, adenoma Urinary bladder Papilloma	•. •.	+ +	+	+ +	+ +	+ +	+	+ •	+ + + +	+ + + .+	- +	+ +	+	+ +	+ +	+	+ +							+				• •
Systemic Lesions Multiple organs Leukemia mononuclear Mesothelioma malignant		 + x	+	+ x	+ x	+	+	+	+ + X	+ + X	- + x x x		+	+	+ x	+	+	+ x	+	+ X	+	+ x	+ X	+ x	+			••

## t-Butylhydroquinone, NTP TR 459

#### TABLE A2

------

Individual Animal Tumor Pathology of Male Rats in the Long-Term Feed Study of *t*-Butylhydroquinone: 5,000 ppm (continued)

The second s																			_	_	-				_	-		 	_
Number of Days on Study		7 0 2	7 0 8	7 1 9	7 3 0	7 3 0	7 3 0	7 3 9	7 4 5	7 4 5	7 5 0	7 6 6	7 6 7	7 7 3	7 7 3	7 8 6	7 8 6	8 0 6	8 0 7	8 0 8	8 1 0	8 3 9	8 5 7	8 5 7	8 5 7	8 5 7			
Carcass ID Number		 2 4 7	2 1 1	2 5 9	2 2 1	2 4 3	2 5 6	2 6 2	2 2 7	2 2 8	2 3 2	2 5 2	2 3 1	2 3 4	2 6 9	2 2 0	2 3 7	2 2 3	2 3 8	2 6 0	2 6 1	2 1 3	2 1 2	2 1 4	1	2 1 6			
Special Senses System Eye Harderian gland Zymbal's gland Adenoma Carcinoma					+						+ x																		
Urinary System Kidney Renal tubule, adenoma Urinary bladder Papilloma	······································	+		++	+ +	++	·+ +	+++	+	++	+	+	+	+	+	+	++	+ X +		++		+ +	+	+		· +			
Systemic Lesions Multiple organs Leukemia mononuclear Mesothelioma malignant		+ X		+ X	+	+	+ X	+ x	+ X	+	+	+ x	+ x	+	+	+ x	+ x	+	+ X	- +	-	 -							

Individual Animal Tumor Pathology of Male Rats in the Long-Term Feed Study of t-Butylhydroquinone: 5,000 ppm (continued)

Number of Days on Study	· · · ·	8 8 5 : 7 *	8 8 5 4 7 1	38 55 77	8 5 7	8 5 7	8 5 7	8 5 7	8 5 7	8 5 7		 · · ·
Carcass ID Number	-	2 .2 1 .2 8 .9	1 2	2 2	2 3 3	2 4 1	2 4 8	2 4 9	2 5 5	2 6 6		Total Tissues/ Tumors
Special Senses System Eye Harderian gland Zymbal's gland Adenoma Carcinoma			÷				<u></u>					2 1 4 1 3
Urinary System Kidney Renal tubule, adenoma Urinary bladder Papilloma		+ +	 + ·	 + +			+	+		+	<u></u>	 60 1 60 1
Systemic Lesions Multiple organs Leukemia mononuclear Mesothelioma malignant	<u></u>	+	+ :	+ + X	- + X	- +	+	+ X	+ X	+		 60 32 3

VIII - AND COM

ala ala ala

Statistical Analysis of Primary Neoplasms in Male Rats in the Long-Term Feed Study of t-Butylhydroquinone

	0 ppm	1,250 ppm	2,500 ppm	5,000 ppm	
Adrenal Medulla: Benign Pheochromocytoma	<u></u>				
Adrenai Meduna: Benigh Fneochromocytoma )verall rate <sup>a</sup>	14/60 (22 %)	20/60 (22.01)	15/59 (760)	12/60 (200)	
Adjusted rate <sup>b</sup>	14/60 (23%)	20/60 (33%)	15/58 (26%)	12/60 (20%)	
	59.8%	85.5%	100.0%	49.8%	
Cerminal rate <sup>C</sup>	2/8 (25%)	5/7 (71%)	1/1 (100%)	5/14 (36%)	
First incidence (days)	667 D= 0.071N	655 D. 0 148	473 D= 0.000	487	
ife table test <sup>d</sup> ogistic regression test <sup>d</sup>	P=0.071N	P=0.148	P=0.090	P = 0.193N	
Cochran-Armitage test <sup>d</sup>	P=0.161N	P=0.123	P=0.224	P=0.351N	
sisher exact test	P=0.223N	<b>D</b> _0.166	P=0.458	D_0 413N	
isher exact test		P=0.156	P=0.438	P=0.412N	
drenal Medulla: Malignant Pheochromocyto					
Overall rate	1/60 (2%)	3/60 (5%)	1/58 (2%)	3/60 (5%)	
Adjusted rate	3.1%	23.8%	5.0%	21.4%	
Cerminal rate	0/8 (0%)	1/7 (14%)	0/1 (0%)	3/14 (21%)	
First incidence (days)	710	702	738	857 (T)	
Life table test	P=0.496	P=0.302	P=0.698	P=0.465	
Logistic regression test	P=0.390	P=0.296	P=0.738	P=0.394	
Cochran-Armitage test	P=0.313				
Fisher exact test		P=0.309	P=0.744	P=0.309	
Adrenal Medulla: Benign or Malignant Pheoc	hromocytoma				
Overall rate	14/60 (23%)	21/60 (35%)	16/58 (28%)	13/60 (22%)	
Adjusted rate	59.8%	85.9%	100.0%	55.4%	
Cerminal rate	2/8 (25%)	5/7 (71%)	1/1 (100%)	6/14 (43%)	
First incidence (days)	667	655	473	487	
Life table test	P=0.090N	P=0.113	P=0.062	P=0.239N	
ogistic regression test	P=0.210N	P=0.087	P=0.159	P=0.431N	
Cochran-Armitage test	P=0.282N				
isher exact test		P=0.114	P=0.375	P=0.500N	
Liver: Hepatocellular Adenoma					
Overall rate	4/60 (7%)	4/60 (7%)	0/58 (0%)	3/60 (5%)	
Adjusted rate	25.1%	23.7%	0.0%	12.7%	
Cerminal rate	1/8 (13%)	1/7 (14%)	0/1 (0%)	1/14 (7%)	
First incidence (days)	642	<b>697</b>	e	708	
Life table test	P = 0.223N	P=0.615	P = 0.170N	P=0.370N	
Logistic regression test	P = 0.291N	P=0.631	P = 0.096N	P≕0.463N	
Cochran-Armitage test	P = 0.322N				
Fisher exact test		P=0.641N	P=0.064N	P=0.500N	
Liver: Hepatocellular Adenoma or Carcinoma	n				
Dverall rate	° 4/60 (7%)	4/60 (7%)	0/58 (0%)	5/60 (8%)	
Adjusted rate	25.1%	23.7%	0.0%	21.0%	
Ferminal rate	1/8 (13%)	1/7 (14%)	0/1 (0%)	1/14 (7%)	
First incidence (days)	642	697	-	708	
Life table test	P=0.504N	P=0.615	P = 0.170N	P=0.611N	
Logistic regression test	P=0.526	P=0.631	P=0.096N	P=0.548	
Cochran-Armitage test	P=0.479				
Fisher exact test		P=0.641N	P=0.064N	P = 0.500	

# TABLE A3

Statistical Analysis of Primary Neoplasms in Male Rats in the Long-Term Feed Study of t-Butylhydroquinone (continued)

-----

- -

-

· .	7 16	0 ppm	1,250 ppm	2,500 ppm	5,000 ppm	
ung: Alveolar/bronchiolar	A denoma		······································		1 ·	
overall rate	/ wentonine	3/60 (5%)	2/60 (3%)	1/58 (2%)	1/60 (2%)	
djusted rate		10.2%	8.2%	2.4%	4.3%	· · · ·
erminal rate		0/8 (0%)	0/7 (0%)	0/1 (0%)	0/14 (0%)	
		618	708	604	773	
irst incidence (days)		P=0.187N	P = 0.518N	P = 0.409N	P = 0.276N	•
ife table test		P = 0.187N P = 0.201N	P = 0.502N	P = 0.409N P = 0.294N	P = 0.276N P = 0.306N	
ogistic regression test		P = 0.201N P = 0.202N	F-0.302N	r=0.2941	P-0.5001	
ochran-Armitage test		F=0.202N	D-0 500N	B-0 222N	D-0 200N	
sher exact test			P = 0.500N	P=0.322N	P=0.309N	•
ung: Alveolar/bronchiolar	Adenoma or Carcin			. •	• 2	•
verall rate		3/60 (5%)	2/60 (3%)	1/58 (2%)	2/60 (3%)	:
djusted rate		10.2%	8.2%	2.4%	11.2%	•
erminal rate	,	0/8 (0%)	0/7 (0%)	0/1 (0%)	1/14 (7%)	
irst incidence (days)		618	708	604	773	
ife table test		P=0.342N	P=0.518N	P=0.409N	P=0.418N	. '
ogistic regression test		P=0.399N	P=0.502N	P=0.294N	P=0.488N	
ochran-Armitage test		P = 0.406N				۰.
sher exact test			P = 0.500N	P=0.322N	P=0.500N	
ammary Gland: Fibroade	noma				- -	a .
verall rate		10/60 (17%)	4/60 (7%)	4/58 (7%)	7/60 (12%)	
djusted rate		72.0%	40.7%	24.8%	40.2%	
erminal rate		5/8 (63%)	2/7 (29%)	0/1 (0%)	5/14 (36%)	
irst incidence (days)		381	786	619	708	
ife table test		P=0.100N	P=0.085N	P = 0.526N	P=0.059N	· · · ·
ogistic regression test		P = 0.195N	P = 0.033N	P = 0.183N	P = 0.107N	
ochran-Armitage test		P = 0.350N	1 0.00511	1 0110011		
isher exact test		1-0.55011	P=0.077N	P=0.087N	P=0.301N	· · · ·
fammary Gland: Fibroade	nomo or Adonomo					
	anoma or Auchoma	11/60 (18%)	4/60 (7%)	5/58 (9%)	7/60 (12%)	
verall rate		72.6%	40.7%	43.6%	40.2%	
djusted rate			2/7 (29%)	0/1 (0%)	5/14 (36%)	
erminal rate		5/8 (63%) 381	786	619	708	•
irst incidence (days)		P = 0.072N	P = 0.055N	P = 0.580N	P = 0.039N	
ife table test			P = 0.033 N P = 0.022 N	P = 0.213N	P = 0.076N	
ogistic regression test		P = 0.145N	r=0.0221	F-0.215N	r =0.07014	
ochran-Armitage test		P = 0.282N	D-0.049N	D-0 101N	P=0.222N	
sher exact test			P=0.048N	P=0.101N	r-0.2221	
ancreas: Adenoma				1100 10 11		н., м
verall rate		3/60 (5%)	0/59 (0%)	1/58 (2%)	0/60 (0%)	· ·
djusted rate		37.5%	0.0%	25.0%	0.0%	• • •
erminal rate		3/8 (38%)	0/7 (0%)	0/1 (0%)	0/14 (0%)	
First incidence (days)		857 (T)		852		
ife table test	`	P=0.050N	P = 0.130N	P=0.599	P = 0.038N	1111 A
ogistic regression test		P=0.044N	P=0.130N	P=0.728N	P = 0.038N	• •
Cochran-Armitage test		P=0.087N				1
isher exact test			P = 0.125N	P=0.322N	P = 0.122N	1. A

/

.

Statistical Analysis of Primary Neoplasms in Male Rats in the Long-Term Feed Study of t-Butylhydroquinone (continued)

•	· 0 ppm	1,250 ppm	2,500 ppm	5,000 ppm
Pancreatic Islets: Adenoma		0150 (011)	10000	0160 (58)
Overall rate	5/60 (8%)	2/59 (3%)	1/58 (2%)	3/60 (5%)
Adjusted rate	32.5%	7.6%	5.3%	15.9%
Ferminal rate	1/8 (13%)	0/7 (0%)	0/1 (0%)	1/14 (7%)
First incidence (days)	667 D. 0 22001	697 D. 0.046N	744	708
life table test	P=0.220N	P=0.246N	P=0.297N	P = 0.208N
Logistic regression test	P = 0.280N	P=0.230N	P=0.173N	P=0.287N
Cochran-Armitage test	P=0.319N	D 0 00(0)	<b>D</b> 0 1111	
Fisher exact test	· · ·	P=0.226N	P=0.111N	P=0.359N
Pancreatic Islets: Adenoma or Carcinoma				
Overall rate	6/60 (10%)	2/59 (3%)	1/58 (2%)	3/60 (5%)
Adjusted rate	42.1%	7.6%	5.3%	15.9%
Terminal rate	2/8 (25%)	0/7 (0%)	0/1 (0%)	1/14 (7%)
First incidence (days)	667	697	744	708
Life table test	P=0.130N	P=0.163N	P=0.269N	P=0.112N
Logistic regression test	P=0.175N	P=0.142N	P = 0.117N	P=0.170N
Cochran-Armitage test	P=0.212N			
Fisher exact test		P = 0.142N	P=0.062N	P=0.245N
Pituitary Gland (Pars Distalis): Adenoma				
Overall rate	19/60 (32%)	16/58 (28%)	17/57 (30%)	6/60 (10%)
Adjusted rate	63.8%	80.0%	100.0%	30.2%
Ferminal rate	2/8 (25%)	4/6 (67%)	1/1 (100%)	3/14 (21%)
First incidence (days)	528	562	562	668
Life table test	P = 0.002N	P = 0.468N	P=0.241	P=0.002N
Logistic regression test	P=0.003N	P=0.410N	P = 0.573	P = 0.002N
Cochran-Armitage test	P=0.003N			
Fisher exact test	:	P=0.389N	P=0.494N	P=0.003N
Pituitary Gland (Pars Distalis): Adenoma or (	Carcinoma			
Overall rate	19/60 (32%)	17/58 (29%)	18/57 (32%)	7/60 (12%)
Adjusted rate	63.8%	81.1%	100.0%	31.6%
Terminal rate	2/8 (25%)	4/6 (67%)	1/1 (100%)	3/14 (21%)
First incidence (days)	528	562	562	627
Life table test	P=0.004N	P=0.539N	P = 0.188	P = 0.004N
Logistic regression test	P = 0.005N	P = 0.494N	P = 0.487	P = 0.006N
Cochran-Armitage test	P = 0.006N	• ••••	• •••••	
Fisher exact test		P=0.469N	P=0.575N	P=0.007N
Preputial Gland: Adenoma				
Overall rate	5/60 (8%)	3/60 (5%)	6/58 (10%)	3/60 (5%)
Adjusted rate	31.1%	20.0%	100.0%	18.4%
Terminal rate	2/8 (25%)	0/7 (0%)	1/1 (100%)	2/14 (14%)
First incidence (days)	528	766	526	786
Life table test	P=0.228N	P≈0.401N	P=0.133	P = 0.205N
Logistic regression test	P = 0.358N	P = 0.369N	P = 0.135 P = 0.436	P = 0.205 N P = 0.312 N
Cochran-Armitage test	P = 0.336N P = 0.386N	1-0.30711	1-0.450	1 -0.5121
	1 -0.3001	P≈0.359N	P=0.476	P=0.359N

.

î

**S**.

Statistical Analysis of Primary Neoplasms in Male Rats in the Long-Term Feed Study of t-Butylhydroquinone (continued)

	0 ppm	1,250 ppm	2,500 ppm	5,000 ppm	
Preputial Gland: Carcinoma			<del></del>		
Overali rate	2160 (20)	2160 (20)	0/60 (0.00)	<b>FICO (000)</b>	
Adjusted rate	2/60 (3%)	2/60 (3%)	2/58 (3%)	5/60 (8%)	
<b>3</b>	3.6%	7.9%	6.0%	18.4%	
Ferminal rate	0/8 (0%)	0/7 (0%)	0/1 (0%)	1/14 (7%)	
First incidence (days)	381	467	604	520	
Life table test	P=0.169	P=0.667	P=0.625	P=0.287	
Logistic regression test	P=0.098	P=0.614N	P=0.622N	P=0.200	
Cochran-Armitage test	P=0.115				:
Fisher exact test	· .	P=0.691N	P=0.678	P=0.219	
Preputial Gland: Adenoma or Carcinoma			•	· · · ·	
Overall rate	7/60 (12%)	5/60 (8%)	7/58 (12%)	8/60 (13%)	
Adjusted rate	33.6%	26.3%	100.0%	34.2%	•
Ferminal rate	2/8 (25%)	0/7 (0%)	1/1 (100%)	3/14 (21%)	• •
First incidence (days)	381	467	526	520	
Life table test	P=0.541N	P=0.435N	P=0.228	P=0.529N	
Logistic regression test	P=0.355	P = 0.373N	P = 0.609	P = 0.556	
Cochran-Armitage test	P=0.350	1-0.5751	1 -0.009	1 =0.550	
Fisher exact test	r =0.550	P=0.381N	P=0.585	P=0.500	
			· •		
Skin: Keratoacanthoma		· · · · · · · · · · · · · · · · · · ·		• • •	
Overall rate	4/60 (7%)	4/60 (7%)	4/58 (7%)	4/60 (7%)	
Adjusted rate	28.6%	18.8%	44.8%	15.5%	
Cerminal rate	2/8 (25%)	0/7 (0%)	0/1 (0%)	1/14 (7%)	
First incidence (days)	667	634	535	647	•
ife table test	P=0.406N	P=0.612	P=0.268	P=0.516N	
ogistic regression test	P=0.538N	P=0.632	P=0.517	P=0.616N	
Cochran-Armitage test	P=0.567				
risher exact test		P=0.641N	P=0.622	P=0.641N	
Skin: Squamous Cell Papilloma or Keratoacantho	ma			,	
Dverall rate	6/60 (10%)	6/60 (10%)	4/58 (7%)	6/60 (10%)	
Adjusted rate	45.1%	42.0%	44.8%	24.2%	
Ferminal rate	3/8 (38%)	2/7 (29%)	0/1 (0%)	2/14 (14%)	
First incidence (days)	667	634	535	647	
Life table test	P=0.297N	P=0.573	P=0.424	P=0.423N	
ogistic regression test	P = 0.468N	P=0.606	P = 0.424 P = 0.543N	P = 0.425 N P = 0.566 N	
Cochran-Armitage test		P=0.000	F-0.345M	F=0.300N	
isher exact test	P=0.533N	P=0.619N	P=0.393N	P=0.619N	
kin: Trichoepithelioma or Basal Cell Carcinoma	2/60 (50)	1/60 (2 %)	0/58 (0%)	1/60 (29)	
Overall rate	3/60 (5%)	1/60 (2%)	. 0/58 (0%)	1/60 (2%)	
Adjusted rate	16.5%	6.3%	0.0%	2.0%	
erminal rate	0/8 (0%)	0/7 (0%)	0/1 (0%)	0/14 (0%)	
irst incidence (days)	759	773	-	626	
ife table test	P = 0.171N	P=0.328N	P=0.179N	P=0.240N	•
ogistic regression test	P=0.197N	P=0.313N	P = 0.168N	P=0.298N	
Cochran-Armitage test	P=0.202N				
Fisher exact test		P=0.309N	P=0.128N	P=0.309N	

# 8-Butylhydroquinone, NTP TR 459

# TABLE A3

Statistical Analysis of Primary Neoplasms in Male Rats in the Long-Term Feed Study of t-Butylhydroquinone (continued)

	0 ppm	1,250 ppm	2,500 ppm	5,000 ppm
Skin: Squamous Cell Papilloma, Keratoacan	thoma Trichoanithaliama	or Rasal Call Car		
)verall rate	8/60 (13%)	7/60 (12%)	4/58 (7%)	7/60 (12%)
Adjusted rate	50.3%	45.6%	44.8%	25.7%
'erminal rate	3/8 (38%)	2/7 (29%)	0/1 (0%)	2/14 (14%)
irst incidence (days)	667	634	535	626
ife table test	P=0.216N	P=0.556N	P=0.599N	P=0.308N
ogistic regression test	P = 0.363N	P = 0.521N	P = 0.320N	P = 0.454N
ochran-Armitage test	P = 0.420N	1-0.5211	1-0.52011	1-0.45411
isher exact test	1 - 0.12010	P=0.500N	P=0.198N	P=0.500N
kin (Subcutaneous Tissue): Fibroma				
verall rate	4/60 (7%)	8/60 (13%)	6/58 (10%)	6/60 (10%)
djusted rate	30.0%	61.8%	26.7%	26.7%
erminal rate	1/8 (13%)	4/7 (57%)	0/1 (0%)	2/14 (14%)
irst incidence (days)	761	619	619	642
ife table test	P=0.434N	P=0.146	P=0.143	P=0.574
ogistic regression test	P=0.491	P=0.161	P=0.274	P=0.448
ochran-Armitage test	P=0.439			
isher exact test		P=0.181	P=0.350	P=0.372
kin (Subcutaneous Tissue): Fibroma or Fib	rosarcoma			
verail rate	5/60 (8%)	9/60 (15%)	7/58 (12%)	7/60 (12%)
djusted rate	40.0%	63.3%	28.2%	29.3%
erminal rate	2/8 (25%)	4/7 (57%)	0/1 (0%)	2/14 (14%)
irst incidence (days)	761	619	562	642
ife table test	P=0.412N	P=0.151	P = 0.106	P≈0.605
ogistic regression test	P=0.491	P=0.173	P≈0.282	P=0.470
ochran-Armitage test	P=0.443			
isher exact test		P=0.197	P=0.357	P=0.381
estes: Adenoma				
verall rate	55/60 (92%)	49/60 (82%)	56/57 (98%)	59/60 (98%)
djusted rate	100.0%	100.0%	100.0%	100.0%
erminal rate	8/8 (100%)	7/7 (100%)	1/1 (100%)	14/14 (100%)
irst incidence (days)	489	535	464	487
ife table test	P = 0.346N	P=0.399N	P=0.019	P=0.306N
ogistic regression test	P=0.009	P=0.116N	P=0.054	P=0.104
ochran-Armitage test	P=0.013			
isher exact test		P = 0.089N	P=0.116	<b>P=0.103</b>
hyroid Gland (C-cell): Adenoma				
overall rate	5/60 (8%)	2/60 (3%)	2/58 (3%)	4/60 (7%)
djusted rate	25.2%	22.9%	10.9%	17.6%
erminal rate	0/8 (0%)	1/7 (14%)	0/1 (0%)	2/14 (14%)
irst incidence (days)	730	831	691	603
ife table test	P=0.357N	P=0.246N	P=0.382N	P=0.355N
ogistic regression test	P = 0.478N	P = 0.221N	P=0.311N	P=0.473N
Cochran-Armitage test	P=0.521N	D 0 0101	D 0 00 00	D 0 0001
risher exact test		P=0.219N	P=0.234N	P=0.500N

\$

. يو.

Statistical Analysis of Primary Neoplasms in Male Rats in the Long-Term Feed Study of t-Butylhydroquinone (continued)

	0 ppm	1,250 ppm	2,500 ppm	5,000 ppm
Thyroid Gland (C-cell): Adenoma or Carcinoma			· · · · · · · · · · · · · · · · · · ·	
Overall rate	5/60 (8%)	2/60 (50)	2150 (20)	(10) (10)
Adjusted rate		3/60 (5%)	2/58 (3%)	6/60 (10%)
Cerminal rate	25.2% 0/8 (0%)	24.7%	10.9%	26.5%
First incidence (days)	730	1/7 (14%)	0/1 (0%)	3/14 (21%)
Life table test		667 D-0 201N	691 Pr: 0.282N	603 D 0 5751
ogistic regression test	P=0.545 P=0.404	P = 0.391N	P = 0.382N	P = 0.575N
Cochran-Armitage test	P = 0.361	P = 0.368N	P=0.311N	P=0.536
Fisher exact test	r =0.501	P=0.359N	P=0.234N	P=0.500
hyroid Gland (Follicular Cell): Carcinoma				
Dyerall rate	0/60 (00)		0/59 (001)	2160 (591)
Adjusted rate	0/60 (0%)	0/60 (0%)	0/58 (0%)	3/60 (5%)
erminal rate	0.0%	0.0%	0.0%	18.8%
erminal rate First incidence (days)	0/8 (0%)	0/7 (0%)	0/1 (0%)	1/14 (7%)
		<b>—</b>		810
Life table test	P=0.053			P=0.237
Logistic regression test	P=0.031	-	<del></del>	P=0.179
Cochran-Armitage test	P=0.012			D 0 100
isher exact test		-	-	P=0.122
Thyroid Gland (Follicular Cell): Adenoma or Carc				
Overall rate	0/60 (0%)	1/60 (2%)	1/58 (2%)	3/60 (5%)
Adjusted rate	0.0%	14.3%	12.5%	18.8%
erminal rate	0/8 (0%)	1/7 (14%)	0/1 (0%)	1/14 (7%)
First incidence (days)	-	857 (T)	806	810
life table test	P=0.174	P=0.473	P=0.419	P=0.237
ogistic regression test	P=0.113	P=0.473	P=0.423	P=0.179
Cochran-Armitage test	P=0.055			
isher exact test		P=0.500	P=0.492	P=0.122
Lymbal's Gland: Carcinoma				
Overall rate	2/60 (3%)	1/60 (2%)	3/58 (5%)	3/60 (5%)
Adjusted rate	9.9%	1.9%	16.3%	7.8%
Terminal rate	0/8 (0%)	0/7 (0%)	0/1 (0%)	0/14 (0%)
First incidence (days)	500	554	642	487
Life table test	P=0.339	P=0.493N	P=0.369	P=0.527
Logistic regression test	P=0.284	P = 0.462N	P=0.495	P=0.483
Cochran-Armitage test	P=0.302			
isher exact test		P=0.500N	P=0.484	P=0.500
Lymbal's Gland: Adenoma or Carcinoma				
Dverall rate	2/60 (3%)	1/60 (2%)	3/58 (5%)	4/60 (7%)
Adjusted rate	9.9%	1.9%	16.3%	10.4%
Ferminal rate	0/8 (0%)	0/7 (0%)	0/1 (0%)	0/14 (0%)
First incidence (days)	500	554	642	487
Life table test	P=0.197	P=0.493N	P=0.369	P=0.366
ogistic regression test	P=0.149	P=0.462N	P=0.495	P=0.321
Cochran-Armitage test	P=0.163			
Fisher exact test		P = 0.500N	P=0.484	P=0.340

.

Statistical Analysis of Primary Neoplasms in Male Rats in the Long-Term Feed Study of t-Butylhydroquinone (continued)

	0 ppm	1,250 ppm	2,500 ppm	5,000 ppm	
All Organs: Mononuclear Cell Leukemia		······································	- <u>-</u> <u></u>		
Overall rate	39/60 (65%)	47/60 (78%)	40/58 (69%)	32/60 (53%)	
Adjusted rate	87.2%	97.2%	100.0%	75.2%	
Terminal rate	4/8 (50%)	6/7 (86%)	1/1 (100%)	6/14 (43%)	
First incidence (days)	534	394	464	423	
Life table test	P=0.035N	P=0.148	P=0.053	P=0.085N	
Logistic regression test	P = 0.034N	P=0.039	P = 0.347	P = 0.065 N P = 0.168 N	
Cochran-Armitage test	P = 0.031N	1-0.039	r~0.347	r -0.10014	•
Fisher exact test	1 = 0.0511	P=0.078	P=0.397	P=0.133N	
All Organs: Malignant Mesothelioma					
Overall rate	1/60 (2%)	0/60 (0%)	1/58 (2%)	3/60 (5%)	
Adjusted rate	12.5%	0.0%	6.3%	7.2%	
Terminal rate	1/8 (13%)	0/7 (0%)	0/1 (0%)	0/14 (0%)	
First incidence (days)	857 (T)		761	626	
Life table test	P=0.151	P=0.527N	P=0.538	P=0.366	
Logistic regression test	P=0.103	P = 0.527N	P=0.676	P=0.306	
Cochran-Armitage test	P=0.097	1 0.52/11	1-0.070	1 -0.500	
Fisher exact test		P=0.500N	P=0.744	P=0.309	
All Organs: Benign Neoplasms					•
Overall rate	60/60 (100%)	56/60 (93%)	56/58 (97%)	59/60 (98%)	
Adjusted rate	100.0%	100.0%	100.0%	100.0%	
Terminal rate	8/8 (100%)	7/7 (100%)	1/1 (100%)	14/14 (100%)	
First incidence (days)	381	535	464	487	
Life table test	P=0.149N	P=0.492N	P=0.056	P=0.154N	
Logistic regression test	P=0.450N	P=0.100N	P=0.282N	P=0.354N	
Cochran-Armitage test	P=0.578				
Fisher exact test		P=0.059N	P=0.239N	P=0.500N	
All Organs: Malignant Neoplasms	ł				
Overall rate	51/60 (85%)	53/60 (88%)	50/58 (86%)	47/60 (78%)	
Adjusted rate	95.5%	97.8%	100.0%	91.2%	
Terminal rate	6/8 (75%)	6/7 (86%)	1/1 (100%)	10/14 (71%)	
First incidence (days)	381	289	464	423	
Life table test	P=0.092N	P=0.363	P=0.054	P=0.123N	
Logistic regression test	P=0.150N	P=0.394	P=0.565N	P=0.249N	
Cochran-Armitage test	P=0.131N				
Fisher exact test		P=0.395	P=0.530	P=0.240N	

. .

×

íe,

Statistical Analysis of Primary Neoplasms in Male Rats in the Long-Term Feed Study of t-Butylhydroquinone (continued)

	0 ppm	1,250 ppm	2,500 ppm	5,000 ppm	
All Organs: Benign or Malignant Neoplasms	- <u></u> .				
Overall rate	60/60 (100%)	59/60 (98%)	57/58 (98%)	60/60 (100%)	
Adjusted rate	100.0%	100.0%	100.0%	100.0%	
Terminal rate	8/8 (100%)	7/7 (100%)	1/1 (100%)	14/14 (100%)	
First incidence (days)	381	289	464	423	
Life table test	P=0.155N	P=0.467	P=0.046	P=0.180N	
Logistic regression test	P=0.673N	P=0.773N	P=0.404N	_f	
Cochran-Armitage test	P=0.595				
Fisher exact test		P=0.500N	P=0.492N	P = 1.000N	

(T)Terminal sacrifice

Number of neoplasm-bearing animals/number of animals examined. Denominator is number of animals examined microscopically for adrenal gland, liver, lung, pancreas, pancreatic islets, pituitary gland, preputial gland, testes, and thyroid gland; for other tissues, denominator is number of animals necropsied.

<sup>b</sup> Kaplan-Meier estimated neoplasm incidence at the end of the study after adjustment for intercurrent mortality

<sup>c</sup> Observed incidence at terminal kill

<sup>d</sup> Beneath the control incidence are the P values associated with the trend test. Beneath the exposure group incidence are the P values corresponding to pairwise comparisons between the controls and that exposure group. The life table test regards neoplasms in animals dying prior to terminal kill as being (directly or indirectly) the cause of death. The logistic regression test regards these lesions as nonfatal. The Cochran-Armitage and Fisher exact tests compare directly the overall incidence rates. For all tests, a negative trend or a lower incidence in an exposure group is indicated by N.
 <sup>e</sup> Not explicitly and explore the control of the contr

<sup>e</sup> Not applicable; no neoplasms in animal group

<sup>1</sup> Value of statistic cannot be computed.

#### Table A4

Summary of the Incidence of Nonneoplastic Lesions in Male Rats in the Long-Term Feed Study of t-Butylhydroquinone<sup>a</sup>

	0 ppm	1,250 ppm	2,500 ppm	5,000 ppm
Disposition Summary		n, sq. nq sq. qq. sq. sq. sq. sq. sq. sq.		
Animals initially in study	70	70	70	70
-Month interim evaluation	10	10	10	10
Early deaths		-		
Moribund	48	51	50	42
Natural deaths	4	2	7	4
urvivors				
Terminal sacrifice	8	7	· 1	14
fissexed	0	0	2	0
Animals examined microscopically	70	70	70 68	
8-Month Interim Evaluation				
limentary System				
ntestine large, colon	(10)	(10)	(10)	(10)
Parasite metazoan		N: 10		1 (10%)
ntestine large, rectum	(10)	(10)	(10)	(10)
Parasite metazoan	1 (10%)		、 <i>,</i>	, ,
ntestine small, ileum	(10)	(10)	(10)	(10)
Hyperplasia, lymphoid		1 (10%)		
iver	(10)	(10)	(10)	(10)
Hepatodiaphragmatic nodule		1 (10%)		
Inflammation, subacute	1 (10%)		1 (10%)	2 (20%)
Bile duct, hyperplasia				1 (10%)
ancreas	(10)	(10)	(10)	(10)
Atrophy	1 (10%)		44.0	2 (20%)
tomach, forestomach	(10)	(10)	(10)	(10)
Hyperplasia		1 (10%)		
Cardiovascular System				
leart	(10)	(10)	(10)	(10)
Cardiomyopathy	2 (20%)	4 (40%)	2 (20%)	2 (20%)
ndoarina Sustam			<u></u>	
E <b>ndocrine System</b> Adrenal cortex	(10)	(10)	(10)	(10)
	(10)	(10)	(10)	(10)
Accessory adrenal cortical nodule slets, pancreatic	1 (10%)	(10)	(10)	1 (10%)
Hyperplasia	(10)	(10)	(10)	(10)
ituitary gland	(10)	1 (10%)	(0)	(10)
Pars intermedia, cyst	(10)	(10)	(9) 1 (11%)	(10)
hyroid gland	(10)	(10)	(10)	(10)
Ectopic thymus	1 (10%)	(10)	(10)	(10)
Ultimobranchial cyst	1 (10%)	1 (10%)		3 (30%)
Sounder and the state of the st	1 (1070)	1 (1070)		3 (30%)

<sup>a</sup> Number of animals examined microscopically at the site and the number of animals with lesion

. \*

.

2

Summary of the Incidence of Nonneoplastic Lesions in Male Rats in the Long-Term Feed Study of *t*-Butylhydroquinone (continued)

	0 ppm	1,250 ppm	2,500 ppm	5,000 ppm
3-Month Interim Evaluation	(continued)			
Genital System	(continued)			
Prostate	(10)	(10)	(10)	(10)
Inflammation, suppurative	(10)	2 (20%)	1 (10%)	
Testes	(10)	(10)	(10)	(10)
Seminiferous tubule, atrophy		1 (10%)		
Iomatanaistia System		· ·		
lematopoietic System ymph node		(1)	(2)	÷
Mediastinal, hemorrhage		1 (100%)	(2)	
Mediastinal, hyperplasia, lymphoid	X	1 (100%)		
Renal, hemorrhage		1 (100,0)	2 (100%)	
ymph node, mesenteric	(10)	(10)	(10)	(10)
Hemorrhage	· · · · · ·	1 (10%)		
pleen	(10)	(10)	(10)	(10)
Pigmentation, hemosiderin	•		3 (30%)	5 (50%)
hymus	(10)	(10)	(10)	(10)
Hemorrhage	<b>.</b>		3 (30%)	1 (10%)
Respiratory System	······································			
ung	(10)	(10)	(10)	(10)
Inflammation, subacute	4 (40%)	5 (50%)	7 (70%)	7 (70%)
Alveolar epithelium, hyperplasia	3 (30%)	1 (10%)	1 (10%)	3 (30%)
lose	(10)	(10)	(10)	(10)
Goblet cell, hyperplasia				7 (70%)
Jrinary System				
Kidney	(10)	(10)	(10)	(10)
Mineralization	1 (10%)	1 (10%)		
Nephropathy	5 (50%)	5 (50%)	4 (40%)	6 (60%)
Systems Examined With No Le	sions Observed		1	· · ·
General Body System				
Integumentary System				
Musculoskeletal System				•
Nervous System		•		
Special Senses System				. ·
·····	<u>,                                     </u>	<u> </u>	. <u> </u>	- <u> </u>
Long-Term Study				
Alimentary System	(58)	(58)	(58)	(60)
intestine large, colon Edema	(30)	(30)	1 (2%)	1 (2%)
Parasite metazoan	7 (12%)	6 (10%)	3 (5%)	2 (3%)
Intestine large, rectum	(59)	(60)	(58)	(59)
Edema	2 (3%)	<	1 (2%)	1 (2%)
Hemorrhage	- (-,-)		· · ·	1 (2%)
-	5 (8%)		1 (2%)	8 (14%)

.

。 1995年,1996年,1997年,1998年,1999年,1999年,1999年,1999年,1998年,1998年,1997年,1997年,1997年,1997年,1997年,1997年,1997年,1997年,1 1997年,1998年,1999年,1999年,1999年,1999年,1999年,1999年,1999年,1999年,1999年,1999年,1997年,1997年,1997年,1997年,1997年,1997年,19 Summary of the Incidence of Nonneoplastic Lesions in Male Rats in the Long-Term Feed Study of *t*-Butylhydroquinone (continued)

	0 p	pm	1,2	50 ppm	2,50	0 ppm	5,00	0 ppm
Long-Term Study (continued)								
Alimentary System (continued)								
	((0))		(50)		(50)		((0))	
Intestine large, cecum Edema	(60)	(60)	(58)	(20)	(58)	(	(60)	(501)
		(5%)		(3%)	3	(5%)		(5%)
Parasite metazoan		(2%)		(3%)	(50)			(5%)
Intestine small, duodenum	(60)		(60)		(58)		(60)	( <b>m m</b> )
Epithelium, hyperplasia		(3%)						(7%)
Intestine small, jejunum	(60)		(60)		(57)		(60)	
Metaplasia, osseous					1	(2%)		
Epithelium, hyperplasia		(2%)						(2%)
Intestine small, ileum	(60)		(59)		(58)		(59)	
Ulcer					1	(2%)		
Liver	· (60)		(60)		(58)		(60)	
Angiectasis	10	(17%)	1	(2%)	4	(7%)	7	(12%)
Basophilic focus	7	(12%)	3	(5%)	2	(3%)	7	(12%)
Clear cell focus	1	(2%)		(5%)		(2%)		(8%)
Degeneration, cystic	23	(38%)		(27%)		(19%)	5	(8%)
Eosinophilic focus		(17%)		(7%)		(2%)		(7%)
Eosinophilic focus, multiple		(2%)						
Fibrosis		(2%)	1	(2%)	1	(2%)		
Hematopoietic cell proliferation		(2%)		(=)		(2%)		
Hemorrhage	-	(270)				(2%)		
Hepatodiaphragmatic nodule	7	(12%)	7	(12%)		(7%)	8	(13%)
Inflammation, subacute	,	(12/0)		(2%)	-	(770)	0	(1570)
Mixed cell focus	2	(3%)		(270)			2	(3%)
Necrosis, focal		(13%)	6	(10%)	2	(5%)		(3%)
Thrombosis		(13%)			3	(3%)		
Bile duct, cyst			3	(5%)			. 1	(2%)
		(3%)	40	(93.01)	42	(74.07)	25	(40.07)
Bile duct, hyperplasia	52	(87%)		(82%)	43	(74%)	25	(42%)
Centrilobular, atrophy			1	(2%)				(0.0)
Centrilobular, fibrosis	•	(0.01)		(0.07)				(2%)
Centrilobular, necrosis		(3%)		(2%)	_			(3%)
Hepatocyte, vacuolization cytoplasmic	6	(10%)		(7%)	7	(12%)	3	(5%)
Kupffer cell, hyperplasia				(2%)				*
Kupffer cell, pigmentation		(18%)		(30%)		(14%)		(17%)
Mesentery	(20)		(11)		(7)		(16)	
Accessory spleen		(5%)		(27%)			4	(25%)
Fat, necrosis	16	(80%)		(64%)		(86%)		(81%)
Pancreas	(60)		(59)		(58)		(60)	•
Atrophy	15	(25%)	19	(32%)	12	(21%)	15	(25%)
Acinus, cytoplasmic alteration	3	(5%)	1	(2%)	1	(2%)	4	(7%)
Acinus, hyperplasia, focal	2	(3%)	3	(5%)	2	(3%)	2	(3%)
Salivary glands	(60)		(60)		(58)		(60)	
Atrophy				(2%)			. ,	
Stomach, forestomach	(60)		(60)		(58)		(59)	
Edema		(15%)		(7%)		(9%)		(10%)
Erosion	-			(3%)	-		-	
Hyperplasia	8	(13%)		(10%)	9	(16%)	12	(20%)
Ulcer		(13%)		(2%)		(5%)		(12%)
Mucosa, hyperplasia		(2%)		(2%)	5	(2,2)	•	(

r

Summary of the Incidence of Nonneoplastic Lesions in Male Rats in the Long-Term Feed Study of *t*-Butylhydroquinone (continued)

	0 ppm	1,250 pj	om 2,500	0 ppm	5,00	0 ppm	
Long-Term Study (continued)						<u></u>	<u></u> .
Alimentary System (continued)		,					
Stomach, glandular	(60)	(60)	(58)		(60)		•
Edema	1 (2%)	1 (2%)		(5%)		(5%)	i
Erosion	1 (2%)	3 (5%)		(3%)		(2%)	
Mineralization	1 (2%)	2 (3%)		(9%)		(270)	
Ulcer	3 (5%)	3 (5%)		(5%)			
Tongue	(1)	(2)	(1)	(370)	(4)		•
Epithelium, hyperplasia	(-)	2 (100	%) 1	(100%)	2	(50%)	
Cardiovascular System		· · · · · · · · · · · · · · · · · · ·			······································		
Blood vessel	(60)	(60)	(58)		(60)		
Hypertrophy	1 (2%)	3 (5%)	1	(2%)		(7%)	
Inflammation, subacute	1 (2%)	1 (2%)	1	(2%)			
Mineralization		1 (2%)		(2%)			
Thrombosis			1	(2%)			
Heart	(60)	(60)	(58)		(60)		
Cardiomyopathy	40 (67%)	39 (65%		(60%)	37	(62%)	
Mineralization		1 (2%)					
Necrosis	1 (2%)						
Thrombosis	6 (10%)	8 (13%	5) , 4	(7%)			
Endocardium, hyperplasia	1 (2%)						
Schwann cell, hyperplasia		1 (2%)	)				
Endocrine System							
Adrenal cortex	(60)	(60)	(58)		(60)		
Accessory adrenal cortical nodule	17 (28%)	10 (179		(21%)	13	(22%)	
Degeneration, cystic		1 (2%)		. •			
Degeneration, fatty	9 (15%)	10 (179	b) 8	(14%)		(12%)	
Hemorrhage	1 (2%)		-	(* M)		(3%)	
Hyperplasia, focal	4 (7%)	2 (3%)		(3%)		(5%)	
Hypertrophy, focal	6 (10%)	5 (8%)	) 2	(3%)	2	(3%)	
Necrosis	1 (2%)	((0))	(60)		(60)		
Adrenal medulla	(60)	(60)	(58)	(26)	(60)	(20%)	
Hyperplasia	26 (43%)		(58)	(26%)	(60)	(20%)	
Islets, pancreatic	(60)	(59)		(3%)		(2%)	÷ .
Hyperplasia	3 (5%)	(54)	(55)	(370)	(58)	(2,10)	
Parathyroid gland	(55) 6 (11%)			(13%)		(16%)	
Hyperplasia Distinguished	(60)	(58)	。)		(60)	(1070)	
Pituitary gland Nuclear alteration	(00)	(30)	(37)			(2%)	
Pars distalis, angiectasis	4 (7%)	2 (3%	) 1	(2%)	-	<u> </u>	
Pars distalis, cyst	6 (10%)			(7%)	7	(12%)	
Pars distalis, cyst, hemorrhagic	1 (2%)	5 (570		(2%)		/	
Pars distalis, hyperplasia, focal	10 (17%)	8 (149	,	(14%)	14	(23%)	
Pars intermedia, angiectasis	10 (1770)	1 (2%		(4%)		(2%)	
Pars intermedia, cyst	1 (2%)	6 (105	,	(7%)		(3%)	
Thyroid gland	(60)	(60)	(58)		(60)		
Ultimobranchial cyst	1 (2%)	1 (2%		(2%)		(8%)	
C-cell, hyperplasia	9 (15%)			(16%)	7	(12%)	
Follicle, cyst	1 (2%)	3 (5%		(2%)			

.

#### t-Butylhydroquinone, NTP TR 459

#### TABLE A4

Summary of the Incidence of Nonneoplastic Lesions in Male Rats in the Long-Term Feed Study of *t*-Butylhydroquinone (continued)

	0 p	pm	1,2	50 ppm	2,50	0 ppm	5,00	0 ppm	
Long-Term Study (continued) General Body System None								·	
Genital System									
Epididymis	(60)		(60)		(57)		(60)		
Atypia cellular		(45%)		(43%)		(49%)		(42%)	
Granuloma sperm				(/				(2%)	
Preputial gland	(60)		(60)		(58)		. (60)		
Cyst		(5%)		(5%)		(7%)	• • •	(7%)	
Hyperplasia		(5%)		(3%)		(7%)		(3%)	
Inflammation, chronic		(43%)		(27%)		(31%)		(20%)	
Inflammation, suppurative		(5%)		(12%)		(5%)		(8%)	
Prostate	(60)	<u>.</u>	(60)	、··	(58)	<u></u>	(60)	(****)	
Cyst		(2%)	()		(20)		(23)		
Fibrosis		(5%)	1	(2%)					
Inflammation, chronic		(8%)		(2%)					
Inflammation, suppurative		(60%)		(65%)	40	(69%)	23	(38%)	
Epithelium, hyperplasia		(18%)	10	(17%)		(10%)		(13%)	
Testes	(60)	. ,	(60)		(57)	(/	(60)		
Interstitial cell, hyperplasia		(7%)		(12%)		(11%)		(5%)	
Seminiferous tubule, atrophy		(12%)	5	(8%)		(4%)		(8%)	
Hematopoietic System Bone marrow Hyperplasia Infiltration cellular, histiocyte Myelofibrosis Lymph node		(10%) (7%)		(8%) (13%)	(58) 2 (34)	(3%)	2	(12%) (3%) (3%)	
Deep cervical, hyperplasia, lymphoid	(55)			(3%)	(34)		(55)		
lliac, hemorrhage	1	(3%)	•	(570)					
Inguinal, hyperplasia, lymphoid		(6%)					1	(3%)	
Mediastinal, congestion	-	····/						(6%)	
Mediastinal, hemorrhage	3	(9%)	2	(6%)	3	(9%)		(9%)	
Mediastinal, hyperplasia, lymphoid		(3%)		(3%)		(3%)		(6%)	
Mediastinal, pigmentation		(39%)		(39%)		(50%)		(46%)	
Pancreatic, ectasia				(3%)					,
			,				1	(3%)	
Pancreatic, hyperplasia, plasma cell			-	(8%)	4	(12%)		(9%)	· •
Pancreatic, hyperplasia, plasma cell	9	(27%)	3			· ·			
•	9	(27%)	3	(0,0)			2	(0%)	
Pancreatic, hyperplasia, plasma cell Pancreatic, pigmentation Renal, ectasia Renal, hemorrhage		(27%) (3%)			1	(3%)		(6%) (6%)	
Pancreatic, hyperplasia, plasma cell Pancreatic, pigmentation Renal, ectasia				(3%)				(6%) (6%)	
Pancreatic, hyperplasia, plasma cell Pancreatic, pigmentation Renal, ectasia Renal, hemorrhage Renal, hyperplasia, lymphoid Renal, pigmentation	1		1		1	(3%) (3%) (24%)	2		
Pancreatic, hyperplasia, plasma cell Pancreatic, pigmentation Renal, ectasia Renal, hemorrhage Renal, hyperplasia, lymphoid Renal, pigmentation	1	(3%)	1	(3%)	1	(3%)	2	(6%)	
Pancreatic, hyperplasia, plasma cell Pancreatic, pigmentation Renal, ectasia Renal, hemorrhage Renal, hyperplasia, lymphoid Renal, pigmentation Lymph node, mandibular Ectasia	1 8 (60)	(3%)	1 8 (60)	(3%)	1 8 (58)	(3%)	2 7 (60)	(6%)	
Pancreatic, hyperplasia, plasma cell Pancreatic, pigmentation Renal, ectasia Renal, hemorrhage Renal, hyperplasia, lymphoid Renal, pigmentation Lymph node, mandibular Ectasia Hemorrhage	1 (60) 3 2	(3%) (24%) (5%) (3%)	1 8 (60)	(3%) (22%)	1 8 (58) 7	(3%) (24%)	2 7 (60) 6	(6%) (20%)	
Pancreatic, hyperplasia, plasma cell Pancreatic, pigmentation Renal, ectasia Renal, hemorrhage Renal, hyperplasia, lymphoid Renal, pigmentation Lymph node, mandibular Ectasia Hemorrhage Hyperplasia, lymphoid	1 (60) 3 2	(3%) (24%) (5%)	1 (60) 8	(3%) (22%)	1 8 (58) 7 2	(3%) (24%) (12%)	2 7 (60) 6 3	(6%) (20%) (10%)	
Pancreatic, hyperplasia, plasma cell Pancreatic, pigmentation Renal, ectasia Renal, hemorrhage Renal, hyperplasia, lymphoid Renal, pigmentation Lymph node, mandibular Ectasia Hemorrhage	1 (60) 3 2 11	(3%) (24%) (5%) (3%)	1 (60) 8 7 1	(3%) (22%) (13%)	1 8 (58) 7 2 10 1	(3%) (24%) (12%) (3%)	2 (60) 6 3 17	(6%) (20%) (10%) (5%)	

• •

#### . TABLE A4

Summary of the Incidence of Nonneoplastic Lesions in Male Rats in the Long-Term Feed Study of *t*-Butylhydroquinone (continued)

. <b>.</b>	0 ppm	1,250 ppm	2,500 ppm	5,000 ppm
Long-Term Study (continued)				
Hematopoietic System (continued)				· · · · · · · · · · · · · · · · · · ·
Lymph node, mesenteric	(60)	(58)	(67)	
Ectasia	(00) 7 (12%)	(38)	(57) 7 (12%)	(60) 10 (17%)
Hemorrhage	1 (2%)	2 (3%)	1 (2%)	2 (3%)
Hyperplasia, lymphoid	3 (5%)	2 (3%) 1 (2%)		
Pigmentation	5 (570)		10 (18%)	6 (10%)
Spleen	(60)	1 (2%)	(59)	(60)
Congestion		(60)	(58)	(00)
Fibrosis	1 (2%)	20 (33%)	0 (160)	12 (22 (22 )
	21 (35%)	· · · ·	9 (16%) 2 (5%)	13 (22%)
Hematopoietic cell proliferation	7 (12%)	6 (10%)	3 (5%)	8 (13%)
Metaplasia, lipocyte	1 (2%)	1 (201)	2 (501)	. <del>.</del>
Necrosis	2 (3%)	2 (3%)	3 (5%)	12 (200)
<sup>•</sup> Pigmentation, hemosiderin	13 (22%)	9 (15%)	11 (19%)	12 (20%)
Lymphoid follicle, atrophy	1 (2%)			
Red pulp, atrophy	(50)	1 (2%)	(54)	
Thymus	(58)	(55)	(54)	(56)
Ectopic parathyroid gland	*. · ·	1 (2%)	2 (4%)	
<u>۲</u>				
Integumentary System				•
Aammary gland	(57)	(57)	(56)	(58)
Dilatation	23 (40%)	24 (42%)	17 (30%)	10 (17%)
Galactocele	5 (9%)	4 (7%)	1 (2%)	2 (3%)
Hyperplasia	7 (12%)	4 (7%)	5 (9%)	6 (10%)
Skin	(60)	(60)	(57)	(60)
Cyst epithelial inclusion	2 (3%)	1 (2%)	1 (2%)	1 (2%)
Hemorrhage				1 (2%)
Hyperkeratosis		1 (2%)	2 (4%)	1 (2%)
Inflammation, chronic		1 (2%)	2 (4%)	
Ulcer		1 (2%)	1 (2%)	
Epidermis, hyperplasia	1 (2%)	1 (2%)	1 (2%)	1 (2%)
Subcutaneous tissue, thrombosis	,		. ,	1 (2%)
			······································	
Musculoskeletal System				
Bone	(60)	(60)	(58)	(60)
Fibrous osteodystrophy	6 (10%)	5 (8%)	5 (9%)	7 (12%)
Hyperostosis	1 (2%)		1 (2%)	
Femur, osteopetrosis	1 (2%)	2 (3%)	1 (2%)	
Nervous System				4
Brain	(60)	(60)	(58)	(60)
Atrophy	12 (20%)	8 (13%)	8 (14%)	3 (5%)
Gliosis			1 (2%)	
Hemorrhage	2 (3%)	1 (2%)	1 (2%)	1 (2%)
Hydrocephalus	4 (7%)	3 (5%)	4 (7%)	
Necrosis	1 (2%)			1 (2%)

#### t-Butylhydroquinone, NTP TR 459

#### Table A4

alt to the two to the total of the second second

Summary of the Incidence of Nonneoplastic Lesions in Male Rats in the Long-Term Feed Study of *t*-Butylhydroquinone (continued)

	0 p	bw	1,2	50 ppm	2,50	0 ppm	5,00	0 ppm
Long-Term Study (continued)		- <del>.</del>						
Respiratory System								
Lung	(60)		(60)		(58)		(60)	
Congestion	• •	(3%)	(00)		(00)		(00)	
Edema		(2%)	,				1	(2%)
Hemorrhage		(5%)	5	(8%)	2	(3%)		(3%)
Infiltration cellular, histiocyte		(32%)		(35%)		(17%)		(23%)
Inflammation, subacute		()		(3%)		(11,00)		(2%)
Metaplasia, osseous	1	(2%)	. –	(2,2)			-	(=///)
Mineralization	-	(=,,,)	1	(2%)	1	(2%)		
Alveolar epithelium, hyperplasia	4	(7%)		(15%)		(9%)	7	(12%)
Nose	(60)	(.,.)	(60)	(-0,0)	(58)	~~ /0 /	(60)	~~/~/
Foreign body	• •	(10%)	• • •	(13%)		(3%)		(3%)
Inflammation, suppurative		(28%)		(37%)		(26%)		(18%)
Goblet cell, hyperplasia		(8%)		(5%)		(16%)		(22%)
Mucosa, hyperplasia		(23%)		(30%)		(22%)		(17%)
Mucosa, metaplasia, squamous		(13%)		(22%)		(14%)		(12%)
Special Senses System Eye Atrophy Cataract Inflammation, chronic		(50%) (25%)	(2)	(50%)	(1)			(50%) (50%)
Retina, degeneration	1	(25%)	1	(30%)			1	(50%)
Jrinary System			·····					
Kidney	(60)		(60)		(58)		(60)	
Cyst	2	(3%)		(5%)		(12%)	• • •	(18%)
Developmental malformation				(2%)				
Inflammation, suppurative	9	(15%)		(13%)	9	(16%)	20	(33%)
Mineralization	12	(20%)	3	(5%)		(3%)		(2%)
Nephropathy	60	(100%)	60	(100%)		(100%)		(100%)
Renal tubule, accumulation, hyaline droplet	1	(2%)	1	(2%)		(3%)		(2%)
Renal tubule, atrophy								(2%)
Renal tubule, hyperplasia, focal					1	(2%)		
Renal tubule, necrosis	3	(5%)	1	(2%)		(2%)		
Renal tubule, pigmentation	18	(30%)		(43%)		(29%)	15	(25%)
Transitional epithelium, hyperplasia		(22%)		(20%)		(19%)		(35%)
Jrinary bladder	(60)		(60)		(58)	•	(60)	
Hemorrhage	1	(2%)						
Inflammation, suppurative		(2%)						
Transitional epithelium, hyperplasia		(3%)						

.

# 

· ·

# APPENDIX B SUMMARY OF LESIONS IN FEMALE RATS IN THE LONG-TERM FEED STUDY OF &BUTYLHYDROQUINONE

Table B1	Summary of the Incidence of Neoplasms in Female Rats	
•	in the Long-Term Feed Study of t-Butylhydroquinone	130
Table B2	Individual Animal Tumor Pathology of Female Rats	
	in the Long-Term Feed Study of t-Butylhydroquinone	134
Table B3	Statistical Analysis of Primary Neoplasms in Female Rats	
	in the Long-Term Feed Study of t-Butylhydroquinone	167
Table B4	Summary of the Incidence of Nonneoplastic Lesions in Female Rats	
	in the Long-Term Feed Study of t-Butylhydroquinone	173

ste deservations and deservation deservations in the second second second second second second second second s A second secon -

## TABLE B1

Summary of the Incidence of Neoplasms in Female Rats in the Long-Term Feed Study of t-Butylhydroquinone<sup>a</sup>

	0 ppm	1,250 ppm	2,500 ppm	5,000 ppm
Disposition Summary Animals initially in study <i>B-Month interim evaluation</i> Early deaths	70 10	70 10	70 10	70 10
Moribund Natural deaths Survivors	40 10	· 41 8	33 9	36 7
Terminal sacrifice Missexed	10 0	11 0	16 2	17 0
Animals examined microscopically	70	70	68	70
Systems Examined At 3 Months Wit Alimentary System Cardiovascular System Endocrine System General Body System Genital System	th No Neoplasms (	Dbserved		
Hematopoietic System Integumentary System Musculoskeletal System Nervous System Respiratory System Special Senses System Urinary System				
Long-Term Study		. <u></u>		
Alimentary System Intestine large, colon Intestine large, rectum Intestine large, cecum Intestine small, duodenum Carcinoma Intestine small, jejunum Carcinoma Intestine small, jejunum Latestine small, ileum Leiomyosarcoma Liver Hepatocellular adenoma Hepatocellular adenoma, multiple Osteosarcoma, metastatic, bone Mesentery Sarcoma stromal, metastatic, uterus Oral mucosa Squamous cell carcinoma	(60) (59) (60) (59) (59) (60) (60) (11) 1 (9%)	(59) (59) (60) (60) (59) (58) (60) 1 (2%) (13)	(56)  (57)  (57)  (57)  (56)  1 (2%)  (56)  1 (2%)  (57)  1 (2%)  (58)  2 (3%)  1 (2%)  (10)  (1)  1 (100%)  (57)	(59) (59) (60) (60) (58) (60) 1 (2%) 1 (2%) (7) (59)
Sarcoma stromal, metastatic, uterus Salivary glands Stomach, forestomach Squamous cell papilloma Stomach, glandular	$ \begin{array}{c} (00) \\ 1 (2\%) \\ (60) \\ (60) \\ (60) \end{array} $	(60) (60) (60)	(58) (57) 1 (2%) (57)	(60) (60) (60)

.

•

#### Table B1

ling of a state of the state of the state of the state of the state of a state of a state of the state of the

Summary of the Incidence of Neoplasms in Female Rats in the Long-Term Feed Study of t-Butylhydroquinone (continued)

	0 ppm	1,250 ppm	2,500 ppm	5,000 ppm
Long-Term Study (continued)			······	
•				
Alimentary System (continued)	(1)	(1)		(1)
Congue	(1)	(1)	(4)	(1)
Squamous cell carcinoma Squamous cell papilloma	1 (100%)	1 (100%)	1 (25%) 1 (25%)	
· · · · · · · · · · · · · · · · · · ·	·····			
Cardiovascular System Heart	(60)	(60)	(69)	(60)
	(60)		(58)	(60)
Schwannoma benign		1 (2%)		1 (2%)
Indocrine System				
drenal cortex	(60)	(60)	(58)	(60)
Adenoma	4 (7%)	1 (2%)		、 <i>′</i>
Adrenal medulla	(60)	(60)	(58)	(60)
Pheochromocytoma malignant				1 (2%)
Pheochromocytoma benign	2 (3%)	2 (3%)	1 (2%)	3 (5%)
slets, pancreatic	(60)	(59)	(57)	(59)
Adenoma	2 (3%)	1 (2%)	3 (5%)	2 (3%)
Carcinoma			1 (2%)	
Parathyroid gland	(52)	(55)	(53)	(54)
Adenoma	2 (4%)			1 (2%)
Carcinoma, metastatic, thyroid gland		((0)		1 (2%)
ituitary gland	(60)	(60)	(57)	(60)
Pars distalis, adenoma	26 (43%)	27 (45%)	34 (60%)	28 (47%)
Pars distalis, carcinoma hyroid gland	2 (3%) (60)	1 (2%) (60)	1 (2%) (57)	3 (5%)
C-cell, adenoma	7 (12%)	7 (12%)		(60) 6 (10%)
C-cell, carcinoma	1 (2%)	/ (12%)	7 (12%) 2 (4%)	1 (2%)
Follicular cell, adenoma	1 (270)		$\frac{2}{1}(2\%)$	1 (270)
Follicular cell, carcinoma	1 (2%)		1 (2%)	2 (3%)
	······	<u></u>		
General Body System	(1)			
	(1)	······································	·	
Genital System				
Clitoral gland	(58)	(59)	(58)	(60)
Adenoma	6 (10%)	6 (10%)	5 (9%)	6 (10%)
Adenoma, multiple				1 (2%)
Carcinoma	6 (10%)	4 (7%)	5 (9%)	8 (13%)
Dvary	(60)	(60)	(57)	(60)
Carcinoma			1 (2%)	
Granulosa cell tumor malignant		1 (2%)		
Granulosa cell tumor benign	1 (2%)	1 (2%)	(50)	1 (2%)
Jtenis	(60)	(60)	(58)	(60)
Adenoma			1 (2%)	1 (2%)
Carcinoma	1 (0 07)	1. (0.01)	1 (30)	1 (2%)
Leiomyoma Polya stromal	1 (2%)	1 (2%) 12 (20%)	1 (2%)	0 (1507)
Polyp stromal Polyp stromal, multiple	6 (10%)	12 (20%)	5 (9%)	9 (15%)
•••	1(2%)	1 (201)	1 (30)	
Sarcoma stromal	2 (3%)	1 (2%)	1 (2%)	

0.1

ŝ

Ξ..

# TABLE B1

Summary of the Incidence of Neoplasms in Female Rats in the Long-Term Feed Study of t-Butylhydroquinone (continued)

	0 pj	pm	1,25	50 ppm	2,50	0 ppm	5,00	0 ppm	
Long-Term Study (continued)		· <u>,,</u> ,	<u> </u>	<u></u>		<u> </u>			
Hematopoietic System			~~~		( <b>***</b> )				
Bone marrow	(60)		(60)		(57)		(60)		·
Lymph node	(20)		(24)		(19)		(18)	· .	
Pancreatic, carcinoma, metastatic, ovary						(5%)			. *
Lymph node, mandibular	(59)		(60)		(55)		(60)		
.ymph node, mesenteric	(58)		(60)		(55)		(60)	• •	
Carcinoma, metastatic, ovary						(2%)			
Spleen	(60)		(60)		(57)		(60)		
Hemangiosarcoma	1 (	(2%)							
Osteosarcoma, metastatic, bone					1	(2%)		· .	
Thymus	(56)		(60)		(57)		(57)		•
Thymoma malignant	•••					(2%)			
							<u></u>		
Integumentary System	(60)		(50)		(50)		(60)		
Mammary gland	(60)	(50)	(59)		(58)	(29)	(60)	(201)	
Adenoma		(5%)		(100)		(2%)		(3%)	
Carcinoma	8 (	(13%)	0	(10%)	2	(3%)		(5%)	
Carcinoma, multiple								(2%)	
Fibroadenoma		(47%)		(27%)		(43%)		(33%)	
Fibroadenoma, multiple		(25%)		(29%)		(16%)		(12%)	••
Skin	(60)		(60)		(58)		(60)		
Basal cell carcinoma	1 (	(2%)	1	(2%)					
Keratoacanthoma					1	(2%)			
Squamous cell papilloma							2	(3%)	
Subcutaneous tissue, fibroma	3 (	(5%)	2	(3%)	1	(2%)	1	(2%)	
Subcutaneous tissue, fibroma, multiple				(2%)					
Subcutaneous tissue, fibrosarcoma	1 (	(2%)			1	(2%)	- 1	(2%)	
Subcutaneous tissue, hemangiosarcoma		()					1	(2%)	
Subcutaneous tissue, lipoma	1	(2%)							
Subcutaneous tissue, raponia	-	(_,,,,					1	(2%)	
Subcutaneous tissue, schwannoma malignant								(2%)	
						<u> </u>			
Musculoskeletal System		ч.	100		180		(20)		
Bone	(60)		(59)		(58)	$(2, \alpha)$	(60)		• •
Osteosarcoma						(2%)			
Skeletal muscle	(1)		(1)		(1)		(1)	(100 %)	
Sarcoma							1	(100%)	
Sarcoma stromal, metastatic, uterus	1	(100%)					· · ·		
Nervous System									
Brain	(60)		(60)		(58)		(60)		
Carcinoma, metastatic, mammary gland	(00)		(00)		(20)			(2%)	
								(2%)	
Carcinoma, metastatic, pituitary gland	1	(2%)					•	()	
Oligodendroglioma malignant		(2%)			(2)		(4)		
Spinal cord	(2)		(2)		(3)		. 1	(25%)	
Astrocytoma malignant							1	(4370)	

A

÷.,

14.00 ·····

# TABLE B1

Summary of the Incidence of Neoplasms in Female Rats in the Long-Term Feed Study of t-Butylhydroquinone (continued)

	0 ppm	1,250 ppm	2,500 ppm	5,000 ppm
Long-Term Study (continued)		<u></u>		
Respiratory System				
Lung	(60)	(60)	(58)	(60)
Alveolar/bronchiolar adenoma	2 (3%)	2 (3%)	1 (2%)	1 (2%)
Alveolar/bronchiolar carcinoma		1 (2%)		
Carcinoma, metastatic, ovary			1 (2%)	1 ( <b>7 1</b> )
Carcinoma, metastatic, thyroid gland	((0))	((0))	(59)	1 (2%)
Nose	(60)	(60)	(58)	(60)
Special Senses System				
Zymbal's gland			(1)	
Carcinoma			1 (100%)	
······································		······································		
Urinary System				
Kidney	(60)	(60)	(57)	(60)
Sarcoma stromal, metastatic, uterus	1 (2%)			
Renal tubule, adenoma	1 (2%)	(10)		
Urinary bladder	(59)	(60)	(58)	(59)
Papilloma	·····			1 (2%)
Systemic Lesions				
Multiple organs <sup>b</sup>	(60)	(60)	(58)	(60)
Leukemia mononuclear	27 (45%)	33 (55%)	22 (38%)	27 (45%)
Mesothelioma malignant	1 (2%)		()	
Neonlagm Cumemony			5 1.1 <sup>19</sup> <sup>19</sup>	
Neoplasm Summary Total animals with primary neoplasms <sup>c</sup>	59	59	84	50
Total primary neoplasms		59 147	56 145	59 148
Total animals with benign neoplasms	52	51	145 49	148 50
Total benign neoplasms	112	99	100	95
Total animals with malignant neoplasms	41	39	38	38
Total malignant neoplasms	52	48	45	53
Total animals with metastatic neoplasms	2		2	4
Total metastatic neoplasms	5		5	4

a b Number of animals examined microscopically at the site and the number of animals with neoplasm Number of animals with any tissue examined microscopically

¢

Primary neoplasms: all neoplasms except metastatic neoplasms

ŝ

#### TABLE B2

2 3 3 5 5 4 4 4 5 5 5 6 66 6 6 6 6 7 777 6 6 7 Number of Days on Study 9 0 8 1 2 9 7 4 4 4 7 1 2 2 3 4 4 6 9 9 0 1 2 2 3 7 2 0 1 7 7 8 0 0 6 8 9 3 8 8 0 9 0 4 4 2 2 4 3 1 3 3 3 3 3 3 3 3 3 3 3 3 3 3. 3 3 3 3 3 3 3 3 3 3 3 **Carcass ID Number** 5 5 9 7 8 9 7 9 6 8 5 5 6 6 5 7 8 5 9 5 7 6 7 6 7 5 7 9 9 0 5 6 9 9 4 5 4 2 8 3 8 7 5 1 1 1 4 6 2 3 **Alimentary System** Esophagus Intestine large, colon Intestine large, rectum Intestine large, cecum Intestine small, duodenum M Intestine small, jejunum Intestine small, ileum Liver Mesentery + Х Sarcoma stromal, metastatic, uterus Pancreas + + + Sarcoma stromal, metastatic, uterus X Salivary glands + + + Stomach, forestomach + + + + + + + + + ++ + + + + + + + + + + 4 Stomach, glandular Tongue Squamous cell papilloma **Cardiovascular System** Blood vessel + Heart 4 + + + + + ÷ + + + + + + + + + + + + **Endocrine System** Adrenal cortex Adenoma Adrenal medulla Pheochromocytoma benign Islets, pancreatic Adenoma Parathyroid gland + + M Adenoma + +Pituitary gland + + + + + Pars distalis, adenoma Х х x х х x Pars distalis, carcinoma Thyroid gland +C-cell, adenoma C-cell, carcinoma Follicular cell, carcinoma **General Body System** Peritoneum + **Genital System** Clitoral gland Adenoma х Х Carcinoma

Individual Animal Tumor Pathology of Female Rats in the Long-Term Feed Study of t-Butylhydroquinone: 0 ppm.

+: Tissue examined microscopically

A: Autolysis precludes examination

M: Missing tissue I: Insufficient tissue X: Lesion present Blank: Not examined

#### t-Butylhydroquinone, NTP TR 459

#### TABLE B2

- Lacritic Courses in the second state

The second second

Individual Animal Tumor Pathology of Female Rats in the Long-Term Feed Study of *t*-Butylhydroquinone: 0 ppm (continued)

	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	0	0	8	8	0	0	0	8	0	8	 	
Number of Days on Study	3		5	6				7	7	8	8	' 9	9	' 9	' 9	0	0 0	о З							о 8		
Number of Days on Study	3	5 6		1		5				5		5			9					4	5		9				
	4	3	3	3	3	3	3	3	3	3	4	3	3	3	3	3	4	3	3	3	4	4	4	3	3	 ·	
Carcass ID Number	0						7		6		1			6		6		7			0	0	0				
			3																								
Alimentary System								_	_	_									ς		_			_		 	
Esophagus	I	+	+	+	+	+	+	+	+	+	+	м	+	+	+	+	+	+	+	+	+	+	+	+	+		
Intestine large, colon	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		
Intestine large, rectum	+	+	Μ	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		
Intestine large, cecum	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		
Intestine small, duodenum	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		
Intestine small, jejunum	+	+	+	+	+	+	+	+	+	+	+	+	+	• +	+	+	+	+	+	+	+	+	+	+	+		
Intestine small, ileum	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		
Liver	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	- +	+	+	+	+	+	+		
Mesentery									+			+			+	+		+					+				
Sarcoma stromal, metastatic, uterus																											
Pancreas	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		
Sarcoma stromal, metastatic, uterus																											
Salivary glands	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		
Stomach, forestomach	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	·+	+	+	+	+	+	+	+	+		
Stomach, glandular	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		
Tongue																											
Squamous cell papilloma																											
Cardiovascular System							-	_												_							
Blood vessel	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		
Heart	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		
Endocrine System																										 	
Adrenal cortex	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	• +	+	+		·
Adenoma					-					-		•	x	·	·	·				X				X			
Adrenal medulla	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+			+	+		+		
Pheochromocytoma benign																						х					
Islets, pancreatic	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		
Adenoma																									Х		
Parathyroid gland	+	M	[+]	+	+	+	+	+	+	+	+	I	+	+	Μ	Μ	Μ	+	+	+	+	+	+	+	+		
Adenoma										х	Х																
Pituitary gland	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	• +	+		
Pars distalis, adenoma							Х	Х		Х				Х	Х	Х	Х	Х	х					X			
Pars distalis, carcinoma	1					Х																					
Thyroid gland	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		
C-cell, adenoma										х																	
C-cell, carcinoma																											
Follicular cell, carcinoma																											
General Body System													-														
Peritoneum					•																			•			
Genital System				_			_				-				_	_		-									
Clitoral gland	+	• +	+	+	+	+	+	+	+	+	+	+	М	+	+	+	+	+	+	М	( +	+	4	• +	+		
		,			•	•	•	x	•	•	,	•		•	•	•	•	•	•					•	•		
Adenoma								~													X						

j,

.

# TABLE B2

ç

Individual Animal Tumor Pathology of Female Rats in the Long-Term Feed Study of *t*-Butylhydroquinone: 0 ppm (continued)

		0	8	0 0	> 0	٥	0	ø	0	2			
Number of Days on Study		8 9			88				8				
aumber of Days on Study		-		99 88		9 8	9 8		9 9 8 8				
		3	3	3 3	3	4	4	4	4 4	4			Total
Carcass ID Number		5		89	-	0	0		0 (	-			Tissues/
· .		2		2 1	8	ĩ	2		7 9				Tumors
Alimontomy System							_	-					
Alimentary System		+	ъ	÷.				т		т			58
intestine large, colon			1	т. Т.			т —	т ш	т.	т 上			50 60
Intestine large, rectum		, +	<u>.</u>	Ļ.	 	, 	÷.	÷	÷.	L.			· 59
ntestine large, cecum		Ļ	+	<b>.</b> .	, , , ,			т Т	÷.	т ⊥			60
ntestine small, duodenum		4	<u>н</u>	<u> </u>		н.	т Т	т	т.	T L			59
intestine small, jejunum			т 1	м.	 	. <u>т</u>	+	Ť	т.	T L			59
intestine small, ileum		т Т	т. Т	ш. 	г т г т	. <u> </u>	т —	т ш	т 	T L			60
Liver		т Т	т 	т. _	гт ∟_⊥	т 	т -	+	+	+			60
Acsentery		Ŧ	Ŧ	т .	г. т	Ŧ	т	т	Ŧ	г	• • • • •	· · ·	11
Sarcoma stromal, metastatic, uterus													1
Pancreas		Т	+	<b>.</b>		<b>.</b>	ъ	+	+ .	÷			60
Sarcoma stromal, metastatic, uterus		т	т.	· ·	· T	• +	+	+	T				1
Salconia stroniar, metastalic, uterus Salivary glands		<u>т</u>	+		<b>ь</b>	<b>.</b>	Ŧ	Ŧ	<u>н</u> .	÷		•	60
Stomach, forestomach		7 1	т -	т _	г Л цэ	т 	T L	т +	т Т	т' 1			60 60
Stomach, glandular		T	т -	т. Т	г † 1	т 	т 	т _	+	T L			60 60
		- -	т	Τ.	r †	-	Ŧ	т	т	٣			
Fongue		+ X											1
Squamous cell papilloma												·	1
Cardiovascular System	-										· · · · · · · · · · · · · · · · · · ·		
Blood vessel		+	+	+ •	+ +	• +	+	+	+	+			60
Heart		+	+	+ •	+ +	+	+	+	+	+			60
Endocrine System													
Adrenal cortex		+	+	+ •	+ +	+	+	+	+ -	+			60
Adenoma								X					4
Adrenal medulla		+	+	+ •	+ +	• +	+		+	+	• • • • •		60
Pheochromocytoma benign		-							X				2
islets, pancreatic		+	+	+ •	+ +	+	+	+	+	+			60
Adenoma													2
Parathyroid gland		+	М	+ •	+ +	• +	+	+	М	+			52
Adenoma			-						-		a second second		2
Pituitary gland		+	+	+ •	+ +	• +	+	+	+	+			60
Pars distalis, adenoma		x	х			X			x :	X			26
Pars distalis, carcinoma													. 2
Thyroid gland		+	+	+ •	+ +	• +	+	+	+	+			60
C-cell, adenoma				x		•	x			x			7
C-cell, carcinoma					ĸ					-			1
Follicular cell, carcinoma			x		-								1
General Body System					-	-		-		. '		•	
Peritoneum													1
Genital System							_	_	_		· ·		
Clitoral gland		+	+	+	+ +	. +	+	+	+	+			58
Adenoma		×x		•		ſ	•	'	$\dot{\mathbf{x}}$				6
Carcinoma		· A	х			x	х	х		-			6
Varvinonia			**										0

#### t-Butylhydroquinone, NTP TR 459

#### Table B2

Individual Animal Tumor Pathology of Female Rats in the Long-Term Feed Study of *t*-Butylhydroquinone: 0 ppm (continued)

۱

(continued)												_																
Number of Days on Study	2 9 7	-	8	1	4 2 1	4 9 7	5 4 0	4	4	5 7 8		1	2	2	3	4	6 4 9	6	9	9	7 0 4	1	2	2	7 3 3			
Carcass ID Number	3 5 5	5	9	3 7 9	3 8 0	3 9 5	3 6 1	3 8 1	7	3 5 1	3 5 9	3 6 4	3 6 9	3 5 6	3 7 4	3 8 5	3 5 4	3 9 2	3 5 8	3 9 3	3 7 8	3 6 2	7	· 3 6 7	7			
Genital System (continued) Ovary							Ŧ	+	+	+	+	+	+	+	- -	+	+	+	+	-	+	+	+					
Granulosa cell tumor benign	'						,	1	•		r		•	•		'	'	'	'	'		'		•	1			
Uterus	+	+ +	+ +	• +	• +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	• +	•		
Leiomyoma Polyp stromal																	x					х						
Polyp stromal, multiple																	л					^						
Sarcoma stromal		Х	C																									
Hematopoietic System			<u> </u>	<u></u>																								
Bone marrow	+	┝╶┥	+ +	- +	• +	+	+	+	+	+	+	+	+	+	+	.+	+	+	+	+	+	+	+	• +	• +	-		
Lymph node		4	+ +	-	+					+						+	+	+	+	+			+	• +				
Mediastinal, mesothelioma malignant, metastatic, peritoneum			х																									
Lymph node, mandibular	-	F 4		- +	• +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	• +	· +	-		
Lymph node, mesenteric	+	⊢⊣	+ +	- +	• +	+	+	+	+	+	+	+	+	+	+	÷	+	+	+	+	+	+	Ι	+	- +	-		
Spleen	+	+ -	+ +	- +	• +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	· +	· +	-		
Hemangiosarcoma Thymus							н.																		- 4			
			- 1	- T	· T	T	т	т	т	т —			т —	т 	т	т —		_										
Integumentary System																												,
Mammary gland Adenoma	4	+ -		- +	• +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	• +	• +	-		
Carcinoma								х				х				X X									х			
Fibroadenoma							х	~		х				х	х		х	х	X		х		х	x				
Fibroadenoma, multiple				Х							Х																	
Skin	-	+ +	+ +	+ +	• +	+	+	+	+	+	+	+	+	+	+		+	+	+	+	+	+	+	- +	• +	-		
Basal cell carcinoma Subcutaneous tissue, fibroma								х								Х			x									
Subcutaneous tissue, fibrosarcoma								Λ											л									
Subcutaneous tissue, lipoma																												
Musculoskeletal System								_							_									_			×	
Bone	-	+ +	+ +	+ +	• +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	- +	- 4	-		
Skeletal muscle			۲																		-							
Sarcoma stromal, metastatic, uterus		2	{						-										_	_								
Nervous System																												
Brain	4	+ -	+ +	+ +	- +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	· +	- `+	+	-		
Oligodendroglioma malignant																												
Peripheral nerve Spinal cord																												,
											_				-													
Respiratory System																												
			+ -	- +	- +	• +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	• +	· +	- +	- 4	-		
Lung Alveolar/bronchiolar adenoma	-	<b>r</b> .	•	• •																								
Lung Alveolar/bronchiolar adenoma Nose	-	+ ·	• • •	· ·	- +	• +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	• +	· +	+	⊢ - <b>1</b>	+		

Ş

137

out the first first of the first

# TABLE B2

ئ.

Individual Animal Tumor Pathology of Female Rats in the Long-Term Feed Study of t-Butylhydroquinone: 0 ppm (continued)

		_			_																						
Number of Days on Study	7 3 3	7 3 6	7 7 3 5 5 8	56			7 6 6	7 7 7	7 7 8	7 8 5	7 8 9	7 9 5	7 9 5	7 9 6	7 9 9	8 0 2	8 0 8	8 3 0	8 3 1	8 5 4	8 5 5	8 5 6	8 7 9	8	8 8 8		
Carcass ID Number	4 0 4	3 7 1	3 3 7 8 1 3	3 6	8	3 9 0	3 7 2	3 8 8	3 6 0	3 9 7	4 1 0	3 8 9	3 9 4		3 8 7	3 6 5	4 0 0	3 7 7	3 8 4	3 6 3	4 0 3	4 0 5	4 0 8	9	3 5 3		
Genital System (continued) Ovary Granulosa cell tumor benign Uterus Leiomyoma Polyp stromal Polyp stromal, multiple Sarcoma stromal	+ + X		 + -	 + +	+ + +	- +	+	+ +	+	+	++	+ + X	+ +	++	+	+	++	+ +	+	++	++	+ + x	+ x + x	+ X	++		
Hematopoietic System Bone marrow Lymph node Mediastinal, mesothelioma malignant, metastatic, peritoneum Lymph node, mandibular Lymph node, mesenteric Spleen Hemangiosarcoma	+++++++++++++++++++++++++++++++++++++++		+ · + · + I + ·	+ - + - ! -	 + + + + + +	- + - + - +	+++++	+++++	+ + + + +	+ + + +	+++++	· + + + + + +	++++	+ + + +	+ + + + +	+ + + + +	+ + + + +	+++++	+ + + + + + + +	+ + + +	+++++++	++++	+++++	++++++	+++++++++++++++++++++++++++++++++++++++		· · · ·
Thymus Integumentary System Mammary gland Adenoma Carcinoma Fibroadenoma	+ + X		+ · + ·	+ - + - x >		- + - +	+ + X	+++	+ + X X	+ + x		+	+ + X	+	+	+ + X	+ + x	+ + X	+ + X	+ + x	+	+	+ X	+	+ + X		 · · · ·
Fibroadenoma, multiple Skin Basal cell carcinoma Subcutaneous tissue, fibroma Subcutaneous tissue, fibrosarcoma Subcutaneous tissue, lipoma	-		+	+ ·	х + +	< ⊦ +	+	+	+	+	x +	+	+	x +	X +	+	+	+	x +		+	x + x	+	+	• +		
Musculoskeletal System Bone Skeletal muscle Sarcoma stromal, metastatic, uterus			+	+ •	+ +	⊦ +	• +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	· +	- +	- +	-	 
Nervous System Brain Oligodendroglioma malignant Peripheral nerve Spinal cord	+		+ + +	+	+ -	+ +	• +	÷	+	+	+	+	+	, <b>+</b>	+	.+	+	+	+	+	+ + +		• +	• +	- +	_	· .
Respiratory System Lung Alveolar/bronchiolar adenoma Nose Trachea		 + +	+ + +	+ + +	 + · + ·	+ + + + + +	 - + - +	· + · +	· +	+ + +	· + · +	++++	+++++++++++++++++++++++++++++++++++++++	+++++	+++++	+ X +	· + · +	+	· + · +	 - + - +	- + - + - +	- + - + - +	- + - + - +		- + - + - +		

#### Table B2

Individual Animal Tumor Pathology of Female Rats in the Long-Term Feed Study of *t*-Butylhydroquinone: 0 ppm (continued)

· ·	888888888	
Number of Days on Study	9 9 9 9 9 9 9 9 9 9	
	8 8 8 8 8 8 8 8 8	
······································	3 3 3 3 3 4 4 4 4 4	Total
Carcass ID Number	578990000	Tissues/
· · · · · · · · · · · · · · · · · · ·	2 0 2 1 8 1 2 6 7 9	Tumors
Genital System (continued)		
Ovary	+ + + + + + + + +	60
Granulosa cell tumor benign		1
Uterus	+ + + + + + + + +	60
Leiomyoma		1
Polyp stromal	X	6
Polyp stromal, multiple		1
Sarcoma stromal		2
Hematopoietic System		
Bone marrow	+ + + + + + + + +	60
Lymph node	+ + +	20
Mediastinal, mesothelioma malignant, metastatic, peritoneum		1
Lymph node, mandibular	+ + + + + + M + + +	59
Lymph node, mesenteric	* * * * * * * * * *	58
Spleen	* + + + + + + + +	60
Hemangiosarcoma	X	
Thymus	+ + + + + + + + +	56
Integumentary System		
Mammary gland	* * * * * * + + + +	60
Adenoma		3
Carcinoma	Х	8.
Fibroadenoma	X X X X	28
Fibroadenoma, multiple	X X X X X X	15
Skin	* * * * * * * * * *	60
Basal cell carcinoma		1
Subcutaneous tissue, fibroma	X	3
Subcutaneous tissue, fibrosarcoma		1
Subcutaneous tissue, lipoma		1
Musculoskeletal System		· · · · · · · · · · · · · · · · · · ·
Bone	+ + + + + + + + +	60
Skeletal muscle		1
Sarcoma stromal, metastatic, uterus		1
Nervous System		
Brain	+ + + + + + + + +	60
Oligodendroglioma malignant	Х	1
Peripheral nerve		2
Spinal cord		2
Respiratory System	<b></b>	
Lung	+ + + + + + + + +	60
Alveolar/bronchiolar adenoma	X	2.
Nose	· + + + + + + + + +	60
Trachea	+ + + + + + + + +	60

139

-\_\_\_\_

#### TABLE B2

Individual Animal Tumor Pathology of Female Rats in the Long-Term Feed Study of t-Butylhydroquinone: 0 ppm (continued)

والمتحد والمتحد والمتحد والمتحد والمتحد والمتحد والمتحد والمتحد والمتحد والمحد و			
Number of Days on Study	2       3       3       4       4       5       5         9       0       8       1       2       9       4       4         7       2       0       8       1       7       0       0	5       5       5       6       6       6       6       6       6         4       7       7       1       2       2       3       4       4         6       8       9       3       7       8       8       0       9	5       6       6       7       7       7       7         6       9       9       0       1       2       2       3         1       0       4       4       2       2       4       3
Carcass ID Number	3 3 3 3 3 3 3 3 3 5 5 9 7 8 9 6 8 5 7 9 9 0 5 1 1	3       3	3       3       3       3       3       3       3         9       5       9       7       6       7       6       7         2       8       3       8       2       3       7       5
Special Senses System Ear Eye		+	+
Urinary System Kidney Sarcoma stromal, metastatic, uterus Renal tubule, adenoma Urinary bladder	+ + + + + + + + + X + + + + + + + + +	+ + + + + + + + + + + + + + + + + + +	+ + + + + + + + + + + + + + + +
Systemic Lesions Multiple organs Leukemia mononuclear Mesothelioma malignant	+ + + + + + + + + + + + + + + + + + +	+ + + + + + + + + + + + + + + + + + +	+ + + + + + + + + X X X X X X

-

# TABLE B2

Individual Animal Tumor Pathology of Female Rats in the Long-Term Feed Study of *t*-Butylhydroquinone: 0 ppm (continued)

						_		_		_												_					 		_
Number of Days on Study	7 3 3	3	7 5 8	7 6 1	7 6 5	7 6 5	7 6 6	7 7 7 7	7 7 8	7 8 5	7 8 9	7 9 5	7 9 5	7 9 6	7 9 9	8 0 2	8 0 8	8 3 0	8 3 1	8 5 4	8 5 5	8 5 6	8 7 9	8		8 8 8			
Carcass ID Number	4 0 4	7	3 8 3	3 6 8	3 8 6	3 9 0	3 7 2	3 8 8	3 6 0	3 9 7	4 1 0	3 8 9	3 9 4	3 6 6	3 8 7	3 6 5	4 0 0	3 7 7	3 8 4	3 6 3	4 0 3	4 0 5	4	3 9 9 8 6		3 5 3	 		-
Special Senses System Ear Eye			-			+		·			-					+				_			-				 		
Urinary System Kidney Sarcoma stromal, metastatic, uterus Renal tubule, adenoma Urinary bladder		 	-	•	•		+	·			•		+ • M	•	·		·							 + - + -				,	
Systemic Lesions Multiple organs Leukemia mononuclear Mesothelioma malignant		 X		• +	+ X	+ X	+ x	+	+	+ X	+ x	+ X	+ X	+	+	+ x	+	+	+ X	+	+	• +		+ -	ł	+ x			

,

# TABLE B2

Individual Animal Tumor Pathology of Female Rats in the Long-Term Feed Study of t-Butylhydroquinone: 0 ppm (continued)

(commuta)		
Number of Days on Study	8 8 8 8 8 8 8 8 8 8 9 9 9 9 9 9 9 9 9 9 8 8 8 8	
Carcass ID Number	3       3       3       3       4       4       4       4         5       7       8       9       9       0       0       0       0         2       0       2       1       8       1       2       6       7       9	Total Tissues/ Tumors
Special Senses System Ear Eye		1 4
Urinary System Kidney Sarcoma stromal, metastatic, uterus Renal tubule, adenoma Urinary bladder	+ + + + + + + + + X + + + + + + + + + +	60 1 1 59
Systemic Lesions Multiple organs Leukemia mononuclear Mesothelioma malignant	+ + + + + + + + + + + + + + + + + + +	60 27 1

• \* 4

· . .

#### t-Butylhydroquinone, NTP TR 459

#### TABLE B2

34

Individual Animal Tumor Pathology of Female Rats in the Long-Term Feed Study of t-Butylhydroquinone: 1,250 ppm

Number of Days on Study	8	4 8 1	4 9 8	5 3 7	5 3 7	5 7 6		6 1 8	6 2 5		4	4		5	6	6	6	6 8 3	6 9 7	0	7 0 5	7 2 2	7 3 3	3	7 3 6	
Carcass ID Number	2	4 2 1	4 3 3	4 3 9	4 6 1	4	4 3 7	4 7 9	4 3 5	4 7 0	4 7 5	4	4 3 0	4 7 8	4	4 4 0	4 4 9	4 8 0	4 6 2	4 7 1	4 7 4			4 6 0		 
Alimentary System																			_							
Esophagus	+	+	+	+	+	+	+	+	+	+	+	+	÷	+	+	+	+	+	+	+	+	+	+	+	+	
Intestine large, colon	м	+	+	+	+	+	`+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Intestine large, rectum	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Intestine large, cecum	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Intestine small, duodenum	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Intestine small, jejunum	M	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
intestine small, ileum	М	+	+	+	+	+	+	+	+	+	+	+	+	+	+	÷	+	+	+	+	+	+	+	+	+	
Liver	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Hepatocellular adenoma																			Х							
Mesentery								+		+		+													+	
Pancreas	+	+	+	+	+	+	÷	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Salivary glands	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Stomach, forestomach	· +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Stomach, glandular	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Tongue Squamous cell papilloma																										
Cardiovascular System																					_					 
Blood vessel	•	+	+	Ŧ	+	+	+	+	+	L.		ъ	L.	ъ	ъ	÷	+	+	Ŧ	÷	+	+	+	+	+	
Heart	+	÷	÷	÷	÷	+	+	+	+	1				Ļ.	1 L	÷	÷	-	-	÷.	+	, +	+	. <u>+</u>	+	
Schwannoma benign	•				•	'	'	'	•	'	'	•	1	1	'	•	•	'	,	'	'	,	•	'		
Endocrine System		-																								 
Adrenal cortex	<u>т</u>		Ŧ	Ŧ	+	+	+	+	+	+	Ъ	ъ	+	ъ	ـد	ъ	ىل.		÷	-	-	-	+		+	
Adenoma	T	т	т	Ŧ	т	т	т	т	Ť	т	т	т	т	т	т	т	т	т	т	т	r	-	.1.		ч.	
Adrenal medulla	+	ъ	ъ		ъ	ъ	1	ъ	+	+	Ŧ	+	+	Ŧ	т		+		-			L.	-	ч	+	
Pheochromocytoma benign	т	т	т	т	т	т	т	т	т	т	т	Ŧ	т	+	т	Ŧ	т	т	т	т	т	T	т	· •	т	
																		1				,				
Islets, pancreatic Adenoma	+	+	+	+ x	+	+	+	+	+	+	+	+	÷	+	+	+	+	+	+	+	+	+	+	• •	+	
									۰.																	
Parathyroid gland	+	+			+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Pituitary gland	+	+	+		+	+	+	+		+		+	+	+	+	+	+			+	+				+	
Pars distalis, adenoma	X			X	Х			х	Х		х							Х				Х	Х			
Pars distalis, carcinoma														-												
Thyroid gland C-cell, adenoma	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+ X	+	+	+	+	+	+	• +	+	
General Body System None																••										 
Genital System	-																									
Clitoral gland	+	+	+	+	+	+	+	+	+	+	+		+	+	+	+	+	+	+	+	+	• +	• +	• +	+	
Adenoma												Х														
Carcinoma	-														x		X		X							
Ovary	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+			+	+	• +	• +	• +	+	
Granulosa cell tumor malignant																		Х								
Granulosa cell tumor benign																										
Uterus	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	• +	• +	- +	• +	
Leiomyoma						_	_																			
Polyp stromal						Х	Х			Х	Х				Х			Х								
Sarcoma stromal																	х									
Individual Animal Tumor Pathology of Female Rats in the Long-Term Feed Study of t-Butylhydroquinone: 1,250 ppm (continued)

(continued)				_				_														_								<u> </u>	•	
				7	7	7	7	7	7	7	7	7	8	8	8	8	8	8	8	8	8	8	8	8	8	8	8	8				
Number of Days on Study				3	4	6	7	8	8	9	9	9	0	0	0	1	3	3	3	4	5	6	6	7	9	9	9	9 ·				
				8	9	1	4	1	9	2	5	9	6	6	7	0	1	1	4	5	9	2	3	3	0	4	7	8				
				4	4	4	4	4	4	4 -	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4				
Carcass ID Number				5	6	3	4	2	6	5	3	2	2	5	6	7	4	7	4	2	5	5	3	4	6	7	6	2				
			t	0	6	1	7	9	7	8	8	6	8	7	9	2	1	6	3	5	9	4	6	2	4	7	8	2				
limontony System					_						•											<u></u>			-							
Alimentary System					L.	-	+	+		L.	1	-	Ŧ	т	ъ	-	-	ъ	Ŧ	Т	-	Ŧ	Т	<u>т</u>	Т	л.						
Esophagus ntestine large, colon				<u>+</u>	<b>T</b>	т 	+ +	+ _	т 	Ŧ	Ŧ	т 	T	Ŧ	Ŧ	Ŧ	Ŧ	Ŧ	Ŧ	Ŧ	Ŧ	т -		Ŧ		- T		Ť				
ntestine large, rectum				т.	Ţ	Ŧ	Ť	т -	Ŧ	Ξ.	Ť	Ŧ	Ξ	Ŧ	Ŧ	Ŧ	т -	Ŧ	Ŧ	Ŧ	т 	т 		т 	т —	т 	т Т	Т.				
				Ξ.	Ť	Ť	Ŧ	т _	Ŧ	Ť	т 	т -	- -	Ť	т -	+ +	т 	т 	Ť	т _	т -	т 		т - т	т _	т 	т —	т - ш'				
ntestine large, cecum ntestine small, duodenum				<b>T</b>	Ŧ	Ŧ	Ŧ	т -	Ŧ	Ŧ	Ŧ	Ŧ	Ŧ	т 	Ŧ	- -	т -	Ŧ	Ŧ	- -	т -	т -		т 	т -	Ť	т 					
				<b>T</b>	Ŧ	Ŧ	т _	Ŧ	Ŧ	Ŧ	т. 	. —	<b>T</b>	Ŧ	Ŧ	т 	- -	т 	Ŧ	Ť	Ŧ	- -	т 	т Т	- -	т -		т -				
ntestine small, jejunum				<u>.</u>	Ť	Τ.	Ţ.	Ţ	Τ.	Ţ	T	Ţ	Ţ	+	Τ.	T.	T.	T	Ŧ	Ţ	7	Ţ	Ţ	т 	Ţ	T	т 	T				
ntestine small, ileum Liver	•			<b>T</b>	T	Ţ	Τ.	Ţ.	<b>.</b>	T	T	÷	+	M	+	Ť	T	T	+	T	Ţ	Ŧ	- T	T	Ţ	T	т 1					
				Ŧ	т	т	т	т	т	Ŧ	Ŧ	т	Ŧ	т	т	т	Ŧ	Ŧ	Ŧ	т	Ŧ	Ŧ	т	т	т	Т.	Т,	. <b>т</b>	-			
Hepatocellular adenoma											т	т	т					т						<u>т</u>	<b>н</b>							
Mesentery Pancreas				Ŧ	ъ.	-	<u>.</u>	-	÷	Ŧ	т -	- -	- -	Ъ	-	Ŧ	+		Ŧ	L.	ъ	ᆂ	ъ	ᅮ	Ŧ		L.	Ŧ				`
				+	<b>T</b>	Ť	-	+	+	+	Ţ	-	Ť	T	Ŧ	Ŧ	Ŧ	<b>T</b>	Ŧ	Ξ	Ŧ	т 	- T			т 		Ť				
Salivary glands Stomach forestomach				Ť	+	+	+ -	+	T 	τ +	<b>⊤</b>	+ +	+	т. –	+ +	Ŧ	Ť	- -	- -	Ŧ	т 	- -	т 	Ţ	т 	7 _	т 	+				
stomach, forestomach				+	+	+	+	+	+	+	+	+	+	Ť	7	Ţ	Τ.	<b>T</b>	<b>T</b>	T	<b>T</b>	T	Ţ	Ţ	<b>T</b>	-	. <b>T</b>	-				
Stomach, glandular				+	+	+	+	+	+	+	Ŧ	+	+	+	Ŧ	Ŧ	Ŧ	Ŧ	Ŧ	Ŧ	T	. 🕇	т		Ŧ	Ŧ	T	Ŧ				
Fongue																								x								
Squamous cell papilloma																			_	_			_	^								
Cardiovascular System																																
Blood vessel				+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		•		
Heart				+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+				
Schwannoma benign																						Х										
En la anima Sustana				_	-		_	-								-			-									4.				
Endocrine System Adrenal cortex				+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+				
Adenoma				•	•	•	•	•	•	•	x	•	•	•	•	•	•	•	•	·	·	·	•		·			-				
Adrenal medulla				т	т	Ъ	ъ	+	+	+		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	÷	1.1	•		
Pheochromocytoma benign				!	•	.'	•	•	•	•	,	•	·		•	·		•	•	-		-	·									
slets, pancreatic		.,		+	м	4	+	+	+	+	+	+	+	+	+	+	+	+	÷	+	+	+	+	+	+	+	+	+				
Adenoma				'	144	'		•	•	•		•	•	•	•	•	•	•				•	•	•			•				, <i>'</i>	
Parathyroid gland				+	4	ъ	÷	+	+	м	+	+	м	+	+	+	+	+	+	+	+	+	+	+	+	м	+	÷				
Pituitary gland				÷	÷	+	÷	÷	+	+	+	+	+	+	+	÷	+	+	+	+	+	÷	+	+	+	+	+	+				
Pars distalis, adenoma				т	x		7		x	T	1			x	-	ÿ	•			x	x		•	x	•	•	·	x		2		
Pars distalis, carcinoma					Λ	Λ		·	л				Λ	Λ	~	~		**	~													
				Т	+	<b>.</b>	ъ	۰	<b>.</b>	L.	+	بد	+	+	+	+	+	+	+	. +	+	+	+	+	+	+	+	+				
Thyroid gland C-cell, adenoma				т	т	x	т	.4.	r	F				'	x	•	•	•	x			x	x	•	•			•		2 .		
				_				_						_	_		_			_				_								
General Body System																	•									·				;		
None												_							_	_	-						_					
Genital System									_								_															
Clitoral gland				+	+	+	+	+	+	+	+	+	+	+	+	+	÷	+	+	+	+	+	+	+	+	+	+	• +				
Adenoma											X	•		Х						х	Х	Х								• •		
Carcinoma																														,		
Ovary				+	+	+	+	+	+	+	+	+	+	+	+	+	+	÷	+	+	+	+	+	+	+	+	+	• +				
Granulosa cell tumor malignant				-	•	•																		4	÷							
Granulosa cell tumor benign												•	х			•															•	
Uterus				+	+	+	+	+	÷	+	+	+	+	+	+	+	`+	+	+	+	+	• +	+	• +	• +	+	• +	• +				
Leiomyoma				•	•	•	•	•	•	•	•	•	•	•	•	x				-												
Polyp stromal															х	x	х					х				х				,		
																						-										
Sarcoma stromal																																

#### TABLE B2

-

(11) (11)

Individual Animal Tumor Pathology of Female Rats in the Long-Term Feed Study of *t*-Butylhydroquinone: 1,250 ppm (continued)

		0	8	8	0	0	8	0	8	8			
Number of Days on Study	8 9	8 9		8 9	8 9	8 9	8 9	° 9	8 9	8 9			
dumber or mays on Study	8			8			8		8				
	4	4	4	4	4	4	4	4	4	4		. <u></u>	Total
Carcass IID Number	2	3	4	5	5	5	5	5	6	7			Tissues/
	7	4	4	1	2	3	5		5		•		Tumors
Alimentary System													
Esophagus	+	• +	- +	+	+	+	+	+	+	+			60
Intestine large, colon	+	• +	• +	+	+	+	+	+	+	+			59
Intestine large, rectum	+	• +	- +	• +	+	I	+	+	+	+			59
Intestine large, cecum	+	- 4	- +	• +	+	+	+	+	+	+			60
Intestine small, duodenum	+	• +	- +	• +	+	+	+	+	+	+			60
Intestine small, jejunum	+	- 4	- +	• +	+	+	+	+	+	+			59
Intestine small, ileum	+	- 4	- +	• +	+	+	+	+	+	+			58
Liver	+	+	- +	• +	+	+	+	+	+	+			60
Hepatocellular adenoma													1
Mesentery		-	- +	•					+				13
Pancreas	.+		- +	• +	+	+	+	+	+	+			60
Salivary glands	+		+ +	• +	+	+	+	+	+	+			60
Stomach, forestomach	+	- 4	- +	• +	+	+	+	+	+	+			60
Stomach, glandular	-+		- +	<b>.</b>	+	+	+	+	+	+			60
Tongue	•		•	•	•	•	•	•	•				1
Squamous cell papilloma													, <b>1</b>
Cardiovascular System			-										
Blood vessel	+				+	+	+	+	+	+			60
Heart			- +	• +	• +	+	+	+	+				60
Schwannoma benign	•			1	ſ	'	'	-	r	'			1
Endocrine System			<b>*</b>		-		_		_				
Adrenal cortex	-4	1	- +	• +	+	+	+	+	+	+			60
Adenoma	•		•					•	•				
Adrenal medulla	+		+	• +	. +	+	+	+	+	+			60
Pheochromocytoma benign					•	•	•	•		x			
Islets, pancreatic	4			- +	• •	+	+	+	+	+			59
Adenoma	-		•		'	•	•	•		•			
Parathyroid gland	+	- 4	+	- M	r +	+	+	Ŧ	+	М			5
Pituitary gland	-		+ +			. <b>.</b>	+	+					60
Pars distalis, adenoma	· X			x		•		'	•	x			27
Pars distalis, carcinoma		۲.								Λ			
Thyroid gland	4				. т	<u>н</u>	+	L.	<u> </u>	ъ			60
C-cell, adenoma	•	r i			т	1		т	-	F			
General Body System					_							**************************************	<del></del>
None												-	
Genital System	· · · · · · · · · · · · · · · · · · ·												
Clitoral gland	4	+ +	+ +	- +	- M	[ +	+	+	+	+			55
Adenoma													
Carcinoma										Х			
Ovary	-	F -	+ +	+ +	- +	• +	• +	+	• +	+			6
Granulosa cell tumor malignant													
Granulosa cell tumor benign													
Uterus	4	<b>⊢</b> -	+ +	+ -	- +	• +	• +	+	• +	+			6
Leiomyoma		-				•	•			•			0
						х							11
Polyp stromal													

145

÷ .

# TABLE B2

Individual Animal Tumor Pathology of Female Rats in the Long-Term Feed Study of *t*-Butylhydroquinone: 1,250 ppm (continued)

(continued)						_						,				,			- , -			- 1.				<b>-</b> ,-		<b>r P</b>	
Number of Days on Study	 4 8 0	4 8 1	9	5 3 7	3	7	5 8 3	1	6 2 5	2	6 4 0	4	5	6 5 9		6	6	8	6 9 7	0	7 0 5	7 2 2	7 3 3	7 3 5	7 3 6	,			
Carcass ID Number	4 2 3	4 2 1	4 3 3	4 3 9	4 6 1	4 4 6	3	7	4 3 5	4 7 0	7	4 4 8	4 3 0	4 7 8	4 4 5	4 4 0	4 4 9	4 8 0	4 6 2	4 7 1	4 7 4	4 2 4	4 3 2	4 6 0	4 6 3				
Hematopoietic System Bone marrow Lymph node Lymph node, mandibular Lymph node, mesenteric Spleen Thymus	 ++++++	+++++++++++++++++++++++++++++++++++++++	+++++++++++++++++++++++++++++++++++++++	+ + + + + +	++++++	++++++	+++++++++++++++++++++++++++++++++++++++	+ + + + +	+ + + + + +	++++++	+++++++++++++++++++++++++++++++++++++++	+ + + + + + + +	+ + + + + + +	+ + + + + + + +	+ + + + +	+++++++	+ + + + + + + +	+++++++++++++++++++++++++++++++++++++++	+ + + + + + +	+ + + + + + + + + + + + + + + + + + +	+ + + + + +	+++++++	+++++++++++++++++++++++++++++++++++++++	· + · + · + · + · +	+ + + + + + + + + + + + + + + + + + + +	· ·			
Integumentary System Mammary gland Carcinoma Fibroadenoma Fibroadenoma, multiple Skin Basal cell carcinoma Subcutaneous tissue, fibroma Subcutaneous tissue, fibroma, multiple	+	+	+ + X	x +	м +	+ x +	+	+	++	+	+ x +	+	++	+ .+	+ x +	+	+	+	++	+ X +	++	· +	+ X +		+ X +		· .		
Musculoskeletal System Bone Skeletal muscle	+	+	I	+	+	+	+	+	+	+	+	+	+	+	+		++	+	+	+	+	+	+		+				·
Nervous System Brain Peripheral nerve Spinal cord	++	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	 +	· +	- ,			
Respiratory System Lung Alveolar/bronchiolar adenoma Alveolar/bronchiolar carcinoma Nose Trachea	 + + +	+++++	++++	+ + +	++++	+ + +	++++	+ + + +	+ + +	+ + +	++++	+++++	+ + +	+ + +	++++	+ + +	+ + +	++++	+ +	+ + +	++++	+	+	· + · +	+ + + ;+				
Special Senses System Ear Eye	 			~				- #		_														~. •				*	
Urinary System Kidney Urinary bladder	+ +	++	++	+ +	++	+++	.+ +	++	++	++	++	++	+ + +	+ + +	+++.	+ + +	+	+++	++++	++	++	 + +	+	- +	• +	-			
Systemic Lesions Multiple organs Leukemia mononuclear	 4	+ x		+	• +	+	+ X	. +	+	+ X			+ X			+ x	+		+ X	+ x	+ X	+	- +	- + X	- + : X				

#### TABLE B2

- AND THE REAL PROPERTY OF

Individual Animal Tumor Pathology of Female Rats in the Long-Term Feed Study of *t*-Butylhydroquinone: 1,250 ppm (continued)

(commucu)																										
Number of Days on Study	7 3 8	7 4 9	7 6 1	7. 7 4	7 8 1	7 8 9	7 9 2	7 9 5	7 9 9	8 0 6	8 0 6		1	3		8 3 4	4		8 6 2	8 6 3	8 7 3	8 9 0	8 9 4	8 9 7	8 9 8	
Carcass ID Number	4 5 0	4 6 6	4 3 1	4 4 7	4 2 9	4 6 7		4 3 8	4 2 6		4 5 7		4 7 2	4	7			4 5 9	4 5 4		4 4 2			4 6 8	2	
Hematopoietic System Bone marrow Lymph node Lymph node, mandibular Lymph node, mesenteric Spleen Thymus	+++++++++++++++++++++++++++++++++++++++		· + · + · +	+++++++++++++++++++++++++++++++++++++++	+++++	+ + + + + + + + + + + + + + + + + + + +	+ + + + +	+ + + + +	+++++++	+ + + + + + + +	+ +	+ + + + + +	+ + + + +	+ + + + + + + + +	+++++++	+ + + + + + + + + + + + + + + + + + + +	+ + + + +	+++++++	+ + + + + + +	+++++++++++++++++++++++++++++++++++++++	+ +	+ + + + + +	+++	+	· -  · -	- - -
Integumentary System Mammary gland Carcinoma Fibroadenoma Fibroadenoma, multiple Skin Basal cell carcinoma Subcutaneous tissue, fibroma Subcutaneous tissue, fibroma, multiple			- + X - +		x +	x	+		+ X +	+ x +		x			х	x		x	+ x +		+ X +		+	+ X +		-
Musculoskeletal System Bone Skeletal muscle	+	+	• +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	· -+		-
Nervous System Brain Peripheral nerve Spinal cord	+	+	- +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+++++		· +		-
Respiratory System Lung Alveolar/bronchiolar adenoma Alveolar/bronchiolar carcinoma Nose Trachea			 · + · +				+++++	++++	+++++	+ + +	+++++	 + +			+++++				+ + +	++++		+++++		· +		
Special Senses System Ear Eye		<u> </u>		<u></u>											+++											
Urinary System Kidney Urinary bladder	+ +	· +	- + - +	· +	+	+ + +	++	++	++	+++	++	+++	+ +	++	++	++	+++	+++	++	++	+++	 + +	· +	- + - +		
Systemic Lesions Multiple organs Leukemia mononuclear		-+ X		• +		+ X	+	+	+		+ x		+		+ x	+ X	+	+ x	+		+ X					

2

:

÷

-----

### 148

## TABLE B2

Individual Animal Tumor Pathology of Female Rats in the Long-Term Feed Study of *t*-Butylhydroquinone: 1,250 ppm (continued)

. . .

$\begin{array}{cccccccccccccccccccccccccccccccccccc$	Total Tissues/ Tumors 60 24
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	Tissues/ Tumors 60
+ +	60
+ + + + + + + + + + + + + + + + + + + +	24 60 60 60 60
+ + + + + + + + + + + + + + + + + + +	59 6 16 17 60 1 2 1
+ + + + + + + + + +	59° 1
+ + + + + + + + + +	60 1 2
+ + + + + + + + + + + + + + + + + + +	60 2 1 60 60
	1
+ + + + + + + + + + + + + + + + + + + +	60 60
++++++++++++++++++++++++++++++++++++	60 33
	$\begin{array}{c} + + + + + + + + + + + + + + + + + + +$

5

v

#### Table B2

No. of Concession, Name

Individual Animal Tumor Pathology of Female Rats in the Long-Term Feed Study of &-Butylhydroquinone: 2,500 ppm

	) + + + + + + + + + + X	29 + + + + + + + +	3 4 A M A M M M M	2 +++++ +	+++++++++++++++++++++++++++++++++++++++	+ + + + + + +	+++++++++++++++++++++++++++++++++++++++	++++++++++	+ + + + + +	2	9 3 + + + + +	-	9 5 + +	1	4 8 +	0	0	5 0 1 + + + + + + + + + + + + + + + + + +	5 1 6 + + + + + + +	+ + + + + + +	4 9 1 + + + + + + + +	4 9 + + + + + + +	5 0 0 + + + + + + + +	4 + + + + + + + +	
 - -	++++++++X	++++ + + +	M A M M M	+++++++++++++++++++++++++++++++++++++++	+ + +	+++++++	+ + + +	+++++	+++++	+++++++++++++++++++++++++++++++++++++++	+ + + +	++++++	++++++	++	+++++ + + +	+ + +	+++++++++++++++++++++++++++++++++++++++	+++++++++++++++++++++++++++++++++++++++	+++++++++++++++++++++++++++++++++++++++	+++++++++++++++++++++++++++++++++++++++	+ + + + + + + + + + + + + + + + + + + +	+++++++++++++++++++++++++++++++++++++++	+++++ + +	+++++++++++++++++++++++++++++++++++++++	
 - -	++++++++X	++++ + + +	M A M M M	+++++++++++++++++++++++++++++++++++++++	+ + +	+++++++	+ + + +	+++++	+++++	+ + + + + + +	+ + + +	++++++	++++++	++	++++++ + + +	+ + +	+++++++++++++++++++++++++++++++++++++++	+ + + + + + + +	+++++	+++++++++++++++++++++++++++++++++++++++	+ + + + + + +	+++++++++++++++++++++++++++++++++++++++	+++++ + +	+ + + + + +	
 - -	++++++++X	+++ + + +	A M M M	+++++++++++++++++++++++++++++++++++++++	+ + +	+++++++	+ + + +	+++++	+++++	+ + + + + +	+ + + +	++++++	++++++	++	+++++++++++++++++++++++++++++++++++++++	+ + +	+++++++++++++++++++++++++++++++++++++++	++++ + + +	+++++++++++++++++++++++++++++++++++++++	+++++++++++++++++++++++++++++++++++++++	+ + + + + +	+++++++++++++++++++++++++++++++++++++++	++++ + +	+++++++++++++++++++++++++++++++++++++++	
 - -	+++++++X	++ + +	M M M	++++++	+ + +	+ + +	+ + +	+++++	+++++	+ + + + +	+++++	++++++	+ + +	+	+++ + +	+	+++++++++++++++++++++++++++++++++++++++	+++++++	+++ + +	+++++++	+++++++++++++++++++++++++++++++++++++++	+++++++	++++++++	+ + + +	
 - -	+ + + + + X	+ + + +	M M	+ + +	+	+	+	+	+	+ + + + + +	+	+	+		++ + +	+	+++++++	++++++	+ + + + +	+ + + + +	++++++	+ + + +	+++++	+ + +	
 - -	+ + + + X	+ + +	м	+ + +	+	+	+	+	+	+ + +	+	+	+	+ + +	+ + +	+	+ + +	+ + +	+ + +	+ + +	++++	+ + +	+ + +	+++	
 - -	+ + + X	+ +		+ +						+ + +		+ + +		+ + +	+ + +	+ + +	+ + +	+ + +	+ + +	+ + +	+	+ +	++	+	
	+ + X	+	м +	+	+	+	+	+	+ +	+	+	+	+	+	+	+	+ +	+	+	+ +	+	+	+	+	
2	Х	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	L				
2	Х	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	L.				
2	Х			+																	· T	+	+	+	
2	Х			+																					
2	Х	` •												+	+				+		+		+		
-																									
-	+																								
-		+	М	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	÷	
• •	+	+	М	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
•	+	+	М	+	+	+	+	+	+	+	+	+	+	+	+	+	+	. +	+	+	+	+	+	+	
					+																				
					X																				
	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
• •	+	+	+	+	+	+	. +	+	+	+	+	+	+	+	+	+	+	+	+	+	• +	+	+	+	
• •	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	• +	+	+	+	
					•																				
• •	+	+	M	+	•	+	+	+	+	+	+	+	+	+	+	+	+	÷	+	+	• +	+	+	+	
• •	+	+	M			+	+	+				+			+	+	+	+	+						
				Х					Х	Х			х		X	х	X	Х		Х	•	.X	Х	х	
- 1	÷	+	A	+	• +	+				+	+	+	+	+	+	+			+			• +	+	+	
							A	Ä									А			X	•				
		+ ++ ++ ++ ++	+ + + + + + + + + + + + + + + + + + + +	+ + M + + + + + + + + + + + M + + M	+ + M + + + + + + + + + + + + + + + + + + M + + + + M + X	+ + M + + + + + + + + + + + + + + + + +	+ + M + + + + + + + + + + + + + + + + +	+ + M + + + + + + + + + + + + + + + + +	+ + M + + + + + + + + + + + + + + + + +	+ + M + + + + + + + + + + + + + + + + +	+ + M + + + + + + + + + + + + + + + + +	+ + M + + + + + + + + + + + + + + + + +	+ + M + + + + + + + + + + + + + + + + +	+ + M + + + + + + + + + + + + + + + + +	+ + M + + + + + + + + + + + + + + + + +	+ + M + + + + + + + + + + + + + + + + +	+ + M + + + + + + + + + + + + + + + + +	+ + M + + + + + + + + + + + + + + + + +	+ + M + + + + + + + + + + + + + + + + +	+ + M + + + + + + + + + + + + + + + + +	+ + M + + + + + + + + + + + + + + + + +	+ + M + + + + + + + + + + + + + + + + +	+ + M + + + + + + + + + + + + + + + + +	+ + M + + + + + + + + + + + + + + + + +	+ + M + + + + + + + + + + + + + + + + +

9

3

149

Individual Animal Tumor Pathology of Female Rats in the Long-Term Feed Study of *t*-Butylhydroquinone: 2,500 ppm (continued)

(continued)																														
Number of Days on Study		7 8 8	8	7 8 9	7 9 9	8 0 1	8 1 6	8 1 7	8 1 7	8 4 5	8 5 6	8 6 0	8 8 3		8	9	8 9 1	8 9 4	8 9 8	8 9 8	8 9 8	8 9 8	8 9 8	8 9 8	8 9 .8	9		,		
	<u> </u>		5	5	5	5	5	4	5	4	5	5	5	5	5	5	5	-	4		<u> </u>	-	-	5		5				
Carcass ID Number		4	1	1 9	3 2	3 9	3 5	9 6	0 7	9 4	0 2	3 1	3	4	5	1	4 7	1 4	9 7	9 8	9 9	0 6	0 8	1 0	1	1 3				
Alimentary System	<u> </u>					<u> </u>		-					_								,									
Esophagus		+	- +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+				
Intestine large, colon		· +	• +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	• +	+	+				
Intestine large, rectum		4	• +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+				
Intestine large, cecum		+	• +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+				
Intestine small, duodenum Carcinoma		+	• +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+				
Intestine small, jejunum		· +	• +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+				
Carcinoma		Х	:																											
Intestine small, ileum		+	- `+	+	+	.+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	÷	+	+	+	+				
Leiomyosarcoma										Х														•					•	
Liver		+	- +	+	+	+	+	+	+	+	+	+	÷	+	+	+	+	+	·+	+	+	+	+	+	+	+				
Hepatocellular adenoma														<b>X</b> -																
Osteosarcoma, metastatic, bone		· X	2																											
Mesentery				• +									+		+															
Oral mucosa															۰.															
Squamous cell carcinoma														· .					١.											
Pancreas		-	- +	+	+	+	+	+	+	+	+	<b>+</b>	+	+	+	+	+	÷	+	+	+	+	+	+	• +	+				
Salivary glands			- +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	.+	+	÷	-+	+				
Stomach, forestomach		-	- +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	· +	+				
Squamous cell papilloma							X										•						•							
Stomach, glandular		4	- +	• +	• +	- +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	• +	• +		× .		,
Tongue															•		+				•		•			+				
Squamous cell carcinoma Squamous cell papilloma																							•			X				:
	· · ·																_					_	_							
Cardiovascular System			L .4	ر .			L .	ь	л.	L.	L.	ъ	Ŧ	ъ	بد	ъ	-	L.	+							+				
Blood vessel		4	r 1	- +	- + 	*	· +	+	- <b>T</b>	T	T	<b>T</b>	τ 	т ⊥	т _	т ц	т -	т 	- <b>T</b>	т 	т 1	പ	т Ц	т 	۰. بر	.⊥			÷	
Heart			+	- +	- +	+	+	+	+	+	+	+	+	+	+	+	+	+		+		т —	+							
Endocrine System																				L.			L.		د .	<b>.</b> .	_			
Adrenal cortex		-		- +	- +	+	• +	+	+	+	+	+	+	+	+	+	+	+	- T	- T-	+	-T -	. + 	· •		- T . J				
Adrenal medulla		-	+ +			• +	• +	+	+	+	+	+	+	+	Ŧ	Ŧ	+	+	-1		+	-	- +	+	1					
Pheochromocytoma benign				X					۰.								Т	-	L.	د .	د .	د.	د .	د .		د				
Islets, pancreatic Adenoma		-	+ +	- +	- +	• +	× + X	• +	+	• +	+	+	+	+	+	+ x	+	+	+	• +	· + X	• +	• +	• +	- + X		-			
Carcinoma Desethurseid sland		•	Ar a		л н	а 1.4	<b>ر ،</b>		د .	د .	<b>ب</b> د .			<b>.</b>	+	ـ	+										-			
Parathyroid gland		r	VI 1	- 1V	1 M	1 IVI		- + 	т 	· +	т 	- <del>-</del>	-	- <del>-</del>	- T - L	۳ ـ	 -		۳ س	т 		т 	т 	т 	ר ב -	- +	-			
Pituitary gland			т 1 И	- 1	ד ד יע	- + - v	- +		+	- +	- +	v	v	x	т	v	v	v	v	x	T Y	· v	•	Y	r y	x				÷
Pars distalis, adenoma		2	K		. ^	X						л	•	л		^	л	Λ	~		. ^		x	•			•			1
Pars distalis, carcinoma											ر .			L	L	-1-	L	<b>د</b> .	بر .	ىر .	ى .	<u>ب</u>	· 4		ہے	- +	-			
Thyroid gland			+ +		r +	- +	- +	• +	+	• +	• •			+	+	. <b>T</b>	Ŧ	- +	- +	- +	+		-		1	· - T				
C-cell, adenoma												Å	Х						х							•				
C-cell, carcinoma															ż		-		~	•									. •	
Follicular cell, adenoma															. ^		•						•							
Follicular cell, carcinoma							`																							
General Body System		• •		_				-							,													• •		
None										•																				

#### TABLE B2

and a state of the s And the state of the Individual Animal Tumor Pathology of Female Rats in the Long-Term Feed Study of &-Butylhydroquinone: 2,500 ppm (continued)

	8	8	8	8			8	8					
Number of Days on Study	9 8	9 8	9 8	9 8		9 8	9 8	9 8					
Carcass ID Number	5	5 2	5 2	5 2	5 2	5 3	5 3	5 4					Total Tissues/
arcass in rumber	1						7						Tumors
limentary System		—		-					 	 	 		<u> </u>
Esophagus	+		. +	-	+	4	+	÷					57
ntestine large, colon			· +	<b>-</b>	+	÷	+	+					56
ntestine large, colon			. +	- + -	+	÷	÷	+					57
ntestine large, cecum	, +	• +	• +	• +	+	÷	+	+					57
ntestine small, duodenum	+	• +				+							57
Carcinoma	т	т	- т	x		-	т	т					1
							+						56
ntestine small, jejunum		· •		· T	т	т	т	т				÷ .	1
Carcinoma													57
ntestine small, ileum	+	• +	• +	- +	+	+	+	Ŧ					
Leiomyosarcoma					,								1
iver	+			+	+	+	+	+					58
Hepatocellular adenoma		Х	•										2
Osteosarcoma, metastatic, bone													1
Aesentery	•												10
Oral mucosa													1
Squamous cell carcinoma											•		1
ancreas	+	- +	• +	• +	+	+	+	+					57
alivary glands	+	• +	• +	• +	+	+	+	+					58
tomach, forestomach	+	• +	• +	• +	+	+	+	+					57
Squamous cell papilloma													. 1
stomach, glandular	+	• +	• +	• +	+	+	+	+					57
longue							+						4
Squamous cell carcinoma													1
Squamous cell papilloma										 •			1
Cardiovascular System									 	 	 		
Blood vessel	+	- +	- +	• +	+	+	+	+					58
leart	+	- +	+ -	• +	+	+	+	+					58
Endocrine System													· · ·
Adrenal cortex	+	- +	• +	• +	+	+	+	+					58
Adrenal medulla	+	• +	- +	• +	+	+	+	+					58
Pheochromocytoma benign													1
slets, pancreatic	+	- +	- +	• +	• +	+	+	+					57
Adenoma													3
Carcinoma													. 1
arathyroid gland	+		- +	- +	• +	+	+	+					53
ituitary gland	-		- +	- +	• +	+	+	+					57
Pars distalis, adenoma		X	x	X	X	x	,	x					34
Pars distalis, carcinoma													1
hyroid gland	4		- +	- +	• +	• +	+	+					57
C-cell, adenoma	•		•		•	x		•					7
C-cell, carcinoma			х										2
Follicular cell, adenoma				-									<b>1</b>
Follicular cell, carcinoma							х						1
					-					 	 	<u> </u>	<u></u>
General Body System													
None													

151

Ą

\$

•••

Individual Animal Tumor Pathology of Female Rats in the Long-Term Feed Study of t-Butylhydroquinone: 2,500 ppm (continued)

Number of Days on Study	1 9 7	2	9		0	1		4	5	5	6	6	66 68 72	0	2	3	7 5 7	7 5 8	7 6 7	7 6 7	7 7 2	7 7 2	7 7 4	7 7 4	 		
Carcass ID Number	5 4 1	-	) 2	2 3	9	5 0 3	3	2	4	4	_	9	5 4 2 9 7 5	1	4	5 0 5	5 0 9	0	5 1 6	5 1 7	4 9 1	5 4 9	-	5 4 4	 		
Genital System																						****			 		
Clitoral gland Adenoma	+	- +	⊦ ⊣	+ +	+	+	+	+	+	+	+ X		+ - X	⊦ +	• +	+	+	+	+	+	+	+	+	+			
Carcinoma Ovary		+	⊦ -	+ M	ι+	+	+	+	+	+	+	+	+ +	⊦ ≁	• +	+	+	+	+	X +		+	+	+			
Carcinoma Uterus	4	- +	F -	+ +	• +	+	+	+	+	+	+	+	+ +	+ +	• +	+	+	Х +	+	+	+	+	+	+			
Adenoma Leiomyoma Polyp stromal		¥	ζ.																								
Sarcoma stromal		~	• •																								
Hematopoietic System																					_				 		
Bone marrow	+	- 1	+ -	+ A	. +	+	+	+	+	+	+	+	+ +	+ +	• +	+	+	+	+	+	+	+	+	+			
Lymph node	+	- +	+ -	ł	+		+	+	+				+					+	+		+					,	
Pancreatic, carcinoma, metastatic, ovary Lymph node, mandibular	+	- +	F 4	+ A	+	+	+	+	Ŧ	+	+	+	<b>ц</b> ц	+ +	м	+	+	X	+	+	+	-	ъ	т.			
Lymph node, mesenteric				+ M		M	+	+	+	+	+	+ +	+ -	+	· +		+		+	+	+	+	+	+			
Carcinoma, metastatic, ovary	•				•													x					•	•			
Spleen	· -	• +	⊦ ⊣	+ M	( +	+	+	+	+	+	+	+	+ +	+ +	• +	+	+	+	+	+	+	+	+	+			
Osteosarcoma, metastatic, bone Thymus	4	1	⊾.	+ +	. +	+	+	+	+	+	+	+	+ -	⊢ <b>→</b>	<b>.</b>	+	+	М	+	+	+	+	+	+			
Thymoma malignant	•	•		•••	•	•	•	• ·	•		•	•	•		•	,		1.1		•		•		•			
Integumentary System				_				_						-					-	_							
Mammary gland	• +	• +	+ -	+ +	+	+	+	+	+	+	+	+ -	+ +	- +	+	+	+	+	+	+	+	+	+	+			
Adenoma																								х			
Fibroadenoma					х				x				,	c	х			х	х				х	х			
Fibroadenoma, multiple																				х							
Skin	+	• +	+ -1	+ +	• +	+	+	+	+.	+	+	+	+ +	⊦ + X		+	+	+	+	+	+	+	+	+			
Keratoacanthoma Subcutaneous tissue, fibroma														л													
Subcutaneous tissue, fibrosarcoma																											
Musculoskeletal System		, <b></b> ,																									÷
Bone	-	⊦ <b>-</b> †	+ -	+ +	• +	+	+	+	+	+	+	+	+ -	+ +	- +	+	+	+	+	+	+	+	+	+			
Osteosarcoma Skeletal muscle																											
Nervous System				·						_															 -		
Brain		⊦ ⊣	+ -	+ +	• +	+	+	+	+	+	+	+	+ -	+ +	• +	+	+	+	+	+	+	+	+	+			
Peripheral nerve	:						+																				
Spinal cord							+					_													 		<del></del>
Respiratory System							i				,													Ŧ			
Lung Alveolar/bronchiolar adenoma	-	- 1	r -	+ +	• +	+	+	+	+	÷	.+	+	+ -	- 4	- +	· +	+	+	+	+	-	Ŧ	+	+			
Carcinoma, metastatic, ovary																		х					·				
Nose		⊢⊣	+ ·	+ +	- +	· +	+	+	+	+	+	+	+ ·	+ +	- +	• +	+	+	+	+	+	+	+	+			
Trachea																											

٢

1

÷.

## TABLE B2

1

ling and the second states of the second states of the second states of the second states of the second second states of the second s

Trail Barrar san

Individual Animal Tumor Pathology of Female Rats in the Long-Term Feed Study of t-Butylhydroquinone: 2,500 ppm (continued)

In the second se

(continued)												_		_												_		 
· ·	7	7	7	7	8	8	8	8	8	8	8	8	8	8	8	8	8	8	8	8	8	8	8	8	8			
Number of Days on Study	8	8	8	9	0	1	1	1	4	5	6	8	8	8	9	9	9	9	9	9	9	9	9	9	9			
	8	9	9	9	1	6	7	7	5	6	0	3	3	8	0	1	4	8	8	8	8	8	8	8	8			
	5	5	5	5	5	5	4	5	4	5	5	5	5	5	5	5	5	4	4	4	5	5	5	5	5			
Carcass ID Number	4	1	1	3	3	3	9	Õ	9	0	3	3	4	5	1	4	1	9	9	9	0	0	1	1				
	3	8	9	2	9	5		7	-	-	1				2									1				
Conital Sustan		_																					_					 -
Genital System Clitoral gland	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+			
Adenoma	•	,	.'	'	•	'	1		•	•	•	1	•	•			•			•	x		•	x				
Carcinoma							х	x			х						х											
Ovary	+	+	+	+	+	+			+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+			
Carcinoma	•	'				•		•		•	•		•		•	•			•	•	•				•			
Uterus	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+			
Adenoma	•	x		•	•	•	'	•		•		•	'	•	•	•	•	•	•	•	•	'		'	•			
Leiomyoma		~											х															
Polyp stromal					х					х						x	х											
Sarcoma stromal										**														х				
								_																				 
Hematopoietic System																												
Bone marrow	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	• •		
Lymph node	+	+		+				+							+					+			+				•	
Pancreatic, carcinoma, metastatic, ovary																												
Lymph node, mandibular	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	•		
Lymph node, mesenteric	+	+	• +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	• +	· +	• +	-		
Carcinoma, metastatic, ovary																												
Spleen	+		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	-		
Osteosarcoma, metastatic, bone	Х																											
Thymus	+	+	+	+	+	+	+	+	+	+	+	+	+	+		+	+	+	+	+	+	+	+	+	+	•		
Thymoma malignant															X													 
Integumentary System						•																						
Mammary gland	+	+	• +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	÷	+	+	+	+	+	• +	•		
Adenoma																												
Carcinoma															Х		х											
Fibroadenoma	· x	x	x	х	х	х			x		х	х			x			х		x			x	x				
Fibroadenoma, multiple			•••		•-			х									х		х			x						
Skin	+	• +	• +	+	+	+			+	+	+	+	+	+	+	+	+		+		+	-+		. 4	• +			
Keratoacanthoma	•			·	•		•	•	•				•	•			•	•	·			•	•		•			
Subcutaneous tissue, fibroma						х																						
Subcutaneous tissue, fibrosarcoma			Х																									
Museuloskolotal System				-				-		-										_	_		-					 
Musculoskeletal System Bone																				,	. ,							
•	+ X		• +	+	+	+	+	+	+	+	+	+	+	+	+	Ŧ	+	+	+	+	• +	• •	• +	• +	• +	-		
Osteosarcoma Skeletal muscle	Х	•																										
									_					+														 
Nervous System																												
Brain	+	+	• +	+	+	+	· +	+	• +	+	+	+	+	+	+	+	+	+	+	+	• +	• +	+	- +	- +	-		
Peripheral nerve														+	• +													
Spinal cord														+	+													
Respiratory System											_						_									_		
Lung	+		+		+			<b>.</b>			· +	+	+		. <b>.</b>	+	-	+	+	. <b>.</b>	<b>.</b>				- +	F		
Alveolar/bronchiolar adenoma	1		'			1		•	'	'	•	'	x		'	•	'		•	'	'	•			'			
Carcinoma, metastatic, ovary													А															
Nose	+				• +		• +	+	- +	• +	. +	+	• +	. +	• +	+	• +	+	+	• +	- +	4		4	+	F		
	т Ц	י ב.			, _																							
Trachea	+	• •	- +	· +	+	+	• +	+	• +	• +	· +	+	+	+	+	+	+	+	+	+	- +	1		- +	- +	⊦ 		 

£,

Individual Animal Tumor Pathology of Female Rats in the Long-Term Feed Study of t-Butylhydroquinone: 2,500 ppm (continued)

(continued)			
Number of Days on Study	8 8 8 8 8 8 8 8 8 9 9 9 9 9 9 9 9 9 8 8 8 8	ί	· .
Carcass ID Number	5       5       5       5       5       5       5         2       2       2       2       2       3       3       4         1       2       3       4       5       6       7       6		Total Tissues/ Tumors
Genital System Clitoral gland Adenoma Carcinoma Ovary Carcinoma Uterus Adenoma Leiomyoma Polyp stromal Sarcoma stromal	+ + + + + + + + + X + + + + + + + + + + + + +	· · · ·	58 5 57 1 58 1 1 5 1
Hematopoietic System Bone marrow Lymph node Pancreatic, carcinoma, metastatic, ovary Lymph node, mandibular Lymph node, mesenteric Carcinoma, metastatic, ovary Spleen Osteosarcoma, metastatic, bone Thymus Thymoma malignant	$\begin{array}{c} + + + + + + + + + + + + + + + + + + +$		57 19 1 55 55 1 57 1 57 1
Integumentary System Mammary gland Adenoma Carcinoma Fibroadenoma Fibroadenoma, multiple Skin Keratoacanthoma Subcutaneous tissue, fibroma Subcutaneous tissue, fibroma	+ + + + + + + + x x x x + + + + + + + +		58 1 2 25 9 58 1 1 1
Musculoskeletal System Bone Osteosarcoma Skeletal muscle	+ + + + + + + +		58 1 1
Nervous System Brain Peripheral nerve Spinal cord	+ + + + + + +		58 3 3
Respiratory System Lung Alveolar/bronchiolar adenoma Carcinoma, metastatic, ovary Nose Trachea	+ + + + + + + + + + + + + + + + + + +		58 1 1 58 58

# TABLE B2

Individual Animal Tumor Pathology of Female Rats in the Long-Term Feed Study of *t*-Butylhydroquinone: 2,500 ppm (continued)

		-		_	_	_					-		_						_					_						
Number of Days on Study	1 9 7	4		-	6 0 0	6 1 3	6 3 2	6 4 9	6 5 7	6 5 8	6 6 1	6 6 6	6 6 7	6 8 2	7 0 3	7 2 1	7 3 8	7 5 7	7 5 8	7 6 7	7 6 7		7 7 2	7 7 2	7 7 4	7 7 4				
Carcass ID Number	5 4 1		5 5 2 2 9	3	4 9 2	5 0 3	5 3 8	5 2 6	5 4 0	5 4 2	5 2 0	4 9 3	5 2 7	4 9 5	5 1 5	5 4 8	5 0 5	5 0 9	5 0 1	5 1 6	1		9	5 4 9	5 0 0	4				
Special Senses System Ear Eye Zymbal's gland Carcinoma	4 <u>44</u>		<u></u>														··	<u> </u>									é	· · ·	· · ·	<b>v</b> .
Urinary System Kidney Urinary bladder		 	+ +	• • •	 . +	• +	+	++	+++	+	· +	+ +	• + • +	+	+++	+	+++++	+	+	· +		 +-	++	++		++				
Systemic Lesions Multiple organs Leukemia mononuclear	- >		+ +		- +	• +	+ X	+	+ X	+	· +	+ x	+ x	•	+ x	+	+ X	+ x	+	+ X		•	+ x	+ x	+	+	- <b>_</b>			

Individual Animal Tumor Pathology of Female Rats in the Long-Term Feed Study of *t*-Butylhydroquinone: 2,500 ppm (continued)

Carcinoma Urinary System Kidney	+					+	+	+	+	+	+	+	+	+	+		+	+	+	+	+	+			 · +		
Special Senses System Ear Eye Zymbal's gland														+ +	+												
Carcass ID Number	5 4 3	5 1 8	5 1 9	3	5 3 9	5 3 5	4 9 6	5 0 7	4 9 4	5 0 2	5 3 1	5 3 3	5 4 5	5 5 0	5 1 2	5 4 7	5 1 4	4 9 7	4 9 8	4 9 9	5 0 6	5 0 8	5 1 0	5 1 1	5 1 3	 	
Number of Days on Study	8	8 9	7 8 9	-	8 0 1	8 1 6	8 1 7	8 1 7	8 4 5	8 5 6	8 6 0	8 8 3	8 8 3	8 8 8	8 9 0	8 9 1	8 9 4	8 9 8									

# Table B2

Individual Animal Tumor Pathology of Female Rats in the Long-Term Feed Study of *t*-Butylhydroquinone: 2,500 ppm (continued)

Number of Days on Study	8 8 8 8 8 8 8 8 9 9 9 9 9 9 9 9 8 8 8 8	
Carcass ID Number	5       5       5       5       5       5       5         2       2       2       2       3       3       4         1       2       3       4       5       6       7       6	Total Tissues/ Tumors
Special Senses System Ear Eye Zymbal's gland Carcinoma	+ . * *	1 3 1 1
Urinary System Kidney Urinary bladder	+ + + + + + + + + + + + + + + + + + +	57 58
Systemic Lesions Multiple organs Leukemia mononuclear	+ + + + + + + + X	58 22

-

----

Individual Animal Tumor Pathology of Female Rats in the Long-Term Feed Study of t-Butylhydroquinone: 5,000 ppm

lumber of Days on Study	0 1	7 2	5 9 1	9 6	0 0	1 3	2	2 8	3	6 4 0	5 9	6 6	6 7 3	7	9	6 9 1	7 0 5	7 1 2	7 5 0	7 5 2	7 7 4	7 7 7	7 8 9	8 9	8 9			1 + 1 +
arcass ID Number	6 0 8	8	5 9 7	5 8 6	6 1 7	5 6 8	8	5 9 1	5 6 6	5 7 0	6 0 7	5 8 5	6	7	9	-	6 0 0	5 6 3		5 8 2	6 1 5	6 0 2	5 6 2	5 9 0	0		,	
limentary System										-																		
sophagus	+	+	+	+	+	+	+	+ ·	· +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+			
testine large, colon	+	+	M	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+			••
itestine large, rectum	+	+	+	+	+	+	+	.+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		•••	•
itestine large, cecum	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+			1.
itestine small, duodenum	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	; <del>†</del> -			
atestine small, jejunum	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+			· •
ttestine small, ileum	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	M	+	+	+			• `
iver Hepatocellular adenoma	• +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+			t
Hepatocellular adenoma, multiple																												
lesentery				+				·			+							+										,
ancreas	+	+	+	+	+	+	М	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	`+			24
alivary glands	+	, <b>+</b>	+	+	÷	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	·.		,
tomach, forestomach	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+			
tomach, glandular ongue	+	+	+	·+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+			•
ardiovascular System				_	,																					•	•	
lood vessel	. +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	÷	+	+			
eart	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+			
Schwannoma benign																								•				
ndocrine System							·,						_															
drenal cortex	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+			
drenal medulla	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	÷.,	- 1	
Pheochromocytoma malignant																									•		•	
Pheochromocytoma benign																			Х								· · ·	
slets, pancreatic	+	+	+	+	+	+	Μ	+	+	+	•.+	+	+	, <b>+</b>	+	+	+	+	+	+	+	+	+	+	+		ι.	
Adenoma																												
arathyroid gland Adenoma	+	+	+	+	·+	+	+	+	+	М	Μ	+	+	+	+	+	+	+	+	+	+	+	+	+	М			
Carcinoma, metastatic, thyroid gland																												
ituitary gland	Ŧ	+		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+			× .
Pars distalis, adenoma		x		•		•	•		x		x	•		•	x	•	•	•		•	•	X		·	X			
Pars distalis, carcinoma												х								х								
hyroid gland	+	· +		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+			+	+	+	+			·
C-cell, adenoma	•		•	•	•	·	•	•	x			•	·	•	•						x							
C-cell, carcinoma									••																			
Follicular cell, carcinoma														х														
Seneral Body System													-	,											,			
					_				_							-	-				,							
Jenital System																						•			΄.			
Clitoral gland	+	: <b>-</b> †	• +	• +	+	+	+	+	+	• +	+	+	+	+	+	+	+	+	+	+	+	+	• +	+	• +			
Adenoma							х																				-	1
Adenoma, multiple Carcinoma																			X		х			,			,	
																			_					_				

158 --

÷.7

Individual Animal Tumor Pathology of Female Rats in the Long-Term Feed Study of *t*-Butylhydroquinone: 5,000 ppm (continued)

(continued)		_				_							_	_														
		8		8	8							8						8	8	8	8	8	8		8			
Number of Days on Study	0 7	1 0		3 1	3 1	3 9	-			5 8	-	6 9						9 7	9 8	9 8	9 8	9 8	9 8	9 8	.9 8	÷		
	5	5	6	• 6	6	6	5	5	5	5	5			5	6	6	5	5	5	5	5	5	5	5	5			
Carcass ID Number	7	6	0	0	1	1	9	8	6	8	9	7	7	6		1	7	9	7	7	7	7		8				
	6	4	3	1	6	9	8	4	5	9	2	1	5	7	6	0	7	9	2	3	4	8	0	3	7			
Alimentary System										_																		
Esophagus	+	• +	+ +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	.+	+	+	+	+	+			
Intestine large, colon	+	• -1	- +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	'+			•
Intestine large, rectum	+	· -	- +	+	+	Ι	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+			
Intestine large, cecum	+	1	- +	+	+	+	÷	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+			
Intestine small, duodenum	4		+ +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+			
Intestine small, jejunum	4		⊦ +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+			
Intestine small, ileum	+	• - 1	- M	( +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+			
Liver	4	1	+ +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+			
Hepatocellular adenoma					Х																		•			,		1
Hepatocellular adenoma, multiple														Х														•
Mesentery								+	+		+													+				
Pancreas	+	- 4	+ +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	÷	+	+	+	+	+	+	+			•
Salivary glands	+	• +	+ +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+			•
Stomach, forestomach	+		+ +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	÷	+	:		
Stomach, glandular	-1		+ +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+			
Tongue																	+											
Cardiovascular System																							_					
Blood vessel	4		+ +	+	.+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+			
Heart	4		- +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+			
Schwannoma benign						-	-	·		-	·		-		-	-		-							X			
Endocrine System			_		-							-							-									
Adrenal cortex	-		ь +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+			
Adrenal medulla	-		⊢ _	. <u>+</u>	+	+	+	÷	+	+	÷	+			+					+	+	+	+	+	+			
Pheochromocytoma malignant					'	•	•	'		•		'	'	'	'	'	x	•	'	'	'	'	'		•			
Pheochromocytoma benign														х			~						,					
Islets, pancreatic			L .L	L		Ŧ	т.	L.	т	<u>т</u>	۲	1	-		+	ъ	+		+	ـــ	-	-		ــــــــــــــــــــــــــــــــــــ	+	ì		
Adenoma				'	'	'	•		'	•	•	x		'	'	•		'	•		x	'		'	•			,
Parathyroid gland			L _L	. <b>.</b> .	<u>т</u>	Ъ	ъ	Ъ	Ъ	1	т		ъ	м	+	ъ	т.	Ň	Ŧ	ᆂ			Ŧ	<u>ـ</u> ـ	Ъ			
Adenoma	7		г т	т	т	Ŧ	ч.	т	т	т	т	т	г	141	т	т	F	141	-	т	1.	.,	T	x				
Carcinoma, metastatic, thyroid gland																			х					~				
Pituitary gland		L _	+ +		. <b>т</b>	Ŧ	т	Т	т	1	Ъ	.ب	÷	Ŧ	Ŧ	ъ	Ŧ	+		ـــ	+	+			+			
Pars distalis, adenoma			x		Y	Y	x	v	Y	Y	x	v	v	1		x	T.	x		Ŧ	x			x	. '			
Pars distalis, carcinoma			л		л	Λ	л	л	Λ	л	л	Λ	Λ			Λ		л			л	х		<u></u>	-			
Thyroid gland		L _	<b>.</b>	. <b>.</b>	<u> </u>		т	т	Ъ	1	т	ъ	Т	Ъ	+	Т	<b>_</b>	+	ـــ	ъ	+			ــــــ	+			
C-cell, adenoma			<b>г</b> т		T	T	+	т	+ X	Ŧ	т	т	т	т	т	+	+	Ŧ	+ X	т	т	· •	x		т			•
C-cell, carcinoma									л					х					Λ				л					
Follicular cell, carcinoma							•							Λ									•					
General Body System							-			-		-			_										_			
None																												
Genital System		_								_												_						۰i
Clitoral gland		F -	+ +		. <b>.</b>	Ъ	Ŧ	ᆂ	Ŧ	ـــ	-	-	Ъ	Ŧ	Ŧ	⊥	<u>ـ</u> ـ	+	+	L.			<b>.</b>		+		•	
Adenoma	-		+ +	- + X		т	т	т	т	т	Т'	Ŧ	x	Ŧ	т	т	т	x	т	Ť	т	-	-	x				
Adenoma, multiple				~					х				л					Λ						л				
Carcinoma				v	x				л							v	x				х		х					
Caromonia					. <b>л</b>											Λ	•••				~							

159

Individual Animal Tumor Pathology of Female Rats in the Long-Term Feed Study of t-Butylhydroquinone: 5,000 ppm (continued)

continued)		
Number of Days on Study	8 8 8 8 8 8 8 8 8 8 9 9 9 9 9 9 9 9 9 9 9 8 8 8 8	· · · · · · · · · · · · · · · · · · ·
	8 8 8 8 8 8 8 8 8	· · · · · · · · · · · · ·
Carcass ID Number	5 5 5 6 6 6 6 6 6 6 9 9 9 0 0 1 1 1 1 2 3 4 5 4 9 1 2 3 4 0	Total Tissues/ Tumors
Alimentary System		······································
Esophagus	* * * * * * * * * *	60
ntestine large, colon	+ + + + + + + + +	59
intestine large, rectum	+ + + + + + + + +	59
ntestine large, cecum	+ + + + + + + + +	60
ntestine small, duodenum	+ + + + + + + + +	60
intestine small, jejunum	+ + + + + + + + +	60
intestine small, ileum	+ + + + + + + + +	58
Liver	+ + + + + + + + +	60
Hepatocellular adenoma		1
Hepatocellular adenoma, multiple Mesentery		1
Pancreas		59
Salivary glands	+ + + + + + + + +	60
Stomach, forestomach	+ + + + + + + + +	60
Stomach, glandular	+ + + + + + + + +	. 60
Fongue		- 1
Cardiovascular System		(0)
Blood vessel	+ + + + + + + + +	60
Heart	+ + + + + + + + +	60 · 1
Schwannoma benign		
Endocrine System		
Adrenal cortex	+ + + + + + + + +	60
Adrenal medulla	+ + + + + + + + +	60
Pheochromocytoma malignant	<b></b>	1
Pheochromocytoma benign	<b>X</b>	3
slets, pancreatic	+ + + + + + + + +	59 2
Adenoma Porethyroid cland	+ + + M + + + + + +	2 54
Parathyroid gland Adenoma	<b>+ + + 1</b> 41 <b>+</b> 37 <b>+ + + + +</b>	54 1
Carcinoma, metastatic, thyroid gland		1
Pituitary gland	+ + + + + + + + +	60
Pars distalis, adenoma	X X X X	28
Pars distalis, carcinoma		3
Thyroid gland	+ + + + + + + + +	60
C-cell, adenoma	X	6
C-cell, carcinoma		- 1
Follicular cell, carcinoma	X	2
General Body System None		
Genital System		
Clitoral gland	+ + + + + + + + +	60
Adenoma	X	6
Adenoma, multiple		1
Carcinoma		8

#### TABLE B2

and an analysis and and the state of the state A state of the state A state of the state - ----

Individual Animal Tumor Pathology of Female Rats in the Long-Term Feed Study of t-Butylhydroquinone: 5,000 ppm (continued)

-----

(continued)																							_				_
Number of Days on Study	5 0 1	5 7 2		9	0	1		6 2 8	-	4	5	6			9 9	) (	) 1	4	5 5	5	7	7 7 7	7 8 9		8	 	
Carcass ID Number	6 0 8	5 8 8	9	8	1	6		5 9 1	6	7	0	8			9 1	C	) 6	(	5 8	8	1	-		5 9 0	0		
Genital System (continued) Ovary	+	+	. 4	- 4	- +	- +	+	+	+	+	+	+	+	+	+ •	+ ·	+ -	<b>-</b>	+	+	+	+	+	+	+		
Granulosa cell tumor benign Uterus Adenoma	+	+	· +		- +	• +	+	+ X	+	+	+	+	+	+	+ ·	+ •	+ -		+	+	+	+	+	+	+		
Carcinoma Polyp stromal			х			x				x						2	x				x	x					
Hematopoietic System			-		_								_					-				-				 	
Bone marrow	+	+	• +	• +	- +	- +	+	+	+	+	+	+	+	+	+	+ •	+ •	F	+ ·	+	+	+	+	+	+		
Lymph node Lymph node, mandibular	т		. <b>.</b>	<b>د</b> .	. 1	+ + -	+ +	++	+	Ŧ	+	+	++	+	+	+ •	+ • + •		+ +	+	++	+	+	+++	+		
Lymph node, mesenteric	+	• +	+	+	- +	- +	+	+	+	+	+	+	+	+	+	+ ·	+ -	F	+	+	+	+	+	+	+		
Spleen	+	- +	• +	- +	- +	· +	+	+	+	+	+	+	+	+	+	+ •	+ •	⊦	+	+	+	+	+	+	+		
Thymus	+	+	• +	+	- +	- +	+	+	+	4	+	+	+	+	+	+ •	+ •	۲	+	+	+	+	+	+	+		
Integumentary System Mammary gland Adenoma	.+	• +	- 4	+	- +	- +	+	+	+	+	+	+	+	+	+	+ ·	+ •	ł	+	+	+	+	+	+	+	 	
Carcinoma																			2	х							
Carcinoma, multiple															Х												
Fibroadenoma Fibroadenoma, multiple					X		X	X								ĸ						X					
Skin Squamous cell papilloma Subcutaneous tissue, fibroma Subcutaneous tissue, fibrosarcoma Subcutaneous tissue, hemangiosarcoma Subcutaneous tissue, sarcoma Subcutaneous tissue, schwannoma malignant	+	• 4	- 4	- +	+ +	- 4	• +	+	+	+	+	+	+	+	+	₽ ·	+ -	÷	+	+	+	+	+	÷	+		
Musculoskeletal System				_		_												_		_						 	
Bone Skeletal muscle Sarcoma	+	• •	1		- 4	+ +	· +	+	+	+	+	+	+	+	+	+	+ •	ł	+	+	+	+	+	+	+		
Nervous System Brain	+		1		 ⊦ -1	+ +	• +	+	+	+	+	+	+	+	+	+	+ ·	ł		+ X	+	+	+	+	+		
Carcinoma, metastatic, mammary gland Carcinoma, metastatic, pituitary gland											+																
Carcinoma, metastatic, pituitary gland Peripheral nerve																											
Carcinoma, metastatic, pituitary gland Peripheral nerve Spinal cord											+																
														_													
Carcinoma, metastatic, pituitary gland Peripheral nerve Spinal cord Astrocytoma malignant Respiratory System Lung Alveolar/bronchiolar adenoma							 - +	 	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	· +		 	
Carcinoma, metastatic, pituitary gland Peripheral nerve Spinal cord Astrocytoma malignant Respiratory System Lung			 				• +	+	+	++	+ x +	+	+	+	+	<del></del> +	 + ·	+	+	+	+	+	+	+	 +	 	

Individual Animal Tumor Pathology of Female Rats in the Long-Term Feed Study of *t*-Butylhydroquinone: 5,000 ppm (continued)

.

(continued)																														· .
Number of Days on Study	0		1	8 3 0	8 3 1	8 3 1	8 3 9	8 4 1	8 4 5	8 5 6	8 5 8	8 6 2	8 6 9	8 7 9	8 8 8	8 9 1	8 9 1	8 9 4	8 9 7	8 9 8	8 9 8	8 9 8	8 9 8	8 9 8	8 9 8	9				
Carcass ID Number	7		6	6 0 3	0	6 1 6	6 1 9	9	5 8 4	6	5 8 9	5 9 2	5 7 1	5 7 5	5 6 7	6 0 6	6 1 0	5 7 7	5 9 9	5 7 2	5 7 3	5 7 4	5 7 8	5 8 0	5 8 3	5 8 7			÷, '	
Genital System (continued)																													۰.	
Ovary	-	ł	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		+	+	+	+	+				
Granulosa cell tumor benign Uterus	_	L	+		-	-	+	ъ	<u>ـ</u>	-	-	<u>т</u>	т.	Ъ	<u>т</u>	т.	-	-	т.	+	X +	+	-	-	-	.г.				
Adenoma		•	•	•			'	'	•	•	•	'		•	•	'	ſ	•	•	•		,		Ŧ	т	7		•	÷.	
Carcinoma																														
Polyp stromal			X																				Х					. •		
Hematopoietic System																_						_		_				· · ·		
Bone marrow	-	ł	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+				
Lymph node			+		+	+					+					+			+				+		+			• •		
Lymph node, mandibular	-	ł	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+				
Lymph node, mesenteric	. •	+	+	+	+	+	·+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	Ŧ	+	+		•		
Spleen	-	ł	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+				. •
Thymus	1	N 	+	+	M	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	_+	+	+				
Integumentary System																									:				•	,
Mammary gland	-	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+			•	
Adenoma	2	K																											,	
Carcinoma				Х			Х			•																		•		
Carcinoma, multiple																														
Fibroadenoma	2	K		Х	-	Х			Х	Х	Х					Х					Х	Х		Х	Х					
Fibroadenoma, multiple												Х	Х	Х	Х				х	Х			Х							
Skin	-	ł	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+				
Squarnous cell papilloma										х																				
Subcutaneous tissue, fibroma													X																	
Subcutaneous tissue, fibrosarcoma								x																						
Subcutaneous tissue, hemangiosarcoma Subcutaneous tissue, sarcoma								л																			,	÷		
Subcutaneous fissue, schwannoma malignant																				•				·						
		_								_			_	<u>.</u>		<u>.</u>	<u> </u>				_				<u> </u>			<u>·</u>	.*	
Musculoskeletal System Bone							,												.1						-	-				
Skeletal muscle	-	۲	Ŧ	Ŧ	Ŧ	Ŧ	· •	т	Ŧ	T	Ŧ	-	· •	· •	т	· •	т	· •	Ŧ	т	т	· •	· •	<b>т</b>	+	. т				
Sarcoma											•														x					·
					<u> </u>		<u> </u>				÷						_									<u>.</u>				
Nervous System																														
Brain		÷	+	+	+	+	• +	+	+	• +	+	· +	• +	• +	+	• +	- +	• +	• +	+	-+	.+	• •	· +	+	+				
Carcinoma, metastatic, mammary gland																							v							
Carcinoma, metastatic, pituitary gland Peripheral nerve							+							+			L						л							
Spinal cord							+							+			+													
Astrocytoma malignant							T							'												,		•	-	
Respiratory System																										<u> </u>		<u> </u>		
		+	+	+	+					+			+	. +	. +	. +	. +	• +			4	- +	- +	. 4	. +	• +				
										•	•		•	•					•	'					•	·				
Lung		•			•																									
Lung Alveolar/bronchiolar adenoma		'	•	•	-										x											,			•	
Lung		' +	+	+	• +	• +	. 4	· +	• +	- +	• +	- +	. +	• +	X +	:	• +	· +	• +	• +	· +	- 4	- +	, - 4	· +	, +			•	

Title of the Public .

10-10-1

Individual Animal Tumor Pathology of Female Rats in the Long-Term Feed Study of *t*-Butylhydroquinone: 5,000 ppm (continued)

	8 8 8 8 8 8 8 8 8	
Number of Days on Study	9 9 9 9 9 9 9 9 9	
tumber of Days on Stady	8 8 8 8 8 8 8 8 8	
	5 5 5 6 6 6 6 6 6	Total
Carcass ID Number	9 9 9 0 0 1 1 1 1 2	Tissues/
	3 4 5 4 9 1 2 3 4 0	Tumors
Genital System (continued)		
Ovary	+ + + + + + + + +	60
Granulosa cell tumor benign		1
Uterus	+ + + + + + + + +	60
Adenoma		1
Carcinoma	Х	1
Polyp stromal	x	9
Hematopoietic System		
Bone marrow	· + + + + + + + + +	60
Lymph node		18
Lymph node, mandibular	+ + + + + + + + +	60
Lymph node, mesenteric	+ + + + + + + + +	60
Spleen	+ + + + + + + + +	60
Thymus	+ + + + M + + + + +	57
Integumentary System		·····
Mammary gland	+ + + + + + + + +	60
Adenoma	X	2
Carcinoma		3
Carcinoma, multiple		1
Fibroadenoma	X X X	20
Fibroadenoma, multiple		. 7
Skin	+ + + + + + + + +	60
Squamous cell papilloma	X	2
Subcutaneous tissue, fibroma	-	- 1
Subcutaneous tissue, fibrosarcoma	X	1
Subcutaneous tissue, hemangiosarcoma		1
Subcutaneous tissue, sarcoma	X	1
Subcutaneous tissue, schwannoma malignant	X	1
 Musculoskeletal System		
Bone	+ + + + + + + + +	60
Skeletal muscle		1
Sarcoma		1
Nervous System		
Brain	+ + + + + + + + +	60
Carcinoma, metastatic, mammary gland		1
Carcinoma, metastatic, pituitary gland		1
Peripheral nerve	· ·	4
Spinal cord		4
Astrocytoma malignant		1
Respiratory System		
Lung	+ + + + + + + + +	60
Alveolar/bronchiolar adenoma	X	. 1
Carcinoma, metastatic, thyroid gland		1
Nose	+ + + + + + + + + .	60
Trachea	+ + + + + + + + +	60

.

ŝ

ŝ

Individual Animal Tumor Pathology of Female Rats in the Long-Term Feed Study of *t*-Butylhydroquinone: 5,000 ppm (continued)

												1																	
<del> </del>		5	5	5	5	6	6	6	6	6	6	6	6 <sup>·</sup>	6	6	6	6	7	7	7	7	7	7	7	7	7			_
Number of Days on Study	(	) '	7	9	9	0	1	2	2	3	4	5	6	7	7	9	9	0	1	5	5	7	7	8	8	8		· ·	
			2	1 —	6	0	3	8	8	3	0	9	6	3	3	0	1	<u> </u>	2	0	2	4		9	9	9			
	e		5	5	5	6	5	5	5	5	5	6	5 <sup>.</sup>	5	5.	5	6	6	5	5	5	6	6	5	5	-			
Carcass ID Number	6		8 8	9 7	8 6	1 7	6 8	8 1	9 1	6 6	7 0	07	8 5	6 1	9	9 6	1	0	6 3	6 9	8	1 5	0	6 2	9 0	•		:	
Special Senses System Ear Eye			-																									·	
Jrinary System		т. Т.	+ .	<u>т</u>	+	-	<u> </u>		+	<u>т</u>	+	т Т		+	+	+	+	+	+	+	+	+	-	+	+	+			
Urinary bladder Papilloma		•			•		-	•	+	•	•	+	+	+	•	•	•	+				•		+		+	:		· *
Systemic Lesions					_																					•			
Multiple organs		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		+	+	+	+		+		· ·	-
Leukemia mononuclear	2	K			Х		х							х	Λ			Χ	Χ	х		х	х	х	Х	A			

## Table B2

-11:52-5

Individual Animal Tumor Pathology of Female Rats in the Long-Term Feed Study of *t*-Butylhydroquinone: 5,000 ppm (continued)

Number of Days on Study	8       8
Carcass ID Number	5       5       6       6       5
Special Senses System Ear Eye	+ +
Urinary System Kidney Urinary bladder Papilloma	* * * + + * * + + + * * * * * * * * * *
Systemic Lesions Multiple organs Leukemia mononuclear	+ + + + + + + + + + + + + + + + + + +

165

£

Individual Animal Tumor Pathology of Female Rats in the Long-Term Feed Study of *t*-Butylhydroquinone: 5,000 ppm (continued)

(continuou)		
Number of Days on Study	8 8 8 8 8 8 8 8 8 8 8 9 9 9 9 9 9 9 9 9	
Carcass ID Number	5       5       5       6       6       6       6       6       6         9       9       0       0       1       1       1       2         3       4       5       4       9       1       2       3       4       0	Total Tissues/ Tumors
Special Senses System Ear Eye		1 1
Urinary System Kidney Urinary bladder Papilloma	+ + + + + + + + + + + + + + + + + + +	60 59 1
Systemic Lesions Multiple organs Leukernia mononuclear	+++++++++++ + + + + + + + + + + + + +	60 27

# TABLE B3

er de la subsectión de service de la subsectión de la subsectión de la subsectión de la subsectión de la subse La subsectión de la subsec Statistical Analysis of Primary Neoplasms in Female Rats in the Long-Term Feed Study of t-Butylhydroquinone

drenal Cortex: Adenoma verall rate <sup>a</sup> djusted rate <sup>b</sup> erminal rate <sup>c</sup> rst incidence (days) ife table test <sup>d</sup> ogistic regression test <sup>d</sup> ochran-Armitage test <sup>d</sup> ochran-Armitage test <sup>d</sup> isher exact test <sup>d</sup> <b>drenal Medulla: Benign Pheochromocytoma</b> verall rate djusted rate erminal rate	4/60 (7%) 25.9% 1/10 (10%) 795 P=0.007N P=0.010N P=0.020N 2/60 (3%) 16.4% 1/10 (10%) 856	1/60 (2%) 3.6% 0/11 (0%) 795 P=0.146N P=0.143N P=0.182N 2/60 (3%) 18.2%	$0/58 (0\%)  0.0\%  0/16 (0\%)  -^{c} P = 0.025N P = 0.030N P = 0.030N P = 0.064N  1/58 (2%)$	0/60 (0%) 0.0% 0/17 (0%) - P=0.019N P=0.024N P=0.059N 3/60 (5%)	
verall rate <sup>a</sup> djusted rate <sup>b</sup> erminal rate <sup>c</sup> irst incidence (days) ife table test <sup>d</sup> ogistic regression test <sup>d</sup> ochran-Armitage test <sup>d</sup> isher exact test <sup>d</sup> <b>drenal Medulla: Benign Pheochromocytoma</b> verall rate djusted rate erminal rate	25.9% $1/10 (10%)$ $795$ $P=0.007N$ $P=0.010N$ $P=0.020N$ $2/60 (3%)$ $16.4%$ $1/10 (10%)$	3.6% 0/11 (0%) 795 P=0.146N P=0.143N P=0.182N 2/60 (3%)	$\begin{array}{c} 0.0\% \\ 0/16 \ (0\%) \\ -^{c} \\ P=0.025N \\ P=0.030N \\ P=0.064N \\ 1/58 \ (2\%) \end{array}$	$0.0\% \\ 0/17 (0\%) \\ \\ P=0.019N \\ P=0.024N \\ P=0.059N$	
djusted rate <sup>b</sup> erminal rate <sup>c</sup> irst incidence (days) ife table test <sup>d</sup> ogistic regression test <sup>d</sup> ochran-Armitage test <sup>d</sup> isher exact test <sup>d</sup> <b>drenal Medulla: Benign Pheochromocytoma</b> verall rate djusted rate erminal rate	25.9% $1/10 (10%)$ $795$ $P=0.007N$ $P=0.010N$ $P=0.020N$ $2/60 (3%)$ $16.4%$ $1/10 (10%)$	3.6% 0/11 (0%) 795 P=0.146N P=0.143N P=0.182N 2/60 (3%)	$\begin{array}{c} 0.0\% \\ 0/16 \ (0\%) \\ -^{c} \\ P=0.025N \\ P=0.030N \\ P=0.064N \\ 1/58 \ (2\%) \end{array}$	$0.0\% \\ 0/17 (0\%) \\ \\ P=0.019N \\ P=0.024N \\ P=0.059N$	
erminal rate <sup>c</sup> irst incidence (days) ife table test <sup>d</sup> ogistic regression test <sup>d</sup> ochran-Armitage test <sup>d</sup> isher exact test <sup>d</sup> <b>drenal Medulla: Benign Pheochromocytoma</b> verall rate djusted rate erminal rate	1/10 (10%) 795 P=0.007N P=0.010N P=0.020N 2/60 (3%) 16.4% 1/10 (10%)	0/11 (0%) 795 P=0.146N P=0.143N P=0.182N 2/60 (3%)	0/16 (0%) $-^{e}$ P=0.025N P=0.030N P=0.064N 1/58 (2%)	0/17 (0%) P=0.019N P=0.024N P=0.059N	
irst incidence (days) ife table test <sup>d</sup> ogistic regression test <sup>d</sup> ochran-Armitage test <sup>d</sup> isher exact test <sup>d</sup> <b>drenal Medulla: Benign Pheochromocytoma</b> verall rate djusted rate erminal rate	795 P=0.007N P=0.010N P=0.020N 2/60 (3%) 16.4% 1/10 (10%)	795 P=0.146N P=0.143N P=0.182N 2/60 (3%)	P=0.025N P=0.030N P=0.064N 1/58 (2%)	P=0.019N P=0.024N P=0.059N	
ife table test <sup>d</sup> ogistic regression test <sup>d</sup> ochran-Armitage test <sup>d</sup> isher exact test <sup>d</sup> <b>drenal Medulla: Benign Pheochromocytoma</b> verall rate djusted rate erminal rate	P = 0.007N $P = 0.010N$ $P = 0.020N$ $2/60 (3%)$ $16.4%$ $1/10 (10%)$	P=0.146N P=0.143N P=0.182N 2/60 (3%)	P=0.025N P=0.030N P=0.064N 1/58 (2%)	P=0.024N P=0.059N	
ogistic regression test <sup>d</sup> ochran-Armitage test <sup>d</sup> isher exact test <sup>d</sup> <b>drenal Medulla: Benign Pheochromocytoma</b> verall rate djusted rate erminal rate	P=0.010N P=0.020N 2/60 (3%) 16.4% 1/10 (10%)	P=0.143N P=0.182N 2/60 (3%)	P=0.030N P=0.064N 1/58 (2%)	P=0.024N P=0.059N	
ochran-Armitage test <sup>d</sup> isher exact test <sup>d</sup> <b>drenal Medulla: Benign Pheochromocytoma</b> verall rate djusted rate erminal rate	P=0.020N 2/60 (3%) 16.4% 1/10 (10%)	P=0.182N 2/60 (3%)	P=0.064N 1/58 (2%)	P=0.059N	
isher exact test <sup>d</sup> drenal Medulla: Benign Pheochromocytoma verall rate djusted rate erminal rate	2/60 (3%) 16.4% 1/10 (10%)	2/60 (3%)	1/58 (2%)		
drenal Medulla: Benign Pheochromocytoma verall rate djusted rate erminal rate	16.4% 1/10 (10%)	2/60 (3%)	1/58 (2%)		
verall rate djusted rate erminal rate	16.4% 1/10 (10%)			3/60 (5%)	
djusted rate erminal rate	16.4% 1/10 (10%)			3/60 (5%)	
erminal rate	1/10 (10%)	18.2%		5/00 (570)	
			3.1%	12.3%	
		2/11 (18%)	0/16 (0%)	1/17 (6%)	
irst incidence (days)	450	898 (T)	789	750	
ife table test	P=0.567N	P=0.649N	P=0.358N	P=0.630N	
ogistic regression test	P=0.568	P=0.632N	P=0.410N	P=0.673	
ochran-Armitage test	P=0.403				
isher exact test		P=0.691N	P=0.513N	P=0.500	
drenal Medulla: Benign or Malignant Pheochromo	evtoma				
verall rate	2/60 (3%)	2/60 (3%)	1/58 (2%)	4/60 (7%)	
djusted rate	16.4%	18.2%	3.1%	16.9%	
erminal rate	1/10 (10%)		0/16 (0%)	1/17 (6%)	
irst incidence (days)	856	2/11 (18%)	789	750	
ife table test	P=0.445	898 (T) P=0.649N ·	P = 0.358N	P=0.601	
ogistic regression test					
ochran-Armitage test	P = 0.387	P=0.632N	P = 0.410N	P=0.539	
isher exact test	P=0.227	P=0.691N	P=0.513N	P=0.340	•
			1 0.51511	. 0.5.0	
litoral Gland: Adenoma					
verall rate	6/58 (10%)	6/59 (10%)	5/58 (9%)	7/60 (12%)	
djusted rate	38.3%	23.5%	22.2%	27.0%	
erminal rate	3/10 (30%)	0/10 (0%)	3/16 (19%)	2/17 (12%)	
irst incidence (days)	579	649	661	628	
ife table test	P=0.323N	P = 0.515N	P=0.275N	P=0.375N	
ogistic regression test	P=0.490N	P≈0.549N	P=0.380N	P=0.513N	
ochran-Armitage test	P=0.464				
isher exact test		P=0.607N	P=0.500N	P=0.526	
litoral Gland: Carcinoma					
overall rate	6/58 (10%)	4/59 (7%)	5/58 (9%)	8/60 (13%)	
djusted rate	43.2%	16.0%	18.8%	29.0%	
erminal rate	4/10 (40%)	1/10 (10%)	0/16 (0%)	2/17 (12%)	
irst incidence (days)	649	666	767	750	
ife table test	P=0.547N	P=0.349N	P=0.244N	P=0.465N	
ogistic regression test	P=0.403	P=0.316N	P = 0.332N	P=0.579N	
cochran-Armitage test	P = 0.258				
isher exact test		P=0.361N	P=0.500N	P=0.415	•

Statistical Analysis of Primary Neoplasms in Female Rats in the Long-Term Feed Study of t-Butylhydroquinone (continued)

, .	<b>0 ppm</b>	1,250 ppm	2,500 ppm	5,000 ppm	
Clitoral Gland: Adenoma or Carcinoma					
Overall rate	12/58 (21%)	10/59 (17%)	10/58 (17%)	14/60 (23%)	
djusted rate	74.9%	35.8%	36.8%	47.4%	
erminal rate	7/10 (70%)	1/10 (10%)	3/16 (19%)	4/17 (24%)	
irst incidence (days)	579	649	661	628	
ife table test	P=0.288N	P=0.320N	P=0.116N	P=0.248N	
ogistic regression test	P=0.519N	P = 0.309N	P=0.210N	P=0.402N	
ochran-Armitage test	P=0.338				
sher exact test		P=0.389N	P=0.407N	P=0.451	· · ·
ung: Alveolar/bronchiolar Adenoma or Carcin	oma				
verall rate	2/60 (3%)	3/60 (5%)	1/58 (2%)	1/60 (2%)	
ijusted rate	14.5%	21.9%	4.5%	5.9%	
erminal rate	1/10 (10%)	2/11 (18%)	0/16 (0%)	1/17 (6%)	
rst incidence (days)	802	831	883	898 (T)	
fe table test	P=0.124N	P=0.574	P=0.331N	P=0.316N	
gistic regression test	P=0.144N	P = 0.569	P=0.389N	P=0.350N	
ochran-Armitage test	P = 0.282N				
sher exact test		P=0.500	P=0.513N	P=0.500N	
ammary Gland: Fibroadenoma				· .	. •
verall rate	43/60 (72%)	33/60 (55%)	34/58 (59%)	27/60 (45%)	
justed rate	100.0%	96.6%	86.0%	74.4%	
rminal rate	10/10 (100%)	10/11 (91%)	11/16 (69%)	9/17 (53%)	
rst incidence (days)	418	537	600	596	
fe table test	P<0.001N	P=0.034N	P=0.004N	P<0.001N	
gistic regression test	P<0.001N	P=0.006N	P=0.009N	P<0.001N	
chran-Armitage test	P=0.005N				
sher exact test		P=0.044N	P=0.098N	P=0.003N	
lammary Gland: Adenoma					
verall rate	3/60 (5%)	0/60 (0%)	1/58 (2%)	2/60 (3%)	
ljusted rate	9.9%	0.0%	2.9%	8.6%	
rminal rate	0/10 (0%)	0/11 (0%)	0/16 (0%)	· 1/17 (6%)	
rst incidence (days)	613		774	807	
fe table test	P=0.417N	P=0.099N	P=0.240N	P=0.326N	
ogistic regression test	P=0.562N	P=0.133N	P=0.345N	P=0.503N	
ochran-Armitage test	P=0.557N				
sher exact test		P=0.122N	P=0.322N	P=0.500N	
fammary Gland: Fibroadenoma or Adenoma					
verall rate	45/60 (75%)	33/60 (55%)	34/58 (59%)	27/60 (45%)	• .
djusted rate	100.0%	96.6%	86.0%	74.4%	
erminal rate	10/10 (100%)	10/11 (91%)	11/16 (69%)	9/17 (53%)	
rst incidence (days)	418	537	600	596	
ife table test	P<0.001N	P=0.019N	P=0.002N	P<0.001N	
ogistic regression test	P<0.001N	P=0.002N	P=0.003N	P<0.001N	
ochran-Armitage test	P=0.002N				
isher exact test		P=0.017N	P=0.045N	P<0.001N	

ť

ġ

ing s

# TABLE B3

1

Statistical Analysis of Primary Neoplasms in Female Rats in the Long-Term Feed Study of t-Butylhydroquinone (continued)

	0 ppm	1,250 ppm	2,500 ppm	5,000 ppm
Aammary Gland: Carcinoma	······································			
Overail rate	8/60 (13%)	6/60 (10%)	2/58 (3%)	4/60 (7%)
Adjusted rate	29.3%	35.4%	10.8%	10.5%
erminal rate	1/10 (10%)	3/11 (27%)	0/16 (0%)	0/17 (0%)
irst incidence (days)	540	640	890	690
ife table test	P=0.029N	P=0.308N	P=0.019N	P=0.070N
ogistic regression test	P = 0.073N	P=0.345N	P = 0.042N	P = 0.177N
ochran-Armitage test	P = 0.105N	1 - 0.04011	1 - 0.04211	1 -0.17710
isher exact test	1 = 0.10510	P=0.389N	P=0.053N	P=0.181N
ammary Gland: Adenoma or Carcinoma				
verall rate	10/60 (17%)	6/60 (10%)	3/58 (5%)	6/60 (10%)
djusted rate	34.9%	35.4%	13.4%	18.2%
erminal rate	1/10 (10%)	3/11 (27%)	0/16 (0%)	1/17 (6%)
irst incidence (days)	540	640	774	690
ife table test	P=0.045N	P = 0.153N	P=0.014N	P=0.064N
ogistic regression test	P = 0.123N	P = 0.180N	P = 0.036N	P = 0.193N
ochran-Armitage test	P=0.170N			
isher exact test		P=0.211N	P=0.043N	P=0.211N
lammary Gland: Fibroadenoma, Adenoma, d	or Carcinoma			
verall rate	48/60 (80%)	34/60 (57%)	34/58 (59%)	30/60 (50%)
djusted rate	100.0%	96.6%	86.0%	76.3%
erminal rate	10/10 (100%)	10/11 (91%)	11/16 (69%)	9/17 (53%)
irst incidence (days)	418	537	600	596
ife table test	P<0.001N	P=0.011N	P<0.001N	P<0.001N
ogistic regression test	P<0.001N	P<0.001N	P<0.001N	P<0.001N
ochran-Armitage test	P = 0.002N			
sher exact test		P=0.005N	P=0.010N	P<0.001N
ral Cavity (Oral Mucosa or Tongue): Squan	ious Cell Papilloma or Squ	uamous Cell Carci	noma	
verall rate	1/60 (2%)	1/60 (2%)	3/58 (5%)	0/60 (0%)
djusted rate	10.0%	6.7%	9.6%	0.0%
erminal rate	1/10 (10%)	0/11 (0%)	1/16 (6%)	0/17 (0%)
irst incidence (days)	898 (T)	873	425	<del>_</del>
ife table test	P = 0.296N	P=0.734N	P=0.403	P=0.394N
ogistic regression test	P=0.435N	P=0.725N	P=0.258	P=0.394N
ochran-Armitage test	P=0.411N			
isher exact test		P=0.752N	P=0.297	P=0.500N
ancreatic Islets: Adenoma				
verall rate	2/60 (3%)	1/59 (2%)	3/57 (5%)	2/59 (3%)
djusted rate	11.2%	1.8%	14.4%	9.8%
erminal rate	0/10 (0%)	0/11 (0%)	1/16 (6%)	1/17 (6%)
irst incidence (days)	661	537	816	869
ife table test	P=0.487N	P=0.458N	P = 0.660N	P=0.509N
ogistic regression test	P=0.561	P=0.537N	P=0.585	P=0.609N
ochran-Armitage test	P=0.493			
ochian-Arinnage (est				

હ

Statistical Analysis of Primary Neoplasms in Female Rats in the Long-Term Feed Study of t-Butylhydroquinone (continued)

	0 ppm	1,250 ppm	2,500 ppm	5,000 ppm	
Pancreatic Islets: Adenoma or Carcinoma	· · · · · · · · · · · · · · · · · · ·				
Overall rate	2/60 (3%)	1/59 (2%)	4/57 (7%)	2/59 (3%)	
Adjusted rate	11.2%	1.8%	20.1%	9.8%	
Ferminal rate	0/10 (0%)	0/11 (0%)	2/16 (13%)	1/17 (6%)	
First incidence (days)	661	537	816	869	
life table test	P = 0.483N	P=0.458N	P = 0.556	P = 0.509N	
ogistic regression test	P=0.561	P=0.537N	P = 0.445	P = 0.609N	
Cochran-Armitage test	P = 0.469		2 0.1.0		
Fisher exact test	x - 0,109	P=0.506N	P=0.315	P=0.684	
ituitary Gland (Pars Distalis): Adenoma					
Overall rate	26/60 (43%)	27/60 (45%)	34/57 (60%)	28/60 (47%)	
Adjusted rate	80.9%	75.2%	90.7%	69.8%	
Ferminal rate	5/10 (50%)	5/11 (45%)	13/16 (81%)	7/17 (41%)	
First incidence (days)	540	480	600	501	
Life table test	P = 0.083N	P=0.408N	P=0.410N	P=0.103N	
Logistic regression test	P = 0.492N	P=0.550N	P=0.207	P=0.481N	
Cochran-Armitage test	P = 0.328				
Fisher exact test		P=0.500	P=0.057	P=0.427	
Pituitary Gland (Pars Distalis): Carcinom	a				
Overall rate	2/60 (3%)	1/60 (2%)	1/57 (2%)	3/60 (5%)	
Adjusted rate	5.0%	9.1%	6.3%	10.1%	
Cerminal rate	0/10 (0%)	1/11 (9%)	1/16 (6%)	1/17 (6%)	
First incidence (days)	540	898 (T)	898 (T)	666	
Life table test	P=0.457	P=0.483N	P=0.418N	P=0.609	
Logistic regression test	P=0.334	P = 0.504N	P=0.535N	P=0.441	
Cochran-Armitage test	P=0.324				
Fisher exact test		P = 0.500N	P=0.519N	P=0.500	
Pituitary Gland (Pars Distalis): Adenoma	or Carcinoma			• .	
Overall rate	28/60 (47%)	28/60 (47%)	35/57 (61%)	31/60 (52%)	
Adjusted rate	81.9%	79.3%	93.8%	74.0%	
Terminal rate	5/10 (50%)	6/11 (55%)	14/16 (88%)	8/17 (47%)	
First incidence (days)	540	480	600	501	
Life table test	P = 0.103N	P = 0.352N	P=0.337N	P = 0.124N	
Logistic regression test	P=0.484	P = 0.474N	P = 0.256	P=0.573	
Cochran-Armitage test	P=0.245				
Fisher exact test		P = 0.573N	P=0.079	P=0.358	
Skin (Subcutaneous Tissue): Fibroma			· · · · · · · · · · · ·		
Overall rate	3/60 (5%)	3/60 (5%)	1/58 (2%)	1/60 (2%)	
Adjusted rate	13.8%	13.5%	3.6%	4.2%	
Terminal rate	1/10 (10%)	1/11 (9%)	0/16 (0%)	0/17 (0%)	
First incidence (days)	540	498	816	869	
Life table test	P = 0.090N	P = 0.628N	P = 0.227N	P = 0.200N	
Logistic regression test	P = 0.178N	P=0.643	P = 0.329N	P=0.313N	
Cochran-Armitage test	P=0.167N			B 0.0001	
Fisher exact test		P=0.660N	P=0.322N	P = 0.309N	

•

\$

· 1

# TABLE B3

Statistical Analysis of Primary Neoplasms in Female Rats in the Long-Term Feed Study of t-Butylhydroquinone (continued)

	0 ppm	1,250 ppm	2,500 ppm	5,000 ppm	
Skin (Subcutaneous Tissue): Fibroma, Fibrosa	rcoma or Sarcoma		<u></u> .		
Overall rate	4/60 (7%)	3/60 (5%)	2/58 (3%)	3/60 (5%)	1
Adjusted rate	19.9%	13.5%	6.6%	15.4%	
Cerminal rate	1/10 (10%)	1/11 (9%)	0/16 (0%)	2/17 (12%)	
First incidence (days)	540	498	789	869	
life table test	P = 0.228N	P=0.450N	P=0.219N	P=0.279N	
ogistic regression test	P=0.382N	P=0.505N	P≈0.337N	P=0.410N	•
Cochran-Armitage test	P = 0.423N				
isher exact test		P = 0.500N	P=0.356N	P=0.500N	
hyroid Gland (C-cell): Adenoma					÷
Overall rate	7/60 (12%)	7/60 (12%)	7/57 (12%)	6/60 (10%)	
Adjusted rate	44.9%	28.1%	21.8%	24.2%	
erminal rate	4/10 (40%)	0/11 (0%)	1/16 (6%)	3/17 (18%)	
irst incidence (days)	540	669	649	633	
ife table test	P=0.156N	P=0.504N	P=0.348N	P = 0.208N	
ogistic regression test	P=0.320N	P=0.550N	P=0.566N	P = 0.351N	
Cochran-Armitage test	P=0.436N				
isher exact test		P=0.611N	P=0.571	P=0.500N	
hyroid Gland (C-cell): Adenoma or Carcinor	na -				:
Overall rate	8/60 (13%)	7/60 (12%)	9/57 (16%)	7/60 (12%)	
djusted rate	54.1%	28.1%	32.2%	27.6%	
erminal rate	5/10 (50%)	0/11 (0%)	3/16 (19%)	3/17 (18%)	
irst incidence (days)	540	669	649	633	
ife table test	P = 0.160N	P=0.393N	P=0.387N	P = 0.174N	
ogistic regression test	P=0.325N	P=0.427N	P = 0.605N	P=0.309N	
ochran-Armitage test	P = 0.492N				
isher exact test		P = 0.500N	P=0.454	P = 0.500N	
Iterus: Stromal Polyp				•	÷
verall rate	7/60 (12%)	12/60 (20%)	5/58 (9%)	9/60 (15%)	· · · · ·
djusted rate	28.7%	38.8%	19.2%	24.8%	
erminal rate	1/10 (10%)	1/11 (9%)	0/16 (0%)	2/17 (12%)	
irst incidence (days)	649	576	425	591	
ife table test	P = 0.267N	P=0.257	P = 0.195N	P=0.554N	
ogistic regression test	P=0.503	P = 0.167	P = 0.363N	P=0.388	
Cochran-Armitage test Fisher exact test	P=0.534	P=0.159	P=0.405N	P≕0.395	
		1 0.107	1 0.10010		
Jterus: Stromal Polyp or Stromal Sarcoma	9/60 (15%)	13/60 (22%)	6/58 (10%)	9/60 (15%)	. 4
Adjusted rate	34.9%	40.2%	24.2%	24.8%	.*
Ferminal rate	1/10 (10%)	1/11 (9%)	1/16 (6%)	2/17 (12%)	
First incidence (days)	302	576	425	591	
Life table test	P=0.132N	P=0.360	P=0.123N	P = 0.332N	
ogistic regression test	P = 0.431N	P = 0.227	P = 0.304N	P=0.536	
Cochran-Armitage test	P = 0.374N				2
Fisher exact test	0.07 - 11	P=0.240	P=0.316N	P = 0.601N	

Statistical Analysis of Primary Neoplasms in Female Rats in the Long-Term Feed Study of t-Butylhydroquinone (continued)

	0 ppm	1,250 ppm	2,500 ppm	5,000 ppm
All Organs: Mononuclear Cell Leukemia				· · · · · · · · · · · · · · · · · · ·
Overall rate	27/60 (45%)	33/60 (55%)	22/58 (38%)	27/60 (45%)
Adjusted rate	76.5%	79.3%	51.6%	63.2%
Ferminal rate	5/10 (50%)	4/11 (36%)	2/16 (13%)	5/17 (29%)
First incidence (days)	421	481	197	501
life table test	P=0.039N	P=0.430	P=0.064N	P=0.106N
ogistic regression test	P=0.355N	P=0.217	P=0.313N	P=0.529N
Cochran-Armitage test	P=0.346N			
Fisher exact test		P=0.181	P=0.277N	P=0.573N
All Organs: Benign Neoplasms				
Dverall rate	52/60 (87%)	51/60 (85%)	49/58 (84%)	50/60 (83%)
Adjusted rate	100.0%	100.0%	96.0%	95.8%
Ferminal rate	10/10 (100%)	11/11 (100%)	14/16 (88%)	15/17 (88%)
First incidence (days)	418	480	425	501
Life table test	P=0.005N	P = 0.251N	P=0.021N	P=0.009N
Logistic regression test	P=0.079N	P=0.225N	P=0.099N	P=0.085N
Cochran-Armitage test	P=0.354N			
Fisher exact test		P=0.500N	P=0.470N	P=0.399N
All Organs: Malignant Neoplasms				
Overall rate	41/60 (68%)	39/60 (65%)	38/58 (66%)	39/60 (65%)
Adjusted rate	100.0%	84.9%	82.2%	82.8%
Cerminal rate	10/10 (100%)	5/11 (45%)	9/16 (56%)	10/17 (59%)
First incidence (days)	302	481	197	501
Life table test	P=0.020N	P=0.246N	P=0.049N	P=0.024N
Logistic regression test	P=0.360N	P=0.374N	P=0.439N	P=0.343N
Cochran-Armitage test	P=0.412N			
fisher exact test		P=0.423N	P=0.448N	P=0.423N
All Organs: Benign or Malignant Neoplasms				
Overall rate	59/60 (98%)	59/60 (98%)	56/58 (97%)	59/60 (98%)
Adjusted rate	100.0%	100.0%	98.2%	98.3%
Terminal rate	10/10 (100%)	11/11 (100%)	15/16 (94%)	16/17 (94%)
First incidence (days)	302	480	197	501
Life table test	P=0.009N	P=0.283N	P = 0.026N	P = 0.016N
Logistic regression test	P=0.508N	P = 0.639N	P = 0.392N	P = 0.624N
Cochran-Armitage test	P=0.589N			
Fisher exact test		P=0.752N	P=0.487N	P=0.752N

(T)Terminal sacrifice

<sup>a</sup> Number of neoplasm-bearing animals/number of animals examined. Denominator is number of animals examined microscopically for adrenal gland, clitoral gland, lung, pancreatic islets, pituitary gland, thyroid gland, and uterus; for other tissues, denominator is number of animals necropsied.

<sup>b</sup> Kaplan-Meier estimated neoplasm incidence at the end of the study after adjustment for intercurrent mortality

<sup>c</sup> Observed incidence at terminal kill

<sup>d</sup> Beneath the control incidence are the P values associated with the trend test. Beneath the exposure group incidence are the P values corresponding to pairwise comparisons between the controls and that exposure group. The life table test regards neoplasms in animals dying prior to terminal kill as being (directly or indirectly) the cause of death. The logistic regression test regards these lesions as nonfatal. The Cochran-Armitage and Fisher exact tests compare directly the overall incidence rates. For all tests, a negative trend or a lower incidence in an exposure group is indicated by N.

<sup>e</sup> Not applicable; no neoplasms in animal group

## TABLE B4

Summary of the Incidence of Nonneoplastic Lesions in Female Rats in the Long-Term Feed Study of t-Butylhydroquinone<sup>a</sup>

3-Month interim evaluation         10         10         10         10         1           Moribund         40         41         33         3           Natural deaths         10         8         9         3           Survivors         10         11         16         1           Missexed         0         0         2         1           Animals examined microscopically         70         70         68         7           3-Month Interim Evaluation         Alimentary System         1         10         10           Animatic examined microscopically         70         70         68         7           3-Month Interim Evaluation         10         10         10         10           Paracise         (10)         (10)         (10)         10           Paracise         (10)         (10)         10         10           Angiectasis         1         (10%)         1         10           Paraces         (10)         (10)         10         10           Arceasory adrenal contical nodule         3         30%)         1         10           Providigand         (10)         (10)         (10)         10 </th <th>1</th> <th></th> <th>1,250 ppm</th> <th>2,500 ppm</th> <th>5,000 ppm</th>	1		1,250 ppm	2,500 ppm	5,000 ppm
numats initially in study       70		ion Summary		· · · · · · · · · · · · · · · · · · ·	
Early deaths       40       41       33       3         Natural deaths       10       8       9       3         Terminal secrifice       10       11       16       1         Missexed       0       0       2       4         Animals examined microscopically       70       70       68       7         B-Month Interim Evaluation       Alimentary System       16       1         Intestine large, rectum       (10)       (10)       (10)       (10)         Paratic metazoan       10       1       10       10         Liver       (10)       (10)       (10)       (10)       10         Animast examined microscopically       70       70       68       7         B-Month Interim Evaluation       10       10       10       10         Animest examined microscopically       70       10       10       10         Animation examine       2 (20%)       1       100       10       10         Animetary System       1       10%       1       10%       1       10         Afternal cortical nodule       3 (30%)       1       10       10       10       10       10			70	70	70
Moribund         40         41         33         3           Natural deaths         10         8         9           Terminal sacrifice         10         11         16         1           Missaced         0         0         2         1           Animal estable         0         0         2         1           Animals examined microscopically         70         70         68         7           Animestine network         (10)         (10)         (10)         (10)         (10)         (10)           Animestine network         (10)         (10)         (10)         (10)         (10)         (10)           Animestine network         (10)         (10)         (10)         (10)         (10)			10	10	10
Natural deaths         10         8         9           urvivors         10         11         16         1           Iterminal servifice         10         11         16         1           Iterminal servifice         0         0         2         1           Animals examined microscopically         70         70         68         7           P-Month Interim Evaluation         Nimentary System         10         (10)         (					
Virviors         10         11         16         1           Terminal secrifice         10         11         16         1           Missexed         0         0         2           Animals examined microscopically         70         70         68         7           P-Month Interim Evaluation         Nimentary System         10         (10)         (10)         (10)         10           Parsite metazoan         (10)         (10)         (10)         (10)         10           Angiectasis         1         1         1         1         1         1           Hepatodiaphragmatic nodule         2         (20%)         1         (10%)         1         (10)           Angreetas         (10)         (10)         (10)         (10)         (10)         (10)           Andrephy         1         (10%)         1         (10%)         1         (10%)           Accessory adrenal cortical nodule         3         (30%)         1         (10%)         1         (10%)           Phyperplasia, focal         1         (10%)         1         (10%)         1         (10%)           Thrord gland         (10)         (10)					36
Terminal sacrifice         10         11         16         1           dissexed         0         0         2         1           Animals examined microscopically         70         70         68         7 <i>R-Month Interim Evaluation</i> 1         10         10         10           Minentary System         10         10         10         10           Paratie metazoan         1         1         1         1           vier         (10)         (10)         10         10           Angictasis         1         1         1         1         1           Paratreas         (10)         (10)         10         10         10           Atcepty         1         1         1         1         1         1           Statemate cortex         (10)         (10)         10         10         10           Atcepty         1         1         10%         1         10%         1           They of gland         100         10         10         10         10         10           They of gland         1         1         1         1         1         1         1 </td <td></td> <td></td> <td>8</td> <td>9</td> <td>7</td>			8	9	7
dissexed         0         0         2           Animals examined microscopically         70         70         68         7           Immais examined microscopically         70         70         68         7           Immais examined microscopically         70         10         <					
Animals examined microscopically         70         70         68         7           P-Month Interim Evaluation         Interim Evaluation         Interim Evaluation         (10) <td< td=""><td></td><td></td><td></td><td></td><td>17</td></td<>					17
P-Month Interim Evaluation           Llimentary System           nestine large, rectum         (10)         (10)         (10)         (10)           Parasite metazoan         1         1         1           Arer (10)         (10)         (10)         (10)         (10)           Angiectasis         1         1         1         1           Hepatodiaphragmatic nodule         2 (20%)         1 (10%)         1         1           Canceras         (10)         (10)         (10)         (10)         100           Atrophy         1 (10%)         1 (10%)         1 (10%)         100         100           Caccesory adrenal cortical nodule         3 (30%)         1 (10%)         100         100         100           Para distalis, cyst         2 (20%)         1 (10%)         100         100         100           Para distalis, cyst         2 (20%)         1 (10%)         100         100         100           Ultimobranchial cyst         2 (20%)         1 (10%)         100         100         100           Storag gland         (10)         (10)         (10)         100         100         100           Inflanmation, chronic         1 (10%)			0	2	0
Alimentary System         (10) <td></td> <td>examined microscopically</td> <td>70</td> <td>68</td> <td>70</td>		examined microscopically	70	68	70
Limentary System         (10) <td></td> <td>th Interim Evaluation</td> <td></td> <td></td> <td>-<u></u></td>		th Interim Evaluation			- <u></u>
metstine large, rectum       (10)       (10)       (10)       (10)         Parasite metazoan       1       (10)       (10)       (10)       1         Angiectasis       (10)       (10)       (10)       (10)       1       (10)         Angiectasis       1       (10)       (10)       (10)       1       (10)       1       (10)         Ancreas       (10)       (10)       (10)       (10)       (10)       (10)       (10)         Antrophy       1       (10%)       1       (10%)       1       (10)       (10)         Adteral cortex       (10)       (10)       (10)       (10)       (10)       (10)       (10)         Accessory adrenal cortical nodule       3<(30%)					
Parasite metazoan       1       1       1         Aver       (10)       (10)       (10)       (10)         Angiectasis       1       1       10%       1         Hepatodiaphragmatic nodule       2       (20%)       1       (10%)       1         Ancreas       (10)       (10)       (10)       (10)       (10)         Atrophy       1       (10%)       1       (10%)       1         Chderal cortical nodule       3       (30%)       1       (10%)       1         Mdrenal cortical nodule       3       (30%)       1       (10%)       1       (10%)         Accessory adrenal cortical nodule       3       (30%)       1       (10%)       1       (10%)         Myperplasia, focal       1       (10%)       1       (10%)       1       (10%)         Pars distalis, cyst       2       (20%)       1       (10%)       1       (10)         Paroid gland       (10)       (10)       (10)       (10)       (10)       (10)       (10)         Contract gland       (10%)       (10%)       1       (10%)       1       (10)       (10)       (10)       (10)			(10)	(10)	(10)
iver       (10)       (10)       (10)       (10)       (10)       (10)         Angicctasis       1       (10)       1       (10%)       1       1       1			()	(**)	1 (10%)
Angiectasis       1       (10)       1       (10)       1       (10)       1       (10)       1       (10)       1       (10) </td <td></td> <td></td> <td>(10)</td> <td>(10)</td> <td></td>			(10)	(10)	
ancreas       (10)       (10)       (10)       (10)       (10)         Atrophy       1       (10%)       1       (10%)       (10)         Atrophy       1       (10%)       1       (10%)       (10)         Atrophy       1       (10%)       (10%)       (10)       (10)         Adrenal cortex       (10)       (10)       (10)       (10)       (10)         Accessory adrenal cortical nodule       3       (30%)       1       (10%)       1       (10%)         Hyperplasia, focal       1       (10%)       1       (10%)       (10)       (10)       (10)         Pars distalis, cyst       2       (20%)       1       (10%)       (10)       (10)       (10)         Pars distalis, cyst       2       (20%)       3       (30%)       1       (10%)         Ultimobranchial cyst       2       (20%)       3       (30%)       1       (10)         System		tasis		<	1 (10%)
ancreas       (10)       (10)       (10)       (10)       (10)         Atrophy       1       (10%)       1       (10%)       (10)         Chdocrine System	)%)	diaphragmatic nodule		1 (10%)	1 (10%)
Andocrine System drenal cortex         (10)         (10)         (10)         (10)           Accessory adrenal cortical nodule         3 (30%)         1 (10%)         1 (10%)         1 (10%)           Hyperplasia, focal         1 (10%)         1 (10%)         1 (10%)         1 (10           Pars distalis, cyst         2 (20%)         1 (10%)         1 (10%)         1 (10%)           Pars distalis, cyst         2 (20%)         1 (10%)         1 (10%)         1 (10%)           Pars distalis, cyst         2 (20%)         1 (10%)         1 (10%)         1 (10%)           Ultimobranchial cyst         2 (20%)         3 (30%)         1 (10%)         1 (10%)           Ultimobranchial cyst         2 (20%)         3 (30%)         1 (10%)         1 (10%)           Senital System         I         I (10%)         1 (10%)         1 (10%)           Inflammation, chronic         1 (10%)         (10)         (10)         (10)         (10)           Cyst         1 (10%)         1 (10%)         1 (10%)         2 (10%)         2 (10%)         2 (10%)           Hyperplasia         1 (10%)         5 (50%)         1 (10%)         2 (10%)         2 (10%)			(10)		
drenal cortex       (10)       (10)       (10)       (10)       (10)         Accessory adrenal cortical nodule       3 (30%)       1 (10%)       1 (10%)       1 (10%)         Hyperplasia, focal       1 (10%)       1 (10%)       (10)       (10)       (10)         Pars distalis, cyst       2 (20%)       1 (10%)       (10)       (10)       (10)         Pars distalis, cyst       2 (20%)       1 (10%)       (10)       (10)       (10)         Ectopic thymus       1 (10%)       1 (10%)       1 (10%)       (10)       (10)       (10)         Ultimobranchial cyst       2 (20%)       3 (30%)       1 (10%)       1 (10%)       1 (10%)         ultiral gland       (10)       (10)       (10)       (10)       (10)       (10)         Inflammation, chronic       1 (10%)       1 (10%)       1 (10%)       1 (10%)       2 (20%)         vary       (10)       (10)       (10)       (10)       (10)       (10)       (10)         Vary       (10)       (10)       (10)       (10)       (10)       (10)       (10)         Vary       (10)       (10)       (10)       (10)       (10)       (10)       (10)         Var		<b>у</b>			
Accessory adrenal cortical nodule       3 (30%)       1 (10%)       1 (10%)         Hyperplasia, focal       1 (10%)       1 (10%)       1 (10%)         itnitary gland       (10)       (10)       (10)       (10)         Pars distalis, cyst       2 (20%)       1 (10%)       1 (10%)         hyroid gland       (10)       (10)       (10)       (10)         Ectopic thymus       1 (10%)       1 (10%)       1 (10%)         Ultimobranchial cyst       2 (20%)       3 (30%)       1 (10         Senital System       1 (10%)       1 (10%)       1 (10%)         Ultimobranchial cyst       2 (20%)       3 (30%)       1 (10%)         Vary       (10)       (10)       (10)       (10)         Vary       (10)       (10)       (10)       (10)         Vary       (10)       (10)       (10)       (10)         Hydrometra       1 (10%)       5 (50%)       1 (10%)       2 (20%)         Hydrometra       1 (10%)       5 (50%)       1 (10%)       2 (20%)         Hydrometra       1 (10%)       1 (10%)       1 (10%)       2 (20%)         Juftamation, granulomatous       1 (10%)       1 (10%)       1 (10%)         <		ne System		······································	
Accessory adrenal cortical nodule       3 (30%)       1 (10%)       1 (10%)         Hyperplasia, focal       1 (10%)       1 (10%)       (10)       (10)         ituitary gland       (10)       (10)       (10)       (10)       (10)         Pars distalis, cyst       2 (20%)       1 (10%)       (10)       (10)       (10)         Ectopic thymus       1 (10%)       1 (10%)       1 (10%)       (10)       (10)       (10)         Ultimobranchial cyst       2 (20%)       3 (30%)       1 (10%)       1 (10%)       1 (10%)         Cenital System         Clitoral gland       (10)       (10)       (10)       (10)       (10)         Inflammation, chronic       1 (10%)       1 (10%)       1 (10%)       1 (10%)         Vary       (10)       (10)       (10)       (10)       (10)         Itrus       (10)       (10)       (10)       (10)       1 (10%)       2         Verst       1 (10%)       5 (50%)       1 (10%)       2       2       2       2       2       1 (10%)       2       1 (10%)       2       1 (10%)       2       1 (10%)       1 (10%)       2       1 (10%)       2       2       2		cortex	(10)	(10)	(10)
Hyperplasia, focal       1 (10%)       1 (10%)         inuitary gland       (10)       (10)       (10)         Pars distalis, cyst       2 (20%)       1 (10%)         hyroid gland       (10)       (10)       (10)         hyroid gland       (10)       (10)       (10)       (10)         byroid gland       (10)       (10)       (10)       (10)         Ultimobranchial cyst       2 (20%)       3 (30%)       1 (10%)         Cenital System         Clitoral gland       (10)       (10)       (10)       (10)         Inflammation, chronic       1 (10%)       1       (10)       (10)       (10)         Vary       (10)       (10)       (10)       (10)       (10)       (10)         Vary       (10)       (10)       (10)       (10)       (10)       (10)         Vary       (10)       (10)       (10)       (10)       (10)       (10)         Hermatopoietic System       I       I       I       I       I       I       I         Kone marrow       (10)       (10)       (10)       (10)       (10)       I       I         Lymph node, mandibular	)%)	ory adrenal cortical nodule			1 (10%)
Pars distalis, cyst       2 (20%)       1 (10%)         hyroid gland       (10)       (10)       (10)         Ectopic thymus       1 (10%)       1 (10%)         Ultimobranchial cyst       2 (20%)       3 (30%)       1 (10%)         Senital System       2 (20%)       3 (30%)       1 (10%)         Senital System	)%)	olasia, focal	1 (10%)		
hyroid gland       (10)       (10)       (10)       (10)       (10)         Ectopic thymus       1 (10%)       1 (10%)       1 (10%)       1 (10%)         Ultimobranchial cyst       2 (20%)       3 (30%)       1 (         Senital System       3 (30%)       1 (         Chital gland       (10)       (10)       (10)       (10)         Inflammation, chronic       1 (10%)       (10)       (10)       (10)         Ovary       (10)       (10)       (10)       (10)       (10)         Cyst       1 (10%)       1 (10%)       1 (10%)       1 (10%)         Iterus       (10)       (10)       (10)       (10)       (10)         Hematopoietic System       1 (10%)       5 (50%)       1 (10%)       2 (10)         Jone marrow       (10)       (10)       (10)       (10)       (10)         Inflammation, granulomatous       1 (10%)       1 (10%)       1 (10%)       (10)				(10)	(10)
Ectopic thymus       1 (10%)       1 (10%)         Ultimobranchial cyst       2 (20%)       3 (30%)       1 (10%)         Senital System       1 (10)       (10)       (10)       (10)         Litoral gland       (10)       (10)       (10)       (10)       (10)         Inflammation, chronic       1 (10%)       (10)       (10)       (10)       (10)         Vary       (10)       (10)       (10)       (10)       (10)       (10)         Cyst       1 (10%)       1 (10%)       1 (10%)       1 (10%)       1 (10%)       2 (10)         Hematopoietic System       1 (10%)       5 (50%)       1 (10%)       2 (10)       (10)       (10)       (10)         Inflammation, granulomatous       1 (10)       (10)       (10)       (10)       (10)       (10)       (10)         Lymph node, mandibular       (10)       (10)       (10)       (10)       (10)       (10)	)%)				
Ultimobranchial cyst       2 (20%)       3 (30%)       1 (         Senital System			(10)		(10)
Genital System         (10)					
litoral gland       (10)       (10)       (10)       (10)         Inflammation, chronic       1 (10%)       (10)       (10)       (10)         Ivary       (10)       (10)       (10)       (10)       (10)         Cyst       1 (10%)       1 (10%)       1 (10)       (10)         Hydrometra       1 (10%)       5 (50%)       1 (10%)       2 (10)         Lematopoietic System       0       (10)       (10)       (10)       (10)         Inflammation, granulomatous       1 (10)       (10)       (10)       (10)       (10)         ymph node, mandibular       (10)       (10)       (10)       (10)       (10)	)%)	branchial cyst		3 (30%)	1 (10%)
Inflammation, chronic       1 (10%)         Ovary       (10)       (10)       (10)         Cyst       1 (10%)       1 (10%)       1 (10%)         Jterus       (10)       (10)       (10)       (10)         Hydrometra       1 (10%)       5 (50%)       1 (10%)       2 (10)         Hematopoietic System       1 (10%)       5 (50%)       1 (10%)       2 (10)         Just System       1 (10%)       1 (10%)       1 (10%)       2 (10)         Just System       1 (10%)       1 (10%)       1 (10%)       1 (10%)         Just System       1 (10)       1 (10)       1 (10%)       1 (10%)         Just System       1 (10)       1 (10%)       1 (10%)       1 (10%)         Just System       1 (10)       1 (10%)       1 (10%)       1 (10%)         Just System       1 (10)       1 (10)       1 (10%)       1 (10%)         Just System       1 (10%)       1 (10%)       1 (10%)       1 (10%)					
Ovary       (10)       (10)       (10)       (10)         Cyst       1       (10%)       1       (10%)       1         Jterus       (10)       (10)       (10)       (10)       (10)         Hydrometra       1       (10%)       5       (50%)       1       (10%)       2         Lematopoietic System       Image: System			(10)	(10)	(10)
Cyst       1 (10%)       1 (10%)       1 (10%)         Jterus       (10)       (10)       (10)       (10)         Hydrometra       1 (10%)       5 (50%)       1 (10%)       2 (10%)         Hematopoietic System       Image: Constraint of the system       Image: Constraint of the system       Image: Constraint of the system         Hematopoietic System       Image: Constraint of the system       Image: Constraint of the system       Image: Constraint of the system         Hematopoietic System       Image: Constraint of the system       Image: Constraint of the system       Image: Constraint of the system         Hematopoietic System       Image: Constraint of the system       Image: Constraint of the system       Image: Constraint of the system         Hematopoietic System       Image: Constraint of the system       Image: Constraint of the system       Image: Constraint of the system         Hematopoietic System       Image: Constraint of the system       Image: Constraint of the system       Image: Constraint of the system         Hematopoietic System       Image: Constraint of the system       Image: Constraint of the system       Image: Constraint of the system         Just of the system       Image: Constraint of the system       Image: Constraint of the system       Image: Constraint of the system         Just of the system       Image: Constraint of the system       Im	J%)	mation, chronic	(10)		(10)
Jterus       (10)       (10)       (10)       (10)         Hydrometra       1       (10%)       5       (50%)       1       (10%)       2         Hematopoietic System         Bone marrow       (10)       (10)       (10)       (10)       (10)         Inflammation, granulomatous       1       (10%)       1       (10%)         Lymph node, mandibular       (10)       (10)       (10)       (10)			(10)		
Hydrometra     1 (10%)     5 (50%)     1 (10%)     2 (10%)       Jematopoietic System       Bone marrow     (10)     (10)     (10)     (10)       Inflammation, granulomatous     1 (10%)     1 (10%)       .ymph node, mandibular     (10)     (10)     (10)			(10)		1 (10%)
Jematopoietic SystemBone marrow(10)(10)(10)Inflammation, granulomatous1(10%).ymph node, mandibular(10)(10)(10)	1%)	metra			(10) 2 (20%)
Bone marrow         (10)         (10)         (10)         (10)         (10)           Inflammation, granulomatous         1         100         1         100         100           ymph node, mandibular         (10)         (10)         (10)         (10)         (10)			5 (50%)	1 (1070)	2 (20%)
Inflammation, granulomatous 1 (10%) ymph node, mandibular (10) (10) (10) (10)					, the second sec
ymph node, mandibular (10) (10) (10) (10)			(10)		(10)
			(10)		(10)
	0.01				
	070)	Thage			2 (20%)
Spleen         (10)         (10)         (10)         (10)         (10)           Pigmentation, hemosiderin         5 (50%)         7 (70%)         8 (80%)         10	0%)	ntation hemosiderin			(10) 10 (100%)

<sup>a</sup> Number of animals examined microscopically at the site and the number of animals with lesion

# TABLE B4

Summary of the Incidence of Nonneoplastic Lesions in Female Rats in the Long-Term Feed Study of *t*-Butylhydroquinone (continued)

	<b>0 ppm</b>	1,250 ppm	2,500 ppm	5,000 ppm
3-Month Interim Evaluation	<b>On</b> (continued)		·······	
Respiratory System				
Lung	(10)	(10)	· (10)	(10)
Infiltration cellular, histiocyte		1 (10%)		<b>~&gt;</b>
Inflammation, subacute	4 (40%)	1 (10%)	3 (30%)	2 (20%)
Alveolar epithelium, hyperplasia	1 (10%)	1 (10%)		1 (10%)
lose	(10)	(10)	(10)	(10)
Inflammation, suppurative	•	1 (10%)		
Goblet cell, hyperplasia				1 (10%)
Jrinary System				
lidney	(10)	(10)	(10)	(10)
Cyst	(10)	(10)		1 (10%)
Mineralization	10 (100%)	10 (100%)	10 (100%)	10 (100%)
ntegumentary System Ausculoskeletal System Jervous System pecial Senses System Cong-Term Study				
limentary System			1 -	
sophagus	(58)	(60)	(57)	(60)
Epithelium, hyperplasia	(30)	1 (2%)		
ntestine large, colon	(60)	(59)	(56)	(59)
Edema	• • • • •			1 (2%)
Parasite metazoan Ulcer	6 (10%)	4 (7%)	4 (7%)	5 (8%) 1 (2%)
ntestine large, rectum	(59)	(59)	(57)	(59)
Edema	1 (2%)			
Parasite metazoan	2 (3%)	2 (3%)	6 (11%)	8 (14%)
ntestine large, cecum	(60)	(60)	(57)	(60)
Edema		2 (3%)	1 (2%)	2 (3%)
Parasite metazoan	2 (3%)	1 (2%)	3 (5%)	(0)
ntestine small, duodenum	<b>(59)</b>	(60)	(57)	(60)
Erosion		1 (2%)	1 (2.4)	
Epithelium, hyperplasia		1 (2%)	1 (2%)	(58)
		(58)	(57)	(50)
ntestine small, ileum	(60)	(55)	1 (2%)	
Intestine small, ileum Inflammation, chronic active Epithelium, hyperplasia	(60)	(30)	1 (2%) 1 (2%)	

a second s

174

ų č

# Table B4

æ

·····

Summary of the Incidence of Nonneoplastic Lesions in Female Rats in the Long-Term Feed Study of *t*-Butylhydroquinone (continued)

	Q F	pm	1,2	50 ppm	2,50	0 ppm	5,00	00 ppm
Long-Term Study (continued)								
Alimentary System (continued)								
Liver	(60)		(60)		(58)		(60)	•
Angiectasis		(2%)		(3%)		(2%)		(2%)
Basophilic focus		(43%)		(52%)		(53%)		(48%)
Clear cell focus		(3%)	51	(5270)		(7%) ·		(8%)
Degeneration, cystic		(2%)			. *	(1,10)		(2%)
Eosinophilic focus		(17%)	13	(22%)	12	(21%)		(28%)
Eosinophilic focus, multiple		(1, ,,,)	15	(2270)	12	(2170)		(2%)
Hematopoietic cell proliferation	1	(2%)			1	(2%)		(3%)
Hemorrhage	-	(= / )	,			(7%)	2	(570)
Hepatodiaphragmatic nodule	12	(20%)	10	(17%)		(14%)	18	(30%)
Inflammation, granulomatous		(20%)		(15%)		(16%)		(17%)
Mixed cell focus		(3%)		(10%)		(14%)		(12%)
Necrosis, focal		(10%)		(5%)		(9%)		(5%)
Bile duct, cyst		<b>、</b>		()		(2%)		(2%)
Bile duct, hyperplasia	17	(28%)	20	(33%)		(31%)		(40%)
Centrilobular, necrosis						()		(2%)
Hepatocyte, vacuolization cytoplasmic	14	(23%)	14	(23%)	9	(16%)	<b>*</b> .	(5%)
Kupffer cell, pigmentation	12	(20%)		(23%)		(12%)		(15%)
Mesentery	(11)		(13)		(10)	()	(7)	()
Accessory spleen	1	(9%)		(8%)				(29%)
Fat, necrosis	9	(82%)	12	(92%)	8	(80%)		(71%)
Pancreas	(60)		(60)		(57)	•	(59)	
Atrophy	20	(33%)	21	(35%)		(23%)		(22%)
Metaplasia, hepatocyte	1	(2%)						
Acinus, cytoplasmic alteration			. 1	(2%)		•	1	(2%)
Acinus, hyperplasia, focal			·. 1	(2%)	2	(4%)		
Salivary glands	(60)		(60)		(58)		(60)	
Atrophy		(3%)			1	(2%)		
Stomach, forestomach	(60)		(60)		(57)		(60)	
Edema		(7%)	3	(5%)	4	(7%)		
Erosion	1	(2%)					1	(2%)
Hyperplasia						(2%)		(2%)
Ulcer		(3%)		(7%)		(5%)		(3%)
Mucosa, hyperplasia		(8%)		(15%)		(14%)		(8%)
Stomach, glandular	(60)		(60)		(57)		(60)	4
Edema		(2%)		(2%)		(4%)		,
Erosion		(5%)		(3%)		(11%)	2	(3%)
Ulcer		(3%)		(7%)		(2%)		
Tongue	(1)		(1)		(4)		(1)	
Epithelium, hyperplasia					2	(50%)	1	(100%)
Cardiovascular System								
Heart	(60)		(60)		(58)		(60)	
Cardiomyopathy		(47%)		(53%)		(45%)		(47%)
Thrombosis		(5%)		(5%)	20	(	20	( <b>( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( </b>
Valve, inflammation, chronic		(2%)	-					

2

.

.

÷

## TABLE B4

Summary of the Incidence of Nonneoplastic Lesions in Female Rats in the Long-Term Feed Study of *t*-Butylhydroquinone (continued)

	0 ppm	1,250 ppm		2,500 ppm	5,000 ppm
Long-Term Study (continued)	-				
Endocrine System					
Adrenal cortex	(60)	(60)		(60)	
Accessory adrenal cortical nodule	11 (18%)	14 (23%)		(58)	(60)
Atrophy	1 (2%)	14 (23%)		9 (16%)	9 (15%)
Degeneration, fatty	9 (15%)	16 (27%)		17 (200)	12 (20 00)
Hemorrhage	1 (2%)	10 (27%)		17 (29%) 2 (3%)	12 (20%)
Hyperplasia, diffuse	3 (5%)	1 (2%)		1 (2%)	1 (2%)
Hyperplasia, focal	3 (5%)	6 (10%)			1 (2%)
Hypertrophy, focal	• •	· · ·		4 (7%)	2 (3%)
Metaplasia, osseous	9 (15%)	6 (10%)		4 (7%)	7 (12%)
Necrosis		a (ag)		1 (2%)	
Adrenal medulla	(60)	2 (3%)		1 (2%)	
	. (60)	(60)		(58)	(60)
Hyperplasia	5 (8%)	11 (18%)		7 (12%)	7 (12%)
slets, pancreatic	(60)	(59)		(57)	(59)
Hyperplasia	1 (2%)				
Parathyroid gland	(52)	(55)		(53)	(54)
Hyperplasia	1 (2%)			1 (2%)	. 1 (2%)
Pituitary gland	(60)	(60)		(57)	(60)
Pars distalis, angiectasis	8 (13%)	3 (5%)		6 (11%)	7 (12%)
Pars distalis, cyst	14 (23%)	24 (40%)		17 (30%)	19 (32%)
Pars distalis, hyperplasia, focal	9 (15%)	15 (25%)		1 (2%)	9 (15%)
Pars intermedia, angiectasis		2 (3%)			
Pars intermedia, cyst	2 (3%)	5 (8%)		4 (7%)	3 (5%)
Thyroid gland	(60)	(60)		(57)	(60)
Ultimobranchial cyst	2 (3%)			1 (2%)	1 (2%)
C-cell, hyperplasia	8 (13%)	9 (15%)	•	3 (5%)	8 (13%)
Follicle, cyst	1 (2%)			2 (4%)	1 (2%)
Follicular cell, hyperplasia		· .			1 (2%)
General Body System None					
Genital System		- <del>.</del>			· · · · · · · · · · · · · · · · · · ·
Clitoral gland	(58)	(59)		(58)	(60)
Cyst	2 (3%)	7 (12%)		6 (10%)	5 (8%)
Cyst, multiple	1 (2%)	. ( /v)		- ()	- ()
Hyperplasia	3 (5%)	6 (10%)		3 (5%)	4 (7%)
Inflammation, chronic	2 (3%)	2 (3%)		2 (3%)	2 (3%)
Inflammation, suppurative	2 (3%)	3 (5%)	*	3 (5%)	1 (2%)
Dvary	(60)	(60)	n. •	(57)	(60)
Cyst	17 (28%)	11 (18%)		18 (32%)	17 (28%)
Uterus	(60)	(60)		(58)	(60)
Hydrometra	3 (5%)	5 (8%)		3 (5%)	7 (12%)
Hyperplasia, cystic	4 (7%)	5 (8%)		2 (3%)	3 (5%)
Cervix, hypertrophy	+ (1/0)	5 (070)		1 (2%)	0 (0/0)

• • • • •

.

## TABLE B4

1. Here<sup>1</sup> for a statistical metric statistics in the statistical states for a statistic states and the statistic states and the states of a state of the states of the

Summary of the Incidence of Nonneoplastic Lesions in Female Rats in the Long-Term Feed Study of *i*-Butylhydroquinone (continued)

	0 p	pm	1,2	50 ppm	2,50	0 ppm	5,00	0 ppm	
Long-Term Study (continued)									
Hematopoietic System									
Bone marrow	(60)		(60)		(57)		(60)		
Depletion cellular		(30)	(60)			(39)	(00)		
•	1	(2%)			1	(2%)		(30)	
Fibrosis		( <b>a M</b> )					1	(2%)	
Hyperplasia	1	(2%)							
Infiltration cellular, histiocyte	_					(2%)			
Myelofibrosis		(3%)		(7%)		(2%)		(5%)	
Lymph node	(20)		(24)		(19)		(18)		
Hyperplasia, lymphoid			1	(4%)					
Inguinal, ectasia					1	(5%)			
Inguinal, hemorrhage					1	(5%)			
Inguinal, hyperplasia, lymphoid						(5%)			
Mediastinal, ectasia	1	(5%)				·			
Mediastinal, hemorrhage		(15%)	1	(4%)	7	(37%)			
Mediastinal, hyperplasia, lymphoid		(5%)	-						
Mediastinal, pigmentation		(70%)	9	(38%)	11	(58%)	6	(33%)	
Pancreatic, hemorrhage				(20.0)		(5%)	0	(20,0)	
Pancreatic, pigmentation	1	(5%)	6	(25%)		(21%)	4	(22%)	
Renal, hemorrhage	•	(570)	0	(2570)	-	(21 /0)		(11%)	
Renal, pigmentation	•	(5%)	2	(8%)				,	
Lymph node, mandibular		(370)		(0/0)	155			(39%)	
Ectasia	(59)	(20)	(60)	(20)	(55)	(7)(1)	(60)	(0)(())	
		(3%) (5%)		(3%)		(7%)	• 1	(2%)	
Hemorrhage		(5%)		(3%)		(5%)	_	(1.0.01)	
Hyperplasia, lymphoid		(22%)	9	(15%)	14	(25%)		(12%)	
Hyperplasia, plasma cell		(2%)			-			(2%)	
Pigmentation		(34%)		(32%)		(47%)		(42%)	
Lymph node, mesenteric	(58)		(60)		(55)		(60)		
Ectasia	2	(3%)		(3%)	2	(4%)	2	(3%)	
Hemorrhage				(2%)	9	(16%)	7	(12%)	
Hyperplasia, lymphoid	2	(3%)	2	(3%)	3	(5%)	4	(7%)	
Pigmentation					1	(2%)	1	(2%)	•
Spleen	(60)		(60)		(57)		(60)		
Fibrosis		(5%)		(8%)		(5%)	• •	(5%)	
Hematopoietic cell proliferation		(25%)		(20%)		(30%)		(18%)	
Hemorrhage								(2%)	
Hyperplasia, lymphoid								(2%)	
Metaplasia, lipocyte								(2%)	
Necrosis			2	(3%)	2	(4%)		(2%)	
Pigmentation, hemosiderin	<b>7</b> 4	(40%)		(45%)		(58%)		(68%)	
Lymphoid follicle, atrophy		(2%)		(2%)	55	(00,0)	41	(00/0)	
Red pulp, atrophy		(2%)	1	(270)			1	(2%)	
	۱ <del>سیستحد میں م</del>	(~ /0 ) 			<u></u>	<u> </u>	I	( <i>e 1</i> 0 )	
Integumentary System									
Mammary gland	(60)		(59)		(58)		(60)		
Dilatation	• •	(62%)		(81%)		(67%)		(57%)	
Galactocele		(8%)		(7%)		(2%)		(8%)	
Hyperplasia		(20%)		(10%)		(19%)		(25%)	
Inflammation, suppurative			. *			·····		(2%)	

÷.,

Summary of the Incidence of Nonneoplastic Lesions in Female Rats in the Long-Term Feed Study of *t*-Butylhydroquinone (continued)

	0 ppm	1,250 ppm	2,500 ppm	5,000 ppm
Cong-Term Study (continued)				· · ·
				÷
Integumentary System (continued)	((0))	((0))	(59)	((0))
Skin	(60)	(60)	(58)	(60)
Cyst epithelial inclusion	1 (2%)			1 (2%)
Hyperkeratosis	1 (2%)			
Inflammation, chronic	1 (2%)		4 (0.01)	
Ulcer		1 (2%)	1 (2%)	2 (3%)
Epidermis, hyperplasia	1 (2%)		2 (3%)	2 (3%)
Ausculoskeletal System				
Bone	(60)	(59)	(58)	(60)
Fibrous osteodystrophy	(,	<u> </u>	1 (2%)	1 (2%)
Hyperostosis	· · ·			1 (2%)
Cranium, osteopetrosis	8 (13%)	9 (15%)	6 (10%)	9 (15%)
Femur, osteopetrosis	9 (15%)	10 (17%)	6 (10%)	5 (8%)
Skeletal muscle	(1)	(1)	(1)	(1)
Hemorrhage	(•)	1 (100%)		
Nervous System				
Brain	(60)	(60)	(58)	(60)
Atrophy	19 (32%)	20 (33%)	25 (43%)	22 (37%)
Hemorrhage				1 (2%)
Hydrocephalus	4 (7%)	1 (2%)	3 (5%)	8 (13%)
Necrosis		1 (2%)	1 (2%)	
Respiratory System			· ·	
Lung	(60)	(60)	(58)	(60)
Congestion	1 (2%)	(00)	(50)	(00)
Edema	1 (2)0)	1 (2%)		
Hemorrhage	2 (3%)	1 (2%)	1 (2%)	2 (3%)
Infiltration cellular, histiocyte	28 (47%)	23 (38%)	30 (52%)	23 (38%)
Inflammation, subacute	3 (5%)	(00,0)		
Thrombosis	1 (2%)			
Alveolar epithelium, hyperplasia	4 (7%)	4 (7%)	2 (3%)	4 (7%)
Nose	(60)	(60)	(58)	(60)
Foreign body	3 (5%)	(00)	3 (5%)	
Inflammation, suppurative	5 (8%)	1 (2%)	11 (19%)	3 (5%)
Goblet cell, hyperplasia	10 (17%)	2 (3%)	3 (5%)	6 (10%)
Mucosa, hyperplasia	5 (8%)	1 (2%)	12 (21%)	1 (2%)
Mucosa, myperplasia Mucosa, metaplasia, squamous	3 (5%)		4 (7%)	<u> </u>
	5 (570)			
Special Senses System				
Eye	(4)	(1)	(3)	(1)
Cataract	3 (75%)	1 (100%)	3 (100%)	1 (100%)
Hemorrhage	1 (25%)		1 (33%)	
Inflammation, chronic			1 (33%)	
Retina, degeneration	4 (100%)	1 (100%)	3 (100%)	1 (100%)

Summary of the Incidence of Nonneoplastic Lesions in Female Rats in the Long-Term Feed Study of *t*-Butylhydroquinone (continued)

	0 pj	pm	1,2	50 ppm	2,50	0 ppm	5,00	0 ppm
Long-Term Study (continued)				<u></u>			<u> </u>	
Urinary System								
Kidney	(60)		(60)		(57)		(60)	
Cyst	()		• •	(2%)	(2.)			(3%)
Hydronephrosis				(2%)				()
Inflammation, chronic	1	(2%)		(2%)	3	(5%)	.5	(8%)
Inflammation, suppurative	2	(3%)	1	(2%)				
Mineralization	57	(95%)	56	(93%)	44	(77%)	48	(80%)
Nephropathy	37	(62%)	38	(63%)	37	(65%)	39	(65%)
Renal tubule, atrophy	1	(2%)	4	(7%)		• •	5	(8%)
Renal tubule, cytoplasmic alteration	5	(8%)	• 3	(5%)	4	(7%)	2	(3%)
Renal tubule, dilatation					1	(2%)	1	(2%)
Renal tubule, necrosis	• 2	(3%)	1	(2%)	1	(2%)	2	(3%)
Renal tubule, pigmentation	15	(25%)	16	(27%)	11	(19%)	16	(27%)
Transitional epithelium, hyperplasia	2	(3%)	2	(3%)	6	(11%)		(5%)
Urinary bladder	(59)		(60)		(58)		(59)	
Transitional epithelium, hyperplasia				(2%)		(2%)		(3%)

ę

۰.
# APPENDIX C SUMMARY OF LESIONS IN MALE MICE IN THE 2-YEAR FEED STUDY OF &BUTYLHYDROQUINONE

Table C1	Summary of the Incidence of Neoplasms in Male Mice	
	in the 2-Year Feed Study of t-Butylhydroquinone	182
Table C2	Individual Animal Tumor Pathology of Male Mice	
	in the 2-Year Feed Study of t-Butylhydroquinone	186
Table C3	Statistical Analysis of Primary Neoplasms in Male Mice	
	in the 2-Year Feed Study of <i>t</i> -Butylhydroquinone	208
TABLE C4a	Historical Incidence of Hepatocellular Neoplasms in Untreated Male B6C3F, Mice	212
Table C4b	Historical Incidence of Spleen Hemangiosarcoma in Untreated Male B6C3F, Mice	212
TABLE C4c	Historical Incidence of Hemangioma and Hemangiosarcoma	
	in Untreated Male B6C3F <sub>1</sub> Mice	212
Table C5	Summary of the Incidence of Nonneoplastic Lesions in Male Mice	
	in the 2-Year Feed Study of t-Butylhydroquinone	213

# Summary of the Incidence of Neoplasms in Male Mice in the 2-Year Feed Study of t-Butylhydroquinone<sup>a</sup>

	0 ppm	1,250 ppm	2,500 ppm	5,000 ppm
Disposition Summary				
Animals initially in study	60	60	60	60
15-Month interim evaluation	10	10	9	9
Early deaths				
Accidental death	1			
Moribund	6	3	7	7
Natural deaths	4	1 *	6	2
Survivors				
Terminal sacrifice	39	46	38	42
Animals examined microscopically	60	60	60	60
15-Month Interim Evaluation	<u> </u>			
Alimentary System				,
ntestine small, jejunum	(10)	(10)	(9)	
Liver	(10)	(10)	(9)	(9) (9)
Hepatocellular carcinoma	(10)	(10)	())	1 (11%)
Hepatocellular adenoma	1 (10%)	1 (10%)	1 (11%)	- ()
Endocrine System		· · · · · · · · · · · · · · · · · · ·		<u> </u>
Thyroid gland	(10)	(10)	(9)	(9)
Follicular cell, adenoma	(10)	(10)	1 (11%)	(*)
		· · · · · · · · · · · · · · · · · · ·		<u></u>
Respiratory System	(10)	(10)		(9)
Lung Alveolar/bronchiolar adenoma	(10)	(10) 1 (10%)	(9) 2 (22%)	1 (11%)
Aiveolar/oronchiolar adenoma			2 (22 %)	I (II%)
Systemic Lesions	· · · ·	· ·		:* · · · · ·
Multiple organs <sup>b</sup>	(10)	(10)	(9)	(9)
Lymphoma malignant				1 (11%)

Cardiovascular System General Body System Genital System

ц,

Hematopoietic System Integumentary System Musculoskeletal System Nervous System Special Senses System Urinary System

# Table C1

Summary of the Incidence of Neoplasms in Male Mice in the 2-Year Feed Study of t-Butylhydroquinone (continued)

- 11

-

Ţ

贫

	0 ppm	1,250 ppm	2,500 ppm	5,000 ppm
2-Year Study				
Alimentary System				
Intestine small, jejunum	(50)	(50)	(48)	(50)
Carcinoma	(00)	1 (2%)	3 (6%)	(50)
Intestine small, ileum	(49)	(49)	(49)	(49)
Carcinoma	1 (2%)	(12)	(13)	(1)
Liver	(50)	(50)	(51)	(51)
Hemangioma	1 (2%)	(50)	(31)	(51)
Hemangiosarcoma	1 (2%)	1 (2%)	1 (2%)	1 (2%)
Hemangiosarcoma, multiple	2 (4%)	(2,0)	1 (270)	1 (2%)
Hepatocellular carcinoma	5 (10%)	9 (18%)	8 (16%)	7 (14%)
Hepatocellular carcinoma, multiple	3 (6%)	2 (4%)	4 (8%)	1 (2%)
Hepatocellular adenoma	21 (42%)	14 (28%)	17 (33%)	11 (22%)
Hepatocellular adenoma, multiple	7 (14%)	8 (16%)	5 (10%)	3 (6%)
Histiocytic sarcoma	/ (1+/0)	8 (10%)	2 (4%)	5 (070)
Mesentery	(2)	(7)	(14)	(1)
Histiocytic sarcoma	(2)	1 (14%)	2 (14%)	(1)
Pancreas	(49)	(50)	(51)	(51)
Histiocytic sarcoma	(+))	1 (2%)	(51)	(51)
Stomach, forestomach	(49)	(50)	(51)	(51)
Squamous cell papilloma	(49)	1 (2%)	1 (2%)	(31)
Stomach, glandular	(49)			
Carcinoid tumor benign	(49)	(50)	(51)	(50)
		1 (2%)		
Cardiovascular System				
Heart	(50)	(50)	(51)	(51)
Hemangiosarcoma	1 (2%)			
Histiocytic sarcoma			1 (2%)	· · · · · ·
Endocrine System				
Adrenal cortex	(50)	(50)	(50)	(51)
Subcapsular, adenoma	1 (2%)	4 (8%)	1 (2%)	2 (4%)
Islets, pancreatic	(50)	(50)	(51)	(51)
Adenoma	1 (2%)	1 (2%)	x/	2 (4%)
Parathyroid gland	(49)	(46)	(50)	(44)
Adenoma	()	(,	(20)	1 (2%)
Pituitary gland	(46)	(42)	(45)	(49)
Pars distalis, adenoma	1 (2%)		N /	··· /
Thyroid gland	(50)	(50)	(50)	(51)
Follicular cell, adenoma	1 (2%)	1 (2%)	1 (2%)	~/
Follicular cell, carcinoma	<u> </u>	- ()	/ _ /	1 (2%)

સં

General Body System None

4

ţ,

Summary of the Incidence of Neoplasms in Male Mice in the 2-Year Feed Study of t-Butylhydroquinone (continued)

	0 p	pm	1,2	50 ppm	2,500 ppm	5,000 ppm
2-Year Study (continued)						
Genital System						
Epididymis	(50)		(50)		(51)	(50)
Hemangioma	(50)	(2%)	(50)		(51)	(50)
Preputial gland	(50)	(270)	(49)		(50)	(51)
Histiocytic sarcoma	(30)		(42)		1 (2%)	(51)
Testes	(50)		(50)		(51)	(51)
Interstitial cell, adenoma	()		()		(/	1 (2%)
Hematopoietic System						
Bone marrow	(50)		(50)		(51)	(51)
Hemangiosarcoma	. /			(2%)		1 (2%)
Histiocytic sarcoma				(2%)	1 (2%)	
Lymph node	(3)		(3)	-	(6)	(3)
Iliac, histiocytic sarcoma	. ,		. ,		2 (33%)	
Inguinal, histiocytic sarcoma			1	(33%)		
Mediastinal, histiocytic sarcoma			1	(33%)	1 (17%)	
Pancreatic, histiocytic sarcoma					1 (17%)	
Renal, histiocytic sarcoma			1	(33%)	1 (17%)	
Lymph node, mandibular	(48)		(48)		(49)	(51)
Histiocytic sarcoma					1 (2%)	
Lymph node, mesenteric	(50)		(48)		(51)	(51)
Histiocytic sarcoma			1	(2%)	1 (2%)	
Spleen	(50)		(50)		(51)	(51)
Hemangioma					1 (2%)	
Hemangiosarcoma	4	(8%)		(2%)		
Histiocytic sarcoma				(2%)	1 (2%)	
Thymus	(44)		(38)		(43)	(42)
Integumentary System						,
Skin	(50)		(50)		(51)	(51)
Basal cell carcinoma	1	(2%)				· · · ·
Subcutaneous tissue, hemangiosarcoma		(4%)	1	(2%)	1 (2%)	
Subcutaneous tissue, lipoma	1	(2%)				
Musculoskeletal System						
Skeletal muscle Hemangiosarcoma, multiple	(2) 1	(50%)			(1)	(1)
Histiocytic sarcoma					1 (100%)	
Nervous System None						
Respiratory System	(ED)		(40)		(51)	(51)
Lung Alveolor/bronchieler adenome	(50)		(48)		(51) 8 (16%)	(51) 9 (18%)
Alveolar/bronchiolar adenoma		(22%) (2%)		(17%) (4%)	1 (2%)	. 7 (1070)
Alveolar/bronchiolar adenoma, multiple Alveolar/bronchiolar carcinoma		(2%) (6%)		(4%)	2 (4%)	4 (8%)
Alveolar/bronchiolar carcinoma Alveolar/bronchiolar carcinoma, multiple	د	(070)		(4%)	1 (2%)	2 (4%)
Hepatocellular carcinoma, metastatic, liver	А	(8%)		(4%)	2 (4%)	1 (2%)
inclassion in a care month, inclassion, inven		(0,0)	1	(~~)	- (+/0)	- (-,-,

.)

#### Table C1

Summary of the Incidence of Neoplasms in Male Mice in the 2-Year Feed Study of t-Butylhydroquinone (continued)

	0 ppm	1,250 ppm	2,500 ppm	5,000 ppm
2-Year Study (continued)				
Special Senses System				
Ear				(1)
External ear, histiocytic sarcoma			~	1 (100%)
Harderian gland	(3)	(9)	(6)	(3)
Adenoma	2 (67%)	8 (89%)	4 (67%)	3 (100%)
Carcinoma	• •		2 (33%)	
Bilateral, adenoma	1 (33%)			
Urinary System				
Kidney	(50)	(50)	(51)	(51)
Histiocytic sarcoma		1 (2%)		· ·
Systemic Lesions				
Multiple organs <sup>b</sup>	(50)	(50)	(51)	(51)
Histiocytic sarcoma	()	1 (2%)	2 (4%)	1 (2%)
Lymphoma malignant	4 (8%)	2 (4%)	6 (12%)	3 (6%)
Neoplasm Summary Total animals with primary neoplasms <sup>c</sup> 15-Month interim evaluation 2-Year study	1 39	2 . 44	3 42	3 36
Total primary neoplasms		2		2
15-Month interim evaluation	1	2	4	3
2-Year study	78	72	69	56
Total animals with benign neoplasms 15-Month interim evaluation	1	2	3	1
2-Year study	33	37	31	26
Total benign neoplasms	55	57	51	20
15-Month interim evaluation	1	2	4	1
2-Year study	50	48	39	34
Total animals with malignant neoplasms 15-Month interim evaluation	50			2
2-Year study	21	23	25	19
Total malignant neoplasms				2
		24	30	22
15-Month interim evaluation 2-Year study	28	24		
15-Month interim evaluation 2-Year study	28	24		
15-Month interim evaluation	28 5	1	2	1
15-Month interim evaluation 2-Year study Total animals with metastatic neoplasms			2	1

<sup>a</sup> Number of animals examined microscopically at the site and the number of animals with neoplasm
 <sup>b</sup> Number of animals with any tissue examined microscopically
 <sup>c</sup> Primary neoplasms: all neoplasms except metastatic neoplasms

ŝ

Individual Animal Tumor Pathology of Male Mice in the 2-Year Feed Study of t-Butylhydroquinone: 0 ppm 5 5 6 6 6 6 6 6 7 77 7 7 7 7 7 7 7 7 7 7 7 7 7 7 Number of Days on Study 3 9 7 1 4 5 5 8 0 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 9 5 9 7 1 1 3 0 5 2 3 7 7 7 7 7 7 7 7 7 7 7 7 7 8 0 **Carcass ID Number** 3 3 3 0 3 4 4 2 0 1 6 0 0 1 1 3 4 4 4 4 5 5 5 5 0 36 671 7 9 4 5 7 7 0 1 08 0 3 4 5 8 5 6 8 9 3 **Alimentary System** Esophagus + Gallbladder + A + Intestine large, colon + + Α Intestine large, rectum + + + + Intestine large, cecum + A Intestine small, duodenum 4 + + + + + + + + Intestine small, jejunum + + + + + + + + + + + + + + + + Intestine small, ileum Carcinoma Liver Hemangioma Hemangiosarcoma Х Hemangiosarcoma, multiple х Hepatocellular carcinoma х Х Х Х Hepatocellular carcinoma, multiple Х Х Х ххх Hepatocellular adenoma хх ххх Х Х Х Hepatocellular adenoma, multiple X x X Х Mesentery Pancreas + Salivary glands Stomach, forestomach + + + + + + Stomach, glandular + + + + + + + Tooth + **Cardiovascular System** Blood vessel + + + + + + + + + + ++ + + + + + + + + + + + Heart Hemangiosarcoma **Endocrine System** Adrenal cortex + + Subcapsular, adenoma Adrenal medulla + + + + + + ++ + Islets, pancreatic + + + Adenoma Parathyroid gland + + + + + + + + + + + + + + + + + + Pituitary gland Μ + + + Pars distalis, adenoma Х Thyroid gland + + + Follicular cell, adenoma **General Body System** 

+: Tissue examined microscopically

A: Autolysis precludes examination

M: Missing tissue I: Insufficient tissue X: Lesion present Blank: Not examined

None

#### TABLE $\mathbb{C}2$

Individual Animal Tumor Pathology of Male Mice in the 2-Year Feed Study of t-Butylhydroquinone: 0 ppm (continued)

Number of Days on Study	7 2 8	7 2 8	7 2 8	2	7 2 8	7 2 8	7 2 8	7 2 8	2	2	2	7 2 8		2	2	2	2	7 2 9	2							
Carcass ID Number	0 0 4	0 0 8	0	1	1	0 2 5	2	2	2	5	5	5	0 5 4	1	1	1		2		2	0 3 1	3	0 3 4		4	Total Tissues/ Tumors
Alimentary System																										
Esophagus	+	• +		- +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Gallbladder	+	• +		- +	+	+	+	+	÷	+	+	+	+	+	+	+	+	+	+	+	·+	+	+	+	+	48
Intestine large, colon	+	• +		+-	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+.	+	+	+	+	+	+	49
Intestine large, rectum	+	· -+	. 4	- +	+	+	+	+	+	+	+	+	+	+		÷	+	÷	+	+	+	+	+	+	+	50
Intestine large, cecum	.+	+		- +	- <del>-</del>	+	+	+	+	+	+	+	+	+		+	+	+	+	+	+	+	+		, ,	49
Intestine small, duodenum	د					_	+	+		÷	+	+	+	+		+	+		_		י ב	, ,	- -	+	+	50
Intestine small, jejunum	ب			, 	, 		т Т	- -	т 	т 	т +	т 	т 	т 		+	т 	т 	T	T	+	т 1	т 1	T	т 1	50 50
Intestine small, ileum	т 1	т 			- -	т 	T	Ť	- -	т	т	т ,	+	Ţ	т	т	т	Ţ	Ţ	Ţ		Ţ	-	+	т ,	30 49
Carcinoma	т	. т			· •	Ŧ	т	Ŧ	т	Ŧ	т	Ŧ	т	т	Ŧ	Ŧ	T	Ŧ	+	+	+	+	+	+	+	
Liver																									X	1
	+	• +		- +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Hemangioma						х																				1
Hemangiosarcoma																										1
Hemangiosarcoma, multiple															Х											2
Hepatocellular carcinoma																					Х					5
Hepatocellular carcinoma, multiple																										3
Hepatocellular adenoma			X	X			Х	Х	•	Х					X	Х	Х						Х	Х		21
Hepatocellular adenoma, multiple													Х								Х				Х	7
Mesentery															+											2
Pancreas	+	• +	• - +	+ +	+	+	+	+	+	+	+	+	÷	+	+	+	+	+	+	+	+	+	+	+	+	49
Salivary glands	+	• +	• - +	+ +	+	+	÷	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Stomach, forestomach	+	• +		- M	[ +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	49
Stomach, glandular	+	• +	• +	- M	[ +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	49
Tooth	+	-	+	F	+		+	+			+	+		+		+		+		+	+	+	+	+		28
Cardiovascular System																										
Blood vessel	-+	• +	• +	- +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Heart	+	• +	• +	+ +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Hemangiosarcoma															x				•							1
Endocrine System		-																								
Adrenal cortex	-+	- +		⊦ +	• +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Subcapsular, adenoma																x										1
Adrenal medulla	+	- +		+ +	• +	+	+	+	+	+	+	+	+	+		+	+	+	+	+	+	+	+	+	+	50
slets, pancreatic	-			, ,	• +	• +	+	+	+	+	+	+	+	+		+	+	+	+		+	+	+	+	+	50
Adenoma	,			. ,	'	'	•	•	•	•	•			•	•	,	•	'	•	•		•	•	'	'	1
Parathyroid gland	4			⊦ +	• +	+	+	4	Ŧ	м	Т	L	÷	Ŧ	Ŧ	ᆂ	L.	+	+	+	+	L.	L.	L.	+	49
Pituitary gland	L L	ר ה		г т - +		· +		+		+	+	+	+ +	+ +		+ +			Ť	+	+	+	т -	+		49 46
Pars distalis, adenoma	1	1		r 1	- 1	+	1	+	+	Ŧ	+	+	Ŧ	т	Ŧ	Ŧ	Ŧ	+	1	+	+	+	+	+	+	
																										1
Thyroid gland	-	+		+ +	• +	• +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Follicular cell, adenoma																							Х			1

None

Individual Animal Tumor Pathology of Male Mice in the 2-Year Feed Study of t-Butylhydroquinone: 0 ppm (continued) 5 5 6 6 6 6 6 6777 7 7 7 7 7 7 7 7 7 7 7 7 7 7 Number of Days on Study 3 9 1 4 5 5 7 801 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 9 5 9 7 1 1 3 0 5 2 3 7 7 7 7 7 777778 77 7 0 0 **Carcass ID Number** 3 3 3 0 3 4 4 2 0 1 6 0 0 1 1 3 4 4 4 4 5 5 5 5 0 7 9 3 6 6 7 1 4 5 7 0 1 7 0 8 0 3 4 5 8 5 6 8 9 3 **Genital System** Coagulating gland Epididymis Hemangioma Preputial gland Prostate + Seminal vesicle + + + + + + + + + + + + + + + + + ++ + + + + + + Testes + + + + ++ ++ + ++ + + ++ + + + + + + + + + + Hematopoietic System Bone marrow + + + Lymph node Lymph node, mandibular Μ + + + + + + + + + + Lymph node, mesenteric + + + + Spleen + + 4 + + + + + Hemangiosarcoma X x Thymus ++ + + + + M + M I M ++ + + + + + + + + + + **Integumentary System** Mammary gland Skin + + + + + + + + + + + + + + + + + Basal cell carcinoma х Subcutaneous tissue, hemangiosarcoma Х Subcutaneous tissue, lipoma Musculoskeletal System Bone Skeletal muscle + х Hemangiosarcoma, multiple **Nervous System** Brain Peripheral nerve Spinal cord **Respiratory System** Lung Alveolar/bronchiolar adenoma Х ХХ х Х х Alveolar/bronchiolar adenoma, multiple Alveolar/bronchiolar carcinoma Х X X ххх Hepatocellular carcinoma, metastatic, liver Х Hepatocholangiocarcinoma, metastatic, liver Nose + + + + + + + + + + + + + + + Trachea + + + + + + ++ + + + + + + + + + + + + + + + + +

#### Table C2

Individual Animal Tumor Pathology of Male Mice in the 2-Year Feed Study of t-Butylhydroquinone: 0 ppm (continued)

																		-	Ш				-	. П.	`	,
Number of Days on Study	7 2 8	7 2 8	7 2 8	7 2 8	7 2 8	7 2 8		-	2	2	2 3	2 :		7722	2	2	7 2 9	7 2 9	7 2 9	7 2 9	7 2 9	7 2 9	2		7 2 9	
	_			_	_		-	-	-	-					_							_	_		-	
Carcass ID Number	0		0 0		0 1	0 2								0 C 1 1				0 2	0 2	0 3	03	03		)	0 4	Total Tissues/
	4	-	9		2						2			4 5				2		1				5		Tumors
Genital System																										
Coagulating gland					+					+																4
Epididymis	+	- +	• +	• +	+	+	+	+	+	+	+	+	+	+ •	+ +	⊦ +	• +	• +	+	• +	• +		+ •	+	+	-50
Hemangioma																	Х									1
Preputial gland	+	- +	• +	• +	+	+	+	+	+	+	+	+	+	+ •	+ +	+ +	• +	• +	+	• +	• +	• +	+ •	+	+	50
Prostate	I	+	- +	• +	+	+	+	+	+	+	+	+	+	+ •	+ +	- +	- +	• +	+	• +	• +				+	49
Seminal vesicle	+	- +	• +	• +	+	+	+	+	+	+	+	+	+	+ •	+ +	+ +	- +	• +	+	• +	• +			+	+	50
Testes	+	• +	• +	• +	+	+	+	+	+	+	+	+	+	+ •	+ +		- +	• +	• +	• +	- +		+ ·	+	+	50
Hematopoietic System																										
Bone marrow	+	- +	- +	• +	+	+	+	+	+	+	+	+	+	+ ·	+ +	+ +	• +	• +	• +	• +	• +		+ •	ł	+	50
Lymph node						+											+									3
Lymph node, mandibular	4	- +	- +	·M	[ +	+	+	+	+	+	+	+	+	+ •	+ +	+ +	- +		• +	• +	• +	• •	+ •	+	+	48
Lymph node, mesenteric	+	+	+	• +	+	+	+	+	+	+	•		-	+ •	•		-		• +	• +	- +			+	+	50
Spleen	4	- +	- +	• +	+	+	+		•	+	+	+	+	+ •	+ -		- +	• +	• +	• +	- +		+ •	÷	+	50
Hemangiosarcoma				Ŧ					X						2											4
Thymus	+	- +	- +	- I	+	+	+	+	+	+	+	+	+	+ 1	VI -		- +	• +	• +	• +			+ •	+	+	44
Integumentary System																										
Mammary gland						Μ																				2 ·
Skin	+	- +	- +	- +	+	+	+	+	+	+	+	+	+	+ •	+ -	+ +	- +	• +	• +	• +	- +		+ ·	+.	+	50
Basal cell carcinoma																										1
Subcutaneous tissue, hemangiosarcoma									х																	2
Subcutaneous tissue, lipoma														2	x											1
Musculoskeletal System																										
Bone	-	+	- +	- +	+	+	+	+	+	+	+	+	+	+	+ -	+ +	- +	- +	• +	- +	+		+	+	+	50
Skeletal muscle																										2
Hemangiosarcoma, multiple																										1
Nervous System																										
Brain	-	1	+	- +	+	+	+	+	+	+	+	+	+	+ -	+ -	+ +	- +	- +	• +	• +		+ -	+	+	+	50 -
Peripheral nerve																										1
Spinal cord																										1
Respiratory System																										
Lung	-	+ -	+ -	- +	• +	+	+	+	+	+	+	+	+	+	+ -	+ +	+	- +	- +	- +		⊢ -	+	+	+	50
Alveolar/bronchiolar adenoma						Х							х			x x	C				Х					11
Alveolar/bronchiolar adenoma, multiple																								Х		1
Alveolar/bronchiolar carcinoma								Х																		3
Hepatocellular carcinoma, metastatic, liver																										-4
																										1
Hepatocholangiocarcinoma, metastatic, liver																										
	-	+ +	⊢ ⊣ ⊢ ⊣	⊦ + ⊦ +	• +	+	+ +	+ +	+	+ +	+	+ +	+ +	+ +	+ •	+ -	+ +	+ +		1	⊢ + ⊢ +	+ -	+ +	+	+ +	50 50

÷

÷.

TABLE C2

Individual Animal Tumor Patholog	gy or mai	ем	IIC	e in	i th	ie 4	2- Y	ea	r F	ee	a S	tuo	1y (		<i>t</i> -В	uty	yın	ya	roc	լու	no	ne:	: U	p	om	(co	ntinue	ed)
	5	5	6	6	6	6	6	6	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7			
Number of Days on Study	3	-	1	4	5	5	7	8	0	1	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2		,	
	9	5	9		1	1	3	U	3	2	3	/	<u>′</u>	′	/	/	<u> </u>		/		/	/	/	/	ð			
	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0			
Carcass ID Number	3	3	3	0	3	4	4	2	0	1	6	0	0	1	1	3	4	4	4	4	5	5	5	5	0		· .	
		9	3	6	6	7	1	4	5	7	0	1	7	0	8	0	3	4	5	8	5	6	8	9	3			
Special Senses System Harderian gland																		+							•			
Adenoma Bilateral, adenoma																		x								· .		
Zymbal's gland	•															M		^										
Urinary System																										1		۰.
Kidney	-	- +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+			
Urinary bladder	4	- +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		`	
Systemic Lesions																												
Multiple organs Lymphoma malignant	• -	- +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+ X	+	+	+	+	+	+ x		х 4 ц -	

rin.

#### TABLE C2 Individual Animal

Individual Animal Tumor Pathol	logy of Ma	le i	Mi	ce	in	th	e 2	- Y	ear	r ŀ	ee	15	tuo	ly (	oľ	t-13	ut	yllh	yd	roc	lai	no	ne:	: 0	P	pm	(continued)
Number of Days on Study	2		7 <sup>-</sup> 2 : 8 -	7 2 8	7 2 9																						
Carcass ID Number	(		0	0 0 9	0 1 1	0 1 2	0 2 5	0 2 7	0 2 8	0 2 9	0 5 0	0 5 2	0 5 3	0 5 4	0 1 4	0 1 5	0 1 6	0 1 9	0 2 0	0 2 2	0 2 3	0 3 1	0 3 2	0 3 4	3	0 4 0	Total Tissues/ Tumors
Special Senses System Harderian gland Adenoma Bilateral, adenoma Zymbal's gland									+					+ x					+ x				·				3 2 1 1
Urinary System Kidney Urinary bladder		+ + +	+ +	+ +	+ +	+ +	+ +	+ +	+++	+++	+++	++	+++	++	+++	+++	++	++	++	+ +	++	++	++	++	++	+ +	50 50
Systemic Lesions Multiple organs Lymphoma malignant		ŧ	+	+	+	+ x	+	+	+	+	+	+	+	+	+	+	+	+	+ X	+	+	+	+	+	+	+	50 4

.

.

	U	•	5 6	,	'	7	'	'	7	7	7	1	7	7	7	7	7	7	7	7	7	7	1	1	7	1		
Number of Days on Study	1 9		35	5	1	2	2	2	2	2	2	2	2	2	2		2	2	2	2	2	2	2	2	2	2		
		_	, 4	•	0	<u></u>	<u> </u>				/	/	/	/	7	7	7		8	8	8	8	8	8	8	-		
arcass ID Number	0				0		0		0	0	0	1	1	1	1			1					-		0			
Larcass ID Number	9 1	2			7 2		6 7		8 0	9 7	9 8	0 0	0 2	5	0 8	1 6	1 7	1 9	6 1	6 4	6 5	6 6.	6 8	0	8 6	9 2		
limentary System																											:	
Lisophagus	+		+ -	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		
Fallbladder	+		+ -	÷	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	M		,	
ntestine large, colon	+		+ -	÷	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+			
ntestine large, rectum	+		+ -	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	÷	+	+	+	+	+	+	+		
ntestine large, cecum	+		+ -	ł	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		
ntestine small, duodenum	+		+ •	ł	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	÷		
ntestine small, jejunum	+		+ -	+	+	+	+	+	+	+	+	+	+	+	+	+	÷	+	+	+	+	+	+	+	+	+		
Carcinoma	·		•	•	•	•			•		•	•	•		÷.		x	•	•	•	•	•	•	•	'	•		
ntestine small, ileum	+		+ -	÷	+	+	+	+	+	+	+	+	+	+	+	+		+	+	+	+	+	+	+	+	+		
liver	, +		+ -	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	÷	÷	÷	+	+	+	+		
Hemangiosarcoma	•		•	•	•	•		•	•		•	·	•	•			•	x	•		•	•			'	. '	•	
Hepatocellular carcinoma	x		ĸ			х			х									**						· 4				
Hepatocellular carcinoma, multiple			•						-														X			X		
Hepatocellular adenoma																	х	x		х					x	x		
Hepatocellular adenoma, multiple									х				х								х					~		
Aesentery														+	+	+			+		+							
Histiocytic sarcoma														•					•		•							
ancreas	+		+ -	ŧ.	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		
Histiocytic sarcoma	•		•	•	•	•	•	•	•	•	•	•	•	•		•	•		•		•	•		•	'			
alivary glands	+		+ -	÷	+	+	+	+	+	+	+	+	+	+	+	+	+	÷	+	+	+	+	+	+	+	+		
tomach, forestomach	. +		+ -	+	÷	÷	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	.+			
Squamous cell papilloma			•	•	•	•	·		·	·	•	•	x	•		•	•	•	•		•	•	•	•	•	•		
tomach, glandular	+		+ -	F	+ '	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		
Carcinoid tumor benign	•		•	•	•	•	•	•	•	•	•	•	•	•	•		•	•	•		•							
Sooth			-	ł				+		+	+	+			+	+	+	+			+			+				
Cardiovascular System																											·.	
Blood vessel	+		+ -	÷	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		
leart	+	•	+ -	ł	+	+	+	+	+	+	+	+	+	+	÷	+	+	+	+	+	+	+	+	+	+	+	•	,
Endocrine System																												
Adrenal cortex Subcapsular, adenoma	+	•	+ -	t	+	+	+	+	+	+	+	+	+	+	` <b>+</b>	+	+	+	+	+	+ X	+	+	+	+	+		•
Adrenal medulla			+ -	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		
slets, pancreatic	•		+ -	+	+	+	+	+	+	+	+	+	+	+	+	+	+	÷	+	+	+	+	+	+	+	+		
Adenoma	•		·		x	·	·	·	·	•	•	•	•	·	•		•	•			•	•	•		•	,		
Parathyroid gland	+		+ •			Ŧ	+	+	4	+	+	+	+	+	I	+	+	+	+	+	+	+	+	+	+	+		
Pituitary gland	-+	-	+ •		Ň					Ň												+	+	+	+	+	-	
Chyroid gland	-+	-	+ •	+	+	+	+	+	+		+	+						+				+	+	+	+	+		
Follicular cell, adenoma	•																		x									

Table C2

Individual Animal Tumor Pathology of Male Mice in the 2-Year Feed Study of t-Butylhydroquinone: 1,250 ppm (continued) 77 Number of Days on Study 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 1 1 1 1 1 1 1 1 1 Total **Carcass IID** Number 9 9 9927777 788888 9000001111 Tissues/ 5 6 0 3 4 7 8 9 1 3 4 4 7 8 9 0 3 4 67 90234 Tumors **Alimentary System** Esophagus 50 + + + + +++ Gallbladder 49 + + + ++ + + + + ++ + + + + + + + + + + + Intestine large, colon 50 + + + + + + + + + + ++ + + + + Intestine large, rectum + 4 + + + + + + + + + + + + + + + + + 50 + + Intestine large, cecum + 50 + + + Intestine small, duodenum +50 Intestine small, jejunum 50 + Carcinoma 1 Intestine small, ileum 49 + + + + + + + + + + M + Liver + + + + + + + + + ++ + + + + + + + + + 50 Hemangiosarcoma 1 Hepatocellular carcinoma х х х х х 9 Hepatocellular carcinoma, multiple 2 Hepatocellular adenoma хх хх ххх х 14 Х хх хх Hepatocellular adenoma, multiple х 8 Mesentery + 7 Histiocytic sarcoma х 1 Pancreas + 50 + + Histiocytic sarcoma Х 1 Salivary glands + + + 50 + + Stomach, forestomach 50 + + + + + + + + 4 + + + + + + + Squamous cell papilloma 1 Stomach, glandular + + 50 + + + + + + Carcinoid tumor benign Х 1 Tooth + 26 + + + + + + + + + + + + **Cardiovascular** System Blood vessel 50 + + + + + + + + 4 + + + + + Heart + + + + 50 + + ++ + + + + + + + + + ++ + + + + **Endocrine System** Adrenal cortex 50 + + + + + + Subcapsular, adenoma х х х 4 Adrenal medulla 50 + + + + + + + + + + + + + + + + Islets, pancreatic 50 + + + + + Adenoma 1 Parathyroid gland M + Μ + + + + 46 + + + + + + + + + + + + + + Μ + Pituitary gland 42 + + + + + + + + + + + + + + ++ + + ++ + + + M Thyroid gland + + + + + + 50 + + ++ + + + + + + + + + + + + + + Follicular cell, adenoma 1 **General Body System** 

None

.

Individual Animal Tumor Pathology of Male Mice in the 2-Year Feed Study of t-Butylhydroquinone: 1,250 ppm (continued) 6 6 6 7 77 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 Number of Days on Study 1 3 51 2 9 0 4 0 7 7 7 7 7 7 7 7 7 7 7. 7 7 8 8 8 8 8 8 8 8 0 0 0 0 0 0 0 0 0 0 1 1 1 1 1 1 1 0 0 0 0 0 0 0 0 **Carcass ID Number** 9 8 9766789 9 0 0 0 0 1 1 1 6 6 6 6 6 89 7 1 2 9 2 2 7 5 0 7 8 0 2 5 8 6 7 9 1 4 5 6 8 0 6 2 **Genital System** Coagulating gland Epididymis Preputial gland Prostate + Seminal vesicle + + + + + + + Testes + + + + + + + **Hematopoietic System** Bone marrow Hemangiosarcoma Histiocytic sarcoma Lymph node + Inguinal, histiocytic sarcoma Mediastinal, histiocytic sarcoma Renal, histiocytic sarcoma Lymph node, mandibular Lymph node, mesenteric Histiocytic sarcoma Spleen х Hemangiosarcoma Histiocytic sarcoma M + + I + + M + + + + + + M M + + + +Thymus + + M + + +**Integumentary System** Mammary gland Skin + + ++ + ++ + + + + Subcutaneous tissue, hemangiosarcoma x Musculoskeletal System Bone + + + + + + **Nervous System** Brain **Respiratory System** + Lung х Alveolar/bronchiolar adenoma x Х Alveolar/bronchiolar adenoma, multiple Alveolar/bronchiolar carcinoma Х Х Alveolar/bronchiolar carcinoma, multiple Х Hepatocellular carcinoma, metastatic, liver Х Nose + + + Trachea + + + + + + **Special Senses System** Harderian gland + + + + + + х хх X, х Adenoma

# t-Butylhydroquinone, NTP, TR 459

# TABLE C2

7

				-	, ,	7 1	7 '	7	7	7	7	7	7	7	7	7	7	7	7	7	7	-	-	-	-	~	
Jumbor of Dove on Study			7 2			7					7	7	7	7	7	7	7	7	7		7	7	2	2		7	
Number of Days on Study	2 8	2 8						2 9			2 9	2 9	2 9	2 9	2 9	2 9	2 9	2 9	2 9	2 9	2 9	2 9	2 9	2 9	29	2 9	
		_																		_				-			
Carcass ID Number	0 9	0 9	9	-				_	0 7	0 7	0 7	0 8	0 8	0 8		0 8	0 9		1 0	1 0	1 0	-	1	1	-	1 1	Total Tissues/
	3	-		-				-	-							° 9								_			Tumors
Genital System			<u> </u>							_			_					-									
Coagulating gland															+					+						+	6
Epididymis	+	H		+ •	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Preputial gland	+	4		+ -	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	÷	+	+	+	+	+	49
Prostate	+	4		+ •	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		50
Seminal vesicle	+	4		₽ -	+	-			+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		+	50
restes	+	-		+ •	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Iematopoietic System																											
Bone marrow	+	-		+ ·	+ ·	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Hemangiosarcoma																					••						1
Histiocytic sarcoma																					X						-1
Lymph node																					+						3
Inguinal, histiocytic sarcoma																					X						1
Mediastinal, histiocytic sarcoma																					X X						1
Renal, histiocytic sarcoma Lymph node, mandibular	L			<b>ـ</b> ـ	+	<b>_</b>	+	+	+	+	Ŧ	ъ	Ŧ	+	+	Ŧ	+	+	-	М		-	+			+	1 48
Jymph node, manufoular	т +			+ .	т -							+	т +	- -	т +	+	+	- -	+	+	+					+	48
Histiocytic sarcoma	•					ſ	•	•		1.1	141	'	•	•	'	'		•		•	x	'			'	•	1
Spleen	+		÷ -	+ •	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		+	+	+	+	+	50
Hemangiosarcoma	•			•	•	•		•		·	•	•	•	•		•	•	•	•	·			•			•	1
Histiocytic sarcoma																					х						1
Thymus	+	• •	۰ ۱	+	+	+	+	Μ	+	М	+	+	+	+	+	+	М	+	+	+	+	+	+	M	Ι	М	38
Integumentary System																											
Mammary gland	N	1 1	л I	M	м	м	м	м	м	м	м	м	м	м	м	м	м	м	м	м	м	M	N	ГМ	ιN	М	4
Skin																										+	50
Subcutaneous tissue, hemangiosarcoma											-					-			-							-	1
Musculoskeletal System	<u> </u>				•					_													_			_	
Bone	+		+ •	ł	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	• +	• +	+	50
Nervous System	·····		_																	_	-		_				
Brain	+		+	+	+	+	+	+	+	+	<b>;+</b>	+	+	+	+	+	+	+	+	+	+	+	+	- +	• +	• +	50
Respiratory System										_			_														
Lung	+		÷ .	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	- +	-	+	48
Alveolar/bronchiolar adenoma			•	•	•	x	•	'		x		•	x		•	•	•	x		• •	,			,		•	8
Alveolar/bronchiolar adenoma, multiple														х													2
Alveolar/bronchiolar carcinoma																						х					3
Alveolar/bronchiolar carcinoma, multiple							Х																				2
Hepatocellular carcinoma, metastatic, liver											·																1
Nose	+	+ ·	ł	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	• +	• -1	+	+	- +	50
Trachea	+	-	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	• +	• -1		• +	+	50
Special Senses System																											
Harderian gland																				+			۲				9
Adenoma		•																	X	Х			Х	C I			8

195

Ĵ

ŝ

TABLE C2

je.

4

Individual Animal Tumor Pathology of Male Mice in the 2-Year Feed Study of t-Butylhydroquinone: 1,250 ppm (continued)

													-			-		-		-				-	-		
Number of Days on Study	6 1	6 3	65	7	7 2	7 2	7 2	7 2	7 2	7 2	7	7 2	7 2	7 2	7 2	7 2	7	7 2	7 2	7 2	7 2	7 2	7	7	7 2		
	9	Ő	4	0	7	7	7	7	7	7	7	7	7	7	7	7	7	8	8	8	8	8	8	8	8		
	-	0	0	0	0	0	0	0	0	0	1	1	1	1	1	1	1	0	0	0	0	0	0		0		
Carcass ID Number	9 1	8 2	-	•	6 2	6 7	7 5				-	0 2	0 5	0 8	1 6	1 7	1 9				6 6			8 6			
Urinary System																				<b>-</b> .						_	
Kidney Histiocytic sarcoma	+	• +	+	• +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	. <b>+</b>		
Urethra Urinary bladder	· +	• +	+	· +	+	+	+	+	+	+	+	+	+	+ +	+	+	+	+	+	+	+	+	+	+	+		
Systemic Lesions Multiple organs Histiocytic sarcoma	+	• +	• +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		
Lymphoma malignant											х																

÷

Ň

#### 8-Butylhydroquinone, NTP, TR 459

#### 197

3

# TABLE C2

Individual Animal Tumor Pat	thology of Ma	le	M	ice	e in	1 th	ne 2	2-¥	ear	r F	'eet	d S	tuc	dy ·	of	<i>t-</i> B	Swi	ylh	yd	roo	ງູໝາ	ino	ne:	: 1	,25	50 j	ppm (continued
		7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	
Number of Days on Study		2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	
		8	8	8	8,	8	9	9	9	9	9	9	9	9 <sup>.</sup>	9	9	9	9	9	9	9	9	9	9	9	9	
		0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	1	1	1	1	1	Total
Carcass ID Number		9	9	9	9	2	7	7	7	7	7	8	8	8	8	8	9	0	0	0	0	0	1	1	1	1	Tissues/
		3	4	5	6	0	3	4	7	8	9	1	4	7	8	9	0	3	4	6	7	9	0	2	3	4	Tumors
Urinary System																											
Kidney		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Histiocytic sarcoma																					Х						1
Urethra																											1
Urinary bladder		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Systemic Lesions											_							-								•	
Multiple organs		Ŧ	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Histiocytic sarcoma							·														Х						1
Lymphoma malignant																							Х				2

.

Individual Animal Tumor Pathology of Male Mice in the 2-Year Feed Study of t-Butylhydroquinone: 2,500 ppm 5 5 6 6 6 6 6 6 6 7 7 4 5 7 7 7 7 7 7 7 7 7 7 7 Number of Days on Study 2 5 0 4 1 5 5 6 6 7 8 1 2 2 2 2 2 2 2 2 2 2 2 2 2 9 0909 4769300 4 77 7 7 7 7 7 7 7777 1 **Carcass ID Number** 5 7 7 3 3 6 2 5 6 2 3 2 4 4 4 3 4 5 5 6 6 6 6 6.6 0 6 2 5 4 9 0 5 3 8 6 1 1 1 4 1 1 2 3 3 4 5 6 7 8 **Alimentary System** Esophagus Gallbladder Intestine large, colon Intestine large, rectum Intestine large, cecum + + + + + ++ Α + + + + + 4 Intestine small, duodenum + A + + A Intestine small, jejunum + Α + + Carcinoma Х Х Intestine small, ileum + Liver + + Hemangiosarcoma Х Hepatocellular carcinoma Х хх Х X X Hepatocellular carcinoma, multiple ХХ Hepatocellular adenoma Х Х х Х ХХ Hepatocellular adenoma, multiple х Х Histiocytic sarcoma х Х Mesentery + + Histiocytic sarcoma x х Pancreas + Salivary glands Stomach, forestomach Squamous cell papilloma Stomach, glandular Tooth + + + + + + + + + Cardiovascular System Blood vessel Heart +Histiocytic sarcoma Х **Endocrine System** Adrenal cortex Subcapsular, adenoma Adrenal medulla Islets, pancreatic + + Parathyroid gland + м + + + ++ + 4 + + + + + + + Pituitary gland Μ M + + Μ Μ + + + + Thyroid gland M + + + + Follicular cell, adenoma Х **General Body System** Peritoneum

												7	7	7	7		7	7							7			
umber of Days on Study		2	7 2	7 2	7 2	7 2	7 2	•	7 2		7 2	•	2	•	•		•	•	7 2	7 2	7 2	7 2	7 2	2	2	7 2		
	7	8	8	8		8	8		8				8						9	9	9	9	9	9	<b>9</b>			
· ·	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	Total	
arcass ID Number	6	2	3	3	4	4	4	4	5	5	5	5	6	7	7		2	2	3	3	7	7	7	7	7	8	Tissues/	
	9	3	7	9	0	4	7	8	0		7		2						Ō	-	5	6	7	8	9	-	Tumors	
limentary System																												-
sophagus	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	51	
allbladder	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	51	
testine large, colon	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50	
testine large, rectum	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50	
testine large, cecum	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50	
testine small, duodenum	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	49	
testine small, jejunum	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	М	+	+	+	+	+	+	+	48	
Carcinoma											х																3	
testine small, ileum	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	49	
iver	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	51	
Hemangiosarcoma																											1	
Hepatocellular carcinoma								х		Х					х			х									8	
Hepatocellular carcinoma, multiple				Х																							4	
Hepatocellular adenoma				х		х		х			х			х			х		х				х		х	х	17	
Hepatocellular adenoma, multiple							Х					Х								х							5	
Histiocytic sarcoma																											2	
lesentery	+			+		+					+			+				+							+		14	
Histiocytic sarcoma																											2	
ancreas	+	+	+	+	+	+	+	+	÷	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	51	
alivary glands	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	51	
comach, forestomach	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	51	
Squamous/cell papilloma																					х						1	
omach, glandular	+	+	+	+	+	+	+	+	+	+	+	+	+	+	÷	+	+	+	+	+	+	+	+	+	+	+	51	
ooth	+								+	+	+			+	+	+							+			+	18	
ardiovascular System																												
lood vessel	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	51	
eart	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	51	
Histiocytic sarcoma																											· 1	
ndocrine System																												-
drenal cortex	I	+	+	+	+	+	+	+	+	+	+	+	+	+	+.	+	+	÷	+	+	+	+	+	+	+	+	51	
Subcapsular, adenoma																			х								1	
drenal medulla	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	51	
lets, pancreatic	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	51	
arathyroid gland	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50	
ituitary gland	+	+	+	+	+	+	+	+	+	+	+	Ι	+	+	+	+	+	+	+	+	+	+	+	I	+	+	45	
hyroid gland	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50	
Follicular cell, adenoma								•	•				•			•	•	•	•	•	•	•	•	•	·	•	1	
																												_

÷

٢

ŝ,

q

Individual Animal Tumor Pathology of Male Mice in the 2-Year Feed Study of t-Butylhydroquinone: 2,500 ppm (continued) 4 5 5 5 6 6 6 6 6 6 6 7 7 7 7 7 7 7 7 7 7 7 7 7 7 Number of Days on Study 7 0 2 4 5 5 5 6 6 8 1 2 2 2 2 2 2 2 2 2 2 2 2 2 1 9 3 0 0 4 7 7 9 0 90947 6 7 7 7 7 7 7 7 7 7 7 1 **Carcass ID Number** 7 7 2 5 6 5 6 3 3 2 4 4 4 2 3 3 4 5 5 6 6 6 6 6 6 5 0 4 6 2 5 4 9 0 3 8 6 2 3 1 1 1 1 1 3 4 5 6 78 **Genital System** Coagulating gland Epididymis Preputial gland + + M Histiocytic sarcoma Х Prostate + + Seminal vesicle + + + + + + + + + + + + ++ + + + + + + + 4 + Testes + Hematopoietic System Bone marrow Histiocytic sarcoma Х Lymph node + + + + X X Iliac, histiocytic sarcoma х Mediastinal, histiocytic sarcoma х Pancreatic, histiocytic sarcoma Renal, histiocytic sarcoma х Lymph node, mandibular +Histiocytic sarcoma x Lymph node, mesenteric + "Histiocytic sarcoma Х Spleen + Hemangioma х Histiocytic sarcoma + M + M + +.+ I Thymus + M ++ + + + +++ + I ++ + + + **Integumentary System** Mammary gland Skin + + + ++ + + + + + + 4 + + + + ++ + + + + х Subcutaneous tissue, hemangiosarcoma Musculoskeletal System + Bone Skeletal muscle + Х Histiocytic sarcoma **Nervous System** Brain + + + + + + + + + **Respiratory System** + + + + Lung + + + Х Х Alveolar/bronchiolar adenoma Х Х Alveolar/bronchiolar adenoma, multiple Х Alveolar/bronchiolar carcinoma Alveolar/bronchiolar carcinoma, multiple Х Hepatocellular carcinoma, metastatic, liver х Х + + Nose ++ + + + ++ + + + + + + Trachea + + + + + + M + + + + + + + +

# 8-Butylhydroquinone, NTP, TR 459

# Table C2

Individual Animal Tumor Pathology of Male Mice in the 2-Year Feed Study of t-Butylhydroquinone: 2,500 ppm (continued)

			_	_																-							
Number of Days on Study	7 2 7	7 2 8	7 2 8	7 2 8	7 2 8	7 2 8	7 2 8	2	2		2	2	7 2 8	2	2	2	2	2	7 2 9	2	7 2 9	7 2 9	7 2 9	7 2 9	7 2 9	7 2 9	
Carcass ID Number	-	2	1 3 7	1 3 9	1 4 0	1 4 4	4	4	5	5	5	-	6	7	7 :	2	2	-	1 3 0	3	1 7 5	1 7 6	1 7 7	1 7 8	1 7 9	8	Total Tissues/ Tumors
Genital System																											
Coagulating gland Epididymis Preputial gland	++	+ +	+ + +	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+	+ +	++	+++	+ +	++	+ +	+ +	2 51 50						
Histiocytic sarcoma Prostate	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	1 51
Seminal vesicle Testes	++	+ +	+ +	++	+++	+ +	+ +	+ +	+ +	++	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+ +	51 51
Hematopoietic System																								_			
Bone marrow Histiocytic sarcoma Lymph node	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	51 1 6
Iliac, histiocytic sarcoma Mediastinal, histiocytic sarcoma Pancreatic, histiocytic sarcoma																										+	2 1 1
Renal, histiocytic sarcoma ymph node, mandibular Histiocytic sarcoma	+	+	+	+	+	+	I	+	+	+	+	+	+	+	+	+	+	+	+	÷	+	+	+	+	+	+	1 49 1
Lymph node, mesenteric Histiocytic sarcoma	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	51 1
Spleen Hemangioma	+	+	+	+	+ X	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	51 , 1
Histiocytic sarcoma Thymus	I	+	+	+	М	+	+	+	+	+	+	+	+	+	+	+	+	+	+	М	+	+	+	+	+	+	1 43
Integumentary System Mammary gland	м	м	м	м	м	м	м	м	м	м	М	м	м	м	M	M	М	м	м	м	м	м	м	м	м	м	1
Skin Subcutaneous tissue, hemangiosarcoma	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	51 1
Musculoskeletal System Bone	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	51
Skeletal muscle Histiocytic sarcoma																											1 1
Nervous System Brain	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	51
Respiratory System Lung Alveolar/bronchiolar adenoma	+	+	+	+	+	+	+	+	+	+ x	+	+ x	+	+	+	+	+	+	+ x	+	+	+ x	+	+	+	+ x	51 8
Alveolar/bronchiolar adenoma, multiple Alveolar/bronchiolar carcinoma Alveolar/bronchiolar carcinoma, multiple Hepatocellular carcinoma, metastatic, liver																	x										1 2 1 2
Nose Trachea	+ +	+ +	+ +	+ +	. + +	+ +	+ +	+++++++++++++++++++++++++++++++++++++++	+ +	+÷ +	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+ +	51 50

Ĵ

ŝ

-

ş

.

6

Individual Animal Tumor Path	hology of Male Mice in the 2-Year Feed Study of t-Butylhydroquinone: 2,500 ppm (continued
Number of Days on Study	4       5       5       6       6       6       6       7
Carcass ID Number	1       1
Special Senses System Harderian gland Adenoma Carcinoma	+ + x x
Urinary System Kidney Urinary bladder	+ + + + + + + + + + + + + + + + + + +
Systemic Lesions Multiple organs Histiocytic sarcoma Lymphoma malignant	+ + + + + + + + + + + + + + + + + + +

Ģ

Individual Animal Tumor Pat	hology of M	ale	M	lice	e in	1 th	ne 2	2-¥	ear	r F	'ee	d S	stu	dly	of	<i>t-</i> E	But	ylh	yd	ro	qui	ino	ne	: 2	,50	)0 I	pm (conti	nued)
	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7		
Number of Days on Study	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2		
· .	7	8	8	8	8	8	8	8	8	8	8	8	8	8	8	9	9	9	9	9	9	9	9	9	9	9		
	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	Total	
Carcass ID Number	6	2	3	3	4	4	4	4	5	5	5	5	6	7	7	2	2	2	3	3	7	7	7	7	7	8	Tissues/	
	9	3	7	9	0	4	7	8	0	5	7	9	2	3	4	7	8	9	0	6	5	6	7	8	9	0	Tumors	
Special Senses System																												
Harderian gland			+	+					+	+																	6	:
Adenoma									Х	Х																	4	
Carcinoma			Х	Х																							2	
Urinary System																	-											
Kidney	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	51	
Urinary bladder	+	+	+	+	+	+	+	+	+	· +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	51	
Systemic Lesions																												
Multiple organs	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	· ·+	•+	+	+	51	
Histiocytic sarcoma																											2	
Lymphoma malignant											Х		Х										Х			Х	6	

204

Individual Animal Tumor Pathology of Male Mice in the 2-Year Feed Study of t-Butylhydroquinone: 5,000 ppm

				. 101	nee			<u> </u>			1.0			uu	iy t	ЛГ	-D(	<u> </u>	<u> </u>		υų	[u1		IC.	5	,000	, hhi	**	
								6	6		7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7			
Number of Days on Study			-	9	1	1.						_	2			2	2	2	2	2	2	2	2	2	2	2			
-	•	1	9	5	4	5	8	0	0	8	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7			
		2	2	1	2	2	1	1	2	2	1	1	1	1	1	1	2	2	2	2	2	2	2	2	2	2			
Carcass ID Number		2	0	8	3	2	9	9	3	0	8	8	8	8	8	9	0	0	0	0	0	0	1	2	3	3			
		4	4	7	4	8	7	3	2																				
Alimentary System												_									•								
Esophagus		т.	-1-	+	т		т	т.	.1																				
Galibladder		т 	т 		т 	т 	т 	++			++	+			+ +	+			++	+	+	+	+	+	+	+			
Intestine large, colon		+	+	- -	Δ	Ť	+			+	т 	Ť		+	т 	т _		+	т _	+	+	- -	-T	+	- <b>T</b>	Ŧ			
Intestine large, rectum		+	+	, +	Â	+	+				+	т +		+	+ +	+			+ +	Ť	т -	Ť	т -	+		- -			
Intestine large, cecum		+	+	+	Â	+	+	+		+	+	+	+	+	+	+		+	+	÷	+	+	+	+	+	+			
Intestine small, duodenum		+	+	+		+					+	+	•	+	+	+			+	+	+	+	+	+	+	+			•
Intestine small, jejunum		+	+	+	A	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	÷			
Intestine small, ileum		M	(+)	+		+	+		+	+	+	+	+	+	+	+	+	+	+	+	+	÷	+	+	+	+			
Liver		+	+			+	+	+		•		+				+				+	+	+	+	+		+			
Hemangiosarcoma		-								-									•			·	•	•	·				
Hemangiosarcoma, multiple			х																										
Hepatocellular carcinoma								х	х																				
Hepatocellular carcinoma, multiple						х																							
Hepatocellular adenoma								х	х											х	х					х			
Hepatocellular adenoma, multiple																													
Mesentery																													
Pancreas	. <b>.</b>	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+			
Salivary glands		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+			
Stomach, forestomach		+	+	+	+	+	+	+		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+			
Squamous cell papilloma										Х					Х														
Stomach, glandular		+	+	+	Α	+	+	+	+	+	+	+		+				+	+	+	+	+	+	+	+	+	•		
Tooth							+			+	+		+	+	+	+	+		+	+	+		+			+			
Cardiovascular System																													
Blood vessel		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	М			
Heart		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+			
Endocrine System Adrenal cortex		-	-	+	т	-	+	-	.1								4						,		1				
Subcapsular, adenoma		т	Ŧ	т	т	т	т	т	т	т	т	Ŧ	т	т	+	+	x	+	Ŧ	т	т	т	T	т	T	+ X			
Adrenal medulla		т	+	+	Т	Ъ	т	т	Ŧ	ᆂ	+	-	т	т	т			-	ᆂ	ъ	<u>ــــ</u> ـ	<b></b>	т	+	<b>_</b>	^ +			
Islets, pancreatic			. <u>+</u>	+	, +	÷	+	+		+	+	+	+	+	+	+					+			+		+ +		-	
Adenoma		1	'	•	,	ſ	'	'	'	•	ſ	1	'		ľ	1	1	r	•		X	А.	т	.4.	т	т			
Parathyroid gland		+	+	+	+	+	+	+	+	м	+	м	+	м	+	+	+	+	+			+	+	+	+	+			
Adenoma		•			'	•	•				'			1.41	•	'	'				•		•						
Pituitary gland		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+			
Thyroid gland		+	· +	+	+	+	+	+	+	+	+	+			+					+	+	+	+	+	+	+			
Follicular cell, carcinoma			•	·	•	•		·	•	•	•	•		•			·			·									
Canaval Bady System																												· · ·	
General Body System Tissue NOS																													
			+			+																				+			
Genital System																													
Coagulating gland																													• .
Epididymis		+	• +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+			
Preputial gland		· +	· +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+			
Prostate		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+			
Seminal vesicle		+	· +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+			
																						1							
Testes Interstitial cell, adenoma		+	• +	+	*	+	+	Ŧ	T	+	+	+	+	+	+	+	Ŧ	+	+	+	+	+	+	+	• +	+			

#### t-Butylhydroquinone, NTP, TR 459

#### TABLE C2

Individual Animal Tumor Pathology of Male Mice in the 2-Year Feed Study of t-Butylhydroquinone: 5,000 ppm (continued) 77 7 7 7 7 7 7 7 7 7 7 77 7 7 7 7 7 7 7 7 7 7 7 7 Number of Days on Study 2 8 8 8 9 9 9 9 9 9 9 99 7 8 8 8 8 8 8 8 8 8 8 8 9 9 2 1 1 1 1 1 1 2 Total **Carcass ID Number** 9 9 9 9 2 4 8 9 1 1 2 2 2 2 2 1 1 1 1 1 2 3 3 3 3 3 Tissues/ 0 7 9 8 0 2 5 6 8 7 8 0 1 2 5 6 1 2 4 5 6 0 6 7 8 9 Tumors **Alimentary System** Esophagus 51 Gallbladder 49 + + + + + + + + + + + + Μ Μ Intestine large, colon 50 + ++ + + + + + + + ++ + + ++ + + ++ + Intestine large, rectum + 50 + Intestine large, cecum + + + + + + + + + + + + + + + + + 50 Intestine small, duodenum 49 + + + + ++ + + + + + + + + + M + + + + + + + + + + Intestine small, jejunum 50 + + + + + + + + + + + + + + ++ + + + + + + + + + + Intestine small, ileum 49 + + + + + + + + + + + + + + ++ + + + + + + + + + + Liver + 51 + + + + + + + + + + + + + + + + Hemangiosarcoma Х 1 Hemangiosarcoma, multiple 1 Hepatocellular carcinoma Х х х Х х 7 Hepatocellular carcinoma, multiple 1 Hepatocellular adenoma х Х х хх Х 11 Hepatocellular adenoma, multiple х Х Х 3 Mesentery 1 + Pancreas 51 + + + Salivary glands 51 + + + + + + + + + + + + + + + Stomach, forestomach 51 Squamous cell papilloma 2 Stomach, glandular 50 + + + + + + + + + + + + + Tooth ++ + + ++ + 26 + + 4 **Cardiovascular** System Blood vessel 50 + Heart + + + + ++ + ++ + + + + + + + + + + + + + ++ 51 **Endocrine System** Adrenal cortex 51 + +Subcapsular, adenoma 2 Adrenal medulla 51 + Islets, pancreatic + 51 ÷ + + + + + + + + + + + + Х Adenoma 2 Parathyroid gland 44 + Μ + + + + M + M ++ + + + Adenoma Х 1 Pituitary gland + M ++ 49 + + + Thyroid gland + 51 + + + + Follicular cell, carcinoma Х 1 **General Body System Tissue NOS** 3 **Genital System** Coagulating gland 1 Epididymis 50 Preputial gland + + + + + + + + + + ++ + + + + + 51 Prostate + + + + + 51 + + + + + + + + + + + + ++ ++ + + + + + Seminal vesicle ++ + + + + + + + ÷ + + + + + + + + + + + + + + + + 51 + + 51 Testes + Interstitial cell, adenoma х 1

#### t-Butylhydroquinone, NTP TR 459

TABLE C2

Store 1

Individual Animal Tumor Pathology of Male Mice in the 2-Year Feed Study of t-Butylhydroquinone: 5,000 ppm (continued) 1 5 6 6 6 5 6 6 6 7 7 7 7. 7 7. 7 7 7 7 7 7 7 7 7 7 Number of Days on Study 7 8 9 1 1 2 3 8 8 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 9 5 4 5 8 0 0 8 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 1 2 2 1 2 2 2 1 1 2 1 1 1 1 1 1 2 2 2 2 2 2 2 2 2 2 **Carcass ID Number** 0 20832 9 9 3 0 8 8 8 8 8 9 0 0 0 0 0 1 2 3 3 4 3 2 9 2 5 9 3 5 8 0 3 3 5 4 7 4 8 7 4 6 9 0 .6 7 Hematopoietic System Bone marrow ++ + х Hemangiosarcoma Lymph node Lymph node, mandibular + Lymph node, mesenteric + + + + 4 + + + + + Spleen + Thymus + + + + I Μ I I Μ ++ Ŧ + + + + + **Integumentary System** Mammary gland Skin + **Musculoskeletal System** Bone + + + Skeletal muscle **Nervous System** Brain Spinal cord **Respiratory System** Lung ++ Alveolar/bronchiolar adenoma х Х Alveolar/bronchiolar carcinoma Х Alveolar/bronchiolar carcinoma, multiple х Hepatocellular carcinoma, metastatic, liver Nose Trachea + **Special Senses System** Ear + X External ear, histiocytic sarcoma Harderian gland + х Adenoma **Urinary System** Kidney + Urinary bladder + + Systemic Lesions Multiple organs + X Histiocytic sarcoma х Х Lymphoma malignant

# *t*-Butylhydroquinone, NTP, TR 459

Table C2

Individual Animal Tumor Pathology	of M	ale	M	lice	e in	t (h	e 2	-¥	ear	r F	eed	1 S	tu	dy	oſ	t-B	ut	ylh	yd	roc	lni.	noi	ne:	5	<b>,0</b> 0	M I	opm	(cont	inued
Number of Days on Study	- 7 2 7	7 2 8	7 2 8	7 2 8	7 2 8	7 2 8	7 2 8	2	7 2 8	7 2 8	7. 2 8	7 2 8	7 2 8	7 2 8	7 2 8	7 2 9	7 2 9	7 2 9	7 2 9	7 2 9	7 2 9	7 2 9	7 2 9	7 2. 9	7 2 9	7 2 9			
Carcass ID Number	4	1 8 8	9	1 9 2	1 9 5	9	1 9 8	1	2 1 8	2 2 0	2 2 1	2 2 2	2 2 5	2 2 6	2 2 7	2 1 1	2 1 2	2 1 4	2 1 5	2 1 6	2 2 9	2 3 0	2 3 6	2 3 7	2 3 8	2 3 9		Total ssues/ umors	
Hematopoietic System Bone marrow Hemangiosarcoma Lymph node	+	+	+	+	.+	+	+	+	+	+	+	+	+	+	+	+	++	+	+	+	+	+	+	+	+	+		51 1 3	· · ·
Lymph node, mandibular Lymph node, mesenteric Spleen Thymus	+ + +	· + · + · +	+ + + +	+ + + M	+ + + M	+ + + +	+ + + +	+ + + +	+ + + +	+ + + +	+ + + +	+ + +	+ + + +	+ + +	+ + + +	+ + +	+ + + M	+ + +	+ + + +	+ + +	+ + + +	+ + +	+ + + +	+ + + M	+ + + +	+ + + +		51 51 51 42	•
I <b>ntegumentary System</b> Mammary gland Skin					і М +																					M +	ų	2 51	
Musculoskeletal System Bone Skeletal muscle	+	• +	. +	+	+	+	+	+	+	+	+	+	+	+	+	÷	+	+	+	+	+	+	+	+	+	+		51 1	
Nervous System Brain Spinal cord	+	• +	+	+	+	+	+	Ŧ	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		51 2	
Respiratory System Lung Alveolar/bronchiolar adenoma Alveolar/bronchiolar carcinoma Alveolar/bronchiolar carcinoma, multiple Hepatocellular carcinoma, metastatic, liver Nose	+	· + x	+	+	+ X	+	+ x	+	+ x	+	+	+	+	+ X	+	+	+	+ x x	+	+	+ x	+	+	+	+	+ x	,	51 9 4 2 1 51	•
Trachea	+	• +	+	+	+ +	+	+	+	+	+	++	+	+	+	++	+	++	+	+	+	+	+	++	+	+	++		51	
Special Senses System Ear External ear, histiocytic sarcoma Harderian gland Adenoma	+ X																								+ X			1 1 3 3	
U <b>rinary System</b> Kidney Urinary bladder	+		+	+	· +	+ +	+ +	++	++	+ +	++	;+ +	++	+++	++	+ +	+	++	+	+ +	++	+ +	+	+ +	+	+ +		51 51	
Systemic Lesions Multiple organs Histiocytic sarcoma Lymphoma malignant	ł	- +	• +	• +	• +	+	+	+	+	+	+	+	+	+	+	+	+ x	+	+	+	+	+	+	+	+	+	:	51 1 3	

ς.

ŗ

the set.

# TABLE C3

Statistical Analysis of Primary Neoplasms in Male Mice in the 2-Year Feed Study of t-Butylhydroquinone

	0 ppm	1,250 ppm	2,500 ppm	5,000 ppm	
Adrenal Cortex: Adenoma					
Overall rate <sup>a</sup>	1/50 (2%)	4/50 (8%)	1/50 (2%)	2/51 (4%)	
Adjusted rate <sup>b</sup>	2.6%	8.7%	2.7%	4.8%	
Cerminal rate <sup>C</sup>	1/39 (3%)	4/46 (9%)	1/37 (3%)	2/42 (5%)	
Virst incidence (days)	727 (T)	727 (T)	727 (T)	727 (T)	
life table test <sup>d</sup>	P=0.592N	P=0.233	P=0.750	P=0.526	
ogistic regression test <sup>d</sup>	P = 0.592N	P=0.233	P = 0.750	P = 0.526	
Cochran-Armitage test <sup>d</sup>	P = 0.588N	1-0.255	1-0.750	1-0.520	
Fisher exact test <sup>d</sup>	1 -0.30014	P=0.181	P=0.753N	P=0.508	
Harderian Gland: Adenoma					
Overall rate	3/50 (6%)	8/50 (16%)	4/51 (8%)	3/51 (6%)	
Adjusted rate	7.7%	17.4%	10.5%	7.0%	
erminal rate	3/39 (8%)	8/46 (17%)	4/38 (11%)	2/42 (5%)	
First incidence (days)	727 (T)	727 (T)	727 (T)	688	
Life table test	P=0.331N	P=0.159	P=0.486	P=0.631N	
Logistic regression test	P=0.351N	P=0.159	P=0.486	P=0.661N	
Cochran-Armitage test	P=0.325N		• • • • • • •		
Fisher exact test		P=0.100	P=0.511	P=0.652N	. •
Iarderian Gland: Adenoma or Carcinoma					
Overall rate	3/50 (6%)	8/50 (16%)	6/51 (12%)	3/51 (6%)	
Adjusted rate	7.7%	17.4%	15.8%	7.0%	
Cerminal rate	3/39 (8%)	8/46 (17%)	6/38 (16%)	2/42 (5%)	
First incidence (days)	727 (T)	727 (T)	727 (T)	688	
life table test	P=0.367N	P=0.159	P=0.228	P = 0.631N	1
ogistic regression test	P=0.389N	P=0.159	P=0.228	P = 0.661N	
Cochran-Armitage test	P=0.360N				
Fisher exact test		P = 0.100	P=0.254	P=0.652N	
Intestine, Small (Jejunum): Carcinoma			•		,
Dverall rate	0/50 (0%)	1/50 (2%)	3/51 (6%)	0/51 (0%)	
Adjusted rate	0.0%	2.2%	7.3%	0.0%	
Ferminal rate	0/39 (0%)	1/46 (2%)	2/38 (5%)	0/42 (0%)	
First incidence (days)	e	727 (T)	654		
Life table test	P=0.632N	P=0.533	P = 0.123	-	
Logistic regression test	P=0.628N	P=0.533	P = 0.124	-	
Cochran-Armitage test	P=0.627N				
Fisher exact test		P = 0.500	P=0.125	-	
Liver: Hepatocellular Adenoma				14161 (000)	
Overall rate	28/50 (56%)	22/50 (44%)	22/51 (43%)	14/51 (27%)	
Adjusted rate	60.6%	47.8%	53.2%	31.7%	
Terminal rate	21/39 (54%)	22/46 (48%)	19/38 (50%)	12/42 (29%)	
First incidence (days)	595	727 (T)	409	630	
Life table test	P=0.005N	P=0.050N	P = 0.208N	P = 0.004N	
Logistic regression test	P = 0.004N	P = 0.144N	P = 0.147N	P = 0.004N	
Cochran-Armitage test	P=0.003N	B 0 ( 60) 1	D_0 137N	B-0.002M	· ·
Fisher exact test	• ,	P=0.159N	P=0.137N	P=0.003N	

Statistical Analysis of Primary Neoplasms in Male Mice in the 2-Year Feed Study of t-Butylhydroquinone (continued)

	0 ppm	1,250 ppm	2,500 ppm	5,000 ppm	
Liver: Hepatocellular Carcinoma	9/50 /160	11/50 (00 01)	10/51 (0401)	9/51 (1601)	
Overall rate	8/50 (16%)	11/50 (22%)	12/51 (24%)	8/51 (16%)	
Adjusted rate	19.1%	22.8%	26.0%	17.6%	
Yerminal rate	6/39 (15%)	9/46 (20%)	6/38 (16%)	5/42 (12%)	
irst incidence (days)	619 D-0 400N	619 B-0.427	409 B=0.225	615 D-0 566N	
ife table test	P = 0.490N	P=0.437 P=0.248	P=0.225	P=0.566N P=0.585N	
Logistic regression test	P = 0.370N	P=0.248	P=0.342	P=0.365N	
Cochran-Armitage test Fisher exact test	P=0.465N	P=0.306	P=0.243	P=0.590N	
Isher exact lest		r=0.300	F=0.245	F=0.3901	
iver: Hepatocellular Adenoma or Carcinoma			· · · · · · · · · · · · · · · · · · ·		
Overall rate	31/50 (62%)	28/50 (56%)	29/51 (57%)	17/51 (33%)	
Adjusted rate	65.8%	58.3%	63.8%	37.7%	
Cerminal rate	23/39 (59%)	26/46 (57%)	22/38 (58%)	14/42 (33%)	
First incidence (days)	595	619	409	615	
Life table test	P=0.006N	P = 0.126N	P=0.480N	P=0.005N	
Logistic regression test	P = 0.002N	P=0.369N	P=0.341N	P = 0.004N	
Cochran-Armitage test	P = 0.002N				
isher exact test		P = 0.342N	P=0.373N	P=0.003N	
iver: Hemangiosarcoma					
Overall rate	3/50 (6%)	1/50 (2%)	1/51 (2%)	2/51 (4%)	
Adjusted rate	7.1%	2.2%	2.6%	4.3%	
erminal rate	2/39 (5%)	1/46 (2%)	1/38 (3%)	1/42 (2%)	
rirst incidence (days)	595	727 (T)	727 (T)	589	
life table test	P=0.471N	P=0.262N	P=0.317N	P=0.478N	
logistic regression test	P=0.423N	P=0.379N	P=0.278N	P=0.446N	
Cochran-Armitage test	P=0.465N				
isher exact test		P=0.309N	P=0.301N	P=0.491N	
Lung: Alveolar/bronchiolar Adenoma					
Overall rate	12/50 (24%)	10/48 (21%)	9/51 (18%)	9/51 (18%)	
Adjusted rate	28.1%	22.0%	22.1%	20.1%	
Ferminal rate	9/39 (23%)	9/44 (20%)	7/38 (18%)	7/42 (17%)	
First incidence (days)	647	619	619	589	
Life table test	P = 0.266N	P=0.304N	P=0.344N	P=0.272N	
Logistic regression test	P=0.250N	P=0.466N	P=0.312N	P=0.295N	
Cochran-Armitage test	P=0.245N				
Fisher exact test		P=0.447N	P=0.294N	P=0.294N	
Lung: Alveolar/bronchiolar Carcinoma		-			
Overall rate	3/50 (6%)	5/48 (10%)	3/51 (6%)	6/51 (12%)	
Adjusted rate	7.0%	11.0%	7.2%	13.3%	
Terminal rate	1/39 (3%)	4/44 (9%)	1/38 (3%)	4/42 (10%)	
First incidence (days)	651	654	666	595	
Life table test	P=0.242	P=0.418	P=0.648	P=0.266	
Logistic regression test	P=0.279	P=0.279	P=0.630N	P=0.271	
Cochran-Armitage test	P=0.252				
Fisher exact test		P=0.335	P=0.652N	P=0.254	

Statistical Analysis of Primary Neoplasms in Male Mice in the 2-Year Feed Study of t-Butylhydroquinone (continued)

	0 ppm	1,250 ppm	2,500 ppm	5,000 ppm	
		A		1. s	
Lung: Alveolar/bronchiolar Adenoma or Care					
Overall rate	15/50 (30%)	15/48 (31%)	11/51 (22%)	14/51 (27%)	
Adjusted rate	33.7%	32.4%	26.3%	30.0%	
Ferminal rate	10/39 (26%)	13/44 (30%)	8/38 (21%)	10/42 (24%)	
irst incidence (days)	647	619	619	589	
ife table test	P=0.394N	P=0.450N	P=0.286N	P=0.445N	
ogistic regression test	P=0.371N	P=0.483	P=0.237N	P=0.459N	
ochran-Armitage test	P=0.361N		D 0 0001	D 0 (77)	
isher exact test		P=0.534	P=0.229N	P=0.475N	
pleen: Hemangiosarcoma	•			· ·	
verall rate	4/50 (8%)	1/50 (2%)	0/51 (0%)	0/51 (0%)	
djusted rate	9.7%	2.2%	0.0%	0.0%	· ·
erminal rate	3/39 (8%)	1/46 (2%)	0/38 (0%)	0/42 (0%)	
rst incidence (days)	647	, 727 (T)	-	-	
ife table test	P=0.020N	P = 0.144N	P=0.068N	P = 0.060N	
ogistic regression test	P=0.019N	P=0.190N	P=0.060N	P=0.060N	•
ochran-Armitage test	P=0.019N				
isher exact test	•	P=0.181N	P = 0.056N	P=0.056N	•
ll Organs: Hemangiosarcoma					
verall rate	7/50 (14%)	3/50 (6%)	2/51 (4%)	2/51 (4%)	,
ljusted rate	15.8%	6.5%	5.3%	4.3%	•
erminal rate	4/39 (10%)	3/46 (7%)	2/38 (5%)	1/42 (2%)	
rst incidence (days)	595	727 (T)	727 (T)	589	
fe table test	P=0.058N	P=0.120N	P=0.093N	P=0.081N	
ogistic regression test	P=0.040N	P=0.242N	P=0.061N	P=0.055N	
ochran-Armitage test	P=0.052N				
sher exact test	*	P=0.159N	P=0.075N	P=0.075N	
Il Organs: Hemangioma or Hemangiosarcon	na		· ·		
verall rate	9/50 (18%)	3/50 (6%)	. 3/51 (6%)	2/51 (4%)	
djusted rate	20.6%	6.5%	7.9%	4.3%	
erminal rate	6/39 (15%)	3/46 (7%)	3/38 (8%)	1/42 (2%)	
irst incidence (days)	595	727 (T)	727 (T)	589	
ife table test	P=0.023N	P=0.041N	P=0.073N	P=0.027N	· · · ·
ogistic regression test	P=0.017N	P=0.095N	P=0.052N	P=0.019N	
ochran-Armitage test	P=0.020N		,		
isher exact test		P=0.061N	P=0.056N	P=0.024N	•
ll Organs: Malignant Lymphoma (NOS)	· .		•		
verall rate	4/50 (8%)	2/50 (4%)	6/51 (12%)	3/51 (6%)	
djusted rate	10.3%	4.3%	14.9%	7.1%	
erminal rate	4/39 (10%)	2/46 (4%)	4/38 (11%)	3/42 (7%)	
irst incidence (days)	727 (T)	727 (T)	673	727 (T)	
ife table test	P=0.547N	P=0.264N	P=0.356	P=0.459N	
ogistic regression test	P = 0.568N	P=0.264N	P=0.353	P=0.459N	
cochran-Armitage test	P=0.541N			•	
fisher exact test		P=0.339N	P=0.383	P=0.489N	

<.

•

Statistical Analysis of Primary Neoplasms in Male Mice in the 2-Year Feed Study of t-Butylhydroquinone (continued)

	0 ppm	1,250 ppm	2,500 ppm	5,000 ppm	,
All Organs: Benign Neoplasms			·····	· · · · · · · · · · · · · · · · · · ·	<sup>0</sup>
Overall rate	33/50 (66%)	38/50 (76%)	32/51 (63%)	27/51 (53%)	
Adjusted rate	70.0%	79.1%	74.1%	57.4%	
Terminal rate	25/39 (64%)	36/46 (78%)	27/38 (71%)	22/42 (52%)	
First incidence (days)	595	619	409	589	
Life table test	P=0.063N	P=0.550N	P=0.557N	P=0.122N	
Logistic regression test	P=0.049N	P=0.209	P = 0.482N	P = 0.140N	
Cochran-Armitage test	P=0.036N				
Fisher exact test		P=0.189	P=0.447N	P=0.128N	
All Organs: Malignant Neoplasms					
Overall rate	21/50 (42%)	23/50 (46%)	25/51 (49%)	20/51 (39%)	
Adjusted rate	47.1%	46.9%	49.9%	41.4%	
Terminal rate	16/39 (41%)	20/46 (43%)	13/38 (34%)	14/42 (33%)	
First incidence (days)	595	619	409	589	
Life table test	P=0.439N	P=0.488N	P=0.279	P=0.427N	
Logistic regression test	P=0.324N	P=0.337	P=0.380	P=0.450N	
Cochran-Armitage test	P=0.392N				
Fisher exact test		P=0.420	P=0.306	P=0.467N	
All Organs: Benign or Malignant Neoplasms					
Overall rate	39/50 (78%)	45/50 (90%)	43/51 (84%)	37/51 (73%)	
Adjusted rate	81.2%	90.0%	86.0%	75.5%	
Terminal rate	30/39 (77%)	41/46 (89%)	31/38 (82%)	30/42 (71%)	
First incidence (days)	595	619	409	589	
Life table test	P=0.253N	P=0.557N	P=0.248	P=0.288N	
Logistic regression test	P=0.158N	P=0.089	P=0.293	P=0.378N	
Cochran-Armitage test	P=0.136N				
Fisher exact test		P=0.086	P=0.289	P=0.343N	

(T)Terminal sacrifice

<sup>A</sup> Number of neoplasm-bearing animals/number of animals examined. Denominator is number of animals examined microscopically for adrenal gland, liver, lung, and spleen; for other tissues, denominator is number of animals necropsied.

<sup>b</sup> Kaplan-Meier estimated neoplasm incidence at the end of the study after adjustment for intercurrent mortality

<sup>c</sup> Observed incidence at terminal kill

<sup>d</sup> Beneath the control incidence are the P values associated with the trend test. Beneath the exposure group incidence are the P values corresponding to pairwise comparisons between the controls and that exposure group. The life table test regards neoplasms in animals dying prior to terminal kill as being (directly or indirectly) the cause of death. The logistic regression test regards these lesions as nonfatal. The Cochran-Armitage and Fisher exact tests compare directly the overall incidence rates. For all tests, a negative trend or a lower incidence in an exposure group is indicated by N.

Ż

<sup>e</sup> Not applicable; no neoptasms in animal group

4.

#### TABLE C4a

Historical Incidence of Hepatocellular Neoplasms in Untreated Male B6C3F1 Micea

		Incidence in Controls	
	Adenoma	Carcinoma	Adenoma or Carcinoma
Overall Historical Incidence			
Total Standard deviation Range	344/1,316 (26.1%) 13.2% 4%-60%	220/1,316 (16.7%) 7.2% 3%-29%	509/1,316 (38.7%) 13.9% 10%-68%
Data as of 17 June 1994			
TABLE C4b Historical Incidence of Spleen He	emangiosarcoma in Untreated Male	B6C3F <sub>1</sub> Mice <sup>a</sup> Incidence in Controls	
	emangiosarcoma in Untreated Male		

#### TABLE C4c

# Historical Incidence of Hemangioma and Hemangiosarcoma in Untreated Male B6C3F1 Mice<sup>a</sup>

		Incidence in Controls				
	Hemangioma	Hemangiosarcoma	Hemangioma or Hemangiosarcoma			
verall Historical Incidence						
verall Historical Incidence Total	7/1,324 (0.5%)	68/1,324 (5.1%)	75/1,324 (5.7%)			
	7/1,324 (0.5%) 1.1%	68/1,324 (5.1%) 4.1%	75/1,324 (5.7%) 3.9%			

ę

a Data as of 17 June 1994

2

Summary of the Incidence of Nonneoplastic Lesions in Male Mice in the 2-Year Feed Study of t-Butylhydroquinone<sup>a</sup>

	0 ррт	1,250 ppm	2,500 ppm	5,000 ppm		
Disposition Summary	,, <u></u> , <u></u> ,		· · · · · · · · · · · · · · · · · · ·			
Animals initially in study	60	60	60	60		
15-Month interim evaluation	10	10	9	9		
Early deaths						
Accidental death	1					
Moribund	6	3	7	7		
Natural deaths	4	1	6	2		
Survivors	20	10	28	40		
Terminal sacrifice	39	46	38	42		
Animals examined microscopically	60	60	60	60		
15-Month Interim Evaluation						
Alimentary System						
Liver	(10)	(10)	(9)	(9)		
Basophilic focus	2 (20%)					
Clear cell focus			2 (22%)			
Fatty change, focal	1 (10%)		1 (11%)			
Hematopoietic cell proliferation				1 (11%)		
Mixed cell focus				1 (11%)		
Necrosis, focal	1 (10%)					
Mesentery			(1)			
Fat, necrosis			1 (100%)			
Pancreas	(10)	(10)	(9)	(9)		
Atrophy, focal			1 (11%)			
Tooth	(1)	(1)		(2)		
Incisor, dysplasia	1 (100%)	1 (100%)		2 (100%)		
Endocrine System	(10)	(10)				
Adrenal cortex	(10)	(10)	(9)	(9)		
Cyst Subconsular, humamlasia	1 (10%)	1 (10 %)		2 (22 %)		
Subcapsular, hyperplasia Islets, pancreatic	(10)	1 (10%) (10)	(9)	2 (22%) (9)		
Cyst	(10)	(10)	1 (11%)	(3)		
Parathyroid gland	(10)	(10)	(8)	(9)		
Cyst	(10)	1 (10%)		()		
Pituitary gland	(9)	(10)	(8)	(8)		
Cyst		()	1 (13%)			
Thyroid gland	(10)	(10)	(9)	(9)		
Degeneration, cystic, focal	1 (10%)					
Fibrosis, focal	1 (10%)					
Genital System				- <u>'a</u> ''		
Preputial gland	(10)	(10)	(9)	(8)		
Degeneration, cystic		2 (20%)	1 (11%)			
Seminal vesicle	(10)	(10)	(9)	(9)		
Inflammation, chronic		1 (10%)				
Testes	(10)	(10)	(9)	(9)		
Granuloma sperm	1 (10%)		•			

ŝ,

<sup>a</sup> Number of animals examined microscopically at the site and the number of animals with lesion

ŝ

Summary of the Incidence of Nonneoplastic Lesions in Male Mice in the 2-Year Feed Study of *t*-Butylhydroquinone (continued)

	0 ppm	1,250 ppm	2,500 ppm	5,000 ppm
15-Month Interim Evaluation (co	ntinued)	······································		
Hematopoietic System Spleen	(10)	(10)	(9)	(9)
Hematopoietic cell proliferation Thymus	(9)	(10)	(9) 1 (11%)	2 (22%) (9)
Cyst			1 (11%)	
Integumentary System Skin Alopecia	(10)	(10)	(9)	(9) 1 (11%)
Respiratory System	(10)	(10)	(0)	
Lung Alveolar epithelium, hyperplasia	(10) 1 (10%)	(10)	(9) 1 (11%)	(9)
Systems Examined With No Lesions Cardiovascular System General Body System	Observed			e e e e e e e e e e e e e e e e e e e
Musculoskeletal System				
Nervous System Special Senses System		e'		
Urinary System			· ·	· · · ·
2 V		. <u></u>		
2-Year Study				,
Alimentary System Intestine small, jejunum	(50)	(50)	(48)	(50)
Perforation	(50)	(50)	1 (2%)	
Peyer's patch, hyperplasia, lymphoid		2 (4%)	1 (2%)	1 (2%)
Intestine small, ileum	(49)	(49)	(49)	(49)
Peyer's patch, hyperplasia, lymphoid				1 (2%)
Liver	(50)	(50)	(51)	(51)
Angiectasis	2 (4%)	1 (2%)		1 (2%)
Basophilic focus	3 (6%)	2 (4%)	2 (4%)	5 (10%)
Clear cell focus	4 (8%)	3 (6%)	5 (10%)	3 (6%)
Clear cell focus, multiple	2 (4%)	4 (8%)	2 (4%)	1 (2%)
Cyst	T (1 4 M)		4 (8%)	1 (2%) 3 (6%)
Eosinophilic focus	7 (14%)	4 (8%)	1 (2%)	1 (2%)
Eosinophilic focus, multiple	1 (2%)	1 (2%)	1 (276)	1 (270)
Fatty change	1 (2%) 6 (12%)	8 (16%)	5 (10%)	3 (6%)
Fatty change, focal Hematopoietic cell proliferation	1 (2%)	0 (10/0)	. (10,0)	- (2)/
Hepatodiaphragmatic nodule	1 (270)	1 (2%)	. ·	
Infiltration cellular, mixed cell	1. (2%)	- (=///		
Inflammation, focal	2 (4%)		1 (2%)	
Mixed cell focus	5 (10%)	8 (16%)	4 (8%)	4 (8%)
Mixed cell focus, multiple				3 (6%)
Necrosis, focal	1 (2%)	1 (2%)	2 (4%)	1 (2%)
Pigmentation, focal	1 (2%)			
Thrombosis	1 (2%)			

.

Summary of the Incidence of Nonneoplastic Lesions in Male Mice in the 2-Year Feed Study of *t*-Butylhydroquinone (continued)

	0 ppm		1,250 ppm		2,500 ppm		5,000 ppm	
2-Year Study (continued)			<del></del>			·····		
Alimentary System (continued)								
Liver (continued)	(50)		(50)		. (61)		(61)	
Bile duct, hyperplasia	(50)		(50)	(201)	(51)		(51)	
Centrilobular, necrosis			1	(2%)	1	() (1)		
Oval cell, hyperplasia						(2%) (2%)		
Mesentery	(2)		(7)			(270)		
Inflammation, chronic	(2)			(14%)	(14)	(21%)	(1)	
Artery, inflammation, chronic	1	(50%)	1	(14%)		(21%)	•	
Fat. necrosis	1	(50%)	5	(71%)		(43%)	. 1	(100%)
Pancreas	(49)		(50)	(11/0)	(51)	(4370)	(51)	(100%)
Atrophy, diffuse		() (()	• •	(20)	(51)		(51)	
Attophy, datuse Atrophy, focal	1	(2%)	1	(2%)	1	(2%)		
Duct, cyst	1	(2%)	r	(4%)	1	(2/0)		
Stomach, forestomach	(49)	(270)	(50)	( 7/0 )	(51)		(51)	
Edema	(4)		(50)			(2%)	(51)	
Erosion	1	(2%)				(2%)		
Inflammation, chronic		(2 <i>%</i> ) (6%)~	2	(4%)		(2%)		*
Epithelium, hyperplasia		(8%)		(4%)		(2%)		
Stomach, glandular	(49)	(0.10)	(50)	( 7/0 )	(51)	(2/0)	(50)	
Edema	(7)		(50)			(2%)	(50)	
Erosion	1	(2%)				(2%)		
Mineralization		(2%)				(2%)		
Pigmentation, focal	I	(270)				(2%)		
Epithelium, hyperplasia, cystic			1	(2%)	1	(~ /0)		
Tooth	(28)		(26)	(2/0)	(18)		(26)	
Incisor, dysplasia		(100%)		(100%)		(100%)		(100%)
	20	(100%)	20	(100 %)		(100%)		(100 %)
Cardiovascular System								
Heart	(50)		(50)		(51)		(51)	
Inflammation, chronic, focal	2	(4%)						
Artery, degeneration							1	(2%)
Artery, inflammation, chronic							1	(2%)
Endocrine System								
Adrenal cortex	(50)		(50)		(50)		(51)	
Accessory adrenal cortical nodule		(6%)		(2%)	(50)			(4%)
Cyst	5	(570)	1	(=,0)	1	(2%)	2	(~/0)
Cytoplasmic alteration, focal	1	(2%)	3	(6%)		(4%)		
Fibrosis		(2%)		(2%)	2	(1)0)		
Subcapsular, hyperplasia, focal		(10%)	4	(8%)	6	(12%)	8	(16%)
Islets, pancreatic	(50)		(50)	(- /• /	(51)	(-= //)	(51)	(-0/0)
Hyperplasia	(50)		(55)			(2%)		(2%)
Parathyroid gland	(49)		(46)		(50)	(2,0)	(44)	(-,-,
Cyst		(4%)		(2%)	(20)		()	
Pituitary gland	(46)	()	(42)	(_,_,	(45)		(49)	
Angiectasis	(40)			(2%)	(45)		(-7)	
·D· · · · · · · · · · · · · · · · ·		(2%)		(5%)	-	(4%)		(6%)

j,

•

4j

.0.

¢

à

Summary of the Incidence of Nonneoplastic Lesions in Male Mice in the 2-Year Feed Study of *t*-Butylhydroquinone (continued)

	0 ppm	1,250 ppm	2,500 ppm	5,000 ppm		
2-Year Study (continued)		- ·				
•						
Endocrine System (continued)						
Thyroid gland	(50)	(50)	(50)	(51)		
Degeneration, cystic, focal	6 (12%)	5 (10%)	6 (12%)	6 (12%)		
C-cell, hyperplasia	1 (2%)					
Follicle, hypertrophy, focal		1 (2%)				
Follicular cell, hyperplasia	6 (12%)	12 (24%)	6 (12%)	6 (12%)		
General Body System						
Tissue NOS				(3)		
Pelvic, inflammation, chronic				2 (67%)		
Genital System	···· = ······					
Coagulating gland	(4)	(6)	(2)	(1)		
Inflammation, chronic	(+)	(0)	(2)	(1) 1 (100%)		
Epididymis	(50)	(50)	(51)			
Spermatocele	(50)	(50)	(51)	(50)		
Preputial gland	(50)	(40)	(50)	1 (2%)		
Degeneration, cystic		(49) 28 (57 <i>%</i> )	(50) 32 (64%)	(51)		
Inflammation, cystic	22 (44%)	28 (57%) 5 (10%)	32 (64%)	29 (57%)		
-	8 (16%)	5 (10%)	8 (16%)	5 (10%)		
Prostate	(49)	(50)	(51)	(51)		
Inflammation, chronic, focal	1 (0.01)		1 (2%)	1 (0.17)		
Epithelium, hyperplasia, focal	1 (2%)	(50)	2 (4%)	1 (2%)		
Seminal vesicle	(50)	(50)	(51)	(51)		
Inflammation, chronic	(50)	(20)	(64)	1 (2%)		
Testes	(50)	(50)	(51)	(51)		
Fibrosis				1 (2%)		
Mineralization, focal		1 (2%)		1 (2%)		
Thrombosis				1 (2%)		
Artery, inflammation, chronic				1 (2%)		
Germinal epithelium, degeneration		1 (2%)				
Hematopoietic System						
Bone marrow	(50)	(50)	(51)	(51)		
Angiectasis	1 (2%)					
Hyperplasia		1 (2%)		•		
Myelofibrosis	1 (2%)					
Lymph node	(3)	(3)	(6)	(3)		
Bronchial, hyperplasia			1 (17%)			
Iliac, hemorrhage			1 (17%)			
Inguinal, hyperplasia	2 (67%)	1 (33%)	· ·			
Inguinal, hyperplasia, lymphoid	· · ·	1 (33%)	1 (17%)			
Inguinal, pigmentation		1 (33%)				
Mediastinal, hyperplasia		1 (33%)				
Mediastinal, hyperplasia, lymphoid	1 (33%)	, <i>,</i>				
Renal, hemorrhage			1 (17%)			
Lymph node, mandibular	(48)	(48)	(49)	(51)		
Hyperplasia, lymphoid		1 (2%)		1 (2%)		

ĉ
#### TABLE C5

Summary of the Incidence of Nonneoplastic Lesions in Male Mice in the 2-Year Feed Study of *t*-Butylhydroquinone (continued)

	0 ppm	1,250 ppm	2,500 ppm	5,000 ppm
2-Year Study (continued)	- · · · · · · · · · · · · · · · · · · ·			47444 - 9.00
• · · · ·				
Hematopoietic System (continued)	(50)	(40)	(51)	· · · · · · · · · · · · · · · · · · ·
Lymph node, mesenteric	(50)	(48)	(51)	(51)
Ectasia	2 (4%)	2 (4.6%)	2 (4.17)	
Hematopoietic cell proliferation	1 (2%)	2 (4%)	2 (4%)	0 (19/7)
Hemorrhage	12 (24%)	11 (23%)	9 (18%)	9 (18%)
Hyperplasia Hyperplasia histicautic		1 (2%)	1 (2%)	1 (20)
Hyperplasia, histiocytic	· · · · · · · · · · · · · · · · · · ·		3 (49)	1 (2%)
Hyperplasia, lymphoid	2 (4%)	3 (6%)	2 (4%) (51)	1 (2%)
Spieen Accessory spieen	(50)	(50)	(31)	(51)
	1 (2%)	12 (24 0)	17 (220)	9 (18%)
Hematopoietic cell proliferation Hyperplasia, lymphoid	8 (16%)	12 (24%) 2 (4%)	17 (33%) 1 (2%)	1 (2%)
Thymus	(44)		(43)	
Cyst	(44) 4 (9%)	(38) 8 (21%)	4 (9%)	(42) 4 (10%)
Cyst	. 4 (9%)	0 (2170)	4 (976)	4 (10%)
Integumentary System				
Skin	(50)	(50)	(51)	(51)
Alopecia	1 (2%)	1 (2%)	1 (2%)	
Inflammation, chronic, focal	2 (4%)			
Ulcer	1 (2%)			
Epidermis, hyperplasia, focal	1 (2%)			
Subcutaneous tissue, edema			2 (4%)	1 (2%)
Subcutaneous tissue, mineralization, focal		1 (2%)		1 (2%)
Subcutaneous tissue, necrosis, focal		1 (2%)		·
Musculoskeletal System				
Skeletal muscle	(2)		(1)	(1)
Mineralization, focal	1 (50%)			
Nervous System				
Brain	(50)	(50)	(51)	(51)
Atrophy, focal	1 (2%)			
Respiratory System				
Lung	(50)	(48)	(51)	(51)
Congestion	N= = /	1 (2%)	1 (2%)	<b>x/</b>
Hemorrhage		2 (4%)	~ ~~~/	
Hyperplasia, histiocytic	2 (4%)	4 (8%)	1 (2%)	1 (2%)
Inflammation, chronic, focal		1 (2%)	1 (2%)	1 (2%)
Thrombosis, multiple			1 (2%)	
Alveolar epithelium, hyperplasia	3 (6%)	5 (10%)	3 (6%)	9 (18%)
Interstitium, edema	• •	· ·	· ·	1 (2%)
Mediastinum, edema			1 (2%)	
Nose	(50)	(50)	(51)	(51)
Inflammation, suppurative	2 (4%)	2 (4%)		
Mucosa, cyst		• •		1 (2%)
Mucosa, polyp, inflammatory		1 (2%)		
Mucosa, glands, dilatation, focal	9 (18%)	18 (36%)	10 (20%)	9 (18%)

è

ą.

3

#### TABLE C5

-...

۰.,

.

Summary of the Incidence of Nonneoplastic Lesions in Male Mice in the 2-Year Feed Study of *t*-Butylhydroquinone (continued)

	0 ppm	1,250 ppm	2,500 ppm	5,000 ppm
2-Year Study (continued)				
Special Senses System			· · ·	
Harderian gland	(3)	(9)	<b>(6)</b>	(3)
Hyperplasia, focal		1 (11%)		
Urinary System				
Kidney	(50)	(50)	(51)	(51)
Cyst	1 (2%)	1 (2%)	1 (2%)	1 (2%)
Fibrosis, focal	1 (2%)			•
Hydronephrosis		1 (2%)		1 (2%)
Hyperplasia, focal				1 (2%)
Necrosis, focal	1 (2%)			
Nephropathy	50 (100%)	47 (94%)	48 (94%)	50 (98%)
Pelvis, inflammation, suppurative			ч.	1 (2%)
Renal tubule, dilatation, diffuse	1 (2%)	2 4	e de la companya de l	
Renal tubule, dilatation, focal	•	1 (2%)		1 (2%)
Renal tubule, hyperplasia, focal	1 (2%)	1 (2%)		
Urinary bladder	(50)	(50)	(51)	(51)
Calculus microscopic observation only		1 (2%)	· *	
Transitional epithelium, hyperplasia		1 (2%)		

Ð

þ

# APPENDIX D

# SUMMARY OF LESIONS IN FEMALE MICE IN THE 2-YEAR FEED STUDY OF &BUTYLHYDROQUINONE

Table D1	Summary of the Incidence of Neoplasms in Female Mice	
· .	in the 2-Year Feed Study of <i>t</i> -Butylhydroquinone	<b>22</b> 1
Table D2	Individual Animal Tumor Pathology of Female Mice	•
	in the 2-Year Feed Study of t-Butylhydroquinone	226
Table D3	Statistical Analysis of Primary Neoplasms in Female Mice	
	in the 2-Year Feed Study of <i>t</i> -Butylhydroquinone	250
Table D4a	Historical Incidence of Hepatocellular Neoplasms in Untreated Female B6C3F <sub>1</sub> Mice	
Table D4b	Historical Incidence of Thyroid Gland (Follicular Cell) Adenoma	
	in Untreated Female B6C3F <sub>1</sub> Mice	254
Table D5	Summary of the Incidence of Nonneoplastic Lesions in Female Mice	
	in the 2-Year Feed Study of t-Butylhydroquinone	255

Summary of the Incidence of Neoplasms in Female Mice in the 2-Year Feed Study of t-Butylhydroquinone<sup>a</sup>

	0 ppm	1,250 ppm	2,500 ppm	5,000 ppm
Disposition Summary				
Animals initially in study	60	60	60	60
15-Month interim evaluation	9	8	9	6
Early deaths				
Moribund sacrifice	11	7	6	6
Natural death	2	10	5	5
Survivors				
Died last week of study	1			1
Terminal sacrifice	37	35	40	42
Animals examined microscopically	60	60	60	60
15-Month Interim Evaluation				
Alimentary System				
Liver	(9)	(8)	(9)	(6)
Hepatocellular carcinoma		1 (13%)		
Hepatocellular adenoma			1 (11%)	
Genital System	· · · · · · · · · · · · · · · · · · ·	· · · · · · · · · · · · · · · · · · ·		
Ovary	(9)	(8)	(9)	(6)
Cystadenoma	(-)		1 (11%)	\~/
Respiratory System Lung Alveolar/bronchiolar adenoma Systems Examined With No Neopla Cardiovascular System	(9) 1 (11%) usms Observed	(8)	(9)	(6)
Endocrine System Endocrine System General Body System Hematopoietic System Integumentary System Musculoskeletal System Nervous System Special Senses System Urinary System				
Endocrine System General Body System Hematopoietic System Integumentary System Musculoskeletal System Nervous System Special Senses System Urinary System				
Endocrine System General Body System Hematopoietic System Integumentary System Musculoskeletal System Nervous System Special Senses System Urinary System 2-Year Study				
Endocrine System General Body System Hematopoietic System Integumentary System Musculoskeletal System Nervous System Special Senses System Urinary System 2-Year Study Alimentary System	(50)	(50)	(47)	(54)
Endocrine System General Body System Hematopoietic System Integumentary System Musculoskeletal System Nervous System Special Senses System Urinary System 2-Year Study Alimentary System Galibladder	(50) (51)	(50)	(47) (48)	(54)
Endocrine System General Body System Hematopoietic System Integumentary System Musculoskeletal System Nervous System Special Senses System Urinary System 2-Year Study Alimentary System Galibladder Intestine large, cecum	(51)	(50)	(48)	(53)
Endocrine System General Body System Hematopoietic System Integumentary System Musculoskeletal System Nervous System Special Senses System Urinary System 				(53) (53)
Endocrine System General Body System Hematopoietic System Integumentary System Musculoskeletal System Nervous System Special Senses System Urinary System 	(51)	(50)	(48)	(53)

Summary of the Incidence of Neoplasms in Female Mice in the 2-Year Feed Study of t-Butylhydroquinone (continued)

	0 ppm	1,250 ppm	2,500 ppm	5,000 ppm
2-Year Study (continued)				· · ·
Alimentary System (continued)				
Liver	· (51)	(52)	(51)	(54)
Hemangioma		1 (2%)		1
Hemangiosarcoma	1 (2%)		· ,	1 (2%)
Hepatoblastoma			1 (2%)	· · · · ·
Hepatocellular carcinoma	7 (14%)	8 (15%)	7 (14%)	4 (7%)
Hepatocellular carcinoma, multiple	1 (2%)		1 (2%)	1 (2%)
Hepatocellular adenoma	8 (16%)	11 (21%)	11 (22%)	4 (7%)
"Hepatocellular adenoma, multiple	1 (2%)	9 (17%)	5 (10%)	1 (2%)
Histiocytic sarcoma	1 (2%)	1 (2%)	1 (2%)	2 (4%)
Mesentery	(10)	(13)	(7)	(8)
Hepatocellular carcinoma, metastatic, liver			1 (14%)	
Histiocytic sarcoma			1 (14%)	
Squamous cell carcinoma, metastatic, stoma	ach.			
forestomach	· · · · · · · · · · · · · · · · · · ·	1 (8%)	•	•
Pancreas	(51)	(52)	(49)	(54)
Carcinoma	(01)	1 (2%)	(12)	(01)
Hepatocellular carcinoma, metastatic, liver		1 (270)	1 (2%)	
Salivary glands	(51)	(52)	(51)	(53)
Sarcoma	(51)	1 (2%)	(51)	(55)
		· ·		
Sarcoma, metastatic, skin	(51)	1 (2%)	(51)	(54)
Stomach, forestomach	(51)	(52)	(51)	(54)
Squamous cell carcinoma		1 (2%)		0 (4.01)
Squamous cell papilloma	1 (2%)		(10)	2 (4%)
Stomach, glandular	(51)	(52)	(49)	(54)
Cardiovascular System		······································		· · ·
None			• · · · · ·	
Endocrine System	(51)	(61)	(50)	(54)
Adrenal cortex	(51)	(51)	(50)	(54)
Capsule, hepatocellular carcinoma,			1 (2)77)	
metastatic, liver	(54)	(61)	1 (2%)	(54)
Adrenal medulla	(51)	(51)	(51)	(54)
Pheochromocytoma malignant			1 (2%)	
Pheochromocytoma benign	1 (2%)	1 (2%)	(10)	· · · ·
Pheochromocytoma benign Islets, pancreatic	(51)	(52)	(48)	(54)
Pheochromocytoma benign Islets, pancreatic Adenoma	(51) 1 (2%)	. (52)	1 (2%)	
Pheochromocytoma benign Islets, pancreatic Adenoma Pituitary gland	(51) 1 (2%) (49)	. (52) (44)	1 (2%) (46)	(49)
Pheochromocytoma benign Islets, pancreatic Adenoma Pituitary gland Pars distalis, adenoma	(51) 1 (2%)	(52) (44) 5 (11%)	1 (2%)	
Pheochromocytoma benign Islets, pancreatic Adenoma Pituitary gland	(51) 1 (2%) (49)	. (52) (44)	1 (2%) (46)	(49) 4 (8%)
Pheochromocytoma benign Islets, pancreatic Adenoma Pituitary gland Pars distalis, adenoma	(51) 1 (2%) (49)	(52) (44) 5 (11%) 1 (2%)	1 (2%) (46) 5 (11%)	(49) 4 (8%) 1 (2%)
Pheochromocytoma benign Islets, pancreatic Adenoma Pituitary gland Pars distalis, adenoma Pars distalis, carcinoma Pars intermedia, adenoma	(51) 1 (2%) (49) 5 (10%)	(52) (44) 5 (11%) 1 (2%)	1 (2%) (46)	(49) 4 (8%) 1 (2%) (54)
Pheochromocytoma benign Islets, pancreatic Adenoma Pituitary gland Pars distalis, adenoma Pars distalis, carcinoma Pars intermedia, adenoma	(51) 1 (2%) (49)	(52) (44) 5 (11%)	1 (2%) (46) 5 (11%)	(49) 4 (8%) 1 (2%)
Pheochromocytoma benign Islets, pancreatic Adenoma Pituitary gland Pars distalis, adenoma Pars distalis, carcinoma Pars intermedia, adenoma Thyroid gland Follicular cell, adenoma	(51) 1 (2%) (49) 5 (10%) (51)	(52) (44) 5 (11%) 1 (2%) (51)	1 (2%) (46) 5 (11%) (50)	(49) 4 (8%) 1 (2%) (54)
Pheochromocytoma benign Islets, pancreatic Adenoma Pituitary gland Pars distalis, adenoma Pars distalis, carcinoma Pars intermedia, adenoma Thyroid gland Follicular cell, adenoma General Body System	(51) 1 (2%) (49) 5 (10%) (51)	(52) (44) 5 (11%) 1 (2%) (51) 3 (6%)	1 (2%) (46) 5 (11%) (50) 2 (4%)	(49) 4 (8%) 1 (2%) (54)
Pheochromocytoma benign Islets, pancreatic Adenoma Pituitary gland Pars distalis, adenoma Pars distalis, carcinoma Pars intermedia, adenoma Thyroid gland Follicular cell, adenoma	(51) 1 (2%) (49) 5 (10%) (51)	(52) (44) 5 (11%) 1 (2%) (51)	1 (2%) (46) 5 (11%) (50)	(49) 4 (8%) 1 (2%) (54)

ż,

# e-Butylhydroquinone, NTP TR 459

# Table D1

Summary of the Incidence of Neoplasms in Female Mice in the 2-Year Feed Study of t-Butylhydroquinone (continued)

	• 0 ppm	1,250 ppm	2,500 ppm	5,000 ppm
2-Year Study (continued)		· · · · · · · · · · · · · · · · · · ·		
Genital System				
	(51)		(50)	
Clitoral gland Ovary	(51)	(52)	(50)	(54)
Cystadenoma	(50)	(49)	(47)	(50)
	2 (4%)	2 (4%)	3 (6%)	2 (4%)
Granulosa cell tumor malignant Histiocytic sarcoma	1 (0 (1))		1 (2%)	
Luteoma	1 (2%)	1 (2%)	1 (2%)	1
Teratoma NOS	1 (2%)			
Uterus	(61)		(50)	1 (2%)
Hemangiosarcoma	(51)	(52)	(50)	(54)
	1 (2%)	1 (2 %)	0 (19)	
Histiocytic sarcoma Leiomyosarcoma	1 (2%)	1 (2%)	2 (4%)	1 (2%)
Endometrium, adenoma	1 (30)		1 (0.01)	1 (2%)
Endometrium, adenoma Endometrium, carcinoma	1 (2%)		1 (2%)	
Endometrium, caremonia Endometrium, polyp stromal	1 (2%)		2 1601	1 (20)
Endomentum, polyp stromat			3 (6%)	1 (2%)
Hematopoietic System				, ,
Bone marrow	(51)	(52)	(51)	(54)
_ymph node	(7)	(8)	(12)	(9)
Iliac, histiocytic sarcoma	1 (14%)		1 (8%)	
Inguinal, histiocytic sarcoma		1 (13%)	- ()	
Mediastinal, hepatocellular carcinoma,				
metastatic, liver			1 (8%)	,
Mediastinal, histiocytic sarcoma			1 (8%)	
Renal, histiocytic sarcoma	1 (14%)		1 (8%)	
ymph node, mandibular	(48)	(52)	(50)	(52)
Lymph node, mesenteric	(50)	(48)	(49)	(50)
Hepatocellular carcinoma, metastatic, liver			1 (2%)	(20)
Histiocytic sarcoma	1 (2%)		1 (2%)	2 (4%)
pleen	(51)	(52)	(50)	(54)
Hemangiosarcoma			1 (2%)	x- ·/
Histiocytic sarcoma	1 (2%)	1 (2%)	··/	
Thymus	(45)	(51)	(47)	(48)
Histiocytic sarcoma			. /	1 (2%)
mtammantanu Suctor			······································	· .
Integumentary System Mammary gland	(51)	(51)	(51)	(54)
Carcinoma	(51)	(31)	(51)	(54)
Myoepithelioma			1 (20)	1 (2%)
Skin	(51)	(52)	1 (2%)	(54)
Basal cell carcinoma	1 (2%)	(32)	(51)	(54)
Squamous cell papilloma	1 (270)			1 (2%)
Subcutaneous tissue, fibrosarcoma			1 (2%)	
Subcutaneous tissue, histiocytic sarcoma	1 (2%)	2 (4%)	1 (2%) 1 (2%)	1 (2%)
Subcutaneous tissue, sarcoma	2 (4%)	2 (4%)	1 (2%)	1 (2%)

,

223

Summary of the Incidence of Neoplasms in Female Mice in the 2-Year Feed Study of t-Butylhydroquinone (continued)

	0 ppm	1,250 ppm	2,500 ppm	5,000 ppm
2-Year Study (continued)				
Musculoskeletal System				×
Bone	(51)	(52)	(51)	(54)
Osteosarcoma	(51)	(32)	(51)	
Skeletal muscle	(1)	(1)	(2)	1 (2%)
Hepatocellular carcinoma, metastatic, liver	(1)	(1)	(2) 1 (50%)	; *
			I (30%)	, ,
Nervous System				
lone			·	
Denningtonen Gustone	· · · · ·			· · · · · · · · · · · · · · · · · · ·
Respiratory System	(51)	(53)	(51)	(64)
Lung	(51)	(52)	(51)	(54)
Alveolar/bronchiolar adenoma	2 (4%)	2 (4%)	4 (8%)	3 (6%)
Alveolar/bronchiolar adenoma, multiple	1 (2%)			
Alveolar/bronchiolar carcinoma	2 (4%)		1 (2%)	
Basal cell carcinoma, metastatic, skin	1 (2%)			
Hepatoblastoma, metastatic, liver			1 (2%)	
Hepatocellular carcinoma, metastatic, liver	1 (2%)	1 (2%)	4 (8%)	2 (4%)
Histiocytic sarcoma		1 (2%)	1 (2%)	1 (2%)
Osteosarcoma, metastatic, bone				1 (2%)
Sarcoma, metastatic, skin			1 (2%)	-
Squamous cell carcinoma, metastatic, stomach,				• * .
forestomach		1 (2%)		
Mediastinum, squamous cell carcinoma, metastatic, stomach, forestomach		1 (2%)		•
Special Senses System			×	· .
Harderian gland		(1)	(6)	(1)
Adenoma			6 (100%)	1 (100%)
Carcinoma		1 (100%)		
Urinary System				
Kidney	(51)	(52)	(50)	(53)
Histiocytic sarcoma	1 (2%)	1 (2%)	1 (2%)	(
Squamous cell carcinoma, metastatic, stomach,	- (	- (-,-,	- (-/-/	
forestomach		1 (2%)		
Urinary bladder	(51)	(51)	(50)	(53)
Histiocytic sarcoma	. /	• •	1 (2%)	• • •
			i an	
Systemic Lesions	(21)	(52)	(51)	(54)
Multiple organs <sup>b</sup>	(51)	(52)	(51)	(54)
Histiocytic sarcoma	2 (4%)	2 (4%)	3 (6%)	4 (7%)
Lymphoma malignant	3 (6%)	9 (17%)	10 (20%)	8 (15%)
Lymphoma malignant mixed		1 (2%)		

#### Table D1

Summary of the Incidence of Neoplasms in Female Mice in the 2-Year Feed Study of t-Butylhydroquinone (continued)

	0 ppm	1,250 ppm	2,500 ppm	5,000 ppm
Neoplasm Summary			<u></u>	
Total animals with primary neoplasms <sup>c</sup>				
15-Month interim evaluation	1	1	2	
2-Year study	32	41	36	33
Total primary neoplasms				
15-Month interim evaluation	- 1	1	2	
2-Year study	46	61	71	49
Total animals with benign neoplasms				
15-Month interim evaluation	1		2	
2-Year study	22	26	25	19
Total benign neoplasms				
15-Month interim evaluation	1		2	
2-Year study	25	34	42	25
Total animals with malignant neoplasms				
15-Month interim evaluation		1		
2-Year study	18	22	22	22
Total malignant neoplasms				
15-Month interim evaluation		· 1		
2-Year study	21	27	29	23
Total animals with metastatic neoplasms				
2-Year study	2	3	6	3
Total metastatic neoplasms				
2-Year study	2	6	12	3
Total animals with uncertain neoplasms —				
benign or malignant				
2-Year study				1
Total uncertain neoplasms				
2-Year study				. 1

Number of animals examined microscopically at the site and the number of animals with neoplasm Number of animals with any tissue examined microscopically Primary neoplasms: all neoplasms except metastatic neoplasms a b

с

TABLE D2

Individual Animal Tumo	r Patho	logy of	Fen	18	Ie N	/1i	ce í	n	the	2-	·Ye	ear	ľ	eed	I SI	tud	IY C	) t	-B	uty	'lh	ydi	•oq	lnii	10r	ne:	U	ppn	1		,
			3	;	4 5	5	5 5	5	6	6	6	6	6	6	6	7	7	7	7	7	7	7	7	7	7	7	7	7			
Number of Days on Study			6	5	65	5	6 8	8	1	1	1	2	6	7	7	·2	3	3	3	3	3	3	3	3	3	3	3	3	••		• •
			4	ŀ	1 (		7 2			8	9	2	7	3	7	3	4	4	4	4	4	4	4	4	4	4	4	4			
· · · · ·			2	2	2 2	2	2 2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2			
Carcass ID Number			7	,	68	2	6 4	1	6	8	4	6	7	5	7	8	4	5	5	5	5	5	6	8	9	9	9	9			:
							1 8	•	9							4									-	3		-			
Alimentary System																															
Esophagus				F	+ -	ŧ.	+ .	+	+	+	+	·+-	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+			
Gallbladder	÷			Ľ	Δ.	Ļ	Ļ.	÷	÷	÷	÷.	÷		+	÷	÷		÷	÷	+	+	, +	+	, +	, +	+	+	- -			
Intestine large, colon				L.	л	Ļ	т. 	÷	÷	Ť.	т Т	÷	1	1	÷			÷	÷.	+	+	, _		, _	+	+	+	1	•		
Intestine large, rectum				Г L	т : 	T L	т.	T L	т т	т ⊥	т _	т _	т 	Ť	T L	т -	т 	т 	+	т 	т Т	т 	т 	- -	т 	т 	Ť	́т т		•	
			-	Г L	т - 1	T L	т : _	Ť	Ť	т -	T	T.		T	т 		т 	т 	т 	т -	т 	т -	т 	т -	т -	т 	т 	т - Г			
Intestine large, cecum				г L	т. т	τ" 1	т. Т	7 1	т ⊥	т т	т -	Ţ	т 	+	+	T L	т 	т 	+	+	Ť	T	т 	T	T L	T L	т .1	т _			
Intestine small, duodenum			-	г L	т. -	T L	т · т	+ +	т 1	т _	Ţ.,	 	+			+	+	- <b>-</b>			+	+	+	+	+	+	T.	т J			
Intestine small, jejunum Intestine small, ileum	• .		·.	т <sup>.</sup> 1.	+ · +	Ť	+ ·	+	+ +	т _	+ +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	. + +	Ŧ			
Liver			-	r I	+ ·	Ť	+ ·	+	+	T	T	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+			
Liver Hemangiosarcoma			-	Γ.	+ · X	т	+ .	Ť	+	+	+	+	+	+	Ŧ	Ŧ	Ŧ	Ŧ	Ŧ	Ŧ	+	+	+	+	+	+	1	+			
					х Х				х		,	х				x															
Hepatocellular carcinoma	ultinla .				л				л			л				л															
Hepatocellular carcinoma, mu	unpie						,	x												x						v	v	х			
Hepatocellular adenoma							4	A												Ā						· <b>A</b>	л	Å			
Hepatocellular adenoma, mul	upie													x																	
Histiocytic sarcoma														Å																	
Mesentery		÷.,						+		+	+					+	۰.		+							+					
Pancreas	4		-	+	+ -	+	+ •	+	+	+	+	+	+	·†	+	+	+	+	+	+	+	+	+	+	+	+	+	+			
Salivary glands				+	+ •	+	+ ·	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+			
Stomach, forestomach			-	t	+ -	t	+ ·	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	<b>+</b> .			
Squamous cell papilloma																															
Stomach, glandular			-	+	+ •	+	+ ·	+	+	+	.+	+	+	+	+	+	+	+	+	+	+	· +	+	+	+	+	+	+			
Cardiovascular System	· ·																								_	·					
Blood vessel			-	t	+ •	ł	+ •	+	+	+	+	+	+	+	+	+	+	.+	+	+	+	+	+	+	Μ	+	+	+ '		•	•
Heart	,			+	÷ •	+	+ •	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+			
Endocrine System																															
Adrenal cortex	•		-	ł	+ •	÷	+ •	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+			
Adrenal medulla			-	ł	+ •	+	+ •	+	+	+	+	+	+	+	+	·+	+	+	+	+	+	+	+	+	+	+	+	+			•
Pheochromocytoma benign																	х											,			
Islets, pancreatic				ł	+ •	+	+ -	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+			
Adenoma													х																		•
Parathyroid gland				ŧ.	+ •	+	+ 1	М	+	+	+	+	+	+	+	·+	+	+	+	+	+	+	+	+	+	+	+	+			
Pituitary gland				+	+ •	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	Μ	+	+	+	+			
Pars distalis, adenoma							x				X	-									х										
Thyroid gland				+	+ •			+	÷	·+-	+	+	+	+	+	÷+	+	+	+	+			+	+	+	+	+	+		·	
Follicular cell, adenoma				•	•		•	•	•	•	•			·	•		-		-	x		ć			,						
General Body System																											•		:	;	-
None																															

+: Tissue examined microscopically A: Autolysis precludes examination

M: Missing tissue I: Insufficient tissue

X: Lesion present Blank: Not examined

#### t-Butylhydroquinone, NTP TR 459

TABLE D2

Individual Animal Tumor Pathology of Female Mice in the 2-Year Feed Study of t-Butylhydroquinone: 0 ppm (continued) 7 7 7 7 7 7 7 7777 7 7 7 7 7 Number of Days on Study 3 5 5 5 5 5 5 5 5 5 5 5 5 4 5 6 6 6 6 6 6 6 6 6 6 66 
 2
 2
 2
 2
 2
 2
 2
 2
 2
 2
 2
 2
 2
 2
 2
 2
 2
 2
 2
 2
 2
 2
 2
 2
 2
 2
 2
 2
 2
 2
 2
 2
 2
 2
 2
 2
 2
 2
 2
 2
 2
 2
 2
 2
 2
 2
 2
 2
 2
 2
 2
 2
 2
 2
 2
 2
 2
 2
 2
 2
 2
 2
 2
 2
 2
 2
 2
 2
 2
 2
 2
 2
 2
 2
 2
 2
 2
 2
 2
 2
 2
 2
 2
 2
 2
 2
 2
 2
 2
 2
 2
 2
 2
 2
 2
 2
 2
 2
 2
 2
 2
 2
 2
 2
 2
 2
 2
 2
 2
 2
 2
 2
 2
 2
 2
 2
 2
 2
 2
 2
 2
 2
 2
 2
 2
 2
 2
 2
 2
 2
 2
 2
 2
 2
 2
 2</t Total Carcass ID Number 9 4 4 4 4 4 5 5 8899 9 0 5 6 6 7 7 7 7 7 8 8 Tissues/ 6 7 8 3 4 67901 5 8 1 5 6 0 9 2 4 5 0 3 4 5 9 0 2 Tumors 6 **Alimentary System** Esophagus 51 Gallbladder 50 + + Intestine large, colon 51 50 Intestine large, rectum + + M Intestine large, cecum 51 Intestine small, duodenum 51 + Intestine small, jejunum 51 + + + + + + + + + .<del>t</del> + + + + + Intestine small, ileum 51 + + 51 Liver Hemangiosarcoma 1 Hepatocellular carcinoma Х хх 7 Hepatocellular carcinoma, multiple х 1 Hepatocellular adenoma Х хх 8 Hepatocellular adenoma, multiple х 1 Histiocytic sarcoma 1 Mesentery 10 Pancreas 51 + + + + Salivary glands 51 51 Stomach, forestomach + + Squamous cell papilloma Х 1 Stomach, glandular 51 + + + + + + + + + + + + 4 + + **Cardiovascular System** Blood vessel 50 + + + + + + Heart 51 + **Endocrine System** Adrenal cortex 51 Adrenal medulla + 51 Pheochromocytoma benign 1 Islets, pancreatic + 51 Adenoma 1 Parathyroid gland Μ + Μ Μ + Μ + 46 + 49 Pituitary gland + + + Pars distalis, adenoma Х 5 Х + 51 Thyroid gland + + Follicular cell, adenoma · 1 **General Body System** 

Ĵ

ŝ

None

Ň

Individual Animal Tumor Pathology of Female Mice in the 2-Year Feed Study of t-Butylhydroquinone: 0 ppm (continued) 3 4 5 5 5 6 6 6 6 6 6 6 7 7 7 7 7 7 7 7 7 7 7 7 7 Number of Days on Study 6 6 5 6 8 1 1 1 26 7723 3 3 3 3 3 3 3 3 3 3 3 4 1 0 7 2 7 8 9 2 37 7 3 4 4 4 4 4 4 4 4 4 4 4 4 2 **Carcass ID Number** 7 68 6 4 6 8 4 6 7 5 7 8 4 5 5 5 5 5 6 8 9 9 9 9 2 3 7 1 8 9 6 1 8 7 2 1 4 5 4 5 67 8 6 1 0 347 **Genital System** Clitoral gland Ovary Cystadenoma Y Histiocytic sarcoma Х Luteoma Uterus Hemangiosarcoma Histiocytic sarcoma Х Endometrium, adenoma Endometrium, carcinoma Hematopoietic System Bone marrow Lymph node Iliac, histiocytic sarcoma Х Renal, histiocytic sarcoma х Lymph node, mandibular Lymph node, mesenteric Histiocytic sarcoma X Spleen Histiocytic sarcoma х Thymus Ι M M M ++ + Μ Ι + + + + **Integumentary System** Mammary gland Skin + + + Basal cell carcinoma х Subcutaneous tissue, histiocytic sarcoma Subcutaneous tissue, sarcoma х х **Musculoskeletal System** Bone Skeletal muscle **Nervous System** Brain Spinal cord + **Respiratory System** Lung Alveolar/bronchiolar adenoma Alveolar/bronchiolar adenoma, multiple x Alveolar/bronchiolar carcinoma х Х х Basal cell carcinoma, metastatic, skin Hepatocellular carcinoma, metastatic, liver х Nose + + Trachea + + + + + + + + + + + + + + + + + + +

÷

ŵ

Individual Animal Tumor Pathology o	f Fe	m	ale	M	ice	in	the	e 2-	-¥¢	ear	F	eed	St	ud	y c	of t	-Bı	ıty	lhy	/dr	ωđ	uir	lon	ne:	0	ppi	M (continued)
Number of Days on Study	7 3 4	7 3 5	7 3 5	7 3 5	7 3 5	7 3 5	3	7 3 5	7 3 5	7 3 5	3	7 3 5	7 3 5		3	7 3 6	3	3	3	3	3	7 3 6	3	3	7 3 6	3	
Carcass ID Number	9	4	2 4 4	4	2 4 7		2 5 0			8	2 9 1	9		0	5		6	6				2 7 5		2 7 9	2 8 0	8	Total Tissues/ Tumors
Genital System																											
Clitoral gland	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	51
Ovary	+	+	+	+	+	М	+	+	+	+	+	+	+	+	+	+		+	+	+	+	+	+	+	+	+	50
Cystadenoma Histiocytic sarcoma Luteoma					x												х										2 1 1
Uterus														,													51
Hemangiosarcoma Histiocytic sarcoma	+	• +	+	Ŧ	+	Ŧ	Ŧ	+	Ŧ	+	+	+	+	Ŧ	x	Ŧ	Ŧ	Ŧ	Ŧ	Ŧ	Ŧ	Ŧ	Ŧ	+	Ŧ	+	1
Endometrium, adenoma												•••				х											1
Endometrium, carcinoma										-		x			-									_	_		1
Hematopoietic System																											•
Bone marrow	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	51
Lymph node																											7
Iliac, histiocytic sarcoma																											1
Renal, histiocytic sarcoma																											1
Lymph node, mandibular	+	M	[ +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	М	+	+	+	+	+	+	48
Lymph node, mesenteric	+	• +	+	+	+	+	+	+	+	M	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Histiocytic sarcoma																											1
Spleen	- 1	• +	• +	+	+	+	+	+	+	+	+	+	+	Ŧ	+	Ť	Ŧ	Ŧ	+	+	+	+	+	+	Ŧ	+	51
Histiocytic sarcoma																											1 45
Thymus	+	• +		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	43
Integumentary System																											
Mammary gland	+	• +	• +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	51
Skin	-+	- +	• +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	51
Basal cell carcinoma																											1
Subcutaneous tissue, histiocytic sarcoma Subcutaneous tissue, sarcoma							Х																				1 2
Musculoskeletal System														-		_											
Bone	-	- +	• +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	51
Skeletal muscle																_		_									1
Nervous System																											
Brain	-	- +	• +	• +	• +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	51
Spinal cord										_																	2
Respiratory System																											
Lung	4	- +	- +	• +	• +	+	+		+	+	+	+	+	+	+	+	+	+		+	+	+	+	+	+	+	51
Alveolar/bronchiolar adenoma							Х											Х									2
Alveolar/bronchiolar adenoma, multiple																											1
Alveolar/bronchiolar carcinoma					`																						2
Basal cell carcinoma, metastatic, skin																											1
Hepatocellular carcinoma, metastatic, liver																											1
Nose	-	+ -		- +	- +	• +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	• +	• +	· +	51
Trachea																											51

ŝ

5

----

ä

of F	em	ale	Μ	ice	in	th	e 2	-Y	ear	F	eed	I St	tud	ly o	of	<b>-B</b>	uty	lh	ydı	<b>:0</b> 0	lni	noi	ne:	0	ppn	<b>1</b> (con	inue	<b>1</b> )
	- T	5 5	5	5	6 1	6 1	6 1	6 2	6	67	6 7	7 2	7 3	7 3	73	7 3	73	73	7	7	73	73	7	7 3				
2	2 6	2 8	2 6 1	2 2 4 8	2 6 9	8 2 8 6	9 2 4 1	2 2 6 8	2 7 7	3 2 5 2	2 7 1	3 2 8 4	4 2 4 5	4 2 5 4	4 2 5 5	4 2 5 6	4 2 5 7	4 2 5 8	4 2 6 6	4 2 8 1	4 2 9 0	4 2 9 3	4 2 9 4	4 2 9 7		· · · ·		
			_				+		-				_			-						_	+		•			•
+	· + - +	· +	+	++	++	++	+	+++	++	x	·	++	+	++	++	+	++	++	+ +	·			+	+		· * · ·		
+	- +		+	+ x	+	:+	+	+	+	+ x	+ x	+	+	+	+	+	+	+	+	+	+	+		+				•
-	3 6 4 2 7	3 4 6 6 4 1 2 2 7 6	3 4 5	3 4 5 5 6 6 5 6 4 1 0 7 2 2 2 2 7 6 8 6	$\begin{array}{cccccccccccccccccccccccccccccccccccc$																							

÷

# t-Butylhydroquinone, NTP TR 459

# Table D2

Individual Animal Tumo	 - 87																						_					
		7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	
Number of Days on Study		3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	
	 	4	5	5	5	5	5	5	5	5	5	5	5	5	5	6	6	6	6	6	6	6	6	6	6	6	6	
		2	2	2	2	2	2	2	2	2	2	2	2	2	3	2	2	2	2	2	2	2	2	- 2	2	2	2	Total
Carcass ID Number		9	4	4	4	4	4	5	5	8	8	9	9	9	0	5	6	6	6	7	7	7	7	7	7	8	8	Tissues/
		8	3	4	6	7	9	0	1	5	8	1	5	6	0	9	2	4	<b>5</b> .	0	3	4	5	6	9	0	2	Tumors
Special Senses System Ear																												1
Lacrimal gland																												1
Urinary System	 																											·
Kidney		-	+ +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	51
Histiocytic sarcoma								-																				1
Urinary bladder		-	+ +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	51
Systemic Lesions																											ţ.	
Multiple organs		-	+ +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+.	+	+	+	+	+	+	+	51
Histiocytic sarcoma								Х																				2
Lymphoma malignant											Х																	3

Ŷ

.

T

231

â

Ť

Individual Animal Tumor Pathology of Female Mice in the 2-Year Feed Study of t-Butylhydroquinone: 1,250 ppm

·

Number of Days on Study		3 9 9	4 6 9	4 9 4	5 0 3	5 6 2	5 9 8	6 1 2	6 2 3		6 5 4	6 6 8	6 9 7	0	1	7 2 5	7 2 9	7 · 3 4	7 3 4								
Carcass ID Number	5	3 3 0	3 4 4	3 4 2		3 0 4	3 1 8	3 6 0	3 2 9	3	3 5 0	3 3 1	1	3 1 5	3 4 5	2	3 4 6	3 0 1	3 0 3	0	3 0 8	3 0 9	3 1 1		3 3 8		
Alimentary System																									-		
Esophagus	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		
Gallbladder	+	+	+	+	+	+	+	+	+	+	+	Α	+	+	+	+	+	÷	+	+	+	+	+	+	+		
Intestine large, colon	+	+	+	+	+	+'	+	+	+	+	+	+	+	Α	+	+	+	+	+	+	+	+	+	+	+		
Intestine large, rectum	+	+	+	+	+	+	+	+	+	+	+	+	+	Α	+	+	+	+	+	+	+	+	+	+	+		
Intestine large, cecum	+	+	+	+	+	+	+	+	+	+	+	+	М	Α	+	+	+	+	+	+	+	+	+	+	+		
Intestine small, duodenum	+	+	+	+	+	+	+	+	+	+	+	+	+	Α	+	+	+	+	+	+	+	+	+	+	+		
Intestine small, jejunum	+	+	+	+	+	+	+	+	+	+	+	+	+	Α	+	+	+	+	+	+	+	+	+	+	+		
Intestine small, ileum	+	+	+	+	+	+	+	+	+	+	+	+	+	Α	+	+	+	+	+	+	+	+	+	+	+		
Liver	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		•
Hemangioma Hepatocellular carcinoma			x			x				x						v		x		x				X X			
			л			л	v			л				х	v	х		л		л		v		л			
Hepatocellular adenoma							Х							л	л		х					Х	х		x		
Hepatocellular adenoma, multiple																	л		x				л		л		
Histiocytic sarcoma														+				+	Λ								
Mesentery				+				+				Ŧ	Ŧ	т	+	+		Ŧ			+						
Squamous cell carcinoma, metastatic,				x																							
stomach, forestomach Pancreas				л +	+																						
Carcinoma	Ŧ	т	+	т	т	т	т	т	т	т	т	т	т	т	т	т	т	Ŧ	т	т	т	т	т	т	т		
Salivary glands	<u>т</u>	-	л.	т	<u>т</u>	т	т	т	т.	Т	Т	Т	<u>т</u>	+	<u>ــــ</u>	+	<u>т</u>	Ŧ	<u>т</u>	т	Т	-	л.		Т		
Sarcoma	т	т	т	т	т	т	т	т	т	т	т	т	т	т	x	т	т	т	т	т	т	т	т	т	т		
Sarcoma, metastatic, skin									х						л												
Stomach, forestomach	т	ъ	Ŧ	Ŧ	Ŧ	<u>ـ</u> ـ	т.	-	+	+		Ŧ	Ŧ	Ŧ	л.	Ŧ	-	Ŧ	Ŧ	т.	<u>т</u>	Ŧ	+	· _	Т		
Squamous cell carcinoma	Ŧ	т	т	x		т	т	ч.	1	4.	т	T.	•		т	т	'			т	Т.	т			т	· ·	
Stomach, glandular	т	Т	ъ		+	Ŧ	Ŧ	т	ъ	Ŧ	Ŧ	+	+	+	+	Т	+	Ŧ	+	Т	Т	т	Ŧ		ъ		
Tooth	т	т	т	т	т	т	т	т	т	Ŧ	<b>T</b>	т		+	Ŧ	т	т	т	т	т	т	т	Т	т	т		
Cardiovascular System			·												_												
Blood vessel	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		
Heart	+	+	+	+	+	+	+	+	+	÷.	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		
Endocrine System										_																	
Adrenal cortex	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	Μ	+	+	+	+	+	+	+	+	+		
Adrenal medulla	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	М	+	+	+	+	+	+	+	+	+		
Pheochromocytoma benign																											
Islets, pancreatic	+			+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		
Parathyroid gland	+	M			+				+	+	•	+	+			+		+		+		+			+		
Pituitary gland	+	+	+	M	+	+	+	М	+	+	+	+	+	+	+	Μ	I	+	+	+	+	+	+		+		
Pars distalis, adenoma																							Х				
Pars distalis, carcinoma				-		_	Х																				
Thyroid gland	+	+	+	+	+	+	+		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		+		
Follicular cell, adenoma								х															Х				

Ģ

### Table D2

Individual Animal Tumor Pathology of Female Mice in the 2-Year Feed Study of *t*-Butylhydroquinone: 1,250 ppm (continued)

	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	
Number of Days on Study	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	
	4	4	4	4	4	5	5	5		5	5	5	5	5	5	5	5	6	6	6	6	6	6	6	6	6	-	
	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	Total
Carcass ID Number	5	5	5	5	5	0	1	1	1	1	2	3	3	3	3	4	5	2	2	2	2	2	3	4	4	4	4	Tissues/
• •	1	5	6	8	9	2	3	4	6	7	8	2	3	4	5	9	2	0	1	3	5	6	9	0	1	3	7	Tumors
Alimentary System																												
Esophagus	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	52
Gallbladder	+	Μ	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Intestine large, colon	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	51
Intestine large, rectum	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	51
Intestine large, cecum	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Intestine small, duodenum	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	51
Intestine small, jejunum	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	51
Intestine small, ileum	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	51
Liver	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		+	+	+	+	+	+	+	+	+	+	+	52
Hemangioma	-							•		,	•	•	•	•	•	•	•	•	•	•	•	·	•	•	•	•		1
Hepatocellular carcinoma															х													8
Hepatocellular adenoma					х		х	x			х		х		••							x		х				11
Hepatocellular adenoma, multiple		х							х			х	••			х						~ 1		~1	x	х		. 9
Histiocytic sarcoma									~							**									Λ	Λ		1
Mesentery							+				+					+			+									13
Squamous cell carcinoma, metastatic,							'				'					•			'									15
stomach, forestomach																												1
Pancreas	ъ	т	т	ъ	Т	т	Т	Т	Т	Т	т	т	+		+													1
Carcinoma	Ŧ	т	т	т	т	т	T	т	Ŧ	т	т	т	т	x	т	т	Ŧ	т	Ŧ	Ŧ	Ŧ	Ŧ	Ŧ	+	+	+	+	52
Salivary glands										,																		1
Sarcoma	+	+	+	+	+	Ŧ	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	52
Sarcoma, metastatic, skin																												. 1
																												1
Stomach, forestomach	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	52
Squamous cell carcinoma																												1
Stomach, glandular	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	52
Tooth																												2
Cardiovascular System																												
Blood vessel	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	52 -
Heart	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	52
Endocrine System																												
Adrenal cortex	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	51
Adrenal medulla	+	+	+	+	+	+	+	+	+	+	+		+			+	+	+	+	÷	+	÷	+	+	÷	+	+	51
Pheochromocytoma benign		•	•	•	•	·	•	·		•	•	x	•	•	•	•	'	•	•	•	•			•	•	ľ	•	1
Islets, pancreatic	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	52
Parathyroid gland	+	+	+	+	+	+	+	+	+	+	+	+	+		+					÷	+	+	+	+	+	÷	+	49
Pituitary gland				+			+																				+	49 44
Pars distalis, adenoma	Ý	x	'	•	•	'		x	'	141	Υ.	x	1.	141	ι.	1.	141	T	т	т	т	T	Ť	141	Ť	Ŧ	т	5
Pars distalis, carcinoma	л	л						л				л																
Thyroid gland	ــ	<b>–</b>	ᆂ	بد	ъ	Т	ъ	<b>_</b> _	<u>ب</u>	ъ	<u>т</u>	4	<b>.</b>	т.			L	т		<b>.</b> I.,			.1				л.	1
Follicular cell, adenoma	Ŧ	Ŧ	x	Ŧ	т	т	т	т	т	т	т	т	т	Ŧ	Т	T	Ŧ	Ŧ	T	Ŧ	+	+	+	Ŧ	Ŧ	+	+	51
			л																									3
General Body System		_	_				_																					
Tissue NOS					+							+																2

e.

₹

ş

Individual Animal Tumor Pathology of Female Mice in the 2-Year Feed Study of *t*-Butylhydroquinone: 1,250 ppm (continued)

Number of Days on Study	6	9	4 6 9		5 0 3		9	1		6 2 3	6 5 4	6 6 8	6 9 7	7 0 6	7 1 0	7 2 5	7 2 9	7 3 4	7 3 4	7 3 4	7 3 4	7 3 4	7 3 4	7 3 4	7 3 4			•	
Carcass ID Number	5	-	4	3 4 2	5		1			3 3 6		3 3 1	3 1 0	3 1 5	3 4 5		4	3 0 1		3 0 6	3 0 8		3 1 1	3 2 2	3				
Genital System Clitoral gland Ovary Cystadenoma Histiocytic sarcoma Uterus Histiocytic sarcoma	+ + +	+ + +	+++++	++++	++++	+++++	+ + +	+ + +	+ + +								+ + +			+	++++			+					
Hematopoietic System Bone marrow Lymph node Inguinal, histiocytic sarcoma Lymph node, mandibular Lymph node, mesenteric Lymph node, mediastinal Spleen Histiocytic sarcoma Thymus	++++		+ + +	+	+	+ + + +	+	+++++++	+ + + +	+ + + +	+ + + + +	+++++++++++++++++++++++++++++++++++++++	.+	.+ +	+	+		+ + + +	+ + X + + + X +		++++++	+ + + + +	+ + + + +	+	+++++++++++++++++++++++++++++++++++++++				
Integumentary System Mammary gland Skin Subcutaneous tissue, histiocytic sarcoma Subcutaneous tissue, sarcoma	+ +	+ +	+ +	+ +	.+ .+	+ + X	+ +	+ +	+ + X	+ +	+ +	+ +	+ +	+ +	+++	+ +	+ +	+ +	+ + X	+	+ +	+ +	+ +	+ +	+ +		·		
Musculoskeletal System Bone Skeletal muscle	+	+	+	+	+ +	+	+	+	+	+	+	·+	+	+	÷	+	÷	+	+	+	+	+	+	+	+				
Nervous System Brain Peripheral nerve Spinal cord	+	++	+	+	+	+	+ + +	+	+	+	+	+	+	+	+	.+	+ + +	+	+	+	+	+	+	+	+				
Respiratory System Lung Alveolar/bronchiolar adenoma Hepatocellular carcinoma, metastatic, liver Histiocytic sarcoma Squamous cell carcinoma, metastatic, stomach, forestomach	+	+	+	+ x	+	+	+	+	+	+ x	+	+	+	+ x	+	+	+	+	+ x	+	+	+ x	+	+	+				
Mediastinum, squamous cell carcinoma, metastatic, stomach, forestomach Nose Trachea	+ +	+ +	+ +	x + +	+ +	+ +	+ +	+ +	++	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+ +	-			-

Ĝ

· · ·

5

3

Number of Days on Study	7 3 4	7 3 4	7 3 4	7 3 4	7 3 4	7 3 5	7 3 5	7 3 5	3	7 3 5	7 3 6																	
Carcass ID Number		5	3 5 6	3 5 8	3 5 9	3 0 2	3 1 3	3 1 4	1	3 1 7	3 2 8	3 3 2	3 3 3	3	3	3 4 9		3 2 0	3 2 1	3 2 3	3 2 5	3 2 6	3 3 9	3 4 0	3 4 1	3 4 3	4	Total Tissues/ Tumors
Genital System Clitoral gland Ovary Cystadenoma Histiocytic sarcoma		+ +	+ +	+++	++	+++	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+	++	+ +	+ +	++	+ +	+ +	+ +	+ +	· + +	52 49 2 1
Uterus Histiocytic sarcoma	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	52 1
Hematopoietic System Bone marrow Lymph node Inguinal, histiocytic sarcoma	+	+	+	+	+	+	+ +	+	+	+	+ +	+	+	÷	+	+	+	+	+	+	+	+	+	+	+	+	+	52 8
Lymph node, mandibular Lymph node, mesenteric Lymph node, mediastinal Spleen		+ +	`+ +	++	++	++	+ +	+++	+ м	++	+ +	+ +	++	+ +	+ +	1 52 48 1												
Histiocytic sarcoma Thymus	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+ .+	+	+	+	++	++	++	++	+	+	52 1 51
Integumentary System Mammary gland Skin Subcutaneous tissue, histiocytic sarcoma Subcutaneous tissue, sarcoma	+ +	+ +	+ +	+ +	+ +	+ +	+ +	+ + x	+ +	51 52 2 2																		
Musculoskeletal System Bone Skeletal muscle	+	+	+	+	+	+	+	+	+	+	+	+	+	. <b>+</b>	+	+	+	÷	+	+	+	+	+	+	+	+	+	52 1
Nervous System Brain Peripheral nerve Spinal cord	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	52 2 3
Respiratory System Lung Alveolar/bronchiolar adenoma Hepatocellular carcinoma, metastatic, liver Histiocytic sarcoma Squamous cell carcinoma, metastatic,	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	52 2 1 1
stomach, forestomach Mediastinum, squamous cell carcinoma, metastatic, stomach, forestomach Nose Trachea	+	++	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	1 52 52

														•														
Number of Days on Study	3 6 5	3 9 9	4 6 9	4 9 4	5 0 3	5 6 2	5 9 8	6 1 2	6 2 3	6 2 3	6 5 4	6 6 8	6 9 7	7 0 6	7 1 0	7 2 5	7 2 9	7 3 4										
Carcass ID Number	3 5 3	3 3 0	3 4 4	3 4 2	3 5 4	3 0 4	3 1 8	3 6 0	3 2 9	3 3 6	3 5 0	3 3 1	3 1 0	3 1 5	3 4 5	3 2 4	3 4 6	3 0 1	3 0 3	3 0 6	3 0 8	3 0 9	3 1 1	3 2 2	3 3 8			
Special Senses System Harderian gland Carcinoma															_													
Urinary System Kidney Histiocytic sarcoma	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	÷	+	+ x	+	+	+	+	+	+	-		
Squamous cell carcinoma, metastatic, stomach, forestomach Urinary bladder	+	• +	+	X +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	÷			
Systemic Lesions Multiple organs Histiocytic sarcoma Lymphoma malignant Lymphoma malignant mixed	. +	• +	+	+	+	+ X	+	+	+	+	+	+ X X	+ x	+ x	+	+ x	+	+	+ x	+	+ x	+	+	+	+			

Number of Days on Study	7 3 4	7 3 4	7 3 4	7 3 4	7 3 4	7 3 5	7 3 5	7 3 5	7 <sup>.</sup> 3 5	7 3 5	7 3 6																		
Carcass ID Number	3 5 1	3 5 5	3 5 6	3 5 8	3 5 9	3 0 2	3 1 3	3 1 4	3 1 6	3 1 7	3 2 8	3 3 2	3 3 3	3 3 4	3 3 5	3 4 9	3 5 2	3 2 0	3 2 1	3 2 3	3 2 5	3 2 6	3 3 9	3 4 0	3 4 1	3 4 3	3 4 7	Total Tissues/ Tumors	,
Special Senses System Harderian gland Carcinoma															+ x													1	
Urinary System Kidney Histiocytic sarcoma Squamous cell carcinoma, metastatic,	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	÷	+	+	+	- +	. +	52 1	
squamous cen carchiona, metastatic, stomach, forestomach Urinary bladder	+	• +	+	+	+	+	+	+	+	+	÷	+	+	+	+	+	+	·+	+	+	+	+	+	М	( +	• +	• +	1 51	
Systemic Lesions Multiple organs Histiocytic sarcoma Lymphoma malignant Lymphoma malignant mixed	+	• +	+	+	+	+ x	+ x	+	+	+	+ x	+	+	+	+	+	+	+ x	÷	+	+	+	+	+	+	• +	• +	52 2 9 1	

																															·
Number of Days on Study	2 8	4 5	5 4			6		6		7	7	7	7	7	7	7	7	7	7	7	7	7	7		7						
Number of Days on Study	8		4 8	5 5	1 8	5 1	6 4	7 6	1 8	2 3	2 4	3 4	_	·3 5																	
******	3	3	4	4	3	4	4	4	3	4	3	3	3	3	3	3	3	3	3	3	3	3	4	4	3						
Carcass ID Number	9		1	0	8	0	1	1			8		6	6		6		6	7	7	8	9	0	1				4		·	·
	2	3	4	3	9	2	7	3	0	0	4	1	2	3	5	7	8	9	0	2	0	6	7	6	4						
Alimentary System																													·		
Esophagus	М	+	+	+	+	+	÷	+	+	+	+	+	+	+	·+	+	+	+	+	+	+	+	+	+	+						
Gallbladder	+	А	+	+	+	Α	+	Α	+	+	+	+	+	Μ	+	+	+	+	+	+	+	+	+	+	+						
Intestine large, colon	+	Α	+	Α	+	Α	+	+	÷	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		٠		•		1.
Intestine large, rectum	+	Α	+	Α	+	Α	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+						
Intestine large, cecum	+	Α	+	Α	+	Α	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	۰.				1	
Intestine small, duodenum	+	Α	+	Α	+	A	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+					¢	
Intestine small, jejunum	+	Α	+	Α	+	Α	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	÷	+	+	•			+*		
Intestine small, ileum	+	Α	+	Α	+	Α	+	+	Α	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+					. 1	
Liver	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+						
Hepatoblastoma																														,	
Hepatocellular carcinoma			х				х	х												х					х					. • :	
Hepatocellular carcinoma, multiple						х																						. ·			
Hepatocellular adenoma				х						х	x	•	х										х					•			
Hepatocellular adenoma, multiple										••	••	,	••				х						••							•	
Histiocytic sarcoma					х																										
Mesentery	+	+			+		+														+										··.
Hepatocellular carcinoma, metastatic, liver	•	·			•		x														•					,					
Histiocytic sarcoma					х																										
Oral mucosa					~																		+							· ·.	5
Pancreas	<u>т</u>	А	т.	Т	Т	۸	+	+	Т	т	т	Т	+	L.	Ŧ	т	Ŧ	т	т.	L.	Т	-	י ב	Т	Т						
Hepatocellular carcinoma, metastatic, liver	Ŧ	л	Ŧ	-	-	Λ	x	т	т	т	т	т	т	Ŧ	т	т	т	т	т	Ţ	т	Ŧ	т	Ŧ	Т,						
Salivary glands	+	÷	-	т	Т	+	+	+	+	-	+		.1.	л.	ц.	.1.	.1.	1								-					
Stomach, forestomach	т 1	т 1	<b>T</b>	T 4	T	+	+	-+	Ť	T	+	+	+	+	т -	Ť	Ţ	Ť	Ţ	Ţ	Ţ	- -	Ţ	Ť	Ţ					•	
	+	+	+	+	+	-	•		+	+	•	•	-		+	+	+	+	+	+	+	+	+	+	+	-		1			• •
Stomach, glandular Tooth	+	Α	+	+	Ŧ	Α	+	+	+	+	+	+	+	+ +	Ŧ	Ŧ	• +	Ŧ	+ +	+	Ŧ	+	Ŧ	+	Ŧ						•
Condiana contan																							÷								
Cardiovascular System																															
Blood vessel	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+					•	
Heart	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+						
Endocrine System																											۰,				•
Adrenal cortex	+	+	+	+	+	А	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+						
Capsule, hepatocellular carcinoma,																							•		•			•			
metastatic, liver							Х																								
Adrenal medulla	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+						
Pheochromocytoma malignant											х																			1	
Islets, pancreatic	+	Α	+		+	Α	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+						• .
Adenoma		-																													
Parathyroid gland	+	+	+	+	+	•+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+						
Pituitary gland	+	M	+	+	I	+	+	M	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	I	+						
Pars distalis, adenoma		2	•		-	•	•					•				x							·	-				,			-
Thyroid gland	+	+	+	-+	-+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	-+	- +	-+	- +				-		

	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	
Number of Days on Study	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	
	5	5	5	5	5	5	5	5	5	5	5	6	6	6	6	6	6	6	6	6	6	6	6	6	6	6	
· · · · · · · · · · · · · · · · · · ·	3	3	3	3	3	3	4	4	4	4	4	3	3	3	3	3	3	3	3	3	4	4	4	4	4	4	Total
Carcass ID Number	7	7	7	<b>7</b> .	7	8	0	0	1	1	2	8	8	8	9	9	9	9	9	9	0	0	0	1	1	-1	Tissues/
	5	6	7	8	9	2	5	6				5		7				7	8	9	1	4	9	0	1		Tumors
Alimentary System																											- <u></u>
Esophagus	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Gallbladder	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	47
Intestine large, colon	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	48
Intestine large, rectum	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	48
Intestine large, cecum	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	48
Intestine small, duodenum	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	48
Intestine small, jejunum	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	
Intestine small, ileum	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	47
Liver	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	51
Hepatoblastoma											-	-	X			-	-	-				-			-		1
Hepatocellular carcinoma		х											-										х				7
Hepatocellular carcinoma, multiple																											1
Hepatocellular adenoma									Х				х	x	x				х				х				11
Hepatocellular adenoma, multiple							х					х										х				х	- 5
Histiocytic sarcoma																											1
Mesentery								+															+				7
Hepatocellular carcinoma, metastatic, liver Histiocytic sarcoma																											1 1
Oral mucosa																											1
Pancreas	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	49
Hepatocellular carcinoma, metastatic, liver																					•	·	·	·	·	·	1
Salivary glands	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	51
Stomach, forestomach	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	51
Stomach, glandular	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	49
Footh																			+								4
Cardiovascular System																											
Blood vessel	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	51
Heart	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	51
Endocrine System																											
Adrenal cortex	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50
Capsule, hepatocellular carcinoma, metastatic, liver																											1
Adrenal medulla	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	51
Pheochromocytoma malignant	•	•	•	•	•	•			•		•	•	•	·	·	•	•	•	•	•	•			•		•	1
slets, pancreatic	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	48
Adenoma	•	•	•	•	•	•	•	'	•	•	•	x		'	•	•	•	•	•	•	'			•		•	
Parathyroid gland	+	+	+	+	+	+	+	+	м	+	м		+	+	+	+	+	+	+	+	+	+	+	+	+	+	49
Pituitary gland	+	+	+	+	+	+	+	+	+		M		+	+	÷	+	+	+	+	+	+	+	+	+	+	+	46
Pars distalis, adenoma	•		•	x	•	•	x	•	•	•		•	·	•	·	•	•	•	•	·	•		x	•	·	•	5
Thyroid gland	+	+	+	+	+	+		+	м	+	+	+	+	+	+	+	+	+	+	+	+		+	+	+	+	50
Follicular cell, adenoma				x		•					•		•				•	•	•	•		•	•		•	•	2

Number of Days on Study	2 8 8	4 5 6	5 4 8	5 5 5	6 1 8	6 5 1	6 6 4	6 7 6	1	7 2 3	7 2 4	7 3 4	7 3 4	7' 3 4'	7 3 4	7 3 5														
Carcass ID Number	3 9 2	3 8 3	4 1 4	4 0 3	3 8 9	4 0 2	4 1 7	4 1 3	-	4 0 0	8	3 6 1	3 6 2	3 6 3	3 6 5	3 6 7		3 6 9	3 7 0	3 7 2	3 8 0	3 9 6	4 0 7	4 1 6			• :			
General Body System																												÷ .	•	•
Tissue NOS Pelvic, hemangiosarcoma, multiple										+ x																				
Genital System																											,	:	-	
Clitoral gland	+	+	+	+	+	+	+	м	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+					
Ovary	÷	+	+	+	+	Å	+		M	+	+	÷	÷	+	+	+	+	Ň	+	+	+	+	+	+	+					
Cystadenoma	'	1	'	•	•	~	•	'		•	•	•	'	•	•	•	'	1.4	,	•	r	•	'	'	•					
Granulosa cell tumor malignant																							х							
Histiocytic sarcoma					х									•									Λ					· .		
Uterus	<u>ـ</u>	т.	Ŧ	+	+	Α	Т	Ŧ	Ŧ	т	Ŧ	т	ъ	т	т	Ŧ	т	Т	ъ	<u>т</u>	<u>т</u>	<u>т</u>	т.	Т	Ŧ					
Histiocytic sarcoma	т	т	т	т	x	Λ	Ŧ	т	т	т	т	т	т	т.	т	T	т	Т	т	т	т	т	т	т	т					
Endometrium, adenoma					Λ																									
Endometrium, polyp stromal												х																		
												л															· ·			
Hematopoietic System																										۰.	•	•		
Bone marrow	+	+	+	+	+	+	+	+	+	+	+	+	÷	+	+	+	+	+	+	+	+	+	+	+	+					
Lymph node	+	+			+		+		+	+							+	+		+					+					
Iliac, histiocytic sarcoma					Х																				,		~			
Mediastinal, hepatocellular carcinoma,																													•	. *
metastatic, liver							х																							
Mediastinal, histiocytic sarcoma					Х																					•			•	
Renal, histiocytic sarcoma					Х																									
Lymph node, mandibular	+	+	+	+	+	Α	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		•			
Lymph node, mesenteric	+	+	+	+	+	Α	+	+	+	+	+	+	+	+	+	+	+	+	+	+	М	+	+	+	+					
Hepatocellular carcinoma, metastatic, liver							Х															•			•					
Histiocytic sarcoma					Х																									
Lymph node, mediastinal	+	+																												
Spleen	+	+	+	+	+	Α	+	+	+	+	+	+	÷	+	+	+	+	+	+	+	+	+	+	+	+					
Hemangiosarcoma										Х																	· •			
Thymus	+	+	+	М	: +	Α	+	+	+	+	+	+	+	+	+	+	+	Μ	+	+	+	+	+	+	+					
Integrimentony System																														
Integumentary System Mammary gland																		Ŧ	-	-	Т	т.	1	-	Ŧ					
	т	т	т	т	т	т	Τ.	т	т	т	т	т	т	т	т	т	т	т	т	т	т	т	т	Ŧ	Ŧ					
Myoepithelioma Skin				,																	+	+								
	т	т	+	т	T	т	Ŧ	т	т	т	Ŧ	т	т	т	т	т	т	т	т	т	т	т	+	x	+					
Subcutaneous tissue, fibrosarcoma										х														л						
Subcutaneous tissue, histiocytic sarcoma										л													х			,				
Subcutaneous tissue, sarcoma																							л							
Musculoskeletal System																											• •			
Bone	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+					:
Skeletal muscle	+		,		, i		+	-																						
Hepatocellular carcinoma, metastatic, liver							х																						•	
Nervous System Brain															•										+					

### Table D2

								_															_				
Number of Days on Study	3	7 3 5	7 3 5	7 3 5	7 3 5	7 3 5	7 3 5	7 3 5	7 3 5	7 3 5	7 3 5	7 3 6	7 3 6	7 3 6	7 3 6	7 3 6	7 3 6	7 3 6	7 3 6	7 3 6	7 3 6	7 3 6	7 3 6	7 3 6	7 3 6	7 3 6	
Carcass ID Number	7	3 7 6	3 7 7	3 7 8	3 7 9	3 8 2	4 0 5	4 0 6	4 1 5	4 1 9	4 2 0	3 8 5	3 8 6	3 8 7	3 9 3	3 9 4	3 9 5	3 9 7	3 9 8	3 9 9	4 0 1	4 0 4	4 0 9	4 1 0	4 1 1		Total Tissues/ Tumors
General Body System Tissue NOS Pelvic, hemangiosarcoma, multiple																											1 1
Genital System Clitoral gland Ovary Cystadenoma Granulosa cell tumor malignant Histiocytic sarcoma Uterus Histiocytic sarcoma Endometrium, adenoma Endometrium, polyp stromal	+ + +	+ + X +	+ + +	++++	++++	++++	++++	+ + +	+ M +	++++	++++	++++	+++++	+ + + x + x	+	++++	+ + +	+++++++++++++++++++++++++++++++++++++++	++++	+ + + X	+++	++++	++++	+ + X +		++++	50 47 3 1 1 50 2 1 3
Hematopoietic System Bone marrow Lymph node Iliac, histiocytic sarcoma Mediastinal, hepatocellular carcinoma, metastatic, liver Mediastinal, histiocytic sarcoma Renal, histiocytic sarcoma	+	+	+	+	+	+	Ŧ	++	+	+	+	+	+	+	+	+	+	+	+	+	+	+++	+	+	+	+	51 12 1 1 1
Lymph node, mandibular Lymph node, mesenteric Hepatocellular carcinoma, metastatic, liver Histiocytic sarcoma Lymph node, mediastinal Spleen Hemangiosarcoma Thymus	++++++	+++++++++++++++++++++++++++++++++++++++	+++++++++++++++++++++++++++++++++++++++	+ +	+ + +	++++++	+++++++++++++++++++++++++++++++++++++++	++++++	++++++	++ + +	++++++	++++++	+++++++++++++++++++++++++++++++++++++++	+++++++++++++++++++++++++++++++++++++++	+++++++++++++++++++++++++++++++++++++++	+++++++++++++++++++++++++++++++++++++++	+ + + +	+++++	++++++	++++++	++++++	++++++	+++++	+ + +	+	+++++	50 49 1 1 2 50 1
Integumentary System Mammary gland Myoepithelioma Skin Subcutaneous tissue, fibrosarcoma Subcutaneous tissue, histiocytic sarcoma Subcutaneous tissue, sarcoma	+	+ +	+	• + • +	· +	++	+ +	++	++	++	++	++	+	+++	· +	· +	+	+	+ X +	+	+	+	+ +	+++	+	+	51 1
Musculoskeletal System Bone Skeletal muscle Hepatocellular carcinoma, metastatic, liver	+	• +	• +	· +	• +	• +	• +	+	+	+	+	+	• +	· +	- +	• +	+	+	+	+	+	+	+	• +	+	+	51 2 1
Nervous System Brain	+	- +	- +	· +	- +	• +	• +	+	+	+	+	• +	• +	• +	- +	• +	• +	+	· +	+	• +	+	• +	• +	+	• +	51

· • . .

#### TABLE D2

Number of Days on Study	2 8 8	4 5 6	5 4 8	5 5 5	6 1 8	6 5 1	6 6 4	6 7 6	7 1 8	7 2 3	7 2 4	7 3 4	7 3 4	7 3 5			·													
Carcass ID Number	3 9 2	3 8 3	4 1 4	4 0 3	3 8 9	4 0 2	4 1 7	4 1 3	3 9 0	4 0 0	3 8 4	3 6 1	3 6 2	3 6 3	3 6 5	3 6 7	3 6 8	3 6 9	3 7 0	3 7 2	3 8 0	3 9 6	4 0 .7	4 1 6	3 7 4				•	
Respiratory System Lung Alveolar/bronchiolar adenoma Alveolar/bronchiolar carcinoma Hepatoblastoma, metastatic, liver Hepatocellular carcinoma, metastatic, liver Histiocytic sarcoma Sarcoma, metastatic, skin		+	+	+	+ X		+ x	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+ x	+ .	+ X					
Nose Trachea	+ +	+ +	++	+	++	+ +	+ `+	+ +	+	+	+	•																		
Special Senses System Eye Harderian gland Adenoma												+ x																		
Urinary System Kidney Histiocytic sarcoma Urinary bladder Histiocytic sarcoma	+ +	+ +	+ +		+ X + X	A +	+ +	+	+ +	+ M	+ +	+ +	+ +	+	+	+	+	+ +	•											
Systemic Lesions Multiple organs Histiocytic sarcoma Lymphoma malignant	+	• +	• +	• +	+ X	+	+	+	+ X	+ X	+	+	+ x	+	+	+	+ X	+ x	+ x	+ x	+	+	+	+ x	+	- 	*	·	·	·····

Ť

Individual Animal Tumor Pathology of Female Mice in the 2-Year Feed Study of *t*-Butylhydroquinone: 2,500 ppm (continued)

Number of Days on Study	7 3 5	7 3 6																										
	3	3	3	3	3	3	4	4	4	4	4	3	3	3	3	3	3	3	3	3	4	4	4	4	4	4		Total
Carcass ID Number	7 5	7 6	7 7	7 8	7 9	8 2	0 5	0 6	1 5	1 9	2 0	8 5	8 6	8 7	9 3	9 4	9 5	9 7	9 8	9 9	0 1	0 4	0 9	1 0	1 1	1 2		issues/ Fumors
Respiratory System			<u>.</u>		_			_			<u> </u>																	
Lung	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	· +	•	51
Alveolar/bronchiolar adenoma	Х	Х																				Х				Х		4
Alveolar/bronchiolar carcinoma								Х																				1
Hepatoblastoma, metastatic, liver													х															1
Hepatocellular carcinoma, metastatic, liver																							Х					4
Histiocytic sarcoma																												1
Sarcoma, metastatic, skin																												_ 1
Nose	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	- 1	-	49
Trachea	+	+	+	+	+	+	+	+	Μ	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	• +	•	50
Special Senses System								•																				
Eye															+													1
Harderian gland												+	+		+				+					+				6
Adenoma												х	Х		X				x					Х				6
Urinary System																												
Kidney	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	• +	+	+	+	-	50
Histiocytic sarcoma																												1
Urinary bladder	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	• +	+	+		-	50
Histiocytic sarcoma																												1
Systemic Lesions																												
Multiple organs	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	• +	+	+		-	51
Histiocytic sarcoma																				Х								3
Lymphoma malignant		х						Х														X						10

**a** : )

243

2

Ł

÷

TABLE D2

Individual Animal Tumor Pathology of Female Mice in the 2-Year Feed Study of t-Butylhydroquinone: 5,000 ppm

											-	_																	_
	0	2	2 4	4	5	6	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7		_		
Number of Days on Study	8	9	) 1	2	3	2	0	0	2	2	2	3	3	3	3	3	3	3	3	3	3	3	3	3	3		· ·		
	. 2	6	58	9	8	9	1	3	2	3	8	4	4	4	4	4	4	4	4	4	4	4	4	4	4				
	4	. 4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	 			
Carcass ID Number	4	. 3	6	3	4	4	7	5	7	4	5	2	2	2	2	2	2	3	3	3	4	5	6	6	6				
	3	8	5	6	5	8	8	9	9	0	1	4	5	6	7	8	9	0	1	3	6	7	3	4					
limentary System																					_					-			
Isophagus	-	⊦ -	+ +	+ +	+	• +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+				
fallbladder	-	⊦ -	+ +	+ +	- +	- +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+			1	
ntestine large, colon	-1		+ +	+ +	- A	. +	• +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+				
ntestine large, rectum	-1	+ -	+ +	⊢ ⊣	- A	. +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+				
ntestine large, cecum	-	4 م	+ +	+ -	- A	. +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+				
ntestine small, duodenum	-	د ۲	+ +	+ +	- A	. +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+				
Leiomyosarcoma										x				-												`			
ntestine small, jejunum	-	د ج	+ +	+ +	- A	. +	+	+	+	+	+	+	+	+	+	+	+	+ -	+	+	+	+	+	+	+		•		
ntestine small, ileum	-	د م	+ +		- A	. +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+			ľ	
Liver	ب	د ۲			+	- +	+	+			+	+	+	+	+	+	+	+	+	+	+	+	+	+	+				
Hemangiosarcoma	•					•		•	•	•	•	x		•	•	•	•	·	•	•	•	'	•	•	•			Ø	
Hepatocellular carcinoma												**	x						х										
Hepatocellular carcinoma, multiple													1																
Hepatocellular adenoma												х		x													. •		
Hepatocellular adenoma, multiple												Λ		Λ			х											,	
Histiocytic sarcoma			Х						х								Λ												
Aesentery		_	۲	•	L		Ŀ.		Λ	т	· _	ъ																	
ancreas	-	ا اسا	, ∟ _				т —	-	Т	÷	т —	т -	+	т	т	т	т	ъ	Т	ъ	т	т	Т	Ŧ	Ŧ				
Salivary glands	ר נ		г т ц ц		т - ц	- T	т 	т 	т 	т _	т 	т _	т 	Ŧ	т 	Ť	т _	Ŧ	т -	Ť	т -	Ŧ	т 	т 	Ţ				
Stomach, forestomach	ד ע		г 1 ∟ Ј		т - ц		т 	т 	т 	т _	Ť	T	т _	Ŧ	Ŧ	Ŧ	т 	т _	т _	т _	Ť	Ŧ	т _	т 	т 1				
Squamous cell papilloma	т			- 7	- 7		т	т	т	т	т	т	т	т	Ŧ	т	т	т	Ŧ	т	т	т	Ŧ	т	т				
Stomach, glandular												,																	
Footh	, т	• ٦	r · 7			• •	. T	Ŧ	Ŧ	Ŧ	Ŧ	Ŧ	Ŧ	Ŧ	Ŧ	Ŧ	Ŧ	+	Ŧ	Ŧ	Ŧ	+	Ŧ	Ŧ	+				
Cardiovascular System				_										_							-			-		 		•	
Blood vessel											÷																		
Heart	+	- 1	г 1 ∟ 1			- + 	- <b>T</b>	+	+	+	+	+	+	+	+	+	+ ,	+	+	+	+	+	+	+	+				
	+		- 1	- 1	- +	- +	+	+	+	+	+	+	+	+	+	+	+	т —	т	т	+	+	+	+	+	 			
Endocrine System		·																											
drenal cortex	+	1	+ +		- +	- +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	-			
Adrenal medulla	+		+ +		- +	• +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	÷	+	+	+	+				
slets, pancreatic	+		+ +		- +	• +	+	+	+	+	+	+	+	+	+	+	+	+	+	+.	+	+	+	+	+				
Parathyroid gland	-+		+ +		- +	- +	+	+	+	+	+	+	+	+	+		Μ	+	М	+	+	+	+		+				
ituitary gland	+		+ -		- +	- +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		Μ	+				
Pars distalis, adenoma													Х										х						·
Pars intermedia, adenoma																	Х												
	ر.	د ام	+ +		- +	- +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+				
Thyroid gland Follicular cell, adènoma			• •								х								х				х						

5 .

#### Table D2

ĵ

Individual Animal Tumor Pathology of Female Mice in the 2-Year Feed Study of *t*-Butylhydroquinone: 5,000 ppm (continued)

Number of Days on Study	3	7 3	3	3	7 3	7 3	7 3	7 3	7 3	7 3	3	7 3	3	3	3	7 3	3	3	3	7. 3	3	7 3	3	3	3	3	3	7 3		
	4	4	4	5	5	5	5	5	5	5	5	5	5	5	5	5	5	6	6	6	6	6	6	6	6	6	6	6	6	
	4	4	4		4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	Total
Carcass ID Number	6		7		2	3	3	3	5	5	5	5	7	7	7	7	7	3		4	4	4						7		Tissues/
	7	8	6	1	2	2	5	7	3	4	5	6	0	1	3	4	7	9	2	4	7	9	0	8	0	1	2	5	0	Tumors
Alimentary System																														
Esophagus	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	54
Gallbladder	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	54
intestine large, colon	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	53
Intestine large, rectum	+	+	+	+	+	÷	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		+	53
Intestine large, cecum	_		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+			+	53
Intestine small, duodenum	, 1	1	-		, ,	т Т			1	, ,	1	1			-	1		1	- -	+	Ļ		т Т	4	÷	1			+	53
Leiomyosarcoma	т	т	т	т	т	Ŧ	т	т	т	т	т	т	т	т	т	т	т	т	т	т	. т	т	т	т	т	т	т	т	т	1
Intestine small, jejunum	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	53
Intestine small, ileum	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	53
Liver	+	+	+	+	+	+	+	+	+	+	+	+	+	+			+	+	+	+	+	+	+	+	+	+		+		54
Hemangiosarcoma																														1
Hepatocellular carcinoma																			х								х			4
Hepatocellular carcinoma, multiple							х																							1
Hepatocellular adenoma							~										х						x							4
Hepatocellular adenoma, multiple																	Λ						Λ							1
Histiocytic sarcoma																														2
			+																											28
Mesentery			+									+																		
Pancreas	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	54
Salivary glands	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	м	+	·+			+		+	53
Stomach, forestomach	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		+	+	+	54
Squamous cell papilloma				х																						Х				2
Stomach, glandular	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	54
Tooth		+	_																					_						1
Cardiovascular System																														
Blood vessel	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	54
Heart		+	+	+	+	÷	+	+	+	+	+	÷	+	÷	+	+	+	÷	+	+	+	÷	+	+	+	÷	÷	+		54
									· · ·	•							· ·	_	·			<u> </u>	_			•		<u> </u>	•	
Endocrine System																														
Adrenal cortex	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	54
Adrenal medulla	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	54
Islets, pancreatic	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	54
Parathyroid gland	+	Μ	+	+	+	Μ	: +	+	+	+	М	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	49
Pituitary gland	+		Μ	+	+	+	+	+	+	+	+	+	М	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	М	49
Pars distalis, adenoma				x														x												4
Pars intermedia, adenoma																														1
Thyroid gland	+	<b>–</b>	+	+	Ŧ	+			+	+	+	+	+	+	L.	+	+	+	Ŧ	+	+	+	+	+	+	+	+	+	+	54
Ligitude Braine	т	- T	T	r-	T	T	-	T	Ť	Ŧ	T	Τ'	Ŧ	т.	T'	T	7	X	Ŧ	T	-1-	T	Τ.	r		T	· 1-	x		5

Ĵ,

8

è

(continued)																		•			•	•					,			. 1	
Number of Days on Study	8	2 9 6	4 1 8	2	5 3 8	6 2 9	7 0 1	0	7 2 2	7 2 3	7 2 8	7 3 4	3	4			, ,														
Carcass ID Number	4 4 3	3	4 6 5	3	4 4 5	4 4 8	4 7 8	4 5 9	4 7 9	4 4 0	4 5 1	4 2 4	4 2 5	4 2 6	4 2 7	4 2 8	4 2 9	4 3 0	3	4 3 3	4	4 5 7		4 6 4	6					ł.	
Genital System Clitoral gland Ovary	+++	+	+	+	++	+	+	++	+	+	+	++	+	+++	+	+	+	+	++	+++	+ M	+	+++	++	++++	 			2.1	-	
Cystadenoma Teratoma NOS Uterus	x +	+	+	+	+	•	+	•	•	+	+	•	+	+	+	+	-+	+	+	+	+	•	+		+				3	•	
Histiocytic sarcoma Leiomyosarcoma Endometrium, polyp stromal									X		•				x						x				•			•		• .	
Hematopoietic System Bone marrow	+				 									<u>т</u>				-				-				 			,		
Lymph node Lymph node, mandibular	+	+ + +	+	+	+ + +	+	+ +	+	+ + +	+	+ + M	+	+	+ +	+	+	+	+	+	+	+	+	+	+	++						
Lymph node, mesenteric Histiocytic sarcoma Spleen	++	++	++	++	++	++	++	+	++	++	+	++	+	++	+	++	+ X +	++	++	++	++	++	·+ ·+	++	++						
Thymus Histiocytic sarcoma	+	+	М	+	+	М	+	+	* x	+	м	+	+	+	+	+	+	+	+	+	+	+	+	+	+						
Integumentary System Mammary gland Carcinoma	+	+	+	+	÷	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+						
Skin Squamous cell papilloma	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+ x	+	+	+	+	+	+	+						•
Subcutaneous tissue, fibrosarcoma Subcutaneous tissue, histiocytic sarcoma								X	x																						•
Musculoskeletal System Bone Osteosarcoma	+	+	+	+	+	+ x		+	÷	+	+	+	+	+	÷	+	+	+	+	+	+	+	+	+	÷				•	· .	
Nervous System Brain Spinal cord		+	+	++	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+			•		•	
Respiratory System Lung Alveolar/bronchiolar adenoma Hepatocellular carcinoma, metastatic,	+	· +	+	+	• •	+	• +	· +	÷	+	+	+	+	+	+	+	+	+ X		+	+ X	+	+	+	+						•
liver Histiocytic sarcoma Osteosarcoma, metastatic, bone		÷	x			x									<i></i>	•			x						•						
Nose Trachea	++	· + · +	+	· +	• +	· + · +	· + · +	· +	· +	+	+	++	++	++	++	++	++	+	+	++	+	++	+	+	· + · +		•				

Individual Animal Tumor Pathology of Female Mice in the 2-Year Feed Study of *t*-Butylhydroquinone: 5,000 ppm (continued)

	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7.	7		
Number of Days on Study	3 4	3 4	3 4	3 5	3 5	3 5	3 5	3 5	3 5	3 5	3 5	3 5	3 5	3 5	3 5	3 5	3 5	3 6	-												
· ·	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	Total	
Carcass ID Number	6 7	6 8			2 2	3 2	3 5	3 7	.5 3	5 4	5 5	5 6	7 0	7 1	7 3	7 4	7 7	3 9	4 2	4 4	4 7	4 9	5 0				6 2			Tissues/ Tumors	
Genital System				_			·				_																		_		
Clitoral gland	+	+	+	+	+	+	•+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	54	
Ovary	+		+	+	+	+	+	+	+	Μ		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50	
Cystadenoma											х			Х																2	
Teratoma NOS Uterus																							,							1	
Histiocytic sarcoma	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	Ŧ	Ŧ	+	+	+	+	+	+	+	+	+	+	54	
Leiomyosarcoma																												•		1	
Endometrium, polyp stromal		•																				,								1	
	_			-																									~		
Hematopoietic System																															
Bone marrow	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	54	
Lymph node				+					• .		+											+								9	
Lymph node, mandibular	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	М	+	Ŧ	+	+	52	
Lymph node, mesenteric	+		+	.+	+	I	·+	Μ	+	Μ	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	50	
Histiocytic sarcoma									· .									X												. 2	
Spleen	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+			+			+	+				+			54	
Thymus Histiocytic sarcoma	+	+	+	+	+	+	+	М	+	+	+	+	+	+	+	+	+	М	+	+	+	1	+	+	+	Ŧ	+	+	Ŧ	48 1	
Integumentary System									•••																						
Mammary gland	+	<u>ـ</u>	-	+	+	- <b>L</b> -	_ ب	+	+	-	+	+	+	<u>н</u>	+	+	+	Ŧ	+	+	+	+	+	+	+	+	+	+	+	- 54	
Carcinoma	'	•				'	'	'	x	'	'	'	,		•	'	'	•	•		•	•			•		ľ		•	1	
Skin	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	54	
Squamous cell papilloma																														1	
Subcutaneous tissue, fibrosarcoma																														1	
Subcutaneous tissue, histiocytic																															
sarcoma																														1	
Musculoskeletal System																															
Bone	+	+	+	+	+	+	+	+	· +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	54	
Osteosarcoma								_																						1	-
Nervous System																															
Brain	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	54	
Spinal cord																				+										2	
Respiratory System																															
Lung	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	54	
Alveolar/bronchiolar adenoma	Х																													3	
Hepatocellular carcinoma, metastatic,										•																				-	
liver	•																										Х			2	
Histiocytic sarcoma																														1	
Osteosarcoma, metastatic, bone							,		:																					1	
Nose	+	•	+	• +	· +	• +	• +	• +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	• +	• +	• +	· +	+	53	
Trachea	+	• +	+	• +	+	+	• +	• +	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	• +	+	• +	+	+	54	

4

ŝ

Individual Animal Tumor Pathology of Female Mice in the 2-Year Feed Study of *t*-Butylhydroquinone: 5,000 ppm (continued)

Number of Days on Study	0 8 2	9	4 1 8	4 2 9	5 3 8	6 2 9	7 0 1	7 0 3	7 2 2	7 2 3	7 2 8	7 3 4	7 3 4	7 3 4																
Carcass ID Number	4 4 3	3	4 6 5	4 3 6	4 4 5	4 4 8	4 7 8	4 5 9	4 7 9	4 4 0	4 5 1	4 2 4	4 2 5	4 2 6	4 2 7	4 2 8	4 2 9	4 3 0	4 3 1	4 3 3	4 4 6	4 5 7	. 4 6 3	6	4 6 6	 				
Special Senses System Harderian gland Adenoma				-								•		-						· · · ·			+ X							
Urinary System Kidney Urinary bladder		++	++	+ +	+ +	+ +	+ +	+ +	++	+ +	+	++	+ +	++	++	++	+		• +			•								
Systemic Lesions Multiple organs Histiocytic sarcoma Lymphoma malignant	+	+	.+ X	+	+	+	+	.+	+ X	+	+ x	+	+	+ x	+	+	+ x	+	+ x	+	+	+	+	+ + X	+				<del>-</del>	

Ļ

Individual Animal Tumor Pathology of Female Mice in the 2-Year Feed Study of *t*-Butylhydroquinone: 5,000 ppm (continued)

	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7	7		
Number of Days on Study	- 3	3	3	3	3	3.	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3		
	4	4	4	5	5	5	5	5	5	5	5	5	5	5	5	5	5	6	6	6	6	6	6	6	6	6	6	6	6		
	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	Total	
Carcass ID Number	6	6	7	2	2	3	3	3	5	5	5	5	7	7	7	7	7	3	4	4	4	4	5	5	6	6	6	7	8	Tissues/	
	7	8	6	1	2	2	5	7	3	4	5	6	0	1	3	4	7	9	2	4	7	9	0	8	0	1	2	5	0	Tumors	
Special Senses System Harderian gland Adenoma																														1	
Urinary System																										_					
Kidney		F	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	• +	• +	53	
Urinary bladder	-	+ +	- +	• +	+	+	+	+	· +	+	+	+	+	+	+	+	+	+	+	+	+	+		+	+	+	• +	• +	+	53	
Systemic Lesions																															
Multiple organs	-	+ +	- +	• +	+	+	+	+	+	+	+	+	+	+	+	+	+	•	-	+	+	+	+	+	+	+	• +	• +	• +	54	
Histiocytic sarcoma																		Х												4	
Lymphoma malignant			Х	X								Х										Х								8	

÷

ŵ

4

# Statistical Analysis of Primary Neoplasms in Female Mice in the 2-Year Feed Study of t-Butylhydroquinone

· · ·	0 ppm	1,250 ppm	2,500 ppm	<b>5,000 ppm</b>	
Harderian Gland: Adenoma		: · · ·			*
Dverall rate <sup>a</sup>	0/51 (0%)	0/52 (0%)	6/51 (12%)	1/54 (2%)	
Adjusted rate <sup>b</sup>	0.0%	0.0%	15.0%	2.3%	
erminal rate <sup>c</sup>	0/38 (0%)	0/35 (0%)	6/40 (15%)	1/43 (2%)	
irst incidence (days)	e	_	734 (T)	734 (T)	
ife table test <sup>d</sup>	P=0.294	-	P=0.020	P=0.525	
ogistic regression test <sup>d</sup>	P=0.294	_	P=0.020	P=0.525	
ochran-Armitage test <sup>d</sup>	P=0.255				
isher exact test <sup>a</sup>	1	_	P=0.013	P=0.514	. ·
arderian Gland: Adenoma or Carcino	na				
verall rate	0/51 (0%)	1/52 (2%)	6/51 (12%)	1/54 (2%)	
djusted rate	0.0%	2.9%	15.0%	2.3%	
erminal rate	0/38 (0%)	1/35 (3%)	6/40 (15%)	1/43 (2%)	
irst incidence (days)		734 (T)	734 (T)	734 (T)	
ife table test	P=0.379	P=0.484	P=0.020	P=0.525	
ogistic regression test	P = 0.379 P = 0.379	P = 0.484 P = 0.484	P = 0.020 P = 0.020	P = 0.525 P = 0.525	
ochran-Armitage test	P = 0.379 P = 0.334	r=0.404	r =0.020	r =0.525	
isher exact test	1 -0.554	P=0.505	P=0.013	P=0.514	
iver: Hepatocellular Adenoma					
<b>-</b>	0/51 /19 // )	20/52 (29.07)	16/51 (0107)	E/EA (0M)	
verall rate	9/51 (18%)	20/52 (38%)	16/51 (31%)	5/54 (9%)	
djusted rate	22.7%	51.0%	37.1%	11.6%	
erminal rate	8/38 (21%)	16/35 (46%)	13/40 (33%)	5/43 (12%)	
irst incidence (days)	582	598	555	734 (T)	
ife table test	P=0.023N	P=0.008	P = 0.111	P = 0.135N	
ogistic regression test	P = 0.027N	P=0.011	P=0.096	P = 0.146N	
ochran-Armitage test	P=0.041N				
isher exact test		P=0.016	P=0.083	P=0.165N	
iver: Hepatocellular Carcinoma					
verall rate	8/51 (16%)	8/52 (15%)	8/51 (16%)	5/54 (9%)	
djusted rate	18.4%	19.2%	17.6%	11.6%	
erminal rate	4/38 (11%)	4/35 (11%)	4/40 (10%)	5/43 (12%)	
irst incidence (days)	461	469	548	734 (T)	
ife table test	P=0.155N	P=0.566	P=0.561N	P=0.216N	
ogistic regression test ochran-Armitage test	P=0.357N P=0.188N	P=0.559N	P=0.592	P=0.240N	
isher exact test	r 0, 10014	P=0.590N	P=0.607N	P=0.241N	,
	As a Balan Canalasana				
iver: Hepatocellular Adenoma or Hep	17/51 (33%)	28/52 (54%)	23/51 (45%)	10/54 (19%)	
diusted rate	38.9%	64.7%	48.8%	23.3%	
djusted rate ërminal rate		20/35 (57%)	48.8% 16/40 (40%)	10/43 (23%)	
	12/38 (32%)	20/33 (37%) 469	548		
irst incidence (days)	461 D=0.007N			734 (T) D=0.050N	
ife table test	P = 0.007N	P = 0.021	P=0.233	P = 0.050N	
ogistic regression test	P=0.010N	P=0.025	P = 0.155	P = 0.064N	4
Cochran-Armitage test	P=0.011N	<sup>5</sup> D 0.000	<b>D</b> 0 4 5 5	<b>D</b>	e.
Fisher exact test	<u>``</u>	P = 0.028	P=0.155	P=0.065N	•

ċ

Statistical Analysis of Primary Neoplasms in Female Mice in the 2-Year Feed Study of t-Butylhydroquinone (continued)

	0 ррт	1,250 ppm	2,500 ppm	5,000 ppm	
Liver: Hepatocellular Carcinoma or Hepatoblastoma	······				•
Diversi inepatocentrial Caremonia of inepatobiastonia	8/51 (16%)	8/52 (15%)	9/51 (18%)	5/54 (9%)	•
Adjusted rate	18.4%	19.2%	19.9%	11.6%	1
Ferminal rate	4/38 (11%)	4/35 (11%)	5/40 (13%)	5/43 (12%)	· ·
irst incidence (days)	461	469	548	734 (T)	
ife table test	P = 0.163N	P=0.566	P=0.543	P=0.216N	
ogistic regression test	P = 0.197N	P = 0.559N	P = 0.484	P = 0.240N	
ochran-Armitage test	P = 0.200N	1-0.5571	1-0.404	1-0.2+011	•.
isher exact test	1-0.2001	P=0.590N	P=0.500	P=0.241N	•
	• •				
iver: Hepatocellular Adenoma, Hepatocellular Care				10/51 //0 //	
directed rate	17/51 (33%)	28/52 (54%)	23/51 (45%)	10/54 (19%)	1
djusted rate	38.9%	64.7%	48.8%	23.3%	
erminal rate	12/38 (32%)	20/35 (57%)	16/40 (40%)	10/43 (23%)	
irst incidence (days)	461 D 0 00701	469	548	734 (T)	
ife table test	P = 0.007N	P=0.021	P=0.233	P=0.050N	
ogistic regression test	P = 0.010N	P=0.025	P = 0.155	P=0.064N	
ochran-Armitage test	P=0.011N	<b>D</b> 0.000	B 0 1 2 2	<b>D</b>	
sher exact test		P=0.028	P=0.155	P = 0.065N	с. 1
ung: Alveolar/bronchiolar Adenoma					,
verall rate	3/51 (6%)	2/52 (4%)	4/51 (8%)	3/54 (6%)	•
djusted rate	7.9%	5.3%	10.0%	7.0%	、'
erminal rate	3/38 (8%)	1/35 (3%)	4/40 (10%)	3/43 (7%)	· ·
rst incidence (days)	734 (T)	706	734 (T)	734 (T)	
fe table test	P=0.571N	P=0.530N	P=0.528	P=0.605N	
ogistic regression test	P=0.567N	P=0.509N	P=0.528	P = 0.605N	
ochran-Armitage test	P=0.528				
sher exact test		P=0.491N	P=0.500	P=0.633N	4
ung: Alveolar/bronchiolar Adenoma or Carcinoma					
verall rate	5/51 (10%)	2/52 (4%)	5/51 (10%)	3/54 (6%)	
djusted rate	13.2%	5.3%	12.5%	7.0%	•
erminal rate	5/38 (13%)	1/35 (3%)	5/40 (13%)	3/43 (7%)	
rst incidence (days)	734 (T)	706	734 (T)	734 (T)	
ife table test	P=0.321N	P=0.247N	P=0.599N	P=0.290N	
ogistic regression test	P=0.311N	P = 0.223N	P=0.599N	P=0.290N	
ochran-Armitage test	P=0.381N		1 0.0///1	1 = 0.2>011	•
isher exact test		P=0.210N	P=0.630N	P=0.326N	
ware Custodonomo			*		
vary: Cystadenoma verall rate	2/50 (4%)	2/49 (4%)	3/47 (6%)	2/50 (4%)	
djusted rate	5.4%	5.3%	7.9%	5.1%	,
erminal rate	2/37 (5%)	1/34 (3%)	3/38 (8%)	2/39 (5%)	• •
irst incidence (days)	734 (T)	654	734 (T)	734 (T)	· •
ife table test	P=0.571N	P=0.671	P=0.512	P = 0.676N	· .
ogistic regression test	P = 0.586N	P = 0.679	P = 0.512	P = 0.676N	,
ochran-Armitage test	P=0.568				
	- 0.000				

Statistical Analysis of Primary Neoplasms in Female Mice in the 2-Year Feed Study of t-Butylhydroquinone (continued)

$(z_{i}^{i})_{i} \in [z_{i}^{i}] \in [z_{i}^{i}]$		0 ppm	1,250 ppm	2,500 ppm	5,000 ppm
Pituitary Gland (Pars Distalis):	Adenoma				
Overall rate	Auchoma	5/49 (10%)	5/44 (11%)	5/46 (11%)	4/49 (8%)
Adjusted rate		• •	• •		
		12.3%	16.1%	13.2%	10.5%
erminal rate		3/36 (8%)	5/31 (16%)	5/38 (13%)	4/38 (11%)
irst incidence (days)		567	· 734 (T)	734 (T)	734 (T)
ife table test		P=0.351N	P=0.550	P = 0.600N	P=0.465N
ogistic regression test	•	P=0.382N	P=0.554	P=0.593	P=0.502N
ochran-Armitage test		P=0.401N	<b>D</b> 0 770	<b>D</b> 0 <b>C</b> 00	<b>D</b> 0 0001
isher exact test	1		P=0.559	P=0.589	P=0.500N
ituitary Gland (Pars Distalis):	Adenoma or Car	cinoma			
verall rate		5/49 (10%)	6/44 (14%)	5/46 (11%)	4/49 (8%)
djusted rate		12.3%	18.0%	13.2%	10.5%
'erminal rate		3/36 (8%)	5/31 (16%)	5/38 (13%)	4/38 (11%)
First incidence (days)	`	567	598	734 (T)	734 (T)
life table test		P=0.310N	P=0.423	P=0.600N	P = 0.465N
ogistic regression test		P = 0.350N	P = 0.423	P = 0.593	P = 0.502N
Cochran-Armitage test	•	P = 0.358N	<b>↓</b> = 0. <b>7</b> 23	1 -0.375	1 -0.50211
Fisher exact test		1 -0.33011	P=0.423	P=0.589	P=0.500N
			• ••••••		
hyroid Gland (Follicular Cell)	: Adenoma				
Overall rate		1/51 (2%)	3/51 (6%)	2/50 (4%)	5/54 (9%)
djusted rate		2.6%	8.0%	5.1%	11.4%
erminal rate		1/38 (3%)	2/34 (6%)	2/39 (5%)	4/43 (9%)
irst incidence (days)	· ·	734 (T)	612	734 (T)	728
life table test		P=0.120	P=0.276	P=0.509	P=0.137
ogistic regression test		P=0.103	P=0.300	P=0.509	P = 0.142
Cochran-Armitage test		P=0.092			
isher exact test			P=0.309	P=0.492	P=0.116
Jterus: Stromal Polyp Dverall rate		0/51 (0%)	0/52 (0%)	3/51 (6%)	1/54 (2%)
Adjusted rate		0.0%	0.0%	7.5%	2.3%
Cerminal rate		0/38 (0%)	0/35 (0%)	3/40 (8%)	1/43 (2%)
First incidence (days)	, ,	<u> </u>		734 (T)	734 (T)
Life table test		— P=0.291		P=0.130	P=0.525
Logistic regression test		P = 0.291 P=0.291		P = 0.130 P = 0.130	P = 0.525 P = 0.525
Cochran-Armitage test		P = 0.291 P = 0.262		1 -0.150	1 -0.525
risher exact test		r -0.202	-	P=0.121	P=0.514
All Organs: Histiocytic Sarcom	18		A 17 A 17 M 1	0151 16 19	A 15 A (7) 01 \
Overall rate		2/51 (4%)	2/52 (4%)	3/51 (6%)	4/54 (7%)
djusted rate		5.0%	4.9%	6.8%	8.5%
erminal rate		1/38 (3%)	1/35 (3%)	1/40 (3%)	2/43 (5%)
First incidence (days)		673	562	618	418
Life table test		P=0.279	P=0.673	P = 0.526	P=0.397
ogistic regression test		P=0.246	P=0.679N	P=0.498	P=0.376
Cochran-Armitage test		P=0.238			
Fisher exact test			P = 0.684N	P=0.500	P=0.367

Statistical Analysis of Primary Neoplasms in Female Mice in the 2-Year Feed Study of t-Butylhydroquinone (continued)

	0 ppm	1,250 ppm	2,500 ppm	5,000 ppm
All Organs: Malignant Lymphoma (Mixed or NOS)			•	······································
Overall rate	3/51 (6%)	9/52 (17%)	10/51 (20%)	8/54 (15%)
Adjusted rate	7.1%	22.7%	24.3%	18.2%
Ferminal rate	1/38 (3%)	5/35 (14%)	9/40 (23%)	7/43 (16%)
First incidence (days)	582	668	718	728
ife table test	P=0.271	P=0.061	P=0.050	P=0.150
ogistic regression test	P=0.217	P=0.063	P=0.041	P=0.122
Cochran-Armitage test	P=0.190			
risher exact test		P=0.065	P=0.036	P=0.119
All Organs: Benign Neoplasms			ц	
Dverall rate	23/51 (45%)	26/52 (50%)	27/51 (53%)	19/54 (35%)
Adjusted rate	54.3%	63.1%	59.7%	43.2%
Ferminal rate	19/38 (50%)	20/35 (57%)	22/40 (55%)	18/43 (42%)
irst incidence (days)	567	598	288	728
ife table test	P=0.060N	P=0.244	P=0.367	P=0.137N
ogistic regression test	P=0.106N	P=0.326	P=0.289	P=0.168N
ochran-Armitage test	P=0.131N			
isher exact test		P=0.382	P=0.276	P=0.201N
All Organs: Malignant Neoplasms				
Dverall rate	18/51 (35%)	22/52 (42%)	22/51 (43%)	22/54 (41%)
Adjusted rate	39.6%	47.2%	45.8%	44.8%
erminal rate	11/38 (29%)	11/35 (31%)	14/40 (35%)	16/43 (37%)
irst incidence (days)	461	469	548	418
ife table test	P=0.531N	P=0.249	P=0.366	P=0.460
ogistic regression test	P = 0.152	P=0.279	P=0.269	P=0.352
Cochran-Armitage test	P=0.367			
isher exact test		P=0.299	P=0.272	P=0.355
All Organs: Benign or Malignant Neoplasms				· ·
Overall rate	33/51 (65%)	41/52 (79%)	37/51 (73%)	33/54 (61%)
djusted rate	68.7%	83.7%	74.0%	65.9%
'erminal rate	23/38 (61%)	27/35 (77%)	27/40 (68%)	26/43 (60%)
irst incidence (days)	461	469	288	82
life table test	P=0.110N	P=0.074	P=0.419	P=0.312N
ogistic regression test	P=0.206N	P=0.055	P=0.258	P=0.432N
Cochran-Armitage test	P=0.206N			
Fisher exact test		P=0.084	P=0.261	P=0.429N

<sup>(</sup>T)Terminal sacrifice

Number of neoplasm-bearing animals/number of animals examined. Denominator is number of animals examined microscopically for liver, lung, pituitary gland, thyroid gland, and uterus; for other tissues, denominator is number of animals necropsied.

<sup>b</sup> Kaplan-Meier estimated neoplasm incidence at the end of the study after adjustment for intercurrent mortality

<sup>c</sup> Observed incidence at terminal kill

Beneath the control incidence are the P values associated with the trend test. Beneath the exposed group incidence are the P values corresponding to pairwise comparisons between the controls and that exposed group. The life table test regards neoplasms in animals dying prior to terminal kill as being (directly or indirectly) the cause of death. The logistic regression test regards these lesions as nonfatal. The Cochran-Armitage and Fisher exact tests compare directly the overall incidence rates. For all tests, a negative trend or a lower incidence in an exposure group is indicated by N.

<sup>e</sup> Not applicable; no neoplasms in animal group
۱.

# TABLE D4a

Historical Incidence of Hepatocellular Neoplasms in Untreated Female B6C3F<sub>1</sub> Mice<sup>a</sup>

2		Incidence in Controls_	× • •
	Adenoma	Carcinoma	Adenoma
			or Carcinoma
Dverall Historical Incidence		, ,	
Total Standard deviation Range	194/1,312 (14.8%) 10.5% 2%-50%	90/1,312 (6.9%) 6.1% 0%-20%	260/1,312 (19.8%) 12.8% 3%-56%
Data as of 17 June 1994		÷.	
			•
<b>FABLE D4b Historical Incidence of Thyroid Gland (Follicu</b> )	lar Cell) Adenoma in U	ntreated Female B6C3F <sub>1</sub> N	Mice <sup>a</sup>
		Incidence in Controls	
Dverall Historical Incidence	· · · · · · · · · · · · · · · · · · ·		
Total Standard deviation Range		27/1,301 (2.1%) 2.8% 0%-9%	، مربع المربع المربع مربع المربع ال مربع المربع ال
Data as of 17 June 1994	<u>,</u>		
			· • • • •
			л 8 — Дл
· · · · ·			
			4
	· ·		
•			
			۰۰۰ ۲۰۰۰ ۱۰۰۰

and the second second

### TABLE D5

Summary of the Incidence of Nonneoplastic Lesions in Female Mice in the 2-Year Feed Study of t-Butylhydroquinone<sup>a</sup>

	0 ppm	1,250 ppm	2,500 ppm	5,000 ppm
		·	·	
Disposition Summary		14 - A - A - A - A - A - A - A - A - A -		
Animals initially in study	60	60	60	60
15-Month interim evaluation	9	8	9	6 *
Early deaths				
Moribund	11 2	7	6	6
Natural deaths	2	10	5	5
Survivors				
Died last week of study	· 1 ·			1
Terminal sacrifice	- 37	35	40	42
Animals examined microscopically	60	60	60	60
15-Month Interim Evaluation				
Alimentary System				· · ·
Liver	(9)	(8)	(9)	(6)
Mixed cell focus		1 (13%)	1 (11%)	
Vacuolization cytoplasmic, focal	1 (11%)	- (	- (	
Mesentery	- (,0)			(1)
Fat, necrosis				1 (100%)
Pancreas	(9)	(8)	(9)	(6)
Atrophy, focal	1 (11%)	(0)	(3)	(0)
	· (11%)			
Endocrine System		•		
Adrenal cortex	(9)	(8)	(9)	(6)
Accessory adrenal cortical nodule	. (2)		1 (11%)	. (0)
Parathyroid gland	(9)	(7)	(9)	(6)
Hyperplasia	()	1 (14%)	())	(0)
Thyroid gland	(0)	(8)	(9)	(6)
Degeneration, cystic, focal	(9)	(8)	(9)	1 (17%)
Degeneration, cystic, tocal				1 (1776)
Genital System		· · · · ·	· · · ·	·
Dvary	(9)	(8)	(0)	(6)
Cyst		(0)	(9) 1 (11%)	(0)
Uterus	4 (44%)	(8)	1 (11%)	
Hydrometra	(9) A (44 %)	(8)	(9) 1 (11%)	(6) 2 (22 %)
	4 (44%)	1 (13%)	1 (11%)	2 (33%)
Inflammation, suppurative	1 (11%)	2 (25%)	0 (00 // )	6 (100 %)
Endometrium, hyperplasia, cystic	9 (100%)	8 (100%)	8 (89%)	6 (100%)
Hematopoietic System	· ·			
Lymph node, mandibular	(9)	(8)	(9)	(5)
Hyperplasia, lymphoid	1 (11%)	(0)		(5)
Spleen	(9)	(8)	(9)	(6)
Fibrosis, focal	1-1	1 (13%)	\~/	(*/
		······································	· · · · · · · · · · · · · · · · · · ·	
Integumentary System	· · · ·		•	-
Skin	(9)	(8)	(9)	(6)
Alopecia, focal			1 (11%)	

<sup>a</sup> Number of animals examined microscopically at the site and the number of animals with lesion

### TABLE D5

Summary of the Incidence of Nonneoplastic Lesions in Female Mice in the 2-Year Feed Study of *t*-Butylhydroquinone (continued)

· .	0 ppm	1,250 ppm	2,500 ppm	5,000 ppm
15-Month Interim Evaluation (co	ntinued)			
Respiratory System	initiaca)			
Lung	(9)	(8)	(9)	(6)
Alveolar epithelium, hyperplasia		(0)	1 (11%)	
Urinary System				
Kidney	(9)	(8)	(9)	(6)
Renal tubule, dilatation, focal	.,		1 (11%)	
Systems Examined With No Lesions	Observed			····
Cardiovascular System	0000000		·	
General Body System		-		
Musculoskeletal System				
Nervous System				1 <sup>1</sup>
Special Senses System				
2-Year Study				
Alimentary System				· .
Gallbladder	(50)	(50)	(47)	(54)
Cyst			1 (2%)	
Intestine small, duodenum	(51)	(51)	(48)	(53)
Erosion	1 (2%)			
Inflammation, chronic, focal	1 (2%)	(51)	(40)	(50)
Intestine small, jejunum	(51)	(51)	(48)	(53)
Perforation, chronic Peyer's patch, hyperplasia, lymphoid			1 (2%)	· .
Intestine small, ileum	(51)	(51)	(47)	(53)
Peyer's patch, hyperplasia, lymphoid	(51)	(51)	1 (2%)	1 (2%)
Liver	(51)	(52)	(51)	(54)
Angiectasis	2 (4%)			1 (2%)
Basophilic focus	2 (4%)	1 (2%)	1 (2%)	
Clear cell focus			2 (4%)	2 (4%)
Eosinophilic focus	4 (8%)	9 (17%)	9 (18%)	11 (20%)
Eosinophilic focus, multiple	3 (6%)	5 (10%)	1 (2%)	1 (2%)
Fatty change	4 (8%)	1 (2%)	1 (271)	e e e e e
Fatty change, focal	2 (4%)	1 (20)	1 (2%)	2 (4%)
Hematopoietic cell proliferation Hemorrhage, focal	3 (6%)	1 (2%)	1 (2%)	2 (4%) 1 (2%)
Hyperplasia, focal, lymphoid				1 (2%)
Infarct	1 (2%)		1 (2%)	
Infiltration cellular, mixed cell	2 (4%)	1 (2%)	1 (2%)	3 (6%)
Inflammation, focal	3 (6%)	1 (2%)	2 (4%)	2 (4%)
Mineralization, focal	·		1 (2%)	
Mixed cell focus	1 (2%)	3 (6%)	1 (2%)	1 (2%)
Mixed cell focus, multiple			1 (2%)	0 (ADIN
Necrosis, focal	1 (2%)	1 (2%)		2 (4%)
Thrombosis Bile dust, syst	1 (2%)		1 (2%)	
Bile duct, cyst Centrilobular, necrosis	1 (2%) 1 (2%)		1 (2%)	1 (2%)

# Table D5

Summary of the Incidence of Nonneoplastic Lesions in Female Mice in the 2-Year Feed Study of *t*-Butylhydroquinone (continued)

(	0 ppm	1,250 ppm	2,500 ppm	5,000 ppm
2-Year Study (continued)	<u> </u>	· · · · · · · · · · · · · · · · · · ·		
Alimentary System (continued)				
	(10)	(12)		(9)
Mesentery	(10)	(13)	(7)	(8)
Hemorrhage	1 (100)	1 (8%)	2 (42 17)	A (E0.07)
Inflammation, chronic	1 (10%)	1 (8%)	3 (43%)	4 (50%)
Fat, necrosis	8 (80%)	5 (38%)	1 (14%)	1 (13%)
Pancreas	(51)	(52)	(49)	(54)
Atrophy, focal	1 (0 (1))	1 (2%)	2 (4%)	
Duct, cyst	1 (2%)	(52)	(81)	(52)
Salivary glands	(51)	(52)	(51)	(53)
Vacuolization cytoplasmic	( <b>F</b> .)		1 (2%)	(54)
Stomach, forestomach	(51)	(52)	(51)	(54)
Erosion	3 (6%)		1 (2%)	9 15 11
Inflammation, chronic	5 (10%)		1 (2%)	.3 (6%)
Pigmentation, focal				1 (2%)
Ulcer	1 (2%)			2 (4%)
Epithelium, hyperplasia	5 (10%)		1 (2%)	4 (7%)
Stomach, glandular	(51)	(52)	(49)	(54)
Erosion	1 (2%)	1 (2%)		1 (2%)
Inflammation, chronic	,			1 (2%)
Pigmentation, focal		1 (2%)		
Ulcer				1 (2%)
Glands, degeneration, cystic, focal			1 (2%)	
Footh		(2)	(4)	(1)
Incisor, dysplasia		2 (100%)	4 (100%)	1 (100%)
Condiana and a Suratan				
Cardiovascular System Blood vessel	(50)	(52)	(51)	(54)
	(50)	(52)	(51)	(54)
Mesenteric artery, inflammation, chronic	(61)	(50)	1 (2%)	(54)
Heart	(51)	(52)	(51)	(54)
Inflammation, chronic, focal			1 (2%)	
Thrombosis			1 (2%)	
Artery, inflammation, chronic			2 (4%)	1 (0 0)
Myocardium, mineralization, focal		<u></u>		1 (2%)
Endocrine System				
Adrenal cortex	(51)	(51)	(50)	(54)
Accessory adrenal cortical nodule	2 (4%)	4 (8%)		1 (2%)
Cytoplasmic alteration, focal	1 (2%)			
Hematopoietic cell proliferation	1 (2%)			
Capsule, hyperplasia	1 (2%)			
Subcapsular, hyperplasia, focal	·-··/			2 (4%)
Adrenal medulla	(51)	(51)	(51)	(54)
Hyperplasia	1 (2%)	<u>/</u>	N/	4 (7%)
Islets, pancreatic	(51)	(52)	(48)	(54)
	()	( <i>)</i>	()	1 (2%)
Hyperplasia				- (-,,
Hyperplasia Parathyroid gland	(46)	(49)	(49)	(49)

### TABLE D5

Summary of the Incidence of Nonneoplastic Lesions in Female Mice in the 2-Year Feed Study of *t*-Butylhydroquinone (continued)

	0 ppm	1,250 ppm	2,500 ppm	5,000 ppm
2-Year Study (continued)		· · · · · · · · · · · · · · · · · · ·	· · · · · · · · · · · · · · · · · · ·	· · · · · · · · · · · · · · · · · · ·
Endocrine System (continued)				
Pituitary gland	(49)	(44)	(46)	(49)
Angiectasis	2 (4%)		2 (4%)	1 (2%)
Cyst	- (177)		1 (2%)	
Pars distalis, angiectasis	1 (2%)		- (/	
Pars distalis, cytoplasmic alteration, focal	2 (4%)	3 (7%)	2 (4%)	1 (2%)
Pars distalis, hyperplasia, focal	3 (6%)	3 (7%)	2 (4%)	1 (2%)
Pars intermedia, hyperplasia, focal		1 (2%)		
Thyroid gland	(51)	(51)	(50)	(54)
Degeneration, cystic, focal	1 (2%)			
Inflammation			1 (2%)	
Inflammation, chronic, focal	1 (2%)	•		2 (4%)
C-cell, hyperplasia	2 (4%)		1 (2%)	A. (1477)
Follicular cell, hyperplasia	12 (24%)	19 (37%)	24 (48%)	24 (44%)
General Body System None				
Genital System				- •
Clitoral gland	(51)	(52)	(50)	(54)
Degeneration, cystic		4 (8%)	2 (4%)	3 (6%)
Ovary	(50)	(49)	. (47)	(50)
Angiectasis	2 (4%)	2 (4%)		3 (6%)
Cyst	15 (30%)	10 (20%)	10 (21%)	11 (22%)
Hemorrhage	1 (2%)		1	
Hyperplasia, tubular				1 (2%)
Inflammation, suppurative	2 (4%)	2 (4%)	2 (4%)	5 (10%)
Thrombosis		1 (0.00)		1 (2%)
Interstitial cell, hyperplasia	(54)	1 (2%)	(50)	(54)
Uterus	(51)	(52)	(50)	(54) 1 (2%)
Cyst		1 (2%) 1 (2%)		1 (270)
Hemorrhage Hydrometra	13 (25%)	1 (2%)	12 (24%)	14 (26%)
Hyperplasia, focal, histiocytic	13 (2370)	1 (2%)	12 (2470)	14 (20%)
Inflammation, suppurative	3 (6%)	1 (270)		3 (6%)
Endometrium, hyperplasia, cystic	50 (98%)	52 (100%)	50 (100%)	51 (94%)
	· · · · · · · · · · · · · · · · · · ·			
Hematopoietic System	· · · · ·	(50)	(61)	(54)
Bone marrow	(51)	(52)	(51)	(54)
Hyperplasia	2 (4%)		. <i></i>	
Hyperplasia, focal, histiocytic	1 (2%)			
Myelofibrosis Lymph node	1 (2%) (7)	(8)	(12)	(9)
Hyperplasia, cystic	1 (14%)	(0)		(~)
lliac, hemorrhage	1 (14%)			
lliac, hyperplasia	2 (29%)	. 1 (13%)		1 (11%)
Inguinal, hyperplasia	~ ~~~~)	• (*****)	2 (17%)	
			- ()	1 (11%)

.

### TABLE D5

3

Summary of the Incidence of Nonneoplastic Lesions in Female Mice in the 2-Year Feed Study of *t*-Butylhydroquinone (continued)

· · · ·	0 ppm 🧠	1,250 ppm	2,500 ppm	5,000 ppm
2-Year Study (continued)		<u> </u>	- <u> </u>	· · · · · · · · · · · · · · · · · · ·
Hematopoietic System (continued)				
		(8)	(12)	
Lymph Node (continued)	(7)	(8)	(12)	(9)
Mediastinal, hyperplasia	1 (14%)	1 (13%)	2 (17%)	1 (11%)
Mediastinal, hyperplasia, lymphoid	1 (14%)			1 (11%)
Mediastinal, inflammation, focal, suppurative	1 (1 4 77)			1 (11%)
Renal, hemorrhage	1 (14%)		1 (0 77)	2 (22 %)
Renal, hyperplasia	2 (29%)	2 (25%)	1 (8%)	3 (33%)
Lymph node, mandibular	(48)	(52)	(50)	(52)
Hemorrhage	1 (2%)			
Hyperplasia, lymphoid	1 (2%)	2 (4%)	1 (2%)	(=0)
Lymph node, mesenteric	(50)	(48)	(49)	(50)
Amyloid deposition	1 (2%)			
Hematopoietic cell proliferation	1 (2%)		1 (2%)	a .= ==+.
Hemorrhage	1 (2%)	2 (4%)	1 (2%)	1 (2%)
Hyperplasia	1 (2%)	2 (4%)		1 (2%)
Hyperplasia, histiocytic	1 (2%)		4	,
Hyperplasia, lymphoid	6 (12%)	3 (6%)	3 (6%)	1 (2%)
Spleen	(51)	(52)	(50)	(54)
Angiectasis				1 (2%)
Congestion		1 (2%)	t .	
Fibrosis, focal				1 (2%)
Hematopoietic cell proliferation	14 (27%)	14 (27%)	13 (26%)	13 (24%)
Hemorrhage			1 (2%)	
Hyperplasia, lymphoid	3 (6%)	8 (15%)	7 (14%)	7 (13%)
Necrosis, focal	1 (2%)			
Thymus	(45)	(51)	(47)	(48)
Cyst		1 (2%)	1 (2%)	1 (2%)
Hyperplasia, histiocytic	1 (2%)			
Hyperplasia, lymphoid	1 (2%)	1 (2%)	1 (2%)	
Integumentary System				· ·
Mammary gland	(51)	(51)	(51)	(54)
Ectasia	3 (6%)	1 (2%)	N/	N2
Hyperplasia	S	1 (2%)		
Skin	(51)	(52)	(51)	(54)
Alopecia, focal	~/	<u> </u>	N/	1 (2%)
Inflammation, chronic, focal			1 (2%)	×/
Ulcer			1 (2%)	
Epidermis, hyperplasia, focal		-	- (2/0)	1 (2%)
Subcutaneous tissue, edema		1 (2%)		/
Subcutaneous tissue, inflammation, chronic,		- \*/0/		
focal		1 (2%)		1 (2%)
		· (*/*/		- (277)
Musculoskeletal System				
Skeletal muscle	(1)	(1)	(2)	
Inflammation, suppurative	1 (100%)	1 (100%)	1 (50%)	

3

÷

Ç,

### TABLE D5

Summary of the Incidence of Nonneoplastic Lesions in Female Mice in the 2-Year Feed Study of *t*-Butylhydroquinone (continued)

	0 ppm	1,250 ppm	2,500 ppm	5,000 ppm
2-Year Study (continued)				
Nervous System	( <b>**</b> )	(50)		(FA)
Brain	(51)	(52)	(51)	(54)
Atrophy, focal	3 (6%)	4 (8%)	1 (2%)	1 (2%)
Artery, meninges, inflammation, chronic			1 (2%)	
Meninges, cyst			1 (2%)	* <u>.</u> * .
Respiratory System				
Lung	(51)	(52)	(51)	(54)
Congestion	1 (2%)	(54)	(**)	(**)
Hemorrhage	· (~/0)	•	1 (2%)	1 (2%)
Hyperplasia, lymphoid		1 (2%)	1 (270)	1 (270)
Infiltration cellular, mixed cell		1 (270)	1 (2%)	2 (4%)
			1 (270)	2 (4%) 1 (2%)
Inflammation, chronic, focal	1 (3.6%)		1 (30)	
Alveolar epithelium, hyperplasia	1 (2%)		1 (2%)	2 (4%)
Interstitium, inflammation, suppurative	2 (4%)			1 (2%)
Mediastinum, inflammation, chronic			1 (2)(1)	1 (2%)
Pleura, mediastinum, inflammation, chronic	/		1 (2%)	1 (2%)
Nose	(51)	(52)	(49)	(53)
Inflammation, suppurative		1 (2%)		1 (2%)
Mucosa, glands, dilatation, focal	16 (31%)	27 (52%)	16 (33%)	26 (49%)
Nasolacrimal duct, cyst		1 (2%)		
Frachea	(51)	(52)	(50)	(54)
Artery, peritracheal tissue, inflammation,				
chronic			1 (2%)	
Special Senses System				
Bye			(1)	
Cornea, inflammation, chronic			1 (100%)	
Urinary System				
Kidney	(51)	(52)	(50)	(53)
Congestion		2 (4%)		. است.
Cyst				1 (2%)
Hydronephrosis	1 (2%)			
Hyperplasia, lymphoid	1 (2%)	1 (2%)		
Inflammation, chronic	2 (4%)			1 (2%)
Metaplasia, focal, osseous			1 (2%)	
Nephropathy	30 (59%)	32 (62%)	35 (70%)	28 (53%)
Artery, inflammation, chronic			1 (2%)	
Renal tubule, casts				1 (2%)
Renal tubule, dilatation, focal			1 (2%)	
Renal tubule, pigmentation			1 (2%)	
Renal tubule, pigmentation, hemoglobin				1 (2%)
Urinary bladder	(51)	(51)	(50)	(53)
Angiectasis	1 (2%)	()	x/	N/
Hyperplasia, lymphoid	· (=/0)		2 (4%)	
LIVUSIUIASIA, IVIIIUIUIU			~ ( , , , , , ,	

 $\hat{\boldsymbol{\lambda}}_{i}$ 

Ş,

a.

# APPENDIX E GENETIC TOXICOLOGY

SALMONELLA	MUTAGENICITY TEST PROTOCOL	262
CHINESE HA	MSTER OVARY CELL CYTOGENETICS PROTOCOLS	262
MOUSE BON	E MARROW MICRONUCLEUS TEST PROTOCOL	263
RESULTS		264
Table E1	Mutagenicity of t-Butylhydroquinone in Salmonella typhimurium	265
Table E2	Induction of Sister Chromatid Exchanges in Chinese Hamster Ovary Cells	
	by t-Butylhydroquinone	269
Table E3	Induction of Chromosomal Aberrations in Chinese Hamster Ovary Cells	
	by <i>t</i> -Butylhydroquinone	270
Table E4	Frequency of Micronuclei in Bone Marrow Cells of Male Mice	
	Treated with t-Butylhydroquinone by Intraperitoneal Injection	271

# **GENETIC TOXICOLOGY**

### SALMONELLA MUTAGENICITY TEST PROTOCOL

Testing was performed as reported by Zeiger *et al.* (1992). *t*-Butylhydroquinone was sent to the laboratory as a coded aliquot from Radian Corporation (Austin, TX). It was incubated with the Salmonella typhimurium tester strains TA97, TA98, TA100, and TA102 either in buffer or S9 mix (metabolic activation enzymes and cofactors from Aroclor<sup>®</sup> 1254-induced male Sprague-Dawley rat or Syrian hamster liver) for 20 minutes at 37° C. Top agar supplemented with *l*-histidine and *d*-biotin was added, and the contents of the tubes were mixed and poured onto the surfaces of minimal glucose agar plates. Histidine-independent mutant colonies arising on these plates were counted following 2 days incubation at 37° C. All tests were repeated using either the same or different S9 concentrations.

Each trial consisted of triplicate plates of concurrent positive and negative controls and of at least five doses of *t*-butylhydroquinone. The high dose was limited by toxicity. All assays were repeated.

In this assay, a positive response is defined as a reproducible, dose-related increase in histidine-independent (revertant) colonies in any one strain/activation combination. An equivocal response is defined as an increase in revertants which was not dose-related, not reproducible, or of insufficient magnitude to support a determination of mutagenicity. A negative response is obtained when no increase in revertant colonies is observed following chemical treatment. There was no minimum percentage or fold-increase required for a chemical to be judged positive or weakly positive.

# CHINESE HAMSTER OVARY CELL CYTOGENETICS PROTOCOLS

Testing was performed as reported by Galloway *et al.* (1987). *t*-Butylhydroquinone was sent to the laboratory as a coded aliquot by Radian Corporation. It was tested in cultured Chinese hamster ovary (CHO) cells for induction of sister chromatid exchanges (SCEs) and chromosomal aberrations (Abs) both in the presence and absence of Aroclor 1254-induced male Sprague-Dawley rat liver S9 and cofactor mix. Cultures were handled under gold lights to prevent photolysis of bromodeoxyuridine-substituted DNA. Each test consisted of concurrent solvent and positive controls and of at least three doses of *t*-butylhydroquinone; the high dose was limited by toxicity. A single flask per dose was used, and tests yielding equivocal or positive results were repeated.

Sister Chromatid Exchange Test: In the SCE test without S9, CHO cells were incubated for 25.5 hours with t-butylhydroquinone in supplemented McCoy's 5A medium. Bromodeoxyuridine (BrdU) was added 2 hours after culture initiation. After 25.5 hours, the medium containing t-butylhydroquinone was removed and replaced with fresh medium plus BrdU and Colcemid<sup>®</sup>, and incubation was continued for 2 hours. Cells were then harvested by mitotic shake-off, fixed, and stained with Hoechst 33258 and Giemsa. In the SCE test with S9, cells were incubated with t-butylhydroquinone, serum-free medium, and S9 for 2 hours. The medium was then removed and replaced with medium containing serum and BrdU and no t-butylhydroquinone, and incubation proceeded for an additional 25.5 hours, with Colcemid<sup>®</sup> present for the final 2 hours. Harvesting and staining were the same as for cells treated without S9. All slides were scored blind and those from a single test were read by the same person. Fifty second-division metaphase cells were scored for frequency of SCEs/cell from each dose level. Because significant chemical-induced cell cycle delay was observed in the presence of S9, incubation time in the second trial with S9 was lengthened to ensure a sufficient number of scorable (second-division metaphase) cells.

Statistical analyses were conducted on the slopes of the dose-response curves and the individual dose points (Galloway et al., 1987). An SCE frequency 20% above the concurrent solvent control value was chosen as

#### t-Butylhydroquinone, NTP TR 459

a statistically conservative positive response. The probability of this level of difference occurring by chance at one dose point is less than 0.01; the probability for such a chance occurrence at two dose points is less than 0.001. An increase of 20% or greater at any single dose was considered weak evidence of activity; increases at two or more doses resulted in a determination that the trial was positive. A significant trend (P<0.005) in the absence of any responses reaching 20% above background led to a call of equivocal.

Chromosomal Aberrations Test: In the Abs test without S9, cells were incubated in McCoy's 5A medium with t-butylhydroquinone for 8 hours; Colcemid<sup>®</sup> was added and incubation continued for 2 hours. The cells were then harvested by mitotic shake-off, fixed, and stained with Giemsa. For the Abs test with S9, cells were treated with t-butylhydroquinone and S9 for 2 hours, after which the treatment medium was removed and the cells incubated for an additional 18 hours in fresh medium, with Colcemid<sup>®</sup> present for the final 2 hours. Cells were harvested in the same manner as for the treatment without S9. The harvest time for the Abs test was based on the cell cycle information obtained in the SCE test; because cell cycle delay was anticipated in the presence of S9, the incubation period was extended beyond the normal 10 to 12 hour period.

Cells were selected for scoring on the basis of good morphology and completeness of karyotype  $(21 \pm 2 \text{ chromosomes})$ . All slides were scored blind and those from a single test were read by the same person. Two hundred first-division metaphase cells were scored at each dose level in the trial without S9. Because large numbers of aberrations were observed in the cells treated in the presence of S9, fewer cells were scored per dose level. Cells with large numbers of aberrations are difficult to score, and the process is extremely arduous. Because so many aberrations were observed in almost 100% of the cells, use of a smaller sample size does not affect the validity of the statistical analysis of the data. Classes of aberrations scored included "simple" (breaks and terminal deletions), "complex" (rearrangements and translocations), and "other" (pulverized cells, despiralized chromosomes, and cells containing ten or more aberrations).

Chromosomal aberration data are presented as percentage of cells with aberrations. To arrive at a statistical call for a trial, analyses were conducted on both the dose-response curve and individual dose points. For a single trial, a statistically significant (P < 0.05) difference for one dose point and a significant trend (P < 0.015) were considered weak evidence for a positive response; significant differences for two or more doses indicated the trial was positive. A positive trend in the absence of a statistically significant increase at any one dose point led to an equivocal call. Ultimately, the trial calls were based on a consideration of the statistical analyses as well as the biological information available to the reviewers.

### MOUSE BONE MARROW MICRONUCLEUS TEST PROTOCOL

Selection of doses was based upon published  $LD_{50}$  information; no preliminary range-finding studies were required. Male B6C3F<sub>1</sub> mice received three intraperitoneal injections of *t*-butylhydroquinone dissolved in corn oil at 24-hour intervals. Up to five mice were treated per exposure group and the highest dose administered was 400 mg/kg. Solvent control animals received corn oil only, and the positive control mice received injections of 25 mg/kg cyclophosphamide. The mice were killed 24 hours after the final injection and slides were prepared from bone marrow smears obtained from the femurs. Slides were air-dried, fixed, and stained. Two thousand polychromatic erythrocytes (PCEs) were scored per animal for frequency of micronucleated cells. No animals survived in the 400 mg/kg group and only one mouse survived in the 300 mg/kg dose group.

The results were tabulated as the mean of the pooled results from all animals within an exposure group, plus or minus the standard error of the mean. The frequency of micronucleated cells among PCEs was analyzed by a statistical software package that tested for increasing trend over exposure groups using a one-tailed Cochran-Armitage trend test, followed by pairwise comparisons between each exposure group and the control group (Margolin *et al.*, 1990). In the presence of excess binomial variation, as detected by a binomial dispersion test, the binomial variance of the Cochran-Armitage test was adjusted upward in proportion to the excess variation. In the micronucleus test, an individual trial is considered positive if the trend test P value is  $\leq 0.025$  or the P value for any single exposure group is  $\leq 0.025/n$  where n = the number of exposure groups. A final call of positive for micronucleus induction is preferably based on reproducibly positive trials (as noted above). Ultimately, the final call is determined by the scientific staff after considering the results of statistical analyses, reproducibility of any effects observed, and the magnitudes of those effects.

### RESULTS

*t*-Butylhydroquinone (3 to 3,333  $\mu$ g/plate) was tested for induction of mutations in *S. typhimurium* strains TA97, TA98, TA100, and TA102 with and without induced rat or hamster liver S9 (Zeiger *et al.*, 1992; Table E1). No mutagenicity was detected in any of the strain/activation combinations. No induction of SCEs (Table E2) or Abs (Table E3) was noted in cultured CHO cells treated with *t*-butylhydroquinone in the absence of S9 activation. However, in the presence of S9, positive dose-related responses were obtained in both these *in vitro* cytogenetic assays. The response obtained in the Abs test was particularly strong, and up to 90% of treated cells showed multiple Abs at the higher doses (200 to 249  $\mu$ g/mL). These positive results in cultured CHO cells may have resulted from the generation of superoxide and H<sub>2</sub>O<sub>2</sub> within the cell from the autooxidation of *t*-butylhydroquinone to *t*-butylquinone and the further generation of oxidative byproducts, thereby indirectly producing chromosome breakage (Phillips *et al.*, 1989). In contrast to the positive results obtained in the *in vitro* assays for chromosome damage, results of an *in vivo* bone marrow micronucleus test were clearly negative. No significant increase in micronucleated erythrocytes was observed in male mice treated with three intraperitoneal injections of up to 300 mg/kg *t*-butylhydroquinone (Table E4).

### 8-Butylhydroquinone, NTP TR 459

#### Table E1

Mutagenicity of t-Butylhydroquinone in Salmonella typhimurium<sup>a</sup>

249 ± 11.0

227 ± 18.5

224 ± 10.8

 $188 \pm 13.5$ 

63 ± 11.5

Negative

604 ± 165.4

 $0 \pm 0.00$ 

0

3

10

33

100

333

666

1,000 1,666

3,333

Trial summary

Positive control

122 ± 2.6

135 ± 13.0

127 ± 4.0

135 ± 10.6

129 ± 4.8

 $150 \pm 8.7$ 

Negative

J

332 ± 29.4

			·	Revertan	ts/plate <sup>b</sup>		
Strain	Dose	40 - 14 - 14 - 14 - 14 - 14 - 14 - 14 - 14		-59		+ 4	
	(µg/plate)	• •	Tr	ial 1	Trial 2		
TA1 <b>02</b>	0		309	) ± 25.5	202 ± 12.4		
	3			) ± 18.6	213 ± 5.8		
	10			5 ± 9.8	187 ± 9.2		
	33		267	' ± 25.5	166 ± 3.6		
	100	•	234	+ ± 12.3	$180 \pm 7.1$		
	166				191 ± 10.0		
	333		128	$3 \pm 21.4^{c}$			
Trial sun	nmary			gative	Negative		
Positive of	control <sup>a</sup>		1,433	5 ± 26.6	565 ± 18.7		· .
<u></u>				Res	ertants/plate	- MERLAND	<u></u>
				Att			
			+hamster S9			+ rat S9	
		10%	10%	30%	10%	10%	30%
		· · · ·					
	(continued)						

331 ± 25.3

372 ± 27.1

348 ± 10.8

328 ± 12.0

 $200 \pm 10.5$ 

 $0 \pm 0.0^{c}$ 

Negative

2,127 ± 104.3

189 ± 3.1

 $185 \pm 7.2$  $175 \pm 16.3$ 

145 ± 6.7

143 ± 4.5

 $167 \pm 6.8$ 

Negative

939 ± 10.5

233 ± 7.1

279 ± 19.7

 $238 \pm 16.5$ 

169 ± 11.5

58 ± 9.1

31 ± 4.3

Negative

 $1,239 \pm 25.6$ 

÷

342 ± 18.5

370 ± 40.1 363 ± 25.4 363 ± 21.1

277 ± 12.7

 $22 \pm 3.2^{c}$ 

Negative

2,633 ± 58.1

5

ADLC LI	1	'A	BI	E	<b>E</b> 1	
---------	---	----	----	---	------------	--

Mutagenicity of t-Butylhydroquinone in Salmonella typhimurium (continued)

			·	Revertants/p	late		
Strain	Dose	· · · · · · · · · · · · · · · · · · ·		~ <b>S9</b>			
	(µg/plate)		Trial 1	Trial 2	Trial 3		
TA100	0		143 ± 6.0	95 ± 11.0	121 ± 10.3	· · · ·	
	3			83 ± 3.3	111 ± 11.6		
	10		$129 \pm 11.3$		$112 \pm 5.1$		
	33		$115 \pm 1.2$	90 ± 4.8	113 ± 7.9		
	100		145 ± 2.5	85 ± 3.2	$119 \pm 11.2$		
	166	:	·	79 ± 4.4	$106 \pm 3.8$		
	333 666		Toxic				· •
	000		Toxic		. *		
Trial sumi			Negative	Negative	Negative		•
Positive co	ontrol		317 ± 9.3	394 ± 24.4	450 ± 20.9		
,				Revertants/pla	te .	· · · · · ·	
				itever tunto, pre			
		+ h	amster S9		<u>+rat</u>		
					400	30%	
		10%	10	)%	10%	5070	
			10	9%	10%		·
T <b>A100</b> (c	continued)	10%		·. 	<u></u>	<u> </u>	· · ·
T <b>A100</b> (c	0	<b>10%</b> 118 ± 11.0	172	2 ± 1.2	108 ± 4.0	141 ± 10.7	· · · · · · · · · · · · · · · · · · ·
T <b>A100</b> (c	0 33	<b>10%</b> 118 ± 11.0 115 ± 4.7	172	2 ± 1.2 7 ± 16.2	108 ± 4.0 134 ± 3.5	$141 \pm 10.7$ $150 \pm 13.2$	· · · · · · · · · · · · · · · · · · ·
T <b>A100</b> (c	0 33 100	<b>10%</b> 118 ± 11.0 115 ± 4.7 111 ± 7.8	172 127 153	$2 \pm 1.2$ 7 ± 16.2 3 ± 3.4	108 ± 4.0 134 ± 3.5 140 ± 10.7	$141 \pm 10.7$ $150 \pm 13.2$ $111 \pm 14.8$	
T <b>A100</b> (a	0 33 100 333	<b>10%</b> 118 ± 11.0 115 ± 4.7 111 ± 7.8 101 ± 7.7	177 127 153 128	$2 \pm 1.2 7 \pm 16.2 3 \pm 3.4 3 \pm 8.2$	$108 \pm 4.0 \\ 134 \pm 3.5 \\ 140 \pm 10.7 \\ 131 \pm 2.2$	$141 \pm 10.7 \\ 150 \pm 13.2 \\ 111 \pm 14.8 \\ 145 \pm 12.5$	· · · · · · · ·
Τ <b>Α100</b> (α	0 33 100 333 1,000	<b>10%</b> 118 ± 11.0 115 ± 4.7 111 ± 7.8 101 ± 7.7 103 ± 11.3	177 127 153 128	$2 \pm 1.2 7 \pm 16.2 3 \pm 3.4 3 \pm 8.2$	$108 \pm 4.0 \\ 134 \pm 3.5 \\ 140 \pm 10.7 \\ 131 \pm 2.2 \\ 103 \pm 7.5$	$141 \pm 10.7$ $150 \pm 13.2$ $111 \pm 14.8$	· · · · · · · · · · · · · · · · · · ·
T <b>A100</b> (d	0 33 100 333	<b>10%</b> 118 ± 11.0 115 ± 4.7 111 ± 7.8 101 ± 7.7	172 127 153 128 82	$2 \pm 1.2 7 \pm 16.2 3 \pm 3.4 3 \pm 8.2$	$108 \pm 4.0 \\ 134 \pm 3.5 \\ 140 \pm 10.7 \\ 131 \pm 2.2$	$141 \pm 10.7 \\ 150 \pm 13.2 \\ 111 \pm 14.8 \\ 145 \pm 12.5$	
TA100 (c	0 33 100 333 1,000 1,666 3,333	<b>10%</b> 118 ± 11.0 115 ± 4.7 111 ± 7.8 101 ± 7.7 103 ± 11.3	172 127 152 128 82	$2 \pm 1.2 7 \pm 16.2 3 \pm 3.4 8 \pm 8.2 5 \pm 10.7$	$108 \pm 4.0 \\ 134 \pm 3.5 \\ 140 \pm 10.7 \\ 131 \pm 2.2 \\ 103 \pm 7.5$	$141 \pm 10.7 \\ 150 \pm 13.2 \\ 111 \pm 14.8 \\ 145 \pm 12.5 \\ 141 \pm 8.5$	

. . . . .

ò

ŷ

÷ •

## Table E1

		Revertan	ts/plate		
Strain Dose		- S	9		
(µg/plate)	Trial 1	Trial 2	Trial 3	Trial 4	
<b>FA98</b> 0	32 ± 2.6	22 ± 1.2	27 ± 0.9	20 ± 2.3	
3		$19 \pm 1.9$	$25 \pm 0.3$	$19 \pm 1.0$	
10	$26 \pm 0.7$	$25 \pm 4.9$	$27 \pm 0.7$	$21 \pm 2.3$	
33	$24 \pm 3.8$	$21 \pm 2.5$	87 ± 5.5	16 ± 4.9	
100	24 ± 1.9	$20 \pm 0.6$	$11 \pm 1.2^{c}$	$14 \pm 3.1$	
166		30 ± 4.5	$0 \pm 0.0^{c}$	$4 \pm 2.3^{c}$	
333	Toxic				
666	Toxic				• .
Frial summary	Negative	Negative	Equivocal	Negative	•
Positive control	$474 \pm 22.1$	$505 \pm 19.5$	487 ± 44.2	537 ± 36.4	•

# Mutagenicity of t-Butylhydroquinone in Salmonella typhimurium (continued)

	·	Revertan	ts/plate		
Strain Dose	+ hamste	+ hamster S9		t S9	
(µg/plate)	10%	30%	10%	30%	· .
TA98 (continued)			······································		
0	$35 \pm 7.8$	$30 \pm 1.2$	38 ± 3.8	38 ± 1.9	
33	$33 \pm 3.8$	$25 \pm 3.2$	$36 \pm 2.0$	$40 \pm 2.6$	
100	$35 \pm 2.0$	$42 \pm 6.0$	$36 \pm 3.3$	$34 \pm 5.2$	
333	$26 \pm 2.3$	37 ± 2.5	36 ± 4.2	$31 \pm 3.2$	
1,000	$23 \pm 1.8$	$26 \pm 5.5$	$27 \pm 0.7$	$15 \pm 3.5$	:
1,666	$4 \pm 0.9^{c}$		$14 \pm 3.2^{c}$		•
3,333		$0 \pm 0.0^{c}$	•	Toxic .	
Trial summary	Negative	Negative	Negative	Negative	
Positive control	725 ± 35.2	489 ± 16.0	197 ± 20.1	192 ± 3.2	
	· · · · · · · · · · · · · · · · · · ·				

. ••	· · · ·			Revertan	ts/plate	·	
Strain	Dose	- <b>S</b>	9	+ hamst	ter S9	<u>+ rat</u>	<b>S9</b>
	(µg/plate)	Trial 1	Trial 2	10%	30%	10%	30%
т <b>а97</b>	0	127 ± 6.7	151 ± 6.6	154 ± 3.4	163 ± 15.2	176 ± 18.3	223 ± 8.1
	3	155 ± 18.8	141 ± 5.9				
	10	155 ± 4.9	163 ± 8.5				
	33	167 ± 8.6	157 ± 3.3	158 ± 6.7	$228 \pm 3.8$	192 ± 7.1	198 ± 6.4
	100	171 ± 4.0	163 ± 7.1	167 ± 15.8	218 ± 19.8	202 ± 12.2	$176 \pm 6.8$
	166		$124 \pm 11.0$				
	333	$0 \pm 0.0^{c}$		170 ± 12.5	. 150 ± 6.1	181 ± 7.1	146 ± 23.0
	666			•		<b>.</b>	
	1,000			140 ± 7.6	160 ± 10.3	152 ± 9.7	154 ± 15.4
	1,666			55 ± 35.2 <sup>c</sup>	•	$72 \pm 6.2^{c}$	
	3,333				$0 \pm 0.0^{c}$		$0 \pm 0.0^{c}$
Trial sum	тагу	Equivocal	Negative	Negative	Equivocal	Negative	Negative
Positive c	ontrol	415 ± 11.2	388 ± 27.1	620 ± 34.7	368 ± 24.9	617 ± 4.7	454 ± 25.6

### TABLE E1

Mutagenicity of t-Butylhydroquinone in Salmonella typhimurium (continued)

<sup>a</sup> Study performed at SRI International. The detailed protocol and these data are presented in Zeiger et al. (1992).

<sup>b</sup> Revertants are presented as mean  $\pm$  standard error from three plates.

<sup>c</sup> Slight toxicity

<sup>d</sup> The positive controls in the absence of metabolic activation were sodium azide (TA100), 9-aminoacridine (TA97),
4-nitro-o-phenylenediamine (TA98), and mitomycin C (TA102). The positive control for metabolic activation with all strains was 2-aminoanthracene, except 2-aminoanthracene/sterigmatocystin was used for TA102.

# Table E2

Induction of Sister Chromatid Exchanges in Chinese Hamster Ovary Cells by t-Butylhydroquinone<sup>a</sup>

Compound	Dose (µg/mL)	Total Cells	No. of Chromo- somes	No. of SCEs	SCEs/ Chromo- some	SCEs/ Cell	Hrs in BrdU	Relative Change of SCEs/ Chromosome <sup>b</sup> (%)
- S9			• • • • • • • • • • • • • • • • • • • •					- · · ·
Summary: Negative				•				
Dimethylsulfoxide		50	1,014	477	0.47	9.5	25.5	
Mitomycin-C	0.001	50	996 ·	566	0.56	11.3	25.5	20.80
	0.010	5	100	138	1.38	27.6	25.5	193.36
t-Butylhydroquinone	0.5	50	1,024	441	0.43	8.8	25.5	-8.45
	1.7	50	1,020	566	0.55	11.3	25.5	17.96
	5.0 16.7	50 0	1,029	490	0.47	9.8	25.5	1.23
				1	$P = 0.062^{c}$			
+ S9							١	
Trial 1		•						
Summary: Positive								
Dimethylsufoxide		50	1,029	409	0.39	8.2	25.5	
Cyclophosphamide	0.4	50	1,019	706	0.69	14.1	\$ 25.5	74.31
	2.0	5	105	210	2.00	42.0	25.5	403.18
t-Butylhydroquinone	5.0	50	1.031	494	0.47	9.9	25.5	20.55*
, , ,	16.7	50	1,016	598	0.58	12.0	25.5	48.08 <b>*</b>
	50.0	50	1,033	603	0.58	12.1	25.5	46.86*
	166.7	0					25.5	
				]	P<0.001			
Trial 2 Summary: Positive								
Dimethylsulfoxide		25	523	208	0.39	8.3	25.5	
Cyclophosphamide	0.4	25	517	278	0.53	11.1	25.5	35.20
- • •	2.0	5	102	168	1.64	33.6	25.5	314.14
t-Butylhydroquinone	49.8	25	514	318	0.61	12.7	25.5	55.56*
	100.5	25	516	352	0.68	14.1	30.5 <sup>d</sup>	71.53*
	150.0	25	521	359	0.68	14.4	30.5 <sup>d</sup>	73.26*

\* **Positive** (P<0.01)

<sup>a</sup> Study performed at Litton Bionetics, Inc. A detailed description of the protocol is presented in Galloway *et al.* (1987). SCE=sister chromatid exchange; BrdU=bromodeoxyuridine.

b SCEs/chromosome in treated cells versus SCEs/chromosome in solvent control cells

<sup>c</sup> Significance of SCEs/chromosome tested by the linear regression trend test vs. log of the dose

<sup>d</sup> Because t-butylhydroquinone induced a delay in the cell division cycle, harvest time was extended to maximize the proportion of second-division cells available for analysis.

### TABLE E3

Induction of Chromosomal Aberrations in Chinese Hamster Ovary Cells by t-Butylhydroquinone<sup>a</sup>

		- <b>S</b> 9		а. — ал жел.	44 - A.	. • •	+ <b>S9</b>	•	• •
Dose (µg/mL)	Total Cells	No.of Abs	Abs/ Cell	Cells with Abs (%)	Dose (µg/mL)	Total Cells	No. of Abs	Abs/ Cell	Cells with Abs (%)
· .			r		Trial 1				······································
Harvest time: 10.0 Summary: Negative					Harvest time: 20.0 h Summary: Positive	ours <sup>c</sup>			
Dimethylsulfoxide					Dimethylsulfoxide				
- -	200	5	0.03	2.5		200	11	0.06	2.0
Mitomycin-C					Cyclophosphamide				
0.25	200	37	0.19	16.0	6.25	200	43	0.22	20.0
0.75	25	13	0.52	32.0	12.5	25	22	0.88	40.0
-Butylhydroquinona			•	· ·	t-Butylhydroquinone				
5.0	200	6	0.03	3.0	100.5	100	79	0.79	36.0*
7.6	200	5	0.03	2.5	150.0	20	53	2.65	75.0*
10.1	200	4	0.02	2.0	200.0	10	36	3.60	80.0*
25.2	0					* 4 E	۰.		
				$P = 0.410^{b}$				·	P<0.001
		· .							
		-			Trial 2				
					Harvest time: 20.0 h Summary: Positive	ours <sup>c</sup>			
					Dimethylsufoxide				
					Dimoniyisuromuo	100	3	0.03	2.0
	•				Cyclophosphamide				
					6.25	100	22	0.22	18.0
					12.5	25	20	0.80	48.0
					t-Butylhydroquinone				
					149.4	25	22	0.88	
					199.2	10	- 31	3.10	90.0*
•					249.0	10	39	3.90	90.0*
					300.0	0			
									P<0.001
					-				

Positive (P<0.05)

\* a Study performed at Litton Bionetics, Inc. The detailed protocol is presented in Galloway et al. (1987). Abs=aberrations.

ь

Significance of percent cells with aberrations tested by the linear regression trend test vs. log of the dose Because significant chemical-induced cell cycle delay was anticipated, incubation time prior to addition of Colcemid<sup>®</sup> was lengthened to c ensure sufficient metaphases for analysis.

### E-Butylhydroquinone, NTP TR 459

### TABLE E4

Frequency of Micronuclei in Bone Marrow Cells of Male Mice Treated with &-Butylhydroquinone by Intraperitoneal Injection<sup>a</sup>

Dose (mg/kg)	Number of Mice	Micronucleated PCEs/1,000 Cells <sup>b</sup>	e.
Cyclophosphamide <sup>c</sup>		······································	
25.00	5	17.6 ± 1.46	
t-Butylhydroquinone			
0.00	5	$0.8 \pm 0.44$	
9.38	4	$0.9 \pm 0.43$	
18.75	5	$1.7 \pm 0.46$	
37.50	5	$1.3 \pm 0.41$	
75.00	5	$1.0 \pm 0.45$	
150.00	5	$1.4 \pm 0.19$	
300.00	. 1	1.0	
		P=0.367 <sup>d</sup>	

<sup>a</sup> Study performed at Environmental Health Research and Testing, Inc. 0 mg/kg is the solvent (corn oil) control. Frequency of micronuclei was measured in 2,000 polychromatic erythrocytes (PCEs) per mouse. Data presented as mean  $\pm$  standard error b

<sup>c</sup> Positive control

d Trend test

# APPENDIX F ORGAN WEIGHTS

AND ORGAN-WEIGHT-TO-BODY-WEIGHT RATIOS

Table F1	Organ Weights and Organ-Weight-to-Body Weight Ratios for Rats	
	in the 13-Week Feed Study of t-Butylhydroquinone	274
Table F2	Organ Weights and Organ-Weight-to-Body Weight Ratios for Rats	
	at the 3-Month Interim Evaluation in the Long-Term Feed Study	
	of t-Butylhydroquinone	275
Table F <b>3</b>	Organ Weights and Organ-Weight-to-Body Weight Ratios for Mice	
	in the 13-Week Feed Study of <i>t</i> -Butylhydroquinone	276
Table F4	Organ Weights and Organ-Weight-to-Body Weight Ratios for Mice	
	at the 15-Month Interim Evaluation in the 2-Year Feed Study	
	of t-Butylhydroquinone	277

### TABLE F1

Organ Weights and Organ-Weight-to-Body-Weight Ratios for Rats in the 13-Week Feed Study of *t*-Butylhydroquinone<sup>a</sup>

					1	
	, :	0 ppm	2,500 ppm	5,000 ppm	10,000 ppm	• .
n	· :	10	10	10	10	
Male		· .				
Necropsy body wt		340 ± 7	339 ± 3	313 ± 7**	284 ± 6**	
Heart						
Absolute		$0.957 \pm 0.019$	$0.940 \pm 0.019$	$0.876 \pm 0.017 **$	$0.806 \pm 0.016^{**}$	
Relative		$2.82 \pm 0.04$	$2.77 \pm 0.04$	$2.80 \pm 0.04$	$2.84 \pm 0.03$	
R. Kidney	•	2.02 ± 0.04	2.77 ± 0.01	2.00 ± 0.01	2.01 ± 0.05	
Absolute		$1.181 \pm 0.034$	$1.252 \pm 0.019$	$1.205 \pm 0.029$	$1.145 \pm 0.024$	· •
Relative		$3.47 \pm 0.06$	$3.70 \pm 0.06^{**}$	$3.85 \pm 0.05^{**}$	$4.04 \pm 0.04^{**}$	
Liver		5.47 <u>+</u> 0.00	5.76 ± 0.00	5105 ± 0105		
Absolute ,		11.950 ± 0.327	14.411 ± 0.229**	$12.670 \pm 0.441$	$12.557 \pm 0.338$	
Relative		$35.16 \pm 0.67$	$42.52 \pm 0.49^{**}$	$40.42 \pm 0.80^{**}$	$44.23 \pm 0.62^{**}$	
Lung		55.10 ± 0.07	42.00 ± 0.49	10.12 ± 0.00	11.25 <u>1</u> 0.02	
Absolute		$1.567 \pm 0.060$	1.274 ± 0.020**	1.246 ± 0.021**	$1.212 \pm 0.013^{**}$	
Relative		$4.62 \pm 0.18$	$3.76 \pm 0.06^{**}$	$3.99 \pm 0.07^{**}$	$4.29 \pm 0.10$	
R. Testis		4.02 ± 0.10	5.70 ± 0.00	5.77 ± 0.07	4.27 1 0.10	
Absolute		$1.399 \pm 0.030$	$1.471 \pm 0.017$	$1.407 \pm 0.016$	$1.392 \pm 0.017$	
Relative		$4.12 \pm 0.05$	$4.34 \pm 0.04*$	$4.51 \pm 0.08**$	$4.92 \pm 0.09^{**}$	
Thymus		4.12 ± 0.05	4.54 1 0.04	4.51 ± 0.00	4.92 <u>T</u> 0.09	•
Absolute		$0.263 \pm 0.015$	$0.286 \pm 0.009$	$0.276 \pm 0.018$	$0.251 \pm 0.012$	
Relative	¢	$0.78 \pm 0.05$	$0.85 \pm 0.03$	$0.88 \pm 0.05$	$0.88 \pm 0.04$	
Relative		0.70 ± 0.05	0.05 ± 0.05	0.00 1 0.00	0.00 ± 0.01	•
Female		• • • •	·			
Necropsy body wt		201 ± 5	199 ± 3	184 ± 2**	173 ± 3**	
Heart	•			÷	,	
Absolute		$0.631 \pm 0.013$	$0.619 \pm 0.013$	$0.585 \pm 0.014*$	$0.575 \pm 0.011 **$	
Relative		$3.14 \pm 0.06$	$3.11 \pm 0.04$	$3.18 \pm 0.05$	$3.33 \pm 0.05*$	
R. Kidney			···!			
Absolute		$0.726 \pm 0.014$	$0.717 \pm 0.013$	$0.689 \pm 0.012$	$0.675 \pm 0.016*$	•
Relative		$3.61 \pm 0.04$	$3.61 \pm 0.05$	$3.75 \pm 0.06$	$3.91 \pm 0.07 **$	
Liver						,
Absolute		$6.358 \pm 0.210$	$6.781 \pm 0.160$	$6.256 \pm 0.096$	$6.743 \pm 0.198$	
Relative		$31.53 \pm 0.50$	$34.12 \pm 0.64*$	$34.10 \pm 0.54*$	39.08 ± 1.01**	
Lung						
Absolute		$1.033 \pm 0.028$	$0.988 \pm 0.015$	$0.988 \pm 0.037$	0.929 ± 0.017**	
Relative		$5.14 \pm 0.12$	$4.98 \pm 0.10$	$5.37 \pm 0.17$	$5.39 \pm 0.09$	
Thymus						
Absolute		$0.260 \pm 0.016$	$0.271 \pm 0.008$	$0.259 \pm 0.009$	$0.245 \pm 0.006$	
Relative		$1.29 \pm 0.07$	$1.36 \pm 0.04$	$1.41 \pm 0.05$	$1.42 \pm 0.04$	

\* Significantly different (P<0.05) from the control group by Williams' or Dunnett's test

\*\* P≤0.01

<sup>a</sup> Organ weights (absolute weights) and body weights are given in grams; organ-weight-to-body-weight ratios (relative weights) are given as mg organ weight/g body weight (mean ± standard error).

### TABLE F2

Organ Weights and Organ-Weight-to-Body-Weight Ratios for Rats at the 3-Month Interim Evaluation in the Long-Term Feed Study of *t*-Butylhydroquinone<sup>a</sup>

•	0 ppm	1,250 ppm	2,500 ppm	<b>5,000 ppm</b>	
n ···	10	10	10	10	
Male					
Necropsy body wt	355 ± 7	348 ± 4	338 ± 7	341 ± 6	
R. Epididymis					
Absolute	$0.472 \pm 0.020$	$0.492 \pm 0.016$	$0.474 \pm 0.018$	0.479 ± 0.014	
Relative	$1.33 \pm 0.07$	$1.41 \pm 0.05$	$1.40 \pm 0.04$	$1.41 \pm 0.04$	
R. Kidney					
Absolute	$1.389 \pm 0.038$	$1.351 \pm 0.032$	$1.396 \pm 0.038$	$1.385 \pm 0.052$	
Relative	$3.91 \pm 0.06$	$3.88 \pm 0.10$	$4.14 \pm 0.08$	$4.06 \pm 0.10$	
Liver					
Absolute	$13.467 \pm 0.435$	$13.527 \pm 0.388$	$14.531 \pm 0.572$	$14.420 \pm 0.451$	
Relative	$37.88 \pm 0.62$	$38.90 \pm 1.17$	42.95 ± 1.15**	42.26 ± 0.86**	
R. Testis					
Absolute	$1.489 \pm 0.022$	$1.463 \pm 0.022$	1.453 ± 0.031	$1.485 \pm 0.022$	
Relative	$4.21 \pm 0.11$	4.21 ± 0.09	$4.31 \pm 0.06$	$4.36 \pm 0.07$	
	. *				
Female					· .
Necropsy body wt	199 ± 2	191 ± 2**	192 ± 3**	181 ± 2**	
R. Kidney					
Absolute	$0.749 \pm 0.013$	$0.729 \pm 0.012$	0.728 ± 0.017	$0.675 \pm 0.015^{**}$	
Relative	$3.76 \pm 0.07$	$3.82 \pm 0.07$	$3.80 \pm 0.05$	$3.73 \pm 0.07$	
Liver			-		
Absolute	$6.310 \pm 0.150$	$6.625 \pm 0.170$	$6.593 \pm 0.162$	$6.255 \pm 0.096$	
Relative	$31.70 \pm 0.80$	$34.67 \pm 0.76 **$	$34.40 \pm 0.65*$	$34.61 \pm 0.37*$	

\* Significantly different (P $\leq$ 0.05) from the control group by Williams' or Dunnett's test

\*\* P≤0.01

<sup>a</sup> Organ weights (absolute weights) and body weights are given in grams; organ-weight-to-body-weight ratios (relative weights) are given as mg organ weight/g body weight (mean ± standard error).

Ļ.

### TABLE F3

Organ Weights and Organ-Weight-to-Body-Weight Ratios for Mice in the 13-Week Feed Study of t-Butylhydroquinone<sup>a</sup>

	0 ppm	2,500 ppm	5,000 ppm	10,000 ppm	20,000 ppm	40,000 ppm
Male			- - `			· ·
n	10	9	9	10	9	8
Necropsy body wt	34.1 ± 0.7	31.9 ± 0.7*	32.3 ± 0.4*	30.1 ± 0.4**	27.6 ± 0.6**	23.7 ± 0.4**
Heart				·		. * ;
Absolute	$0.143 \pm 0.003$	$0.147 \pm 0.005$	$0.151 \pm 0.004$	$0.134 \pm 0.003$	0.127 ± 0.003**	0.113 ± 0.003**
Relative	$4.20 \pm 0.07$	$4.60 \pm 0.15^{*}$	$4.67 \pm 0.07*$	$4.46 \pm 0.10^*$	$4.60 \pm 0.14*$	4.75 ± 0.10**
R. Kidney		. –				
Absolute	$0.286 \pm 0.006$	$0.298 \pm 0.007$	$0.310 \pm 0.006$	$0.268 \pm 0.007$	0.236 ± 0.005**	0.195 ± 0.007**
Relative	$8.41 \pm 0.16$	$9.34 \pm 0.18 **$	$9.58 \pm 0.15^{**}$	$8.91 \pm 0.16$	$8.54 \pm 0.16$	$8.22 \pm 0.18$
Liver		· · · · · · · · · · · · · · · · · ·		···· <u>-</u> ····		-
Absolute	$1.334 \pm 0.040$	1.448 ± 0.033	1.559 ± 0.032**	$1.313 \pm 0.036$	$1.326 \pm 0.057$	$1.318 \pm 0.033$
Relative	$39.24 \pm 1.19$	45.45 ± 0.92**	$48.19 \pm 0.80 **$	$43.68 \pm 1.01 **$	$47.89 \pm 1.40 **$	55.59 ± 0.90**
Lung	· · · · · · · · · · · · · · ·		-	-		— ,
Absolute	$0.180 \pm 0.005^{b}$	$0.177 \pm 0.005$	$0.174 \pm 0.005$	0.175 ± 0.003	$0.179 \pm 0.008^{c}$	0.168 ± 0.007
Relative	$5.27 \pm 0.20^{b}$	$5.55 \pm 0.16$	$5.39 \pm 0.12$	$5.84 \pm 0.15*$	$6.48 \pm 0.20**^{c}$	7.07 ± 0.27**
R. Testis	-	-				
Absolute	$0.117 \pm 0.002$	$0.119 \pm 0.003$	$0.121 \pm 0.001$	$0.115 \pm 0.002$	$0.112 \pm 0.003$	0.105 ± 0.004**
Relative	$3.44 \pm 0.07$	$3.74 \pm 0.07*$	$3.74 \pm 0.04*$	3.83 ± 0.06**	4.08 ± 0.09**	4.44 ± 0.17**
Thymus	_	_	_			
Absolute	$0.038 \pm 0.003$	$0.039 \pm 0.004$	$0.034 \pm 0.002^{c}$	$0.030 \pm 0.001*$	$0.031 \pm 0.001 *^{c}$	$0.028 \pm 0.003*$
Relative	$1.12 \pm 0.08$	$1.22 \pm 0.12$	$1.06 \pm 0.05^{c}$	$1.00 \pm 0.06$	$1.12 \pm 0.04^{c}$	1.17 ± 0.13
Female						÷. (
n	9	. 9	10 ·	8	10	9
Necropsy body wt	$30.7 \pm 0.7$	28.5 ± 1.0*	28.6 ± 0.7*	24.1 ± 0.4**	22.1 ± 0.4**	20.3 ± 0.5**
Heart			,			
Absolute	$0.128 \pm 0.004$	$0.126 \pm 0.004$	$0.129 \pm 0.003$	$0.115 \pm 0.003*$	0.105 ± 0.002**	0.103 ± 0.003**
Relative	$4.17 \pm 0.16$	$4.43 \pm 0.16$	$4.53 \pm 0.11$	$4.78 \pm 0.11^{**}$	4.77 ± 0.11**	5.10 ± 0.12**
R. Kidney	_					
Absolute	$0.218 \pm 0.006$	$0.211 \pm 0.006$	$0.212 \pm 0.005$	0.185 ± 0.005**	0.170 ± 0.005**	0.160 ± 0.004**
Relative	$7.11 \pm 0.26$	$7.44 \pm 0.24$	7.44 ± 0.18	7.69 ± 0.18	$7.70 \pm 0.14$	7.91 ± 0.22*
Liver						
Absolute	$1.203 \pm 0.030$	1.249 ± 0.038	1.293 ± 0.025	1.030 ± 0.027**	1.051 ± 0.039**	$1.237 \pm 0.032$
Relative	$39.22 \pm 0.96$	43.90 ± 1.00**	45.43 ± 1.06**	42.75 ± 0.54**	47.52 ± 0.93**	61.14 ± 1.73**
Lung						
Absolute	$0.170 \pm 0.008$	0.166 ± 0.006	$0.163 \pm 0.006$	$0.169 \pm 0.005$	$0.164 \pm 0.005$	$0.150 \pm 0.004$
Relative	$5.56 \pm 0.32$	$5.82 \pm 0.15$	$5.73 \pm 0.25$	7.02 ± 0.24**	$7.42 \pm 0.16^{**}$	$7.41 \pm 0.19**$
Thymus						
Absolute	$0.045 \pm 0.002$	$0.048 \pm 0.002^{\circ}$	$0.044 \pm 0.002$	$0.046 \pm 0.002$	$0.037 \pm 0.002*$	$0.028 \pm 0.004 **$
Relative	$1.49 \pm 0.08$	$1.68 \pm 0.05^{c}$	$1.53 \pm 0.07$	$1.92 \pm 0.09*$	$1.65 \pm 0.06$	$1.34 \pm 0.16$

\* Significantly different (P $\leq$ 0.05) from the control group by Williams' or Dunnett's test

\*\* P≤0.01

Organ weights (absolute weights) and body weights are given in grams; organ-weight-to-body-weight ratios (relative weights) are given as mg organ a weight/g body weight (mean  $\pm$  standard error). n=9

÷

b с

n=8

### Table F4

44

Organ Weights and Organ-Weight-to-Body-Weight Ratios for Mice at the 15-Month Interim Evaluation in the 2-Year Feed Study of t-Butylhydroquinone<sup>a</sup>

	0 ppm	1,250 ppm	2,500 ppm	5,000 ppm
Male				
n	10	10	9	9
Necropsy body wt	$49.1 \pm 1.0$	$50.3 \pm 1.2$	49.4 ± 1.0	45.4 ± 1.5
R. Epididymis				
Absolute	$0.051 \pm 0.002$	$0.052 \pm 0.003$	$0.050 \pm 0.002$	$0.048 \pm 0.002$
Relative	$1.05 \pm 0.05$	$1.04 \pm 0.06$	$1.02 \pm 0.03$	$1.06 \pm 0.03$
R. Kidney				•
Absolute	$0.422 \pm 0.014$	$0.441 \pm 0.022$	$0.439 \pm 0.019$	$0.420 \pm 0.018^{b}$
Relative	$8.58 \pm 0.14$	$8.76 \pm 0.33$	8.87 ± 0.21	$9.29 \pm 0.23^{b}$
Liver				
Absolute	$2.042 \pm 0.108^{\circ}$	$2.257 \pm 0.176$	$2.258 \pm 0.155$	$2.401 \pm 0.434$
Relative	$41.57 \pm 1.39^{\circ}$	$45.04 \pm 3.74$	45.42 ± 2.13	55.62 ± 13.39
R. Testis				
Absolute	$0.118 \pm 0.002$	$0.114 \pm 0.002$	$0.116 \pm 0.003$	$0.115 \pm 0.004$
Relative	$2.42 \pm 0.05$	$2.28 \pm 0.06$	$2.36 \pm 0.04$	$2.55 \pm 0.09$
Female				
n	9	8	9	6
Necropsy body wt	$53.5 \pm 1.8$	$53.6 \pm 3.7$	51.9 ± 1.8	44.8 ± 2.0
R. Kidney				
Absolute	$0.279 \pm 0.011$	$0.298 \pm 0.014$	$0.287 \pm 0.013$	$0.272 \pm 0.009$
Relative	$5.24 \pm 0.24$	$5.67 \pm 0.33$	$5.53 \pm 0.19$	$6.12 \pm 0.37$
Liver				
Absolute	$1.696 \pm 0.054$	1.918 ± 0.153	$1.820 \pm 0.047$	1.775 ± 0.029
Relative	$31.73 \pm 0.67$	$36.11 \pm 2.20$	$35.26 \pm 1.03$	39.88 ± 1.46**

\*\* Significantly different (P≤0.01) from the control group by Williams' test

a Organ weights (absolute weights) and body weights are given in grams; organ-weight-to-body-weight ratios (relative weights) are given as mg organ weight/g body weight (mean  $\pm$  standard error). b

۵

÷.

3

n=8 С

n=9

. . .

# APPENIDIX G HIEMATOLOGY AND CLINICAL CHIEMIISTRY RESULTS

Table G1	Hematology and Clinical Chemistry Data for Rats	
	in the 13-Week Feed Study of t-Butylhydroquinone	280
Table G2	Hematology Data for Rats at the 3-Month Interim Evaluation	
	in the Long-Term Feed Study of t-Butylhydroquinone	284
Table G3	Hematology and Clinical Chemistry Data for Mice	
	in the 13-Week Feed Study of <i>t</i> -Butylhydroquinone	285
Table G4	Hematology Data for Mice at the 15-Month Interim Evaluation	
	in the 2-Year Feed Study of <i>t</i> -Butylhydroquinone	289

3

7

ç

5

Hematology and Clinical Chemistry Data for Rats in the 13-Week Feed Study of t-Butylhydroquinone<sup>a</sup>

	0 ppm	2,500 ppm	5,000 ppm	10,000 ppm
Male			· · · · · · · · · · · · · · · · · · ·	· <u>································</u> .
n	10	10	10	10
Hematology				
Hematocrit (%)			· · · · · · · · · · · · · · · · · · ·	
Day 5	$41.1 \pm 0.5$	$40.6 \pm 0.5$	$41.5 \pm 0.6$	$41.3 \pm 0.4$
Week 3	$45.0 \pm 0.7$	$44.6 \pm 0.4$	$44.7 \pm 0.8$	$42.4 \pm 0.4**$
Week 13	$44.7 \pm 1.0$	$45.0 \pm 0.4$	$44.0 \pm 0.8$	$44.6 \pm 0.3$
Hemoglobin (g/dL)	· · · · · <b>-</b> · · ·	<b>-</b>	<b>-</b>	
Day 5	$14.1 \pm 0.2$	$14.0 \pm 0.1$	$14.3 \pm 0.2$	$14.2 \pm 0.1$
Week 3	$15.2 \pm 0.2$	$15.1 \pm 0.1$	$15.0 \pm 0.3$	$14.1 \pm 0.1^{**}$
Week 13	$15.3 \pm 0.3$	$15.3 \pm 0.2$	$14.9 \pm 0.3$	$15.2 \pm 0.1$
Erythrocytes $(10^6/\mu L)$	1010 1 010	,1010 ± 011		· · · · · · · · · · · · · · · · · · ·
Day 5	$7.15 \pm 0.10$	$7.15 \pm 0.08$	$7.35 \pm 0.10$	$7.40 \pm 0.07$
Week 3	$7.79 \pm 0.12$	$7.77 \pm 0.05$	$7.76 \pm 0.16$	$7.34 \pm 0.07**$
Week 13	$8.96 \pm 0.20$	$9.04 \pm 0.09$	$8.80 \pm 0.16$	8.87 ± 0.05
Reticulocytes $(10^6/\mu L)$	0.70 ± 0.20	2.04 T 0.02	0.00 T 0.10	0.07 T 0.05
Day 5	$0.33 \pm 0.04$	$0.44 \pm 0.04$	$0.46 \pm 0.05$	$0.44 \pm 0.04$
Week 3	$0.35 \pm 0.04$ $0.21 \pm 0.03$	$0.24 \pm 0.03$	$0.28 \pm 0.03$	$0.29 \pm 0.03$
	$0.21 \pm 0.03$ $0.18 \pm 0.02$	$0.24 \pm 0.03$ $0.19 \pm 0.01$	$0.23 \pm 0.03$ $0.17 \pm 0.03$	$0.17 \pm 0.03$
Week 13 Nucleated erythrocytes $(10^3/\mu L)$	$0.18 \pm 0.02$	0.19 ± 0.01	0.17 ± 0.05	0.17 ± 0.05
	$0.14 \pm 0.04$	$0.09 \pm 0.02$	$0.14 \pm 0.03$	$0.11 \pm 0.03$
Day 5 Week 2			$0.14 \pm 0.03$ $0.17 \pm 0.05$	$0.11 \pm 0.03$ $0.10 \pm 0.03$
Week 3	$0.12 \pm 0.03$	$0.11 \pm 0.03$	$0.01 \pm 0.03$ 0.01 ± 0.01	$0.02 \pm 0.03$
Week 13	$0.02 \pm 0.01$	$0.04 \pm 0.02$	$0.01 \pm 0.01$	$0.02 \pm 0.01$
Mean cell volume (fL)	57 5 1 0 2	56 P 1 0 0	56 A L 0 2**	550 + 0 1**
Day 5	$57.5 \pm 0.3$	$56.8 \pm 0.2$	56.4 ± 0.3**	$55.9 \pm 0.1**$
Week 3	$57.9 \pm 0.4$	$57.3 \pm 0.3$	$57.8 \pm 0.4$	$57.7 \pm 0.5$
Week 13	$50.0 \pm 0.2$	$49.8 \pm 0.3$	$50.1 \pm 0.2$	$50.0 \pm 0.2$
Mean cell hemoglobin (pg)	10 7 1 0 1	10.5 \ 0.1	10.5 1 0.1*	10.2 + 0.1**
Day 5	$19.7 \pm 0.1$	$19.5 \pm 0.1$	$19.5 \pm 0.1*$	$19.2 \pm 0.1^{**}$
Week 3	$19.5 \pm 0.2$	$19.4 \pm 0.1$	$19.4 \pm 0.1$	$19.3 \pm 0.2$
Week 13	$17.1 \pm 0.1$	$16.9 \pm 0.1$	$16.9 \pm 0.1$	$17.1 \pm 0.1$
Mean cell hemoglobin concentration (			24.4 + 0.2	24.2 + 0.1
Day 5	$34.4 \pm 0.1$	$34.4 \pm 0.2$	$34.4 \pm 0.2$	$34.3 \pm 0.1$
Week 3	$33.8 \pm 0.4$	$33.8 \pm 0.2$	$33.6 \pm 0.2$	$33.4 \pm 0.3$
Week 13	$34.2 \pm 0.1$	$34.0 \pm 0.1$	$33.8 \pm 0.2$	$34.1 \pm 0.1$
Platelets $(10^3/\mu L)$			000 7 . 06 14	044.7 + 16.2
Day 5	$962.9 \pm 9.6$	$938.6 \pm 24.6$	$903.7 \pm 26.1*$	$944.7 \pm 16.2$
Week 3	844.8 ± 38.0	$828.9 \pm 11.5$	$830.3 \pm 17.0$	909.7 ± 15.6**
Week 13	$676.9 \pm 23.2$	$655.7 \pm 23.0$	$745.9 \pm 54.6$	$688.1 \pm 9.8$
Leukocytes $(10^3/\mu L)$	· · · · · · · · ·		0.50 0.00	7.81 + 0.26*
Day 5	$9.02 \pm 0.26$	$8.37 \pm 0.31$	$8.58 \pm 0.32$	7.81 ± 0.36*
Week 3	$9.03 \pm 0.26$	$9.01 \pm 0.11$	$8.84 \pm 0.21$	$8.30 \pm 0.28$
Week 13	8.94 ± 0.45	$8.96 \pm 0.53$	$8.50 \pm 0.63$	$9.44 \pm 0.51$
Segmented neutrophils $(10^3/\mu L)$				0.00
Day 5	$0.90 \pm 0.06$	$0.87 \pm 0.10$	$1.01 \pm 0.11$	$0.80 \pm 0.10$
Week 3	$1.06 \pm 0.11$	$0.80 \pm 0.09$	$0.96 \pm 0.15$	$0.90 \pm 0.07$
Week 13	$1.30 \pm 0.17$	$1.11 \pm 0.09$	$0.92 \pm 0.13$	$1.38 \pm 0.17$
Lymphocytes $(10^3/\mu L)$			<b>.</b>	C 00
Day 5	$7.90 \pm 0.32$	$7.36 \pm 0.30$	$7.39 \pm 0.37$	$6.89 \pm 0.29$
Week 3	7.76 ± 0.24	$8.12 \pm 0.12$	$7.69 \pm 0.21$	$7.29 \pm 0.30$
Week 13	$7.52 \pm 0.36$	$7.72 \pm 0.44$	$7.48 \pm 0.58$	$7.95 \pm 0.44$
Monocytes $(10^3/\mu L)$				·
Day 5	$0.16 \pm 0.05$	$0.10 \pm 0.03$	$0.11 \pm 0.02$	$0.08 \pm 0.05$
Week 3	$0.15 \pm 0.07$	$0.06 \pm 0.02$	$0.09 \pm 0.05$	$0.04 \pm 0.02$
Week 13	$0.04 \pm 0.02$	$0.02 \pm 0.01$	$0.01 \pm 0.01$	$0.00 \pm 0.00$

ō

ž

# Hematology and Clinical Chemistry Data for Rats in the 13-Week Feed Study of t-Butylhydroquinone (continued)

. •	0 ppm	2,500 ppm	5,000 ppm	10,000 ppm	
Male (continued)	e. With a second se				
1	10	10	10	10	
Hematology (continued)					
Eosinophils $(10^3/\mu L)$					
Day 5	$0.03 \pm 0.02$	$0.04 \pm 0.03$	$0.05 \pm 0.02$	$0.04 \pm 0.02$	
Week 3	$0.04 \pm 0.02$	$0.02 \pm 0.01$	$0.09 \pm 0.02$	$0.07 \pm 0.02$	
Week 13	$0.10 \pm 0.03$	$0.11 \pm 0.05$	$0.10 \pm 0.02$	$0.01 \pm 0.03$	
Thromboplastin time (seconds)	0110 <u>T</u> 0100		0.10 <u>+</u> 0.02	0.11 ± 0.04	
Week 13	$10.63 \pm 0.40^{b}$	$10.29 \pm 0.30^{\circ}$	$10.96 \pm 0.28^{c}$	$10.21 \pm 0.36^{d}$	
Activated partial thromboplastin time		10.27 ± 0.50	10.90 1 0.20	10.21 ± 0.50	
Week 13	$19.95 \pm 1.43^{b}$	$19.40 \pm 1.28^{b}$	$18.29 \pm 0.68^{c}$	$19.84 \pm 1.09^{d}$	
Clinical Chamister					
Clinical Chemistry Blood urea nitrogen (mg/dL)					
	22 5 1 0 7	<b>33 0 1 0 3</b>	22.0 + 0.4	01 0 · 0 6	
Day 5 Week 2	$23.5 \pm 0.7$	$22.8 \pm 0.3$	$22.0 \pm 0.4$	$21.9 \pm 0.5$	
Week 3	$21.1 \pm 0.8$	$25.2 \pm 0.6^{**}$	$25.3 \pm 0.7**$	$24.9 \pm 0.6^{**}$	
Week 13	$22.9 \pm 0.4$	$22.1 \pm 0.6$	$22.2 \pm 0.5$	$22.9 \pm 0.3$	
Creatinine (mg/dL)			a sa la ast	<b>.</b> .	
Day 5	$0.51 \pm 0.02$	$0.48 \pm 0.01$	$0.50 \pm 0.03^{d}$	$0.46 \pm 0.02^{D}$	
Week 3	$0.58 \pm 0.02$	$0.56 \pm 0.03$	$0.58 \pm 0.02$	0.55 ± 0.01 `	
Week 13	$0.64 \pm 0.02$	$0.63 \pm 0.02$	$0.68 \pm 0.02$	$0.67 \pm 0.02$	
Fotal protein (g/dL)			5		
Day 5	$6.3 \pm 0.1$	$6.0 \pm 0.1*$	$6.1 \pm 0.1*$	5.6 ± 0.1**	
Week 3	$6.3 \pm 0.1$	$6.4 \pm 0.1$	$6.4 \pm 0.1$	$6.4 \pm 0.1$	
Week 13	$7.3 \pm 0.1$	$7.3 \pm 0.1$	$7.4 \pm 0.1$	$7.5 \pm 0.1$	
Albumin (g/dL)					
Day 5	$3.7 \pm 0.1$	$3.6 \pm 0.1$	$3.5 \pm 0.0$	$3.3 \pm 0.1 **$	
Week 3	$3.7 \pm 0.1$	$3.8 \pm 0.1$	$3.8 \pm 0.1$	$3.8 \pm 0.1$	
Week 13	$4.0 \pm 0.1$	$4.2 \pm 0.1$	$4.2 \pm 0.1$	$4.3 \pm 0.1*$	
Alanine aminotransferase (IU/L)	`				
Week 3	$43 \pm 1$	48 ± 1*	48 ± 1*	48 ± 2*	
Week 13	51 ± 2	63 ± 4*	44 ± 1	$51 \pm 1$	
Alkaline phosphatase (IU/L)					
Day 5	$662 \pm 17$	$603 \pm 12$	$626 \pm 20$	$611 \pm 24$	
Week 3	498 ± 9	494 ± 8	$504 \pm 12$	$496 \pm 9$	
Week 13	$258 \pm 9$	243 ± 9	$244 \pm 3$	$253 \pm 5$	
Creatine kinase (IU/L)					
Day 5	722 ± 98	$635 \pm 55$	781 ± 50	800 ± 47	
Week 3	973 ± 79	$996 \pm 108$	$925 \pm 48$	$1,054 \pm 100$	
Week 13	$376 \pm 47$	492 ± 97	$399 \pm 44$	$428 \pm 39$	
Sorbitol dehydrogenase (IU/L)	—	-			
Day 5	7 ± 0	8 ± 0	8 ± 0*	8 ± 0**	
Week 3	$9 \pm 1$	$9 \pm 1$	$10 \pm 1$	$10 \pm 0$	
Week 13	$11 \pm 1$	$12 \pm 1$	$12 \pm 1$	$10 \pm 1$	
Bile acids (µmol/L)	*	•		•	
Day 5	$21.6 \pm 5.6^{c}$	$19.2 \pm 3.0^{b}$	43.7 ± 1.9** <sup>b</sup>	74.8 ± 10.6** <sup>e</sup>	
Week 3	$28.9 \pm 2.8$	$30.8 \pm 3.0$	$46.5 \pm 5.1^{**}$	$46.2 \pm 4.1^{**}$	
Week 13	$22.1 \pm 3.6$	$21.7 \pm 2.3$	$31.4 \pm 3.7*$	$42.0 \pm 2.2**$	

Hematology and Clinical Chemistry Data for Rats in the 13-Week Feed Study of t-Butylhydroquinone (continued)

	0 ppm	2,500 ppm	5,000 ppm	10,000 ppm	
Female	· · ·				
n	10	10	10	10	
<b>TT</b>					
Hematology					
Hematocrit (%) Day 5	12 2 + 0 5	42.0 + 0.6	$42.0 \pm 0.4$	122 1 0 1	
Week 3	$\begin{array}{r} 42.2 \pm 0.5 \\ 46.2 \pm 0.5 \end{array}$	$42.0 \pm 0.6$ $46.3 \pm 0.6$	$42.0 \pm 0.4$ $45.5 \pm 0.5$	$42.3 \pm 0.4$ $45.8 \pm 0.5$	
Week 13			. —	$43.8 \pm 0.3$ $42.7 \pm 0.5^{\text{f}}$	
Hemoglobin (g/dL)	$43.8 \pm 0.4$	$43.4 \pm 0.4$	$43.6 \pm 0.3$	$42.7 \pm 0.3$	
Day 5	$14.7 \pm 0.1$	$14.5 \pm 0.2$	$14.3 \pm 0.2$	$14.7 \pm 0.1$	
Week 3	$14.7 \pm 0.1$ $15.3 \pm 0.2$		—		
Week 13	$13.5 \pm 0.2$ 14.6 ± 0.1	$15.3 \pm 0.2$ $14.3 \pm 0.1$	$15.3 \pm 0.2$	$15.2 \pm 0.2$ $14.1 \pm 0.2^{f}$	
Erythrocytes $(10^6/\mu L)$	$14.0 \pm 0.1$	$14.3 \pm 0.1$	$14.4 \pm 0.1$	$14.1 \pm 0.2$	
	7 45 1 0 10	7 42 + 0 10	7.54 + 0.07	7 68 1 0 00	
Day 5 Week 3	$7.45 \pm 0.10$	$7.42 \pm 0.10$	$7.54 \pm 0.07$	$7.68 \pm 0.09$	
Week 3 Week 13	$7.78 \pm 0.11$	$7.78 \pm 0.08$	$7.73 \pm 0.09$	$7.85 \pm 0.08$	
Week 13 Potionlocutos (10 <sup>6</sup> /L)	$8.28 \pm 0.06$	$8.16 \pm 0.07$	$8.22 \pm 0.07$	$8.03 \pm 0.11^{t}$	
Reticulocytes $(10^{\circ}/\mu L)$		0.00 + 0.00		0.07 / 0.02	
Day 5	$0.30 \pm 0.03$	$0.33 \pm 0.02$	$0.28 \pm 0.04$	$0.27 \pm 0.03$	
Week 3	$0.26 \pm 0.03$	$0.26 \pm 0.02$	$0.25 \pm 0.03$	$0.21 \pm 0.02$	
Week 13	$0.19 \pm 0.02$	$0.22 \pm 0.03$	$0.23 \pm 0.03$	$0.20 \pm 0.03^{t}$	
Nucleated erythrocytes $(10^3/\mu L)$					
Day 5	$0.12 \pm 0.05$	$0.07 \pm 0.03$	$0.06 \pm 0.03$	$0.07 \pm 0.03$	
Week 3	$0.00 \pm 0.00$	$0.00 \pm 0.00$	$0.00 \pm 0.00$	$0.00 \pm 0.00$	
Week 13	$0.04 \pm 0.02$	$0.03 \pm 0.02$	$0.06 \pm 0.02$	$0.04 \pm 0.04^{r}$	
Mean cell volume (fL)	·				
Day 5	$56.7 \pm 0.3$	$56.6 \pm 0.2$	$55.8 \pm 0.3*$	$55.2 \pm 0.1$ **	
Week 3	$59.4 \pm 0.2$	$59.5 \pm 0.3$	$58.9 \pm 0.2$	$58.4 \pm 0.3^{*}$	
Week 13	$52.9 \pm 0.2$	$53.3 \pm 0.2$	$53.1 \pm 0.2$	$53.0 \pm 0.2^{r}$	•
Mean cell hemoglobin (pg)					
Day 5	$19.7 \pm 0.1$	$19.6 \pm 0.1$	$19.0 \pm 0.3^{**}$	$19.1 \pm 0.1 **$	
Week 3	$19.7 \pm 0.1$	$19.7 \pm 0.1$	$19.8 \pm 0.1$	$19.3 \pm 0.2$	
Week 13	$17.6 \pm 0.1$	$17.6 \pm 0.1$	$17.5 \pm 0.1$	$17.6 \pm 0.1^{r}$	
Mean cell hemoglobin concentration					
Day 5	$34.8 \pm 0.1$	$34.7 \pm 0.2$	$34.1 \pm 0.5$	$34.7 \pm 0.2$	
Week 3	$33.1 \pm 0.1$	$33.2 \pm 0.2$	$33.6 \pm 0.2$	$33.2 \pm 0.2$	
Week 13	$33.3 \pm 0.2$	$33.0 \pm 0.1$	$33.0 \pm 0.2$	$33.1 \pm 0.2^{r}$	
Platelets $(10^3/\mu L)$					
Day 5	$1,036.3 \pm 44.7$	$1,009.3 \pm 44.6$	$945.7 \pm 44.5$	$923.4 \pm 40.6$	
Week 3	$901.6 \pm 25.5$	$959.0 \pm 38.5$	$962.2 \pm 39.1$	$885.0 \pm 31.4$	4 C
Week 13	$700.8 \pm 5.8$	$737.4 \pm 6.3$	$715.9 \pm 23.1$	$744.2 \pm 18.9^{r}$	
Leukocytes $(10^3/\mu L)$					
Day 5	$8.10 \pm 0.28$	$8.45 \pm 0.36$	$8.89 \pm 0.29$	$7.84 \pm 0.35$	
Week 3	$8.02 \pm 0.53$	$9.09 \pm 0.23$	$8.81 \pm 0.26$	$8.62 \pm 0.48_{f}$	
Week 13	$7.53 \pm 0.60$	$7.09 \pm 0.28$	$7.86 \pm 0.32$	$8.34 \pm 0.47^{f}$	
Segmented neutrophils $(10^3/\mu L)$					
Day 5	$0.71 \pm 0.09$	$0.78 \pm 0.07$	$0.77 \pm 0.10$	$0.89 \pm 0.09$	
Week 3	$1.20 \pm 0.12$	$1.10 \pm 0.15$	$0.93 \pm 0.11$	$0.89 \pm 0.08$	
Week 13	$1.36 \pm 0.24$	$1.26 \pm 0.14$	$1.23 \pm 0.13$	$1.12 \pm 0.11^{r}$	
Lymphocytes $(10^3/\mu L)$					۰.
Day 5	$7.25 \pm 0.26$	$7.56 \pm 0.36$	$7.92 \pm 0.27$	$6.80 \pm 0.30$	•
Week 3	$6.33 \pm 0.40$	$7.60 \pm 0.25$	$7.48 \pm 0.31$	$7.30 \pm 0.41$	
Week 13	$6.09 \pm 0.42$	$5.71 \pm 0.31$	$6.50 \pm 0.26$	$.7.03 \pm 0.43^{11}$	
Monocytes $(10^3/\mu L)$					
Day 5	$0.10 \pm 0.03$	$0.07 \pm 0.02$	$0.07 \pm 0.04$	$0.10 \pm 0.04$	· ·
Week 3	$0.43 \pm 0.10$	$0.37 \pm 0.08$	$0.34 \pm 0.08$	$0.39 \pm 0.06$	
Week 13	$0.05 \pm 0.02$	$0.04 \pm 0.02$	$0.08 \pm 0.03$	$0.10 \pm 0.04^{I}$	

.

÷

ť

### Hematology and Clinical Chemistry Data for Rats in the 13-Week Feed Study of t-Butylhydroquinone (continued)

	0 ppm	2,500 ppm	5,000 ppm	10,000 ppm	
Female (continued)		······································			
n .	10	10	10	10	
• · • • · · ·					
Hematology (continued)					
Eosinophils (10 <sup>3</sup> /µL) Day 5	$0.08 \pm 0.03$	$0.05 \pm 0.02$	$0.15 \pm 0.03$	$0.07 \pm 0.03$	
Week 3	$0.08 \pm 0.03$ $0.06 \pm 0.02$	$0.05 \pm 0.02$ $0.06 \pm 0.03$	$0.03 \pm 0.03$ $0.07 \pm 0.03$	$0.07 \pm 0.03$ $0.06 \pm 0.03$	
Week 13	$0.05 \pm 0.02$ $0.05 \pm 0.02$	$0.00 \pm 0.03$ $0.09 \pm 0.02$	$0.07 \pm 0.03$	$0.00 \pm 0.03^{\rm f}$ $0.11 \pm 0.03^{\rm f}$	
Chromboplastin time (seconds)	$0.05 \pm 0.02$	0.09 1 0.02	0.07 ± 0.05	0.11 ± 0.05	
Week 13	$9.82 \pm 0.33$	$9.83 \pm 0.30^{\rm f}$	$10.24 \pm 0.38$	$10.19 \pm 0.37$	•
Activated partial thromboplastin time (s		9.65 ± 0.50	10.24 ± 0.56	10:17 ± 0.57	
Week 13	$20.13 \pm 1.02$	$21.19 \pm 1.61^{f}$	$20.91 \pm 0.91$	$20.12 \pm 1.02$	
	20110 1 1102				
Clinical Chemistry					
Blood urea nitrogen (mg/dL)		*** ***		· · · · · · · ·	
Day 5	$22.7 \pm 0.5$	$21.0 \pm 0.6$	$21.9 \pm 0.6$	$22.4 \pm 0.7$	
Week 3	$22.3 \pm 0.8$	$25.2 \pm 0.9*$	$26.4 \pm 0.9**$	$26.4 \pm 0.8**$	
Week 13	$22.5 \pm 0.6$	$23.4 \pm 0.6$	$21.4 \pm 0.8$	$20.0 \pm 1.0$	
Creatinine (mg/dL)		0.51 . 0.02	0.55 . 0.00	0.55 + 0.02	
Day 5	$0.54 \pm 0.02$	$0.51 \pm 0.02$	$0.55 \pm 0.02$	$0.57 \pm 0.03$	
Week 3	$0.54 \pm 0.02$	$0.51 \pm 0.02$	$0.48 \pm 0.02^{\rm f}$	$0.52 \pm 0.02$	
Week 13	$0.72 \pm 0.01$	$0.78 \pm 0.02*$	$0.78 \pm 0.02$	$0.79 \pm 0.02$	
Fotal protein (g/dL)		59 1 0 1	50 1 0 1	<b>5</b> 9 1 0 1	
Day 5 Work 2	$6.0 \pm 0.1$	$5.8 \pm 0.1$	$5.9 \pm 0.1$	$5.8 \pm 0.1$	
Week 3	$6.0 \pm 0.1$	$6.2 \pm 0.1^*$	$6.1 \pm 0.1$	$6.2 \pm 0.1*$	
Week 13 Albumin (g/dL)	$7.0 \pm 0.1$	$7.0 \pm 0.1$	$7.2 \pm 0.1$	$7.0 \pm 0.1$	-
Day 5	$4.0 \pm 0.1$	$3.8 \pm 0.1$	$3.9 \pm 0.1$	$3.8 \pm 0.1$	
Week 3	$4.0 \pm 0.1$ $3.7 \pm 0.1$	$3.8 \pm 0.1$ $3.8 \pm 0.1$	$3.7 \pm 0.1$	$3.9 \pm 0.1^*$	
Week 13	$\frac{5.7 \pm 0.1}{4.3 \pm 0.1}$	$3.8 \pm 0.1$ $4.3 \pm 0.1$	$3.7 \pm 0.1$ $4.3 \pm 0.1$	$4.2 \pm 0.1$	
Alanine aminotransferase (IU/L)	4.5 ± 0.1	4.5 <u>1</u> 0.1	4.5 ± 0.1	4.2 ± 0.1	
Day 5	$47 \pm 2^{d}$	49 ± 2	$50 \pm 3^{f}$	$69 \pm 2^{**d}$	
Week 3	$36 \pm 1$	$43 \pm 1**$	$30 \pm 1^{*f}$	$46 \pm 1^{**f}$	
Week 13	$47 \pm 3$	$46 \pm 1$	$46 \pm 3$	$45 \pm 2$	
Alkaline phosphatase (IU/L)	11 7 9	10 T I	10 7 9	10 1 2	
Day 5	598 ± 20	$556 \pm 12$	535 + 20	$603 \pm 17$	
Week 3	$439 \pm 11$	$440 \pm 12$	$415 \pm 8$	$460 \pm 11$	•
Week 13	$254 \pm 6$	$266 \pm 9$	$267 \pm 9$	$257 \pm 7$	
Creatine kinase (IU/L)	<b>20</b> . ± 0				
Day 5	$1,030 \pm 52$	$1,214 \pm 67$	$1,248 \pm 90$	$1,100 \pm 92$	
Week 3	$865 \pm 94$	$802 \pm 60$	$836 \pm 132$	$692 \pm 58$	
Week 13	$261 \pm 30$	$245 \pm 19$	$240 \pm 26$	$274 \pm 34$	
Sorbitol dehydrogenase (IU/L)		-	-	_	
Day 5	$7 \pm 0$	$7 \pm 0$	$7 \pm 0*$	8 ± 1** <sup>f</sup>	
Week 3	$9 \pm 0$	9 ± 0	$8 \pm 0$	9 ± 0	
Week 13	$15 \pm 1$	$14 \pm 1$	13 ± 1	$14 \pm 1$	
Bile acids (µmol/L)					
Day 5	$18.6 \pm 2.0$	$25.5 \pm 2.5*$	34.5 ± 3.9**	53.1 ± 3.5** <sup>d</sup>	
Week 3	$26.5 \pm 3.4$	$31.5 \pm 5.9$	$43.9 \pm 5.2^{*t}$	46.9 ± 5.0**	
Week 13	$29.8 \pm 3.9$	$38.4 \pm 4.0$	$36.7 \pm 4.1$	49.4 ± 4.6**	

\* Significantly different (P≤0.05) from the control group by Dunn's or Shirley's test

\*\* P≤0.01

<sup>a</sup> Mean  $\pm$  standard error. Statistical tests were performed on unrounded data. <sup>b</sup> n=6 <sup>c</sup> n=7 <sup>d</sup> n=8 <sup>e</sup> n=4

f n=9

.

### TABLE G2

Hematology Data for Rats at the 3-Month Interim Evaluation in the Long-Term Feed Study of t-Butylhydroquinone<sup>a</sup>

	0 ppm	1,250 ppm	2,500 ppm	5,000 ppm	
Male				**************************************	
n	10	10	10	10	
Hematocrit (%)	$46.4 \pm 0.3$	46.9 ± 0.5	46.6 ± 0.9	45.9 ± 0.5	
Hemoglobin (g/dL)	$15.3 \pm 0.1$	$15.3 \pm 0.1$	$15.2 \pm 0.3$	$15.1 \pm 0.1$	
Erythrocytes $(10^6/\mu L)$	$9.03 \pm 0.07$	9.14 ± 0.07	$9.04 \pm 0.17$	$9.00 \pm 0.11$	
Reticulocytes $(10^{6}/\mu L)$	$0.16 \pm 0.02$	$0.17 \pm 0.02$	$0.17 \pm 0.02$	$0.17 \pm 0.01$	
Nucleated erythrocytes $(10^3/\mu L)$	$0.00 \pm 0.00$	$0.00 \pm 0.00$	$0.05 \pm 0.03$	$0.01 \pm 0.01$	
Mean cell volume (fL)	$51.4 \pm 0.3$	$51.4 \pm 0.4$	$51.6 \pm 0.2$	$51.0 \pm 0.3$	
Mean cell hemoglobin (pg)	$16.9 \pm 0.1$	$16.8 \pm 0.1$	$16.8 \pm 0.0$	$16.8 \pm 0.1$	
Mean cell hemoglobin			- ,		
concentration (g/dL)	$32.9 \pm 0.2$	$32.6 \pm 0.2$	$32.5 \pm 0.1$	$32.9 \pm 0.2$	1
Platelets $(10^3/\mu L)$	797.3 ± 48.7	821.9 ± 12.7	$817.1 \pm 33.3$	759.8 ± 26.3	
Leukocytes $(10^3/\mu L)$	$10.20 \pm 0.84$	10.66 ± 0.89	$10.89 \pm 1.06$	10.74 ± 0.94	
Segmented neutrophils $(10^3/\mu L)$	$2.09 \pm 0.22$	$1.93 \pm 0.34$	$1.62 \pm 0.25$	$1.71 \pm 0.17$	
Lymphocytes $(10^3/\mu L)$	$7.80 \pm 0.74$	8.28 ± 0.59	8.96 ± 0.83	8.64 ± 0.79	
Atypical lymphocytes $(10^3/\mu L)$	$0.00 \pm 0.00$	$0.00 \pm 0.00$	$0.00 \pm 0.00$	$0.00 \pm 0.00$	
Monocytes $(10^3/\mu L)$	$0.18 \pm 0.05$	$0.31 \pm 0.09$	$0.24 \pm 0.06$	$0.28 \pm 0.08$	
Eosinophils $(10^3/\mu L)$	$0.13 \pm 0.03$	$0.15 \pm 0.05$	0.06 ± 0.04	$0.11 \pm 0.03$	
Female			i.		
n	9	10	10	10	
Hematocrit (%)	44.8 ± 0.4	45.4 ± 0.5	$44.5 \pm 0.4$	44.5 ± 0.4	
Hemoglobin (g/dL)	$15.0 \pm 0.2$	$15.2 \pm 0.1$	$15.1 \pm 0.2$	$15.2 \pm 0.1$	
Erythrocytes $(10^6/\mu L)$	$8.41 \pm 0.08$	8.39 ± 0.06	$8.39 \pm 0.08$	$8.42 \pm 0.05$	
Reticulocytes $(10^{\circ}/\mu L)$	$0.15 \pm 0.01$	$0.14 \pm 0.02$	$0.13 \pm 0.03$	$0.14 \pm 0.02$	
Nucleated erythrocytes $(10^3/\mu L)$	$0.02 \pm 0.02$	$0.05 \pm 0.02$	$0.04 \pm 0.01$	$0.06 \pm 0.02$	
Mean cell volume (fL)	$53.3 \pm 0.4$	$54.2 \pm 0.7$	$53.0 \pm 0.3$	$52.9 \pm 0.4$	• .
Mean cell hemoglobin (pg)	$17.8 \pm 0.1$	$18.2 \pm 0.1^*$	$18.0 \pm 0.1$	$18.0 \pm 0.1$	*
Mean cell hemoglobin concentration (g/dL)	$33.5 \pm 0.3$	$33.6 \pm 0.3$	$34.0 \pm 0.2$	34.1 ± 0.3	
Platelets $(10^3/\mu L)$	$763.8 \pm 27.4$	$823.7 \pm 21.4$	$34.0 \pm 0.2$ 819.8 ± 26.7	$34.1 \pm 0.3$ 840.7 ± 15.5 <sup>b</sup>	
Leukocytes $(10^3/\mu L)$	$7.35 \pm 27.4$ 7.35 ± 0.59		—	$840.7 \pm 15.5^{-1}$ 6.72 ± 0.43	
Segmented neutrophils $(10^3/\mu L)$	$1.15 \pm 0.11$	$6.63 \pm 0.59$ $1.20 \pm 0.24$	$7.35 \pm 0.52$ $1.24 \pm 0.16$	$0.72 \pm 0.43$ $0.90 \pm 0.13$	
Lymphocytes $(10^3/\mu L)$	$1.13 \pm 0.11$ 6.04 ± 0.53			$0.90 \pm 0.13$ 5.67 ± 0.38	
Atypical lymphocytes $(10^{7}/\mu L)$	$0.04 \pm 0.03$ $0.00 \pm 0.00$	$5.18 \pm 0.36$	$5.95 \pm 0.38$		
Monocytes ( $10^{3}/\mu$ L)	—	$0.00 \pm 0.00$	$0.00 \pm 0.00$	$0.00 \pm 0.00$	
	$0.12 \pm 0.04$ $0.06 \pm 0.02^{c}$	$0.18 \pm 0.03$	$0.13 \pm 0.03$	$0.10 \pm 0.02$	
Eosinophils $(10^3/\mu L)$	$0.00 \pm 0.02$	$0.06 \pm 0.02$	$0.04 \pm 0.02$	$0.04 \pm 0.02$	•

\* Significantly different (P<0.05) from the control group by Dunn's or Shirley's test

a Mean  $\pm$  standard error. Statistical tests were performed on unrounded data. b

n=9 с

n=8

Hematology and Clinical Chemistry Data for Mice in the 13-Week Feed Study of t-Butylhydroquinone<sup>a</sup>

······································	0 ppm	2,500 ppm	5,000 ppm	10,000 ppm	20,000 ppm	40,000 ppm
				•••		· • •
Male						
1	10	10	- 10	9	10	10
Hematology						
Hematocrit (%)						
Day 5	45.0 ± 0.7	44.6 ± 0.8	45.9 ± 0.8	$46.5 \pm 1.0$	$45.5 \pm 0.8$	$46.5 \pm 1.2^{c}$
Week 3	$48.6 \pm 0.6$	$47.4 \pm 0.5$	$47.2 \pm 0.6$	$47.3 \pm 0.5^{b}_{d}$	47.3 ± 0.7 <sup>c</sup>	$50.5 \pm 1.3^{b}$
Week 13	47.7 ± 0.6 <sup>c</sup>	47.7 ± 0.5	48.6 ± 0.5	$48.3 \pm 0.4^{d}$	47.9 ± 0.6	47.8 ± 0.9
Hemoglobin (g/dL)						
Day 5	$15.2 \pm 0.2$	$15.1 \pm 0.3$	$15.1 \pm 0.2$	$15.4 \pm 0.3$	$15.1 \pm 0.4$	15.6 ± 0.3 <sup>c</sup>
Week 3	$16.5 \pm 0.2$	$16.1 \pm 0.2$	$16.1 \pm 0.1$	$16.1 \pm 0.2^{D}$	$16.3 \pm 0.2^{c}$	17.4 ± 0.5 <sup>b</sup>
Week 13	$16.0 \pm 0.2^{c}$	$15.7 \pm 0.4$	$16.1 \pm 0.1^{c}$	$16.0 \pm 0.2$	$16.1 \pm 0.2^{c}$	$15.9 \pm 0.3^{c}$
Erythrocytes (10 <sup>6</sup> /µL)						
Day 5	9.05 ± 0.15	9.01 ± 0.18	9.22 ± 0.16	9.38 ± 0.20	9.21 ± 0.17	$9.39 \pm 0.23$
Week 3	$10.15 \pm 0.15$	$9.92 \pm 0.12$	$9.91 \pm 0.12$	9.94 ± 0.09 <sup>b</sup>	$10.08 \pm 0.16^{c}$	$10.92 \pm 0.29^{b}$
Week 13	$10.07 \pm 0.12^{c}$	$10.23 \pm 0.12$	$10.24 \pm 0.12^{c}$	$10.16 \pm 0.12$	$10.38 \pm 0.12$	$10.38 \pm 0.10^{\circ}$
Reticulocytes $(10^6/\mu L)$	-					-
Day 5	$0.51 \pm 0.08^{\circ}$	$0.45 \pm 0.08$	$0.62 \pm 0.17^{b}$	$0.41 \pm 0.08$	$0.59 \pm 0.14^{c}$	$0.68 \pm 0.20^{b}$
Week 3	$0.21 \pm 0.02^{c}$	$0.26 \pm 0.02^{c}$	$0.19 \pm 0.01^{\circ}$	$0.24 \pm 0.02^{e}$	$0.31 \pm 0.04^{c}$	$0.33 \pm 0.04^{*b}$
Week 13	$0.16 \pm 0.06^{f}$	$0.22 \pm 0.03^{g}$	$0.21 \pm 0.02^{h}$	$0.21 \pm 0.04^{i}$	$0.25 \pm 0.04^{e}$	$0.25 \pm 0.03^{i}$
Mean cell volume (fL)		<u>-</u>				
Day 5	$49.7 \pm 0.3$	$49.6 \pm 0.3$	49.8 ± 0.4	$49.4 \pm 0.3$	$49.3 \pm 0.3$	$49.6 \pm 0.2^{c}$
Week 3	$47.8 \pm 0.3$	$47.7 \pm 0.2$	$47.5 \pm 0.2$	$47.4 \pm 0.3^{b}$	$47.0 \pm 0.3^{c}$	$46.1 \pm 0.4^{**b}$
Week 13	$47.4 \pm 0.8^{\circ}$	$46.6 \pm 0.4$	$47.4 \pm 0.5^{\circ}$	$47.7 \pm 0.6$	$46.1 \pm 0.4$	$46.1 \pm 0.7^{\circ}$
Mean cell hemoglobin (pg)		40.0 <u>T</u> 0.1	41.4 1 0.5	47.7 1 0.0		1011 1 017
Day 5	$16.8 \pm 0.1$	$16.7 \pm 0.1$	$16.4 \pm 0.1$ **	$16.5 \pm 0.1$ **	$16.3 \pm 0.1 **$	$16.5 \pm 0.1^{**^{c}}$
Week 3	$16.3 \pm 0.1$	$16.3 \pm 0.1$	$16.3 \pm 0.1$	$16.2 \pm 0.1^{b}$	$16.2 \pm 0.1^{\circ}$	$15.9 \pm 0.1^{**b}$
Week 13	$15.9 \pm 0.1^{\circ}$	$15.3 \pm 0.1$	$10.3 \pm 0.1^{\circ}$ 15.7 ± 0.1°	$15.2 \pm 0.1$ 15.8 ± 0.1	$15.5 \pm 0.1^{**^{c}}$	$15.3 \pm 0.2^{**^{c}}$
Mean cell hemoglobin conc		15.5 ± 0.5	15.7 ± 0.1	15.0 ± 0.1	10.0 ± 0.1	10.0 ± 0.2
Day 5	$33.8 \pm 0.1$	33.7 ± 0.2	32.9 ± 0.2*	$33.2 \pm 0.2$	$33.1 \pm 0.3$	$33.2 \pm 0.2^{b}$
Week 3	$33.8 \pm 0.1$ $34.1 \pm 0.3$	$33.7 \pm 0.2$ $34.1 \pm 0.1$	$34.2 \pm 0.3$	$33.2 \pm 0.2$ $34.0 \pm 0.2^{b}$	$34.5 \pm 0.3^{\circ}$	$34.4 \pm 0.1^{b}$
Week 13	$33.5 \pm 0.5^{\circ}$	$34.1 \pm 0.1$ $32.8 \pm 0.6$	$34.2 \pm 0.3$ $33.2 \pm 0.4^{c}$	$33.2 \pm 0.4$	$33.5 \pm 0.4^{\circ}$	$33.3 \pm 0.4^{\circ}$
Platelets $(10^3/\mu L)$	33.3 ± 0.3	$52.0 \pm 0.0$	$33.2 \pm 0.4$	JJ.2 I 0.4	55.5 ± 0.4	$55.5 \pm 0.4$
	1 106 1 62	1 139 1 57	1 104 + 61	$1,224 \pm 56$	1,229 ± 87	$1,245 \pm 48$
Day 5	$1,186 \pm 63$	$1,128 \pm 57$	$1,124 \pm 61$	$1,224 \pm 50$ $1,001 \pm 19^{b}$	$1,229 \pm 87$ $1,030 \pm 47^{c}$	$1,245 \pm 48$ $1,034 \pm 20**^{b}$
Week 3	$937 \pm 19$	901 ± 34	956 ± 34 834 ± 42 <sup>c</sup>	$887 \pm 63$	$931 \pm 50*$	$933 \pm 53^{*^{c}}$
Week 13	$754 \pm 58^{c}$	796 ± 39	834 ± 42	80/ ± 05	$931 \pm 30^{+1}$	333 T 33.
Leukocytes $(10^3/\mu L)$	(17 + 0.00	E 7E 1 0 40	E 00 1 0 22	6 50 1 0 20	6 56 1 0 20	777 1 0 63*
Day 5	$6.17 \pm 0.29$	$5.75 \pm 0.42$	$5.99 \pm 0.33$	$6.59 \pm 0.38$	$6.56 \pm 0.28$	7.77 ± 0.62* 8.74 ± 0.98 <sup>b</sup>
Week 3	$7.93 \pm 0.38$	$8.36 \pm 0.47$	$7.65 \pm 0.60$	$9.11 \pm 0.30^{*b}$	$9.56 \pm 0.60^{*c}$ $8.30 \pm 0.52$	$8.74 \pm 0.98$ 7.47 ± 0.69 <sup>c</sup>
Week 13	$6.67 \pm 0.61^{\circ}$	$7.31 \pm 0.50$	$7.71 \pm 0.63^{\circ}$	$9.82 \pm 0.70*$	$8.30 \pm 0.52$	7.47 ± 0.09
Segmented neutrophils (10		0.40 . 0.40	0.46.4.0.07	0.71 . 0.11	0.72 . 0.11	1 00 + 0 12
Day 5	$0.61 \pm 0.10$	$0.43 \pm 0.12$	$0.46 \pm 0.07$	$0.71 \pm 0.11$	$0.73 \pm 0.11$	$1.00 \pm 0.13$
Week 3	$1.10 \pm 0.14$	$0.90 \pm 0.15$	$0.91 \pm 0.15$	$1.55 \pm 0.14^{b}$	$2.80 \pm 0.42^{**^{c}}$	$2.91 \pm 0.45^{**b}$
Week 13	$0.94 \pm 0.14^{e}$	$0.77 \pm 0.17^{h}$	$1.09 \pm 0.15^{c}$	$1.51 \pm 0.21$	1.85 ± 0.44*	$2.27 \pm 0.41^{**^{c}}$
Lymphocytes $(10^3/\mu L)$			e 40 · 0 e4	E 04 · 0.00	E 77 I A AA	
Day 5	$5.53 \pm 0.24$	$5.27 \pm 0.36$	$5.49 \pm 0.31$	$5.84 \pm 0.33$	$5.77 \pm 0.29$	$6.60 \pm 0.56$
Week 3	$6.71 \pm 0.29$	$7.41 \pm 0.48$	$6.60 \pm 0.52$	$7.45 \pm 0.34^{\text{D}}$	$6.57 \pm 0.33^{\circ}$	$5.70 \pm 0.57^{b}$
Week 13	5.37 ± 0.67 <sup>e</sup>	$5.78 \pm 0.31^{\rm h}$	6.49 ± 0.64 <sup>c</sup>	8.19 ± 0.55*	$6.33 \pm 0.18$	$5.11 \pm 0.39^{c}$
Eosinophils $(10^3/\mu L)$						
Day 5	$0.02 \pm 0.01$	$0.05 \pm 0.02$	$0.04 \pm 0.02$	$0.07 \pm 0.02$	$0.03 \pm 0.02$	$0.16 \pm 0.04^{**}$
Week 3	$0.10 \pm 0.04$	$0.07 \pm 0.03$	$0.14 \pm 0.03$	$0.15 \pm 0.07^{b}$	$0.18 \pm 0.04^{c}$	$0.13 \pm 0.04^{b}$
Week 13	$0.04 \pm 0.02^{e}$	$0.12 \pm 0.03^{n}$	0.14 ± 0.04 <sup>c</sup>	$0.16 \pm 0.05$	$0.13 \pm 0.04$	$0.08 \pm 0.03^{c}$
Thromboplastin time (seco			-	1-	L	
Week 13	$8.01 \pm 0.18^{c}$	$7.62 \pm 0.17^{c}$	7.97 ± 0.20 <sup>e</sup>	$8.23 \pm 0.31^{h}$	$8.03 \pm 0.23^{b}$	$7.97 \pm 0.35^{e}$
Activated partial thrombop	plastin time (seconds)	-		۱.		
Week 13	$25.65 \pm 0.25^{\text{J}}$	$27.57 \pm 1.17^{f}$	$26.15 \pm 1.25^{1}$	k	_	

7

### TABLE G3

Hematology and Clinical Chemistry Data for Mice in the 13-Week Feed Study of t-Butylhydroquinone (continued)

	0 ppm	2,500 ppm	5,000 ppm	10,000 ppm	20,000 ppm	40,000 ppm
Male (continued)						
n	. 8	10	8	8	er 9	9
Clinical Chemistry						· · · · .
Blood urea nitrogen (mg/dL)						· · · ·
Day 5	$30.1 \pm 1.1$	$27.2 \pm 1.2$	25.5 ± 1.4*	$25.2 \pm 1.0^*$	<sup>4</sup> 24.2 ± 1.3**	$20.9 \pm 1.3^{**e}$
Week 3	$27.1 \pm 1.5$	$28.8 \pm 1.5^{\circ}$	$25.4 \pm 1.6^{d}$	$21.2 \pm 1.0^*$	$17.1 \pm 0.7^{**b}$	$17.0 \pm 0.6^{**i}$
Week 13	$27.5 \pm 2.6^{e}$	$23.6 \pm 1.7^{b}$	$25.1 \pm 1.4^{e}$	$22.9 \pm 0.6$	$19.1 \pm 1.2^{**e}$	$20.3 \pm 0.6^{**}$
Creatinine (mg/dL)						
Day 5	$0.34 \pm 0.05^{i}$	$0.38 \pm 0.02^{h}$	$0.43 \pm 0.04^{i}$	$0.34 \pm 0.04^{g}$	$0.36 \pm 0.02^{i}$	$0.33 \pm 0.03^{f}$
Week 3	$0.35 \pm 0.02^{i}$	$0.38 \pm 0.02^{g}$	$0.36 \pm 0.03^{e}$	$0.28 \pm 0.02^{\rm h}$	$0.33 \pm 0.01^{\rm h}$	$0.34 \pm 0.02^{f}$
Total protein (g/dL)	0.00 1 0.02	, 0.00 T 0.02	0.50 1 0.05	0.20 1 0.02	0.55 ± 0.01	0.54 ± 0.02
Day 5	$4.9 \pm 0.1^{i}$	$4.9 \pm 0.1^{h}$	$5.1 \pm 0.1^{i}$	$5.1 \pm 0.1^{g}$	$5.0 \pm 0.1^{i}$	$5.2 \pm 0.1^{f}$
Albumin (g/dL)	4.7 <u>T</u> 0.1	4.7 <u>1</u> 0.1	5.1 <u>1</u> 0.1	5.1 ± 0.1	5.0 <u>1</u> 0.1	5.2 1 0.1
Day 5	$2.8 \pm 0.1^{g}$	$2.6 \pm 0.1^{h}$	$2.8 \pm 0.1^{g}$	$2.8 \pm 0.1^{f}$	$2.9 \pm 0.1^{i}$	$3.0 \pm 0.1^{\mathrm{f}}$
Alanine aminotransferase (IU/I		2.0 1 0.1	$2.0 \pm 0.1$	$2.0 \pm 0.1$	. 2.9 1 0.1	5.0 ± 0.1
Day 5	$51 \pm 6^{c}$	43 ± 9	$35 \pm 5$	29 ± 5**	$38 \pm 4^{b}$	$37 \pm 6^{d}$
Week 3	$22 \pm 2$	$43 \pm 9$ 24 ± 2 <sup>c</sup>	$21 \pm 2^{d}$	$18 \pm 2$	$38 \pm 4$ 22 ± 4 <sup>b</sup>	$16 \pm 2^{h}$
Week 13	$\frac{22 \pm 2}{83 \pm 41^{f}}$	$175 \pm 93^{g}$	$111 \pm 61^{i}$	$10 \pm 2$ 110 ± 49 <sup>h</sup>	$118 \pm 45^{i}$	$10 \pm 2$ $124 \pm 22^{h}$
Alkaline phosphatase (IU/L)	0J I 41	175 <u>T</u> 95-	$111 \pm 01$	110 ± 49	$110 \pm 43$	$124 \pm 22$
	161 1 6	160 1 4	164 1 6	152 1 6	140 1 5	$139 \pm 4^{e}$
Day 5	$161 \pm 6$	$158 \pm 4$	$154 \pm 6$	$153 \pm 6$	$149 \pm 5$	
Week 3	118 ± 4 <sup>g</sup>	$122 \pm 7^{1}$	$122 \pm 7^{g}$	$95 \pm 2^{*e}$	84 ± 6** <sup>n</sup>	80 ± 6* <sup>J</sup>
Creatine kinase (IU/L)	202 . 26	161 . 47	147 . 00	141 . 00		150 . 00
Day 5	292 ± 75	161 ± 47	· 147 ± 30	$141 \pm 28$	$223 \pm 53$	$150 \pm 28$
Sorbitol dehydrogenase (IU/L)	an ai		A.C			a of
Week 3	$37 \pm 3^{i}$	$46 \pm 6^{h}$	$36 \pm 2^{c}$	37 ± 4	$34 \pm 3^{e}_{f}$	$42 \pm 5^{f}$
Week 13	30 ± 4 <sup>j</sup>	$31 \pm 2^{f}$	$34 \pm 3^{j}$	$42 \pm 16^{10}$	$27 \pm 4^{t}$	27 <sup>1</sup>
Bile acids (µmol/L)			, , ,			h
Week 3	$10.7 \pm 1.3^{c}$	$7.9 \pm 0.5^{*}$	$7.6 \pm 0.4^{*d}$	$7.1 \pm 0.6^{**}$	$7.5 \pm 0.7^{*b}$	$7.0 \pm 0.9^{**h}$
Week 13	$21.2 \pm 0.9^{i}$	$22.3 \pm 0.8^{g}$	$22.0 \pm 2.0^{h}$	$16.7 \pm 2.5^{e}$	$19.8 \pm 1.3^{i}$	$16.2 \pm 1.3^{h}$
7				•		
				•		
Female						
n	10	10	· 10	10	10	10
						• •
Hematology		*	•	1	,	,
Hematocrit (%)				•	м. М	
Day 5	$45.2 \pm 0.3$	$44.6 \pm 0.5$	45.0 ± 0.6	$45.7 \pm 0.3$	$45.6 \pm 1.2$	47.9 ± 0.6**
Week 3	$46.2 \pm 1.4$	49.5 ± 0.9	46.4 ± 0.6	$46.9 \pm 0.5$	$48.8 \pm 1.5$	$46.9 \pm 0.8^{\circ}$
Week 13	$47.4 \pm 0.4$	47.4 ± 0.4	$48.0 \pm 0.4$	48.9 ± 1.4 <sup>c</sup>	$47.4 \pm 0.4$	$48.5 \pm 1.0^{c}$
Hemoglobin (g/dL)					•	•
Day 5	$15.0 \pm 0.1$	$14.9 \pm 0.2$	$15.1 \pm 0.2$	$15.3 \pm 0.1$	$15.4 \pm 0.4$	$16.2 \pm 0.2^{**}$
Week 3	$15.6 \pm 0.4$	$16.6 \pm 0.3$	$15.7 \pm 0.2$	$15.9 \pm 0.2$	$16.9 \pm 0.5^{c}$	$16.2 \pm 0.2^{c}$
Week 13	$15.7 \pm 0.2$	$15.6 \pm 0.2$	$15.9 \pm 0.1$	$16.2 \pm 0.4^{c}$	$15.7 \pm 0.2$	$16.3 \pm 0.4^{c}$
Erythrocytes (10 <sup>6</sup> /µL)						
Day 5	$9.14 \pm 0.12$	$9.04 \pm 0.13$	$9.24 \pm 0.15$	9.51 ± 0.09*	$9.55 \pm 0.26$	$10.20 \pm 0.16^{**}$
Week 3	9.40 ± 0.27	10.15 ± 0.17**	9.63 ± 0.09	9.98 ± 0.08*	$10.60 \pm 0.31^{**}$	$10.29 \pm 0.15^{**^{c}}$
Week 13	9.99 ± 0.11	$10.07 \pm 0.08$	$10.18 \pm 0.09$	$10.50 \pm 0.32^{c}$	$10.17 \pm 0.07$	$10.58 \pm 0.27^{c}$
Reticulocytes (10 <sup>6</sup> /µL)						
Day 5	$0.44 \pm 0.05^{b}$	$0.42 \pm 0.04^{c}$	$0.31 \pm 0.04^{e}$	$0.42 \pm 0.08$	$0.27 \pm 0.04$ *	$0.22 \pm 0.04 **$
Week 3	$0.14 \pm 0.03^{h}$	$0.13 \pm 0.02^{i}$	$0.15 \pm 0.02^{h}$	$0.17 \pm 0.03^{b}$	$0.24 \pm 0.03^{i}$	$0.24 \pm 0.04^{e}$
					—	$0.29 \pm 0.04^{*b}$

Hematology and Clinical Chemistry Data for Mice in the 13-Week Feed Study of t-Butylhydroquinone (continued)

· · · ·	0 ppm	2,500 ppm	5,000 ppm	10,000 ppm	20,000 ppm	40,000 ppm
Female (continued)				··· ·· · · · · · · · · · · · ·		
n	10	10	10	10	10	10
Hematology (continued) Mean cell volume (fL)						
Day 5	49.6 ± 0.5	49.4 ± 0.3	48.8 ± 0.4	48.0 ± 0.3*	47.7 ± 0.2**	47.2 ± 0.4**
Week 3	$48.9 \pm 0.2$	48.9 ± 0.4	48.3 ± 0.3	47.0 ± 0.2**	45.9 ± 0.2**	45.6 ± 0.3** <sup>c</sup>
Week 13	47.5 ± 0.2	$47.0 \pm 0.2$	47.1 ± 0.3	46.4 ± 0.2** <sup>c</sup>	46.6 ± 0.3**	$46.0 \pm 0.3^{**^{c}}$
Mean cell hemoglobin (pg	)					
Day 5	$16.4 \pm 0.2$	$16.5 \pm 0.1$	$16.4 \pm 0.1$	$16.1 \pm 0.1$	$16.2 \pm 0.1$	$15.9 \pm 0.2$
Week 3	16.6 ± 0.1	$16.4 \pm 0.1$	$16.3 \pm 0.1^{*}$	$15.9 \pm 0.1^{**}$	$15.7 \pm 0.1 * *^{c}$	$15.8 \pm 0.1 **^{c}$
Week 13	$15.7 \pm 0.1$	$15.5 \pm 0.1$	15.7 ± 0.1	$15.4 \pm 0.1^{c}$	$15.5 \pm 0.1$	$15.4 \pm 0.1^{c}$
Mean cell hemoglobin con	centration (g/dL)				4 4 K	
Day 5	$33.1 \pm 0.2$	$33.4 \pm 0.1$	$33.6 \pm 0.2$	33.5 ± 0.2	33.8 ± 0.2**	$33.9 \pm 0.2 $ **
Week 3	$33.9 \pm 0.3$	$33.6 \pm 0.2$	33.8 ± 0.2	$33.9 \pm 0.3$	$34.2 \pm 0.2^{c}$	$34.6 \pm 0.3^{c}$
Week 13	$33.1 \pm 0.2$	$32.9 \pm 0.1$	$33.2 \pm 0.2$	$33.1 \pm 0.1^{c}$	$33.2 \pm 0.2$	$33.6 \pm 0.2^{*^{c}}$
Platelets (10 <sup>3</sup> /µL)					•	
Day 5	901.5 ± 21.6	900.0 ± 19.3	820.5 ± 38.6	915.0 ± 28.6	913.3 ± 34.3	914.5 ± 41.9
Week 3	788.8 ± 33.8	882.3 ± 29.6	814.6 ± 27.8 <sup>c</sup>	938.9 ± 41.5**	1,040.8 ± 34.0**	$1,158.2 \pm 63.7**^{\circ}$
Week 13	853.4 ± 23.1	$880.2 \pm 42.5$	867.9 ± 35.6	$1,005.6 \pm 31.0^{**^{c}}$	966.7 ± 26.6**	$1,141.9 \pm 46.6**^{\circ}$
Leukocytes (10 <sup>3</sup> /µL)						
Day 5	6.91 ± 0.50	$6.60 \pm 0.45$	6.44 ± 0.36	$7.00 \pm 0.50$	$6.85 \pm 0.56$	7.92 ± 0.70
Week 3	7.49 ± 0.37	$7.85 \pm 0.66$	8.08 ± 0.39	$8.23 \pm 0.37$	9.67 ± 1.01	10.64 ± 0.55**°
Week 13	5.67 ± 0.30	$6.46 \pm 0.41$	5.66 ± 0.42	8.69 ± 0.65** <sup>c</sup>	8.88 ± 0.79**	$8.11 \pm 0.78^{**^{\circ}}$
Segmented neutrophils (10	) <sup>3</sup> /μL)					
Day 5	$0.65 \pm 0.10$	$0.65 \pm 0.10$	0.49 ± 0.06	$0.83 \pm 0.10$	0.97 ± 0.24	2.12 ± 0.48**
Week 3	$0.98 \pm 0.17$	$1.11 \pm 0.07$	1.19 ± 0.14	$1.61 \pm 0.21^{**}$	1.76 ± 0.23**	3.78 ± 0.28** <sup>6</sup>
Week 13	$0.82 \pm 0.11$	$1.13 \pm 0.13$	$0.87 \pm 0.12$	$2.31 \pm 0.56^{**^{c}}$	$2.14 \pm 0.23^{**}$	$2.74 \pm 0.52**^{\circ}$
Lymphocytes (10 <sup>3</sup> /µL)						
Day 5	$6.13 \pm 0.47$	5.92 ± 0.44	5.85 ± 0.32	$6.06 \pm 0.43$	5.77 ± 0.44	5.72 ± 0.82
Week 3	$6.32 \pm 0.22$	$6.59 \pm 0.62$	$6.59 \pm 0.32$	6.51 ± 0.20	7.77 ± 0.82	$6.66 \pm 0.52^{\circ}$
Week 13	4.78 ± 0.23	5.28 ± 0.37	4.72 ± 0.36	6.28 ± 0.30 <sup>≠<sup>c</sup></sup>	$6.63 \pm 0.63*$	$5.20 \pm 0.51^{c}$
Monocytes $(10^3/\mu L)$						
Week 13	$0.01 \pm 0.01$	$0.00 \pm 0.00$	$0.01 \pm 0.01$	$0.01 \pm 0.01^{c}$	$0.02 \pm 0.01$	$0.02 \pm 0.02^{c}$
Eosinophils $(10^3/\mu L)$						
Day 5	$0.11 \pm 0.04$	$0.06 \pm 0.02$	$0.09 \pm 0.01$	$0.12 \pm 0.04$	$0.08 \pm 0.02$	$0.12 \pm 0.04$
Week 3	$0.18 \pm 0.06$	$0.15 \pm 0.04$	$0.32 \pm 0.08$	$0.12 \pm 0.04$	$0.11 \pm 0.05$	$0.19 \pm 0.06^{\circ}$
Week 13	$0.07 \pm 0.02$	$0.07 \pm 0.03$	$0.06 \pm 0.02$	$0.10 \pm 0.03^{c}$	$0.08 \pm 0.03$	$0.11 \pm 0.05^{c}$
Thromboplastin time (seco						
Week 13	$7.85 \pm 0.23$	7.95 ± 0.19	7.62 ± 0.28	$7.60 \pm 0.20$	$7.55 \pm 0.18$	7.56 ± 0.20 <sup>b</sup>
Activated partial thrombog						,
Week 13	$29.34 \pm 1.32^{e}$	27.15 ± 1.23 <sup>h</sup>	26.57 ± 1.79 <sup>h</sup>	$28.00 \pm 1.37^{i}$	28.90 ± 0.82 <sup>h</sup>	$28.53 \pm 1.05^{g}$

Hematology and Clinical Chemistry Data for Mice in the 13-Week Feed Study of t-Butylhydroquinone (continued)

	0 ppm	2,500 ppm	5,000 ppm	10,000 ppm	20,000 ppm	40,000 ppm
Female (continued)	· · ·				· · · · ·	
n	10	9	10	8	9	8
Clinical Chemistry						
Blood urea nitrogen (mg/dL)	)					· •
Day 5	$20.2 \pm 1.6^{i}$	$21.5 \pm 1.0^{b}$	$20.5 \pm 1.2^{\circ}$	$17.8 \pm 1.4^{e}$	$15.5 \pm 1.0 *^{e}$	22.5 <sup>1</sup>
Week 3	$27.9 \pm 1.3^{e}$	$22.9 \pm 1.3^*$	$23.3 \pm 1.3 \pm 1$	$21.2 \pm 1.8^{**d}$	$16.4 \pm 0.7**^{e}$	$15.8 \pm 1.6^{**g}$
Week 13	$29.2 \pm 1.9$	$25.1 \pm 2.3^{b}$	$28.5 \pm 1.9^{c}$	$19.0 \pm 1.1^{**e}$	$18.1 \pm 0.8**$	$20.6 \pm 2.6^{**i}$
Creatinine (mg/dL)	_	-				
Week 3	$0.31 \pm 0.03^{g}$	$0.32 \pm 0.03^{f}$	$0.29 \pm 0.02^{\rm h}$	$0.26 \pm 0.02^{g}$	$0.29 + 0.01^{j}$	· · · ·
Week 13	$0.32 \pm 0.01^{i}$	$0.34 \pm 0.04^{i}$	$0.34 \pm 0.03^{g}$	$0.26 \pm 0.03^{\rm f}$	$0.24 \pm 0.02^{g}$	$0.33 \pm 0.03^{j}$
Total protein (g/dL)			···· <b>-</b> ····	<b>-</b>	<u>+</u> <u>-</u>	
Week 3	$5.3 \pm 0.1^{f}$		$5.7 \pm 0.1^{j}$	5.0 <sup>1</sup>	$5.5 \pm 0.1^{f}_{}$	
Week 13	$5.6 \pm 0.1^{g}$	5.7 <sup>1</sup>	$5.4 \pm 0.1^{f}$		$5.3 \pm 0.1^{j}$	
Albumin (g/dL)			<b></b>		<u>-</u>	
Week 3	$3.2 \pm 0.0^{f}$	· _	$3.5 \pm 0.1^{j}$	3.0 <sup>1</sup>	$3.4 \pm 0.1^{j}$	
Week 13	$3.5 \pm 0.0^{e}$	$3.7 \pm 0.2^{f}$	$3.4 \pm 0.1^{f}$	$3.5 \pm 0.1^{j}$	$3.4 \pm 0.2^{j}$	. <u> </u>
Alanine aminotransferase (II	U/L)			····		•
Day 5	$28 \pm 3^{h}$	$30 \pm 5^{b}$	$28 \pm 4^{c}$	$33 \pm 4^{e}$	$25 \pm 2^{h}$	$31 \pm 3^{f}$
Week 3	$40 \pm 13^{e}$	$29 \pm 4$	$24 \pm 4^{b}$	$39 \pm 7^{d}$	$34 \pm 4^{e}$	$35 \pm 7^{g}$
Week 13	$39 \pm 6$	$30 \pm 2^{e}$	$40 \pm 5^{e}$	$40 \pm 7^{i}$	$36 \pm 4$	$53 \pm 19^{f}$
Alkaline phosphatase (IU/L)		50 <u>T</u> =	10 1 0	··· + ·	50 <u>T</u> .	00 ± 12
Day 5	$229 \pm 8^{i}$	$199 \pm 9^{b}$	$204 \pm 9^{c}$	$210 \pm 6^{e}$	172 ± 11** <sup>e</sup>	156 ± 18** <sup>f</sup>
Week 3	$156 \pm 7^{i}$	$154 \pm 4^{i}$	$155 \pm 3^{e}$	$133 \pm 7^{*h}$	$111 \pm 7^{**h}$	$98 \pm 14^{*j}$
Week 13	$92 \pm 4^{b}$	$103 \pm 5^{h}$	$110 \pm 7^{f}$	$102 \pm 9^{g}$	$91 \pm 5^{g}$	77 <sup>1</sup>
Creatine kinase (IU/L)	~~ <u> </u>	100 <u>T</u> 0	<u>-</u> -	10 <b>2</b> 1 /	77 <u>T</u> V	
Day 5	$160 \pm 42$	88 ± 16	99 ± 15	$152 \pm 43$	73 ± 6	65 ± 10*
Week 3	$32 \pm 2^{\tilde{f}}$	$34 \pm 8^{j}$	$39 \pm 16^{g}$	38 <sup>1</sup>	$37 \pm 8^{g}$	$42^{l}$
Week 13	$41 \pm 6^{e}$	$60 \pm 26^{g}$	$38 \pm 3^{g}$	30 <sup>1</sup>	$35 \pm 3^{j}$	
Sorbitol dehydrogenase (IU/	L)	00 T 20	20 T 2	20	00 <u>T</u> 0	
Week 3	$27 \pm 3^{h}$	$23 \pm 2^{h}$	$27 \pm 4^{b}$	$23 \pm 3$	$25 \pm 5^{h}$	$22 \pm 3^{g}$
Week 13	$27 \pm 1^{\circ}$	$\frac{25 \pm 2}{28 \pm 3^{e}}$	$26 \pm 3^{h}$	$23 \pm 2^{f}$	$30 \pm 4^{e}$	$\frac{1}{32 \pm 1^{f}}$
Bile acids (µmol/L)		10 1 0	20 1 0			
Day 5	$12.3 \pm 0.8^{g}$	$17.2 \pm 1.9^{i}$	$11.3 \pm 0.3^{g}$	$14.0 \pm 1.5^{f}$	$13.0 \pm 1.5^{g}$	18.0 <sup>1</sup>
Week 3	$9.6 \pm 1.1^{\circ}$	$9.9 \pm 1.7^{\rm d}$	$9.3 \pm 1.2$	$12.1 \pm 2.2^{d}$	$8.8 \pm 0.8$	$10.5 \pm 1.4$
Week 13	$16.0 \pm 1.3^{\circ}$	$14.9 \pm 1.8^{b}$	$17.0 \pm 1.6^{c}$	$12.1 \pm 2.2$ $18.4 \pm 1.9^{e}$	$12.5 \pm 1.4^{d}$	$13.8 \pm 2.9^{i}$
		1007 I 100				

\* Significantly different (P $\leq$ 0.05) from the control group by Dunn's or Shirley's test

\*\* P≤0.01

а Mean  $\pm$  standard error. Statistical tests were performed on unrounded data.

- b n=8С
- n=9 d n = 10
- e n=7
- f n=3
- g n=4
- h n=6 i
- n=5 j n=2
- k

Not measured at this exposure level 1 n=1; no standard error calculated

• •

# s-Butylhydroquinone, NTP TR 459

### TABLE G4

Hematology Data for Mice at the 15-Month Interim Evaluation in the 2-Year Feed Study of t-Butylhydroquinone<sup>a</sup>

· · ·	0 ppm	1,250 ppm	2,500 ppm	5,000 ppm
Male				· · · · · · · · · · · · · · · · · · ·
n	10	10	9	9
Hematocrit (%)	$45.1 \pm 0.4$	$46.2 \pm 0.8$	$45.3 \pm 0.4$	46.0 ± 2.2
Hemoglobin (g/dL)	$15.0 \pm 0.1$	$15.3 \pm 0.2$	$15.2 \pm 0.1$	$15.1 \pm 0.7$
Erythrocytes $(10^6/\mu L)$	$9.66 \pm 0.08$	$10.08 \pm 0.20$	$9.77 \pm 0.12$	$9.92 \pm 0.74$
Reticulocytes $(10^6/\mu L)$	$0.21 \pm 0.01$	$0.20 \pm 0.02$	$0.20 \pm 0.02$	$0.47 \pm 0.15*$
Nucleated erythrocytes $(10^3/\mu L)$	$0.04 \pm 0.02$	$0.01 \pm 0.01$	$0.02 \pm 0.01$	$0.01 \pm 0.01$
Mean cell volume (fL)	$46.7 \pm 0.2$	$45.9 \pm 0.4$	$46.4 \pm 0.2$	$47.2 \pm 1.6$
Mean cell hemoglobin (pg)	$15.6 \pm 0.1$	$15.2 \pm 0.1*$	$15.6 \pm 0.1$	$15.5 \pm 0.4$
Mean cell hemoglobin				
concentration (g/dL)	$33.4 \pm 0.1$	$33.1 \pm 0.2$	$33.6 \pm 0.2$	$32.9 \pm 0.5$
Platelets $(10^3/\mu L)$	$1,283 \pm 57$	1,301 ± 75	$1,240 \pm 65$	$1,294 \pm 94$
Leukocytes $(10^3/\mu L)$	$7.84 \pm 0.38$	$8.63 \pm 0.57$	$8.77 \pm 0.40$	$8.21 \pm 0.46$
Segmented neutrophils $(10^3/\mu L)$	$1.46 \pm 0.16$	$1.73 \pm 0.10$	$1.63 \pm 0.16$	$1.54 \pm 0.14^{b}$
Lymphocytes $(10^3/\mu L)$	$6.13 \pm 0.24$	$6.55 \pm 0.59$	$6.80 \pm 0.30$	$6.03 \pm 0.38^{b}$
Atypical lymphocytes $(10^3/\mu L)$	$0.00 \pm 0.00$	$0.00 \pm 0.00$	$0.00 \pm 0.00$	$0.00 \pm 0.00$
Monocytes $(10^3/\mu L)$	$0.12 \pm 0.03$	$0.19 \pm 0.09$	$0.21 \pm 0.05$	$0.19 \pm 0.05$
Eosinophils $(10^3/\mu L)$	$0.13 \pm 0.03$	$0.17 \pm 0.03$	$0.13 \pm 0.05$	$0.10 \pm 0.04$
Female				
n N	9	8	9	6
Hematocrit (%)	44.5 ± 0.3	45.0 ± 0.4	$44.4 \pm 0.5$	$44.6 \pm 0.2$
Hemoglobin (g/dL)	$14.7 \pm 0.1$	$14.9 \pm 0.1$	$14.7 \pm 0.2$	$14.9 \pm 0.1$
Erythrocytes $(10^6/\mu L)$	9.78 ± 0.06	9.97 ± 0.10	9.79 ± 0.12	$9.97 \pm 0.08$
Reticulocytes $(10^{6}/\mu L)$	$0.19 \pm 0.02$	$0.24 \pm 0.02$	$0.25 \pm 0.03$	$0.23 \pm 0.02$
Nucleated erythrocytes $(10^3/\mu L)$	$0.00 \pm 0.00$	$0.02 \pm 0.01$	$0.00 \pm 0.00$	$0.01 \pm 0.01$
Mean cell volume (fL)	$45.5 \pm 0.3$	$45.2 \pm 0.4$	$45.3 \pm 0.3$	$44.8 \pm 0.3$
Mean cell hemoglobin (pg) Mean cell hemoglobin	$15.1 \pm 0.1$	$15.0 \pm 0.1$	$15.0 \pm 0.1$	$14.9 \pm 0.1$
concentration (g/dL)	$33.1 \pm 0.1$	$33.1 \pm 0.1$	$33.1 \pm 0.2$	$33.3 \pm 0.2$
Platelets $(10^3/\mu L)$	1,165 ± 45	$1,242 \pm 48$	$1,249 \pm 51$	$1,288 \pm 58$
Leukocytes $(10^3/\mu L)$	5.51 ± 0.39	5.78 ± 0.49	$7.00 \pm 0.45$	$6.28 \pm 0.67$
Segmented neutrophils $(10^3/\mu L)$	$1.22 \pm 0.15$	$1.03 \pm 0.11$	$1.62 \pm 0.15$	$1.80 \pm 0.23$
Lymphocytes $(10^3/\mu L)$	$4.02 \pm 0.27$	4.46 ± 0.43	$5.03 \pm 0.36$	$4.23 \pm 0.43$
Atypical lymphocytes (10 <sup>3</sup> /µL)	$0.00 \pm 0.00$	$0.00 \pm 0.00$	$0.00 \pm 0.00$	$0.00 \pm 0.00$
Monocytes $(10^3/\mu L)$	$0.08 \pm 0.04$	$0.11 \pm 0.03$	$0.13 \pm 0.05$	$0.09 \pm 0.04$
Eosinophils $(10^3/\mu L)$	$0.19 \pm 0.04$	$0.17 \pm 0.03$	$0.21 \pm 0.05$	$0.16 \pm 0.06$

≠ a Significantly different (P<0.05) from the control group by Dunn's test Mean  $\pm$  standard error. Statistical tests were performed on unrounded data.

b n=8
### APPENDIX H REPRODUCTIVE TISSUE EVALUATIONS, ESTROUS CYCLE CHARACTERIZATION, AND TERATOLOGY

÷ , :

Table H1	Summary of Reproductive Tissue Evaluations and Estrous Cycle Characterization	
	for Rats in the 13-Week Feed Study of t-Butylhydroquinone	292
Table H2	Maternal Toxicity in F344/N Rats ( $F_0$ ) Exposed to <i>t</i> -Butylhydroquinone in Feed	
	During the Perinatal Exposure Phase of the 13-Week Study	293
TABLE H3	Developmental Toxicity in F344/N Rats (F1) Following Maternal Exposure	
	to t-Butylhydroquinone in Feed During the Perinatal Exposure Phase	
	of the 13-Week Study	293
Table H4	Summary of Reproductive Tissue Evaluations and Estrous Cycle Characterization	
	for Mice in the 13-Week Feed Study of t-Butylhydroquinone	294

	0 ppm	2,500 ppm	5,000 ppm	10,000 ppm	
Male					
n	10	10	10	10	на. На 1
Weights (g)					
Necropsy body wt	340 ± 7	$339 \pm 3$	313 ± 7**	284 ± 6**	*
L. cauda	$0.138 \pm 0.004$	$0.149 \pm 0.003*$	$0.142 \pm 0.003$	$0.139 \pm 0.003$	,
L. testis	$1.48 \pm 0.03$	$1.58 \pm 0.02^{**}$	$1.49 \pm 0.02$	$1.47 \pm 0.01$	
L. epididymis	$0.414 \pm 0.008$	$0.434 \pm 0.004*$	$0.412 \pm 0.006$	$0.410 \pm 0.004$	•
Spermatid parameters					
Spermatid heads (10 <sup>7</sup> /g testis)	$12.45 \pm 0.68$	$11.28 \pm 0.52$	$10.02 \pm 0.42*$	11.57 ± 0.50	
Spermatid heads (10 <sup>7</sup> /testis)	$18.35 \pm 1.00$	$17.76 \pm 0.72$	14.89 ± 0.67*	16.96 ± 0.74	
Spermatid count (mean/10 <sup>-4</sup> mL susp	ension)				
	917.3 ± 50.1	887.8 ± 36.2	744.3 ± 33.7*	848.0 ± 37.2	
Epididymal spermatozoal parameters			÷ 1		
Motility (%)	92.77 ± 0.69	91.87 ± 0.48	92.79 ± 0.39	90.91 ± 0.72	
Concentration (10 <sup>6</sup> /g cauda epididyma					
	680.7 ± 42.2	661.0 ± 39.8	632.7 ± 35.7	592.3 ± 28.5	
Female	e La seconda de la seconda de				
		10	10	10	
n	10	10	10	10	
Necropsy body wt (g)	201 ± 5	199 ± 3	184 ± 2**	173 ± 3**	
Estrous cycle length (days)	5.00 ± 0.007	$6.25 \pm 0.35^{**b}$	6.10 ± 0.34*	$5.44 \pm 0.27^{b}$	
Estrous stage (% of cycle)					•
Diestrus	49.2	50.8	43.3	56.7	
Proestrus	10.8	8.3	14.2	8.3	
Estrus	32.5	32.5	32.5	27.5	
Metestrus	7.5	8.3	10.0	7.5	

### **TABLE H1**

Summary of Reproductive Tissue Evaluations and Estrous Cycle Characterization for Rats in the 13-Week Feed Study of *t*-Butylhydroquinone<sup>a</sup>

Significantly different (P<0.05) from the control group by Williams' or Dunnett's test (organ and body weights) or Dunn's test (spermatid and epididymal spermatozoal parameters)</li>

ç

\*\* P≤0.01

<sup>a</sup> Data are presented as mean  $\pm$  standard error.

ð,

<sup>b</sup> Estrous cycle was longer than 12 days or unclear in 2 of 10 animals.

### Table H2

Maternal Toxicity in F344/N Rats ( $F_0$ ) Exposed to *t*-Butylhydroquinone in Feed During the Perinatal Exposure Phase of the 13-Week Study<sup>a</sup>

	0 ppm	2,500 ppm	5,000 ppm	10,000 ppm	20,000 ppm	40,000 ppm
Number examined	16	16	16	16	16	16
Number pregnant	9 (56%)	10 (63%)	10 (63%)	11 (69%)	0**	0**
Maternal body weight (g)						
Day 1	141 ± 6	$142 \pm 6$	$141 \pm 5$	$141 \pm 6$	$140 \pm 5$	$141 \pm 5$
Day 7	$149 \pm 6$	$152 \pm 7$	$147 \pm 5$	143 ± 7**	$131 \pm 4**$	$114 \pm 6^{**}$
Day 15	$161 \pm 8$	$163 \pm 7$	$158 \pm 5$	$153 \pm 8**$	$141 \pm 5**$	112 ± 10**
Duration of gestation (days)	$22.9 \pm 0.3$	$23.0\pm0.0$	$23.0\pm0.0$	$23.3\pm0.5$	-	_
•						

\*\* Significantly different (P $\leq$ 0.01) from the control group

<sup>a</sup> Data are presented as mean  $\pm$  standard deviation.

#### TABLE H3

Developmental Toxicity in F344/N Rats ( $F_1$ ) Following Maternal Exposure to *t*-Butylhydroquinone in Feed During the Perinatal Exposure Phase of the 13-Week Study<sup>a</sup>

	0 ppm	2,500 ppm	5,000 ppm	10,000 ppm	
Number of dams/litters examined	9	10	10	11	
Pups delivered (total)	68	106	78	92	
Pups delivered per litter	$7.6 \pm 3.6$	$10.6 \pm 1.8$	$7.8 \pm 3.4$	$8.4 \pm 3.1$	
Pups surviving 4 days (precull)					
per number of pups delivered	66/68 (97%)	105/106 (99%)	77/78 (99%)	83/92 (90%)**	
Pup weight per litter (g)				r o , o <b>c</b> h	
Day 4 (precull)	$6.8 \pm 0.6$	$7.0 \pm 0.7$	$6.6 \pm 0.7$	$6.8 \pm 0.7^{b}$	
Pups surviving 28 days per number of	pups				
selected on day 4 (postcull)	58/58 (100%)	78/79 (99%)	58/66 (88%)	43/69 (62%)**	
Pup weight per litter (g)			<b>b</b>	0	
Day 28	$49.2 \pm 5.6$	$50.8 \pm 6.3$	$45.1 \pm 4.3^{b}$	$42.0 \pm 3.6^{c}$	

ż

\*\* Significantly different ( $P \le 0.01$ ) from the control group a Data are presented as mean + standard deviation

<sup>a</sup> Data are presented as mean  $\pm$  standard deviation.

n=9 n=6

5

÷

### TABLE H4

Summary of Reproductive Tissue Evaluations and Estrous Cycle Characterization for Mice in the 13-Week Feed Study of *t*-Butylhydroquinone<sup>a</sup>

	0 ppm	2,500 ppm	10,000 ppm	40,000 ppm	
Male					
n	10	9	10	8	
NT-1-La- (-)	, ,			· · · ·	•
Weights (g)	$34.1 \pm 0.7$	31.9 ± 0.7*	30.1 ± 0.4**	23.7 ± 0.4**	1
Necropsy body wt	$34.1 \pm 0.7$ $0.013 \pm 0.001$	$31.9 \pm 0.011$ 0.012 ± 0.001	$0.007 \pm 0.001^{**b}$	$23.7 \pm 0.4^{++}$ 0.009 ± 0.001**	
L. cauda L. testis	$0.013 \pm 0.001$ $0.114 \pm 0.003$	$0.012 \pm 0.001$ $0.109 \pm 0.003$	$0.007 \pm 0.001$	$0.009 \pm 0.001^{**}$ $0.101 \pm 0.004^{**}$	. '
		$0.038 \pm 0.003$	$0.036 \pm 0.002$	$0.031 \pm 0.001^{**}$	
L. epididymis	$0.042 \pm 0.002$	0.058 ± 0.002	$0.030 \pm 0.001$	$0.031 \pm 0.001$	
Spermatid parameters		· · · ·			
Spermatid heads (10 <sup>7</sup> /g testis)	$22.84 \pm 0.58$	$24.46 \pm 0.95^{\circ}$	$24.88 \pm 1.36$	$25.65 \pm 1.28^{\circ}$	
Spermatid heads (10 <sup>7</sup> /testis)	$2.60 \pm 0.10$	$2.67 \pm 0.11^{c}$	$2.63 \pm 0.13$	$2.61 \pm 0.17^{c}$	
Spermatid count (mean/10 <sup>-4</sup> mL sus	pension)		•		
•	811.8 ± 31.4	$833.6 \pm 35.0^{\circ}$	823.8 ± 41.9	$815.0 \pm 51.9^{c}$	
Epididymal spermatozoal parameters		· · · · ·			
Motility (%)	$92.54 \pm 0.83$	88.71 ± 1.17*	$91.25 \pm 0.64$	$89.21 \pm 2.83$	
Concentration (10% cauda epididyr			· · · · · · · · · · · · · · · · · · ·		
	$1,732 \pm 123$	$2,054 \pm 184$	2,922 ± 426	$1,822 \pm 228$	
			÷ *		
Female					
n	10	10	9	.9	
Necropsy body wt (g)	30.7 ± 0.7 <sup>b</sup>	$28.5 \pm 1.0^{*b}$	$24.1 \pm 0.4^{**d}$	20.3 ± 0.5**	
Estrous cycle length (days)	4.25 ± 0.13	$4.25 \pm 0.13$	4.94 ± 0.40	$5.80 \pm 0.86^{*e}$	
Estrous stage (% of cycle)	21 7	33.3	27.8	44.4	
Diestrus	31.7		13.9	44.4	
Proestrus	17.5	15.0 41.7	43.5	31.5	
Estrus	36.7		43.5	9.3	
Metestrus	14.2	9.2	0.0	9.3 0.0	
Unclear diagnosis	0.0	0.0	0.0	0.0	

\* Significantly different (P<0.05) from the control group by Williams' or Dunnett's test (organ and body weights) or Dunn's test (spermatid and epididymal spermatozoal parameters)

\*\* P≤0.01

<sup>a</sup> Data are presented as mean  $\pm$  standard error.

<sup>b</sup> n=9

c n=7

<sup>d</sup> n=8

• Estrous cycle was longer than 12 days or unclear in 4 of 9 animals.

### APPENDIX I CHEMICAL CHARACTERIZATION AND DOSE FORMULATION STUDIES

PROCUREMEN	NT AND CHARACTERIZATION OF <i>t</i> -BUTYLHYDROQUINONE	296
PREPARATION	N AND ANALYSIS OF DOSE FORMULATIONS	297
FIGURE I1	Infrared Absorption Spectrum of t-Butylhydroquinone	298
FIGURE I2	Nuclear Magnetic Resonance Spectrum of <i>t</i> -Butylhydroquinone	299
Table I1	Preparation and Storage of Dose Formulations in the Feed Studies	
	of t-Butylhydroquinone	300
TABLE I2	Results of Analyses of Dose Formulations Administered to Rats and Mice	
	in the 13-Week Feed Studies of t-Butylhydroquinone	301
TABLE I3	Results of Analyses of Dose Formulations Administered to Rats and Mice	
	in the Long-Term and 2-Year Feed Studies of t-Butylhydroquinone	303
TABLE I4	Results of Referee Analyses of Dose Formulations Administered to Rats and Mice	
	in the 13-Week, Long-Term, and 2-Year Feed Studies of <i>t</i> -Butylhydroquinone	309

3

# CHEMICAL CHARACTERIZATION AND DOSE FORMULATIONS

### **PROCUREMENT AND CHARACTERIZATION OF t-BUTYLHYDROQUINONE**

t-Butylhydroquinone was obtained in two lots (187-1 and 1089-1) from U.O.P., Inc., (Des Plaines, IL). Lot 187-1 was used in the 13-week, long-term, and 2-year studies. Lot 1089-1 was used in the long-term and 2-year studies. Identity, purity, and stability analyses were conducted by the analytical chemistry laboratory, Midwest Research Institute (Kansas City, MO). Reports on analyses performed in support of the *t*-butylhydroquinone studies are on file at the National Institute of Environmental Health Sciences (NIEHS).

Each lot of the chemical, a fine beige powder, was identified as *t*-butylhydroquinone by infrared, ultraviolet/visible, and nuclear magnetic resonance spectroscopy. All spectra were consistent with the literature spectra (*Sadtler Standard Spectra*) of *t*-butylhydroquinone (Figures I1 and I2).

The purity of each lot was determined by elemental analyses, Karl Fischer water analysis, functional group titration, thin-layer chromatography (TLC), and high-performance liquid chromatography (HPLC). Functional group titration was performed by dissolving samples in methanol, water, and 1 N sulfuric acid. Diphenylamine indicator solution was added to the samples and the samples were titrated with 0.1 N ceric sulfate to a colorimetric endpoint. TLC was performed on Silica Gel 60 F-254 plates with two solvent systems: 1) acetone:toluene:chloroform (40:35:25), and 2) toluene:acetone (95:5) with phenol as a reference standard. Plates were examined under visible and ultraviolet light at 254 nm and sprayed with first a 0.4% methanolic solution of 2,6-dichloroquinonechloroimide and then 10% aqueous sodium carbonate. HPLC was performed for lot 187-1 using a Waters Resolve  $C_{18}$  column with a solvent system containing water:acetonitrile (90:10) with 1% glacial acetic acid at a flow rate of 1.0 mL/minute, and detection at 280 nm. HPLC was performed for lot 1089-1 using a Waters Resolve  $C_{18}$  column with a solvent system containing water:acetonitrile (75:25) with 1% glacial acetic acid for 20 minutes followed by 100% acetonitrile with 1% glacial acetic acid at a flow rate of 1.0 mL/minute, and

Elemental analyses for carbon and hydrogen were in agreement with the theoretical values for t-butylhydroquinone. Karl Fischer water analysis indicated less than 0.4% water for lot 187-1 and 0.16% water for lot 1089-1. Functional group titration indicated a purity of 99.6%  $\pm$  0.5% for lot 187-1 and 99.1%  $\pm$  0.4% for lot 1089-1. TLC of lot 187-1 indicated a major spot and two trace impurities using the first system and a major spot, one minor impurity, and one trace impurity using the second system. For lot 1089-1, both TLC systems indicated a major spot, one minor impurity, and one trace impurity. HPLC of lot 187-1 indicated a major peak and one impurity peak with an approximate area of 0.13% relative to the major peak. HPLC of lot 1089-1 indicated a major peak and no impurities with peak areas greater than 0.1% relative to the major peak. Additional HPLC analyses were performed using a linear gradation in the solvent system, changing it from 90:10 to 0:100 (lot 187-1) or from 75:25 to 0:100 (lot 1089-1) over a 20-minute period. These analyses resolved additional impurities for lots 187-1 and 1089-1 with peak areas of 0.3% to 0.4% relative to the major peak. Lots 1089-1 and 187-1 were concomitantly analyzed by the same HPLC method used for the initial purity analyses. The overall purity for each lot was 99%.

Stability studies of the bulk chemical were performed by the analytical chemistry laboratory. Stability studies were performed using the HPLC methods described previously for the purity analysis, but with a solvent system ratio of 80:20. These studies indicated that *t*-butylhydroquinone was stable as a bulk chemical when stored for 2 weeks, protected from light, at temperatures up to  $60^{\circ}$  C. To ensure stability, the chemical was stored at room temperature in sealed containers, protected from light. Stability was monitored 9 weeks after the beginning of the 13-week studies and within 30 days after the end of the studies

.7

Ŀ.

#### t-Butylhydroquinone, NTP TR 459

using HPLC. For the long-term and 2-year studies, stability was monitored at approximately 4-month intervals and within 30 days after the end of the studies using HPLC. No degradation of the bulk chemical was detected.

### PREPARATION AND ANALYSIS OF DOSE FORMULATIONS

The dose formulations for the 13-week, long-term, and 2-year studies were prepared weekly. Formulations were prepared by first forming a premix of a small amount of feed and the required weight of chemical. This premix and additional feed were then mixed in a twin-shell blender for 15 minutes, with an intensifier bar used for the initial 5 minutes. Each dose formulation was poured into a labeled, double-thickness plastic bag that was placed in labeled containers and protected from light. Formulations were stored for no longer than 21 days (13-week studies) or 18 days (long-term and 2-year studies) at 5° C (Table I1).

Homogeneity analyses of the dose formulations were conducted by the analytical chemistry laboratory. Prior to the start of the 13-week studies, a preliminary mixing of the 2,500 ppm and 40,000 ppm dose formulations was performed. Triplicate samples were analyzed for homogeneity, and analytical results indicated that the samples were not homogeneous. The study laboratory changed the analytical method slightly (samples were diluted with mobile phase instead of the MRI-recommended acetonitrile) and 2 weeks after the start of the 13-week studies, results from the analysis of the 2,500 ppm dose formulations were within 10% of the theoretical value. Prior to the start of the long-term and 2-year studies, the study laboratory performed homogeneity analyses on the 125 ppm dose formulation (homogeneity determinations had been previously performed on greater concentrations). Three samples from this dose formulation, taken from three different areas of the blender, were analyzed in duplicate; results of the analyses were unacceptable, and a remix and second analysis were performed. Results of the second analyses were within 10% of theoretical values.

Stability studies of the 5,000 ppm dose formulation were conducted by the analytical chemistry laboratory. Samples (10 g) of the dose formulation were extracted with 100 mL of acetonitrile and shaken for 5 minutes. The extracts were centrifuged, and 25 mL aliquots of the extracts were mixed with 2 mL of internal standard solution (propiophenone, 10 mg/mL acetonitrile) and diluted to 100 mL with acetonitrile. Portions of the final diluted solutions were filtered (0.45  $\mu$ m pore size) and analyzed using HPLC. HPLC was performed using a Waters  $\mu$ Bondapack C<sub>18</sub> column with a solvent system of water:acetonitrile:acetic acid (50:50:1) at a flow rate of 1.0 mL/minute. For the stability analysis, the 5,000 ppm formulation was prepared and stored for up to 21 days in the dark at room temperature, 5° C, or -20° C, or was stored for up to 7 days under animal room conditions. Stability of the 5,000 ppm formulation was confirmed for at least 3 weeks when stored in sealed containers in the dark at 5° C. A 5.3% loss of chemical was observed after 2 days of storage under animal room conditions. Based on these findings, the dose formulations were stored in sealed containers in the dark at 5° C for no longer than 3 weeks.

Periodic analyses of the dose formulations of *t*-butylhydroquinone were conducted at the study laboratory using HPLC. For the 13-week studies, dose formulations were analyzed at the beginning, in the middle, and at the end of the studies (Table I2). During the long-term and 2-year studies, dose formulations were analyzed approximately every 8 weeks (Table I3). In the 13-week studies, 98% (43/44) of the dose formulations used were within 10% of the target concentration with no value greater than 16% from the target concentration. In the long-term studies, 219 of the 220 dose formulations used for rats and 185 of the 186 dose formulations used for mice were within 10% of the target concentration. Results of periodic referee analyses performed by the analytical chemistry laboratory agreed with the results obtained by the study laboratory (Table I4).

σ

ŝ



(%) NOISSIMSNAAT

Ø

FIGURE I1 Infrared Absorption Spectrum of *t*-Butylhydroquinone

Ľ.



Preparation and Storage of Dose Formulations in the Feed Studies of *t*-Butylhydroquinone

13-Week Studies	Long-Term Study	2-Year Study
Preparation	· · · · · · · · · · · · · · · · · · ·	······································
A premix of feed and t-butylhydro- quinone was prepared by mixing the chemical and feed in a beaker and	Same as 13-week studies	Same as 13-week study
stirring until a homogeneous mixture was obtained. The premix was then blended with feed in a Patterson-Kelly		
win-shell blender with the intensifier oar on for 5 minutes and off for 0 minutes. Doses were prepared weekly.		
Chemical Lot Number 87-1	187-1 and 1089-1	187-1 and 1089-1
faximum Storage Time	18 days	18 days
torage Conditions ormulations were stored in sealed ontainers in the dark at 5° C.	Same as 13-week studies	Same as 13-week studies
Study Laboratory Southern Research Institute Birmingham, AL)	Southern Research Institute (Birmingham, AL)	Southern Research Institute (Birmingham, AL)
Referee Laboratory Aidwest Research Institute Kansas City, MO)	Midwest Research Institute (Kansas City, MO)	Midwest Research Institute (Kansas City, MO)

### 8-Butylhydroquinone, NTP TR 459

### Table 12

Results of Analyses of Dose Formulations Administered to Rats and Mice in the 13-Week Feed Studies of t-Butylhydroquinone<sup>a</sup>

Date Prepared	Date Analyzed	Target Concentration (mg/g)	Determined Concentration (mg/g) <sup>b</sup>	% Difference from Target
15 August 1988	22-23 August 1988	2.5	2.17 <sup>c,d</sup>	-13
IS AUGUST 1900		2.5	2.34 <sup>c,d</sup>	-6
		2.5	2.44 <sup>c,d</sup>	-2
		40	36.0 <sup>c,d</sup>	-10
		40	38.1 <sup>c,d</sup>	5
		40	38.2 <sup>c,d</sup>	-4
lats and Mice				
1 December 1988	2-3 December 1988	2.5	2.60 <sup>d,e</sup>	+4
		2.5	2 61d,f	+6
		2.5	2.33 <sup>d,g,h</sup>	-7
		2.5	2.50	0
		2.5	2.71	+8
		2.5	2.39 <sup>h</sup>	-4
		5	4.98	0
		5	4.73 <sup>h</sup>	-5
		5	5.05	+1
		5	5.00	0
		10	9.58	-4
		10	9.04 <sup>h</sup>	-10
		10	9.68	-3
		20	20.2	+1
		40	38.5	-4
	4 December 1988	10	9.74	-3
12 January 1989	13 January 1989	2.5	2.30	-8
		2.5	2.29	-8
		2.5	2.18 <sup>c</sup>	-13
		2.5	2.28	-9
		5	4.50	-10
		5	4.50	-10
		5	4.74	-5
		5	4.74	-5
		10	9.56	-4
		10	10.2	+2
		10	9.10	-9
		10	9.07	-9
		20	19.2	-4
		40	39.4	-2
17 January 1989	18 January 1989	2.5	2.52 <sup>i</sup>	+1

<b>Results of Analyses of Dose Formulations Administered to</b>	Rats and Mice in the 13-We	ek Feed Studies
of t-Butylhydroquinone (continued)	· · · · · ·	· ·

Date Prepared	Date Analyzed	Target Concentration (mg/g)	Determined Concentration (mg/g)	% Difference from Target
Rats and Mice (continued	1)	···· ,		
9 February 1989	10 February 1989	2.5	2.62	+5
		2.5	2.26	- 10
		2.5	2.39 <sup>h</sup>	-4
		2.5	2.51 <sup>h</sup>	0
		5	4.19	-16
		5	4.84	-3
		5	5.12	+2
		5	5.02	0
		· 10	9.50	-5
		10	9.82	-2
		10	9.08	. <b>-9</b>
		10	9.42	-6
		20	19.0	-5
		40	38.0	-5
• •			. ,	
13 February 1989	14 February 1989	5	4.80 <sup>i</sup>	-4

а 2.5 mg/g=2,500 ppm; 5 mg/g=5,000 ppm; 10 mg/g=10,000 ppm; 20 mg/g=20,000 ppm; 40 mg/g=40,000 ppm

b Results of duplicate analyses c

d

Not used for dosing Homogeneity analysis

e Sample selection from top of twin-shell blender

f

Sample selection from middle of twin-shell blender Sample selection from bottom of twin-shell blender g

h Results of triplicate analysis

i Results of remix

Results of Analyses of Dose Formulations Administered to Rats and Mice in the Long-Term and 2-Year Feed Studies of *t*-Butylhydroquinone<sup>a</sup>

Date Prepared	Date Analyzed	Target Concentration (mg/g)	Determined Concentration (mg/g) <sup>b</sup>	% Difference from Target
Rats				
6 November 1989	7 November 1989	1.05	1.14	0
o November 1989	/ November 1989	1.25	1.14	-9.
,		1.25	1.14	-9
		1.25	1.10 <sup>c</sup>	-12
		2.5	2.44	-2
		2.5	2.44	-2
		2.5	2.46	-2
		5	4.87	-3
		5	4.86	-3
		5	4.85	-3
9 November 1989	9 November 1989	1.25	1.22 <sup>d</sup>	-2
Rats and Mice				
20 November 1989	20-21 November 1989	1.25	1.32	+6
20 November 1989	20-21 November 1989	1.25	1.32	+8
		1.25	1.35	+1
				+1
		1.25	1.26	
		2.5	2.54	+2
		2.5	2.55	+2
		2.5	2.62	+5
		2.5	2.66	+6
		5	5.23	+5
		5	5.14	+3 ·
		5	5.20	+4
		5	5.18	_+4
		5	5.24	+5
		5	5.12	+2
17 January 1990	18 January 1990	1.25	1.23	-2
•	•	1.25	1.22	-2
		1.25	1.21	-3
		1.25	1.22	-2
		2.5	2.53	+1
		2.5	2.44	-2
		2.5	2.38	-5
		2.5	2.36	-2
		5	4.66	-7
		5	4.60	-8
		5	4.88	-8 -2
		5	4.00	-2 -5
			4.76	-5 -6
		5		
		5	4.88	-2

## **Results of Analyses of Dose Formulations Administered to Rats and Mice in the Long-Term and 2-Year Feed Studies of t-Butylhydroquinone** (continued)

Date Prepared	Date Analyzed	Target Concentration (mg/g)	Determined Concentration (mg/g)	% Difference from Target
Rats and Mice (continued	)			÷
21 March 1990	, 22-23 March 1990	1.25	1.16	-7
		1.25	1.20	-4
		1.25	1.18	-6
		1.25	1.17	-6
		1.25	1.23	-2
	·	2.5	2.35	-6
		2.5	2.33	-7
		2.5	2.25	-10
		2.5	2.30	-8
		2.5	2.30	-8
		. 5	4.72	-6
		5	4.64	-7
		5	4.69	-6
		5	4.78	-4
		5	4.54	-9
		5	4.54	
16 May 1990	17 May 1990	1.25	1.26	+1
10 May 1990	17 May 1990	1.25	1.20	+2
		1.25	1.23	-2
		1.25	1.18	-6
		2.5	2.44	-2
		2.5	2.45	-2
	·	2.5	2.45	-4
		2.5	2.41	-4
		2.5 5	4.77	-5
				-3
		5	4.86 5.01	-3
		5	5.01 4.92	-2
,		5	4.92	-2 -8
		3	4.01	-0
11 July 1990	12 July 1990	1.25	1.20	-4
11 July 1990	12 July 1990	1.25	1.20	-4
		1.25	1.23	-2
		1.25	1.18	-6
		2.5	2.44	-0
			2.44 2.41	-2 -4
		2.5	2.41	-4
		2.5	2.44	-2 -8
		2.5		-8 -5
		5	4.75 4.92	-3 -2
		5	4.92	-2 -2
		5	4.91	-2 -1
		5		-1
		5	4.96	-1 .

Results of Analyses of Dose Formulations Administered to Rats and Mice in the Long-Term and 2-Year Feed Studies of *i*-Butylhydroquinone (continued)

Date Prepared	Date Analyzed	Target Concentration (mg/g)	Determined Concentration (mg/g)	% Difference from Target
Rats and Mice (continued)				
5 September 1990	7 September 1990	1.25	1.24	-1
5 September 1990	/ September 1990	1.25	1.24	-1 -2
		1.25	1.22	-1
		1.25	1.18	-6
		2.5	2.42	-3
		2.5	2.42	-1
				-1 -2
		2.5	2.44	
		2.5	2.54	+2
		5	4.86	-3
		5	4.78	-4
		5	4.89	-2
		5	5.06	+1
		5	4.96	-1
7 November 1990	8 November 1990	1.25	1.20	-4
		1.25	1.17	-6
		1.25	1.23	-2
		1.25	1.23	-2
		2.5	2.49	0
		2.5	2.44	-3
		2.5	2.50	0
		2.5	2.41	-4
		5	5.00	Ó
		5	4.91	-2
		5	5.05	+1
		5	4.91	-2
		5	4.86	-3
9 January 1991	10-11 January 1991	1.25	1.205	-4
		1.25	1.086 <sup>c</sup>	-13
		1.25	1.201	-4
		1.25	1.163	-7
		2.5	2.459	-2
		2.5	2.424	-3
		2.5	2.459	-2
		2.5	2.362	-6
		5	4.889	-2
		5	4.545	-9
		5	4.689	-6
		5	4.462	-11
		5	4.902	-2
14 January 1991	14 January 1991	1.25	1.22 <sup>d</sup>	-3

## **Results of Analyses of Dose Formulations Administered to Rats and Mice in the Long-Term and 2-Year Feed Studies of t-Butylhydroquinone** (continued)

Date Prepared	Date Analyzed	Target Concentration (mg/g)	Determined Concentration (mg/g)	% Difference from Target
Rats and Mice (continued	) .	18 mariyar ( 201 201 201 201 201 201 201 201 201 201		· · ·
26-27 February 1991	28 February 1991	1.25	*1.31	+5
-	· ·	1.25	1.24	-1
	•	1.25	1.25	0
		1.25	1.20	-4
	•	2.5	2.31	
		2.5	2.45	-2
		2.5	2.47	-1
		2.5	2.42	-3
	,	5	4.91	-2
		5	5.07	+1
		5	4.80	-4
		5	4.77	-5
		5	4.97	-1
1 May 1991	2 May 1991	1.25	1.28	+2
		1.25	1.22	-2
		1.25	1.32	+6
		1.25	1.29	+3
,	-	2.5	2.59	+4
		2.5	2.50	0
		2.5	2.55	+2
		2.5	2.39	-4
		5	5.05	+1
		5	4.88	-2
		5	5.10	+2
		5	4,94	-1
		5	5.08	+2
19 June 1991	20 June 1991	1.25	1.31	+5
		1.25	1.25	0
		1.25	1.25	0
÷	3	1.25	1.33	+6
	1. C.	2.5	2.42	-3
•		2.5	2.53	+1
		2.5	2.48	-1
		2.5	2.45	-2
	×	5	4.84	-3
		5	4.84	-3
		5	4.82	-4
		5	4.97	-1
		5	4.93	-1
		0	7.75	*

Results of Analyses of Dose Formulations Administered to Rats and Mice in the Long-Term and 2-Year Feed Studies of *t*-Butylhydroquinone (continued)

Date Prepared	Date Analyzed	Target Concentration (mg/g)	Determined Concentration (mg/g)	% Difference from Target
Rats and Mice (continue	:d)	<u> </u>		
14 August 1991	15-16 August 1991	1.25	1.27	+2
	-	1.25	1.17	-6
		1.25	1.20	-4
		1.25	1.21	-3
		2.5	2.38	-5
		2.5	2.37	-5
		2.5	2.48	-1
		2.5	2.25	-10
		5	4.76	-5
		5	4.91	-2
		5	4.76	-5
		5	4.83	-3
		5	4.79	-4
9 October 1991	10-11 October 1991	1.25	1.25	0
		1.25	1.21	-3
		1.25	1.22	-2
		1.25	1.26	+1
		2.5	2.46	-2
		2.5	2.45	-2
		2.5	2.50	0
		2.5	2.46	-2
		5	4.91	-2
		5	4.85	-3
		5	4.85	-3
		5	4.78	-4
		5	4.85	-3
20 November 1991	21-25 November 1991	1.25	1.19	-5
		1.25	1.19	-5
		1.25	1.20	-4
		1.25	1.19	-5
		2.5	2.42	-3
		2.5	2.48	-1
		2.5	2.26	-10
		2.5	2.44	-2
		5	4.95	-1
		5	4.80	-4
		5	4.80	-4
		5	4.67	-7
	-1	5	4.78	-4

đ

5

Date Prepared	Date Analyzed	Target Concentration (mg/g)	Determined Concentration (mg/g)	% Difference from Target
Rats (continued)	···· ·····			······································
22 January 1992	23 January 1992	1.25	1.21	-3
	,,	1.25	1.20	-4
		1.25	1.24	-1
		2.5	2.49	0
		2.5	2.42	-3
,		2.5	2.60	+4
•		5	5.01	· 0
		5	4.98	0
		5	4.90	-2
		5	5.03	+1
18 March 1992	19 March 1992	1.25	1.25	0
	· .	1.25	1.26	+1
		2.5	2.52	· +1
		2.5	2.48	-1
		5	5.03	+1
		5	5.00	0
		5 5	5.01	0
27 May 1992	28 May 1992	1.25	1.25	0
•	•	1.25	1.26	+1
		2.5	2.47	· -1 · ·
		2.5	2.49	. 0
· · · · · ·	•	5	4.90	-2
		5	4.86	-3
		5	5.12	+2
22 July 1992	23 July 1992	5	4.92	-2

Ł,

### TABLE I3

Results of Analyses of Dose Formulations Administered to Rats and Mice in the Long-Term and 2-Year Feed Studies of t-Butylhydroquinone (continued)

a 1.25 mg/g=1,250 ppm; 2.5 mg/g=2,500 ppm; 5 mg/g=5,000 ppm
 b Duplicate analyses
 c Not used for dosing
 d Results of remix

ŝ

Results of Referee Analyses of Dose Formulations Administered to Rats and Mice in the 13-Week, Long-Term, and 2-Year Feed Studies of t-Butylhydroquinone

		Determined Con	centration (mg/g)	
Date Prepared	Target Concentration (mg/g)	Study Laboratory <sup>a</sup>	Referee Laboratory <sup>b</sup>	
13-Week Studies				
1 December 1988	2.5	2.44	2.13	
12 January 1989	5	4.74	4.68	
Long-Term Study				
<b>Rats</b> 6 November 1989 20 November 1989 17 January 1990	1.25 5 2.5	1.14 5.14 2.53	1.20 4.53 2.20	
2-Year Study				
Mice 20 November 1989 17 January 1990	5 2.5	5.14 2.53	4.53 2.20	

£

ć

\$

Results of duplicate analyses Results of triplicate analyses a b

٠.

### APPENDIX J

### FEED AND COMPOUND CONSUMPTION IN THE LONG-TERM AND 2-YEAR FEED STUDIES OF &-BUTYLHYDROQUINONE

TABLE J1	Feed and Compound Consumption by Male Rats in the Long-Term Feed Study	
	of <i>t</i> -Butylhydroquinone	312
TABLE J2	Feed and Compound Consumption by Female Rats in the Long-Term Feed Study	
	of <i>t</i> -Butylhydroquinone	313
TABLE J3	Feed and Compound Consumption by Male Mice in the 2-Year Feed Study	
	of <i>t</i> -Butylhydroquinone	314
TABLE J4	Feed and Compound Consumption by Female Mice in the 2-Year Feed Study	
	of <i>t</i> -Butylhydroquinone	315

E

2	1	2	,
•	-	-	

TABLE J1

Feed	and	Compound	d Consumption b	y Male Rat	ts in the	Long-Term	Feed Study	of t-Butylhy	droquinone <sup>a</sup>
------	-----	----------	-----------------	------------	-----------	-----------	------------	--------------	-------------------------

0 ppm			1.250 ppr	n		2.500 pp	m		5.000 pp	n	
	Feed	Body	Feed	Body	Dose/	Feed	Body	Dose/	Feed	Body	Dose/
	(g/day) <sup>b</sup>	Weight	(g/day)	Weight	Day <sup>c</sup>	(g/day)	Weight		(g/day)	Weight	Day
Week		(g)	,	<b>(g)</b>	(mg/kg/day)		(g)	(mg/kg/day)		(g)	(mg/kg/day
1	13.9	99			,		·	, , , ,			
2	15.2	141	16.4	148	138	15.7	141	280	15.7	127	619
3	16.5	175									
4	18.2	209									
5	17.4	233									
6	20.8	267	19.0	266	89	19.0	260	183	18.3	244	375
7	17.2	283				`					
8	17.0	299							· .		
9	16.9	313									
10	13.1	316	13.2	319	52	17.3	320	135	17.5	299	293
11	19.2	324								•	
12.	. 17.4	344							÷		
13 ·	16.8	356	17.2	348	62	18.7	343	136	17.6	320	275
17	16.5	379	17.6	370	60	16.5	366	113	17.2	346	248
21	16.4	400	18.6	391	59	18.5	379	122	17.2	358	241
25	15.6	413	16.5	408	51	16.0	399	100	15.9	376	211
29	16.5	419	17.0	416	51	16.5	408	101	16.4	386	213
33	16.4	428	17.1	425	50.	17.4	417	104	16.7	392	213
37	17.4	437	17.4	435	50	16.8	430	· 98	16.4	402	204
41	14.7	450	14.8	.445	42	14.5	437	83	15.2	416	182
45 ·	16.5	452	16.0	450	44	17.7	439	101	16.9	415	203
49.	16.9	444	17.0	448	47	17.2	440	98	16.0	415	193
53	19.9	468	19.7	466	53	20.5	457	112	20.8	431	242
57	14.8	468	16.2	468	43	16.6	462	90	16.8	435	193
61	16.1	467	17.0	468	45	18.2	463	98	17.7	440	202
65	16.3	470	17.3	471	46	17.2	463	93	17.6	440	200
69 72	15.8	468	16.5	472	44	16.6	463	90	16.7	437	191
73	15.3	472	15.7	471	42	16.3	459	89 89	16.0	433	185
77 81	17.0 16.6	463 464	17.6	463 466	47 46	16.3 17.5	458 458	89 95	16.3 17.3	438 436	186 199
85	15.4	464	17.0 15.7	400 470	40	17.5	438	83	17.5	430	176
89	15.4	462	15.0	470	42	15.3	455	84	14.0	425	164
93	14.3	455	14.9	451	41	15.5	456	85	15.1	419	180
97 97	15.4	455	15.5	452	43	16.5	453	91	16.0	421	190
101	15.2	447	15.6	444	44	14.9	443	84	15.7	421	186
105	13.2	440	15.0	435	44	15.9	430	93	16.4	409	201
109	15.7	420	14.3	421	42	14.4	414	87	14.2	412	173
113	14.8	429	16.5	427	48	16.5	420	98	15.7	395	198
117	14.0	428	15.5	422	46	16.7	400	104	15.0	397	189
121	14.4	417	11.5	402	36	16.1	359	112	15.5	386	200
Mean f	or weeks										•
-13	16.9	258	16.5	271	85	17.7	266	183	17.3	247	390
14-52	16.3	425	16.9	421	51	16.8	413	102	16.4	390	212
53-121	15.6	453	15.9	452	44	16.4	443 .	93	16.2	422	192

4

Feed consumption for controls measured weekly for the first 13 weeks and monthly thereafter. Grams of feed consumed per animal per day Milligrams of *t*-butylhydroquinone consumed per kilogram body weight per day a

b

ĩ

С

### TABLE J2

Feed and Compound Consumption by Female Rats in the Long-Term Feed Study of t-Butylhydroquinone\*

	0 n	0 ppm 1,250 ppm					2.500 ppm			5.000 ppm		
Week	Feed (g/day) <sup>b</sup>	Body Weight (g)	Feed (g/day)	Body Weight (g)	Dose/ Day <sup>c</sup> (mg/kg/day)	Feed (g/day)	Body Weight (g)	Dose/	Feed (g/day)	Body Weight (g)	Dose/	
1	10.8	92										
2	11.3	121	12.0	124	122	12.0	120	249	11.9	110	541	
3	11.3	135										
4	11.6	147										
5	11.1	159										
6	13.7	171	12.4	168	93	12.2	162	188	11.3	154	367	
7	11.6	177										
8	10.8	181										
9	10.7	186										
10	9.4	176	8.8	181	61	11.2	183	154	11.1	176	316 ·	
11	11.9	193										
12	10.5	196										
13	10.2	198	10.5	194	68	10.8	191	141	11.2	184	304	
17	10.7	203	10.5	203	65	10.4	197	133	9.8	188	262	
21	10.7	224	11.1	212	65	10.4	205	127	10.8	200	270	
25	9.4	222	11.0	216	64	10.0	212	118	9.5	203	235	
29	9.2	229	10.4	222	59	9.8	217	114	10.1	210	240	
33	10.1	231	11.0	227	60	10.4	219	118	10.0	210	239	
37	10.9	232	11.1	230	60	11.0	223	123	10.4	213	244	
41	10.1	240	10.4	238	55	10.4	231	112	9.1	219	207	
45	10.8	248	11.1	246	56	11.6	239	122	11.0	227	242	
49	11.6	257	11.8	256	57	11.4	244	117	10.7	232	232	
53	15.3	264	15.7	263	74	14.7	247	149	14.1	236	299	
57	9.6	279	10.2	277	46	10.7	264	102	10.8	246	219	
61	11.3	285	11.4	285	50	12.0	269	111	11.2	257	217	
65	12.2	292	12.3	291	53	12.8	274	117	11.5	263	219	
69	11.6	301	11.5	299	48	11.3	282	100	10.7	265	202	
73	12.2	309	11.9	301	49	11.5	286	101	11.0	270	204	
77	12.2	315	12.4	311	50	11.6	200	98	11.5	274	209	
81	12.4	323	12.4	319	49	12.7	300	106	11.8	278	213	
85	11.5	323	11.9	325	46	11.0	308	90	11.3	282	200	
89	11.5	333	12.5	323	48	11.9	309	90 96	10.9	282	190	
93	12.3	333	11.6	339	48	11.5	316	90 91	10.9	290	190	
93 97	12.5	342	12.9	343	43	12.9	325	99	12.5	290	209	
	12.0					12.9	323	99 91	12.5	301	197	
101		347	12.8	346	46				12.3	303	203	
105	13.0	345	13.6	347	49	12.8	333	97 92			203	
109	12.5	341	13.3	354	47	12.2	329	92 05	12.0	300		
113	11.1	337	12.3	350	44	12.8	337	95	12.4	301	205	
117	11.7	348	12.1	355	43	12.0	337	89	11.4	309	184	
121	12.3	341	12.3	353	44	11.1	335	83	12.0	315	190	
125	11.9	336	13.0	340	48	12.3	326	95	12.0	307	196	
Mean	for weeks											
1-13	11.2	164	11.0	167	86	11.5	164	183	11.4	156	382	
14-52	10.4	232	10.9	228	60	10.6	221	120	10.2	211	241	
53-125	12.1	322	12.4	322	49	12.1	305	100	11.7	283	208	

а Feed consumption for controls measured weekly for the first 13 weeks and monthly thereafter.

3

b

Grams of feed consumed per animal per day Milligrams of *t*-butylhydroquinone consumed per kilogram body weight per day ¢

£.

.

.31	4

### TABLE J3

Feed and Compound	Consumption b	y Male Mice in the 2-Year Fe	ed Study of <i>t</i> -Butylhydroquinone

	0 ppm		0 ppm 1.250 ppm			2,500 ppm			5.000 ppm		
Week	Feed (g/day) <sup>a</sup>	Body Weight (g)	Feed (g/day)	Body Weight (g)	Dose/ Day <sup>b</sup> (mg/kg/day)	Feed (g/day)	Body Weight (g)	Dose/ Day (mg/kg/day)	Feed (g/day)	Body	Dose/
1	. 3.9	23.7	3.6	23.5	191	3.3	23.4	351	4.3	23.0	932
2	4.4	25.4	4.2	25.3	206	4.4	25.3		4.6	24.7	940
6	3.7	30.0	3.7	29.6	156	4.1	29.7	345	4.6	29.2	790
9	3.8	32.3	4.0	32.1	157	3.7	31.7	294	4.2	30.5	682
10	4.7	33.1	4.2	32.9	158	4.4	32.8	336	4.2	30.8	675
13	4.8	36.6	4.6	35.6	160	4.5	35.2	320	4.8	33.4	715
17	4.7	38.8	4.0	38.3	130	4.4	38.0	289	4.4	35.4	619
21	4.9	39.4	3.8	39.6	120	4.4	39.2	280	5.4	36.7	737
25	4.5	41.9	4.8	41.3	146	4.8	40.9	294	4.7	38.3	607
29	4.6	44.4	4.1	43.3	119	3.9	43.1	226	4.2	40.2	528
33	5.1	44.9	5.1	44.4	144	5.1	44.2	287	5.2	40.9	637
37	4.5	45.0	4.9	43.9	140	5.5	43.6		5.4	40.6	669
41	4.6	46.1	4.6	44.9	129	4.4	45.0	246	4.4	41.2	528
45	3.7	48.1	4.1	46.5	110	4.6	46.5	248	4.8	43.4	550
49	3.9	49.7	3.8	48.8	98	4.0	48.6	208	4.0	45.8	441
53	3.9	50.8	4.1	49.3	103	4.0	49.2	203	4.2	46.3	449
57	4.5	51.1	4.4	50.0	111	4.6	49.8	229	4.8	47.5	503
61	4.6	51.5	4.7	50.1	118	5.4	49.6	271	6.0	47.3	637
65	5.1	51.5	5.0	49.8	126	5.3	49.2		5.5	46.9	586
69	4.9	51.9	4.7	49.9	118	5.2	49.7	260	4.9	47.4	517
73	5.6	51.8	5.8	49.8	146	5.3	49.8	267	5.0	47.6	526
77	4.3	52.7	4.5	51.0	111	4.6	50.3	229	4.4	48.4	452
81	4.6	52.6	4.2		102	4.0	50.2	200.	4.5	48.1	464
85	3.9	52.4	3.9	50.8	97	4.3	50.5	214	5.2	47.4	544
89	4.3	52.6	5.0	50.5	123	5.0	50.3	249	5.4	47.8	565
93	3.9	51.4	4.4	50.0	109	4.1	49.1	207	5.2	48.0	545
97	4.3	51.4	4.8	49.6	122	4.5	49.4	229	4.9	47.3	514
101	4.2	49.9	4.3	48.2	112	4.1	49.4	208	4.4	47.8	458
Mean f	or weeks										
1-13	4.2	30.2	4.0	29.8	171	4.1	29.7	347	4.4	28.6	789
14-52	4.5	44.3	4.4	43.4	126	4.6	43.2	266	4.7	40.3	591
53-101	4.5	51.7	4.6	50.0	115	4.6	49.7	234	4.9	47.5	520

5

a

.

Grams of feed consumed per animal per day Milligrams of *t*-butylhydroquinone consumed per kilogram body weight per day b

### t-Butylhydroquinone, NTP TR 459

### Table J4

Feed and Compound Consumption by Female Mice in the 2-Year Feed Study of t-Butylhydroquinone

	0 ppm				2,500 ppm		5.000 ppm				
Week	Feed (g/day) <sup>a</sup>	Body Weight (g)	Feed (g/day)	Body Weight (g)	Dose/ Day <sup>b</sup> (mg/kg/day)	Feed (g/day)	Body Weight (g)	Dose/ Day (mg/kg/day)	Feed (g/day)	Body Weight (g)	Dose/ Day (mg/kg/day
2	4.4	20.1	4.3	20.4	261	3.6	20.2	445	6.1	20.1	1,520
3	3.6	21.5	4.0	21.6	229	4.1	21.3	477	3.9	20.9	933
6	3.0	24.9	3.2	25.2	158	3.5	25.0	353	3.0	24.5	610
7	3.7	26.0	3.7	26.3	176	3.8	26.2	367	4.2	25.2	827
10	3.3	28.3	3.3	28.5	146	3.7	28.0	331	4.4	26.7	821
11	4.3	28.9	4.5	29.3	192	4.3	28.8	369	4.4	27.5	793
17	4.0	33.9	4.2	34.9	150	4.1	34.1	303	4.1	31.8	646
21	4.9	36.0	4.6	36.2	158	4.8	35.6	337	4.8	33.6	713
25	3.9	37.1	4.8	37.1	161	5.1	35.6	° 359	5.1	32.8	772
29	5.3	38.5	5.3	39.2	168	5.6	38.0	367	5.8	35.1	828
33	4.5	39.9	5.1	40.8	157	5.3	39.8	336	4.9	36.7	669
37	4.8	39.9	4.6	40.8	140	4.8	39.9	303	5.0	36.5	678
41	4.7	41.5	4.8	42.1	142	5.0	41.2	305	5.2	37.7	691
45	4.3	43.2	4.5	44.3	127	5.1	43.4	293	4.7	39.0	603
49	4.8	. 46.4	4.8	47.6	127	4.8	46.5	260	4.7	41.9	562
53	4.9	48.5	4.9	49.5	124	5.1	48.7	264	5.1	43.5	587
57	5.2	50.2	6.0	51.4	145	5.9	50.5	291	5.6	44.9	622
61	5.1	51.3	5.6	52.9	132	5.7	51.6	277	5.5	45.6	603
65	5.4	52.3	5.4	53.2	127	5.4	51.9	260	5.0	46.6	532
69	5.5	52.6	5.0	53.7	117	5.4	52.7	256	5.4	46.8	581
73	4.3	53.9	4.8	55.4	109	4.8	54.3	220	4.8	47.9	502
77	5.3	55.4	5.3	56.0	118	5.3	54.9	241	5.2	48.3	542
81	4.8	55.5	4.8	56.8	107	4.9	55.1	223	5.1	49.0	524
85	5.0	56.2	4.9	56.9	107	5.2	55.7	232	5.1	49.6	511
89	4.9	56.0	5.1	57.8	110	5.1	55.5	230	4.9	49.7	492
93	5.0	56.1	5.0	57.9	109	5.3	55.7	236	5.2	49.6	527
97	4.9	55.1	4.8	57.0	106	5.4	54.7	246	5.3	49.0	538
101	4.8	54.5	4.9	55.8	111	5.1	54.2	235	4.7	48.6	485
105	4.6	52.9	4.6	55.6	104	5.1	53.2	239	4.6	47.3	482
Mean f	ior weeks										
1-13	3.7	25.0	3.8	25.2	194	3.8	24.9	391	4.3	24.2	917
14-52	4.6	39.6	4.7	40.3	148	5.0	39.3	318	4.9	36.1	685
53-105	5.0	53.6	5.1	55.0	116	5.3	53.5	247	5.1	47.6	538

а b

Grams of feed consumed per animal per day Milligrams of *t*-butylhydroquinone consumed per kilogram body weight per day

### APPENDIX K

### INGREDHENTS, NUTRHENT COMPOSITION, AND CONTAMINANT LEVELS IN NIHI-07 RAT AND MOUSE RATION

Table K1	Ingredients of NIH-07 Rat and Mouse Ration	318
Table K2	Vitamins and Minerals in NIH-07 Rat and Mouse Ration	318
Table K3	Nutrient Composition of NIH-07 Rat and Mouse Ration	319
Table K4	Contaminant Levels in NIH-07 Rat and Mouse Ration	320

.4

All and the state of a second

Ingredients <sup>b</sup>	Percent by Weight	
Ground #2 yellow shelled corn	24.50	· · · · ·
Ground hard winter wheat	23.00	
Soybean meal (49% protein)	12.00	5 - C C C C C C C C
Fish meal (60% protein)	10.00	4
Wheat middlings	10.00	
Dried skim milk	5.00	
Alfalfa meal (dehydrated, 17% protein)	4.00	· · .
Corn gluten meal (60% protein)	3.00	
Soy oil	2.50	
Dried brewer's yeast	2.00	
Dry molasses	1.50	
Dicalcium phosphate	1.25	
Ground limestone	0.50	,
Salt	0,50	
Premixes (vitamin and mineral)	0.25	

### TABLE K1 Ingredients of NIH-07 Rat and Mouse Ration<sup>a</sup>

<sup>a</sup> NCI, 1976; NIH, 1978

<sup>b</sup> Ingredients were ground to pass through a U.S. Standard Screen No. 16 before being mixed.

### TABLE K2

### Vitamins and Minerals in NIH-07 Rat and Mouse Ration<sup>a</sup>

	Amount	Source	•
Vitamins			
Α	5,500,000 IU	Stabilized vitamin A palmitate or acetate	
D <sub>2</sub>	4,600,000 IU	D-activated animal sterol	
D <sub>3</sub> K <sub>3</sub>	2.8 g	Menadione	
$d - \alpha$ -Tocopheryl acetate	20,000 IU		-
Choline	560.0 g	Choline chloride	
Folic acid	2.2 g		•. •2
Niacin	30.0 g		*. N2
d-Pantothenic acid	18.0 g	d-Calcium pantothenate	
Riboflavin	3.4 g		••
Thiamine	10.0 g	Thiamine mononitrate	•
B <sub>12</sub>	4,000 μg		÷ )
Pyridoxine	1.7 g	Pyridoxine hydrochloride	
Biotin	140.0 mg	d-Biotin	4 a.
Minerals			
	100.0	Toran	-
Iron	120.0 g	Iron sulfate	
Manganese	60.0 g	Manganous oxide	
Zinc	16.0 g	Zinc oxide	
Copper	4.0 g	Copper sulfate	
Iodine	1.4 g	Calcium iodate	
Cobalt	0.4 g	Cobalt carbonate	j.

<sup>a</sup> Per ton (2,000 lb) of finished product

### Table K3

### Nutrient Composition of NIIH-07 Rat and Mouse Ration

Mean ± Standard				
Nutrient	Deviation	Range	Number of Samples	
Protein (% by weight)	23.6 ± 0.52	22.50 - 25.20	34	
Crude Fat (% by weight)	$5.30 \pm 0.23$	4.80 - 5.80	34	
Crude Fiber (% by weight)	$3.50 \pm 0.42$	2.60 - 4.80	34	
Ash (% by weight)	$6.50 \pm 0.22$	6.12 - 7.03	34	
mino Acids (% of total diet)			•	
Arginine	$1.287 \pm 0.084$	1.100 - 1.390	10	
Cystine	$0.306 \pm 0.075$	0.181 - 0.400	10	
Glycine	$1.160 \pm 0.050$	1.060 - 1.220	10	
Histidine	$0.580 \pm 0.024$	0.531 - 0.608	10	
Isoleucine	$0.917 \pm 0.034$	0.867 - 0.965	10	
Leucine	$1.972 \pm 0.052$	1.850 - 2.040	10	
Lysine	$1.273 \pm 0.051$	1.200 - 1.370	10	
Methionine	$0.437 \pm 0.115$	0.306 - 0.699	10	
Phenylalanine	$0.437 \pm 0.113$ $0.994 \pm 0.125$	0.665 - 1.110	10	
Threonine			10	
	$0.896 \pm 0.055$	0.824 - 0.985		
Tryptophan	$0.223 \pm 0.160$	0.107 - 0.671	10	
Tyrosine	$0.677 \pm 0.105$	0.564 - 0.794	10	
Valine	$1.089 \pm 0.057$	0.962 - 1.170	10	
ssential Fatty Acids (% of total				
Linoleic	$2.389 \pm 0.233$	1.830 - 2.570	9	
Linolenic	$0.277 \pm 0.036$	0.210 - 0.320	9	
itamins				
Vitamin A (IU/kg)	6,725 ± 1,375	4,290 - 12,540	34	
Vitamin D (IU/kg)	$4,450 \pm 1,382$	3,000 - 6,300	4	
α-Tocopherol (ppm)	$36.92 \pm 9.32$	22.5 - 48.9	9	
Thiamine (ppm)	$18.40 \pm 2.50$	12.0 - 25.0	34	
Riboflavin (ppm)	$7.92 \pm 0.93$	6.10 - 9.00	10	
Niacin (ppm)	$100.95 \pm 25.92$	65.0 - 150.0	9	
Pantothenic Acid (ppm)	$30.30 \pm 3.60$	23.0 - 34.6	10	
Pyridoxine (ppm)	$9.25 \pm 2.62$	5.60 - 14.0	10	
Folic Acid (ppm)	$2.51 \pm 0.64$	1.80 - 3.70	10	
Biotin (ppm)	$0.267 \pm 0.049$	0.19 - 0.35	10	
Vitamin B <sub>12</sub> (ppb)	$40.14 \pm 20.04$	10.6 - 65.0	10	
Choline (ppm)	$3,068 \pm 314$	2,400 - 3,430	9	
linerals				
Calcium (%)	$1.20 \pm 0.09$	1.00 - 1.37	34	
Phosphorus (%)	$0.94 \pm 0.05$	0.80 - 1.03	34	
Potassium (%)		0.80 - 1.05	34 8	
Chloride (%)	$0.887 \pm 0.067$			
	$0.526 \pm 0.092$	0.380 - 0.635	8	
Sodium (%)	$0.315 \pm 0.034$	0.258 - 0.370	10	
Magnesium (%)	$0.168 \pm 0.008$	0.151 - 0.180	10	
Sulfur (%)	$0.274 \pm 0.063$	0.208 - 0.420	10	
Iron (ppm)	$356.2 \pm 90.0$	255.0 - 523.0	10	
Manganese (ppm)	$92.24 \pm 5.35$	81.70 - 99.40	10	
Zinc (ppm)	58.14 ± 9.91	46.10 - 81.60	10	
Copper (ppm)	$11.50 \pm 2.40$	8.090 - 15.39	10	
Iodine (ppm)	$3.70 \pm 1.14$	1.52 - 5.83	10	
Chromium (ppm)	$1.71 \pm 0.45$	0.85 - 2.09	9	
Cobalt (ppm)	0.797 ± 0.23	0.490 - 1.150	. 6	

	Mean ± Standard Deviation <sup>b</sup>	Range	Number of Samples
Contaminants			<u> </u>
Arsenic (ppm)	$0.44 \pm 0.21$	0.10 - 0.80	34
Cadmium (ppm)	$0.13 \pm 0.08$	0.05 - 0.40	34
Lead (ppm)	$0.35 \pm 0.37$	0.10 - 2.10	34
Mercury (ppm)	$0.02 \pm 0.01$	0.02 - 0.05	34
Selenium (ppm) <sup>c</sup>	$0.32 \pm 0.11$	0.02 - 0.44	33
Aflatoxins (ppb) <sup>d</sup>	<5.0	0.02 - 0.44	24
Nitrate nitrogen (ppm) <sup>e</sup>	$9.94 \pm 5.02$	1.80 - 20.0	34
Nitrite nitrogen (ppm) <sup>e</sup>	$0.24 \pm 0.20$	0.10 - 1.00	34
BHA (ppm) <sup>I</sup>	$1.33 \pm 0.82$	1.00 - 4.00	33
BHA (ppm) <sup>f</sup>		1.00 - 7.00	33
	$1.28 \pm 0.61$	4,700 - 630,000	33
Aerobic plate count (CFU/g)	$139,873 \pm 169,234$		34
Coliform (MPN/g)	$19.4 \pm 22.20$	3.00 - 93.00	
Escherichia coli (MPN/g)	$3.24 \pm 1.04$	3.00 - 9.0	34
Total Nitrosoamines (ppb) <sup>g</sup>	$7.08 \pm 2.40$	2.90 - 13.70	34
N-Nitrosodimethylamine (ppb) <sup>g</sup>	$5.23 \pm 1.35$	2.90 - 9.40	34
N-Nitrosopyrrolidine (ppb) <sup>g</sup>	$1.61 \pm 1.17$	0.00 - 4.70	34
Pesticides (ppm)			·
α-BHC <sup>j</sup>	< 0.01		31
β-BHC	< 0.02		31
y-BHC	< 0.01		31
8-BHC	< 0.01		31
Heptachlor	<0.01		31
Aldrin	< 0.01		31
Heptachlor epoxide	< 0.01		31
DDE	< 0.01		31
DDD	< 0.01		31
DDT	< 0.01		31
HCB	<0.01		31
Mirex	<0.01		31
Methoxychlor	< 0.05		31
Dieldrin	<0.03		31
Endrin	<0.01		31
Telodrin	< 0.01		31
Chlordane	< 0.01		31
· ·····	< 0.05		31
Toxaphene	<0.1		31
Estimated PCBs			31
Ronnel	< 0.01		31
Ethion	<0.02	•	31
Trithion	< 0.05		
Diazinon	< 0.1		31
Methyl parathion	<0.02		31
Ethyl parathion	< 0.02		31
Malathion	$0.28 \pm 0.26$	< 0.05 - 1.00	34
Endosulfan I	< 0.01		31
Endosulfan II	< 0.01		31
Endosulfan sulfate	< 0.03		. 31

#### **TABLE K4**

### Contaminant Levels in NIH-07 Rat and Mouse Ration<sup>a</sup>

<sup>a</sup> CFU = colony forming units, MPN = most probable number, BHC is hexachlorocyclohexane or benzene hexachloride.

<sup>b</sup> For values less than the limit of detection, the detection limit is given as the mean.

<sup>c</sup> No selenium measurement was recorded for the lot milled on 4 May 1990.

<sup>d</sup> No aflatoxin measurement was recorded for the lot milled on 2 October 1989.

<sup>e</sup> Sources of contamination: alfalfa, grains, and fish meal

f Sources of contamination: soy oil and fish meal; no BHA or BHT measurements were recorded for the lot milled on 1 November 1989.

<sup>g</sup> All values were corrected for percent recovery.

### APPENDIX L SENTINEL ANIMAL PROGRAM

Methods		322
Table L1	Murine Virus Antibody Determinations for Rats and Mice in the 13-Week,	
	Long-Term, and 2-Year Studies of <i>t</i> -Butylhydroquinone	325

### SENTINEL ANIMAL PROGRAM

### METHODS

Rodents used in the Carcinogenesis Program of the National Toxicology Program are produced in optimally clean facilities to eliminate potential pathogens that may affect study results. The Sentinel Animal Program is part of the periodic monitoring of animal health that occurs during the toxicologic evaluation of chemical compounds. Under this program, the disease state of the rodents is monitored via serology on sera from extra (sentinel) animals in the study rooms. These animals and the study animals are subject to identical environmental conditions. The sentinel animals come from the same production source and weanling groups as the animals used for the studies of chemical compounds.

Most serum samples were collected from sentinel, untreated, or vehicle control rats and mice. At the end of the 13-week studies, blood was collected from five male and five female control rats and five male and five female sentinel mice. During the long-term rat study, samples were collected from 10 first-generation ( $F_0$ ) females at necropsy; five male and five female sentinels at 6, 7, 12, and 13 months; one male sentinel at 14 months (insufficient serum was collected for analysis); one male sentinel at 16 months; five male and four female sentinels at 18 months; three male and four female sentinels at 19 months; one male and four female sentinels at 24 months; four male and one female sentinels at 25 months; five vehicle control or untreated females at 30 months; and four vehicle control or untreated females at 31 months. During the 2-year mouse study, samples were collected from four to five male and four to five female sentinels or controls at 6, 12, 18, and 24 months. Additional samples for ELISA determination of mouse hepatitis virus and Sendai, were taken from ten naive male sentinels at 17, 18, 19, 20, and 23 months. Blood from each animal was collected and allowed to clot, and the serum was separated. The samples were processed appropriately and sent to Microbiological Associates, Inc. (Bethesda, MD), for determination of antibody titers. The laboratory serology methods and viral agents for which testing was performed are tabulated below; the times at which blood was collected during the studies are also listed.

#### Method and Test

Time of Analysis

### RATS

13-Week Study ELISA PVM (pneumonia virus of mice) RCV/SDA (rat coronavirus/ sialodacryoadenitis virus) Sendai

Hemagglutination Inhibition H-1 (Toolan's H-1 virus) KRV (Kilham rat virus)

Long-Term Study ELISA Mycoplasma arthritidis

Mycoplasma pulmonis PVM RCV/SDA Sendai Study termination

Study termination Study termination

Study termination Study termination

30, 31 months 30, 31 months  $F_0$  necropsy, 6, 7, 12, 13, 16, 18, 19, 24, 25, 30, 31 months  $F_0$  necropsy, 6, 7, 12, 13, 18, 19, 25, 30 months  $F_0$  necropsy, 6, 7, 12, 13, 16, 18, 19, 24, 25, 30, 31 months

#### t-Butylhydroquinone, NTP TR 459

### Method and Test

#### Time of Analysis

RATS (continued) Long-Term Study (continued) Immunofluorescence Assay PVM RCV/SDA

Hemagglutination Inhibition H-1 KRV

#### MICE

13-Week Study

ELISA

Ectromelia virus GDVII (mouse encephalomyelitis virus) MVM (minute virus of mice) Mouse adenoma virus MHV (mouse hepatitis virus) PVM Reovirus 3 Sendai

## Immunofluorescence Assay

EDIM (epizootic diarrhea of infant mice) LCM (lymphocytic choriomeningitis virus)

Study termination

Study termination

Study termination

Study termination

Hemagglutination Inhibition

K (papovavirus) Polyoma virus

2-Year Study ELISA Ectromelia virus EDIM GDVII LCM Mouse adenoma virus MHV *M. arthritidis M. pulmonis* PVM Reovirus 3 Sendai

6, 12, 18, and 24 months
12, and 24 months
6, 12, 18, and 24 months
6, 12, 18, and 24 months
6, 12, 18, and 24 months
6, 12, 17, 18, 19, 20, 23, and 24 months
24 months (females only)
24 months (females only)
6, 12, 18, and 24 months

0.0

Study termination Study termination Study termination Study termination Study termination Study termination

 $F_0$  necropsy, 6, 7, 12, 13, 16, 18, 19, 24, 25, 30, 31 months  $F_0$  necropsy, 6, 7, 12, 13, 16, 18, 19, 24, 25, 30, 31 months

Study termination

31 months 16, 18, 19, 24, 25 months

### t-Butylhydroquinone, NTP TR 459

### Method and Test

MICE (continued) 2-Year Study (continued) Immunofluorescence Assay EDIM GDVII MVM Mouse adenoma virus Reovirus 3

### **Time of Analysis**

6, 18, and 24 (one female only) months
18, and 24 (one male only) months
6 months
24 (one female only) months
6 and 24 (one male and one female only) months

Hemagglutination Inhibition K MVM Polyoma virus Reovirus 3

ŧv.

6, 12, 18, and 24 months 12, 18, and 24 months 6, 12, 18, and 24 months 6 months

> , L

Results of serology tests are presented in Table L1.

### Table L1

## Murine Virus Antibody Determinations for Rats and Mice in the 13-Week, Long-Term, and 2-Year Studies of *t*-Butylhydroquinone

Interval	Incidence of Antibody in Sentinel Animals	Positive Serologic Reaction for
13-Week Studies		
Rats		
Study termination	0/10	None
Mice		
Study termination	0/10	None
Long-Term Study		
Rats		
F <sub>0</sub> necropsy	0/10	None
6 months	0/10	None
7 months	0/10	None
12 months	0/10	None
13 months	0/10	None
16 months	0/1	None
18 months	0/11	None
19 months	0/7	None
24 months	0/5	None
25 months	0/5	None
30 months	1/5	M. arthritidis <sup>a</sup>
31 months	2/4	M. arthritidis <sup>a</sup>
2-Year Study		
Mice		
6 months	3/10 <sup>b</sup>	Reovirus 3
12 months	0/10	None
17 months	0/10	None
18 months	0/18	None
19 months	0/10	None
20 months	· 0/10	None
23 months	0/10	None
24 months	1/10	Mouse hepatitis virus

<sup>a</sup> Further evaluation of samples positive for *M. arthritidis* by immunoblot and Western blot procedures indicated that the positive titers may be due to cross reaction with antibodies of nonpathogenic *Mycoplasma* or other agents. Only sporadic samples were positive and there were no clinical findings or histopathologic changes of *M. arthritidis* infection in rats with positive titers. Accordingly, *M. arthritidis*-positive titers were considered to be false positives.
 <sup>b</sup> Western blot analysis of the three sera testing positive for Reovirus 3 were negative for specific antibodies. Therefore, the low level

<sup>D</sup> Western blot analysis of the three sera testing positive for Reovirus 3 were negative for specific antibodies. Therefore, the low level ELISA and immunofluorescence assay results were considered to be nonspecific due to the lack of increasing titer and the incidence in the colonies in which the positive results occurred.

.,9

đ



### DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service National Toxicology Program Central Data Management P.O. Box 12233, MD E1-02 Research Triangle Park, NC 27709

> Official Business Penalty for Private Use - \$300

SPECIAL FOURTH-CLASS RATE POSTAGE AND FEES PAID DHHS/NIH Permit No. G-811

> NIH Publication No. 97-3375 May 1997